DrugBank ID,Name,Drug Groups,SMILES,Formula,Doping,Drug Categories,Target_Names,Similar Structure,State
DB00006,Bivalirudin,approved; investigational,CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O,C98H138N24O33,,"Amino Acids, Peptides, and Proteins, Anticoagulants, Antithrombins, Blood and Blood Forming Organs, Enzyme Inhibitors, Hematologic Agents, Peptides, Protease Inhibitors, Serine Protease Inhibitors, Thrombin Inhibitors"," Prothrombin,  Myeloperoxidase","DB00006, DB16152, DB05660, DB15231, DB11890, DB15195, DB16146, DB03632, DB12126, DB17352, DB05034, DB16687, DB05625, DB15272, DB11720, DB15366, DB15340, DB08890, DB11996, DB18283, DB06260, DB18634, DB13798, DB00035, DB13742, DB05724, DB15636, DB14806, DB09059, DB14786",
DB00007,Leuprolide,approved; investigational,CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1,C59H84N16O12,,"Adrenal Cortex Hormones, Agents Causing Muscle Toxicity, Amino Acids, Peptides, and Proteins, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Antineoplastic and Immunomodulating Agents, Drugs causing inadvertant photosensitivity, Drugs that are Mainly Renally Excreted, Endocrine Therapy, Fertility Agents, Fertility Agents, Female, Gonadotropin Releasing Hormone Receptor Agonist, Gonadotropin Releasing Hormone Receptor Agonists, Gonadotropin-releasing hormone agonist, Gonadotropins, Hormones and Related Agents, Hyperglycemia-Associated Agents, Hypothalamic Hormones, Moderate Risk QTc-Prolonging Agents, Nerve Tissue Proteins, Neuropeptides, Oligopeptides, Peptides, Photosensitizing Agents, Pituitary Hormone-Releasing Hormones, Proteins, QTc Prolonging Agents, Reproductive Control Agents", Gonadotropin-releasing hormone receptor,"DB00007, DB06825, DB11510, DB00666, DB18169, DB06719, DB00644, DB04931, DB06788, DB14027, DB05479, DB15314, DB15194, DB01284, DB13298, DB15687, DB00014, DB11724, DB13928, DB14803, DB15272, DB17938, DB12199, DB11700, DB16013, DB14786, DB06610, DB14777, DB11720, DB16146",
DB00014,Goserelin,approved,CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O,C59H84N18O14,,"Adrenal Cortex Hormones, Amino Acids, Peptides, and Proteins, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Antineoplastic and Immunomodulating Agents, Drugs that are Mainly Renally Excreted, Endocrine Therapy, Gonadotropin Releasing Hormone Receptor Agonist, Gonadotropin Releasing Hormone Receptor Agonists, Gonadotropin-releasing hormone agonist, Gonadotropins and Antigonadotropins, Hormones, Hormones and Related Agents, Hormones, Hormone Substitutes, and Hormone Antagonists, Hyperglycemia-Associated Agents, Hypothalamic Hormones, Miscellaneous Therapeutic Agents, Moderate Risk QTc-Prolonging Agents, Nerve Tissue Proteins, Neuropeptides, Oligopeptides, Peptide Hormones, Peptides, Pituitary Hormone-Releasing Hormones, QTc Prolonging Agents"," Lutropin-choriogonadotropic hormone receptor,  Gonadotropin-releasing hormone receptor","DB00014, DB06719, DB00644, DB00007, DB06825, DB11510, DB00666, DB04931, DB18169, DB13298, DB05479, DB15314, DB14027, DB01284, DB06788, DB15687, DB15194, DB14803, DB13928, DB11700, DB11724, DB11975, DB15272, DB13742, DB16146, DB01278, DB12631, DB05724, DB14786, DB06763",
DB00027,Gramicidin D,approved,CC(C)C[C@@H](NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCCO,C96H135N19O16,,"Amino Acids, Peptides, and Proteins, Anti-Bacterial Agents, Anti-Infective Agents, Anti-Infective Agents, Local, Membrane Proteins, P-glycoprotein inhibitors, P-glycoprotein substrates, Peptides, Peptides, Cyclic, Pore Forming Cytotoxic Proteins, Proteins, Throat Preparations", P-glycoprotein 1,"DB00027, DB12748, DB14777, DB12054, DB18252, DB06610, DB12777, DB17938, DB02255, DB18527, DB16013, DB04894, DB12292, DB13074, DB06791, DB17503, DB06645, DB15272, DB12088, DB14786, DB12602, DB18190, DB15494, DB17969, DB16146, DB17160, DB17278, DB18169, DB17536, DB11628",
DB00035,Desmopressin,approved,NC(=O)CC[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O,C46H64N14O12S2,,"Agents that produce hypertension, Amino Acids, Peptides, and Proteins, Antidiuretic Agents, Arginine Vasopressin, Cardiovascular Agents, Coagulants, Drugs that are Mainly Renally Excreted, Factor VIII Activator, Hematologic Agents, Hemostatics, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Increased Coagulation Factor VIII Activity, Increased Coagulation Factor VIII Concentration, Natriuretic Agents, Nerve Tissue Proteins, Neuropeptides, Oligopeptides, Peptide Hormones, Peptides, Pituitary, Pituitary and Hypothalamic Hormones and Analogues, Pituitary Hormones, Pituitary Hormones, Posterior, Posterior Pituitary Lobe Hormones, Proteins, Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins, Vasopressin Analog, Vasopressin and Analogues, Vasopressins"," Vasopressin V2 receptor,  Vasopressin V1a receptor,  Vasopressin V1b receptor,  Prostaglandin G/H synthase 2,  Prostaglandin G/H synthase 1","DB00035, DB14642, DB13798, DB00067, DB09059, DB15195, DB12495, DB08890, DB05034, DB06283, DB01278, DB05724, DB00006, DB01282, DB08861, DB15231, DB15355, DB17352, DB05660, DB03632, DB16152",
DB00050,Cetrorelix,approved; investigational,CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CN=CC=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=CC=CC=C2C=C1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,C70H92ClN17O14,,"Amino Acids, Peptides, and Proteins, Anti-Gonadotropin-Releasing Hormones, Decreased GnRH Secretion, Fertility Agents, Fertility Agents, Female, Gonadotropin Releasing Hormone Receptor Antagonists, Gonadotropin-releasing Hormone Antagonists, Hormone Antagonists, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hypothalamic Hormones, Nerve Tissue Proteins, Neuropeptides, Oligopeptides, Peptide Hormones, Peptides, Pituitary and Hypothalamic Hormones and Analogues, Pituitary Hormone-Releasing Hormones, Proteins, Reproductive Control Agents, Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins"," Gonadotropin-releasing hormone receptor,  Lutropin-choriogonadotropic hormone receptor","DB00050, DB12581, DB05624, DB00106, DB06785, DB11906, DB06610, DB00666, DB16013, DB17938, DB15272, DB00007, DB06825, DB11510, DB14786, DB14777, DB18169, DB16146, DB06719, DB11975, DB12777, DB06699, DB00644, DB18527, DB12199, DB00027, DB05625, DB04931, DB12054, DB17277",
DB00067,Vasopressin,approved,NCCCCC(NC(=O)C1CCCN1C(=O)C1CSSCC(N)C(=O)NC(CC2=CC=C(O)C=C2)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(N)=O)C(=O)N1)C(=O)NCC(N)=O.NC1CSSCC(NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC2=CC=C(O)C=C2)NC1=O)C(=O)N1CCCC1C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O,C92H130N28O24S4,,"Amino Acids, Peptides, and Proteins, Antidiuretic Agents, Arginine Vasopressin, Arginine Vasopressin, analogs & derivatives, Cardiovascular Agents, Coagulants, Decreased Diuresis, Hematologic Agents, Hemostatics, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Natriuretic Agents, Nerve Tissue Proteins, Neuropeptides, Oligopeptides, Peptide Hormones, Peptides, Pituitary, Pituitary Hormones, Pituitary Hormones, Posterior, Proteins, Vasoconstriction, Vasoconstrictor Agents, Vasopressin and Analogues, Vasopressins"," Vasopressin V2 receptor,  Vasopressin V1a receptor,  Vasopressin V1b receptor,  Oxytocin receptor,  Canalicular multispecific organic anion transporter 1","DB00067, DB14642, DB00035, DB13798, DB12495, DB09059, DB15195, DB08890, DB06283, DB05034, DB01278, DB01282, DB04697",
DB00080,Daptomycin,approved; investigational,CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)C2=CC=CC=C2N)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)[C@H](C)CC(O)=O,C72H101N17O26,,"Agents Causing Muscle Toxicity, Amino Acids, Peptides, and Proteins, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Cyclic Lipopeptides, Drugs that are Mainly Renally Excreted, Lipids, Lipopeptide Antibacterial, Lipopeptides, P-glycoprotein substrates, Peptides, Peptides, Cyclic"," Serum albumin,  Alpha-1-acid glycoprotein 1,  Alpha-1-antitrypsin,  Low-density lipoprotein receptor,  Sex hormone-binding globulin,  Hemopexin,  P-glycoprotein 1","DB00080, DB12076, DB16146, DB13928, DB15194, DB14806, DB15272, DB14027, DB15636, DB14786, DB01284, DB15687, DB13298, DB17277, DB04931, DB05479, DB15314, DB00403, DB12538, DB13742, DB06719, DB17503, DB06663, DB13345, DB17536, DB14777, DB00320, DB12292, DB12755, DB11274",
DB00091,Cyclosporine,approved; investigational; vet_approved,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,C62H111N11O12,,"Agents causing hyperkalemia, Agents Causing Muscle Toxicity, Agents that produce hypertension, Agents that produce neuromuscular block (indirect), Agents that reduce seizure threshold, Amino Acids, Peptides, and Proteins, Anti-Inflammatory Agents, Antirheumatic Agents, BCRP/ABCG2 Inhibitors, BSEP/ABCB11 Inhibitors, BSEP/ABCB11 Substrates, BSEP/ABCB11 Substrates with a Narrow Therapeutic Index, Calcineurin Inhibitor Immunosuppressant, Calcineurin Inhibitors, Cyclosporins, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (moderate), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dermatologicals, Enzyme Inhibitors, Immunologic Factors, Immunosuppressive Agents, Narrow Therapeutic Index Drugs, Nephrotoxic agents, Neurotoxic agents, NTCP Inhibitors, OAT1/SLC22A6 inhibitors, OAT1/SLC22A6 Substrates, OATP1B1/SLCO1B1 Inhibitors, OATP1B1/SLCO1B1 Substrates, OATP1B3 inhibitors, Ophthalmologicals, P-glycoprotein inhibitors, P-glycoprotein substrates, P-glycoprotein substrates with a Narrow Therapeutic Index, Peptides, Peptides, Cyclic"," Calcium signal-modulating cyclophilin ligand,  Calcineurin subunit B type 2,  Peptidyl-prolyl cis-trans isomerase A,  Peptidyl-prolyl cis-trans isomerase F, mitochondrial,  Cytochrome P450 2C19,  Cytochrome P450 2D6,  Cytochrome P450 3A5,  Cytochrome P450 3A4,  P-glycoprotein 1,  Bile salt export pump,  Ileal sodium/bile acid cotransporter,  Sodium/bile acid cotransporter,  Solute carrier family 22 member 6,  Multidrug resistance-associated protein 7,  Canalicular multispecific organic anion transporter 1,  ATP-binding cassette sub-family G member 2,  Solute carrier organic anion transporter family member 1B1, 10. Solute carrier organic anion transporter family member 1B3","DB00091, DB12139, DB13068, DB11693, DB18246, DB11869, DB00803, DB11801, DB05434",
DB00106,Abarelix,approved; investigational; withdrawn,CC(C)C[C@H](NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC1=CN=CC=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=C(C=CC=C2)C=C1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,C72H95ClN14O14,,"Amino Acids, Peptides, and Proteins, Antineoplastic and Immunomodulating Agents, Endocrine Therapy, Hormone Antagonists, Hormone Antagonists and Related Agents, Hormones, Hormone Substitutes, and Hormone Antagonists, Peptides", Gonadotropin-releasing hormone receptor,"DB00106, DB05624, DB00050, DB12581, DB06785, DB11906, DB14777, DB18527, DB06699, DB16146, DB12777, DB15272, DB06610, DB16013, DB17938, DB18169, DB09099, DB14806, DB17503, DB00666, DB06791, DB11628, DB12054, DB11975, DB14786, DB18252, DB00027, DB00007, DB06825, DB11510",
DB00114,Pyridoxal phosphate,approved; investigational; nutraceutical,CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O,C8H10NO6P,,"Alimentary Tract and Metabolism, Coenzymes, Dietary Supplements, Enzymes and Coenzymes, Food, Micronutrients, Physiological Phenomena, Picolines, Pyridines, Supplements, Vitamin B Complex, Vitamins"," Alanine--glyoxylate aminotransferase 2, mitochondrial,  Glutamate decarboxylase 1,  Cystathionine beta-synthase,  Kynureninase,  Serine hydroxymethyltransferase, cytosolic,  Cysteine desulfurase, mitochondrial,  Aspartate aminotransferase, cytoplasmic,  Ornithine aminotransferase, mitochondrial,  Ornithine decarboxylase, 10. Kynurenine/alpha-aminoadipate aminotransferase, mitochondrial, 11. 4-aminobutyrate aminotransferase, mitochondrial, 12. Pyridoxine-5'-phosphate oxidase, 13. Sphingosine-1-phosphate lyase 1, 14. Tyrosine aminotransferase, 15. Kynurenine--oxoglutarate transaminase 1, 16. Glycogen phosphorylase, liver form, 17. Serine palmitoyltransferase 2, 18. Cysteine sulfinic acid decarboxylase, 19. Histidine decarboxylase, 20. Arginine decarboxylase, 21. L-serine dehydratase/L-threonine deaminase, 22. 2-amino-3-ketobutyrate coenzyme A ligase, mitochondrial, 23. Glycine dehydrogenase [decarboxylating], mitochondrial, 24. Alanine aminotransferase 1, 25. Phosphoserine aminotransferase, 26. 5-aminolevulinate synthase, nonspecific, mitochondrial, 27. Serine--pyruvate aminotransferase, 28. Pyridoxal phosphate phosphatase, 29. Serine palmitoyltransferase 1, 30. Cystathionine gamma-lyase, 31. Branched-chain-amino-acid aminotransferase, cytosolic, 32. Branched-chain-amino-acid aminotransferase, mitochondrial, 33. Proline synthase co-transcribed bacterial homolog protein, 34. Aspartate aminotransferase, mitochondrial, 35. Glycogen phosphorylase, brain form, 36. Glycogen phosphorylase, muscle form, 37. Aromatic-L-amino-acid decarboxylase, 38. Serine hydroxymethyltransferase, 39. Glutamate decarboxylase 2, 40. Kynurenine--oxoglutarate transaminase 3, 41. Glutamate decarboxylase-like protein 1, 42. Selenocysteine lyase, 43. Immunoglobulin superfamily member 10, 44. 5-phosphohydroxy-L-lysine phospho-lyase, 45. Serine hydroxymethyltransferase, mitochondrial, 46. 5-aminolevulinate synthase, erythroid-specific, mitochondrial, 47. Alanine aminotransferase 2, 48. Molybdenum cofactor sulfurase, 49. Serine dehydratase-like, 50. Serine racemase, 51. O-phosphoseryl-tRNA(Sec) selenium transferase, 52. Serine palmitoyltransferase 3, 53. Glutamic acid decarboxylase, 54. Aspartate aminotransferase (Protein Group)","DB00114, DB02209, DB01639, DB03629, DB02142, DB00147, DB02824, DB01993, DB04467, DB02783, DB04241, DB03433",
DB00115,Cyanocobalamin,approved; nutraceutical,C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2N=C1\C(C)=C1/N=C(/C=C3\N=C(\C(\C)=C4\[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)OP([O-])(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)N1C=NC2=C1C=C(C)C(C)=C2,C63H88CoN14O14P,,"Antianemic Preparations, Blood and Blood Forming Organs, Corrinoids, Diet, Food, and Nutrition, Drugs that are Mainly Renally Excreted, Food, Growth Substances, Heterocyclic Compounds, Fused-Ring, Micronutrients, Vitamin B 12, biosynthesis, Vitamin B Complex, Vitamin B12 and Folic Acid, Vitamins"," Methionine synthase,  Methylmalonyl-CoA mutase, mitochondrial,  Methionine synthase reductase,  Methylmalonic aciduria type A protein, mitochondrial,  Methylmalonic aciduria and homocystinuria type C protein,  Methylenetetrahydrofolate reductase,  Cob(I)yrinic acid a,c-diamide adenosyltransferase, mitochondrial,  Bifunctional adenosylcobalamin biosynthesis protein CobU,  Protein amnionless,  Transcobalamin-1,  Transcobalamin-2,  Gastric intrinsic factor,  Cubilin,  Low-density lipoprotein receptor-related protein 2,  Multidrug resistance-associated protein 1","DB00115, DB09387, DB14098, DB14092, DB00200, DB03614, DB11191, DB02667, DB05168, DB11467, DB03469, DB04803, DB09385, DB05735, DB03906, DB16186, DB03317, DB12674, DB02832, DB00361, DB13013, DB11641, DB02975, DB17385, DB15673, DB02949, DB12586, DB16312, DB02868, DB00615",
DB00116,Tetrahydrofolic acid,nutraceutical,NC1=NC(=O)C2=C(NCC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2)N1,C19H23N7O6,,"Coenzymes, Dietary Supplements, Enzymes and Coenzymes, Folic Acid and Derivatives, Heterocyclic Compounds, Fused-Ring, Pteridines, Pterins, Supplements, Vitamin B Complex, Vitamins"," C-1-tetrahydrofolate synthase, cytoplasmic,  Bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase, mitochondrial,  Aminomethyltransferase, mitochondrial,  Cytosolic 10-formyltetrahydrofolate dehydrogenase,  Methionine synthase,  Formimidoyltransferase-cyclodeaminase,  Bifunctional purine biosynthesis protein PURH,  Serine hydroxymethyltransferase, cytosolic,  Serine hydroxymethyltransferase, mitochondrial, 10. Methylenetetrahydrofolate reductase, 11. Serine hydroxymethyltransferase, 12. Methionyl-tRNA formyltransferase, mitochondrial,  Canalicular multispecific organic anion transporter 1","DB00116, DB02031, DB04789, DB11256, DB00650, DB03256, DB11596, DB02067, DB12676, DB17113, DB02800, DB02358, DB02301",
DB00117,Histidine,investigational; nutraceutical,N[C@@H](CC1=CNC=N1)C(O)=O,C6H9N3O2,,"Amino Acids, Amino Acids, Cyclic, Amino Acids, Essential, Amino Acids, Peptides, and Proteins, Dietary Supplements, Proteinogenic Amino Acids, Supplements"," Histidine decarboxylase,  Histidine--tRNA ligase, cytoplasmic,  Sodium-coupled neutral amino acid transporter 3,  Histidine ammonia-lyase,  Monocarboxylate transporter 10","DB00117, DB18516, DB04151, DB03811, DB17614",
DB00118,Ademetionine,approved; investigational; nutraceutical,C[S+](CC[C@H](N)C([O-])=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1N=CN=C2N,C15H22N6O5S,,"Alimentary Tract and Metabolism, Amino Acids, Amino Acids and Derivatives, Amino Acids, Peptides, and Proteins, Amino Acids, Sulfur, Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (weak), Cytochrome P-450 Enzyme Inhibitors, Dietary Supplements, Heterocyclic Compounds, Fused-Ring, Nucleic Acids, Nucleotides, and Nucleosides, Nucleosides, Purine Nucleosides, Purines, Ribonucleosides, Sulfur Compounds, Supplements"," Catechol O-methyltransferase,  Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase 1,  Arsenite methyltransferase,  Glycine N-methyltransferase,  S-adenosylmethionine decarboxylase proenzyme,  S-adenosylmethionine synthase isoform type-2,  Cystathionine beta-synthase,  S-adenosylmethionine synthase isoform type-1,  Spermidine synthase,  Cytochrome P450 2E1","DB00118, DB01752, DB02523, DB07052, DB02282, DB07413, DB02844, DB03716, DB00194, DB00640, DB03528, DB03423, DB01910, DB01073, DB04441, DB12156, DB03273, DB03458, DB16075, DB03011, DB07170, DB02162, DB02607, DB02916, DB04954, DB02933, DB01755, DB02684, DB03869, DB03355",
DB00119,Pyruvic acid,approved; investigational; nutraceutical,CC(=O)C(O)=O,C3H4O3,,"Dietary Supplements, Keto Acids, Pyruvates, Supplements"," Monocarboxylate transporter 4,  Monocarboxylate transporter 8,  Alanine--glyoxylate aminotransferase 2, mitochondrial,  Monocarboxylate transporter 6,  Pyruvate kinase PKLR,  Monocarboxylate transporter 7,  Monocarboxylate transporter 2,  Pyruvate dehydrogenase E1 component subunit beta, mitochondrial,  Pyruvate kinase PKM, 10. 4-aminobutyrate aminotransferase, mitochondrial, 11. Monocarboxylate transporter 5, 12. Monocarboxylate transporter 3, 13. Monocarboxylate transporter 1, 14. Pyruvate carboxylase, mitochondrial,  Monocarboxylate transporter 2,  Monocarboxylate transporter 1,  Monocarboxylate transporter 10,  Solute carrier organic anion transporter family member 2A1,  Monocarboxylate transporter 4","DB00119, DB02951, DB03589, DB04553",
DB00120,Phenylalanine,approved; investigational; nutraceutical,N[C@@H](CC1=CC=CC=C1)C(O)=O,C9H11NO2,,"Amino Acids, Amino Acids, Aromatic, Amino Acids, Cyclic, Amino Acids, Essential, Amino Acids, Peptides, and Proteins, Dietary Supplements, Immunosuppressive Agents, Myelosuppressive Agents, Proteinogenic Amino Acids, Supplements"," Tyrosine aminotransferase,  Large neutral amino acids transporter small subunit 2,  Phenylalanine--tRNA ligase alpha subunit,  Phenylalanine-4-hydroxylase,  Phenylalanine--tRNA ligase, mitochondrial,  Phenylalanine--tRNA ligase beta subunit,  Tyrosine 3-monooxygenase,  Monocarboxylate transporter 10","DB00120, DB02556, DB06838, DB02685, DB01766, DB00135, DB03839, DB04639, DB07365, DB03660, DB04713, DB17137, DB04484, DB08617, DB02024, DB00765, DB08371, DB16306, DB03400, DB03552, DB13455, DB07910, DB04292, DB07673",
DB00121,Biotin,approved; investigational; nutraceutical,[H][C@]12CS[C@@H](CCCCC(O)=O)[C@@]1([H])NC(=O)N2,C10H16N2O3S,,"Alimentary Tract and Metabolism, Coenzymes, Diet, Food, and Nutrition, Dietary Supplements, Enzymes and Coenzymes, Food, Growth Substances, Imidazoles, Micronutrients, Physiological Phenomena, Supplements, Vitamin B Complex, Vitamins"," Propionyl-CoA carboxylase beta chain, mitochondrial,  Biotin--protein ligase,  Methylcrotonoyl-CoA carboxylase beta chain, mitochondrial,  Acetyl-CoA carboxylase 2,  Methylcrotonoyl-CoA carboxylase subunit alpha, mitochondrial,  Pyruvate carboxylase, mitochondrial,  Propionyl-CoA carboxylase alpha chain, mitochondrial,  Acetyl-CoA carboxylase 1,  Cytochrome P450 1B1,  Sodium-dependent multivitamin transporter,  Sodium-coupled monocarboxylate transporter 1","DB00121, DB04650, DB03112, DB02674, DB07497, DB03139",
DB00122,Choline,approved; nutraceutical,C[N+](C)(C)CCO,C5H14NO,,"Alcohols, Amines, Amino Alcohols, Analgesics, Antimetabolites, Central Nervous System Agents, Dietary Supplements, Ethanolamines, Gastrointestinal Agents, Hypolipidemic Agents, Lipid Regulating Agents, Lipotropic Agents, Nervous System, Nootropic Agents, OCT1 inhibitors, OCT1 substrates, OCT2 Inhibitors, OCT2 Substrates, Onium Compounds, Other Nutritional Agents, Quaternary Ammonium Compounds, Salicylic Acid and Derivatives, Supplements, Trimethyl Ammonium Compounds, Vitamin B Complex, Vitamins"," Neuronal acetylcholine receptor subunit alpha-7,  Choline-phosphate cytidylyltransferase B,  Acetylcholinesterase,  Choline-phosphate cytidylyltransferase A,  Phospholipase D2,  Cholinesterase,  Phospholipase D1,  Phosphoethanolamine/phosphocholine phosphatase,  Choline/ethanolaminephosphotransferase 1,  Choline/ethanolamine kinase,  Choline O-acetyltransferase,  Choline kinase alpha,  Choline dehydrogenase, mitochondrial,  Solute carrier family 22 member 2,  Solute carrier family 22 member 1,  Solute carrier family 22 member 3,  Solute carrier family 22 member 5,  Solute carrier family 22 member 4,  Choline transporter-like protein 1,  Choline transporter-like protein 4,  Choline transporter-like protein 2,  Choline transporter-like protein 3, 10. High affinity choline transporter 1","DB00122, DB09563, DB12628, DB13352, DB09277, DB13747",
DB00123,Lysine,approved; nutraceutical,NCCCC[C@H](N)C(O)=O,C6H14N2O2,,"Amino Acids, Amino Acids, Basic, Amino Acids, Diamino, Amino Acids, Essential, Amino Acids, Peptides, and Proteins, Blood and Blood Forming Organs, Blood Substitutes and Perfusion Solutions, Detoxifying Agents for Antineoplastic Treatment, Dietary Supplements, I.V. Solution Additives, Lysine, Proteinogenic Amino Acids, Supplements"," High affinity cationic amino acid transporter 1,  Cationic amino acid transporter 4,  Cationic amino acid transporter 3,  Low affinity cationic amino acid transporter 2,  Lysine--tRNA ligase,  Monocarboxylate transporter 10,  Solute carrier family 22 member 4","DB00123, DB03252, DB03590, DB03134, DB04419, DB15458, DB01714, DB02233, DB03412, DB04486, DB03362, DB03977, DB02571, DB00513, DB04185, DB04620, DB01715, DB04296, DB03774, DB04388",
DB00125,Arginine,investigational; nutraceutical,N[C@@H](CCCNC(N)=N)C(O)=O,C6H14N4O2,,"Acids, Acyclic, Amino Acids, Amino Acids, Basic, Amino Acids, Diamino, Amino Acids, Peptides, and Proteins, Arginine, Blood and Blood Forming Organs, Blood Substitutes and Perfusion Solutions, Detoxifying Agents for Antineoplastic Treatment, Dietary Supplements, Fatty Acids, Fatty Acids, Volatile, I.V. Solution Additives, Lipids, Pituitary Function, Proteinogenic Amino Acids, Supplements"," Cationic amino acid transporter 3,  Arginine decarboxylase,  Argininosuccinate lyase,  Nitric oxide synthase, inducible,  High affinity cationic amino acid transporter 1,  Arginase-2, mitochondrial,  Cationic amino acid transporter 4,  Argininosuccinate synthase,  Nitric oxide synthase, endothelial,  Solute carrier family 22 member 5,  Monocarboxylate transporter 10,  Solute carrier family 22 member 4","DB00125, DB04027, DB11815, DB03144, DB02302, DB13207, DB15993, DB02644, DB03305, DB04223, DB03974, DB03953",
DB00126,Ascorbic acid,approved; nutraceutical,[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO,C6H8O6,,"Acids, Acyclic, Alimentary Tract and Metabolism, Antioxidants, Biological Factors, Carbohydrates, Compounds used in a research, industrial, or household setting, Diet, Food, and Nutrition, Food, Gastrointestinal Acidifying Agents, Genito Urinary System and Sex Hormones, Growth Substances, Gynecological Antiinfectives and Antiseptics, Hydroxy Acids, Micronutrients, Ophthalmologicals, Organic Acids, Physiological Phenomena, Protective Agents, Sensory Organs, Sugar Acids, Urinary Acidifying Agents, Vitamin C and analogues, Vitamins"," Hyaluronate lyase,  DNA,  Xylose isomerase,  Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2,  Phytanoyl-CoA dioxygenase, peroxisomal,  Procollagen-lysine,2-oxoglutarate 5-dioxygenase 3,  Gamma-butyrobetaine dioxygenase,  Dopamine beta-hydroxylase,  Peptidyl-glycine alpha-amidating monooxygenase, 10. Prolyl 3-hydroxylase 1, 11. Prolyl 3-hydroxylase 2, 12. Prolyl 3-hydroxylase 3, 13. Prolyl 4-hydroxylase subunit alpha-1, 14. 2-oxoglutarate and iron-dependent oxygenase domain-containing protein 1, 15. 2-oxoglutarate and iron-dependent oxygenase domain-containing protein 2, 16. Alpha-ketoglutarate-dependent dioxygenase alkB homolog 2, 17. Alpha-ketoglutarate-dependent dioxygenase alkB homolog 3, 18. Lysine-specific demethylase 5D, 19. Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1, 20. Trimethyllysine dioxygenase, mitochondrial, 21. Transmembrane prolyl 4-hydroxylase, 22. Egl nine homolog 1, 23. Egl nine homolog 2, 24. Egl nine homolog 3,  Thioredoxin reductase 1, cytoplasmic,  Serum albumin,  Solute carrier family 23 member 1,  Solute carrier family 23 member 2,  Solute carrier family 2, facilitated glucose transporter member 1,  Solute carrier family 2, facilitated glucose transporter member 3,  Solute carrier family 2, facilitated glucose transporter member 4","DB00126, DB14483, DB14490, DB14482, DB14484, DB14485, DB14486",
DB00127,Spermine,experimental; nutraceutical,NCCCNCCCCNCCCN,C10H26N4,,"Amines, Biogenic Amines, Biogenic Polyamines, Dietary Supplements, OCT1 substrates, Polyamines, Supplements"," Spermine synthase,  Spermine oxidase,  DNA,  Ornithine decarboxylase,  Extracellular calcium-sensing receptor,  Beta-1 adrenergic receptor,  Beta-2 adrenergic receptor,  Diamine acetyltransferase 1,  Diamine acetyltransferase 2,  Xanthine dehydrogenase/oxidase,  Solute carrier family 22 member 4,  Solute carrier family 22 member 1","DB00127, DB03566, DB13011",
DB00128,Aspartic acid,approved; nutraceutical,N[C@@H](CC(O)=O)C(O)=O,C4H7NO4,,"Amino Acids, Amino Acids, Acidic, Amino Acids, Dicarboxylic, Amino Acids, Peptides, and Proteins, Dietary Supplements, Excitatory Amino Acids, Proteinogenic Amino Acids, Supplements"," Adenylosuccinate Synthetases (Protein Group),  Calcium-binding mitochondrial carrier protein Aralar2,  Aspartate aminotransferase, cytoplasmic,  Aspartoacylase,  Asparagine synthetase [glutamine-hydrolyzing],  Argininosuccinate synthase,  Aminoacylase-1,  Aspartate aminotransferase, mitochondrial,  Aspartate--tRNA ligase, cytoplasmic, 10. Calcium-binding mitochondrial carrier protein Aralar1, 11. Aspartyl/asparaginyl beta-hydroxylase, 12. Multifunctional protein ADE2, 13. Adenylosuccinate synthetase isozyme 2, 14. Excitatory amino acid transporter 3, 15. Aspartate--tRNA ligase, mitochondrial, 16. Isoaspartyl peptidase/L-asparaginase, 17. Ribonuclease pancreatic, 18. Lysozyme C,  CAD protein,  Monocarboxylate transporter 10","DB00128, DB02655, DB13220, DB13359, DB15819, DB15998, DB16006, DB16619, DB04193, DB04498, DB04313, DB04538, DB04802, DB04804, DB03640, DB02821, DB04454",
DB00129,Ornithine,approved; nutraceutical,NCCC[C@H](N)C(O)=O,C5H12N2O2,,"Alimentary Tract and Metabolism, Amino Acids, Amino Acids, Basic, Amino Acids, Diamino, Amino Acids, Peptides, and Proteins, Bile and Liver Therapy, Dietary Supplements, Liver Therapy, Liver Therapy, Lipotropics, Oligopeptides, Peptides, Supplements"," Ornithine aminotransferase, mitochondrial,  Ornithine carbamoyltransferase, mitochondrial,  Arginase-1,  Ornithine decarboxylase antizyme 1,  High affinity cationic amino acid transporter 1,  Low affinity cationic amino acid transporter 2,  Mitochondrial ornithine transporter 2,  Arginase-2, mitochondrial,  Mitochondrial ornithine transporter 1, 10. Glycine amidinotransferase, mitochondrial","DB00129, DB04185, DB02068, DB03774, DB04388, DB00167, DB01739, DB03105, DB04419, DB15458, DB00130, DB02174, DB00149, DB01746, DB02233, DB02571, DB03412, DB04063, DB04454, DB00142, DB02517",
DB00130,L-Glutamine,approved; investigational; nutraceutical,N[C@@H](CCC(N)=O)C(O)=O,C5H10N2O3,,"Alimentary Tract and Metabolism, Amino Acids, Amino Acids and Derivatives, Amino Acids, Basic, Amino Acids, Diamino, Amino Acids, Neutral, Amino Acids, Peptides, and Proteins, Dietary Supplements, Glutamine, Proteinogenic Amino Acids, Supplements"," CTP synthase 1,  Amidophosphoribosyltransferase,  Glutamine synthetase,  Coagulation factor XIII A chain,  Glutaminase kidney isoform, mitochondrial,  Glutaminase liver isoform, mitochondrial,  Protein-glutamine gamma-glutamyltransferase 2,  Protein-glutamine gamma-glutamyltransferase 5,  Protein-glutamine gamma-glutamyltransferase 6,  Protein-glutamine gamma-glutamyltransferase K,  Protein-glutamine gamma-glutamyltransferase 4,  Protein-glutamine gamma-glutamyltransferase E, 10. Protein-glutamine gamma-glutamyltransferase Z, 11. GMP synthase [glutamine-hydrolyzing], 12. Asparagine synthetase [glutamine-hydrolyzing], 13. Kynurenine--oxoglutarate transaminase 1, 14. Phosphoribosylformylglycinamidine synthase, 15. Glutamyl-tRNA(Gln) amidotransferase subunit B, mitochondrial, 16. Glutamine--fructose-6-phosphate aminotransferase [isomerizing] 2, 17. CAD protein, 18. Glutamine--tRNA ligase, 19. Glutamine-dependent NAD(+) synthetase,  Sodium-coupled neutral amino acid transporter 1,  Sodium-coupled neutral amino acid transporter 2,  Sodium-coupled neutral amino acid transporter 3,  Neutral amino acid transporter B(0),  Sodium- and chloride-dependent neutral and basic amino acid transporter B(0+),  Y+L amino acid transporter 1,  Y+L amino acid transporter 2,  Large neutral amino acids transporter small subunit 1,  Large neutral amino acids transporter small subunit 2, 10. B(0,+)-type amino acid transporter 1, 11. Monocarboxylate transporter 10","DB00130, DB02174, DB03473, DB02446, DB03091, DB00129, DB12444, DB03774, DB04388",
DB00131,Adenosine phosphate,approved; investigational; nutraceutical; withdrawn,NC1=C2N=CN([C@@H]3O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]3O)C2=NC=N1,C10H14N5O7P,,"Adenine Nucleotides, Dietary Supplements, Heterocyclic Compounds, Fused-Ring, Nucleic Acids, Nucleotides, and Nucleosides, Nucleotides, Purine Nucleotides, Purines, Ribonucleotides, Supplements"," 5'-AMP-activated protein kinase (Protein Group),  Adenosine kinase,  5'-AMP-activated protein kinase subunit beta-1,  Acetyl-coenzyme A synthetase, cytoplasmic,  5'-AMP-activated protein kinase catalytic subunit alpha-1,  Adenylate cyclase type 1,  Long-chain-fatty-acid--CoA ligase 1,  Cyclic AMP-responsive element-binding protein 1,  DNA, 10. cAMP-specific 3',5'-cyclic phosphodiesterase 4B, 11. Glycogen phosphorylase, liver form, 12. Histidine triad nucleotide-binding protein 1, 13. cAMP-specific 3',5'-cyclic phosphodiesterase 4D, 14. Fructose-1,6-bisphosphatase 1,  AMP deaminase 1,  Adenine phosphoribosyltransferase","DB00131, DB03230, DB01812, DB16833, DB03708, DB02527, DB02098, DB02694, DB00171, DB01690, DB01842, DB02798, DB01717, DB02738, DB02902, DB03349, DB02930, DB01895, DB02059, DB07205, DB03726, DB02363, DB02454, DB04554, DB01860, DB01790, DB03148, DB03222, DB03909, DB04395",
DB00132,alpha-Linolenic acid,approved; investigational; nutraceutical,CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O,C18H30O2,,"Dietary Fats, Dietary Fats, Unsaturated, Dietary Supplements, Fats, Fatty Acids, Fatty Acids, Essential, Fatty Acids, Omega-3, Fatty Acids, Unsaturated, Linolenic Acids, Lipids, Supplements"," Fatty acid desaturase 1,  Fatty acid desaturase 2,  Transient receptor potential cation channel subfamily V member 1,  Peroxisome proliferator-activated receptor alpha,  Bile acid receptor,  Peroxisome proliferator-activated receptor delta,  Peroxisome proliferator-activated receptor gamma,  Retinoic acid receptor RXR-alpha,  Elongation of very long chain fatty acids protein 2, 10. Elongation of very long chain fatty acids protein 5, 11. Sodium/calcium exchanger 1,  Fatty acid-binding protein, brain","DB00132, DB00154, DB14104, DB13854, DB04224, DB04257, DB04801, DB14073, DB16027, DB04557, DB06689, DB16949, DB00159, DB04746, DB11117, DB14088, DB15678, DB18213",
DB00133,Serine,investigational; nutraceutical,N[C@@H](CO)C(O)=O,C3H7NO3,,"Amino Acids, Amino Acids, Neutral, Amino Acids, Peptides, and Proteins, Dietary Supplements, Proteinogenic Amino Acids, Supplements"," Cystathionine beta-synthase,  L-serine dehydratase/L-threonine deaminase,  Serine racemase,  Serine palmitoyltransferase 2,  Serine palmitoyltransferase 1,  Serine--tRNA ligase, cytoplasmic,  Serine--pyruvate aminotransferase,  Monocarboxylate transporter 10","DB00133, DB03929, DB02289, DB00160, DB01786, DB02952, DB00156, DB03700, DB03320, DB04454",
DB00134,Methionine,approved; nutraceutical,CSCC[C@H](N)C(O)=O,C5H11NO2S,,"Amino Acids, Amino Acids, Essential, Amino Acids, Neutral, Amino Acids, Peptides, and Proteins, Amino Acids, Sulfur, Antidotes, Dietary Supplements, Proteinogenic Amino Acids, Sulfur Compounds, Supplements"," Methionine synthase reductase,  Methionine synthase,  Methionine aminopeptidase 2,  Betaine--homocysteine S-methyltransferase 1,  S-methylmethionine--homocysteine S-methyltransferase BHMT2,  S-adenosylmethionine synthase isoform type-2,  Methionine-R-sulfoxide reductase B2, mitochondrial,  S-adenosylmethionine synthase isoform type-1,  Methionine-R-sulfoxide reductase B1,  Mitochondrial peptide methionine sulfoxide reductase,  Methionine--tRNA ligase, cytoplasmic,  Methionine--tRNA ligase, mitochondrial,  Methionine adenosyltransferase 2 subunit beta,  S-methylmethionine--homocysteine S-methyltransferase BHMT2, 10. Glutamine synthetase, 11. Methylenetetrahydrofolate reductase,  Monocarboxylate transporter 10","DB00134, DB02893, DB13972, DB17147, DB13250, DB04422, DB02235, DB02467, DB03816, DB03799, DB04464",
DB00135,Tyrosine,approved; investigational; nutraceutical,N[C@@H](CC1=CC=C(O)C=C1)C(O)=O,C9H11NO3,,"Amino Acids, Amino Acids, Aromatic, Amino Acids, Cyclic, Amino Acids, Peptides, and Proteins, Dietary Supplements, Proteinogenic Amino Acids, Supplements"," Tyrosine 3-monooxygenase,  Tyrosine--tRNA ligase, mitochondrial,  Tyrosine--tRNA ligase, cytoplasmic,  Tyrosine aminotransferase,  Monocarboxylate transporter 8,  Monocarboxylate transporter 10","DB00135, DB03839, DB00765, DB16306, DB03978, DB00120, DB02556, DB15296, DB01235, DB03552, DB03897, DB15405, DB00968, DB13313, DB02685, DB06838, DB03380, DB01758, DB04436, DB01962, DB09352, DB03374, DB06535, DB01766, DB11102, DB00190, DB07637, DB04639, DB06262, DB07365",
DB00136,Calcitriol,approved; nutraceutical,C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C,C27H44O3,,"Alimentary Tract and Metabolism, Antipsoriatics, Antipsoriatics for Topical Use, Bone Density Conservation Agents, Calcium-Regulating Hormones and Agents, Cholestanes, Cholestenes, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Substrates, Diet, Food, and Nutrition, Food, Fused-Ring Compounds, Growth Substances, Lipids, Membrane Lipids, Membrane Transport Modulators, Micronutrients, Misc. Skin and Mucous Membrane Agents, Physiological Phenomena, Secosteroids, Steroids, Sterols, Vitamin D and Analogues, Vitamins, Vitamins (Fat Soluble)"," Vitamin D3 receptor,  Homeobox protein Hox-A10,  1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial,  Cytochrome P450 3A4,  Vitamin D-binding protein","DB00136, DB15557, DB13689, DB01436, DB13097, DB06410, DB00146, DB04258, DB00169, DB18029, DB18406, DB00153, DB04891, DB06117, DB02300, DB03451, DB06272, DB00910, DB01070, DB04038, DB05295, DB08742",
DB00137,Lutein,approved; investigational; nutraceutical,C\C(\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)C[C@@H](O)CC1(C)C,C40H56O2,,"Alkenes, Biological Factors, Carotenoids, Cyclohexanes, Cyclohexenes, Cycloparaffins, Dietary Supplements, Hydrocarbons, Acyclic, Pigments, Biological, Polyenes, Supplements, Terpenes, Xanthophylls", Serum albumin,"DB00137, DB11176, DB15914, DB02253, DB02300, DB06117",
DB00138,Cystine,approved; nutraceutical,N[C@@H](CSSC[C@H](N)C(O)=O)C(O)=O,C6H12N2O4S2,,"Amino Acids, Amino Acids, Diamino, Amino Acids, Dicarboxylic, Amino Acids, Peptides, and Proteins, Amino Acids, Sulfur, Anions, Cysteine, Dietary Supplements, Disulfides, Electrolytes, Hydrogen Sulfide, Ions, Sulfides, Sulfur Compounds, Supplements"," Cystine/glutamate transporter,  Cystinosin,  Monocarboxylate transporter 10,  B(0,+)-type amino acid transporter 1,  Neutral and basic amino acid transport protein rBAT","DB00138, DB02361, DB04530, DB03654",
DB00139,Succinic acid,approved; nutraceutical,OC(=O)CCC(O)=O,C4H6O4,,"Acids, Acyclic, Dicarboxylic Acids, Dietary Supplements, OAT3/SLC22A8 Substrates, Succinates, Supplements"," Succinate-semialdehyde dehydrogenase, mitochondrial,  Succinate receptor 1,  Succinate dehydrogenase cytochrome b560 subunit, mitochondrial,  Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial,  Succinyl-CoA ligase [GDP-forming] subunit beta, mitochondrial,  Prolyl 4-hydroxylase (Protein Group),  Procollagen-lysine,2-oxoglutarate 5-dioxygenase 3,  Prolyl 3-hydroxylase 1,  Prolyl 3-hydroxylase 2,  Prolyl 3-hydroxylase 3,  Succinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrial, 10. Aspartyl/asparaginyl beta-hydroxylase,  Solute carrier family 22 member 8,  Mitochondrial dicarboxylate carrier,  Solute carrier family 13 member 1,  Solute carrier family 13 member 2,  Solute carrier family 13 member 3","DB00139, DB14489, DB14508, DB01440, DB09072, DB03568",
DB00140,Riboflavin,approved; investigational; nutraceutical; vet_approved,CC1=C(C)C=C2N(C[C@H](O)[C@H](O)[C@H](O)CO)C3=NC(=O)NC(=O)C3=NC2=C1,C17H20N4O6,,"Alimentary Tract and Metabolism, Biological Factors, Coenzymes, Dermatologicals, Enzymes and Coenzymes, Flavins, Heterocyclic Compounds, Fused-Ring, Micronutrients, OAT1/SLC22A6 inhibitors, Ophthalmologicals, Photosensitizing Agents, Pigments, Biological, Pteridines, Radiation-Sensitizing Agents, Sensory Organs, Vitamin B Complex, Vitamins"," Riboflavin kinase,  Riboflavin synthase,  Flavin reductase (NADPH),  Amine oxidase [flavin-containing] A,  Methylenetetrahydrofolate reductase,  Solute carrier family 22 member 6","DB00140, DB03247, DB14727, DB02164, DB02332, DB03147, DB02654, DB04726, DB03482, DB02214, DB03883",
DB00141,N-Acetylglucosamine,approved; investigational; nutraceutical,[H]C(=O)[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@H](O)CO,C8H15NO6,,"Amino Sugars, Carbohydrates, Dietary Supplements, Hexosamines, Supplements"," Beta-1,4-galactosyltransferase 1,  Beta-1,4-galactosyltransferase 4,  N-acetyl-D-glucosamine kinase,  N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase,  Alpha-N-acetylglucosaminidase,  N-acylglucosamine 2-epimerase","DB00141, DB12536, DB11797",
DB00142,Glutamic acid,approved; nutraceutical,N[C@@H](CCC(O)=O)C(O)=O,C5H9NO4,,"Acid Preparations, Alimentary Tract and Metabolism, Amino Acids, Amino Acids, Acidic, Amino Acids, Dicarboxylic, Amino Acids, Peptides, and Proteins, Dietary Supplements, Digestives, Incl. Enzymes, Excitatory Amino Acids, Gastrointestinal Acidifying Agents, Gastrointestinal Agents, Glutamates, Proteinogenic Amino Acids, Supplements"," Metabotropic glutamate receptor 1,  Metabotropic glutamate receptor 4,  Glutamate receptor ionotropic, kainate 4,  Glutamate receptor ionotropic, kainate 5,  Metabotropic glutamate receptor 7,  Metabotropic glutamate receptor 8,  Excitatory amino acid transporter 5,  5-oxoprolinase,  Phosphoribosylformylglycinamidine synthase, 10. Branched-chain-amino-acid aminotransferase, mitochondrial, 11. Glutamate receptor ionotropic, NMDA 2D, 12. Glutaminase kidney isoform, mitochondrial, 13. Aspartate aminotransferase, mitochondrial, 14. Bifunctional glutamate/proline--tRNA ligase, 15. Asparagine synthetase [glutamine-hydrolyzing], 16. Glutamine synthetase, 17. Aspartate aminotransferase, cytoplasmic, 18. Tyrosine aminotransferase, 19. Alanine aminotransferase 1, 20. Vitamin K-dependent gamma-carboxylase, 21. Excitatory amino acid transporter 1, 22. Excitatory amino acid transporter 2, 23. Excitatory amino acid transporter 3, 24. Glutamate--cysteine ligase catalytic subunit, 25. Excitatory amino acid transporter 4, 26. Glutamate dehydrogenase 2, mitochondrial, 27. GMP synthase [glutamine-hydrolyzing], 28. Branched-chain-amino-acid aminotransferase, cytosolic, 29. 4-aminobutyrate aminotransferase, mitochondrial, 30. Glutamate receptor ionotropic, NMDA 1, 31. Folylpolyglutamate synthase, mitochondrial, 32. Glutamyl aminopeptidase, 33. Glutamate receptor ionotropic, NMDA 2A, 34. Glutamate receptor ionotropic, NMDA 2B, 35. Glutamate receptor ionotropic, NMDA 2C, 36. Probable glutamate--tRNA ligase, mitochondrial, 37. Glutamine-dependent NAD(+) synthetase, 38. N-acetylglutamate synthase, mitochondrial, 39. Kynurenine/alpha-aminoadipate aminotransferase, mitochondrial, 40. Glutamate receptor ionotropic, NMDA 3A, 41. Alanine aminotransferase 2, 42. Alpha-aminoadipic semialdehyde synthase, mitochondrial, 43. Glutaminase liver isoform, mitochondrial, 44. Aspartyl aminopeptidase, 45. Cystine/glutamate transporter, 46. Carboxypeptidase Q, 47. Phosphoserine aminotransferase, 48. Glutamate dehydrogenase 1, mitochondrial, 49. Glutamate receptor ionotropic, kainate 1, 50. Glutamate receptor 1, 51. Glutamate--cysteine ligase regulatory subunit, 52. Glutamate carboxypeptidase 2, 53. Glutamate decarboxylase 2, 54. Glutamate decarboxylase 1, 55. Formimidoyltransferase-cyclodeaminase, 56. Glutamate receptor 2, 57. Glutamate receptor 3, 58. Glutamate receptor 4, 59. Delta-1-pyrroline-5-carboxylate synthase, 60. Glutamate receptor ionotropic, kainate 2, 61. Glutamate receptor ionotropic, kainate 3, 62. Aspartate aminotransferase (Protein Group),  Monocarboxylate transporter 10,  Monocarboxylate transporter 1,  Mitochondrial glutamate carrier 2,  Mitochondrial glutamate carrier 1","DB00142, DB02517, DB03105, DB01898, DB03810, DB03774, DB04388, DB03425, DB04185, DB03847, DB04235, DB03817, DB00129, DB00167, DB01739, DB04419, DB15458",
DB00143,Glutathione,approved; investigational; nutraceutical,N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O,C10H17N3O6S,,"Amino Acids, Peptides, and Proteins, Antidotes, Dietary Supplements, Glutathione, antagonists & inhibitors, Oligopeptides, Peptides, Supplements"," Aldose reductase,  Matrix metalloproteinase-9,  Cytochrome P450 3A4,  Glutathione peroxidase (Protein Group),  Glutathione reductase, mitochondrial,  Glutathione synthetase,  Glutathione S-transferase Mu 1,  Glutathione S-transferase kappa 1,  Glutathione S-transferase A3, 10. Glutathione S-transferase Mu 3, 11. Glutathione S-transferase A4, 12. Glutathione S-transferase Mu 4, 13. Glutathione S-transferase A5, 14. Glutathione S-transferase P, 15. Glutathione S-transferase omega-1, 16. Glutathione peroxidase 1, 17. Glutathione peroxidase 2, 18. Glutathione S-transferase theta-1, 19. Maleylacetoacetate isomerase, 20. Epididymal secretory glutathione peroxidase, 21. Glutathione peroxidase 3, 22. Lactoylglutathione lyase, 23. Leukotriene C4 synthase, 24. Microsomal glutathione S-transferase 3, 25. Hematopoietic prostaglandin D synthase, 26. Glutathione S-transferase A1, 27. Glutathione S-transferase A2, 28. Microsomal glutathione S-transferase 1, 29. S-formylglutathione hydrolase, 30. Gamma-glutamyltranspeptidase 1, 31. Glutathione S-transferase Mu 2, 32. Glutaredoxin-1, 33. Phospholipid hydroperoxide glutathione peroxidase, mitochondrial, 34. Glutathione S-transferase Mu 5, 35. Glutathione peroxidase 6, 36. Hydroxyacylglutathione hydrolase, mitochondrial, 37. Glutathione peroxidase, 38. Glutathione peroxidase 7, 39. Microsomal glutathione S-transferase 2, 40. Glutathione S-transferase omega-2, 41. Glutaredoxin-2, mitochondrial,  Glutathione S-transferase A2,  Glutathione S-transferase A1,  Multidrug resistance-associated protein 1,  Canalicular multispecific organic anion transporter 1,  Canalicular multispecific organic anion transporter 2,  Multidrug resistance-associated protein 4,  Multidrug resistance-associated protein 5","DB00143, DB04701, DB17877, DB04153, DB05446, DB03310, DB03408, DB03295, DB04700, DB06179, DB04132, DB03032, DB03470, DB03003, DB03427, DB02025",
DB00144,Phosphatidyl serine,investigational; nutraceutical,CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC,C42H82NO10P,,"Dietary Supplements, Glycerophosphates, Glycerophospholipids, Lipids, Membrane Lipids, Phosphatidic Acids, Phosphatidylserines, Phospholipids, Supplements"," Phosphatidylserine decarboxylase proenzyme,  Scavenger receptor class B member 1,  Protein kinase C alpha type,  Phosphatidylserine synthase 1,  Diacylglycerol kinase gamma,  Diacylglycerol kinase delta,  Phosphatidylserine synthase 2,  Sphingomyelin phosphodiesterase 4,  Sphingomyelin phosphodiesterase 3, 10. Probable phospholipid-transporting ATPase IA","DB00144, DB18573, DB01728, DB01966, DB04327, DB14096, DB02777, DB04178, DB09114, DB11283, DB14099, DB02043, DB07349, DB11284, DB14105, DB03429, DB03979, DB11318, DB03690, DB05456, DB03047, DB04683, DB04752, DB11331, DB02306, DB04372, DB08376, DB18093, DB02261, DB01707",
DB00145,Glycine,approved; nutraceutical; vet_approved,NCC(O)=O,C2H5NO2,,"Amino Acids, Amino Acids, Peptides, and Proteins, Blood and Blood Forming Organs, Blood Substitutes and Perfusion Solutions, Dietary Supplements, Glycine Agents, Irrigating Solutions, Neurotransmitter Agents, Proteinogenic Amino Acids, Supplements"," 2-amino-3-ketobutyrate coenzyme A ligase, mitochondrial,  5-aminolevulinate synthase, nonspecific, mitochondrial,  5-aminolevulinate synthase, erythroid-specific, mitochondrial,  Glycine--tRNA ligase,  Glutamate receptor ionotropic, NMDA 2A,  Bile acid-CoA:amino acid N-acyltransferase,  N-arachidonyl glycine receptor,  Glutathione synthetase,  Glutamate receptor ionotropic, NMDA 2C, 10. Serine hydroxymethyltransferase, 11. Glycine N-acyltransferase, 12. Serine hydroxymethyltransferase, mitochondrial, 13. Glycine N-acyltransferase-like protein 2, 14. Glycine N-acyltransferase-like protein 1, 15. Alanine--glyoxylate aminotransferase 2, mitochondrial, 16. Peroxisomal sarcosine oxidase, 17. Glutamate receptor ionotropic, NMDA 3B, 18. Glycine receptor subunit alpha-1, 19. Serine--pyruvate aminotransferase, 20. Glycine receptor subunit beta, 21. Serine hydroxymethyltransferase, cytosolic, 22. Glycine receptor subunit alpha-3, 23. Glycine receptor subunit alpha-2, 24. Glycine N-methyltransferase, 25. Glycine amidinotransferase, mitochondrial,  Aminomethyltransferase, mitochondrial,  Glycine dehydrogenase [decarboxylating], mitochondrial,  Dihydrolipoyl dehydrogenase, mitochondrial,  Glycine cleavage system H protein, mitochondrial,  Monocarboxylate transporter 10,  Proton-coupled amino acid transporter 1,  Vesicular inhibitory amino acid transporter,  Sodium- and chloride-dependent glycine transporter 2,  Sodium- and chloride-dependent glycine transporter 1","DB00145, DB11189, DB11210, DB11509, DB13626, DB14493, DB11200, DB12519",
DB00146,Calcifediol,approved; nutraceutical,C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C,C27H44O2,,"Alimentary Tract and Metabolism, Anti-Parathyroid Agents, Bone Density Conservation Agents, Calcium Homeostasis, Cholestanes, Cholestenes, Diet, Food, and Nutrition, Food, Fused-Ring Compounds, Lipids, Membrane Lipids, Micronutrients, Physiological Phenomena, Secosteroids, Steroids, Sterols, Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins, Vitamin D and Analogues, Vitamins, Vitamins (Fat Soluble)"," Vitamin D3 receptor,  25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial,  1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial","DB00146, DB00169, DB18029, DB18406, DB00153, DB00136, DB15557, DB13689, DB01436, DB13097, DB06410, DB04258, DB01070, DB06117, DB04891, DB04038, DB00910, DB02300, DB03451, DB06272, DB11176, DB15914, DB15614",
DB00147,Pyridoxal,experimental; nutraceutical,CC1=NC=C(CO)C(C=O)=C1O,C8H9NO3,,"Dietary Supplements, Micronutrients, Picolines, Pyridines, Supplements, Vitamin B Complex, Vitamins", Pyridoxal kinase,"DB00147, DB00165, DB11673, DB00114",
DB00148,Creatine,approved; investigational; nutraceutical,CN(CC(O)=O)C(N)=N,C4H9N3O2,,"Amidines, Amino Acids, Amino Acids, Peptides, and Proteins, Dietary Supplements, Guanidines, Supplements"," Creatine kinase M-type,  Creatine kinase U-type, mitochondrial,  Creatine kinase B-type,  Creatine kinase S-type, mitochondrial,  Sodium- and chloride-dependent creatine transporter 1,  Guanidinoacetate N-methyltransferase,  Solute carrier family 22 member 5",DB00148,
DB00149,Leucine,investigational; nutraceutical,CC(C)C[C@H](N)C(O)=O,C6H13NO2,,"Amino Acids, Amino Acids, Branched-Chain, Amino Acids, Essential, Amino Acids, Peptides, and Proteins, Dietary Supplements, Proteinogenic Amino Acids, Supplements"," Probable leucine--tRNA ligase, mitochondrial,  Leucine carboxyl methyltransferase 2,  Leucine carboxyl methyltransferase 1,  Leucine--tRNA ligase, cytoplasmic,  Branched-chain-amino-acid aminotransferase, mitochondrial,  Branched-chain-amino-acid aminotransferase, cytosolic,  Monocarboxylate transporter 10,  Monocarboxylate transporter 8","DB00149, DB01746, DB04063, DB04185, DB00167, DB01739, DB02978, DB04487, DB02542, DB03425, DB03774, DB04388, DB00129, DB03105, DB04419, DB15458, DB04620, DB02884, DB03847, DB04171",
DB00150,Tryptophan,approved; nutraceutical; withdrawn,N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O,C11H12N2O2,,"Amino Acids, Amino Acids, Aromatic, Amino Acids, Cyclic, Amino Acids, Essential, Amino Acids, Peptides, and Proteins, Antidepressive Agents, Antidepressive Agents, Second-Generation, Central Nervous System Agents, Central Nervous System Depressants, Dietary Supplements, Miscellaneous Antidepressants, Nervous System, Proteinogenic Amino Acids, Psychoanaleptics, Psychotropic Drugs, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Supplements"," Tryptophan--tRNA ligase, cytoplasmic,  Tryptophan--tRNA ligase,  Tryptophan--tRNA ligase, mitochondrial,  Tryptophan--tRNA ligase,  Tryptophan--tRNA ligase, mitochondrial,  Tryptophan 5-hydroxylase 1,  Tryptophan 5-hydroxylase 2,  Tryptophan--tRNA ligase, cytoplasmic,  Indoleamine 2,3-dioxygenase 1,  Tryptophan 2,3-dioxygenase,  Aromatic-L-amino-acid decarboxylase,  Monocarboxylate transporter 8,  Monocarboxylate transporter 10","DB00150, DB03225, DB04236, DB12827, DB03314, DB02959, DB02758, DB04159, DB01446, DB02286, DB03386, DB04537, DB03679, DB01546, DB08638, DB02988, DB07060, DB04206, DB08653, DB02740, DB07723",
DB00151,Cysteine,approved; nutraceutical,N[C@@H](CS)C(O)=O,C3H7NO2S,,"Amino Acids, Amino Acids, Neutral, Amino Acids, Peptides, and Proteins, Amino Acids, Sulfur, Caloric Agents, Cysteine, Dietary Supplements, Nutritional Support, Proteinogenic Amino Acids, Sulfhydryl Compounds, Sulfur Compounds, Supplements"," Glutamate--cysteine ligase regulatory subunit,  Glutamate--cysteine ligase catalytic subunit,  Aspartate aminotransferase, cytoplasmic,  Aspartate aminotransferase, mitochondrial,  Cystathionine gamma-lyase,  Cystathionine beta-synthase,  Cysteine--tRNA ligase, cytoplasmic,  Methylated-DNA--protein-cysteine methyltransferase,  Glutathione synthetase, 10. Probable cysteine--tRNA ligase, mitochondrial, 11. Cysteine sulfinic acid decarboxylase, 12. Cysteine desulfurase, mitochondrial, 13. Cysteine dioxygenase type 1,  Monocarboxylate transporter 10","DB00151, DB03201, DB11197, DB02761, DB02216, DB03382, DB01915, DB03049, DB00160, DB01786",
DB00152,Thiamine,approved; investigational; nutraceutical; vet_approved,CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N,C12H17N4OS,,"Alimentary Tract and Metabolism, Diet, Food, and Nutrition, Food, Growth Substances, Micronutrients, OCT1 substrates, OCT2 Inhibitors, Physiological Phenomena, Pyrimidines, Sulfur Compounds, Thiazoles, Vitamin B Complex, Vitamins"," Thiamin pyrophosphokinase 1,  Cytochrome P450 4B1,  Thiamin pyrophosphokinase 1,  Ectonucleoside triphosphate diphosphohydrolase 5,  Thiamine-triphosphatase,  Serum albumin,  Solute carrier family 22 member 2,  Solute carrier family 22 member 1,  Solute carrier family 22 member 5,  Thiamine transporter 1,  Thiamine transporter 2","DB00152, DB03416, DB16023, DB01987, DB02254, DB01682",
DB00153,Ergocalciferol,approved; nutraceutical,CC(C)[C@@H](C)\C=C\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C,C28H44O,,"Alimentary Tract and Metabolism, Bone Density Conservation Agents, Calcium-Regulating Hormones and Agents, Diet, Food, and Nutrition, Food, Fused-Ring Compounds, Growth Substances, Lipids, Micronutrients, Physiological Phenomena, Secosteroids, Vitamin D and Analogues, Vitamins, Vitamins (Fat Soluble)"," Vitamin D3 receptor,  Voltage-dependent calcium channel (Protein Group),  Ribulose-phosphate 3-epimerase,  Cholesterol side-chain cleavage enzyme, mitochondrial,  1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial,  25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial,  Sterol 26-hydroxylase, mitochondrial,  Vitamin D 25-hydroxylase,  Vitamin D-binding protein","DB00153, DB00169, DB00146, DB06410, DB01070, DB18029, DB18406, DB01436, DB13097, DB15557, DB00136, DB13689, DB06117, DB00910, DB04258, DB02300, DB04038, DB04891, DB11176, DB15914, DB15614, DB03451, DB06272, DB02253",
DB00154,Dihomo-gamma-linolenic acid,investigational; nutraceutical,CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O,C20H34O2,,"Dietary Supplements, Eicosanoids, Fatty Acids, Fatty Acids, Unsaturated, Lipids, Supplements"," Prostaglandin G/H synthase 2,  Prostaglandin G/H synthase 1,  Fatty acid-binding protein, brain","DB00132, DB00154, DB14104, DB13854, DB04224, DB04257, DB04801, DB14073, DB16027, DB04557, DB06689, DB16949, DB00159, DB04746, DB11117, DB14088, DB15678, DB18213",
DB00155,Citrulline,investigational; nutraceutical,N[C@@H](CCCNC(N)=O)C(O)=O,C6H13N3O3,,"Acids, Acyclic, Amino Acids, Amino Acids, Diamino, Amino Acids, Peptides, and Proteins, Dicarboxylic Acids, Dietary Supplements, Hydroxy Acids, OAT1/SLC22A6 Substrates, OAT3/SLC22A8 Substrates, Proteins, Supplements"," Nitric oxide synthase, endothelial,  Argininosuccinate synthase,  N(G),N(G)-dimethylarginine dimethylaminohydrolase 2,  N(G),N(G)-dimethylarginine dimethylaminohydrolase 1,  Ornithine carbamoyltransferase, mitochondrial,  Nitric oxide synthase, brain,  Nitric oxide synthase, inducible,  Protein-arginine deiminase type-4,  Protein-arginine deiminase type-6, 10. Protein-arginine deiminase type-1, 11. Protein-arginine deiminase type-3, 12. Protein-arginine deiminase type-2,  Solute carrier family 22 member 6","DB00155, DB02368",
DB00156,Threonine,approved; nutraceutical,C[C@@H](O)[C@H](N)C(O)=O,C4H9NO3,,"Amino Acids, Amino Acids, Essential, Amino Acids, Neutral, Amino Acids, Peptides, and Proteins, Dietary Supplements, Proteinogenic Amino Acids, Supplements, Threonine, antagonists & inhibitors"," Threonine--tRNA ligase, cytoplasmic,  Threonine--tRNA ligase, mitochondrial,  Beta-lactamase Toho-1,  Monocarboxylate transporter 10","DB00156, DB03700, DB04454, DB04171, DB15985, DB02978, DB02085, DB03640, DB00133, DB03929",
DB00157,NADH,approved; nutraceutical,NC(=O)C1=CN(C=CC1)[C@@H]1O[C@H](CO[P@](O)(=O)O[P@](O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)N2C=NC3=C(N)N=CN=C23)[C@@H](O)[C@H]1O,C21H29N7O14P2,,"Adenine Nucleotides, Coenzymes, Dietary Supplements, Enzymes and Coenzymes, Heterocyclic Compounds, Fused-Ring, Nucleic Acids, Nucleotides, and Nucleosides, Nucleotides, Purine Nucleotides, Purines, Ribonucleotides, Supplements"," UDP-glucose 6-dehydrogenase,  Alcohol dehydrogenase 1A,  Sorbitol dehydrogenase,  Alcohol dehydrogenase 4,  Alcohol dehydrogenase 1C,  Alcohol dehydrogenase 1B,  Alcohol dehydrogenase class 4 mu/sigma chain,  Glycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic,  L-lactate dehydrogenase A-like 6A, 10. Alcohol dehydrogenase class-3, 11. Aldose reductase, 12. 3-hydroxyacyl-CoA dehydrogenase type-2, 13. Malate dehydrogenase, mitochondrial, 14. L-lactate dehydrogenase A chain, 15. NAD-dependent malic enzyme, mitochondrial, 16. Peroxisomal multifunctional enzyme type 2, 17. L-lactate dehydrogenase A-like 6B, 18. L-lactate dehydrogenase C chain, 19. L-lactate dehydrogenase B chain, 20. Peroxisomal bifunctional enzyme, 21. Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial, 22. NADP-dependent malic enzyme, mitochondrial, 23. D-beta-hydroxybutyrate dehydrogenase, mitochondrial, 24. Malate dehydrogenase, cytoplasmic, 25. 3-hydroxyisobutyrate dehydrogenase, mitochondrial, 26. Testosterone 17-beta-dehydrogenase 3, 27. 3-hydroxy-3-methylglutaryl-coenzyme A reductase, 28. NADP-dependent malic enzyme, 29. D-3-phosphoglycerate dehydrogenase, 30. 3-keto-steroid reductase, 31. Isocitrate dehydrogenase [NAD] subunit gamma, mitochondrial, 32. Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial, 33. Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial, 34. Estradiol 17-beta-dehydrogenase 1, 35. Estradiol 17-beta-dehydrogenase 2, 36. 11-cis retinol dehydrogenase, 37. GDH/6PGL endoplasmic bifunctional protein, 38. Estradiol 17-beta-dehydrogenase 8, 39. Aldo-keto reductase family 1 member C4, 40. Inosine-5'-monophosphate dehydrogenase 2, 41. Aldo-keto reductase family 1 member C3, 42. 15-hydroxyprostaglandin dehydrogenase [NAD(+)], 43. GDP-L-fucose synthase, 44. Aldo-keto reductase family 1 member C1, 45. Corticosteroid 11-beta-dehydrogenase isozyme 1, 46. 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2, 47. 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1, 48. Inosine-5'-monophosphate dehydrogenase 1, 49. Trifunctional enzyme subunit alpha, mitochondrial, 50. Aldehyde dehydrogenase, mitochondrial, 51. Corticosteroid 11-beta-dehydrogenase isozyme 2, 52. Aldo-keto reductase family 1 member C2, 53. Sterol-4-alpha-carboxylate 3-dehydrogenase, decarboxylating, 54. Aldehyde dehydrogenase family 3 member B2, 55. Methylmalonate-semialdehyde dehydrogenase [acylating], mitochondrial, 56. Aldehyde dehydrogenase, dimeric NADP-preferring, 57. Retinal dehydrogenase 1, 58. Glyceraldehyde-3-phosphate dehydrogenase, testis-specific, 59. 4-trimethylaminobutyraldehyde dehydrogenase, 60. Aldehyde dehydrogenase family 1 member A3, 61. Aldehyde dehydrogenase X, mitochondrial, 62. Aldehyde dehydrogenase family 3 member B1, 63. Glyceraldehyde-3-phosphate dehydrogenase, 64. Retinal dehydrogenase 2, 65. Fatty aldehyde dehydrogenase, 66. Succinate-semialdehyde dehydrogenase, mitochondrial, 67. Alpha-aminoadipic semialdehyde dehydrogenase, 68. Flavin reductase (NADPH), 69. Pyrroline-5-carboxylate reductase 2, 70. Pyrroline-5-carboxylate reductase 1, mitochondrial, 71. Glutamate dehydrogenase 1, mitochondrial, 72. Pyruvate dehydrogenase E1 component subunit beta, mitochondrial, 73. Pyruvate dehydrogenase E1 component subunit alpha, testis-specific form, mitochondrial, 74. Pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrial, 75. Biliverdin reductase A, 76. Short-chain specific acyl-CoA dehydrogenase, mitochondrial, 77. Dihydrofolate reductase, 78. 2-oxoglutarate dehydrogenase, mitochondrial, 79. Glutamate dehydrogenase 2, mitochondrial, 80. 7-dehydrocholesterol reductase, 81. Ribosyldihydronicotinamide dehydrogenase [quinone], 82. NADH-ubiquinone oxidoreductase chain 2, 83. Alpha-aminoadipic semialdehyde synthase, mitochondrial, 84. NADH-ubiquinone oxidoreductase chain 3, 85. NADH dehydrogenase [ubiquinone] iron-sulfur protein 7, mitochondrial, 86. C-1-tetrahydrofolate synthase, cytoplasmic, 87. Bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase, mitochondrial, 88. Delta-1-pyrroline-5-carboxylate dehydrogenase, mitochondrial, 89. NADH-cytochrome b5 reductase 3, 90. NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 11, 91. NADH-ubiquinone oxidoreductase chain 4, 92. Dihydropteridine reductase, 93. NADH-ubiquinone oxidoreductase chain 1, 94. NAD(P) transhydrogenase, mitochondrial, 95. NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5, 96. NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9, mitochondrial, 97. NADH-ubiquinone oxidoreductase chain 4L, 98. NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10, mitochondrial, 99. NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 7, 100. NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 1, 101. NADH-ubiquinone oxidoreductase chain 6, 102. NADH-ubiquinone oxidoreductase chain 5, 103. NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 4, 104. NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 6, 105. Acyl carrier protein, mitochondrial, 106. NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 2, 107. NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 8, 108. NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 3, 109. NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 8, mitochondrial, 110. NADH dehydrogenase [ubiquinone] 1 subunit C2, 111. NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 1, 112. NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial, 113. NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 10, 114. NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 4, 115. NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 3, 116. NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 2, mitochondrial, 117. NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 7, 118. NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9, 119. NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrial, 120. NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 5, mitochondrial, 121. NADH dehydrogenase [ubiquinone] 1 subunit C1, mitochondrial, 122. NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 6, 123. NADH dehydrogenase [ubiquinone] flavoprotein 3, mitochondrial, 124. Dihydrolipoyl dehydrogenase, mitochondrial, 125. NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial, 126. Glutathione reductase, mitochondrial, 127. NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 12, 128. NADH dehydrogenase [ubiquinone] iron-sulfur protein 5, 129. NADH dehydrogenase [ubiquinone] iron-sulfur protein 4, mitochondrial, 130. NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial, 131. NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial, 132. NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13, 133. Cysteine dioxygenase type 1, 134. NADH dehydrogenase [ubiquinone] iron-sulfur protein 6, mitochondrial, 135. NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 4-like 2, 136. NADH dehydrogenase [ubiquinone] iron-sulfur protein 8, mitochondrial, 137. Cytochrome P450 4A11, 138. Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial, 139. Aminomethyltransferase, mitochondrial, 140. Methylsterol monooxygenase 1, 141. Heme oxygenase 1, 142. Heme oxygenase 2, 143. Steroid 17-alpha-hydroxylase/17,20 lyase, 144. Tyrosinase,  Alcohol dehydrogenase [NADP(+)],  Alcohol dehydrogenase 1A,  Alcohol dehydrogenase 1B,  Alcohol dehydrogenase 4,  Alcohol dehydrogenase class-3,  Alcohol dehydrogenase class 4 mu/sigma chain,  Xanthine dehydrogenase/oxidase,  Aldehyde oxidase,  Alcohol dehydrogenase 6","DB00157, DB02338, DB02319, DB01753, DB01842, DB03905, DB02363, DB00171, DB01690, DB16833, DB01829, DB01717, DB02738, DB03182, DB04524, DB04230, DB01992, DB02059, DB04045, DB03117, DB03070, DB01846, DB01675, DB01969, DB02912, DB03699, DB03170, DB03059, DB02930, DB03186",
DB00158,Folic acid,approved; nutraceutical; vet_approved,NC1=NC(=O)C2=NC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CN=C2N1,C19H19N7O6,,"Antianemic Preparations, Autacoids, BCRP/ABCG2 Substrates, Biological Factors, Diagnostic Agents, Diet, Food, and Nutrition, Dietary Supplements, Drugs that are Mainly Renally Excreted, Folic Acid and Derivatives, Food, Growth Substances, Hematinics, Hematologic Agents, Heterocyclic Compounds, Fused-Ring, Micronutrients, OAT1/SLC22A6 inhibitors, Pteridines, Pterins, Supplements, Vitamin B Complex, Vitamin B12 and Folic Acid, Vitamins"," Folate receptor gamma,  Folate receptor beta,  Folate receptor alpha,  Gamma-glutamyl hydrolase,  Methylenetetrahydrofolate reductase,  Dihydrofolate reductase,  ATP-binding cassette sub-family C member 11,  Canalicular multispecific organic anion transporter 2,  Solute carrier family 22 member 6,  Multidrug resistance-associated protein 4,  ATP-binding cassette sub-family G member 2,  Proton-coupled folate transporter,  Mitochondrial folate transporter/carrier","DB00158, DB16620, DB08878, DB00563, DB06178, DB11810, DB07689, DB04196, DB07765, DB03830",
DB00159,Icosapent,approved; nutraceutical,CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O,C20H30O2,,"Agents causing hyperkalemia, Agents that produce hypertension, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Dietary Fats, Dietary Fats, Unsaturated, Dietary Supplements, Eicosanoids, Fats, Fatty Acids, Fatty Acids, Omega-3, Fatty Acids, Unsaturated, Fish Oils, Hypolipidemic Agents, Lipids, Nephrotoxic agents, Non COX-2 selective NSAIDS, Oils, Supplements"," Prostaglandin G/H synthase 2,  Prostaglandin G/H synthase 1,  Peroxisome proliferator-activated receptor gamma,  Peroxisome proliferator-activated receptor delta,  Free fatty acid receptor 1,  Sodium/calcium exchanger 1,  Fatty acid-binding protein, brain,  Fatty acid desaturase 1,  Long-chain-fatty-acid--CoA ligase 4, 10. Transient receptor potential cation channel subfamily V member 1, 11. Peroxisome proliferator-activated receptor alpha, 12. Arachidonate 5-lipoxygenase,  Serum albumin","DB00159, DB04557, DB08887, DB13854, DB00132, DB00154, DB14104",
DB00160,Alanine,nutraceutical,C[C@H](N)C(O)=O,C3H7NO2,,"Alanine, Amino Acids, Amino Acids, Peptides, and Proteins, Dietary Supplements, Proteinogenic Amino Acids, Supplements"," Serine--pyruvate aminotransferase,  Alanine aminotransferase 1,  Cysteine desulfurase, mitochondrial,  Proton-coupled amino acid transporter 1,  Large neutral amino acids transporter small subunit 2,  Alanine--glyoxylate aminotransferase 2, mitochondrial,  Alanine--tRNA ligase, cytoplasmic,  Neutral amino acid transporter A,  4-aminobutyrate aminotransferase, mitochondrial, 10. Kynureninase, 11. Alanine--tRNA ligase, mitochondrial, 12. 5-phosphohydroxy-L-lysine phospho-lyase, 13. Alanine aminotransferase 2,  Monocarboxylate transporter 10","DB00160, DB01786, DB00133, DB02952, DB03929, DB02289, DB03320, DB04454, DB01804, DB02167, DB03214, DB04217, DB00151, DB01735, DB02345, DB03201",
DB00161,Valine,approved; nutraceutical,CC(C)[C@H](N)C(O)=O,C5H11NO2,,"Amino Acids, Amino Acids, Branched-Chain, Amino Acids, Essential, Amino Acids, Peptides, and Proteins, Dietary Supplements, Proteinogenic Amino Acids, Supplements"," Propionyl-CoA carboxylase beta chain, mitochondrial,  Branched-chain-amino-acid aminotransferase, cytosolic,  Valine--tRNA ligase,  Valine--tRNA ligase,  Propionyl-CoA carboxylase beta chain, mitochondrial,  Branched-chain-amino-acid aminotransferase, cytosolic,  Monocarboxylate transporter 10","DB00161, DB04171, DB04454, DB00167, DB01739, DB02085, DB04193, DB04498, DB04313, DB04538, DB00859, DB03817, DB04185",
DB00162,Vitamin A,approved; nutraceutical; vet_approved,C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C,C20H30O,,"Adjuvants, Immunologic, Alimentary Tract and Metabolism, Alkenes, Anti-Acne Preparations, Anti-Acne Preparations for Topical Use, Anticarcinogenic Agents, Antioxidants, Biological Factors, Carotenoids, Compounds used in a research, industrial, or household setting, Cyclohexanes, Cyclohexenes, Cycloparaffins, Dermatologicals, Diagnostic Agents, Diet, Food, and Nutrition, Diterpenes, Esters, Food, Growth Substances, Immunologic Factors, Micronutrients, Nasal Preparations, Ophthalmologicals, Physiological Phenomena, Pigments, Biological, Polyenes, Protective Agents, Retinoids, Retinoids for Topical Use in Acne, Sensory Organs, Terpenes, Tests for Fat Absorption, Vitamin A, Vitamins, Vitamins (Fat Soluble)"," Apolipoprotein D,  Prostaglandin-H2 D-isomerase,  Retinol dehydrogenase 12,  11-cis retinol dehydrogenase,  Retinol dehydrogenase 13,  Retinal dehydrogenase 2,  Retinal dehydrogenase 1,  Lecithin retinol acyltransferase,  Short-chain dehydrogenase/reductase 3, 10. Aldehyde dehydrogenase family 1 member A3, 11. All-trans-retinol 13,14-reductase, 12. Retinol dehydrogenase 11, 13. Dehydrogenase/reductase SDR family member 4, 14. Retinol dehydrogenase 14, 15. Retinol dehydrogenase 8,  Cytochrome P450 26A1,  Serum albumin,  Retinaldehyde-binding protein 1,  Retinol-binding protein 3,  Retinol-binding protein 1,  Retinol-binding protein 5,  Retinoid-binding protein 7,  Retinol-binding protein 4,  Retinol-binding protein 2,  Receptor for retinol uptake STRA6","DB00162, DB06755, DB08127, DB00523, DB00755, DB00982, DB12112, DB15909, DB02699, DB02253, DB02914",
DB00163,Vitamin E,approved; nutraceutical; vet_approved,CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCC2=C(O1)C(C)=C(C)C(O)=C2C,C29H50O2,,"Antioxidants, Basic Ointments and Protectants, Benzopyrans, Biological Factors, Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Substrates, Diet, Food, and Nutrition, Dietary Supplements, Food, Growth Substances, Heterocyclic Compounds, Fused-Ring, Micronutrients, Physiological Phenomena, Protective Agents, Pyrans, Supplements, Vitamin E, Vitamin E, analogs & derivatives, Vitamins, Vitamins (Fat Soluble)"," SEC14-like protein 4,  SEC14-like protein 3,  SEC14-like protein 2,  Nuclear receptor subfamily 1 group I member 2,  Protein kinase C beta type,  Arachidonate 5-lipoxygenase,  Protein kinase C alpha type,  Diacylglycerol kinase alpha,  Serine/threonine-protein phosphatase 2A catalytic subunit beta isoform, 10. Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform,  Glutathione S-transferase P,  Glutathione S-transferase omega-1,  Glutathione S-transferase Mu 3,  Glutamate--cysteine ligase catalytic subunit,  NAD(P)H dehydrogenase [quinone] 1,  Heme oxygenase 1,  Superoxide dismutase [Cu-Zn],  Cytochrome P450 3A4,  Glutathione S-transferase A2,  SEC14-like protein 2,  SEC14-like protein 3,  Phospholipid transfer protein,  Alpha-tocopherol transfer protein,  Scavenger receptor class B member 1,  ATP-binding cassette sub-family A member 1,  Niemann-Pick C1-like protein 1,  ATP-binding cassette sub-family G member 1","DB00163, DB14476, DB15394, DB14002, DB14477, DB13111, DB14001, DB15921, DB12647, DB07933",
DB00165,Pyridoxine,approved; investigational; nutraceutical; vet_approved,CC1=C(O)C(CO)=C(CO)C=N1,C8H11NO3,,"Alimentary Tract and Metabolism, Analogs/Derivatives, Antiinfectives for Systemic Use, Antimycobacterials, Diet, Food, and Nutrition, Drugs for Treatment of Tuberculosis, Drugs that are Mainly Renally Excreted, Food, Micronutrients, Picolines, Pyridines, Vitamin B Complex, Vitamins"," Pyridoxal kinase,  Cytochrome P450 1A1,  Pyridoxal kinase,  Pyridoxal phosphate phosphatase,  Alkaline phosphatase, tissue-nonspecific isozyme,  Serum albumin,  Alkaline phosphatase, tissue-nonspecific isozyme","DB00165, DB00147, DB11673, DB02209",
DB00166,Lipoic acid,approved; investigational; nutraceutical,OC(=O)CCCC[C@@H]1CCSS1,C8H14O2S2,,"Alimentary Tract and Metabolism, Antioxidants, Biological Factors, Coenzymes, Compounds used in a research, industrial, or household setting, Dietary Supplements, Enzymes and Coenzymes, Fatty Acids, Hypoglycemia-Associated Agents, Lipids, Micronutrients, Protective Agents, Sulfur Compounds, Supplements, Thiophenes, Various Alimentary Tract and Metabolism Products, Vitamin B Complex, Vitamins"," Lipoyltransferase 1, mitochondrial,  Sodium-dependent multivitamin transporter,  Lipoyl synthase, mitochondrial,  NADPH--cytochrome P450 reductase","DB00166, DB06253, DB03760",
DB00167,Isoleucine,investigational; nutraceutical,CC[C@H](C)[C@H](N)C(O)=O,C6H13NO2,,"Amino Acids, Amino Acids, Branched-Chain, Amino Acids, Essential, Amino Acids, Peptides, and Proteins, Dietary Supplements, Proteinogenic Amino Acids, Supplements"," Short/branched chain specific acyl-CoA dehydrogenase, mitochondrial,  Branched-chain-amino-acid aminotransferase, cytosolic,  Branched-chain-amino-acid aminotransferase, mitochondrial,  Isoleucine--tRNA ligase, cytoplasmic,  Isoleucine--tRNA ligase, mitochondrial,  Monocarboxylate transporter 10","DB00167, DB01739, DB04185, DB00161, DB00149, DB01746, DB01898, DB03810, DB04063, DB03774, DB04388, DB00129, DB03105, DB04419, DB15458, DB04171, DB04620, DB04454, DB00142, DB02233, DB02517, DB02571, DB03412, DB02978",
DB00168,Aspartame,investigational; nutraceutical,COC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](N)CC(O)=O,C14H18N2O5,,"Amino Acids, Peptides, and Proteins, Compounds used in a research, industrial, or household setting, Diet, Food, and Nutrition, Dietary Supplements, Dipeptides, Flavoring Agents, Food, Food Additives, Food Ingredients, OAT1/SLC22A6 inhibitors, OAT3/SLC22A8 Inhibitors, Oligopeptides, Peptides, Physiological Phenomena, Supplements, Sweetening Agents"," Taste receptor type 1 member 3,  Taste receptor type 1 member 2,  Transient receptor potential cation channel subfamily V member 1,  Solute carrier family 22 member 6,  Solute carrier family 22 member 8,  Solute carrier family 22 member 11","DB00168, DB08505, DB15991",
DB00169,Cholecalciferol,approved; nutraceutical,CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C,C27H44O,,"Alimentary Tract and Metabolism, Bone Density Conservation Agents, Calcium-Regulating Hormones and Agents, Cholecalciferol, antagonists & inhibitors, Cholestanes, Cholestenes, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Diet, Food, and Nutrition, Drugs Affecting Bone Structure and Mineralization, Drugs for Treatment of Bone Diseases, Food, Fused-Ring Compounds, Growth Substances, Lipids, Membrane Lipids, Micronutrients, Musculo-Skeletal System, Physiological Phenomena, Secosteroids, Steroids, Sterols, Vitamin D and Analogues, Vitamins, Vitamins (Fat Soluble)"," Vitamin D3 receptor,  Vitamin D 25-hydroxylase,  Sterol 26-hydroxylase, mitochondrial,  Cytochrome P450 2J2,  Cytochrome P450 3A4,  Cholesterol side-chain cleavage enzyme, mitochondrial,  Cytochrome P450 1A1,  Cytochrome P450 2C8,  Vitamin D-binding protein","DB00169, DB00146, DB00153, DB18029, DB18406, DB01436, DB13097, DB15557, DB00136, DB06410, DB13689, DB04258, DB01070, DB04891, DB06117, DB00910, DB02300, DB04038, DB11176, DB15914, DB03451, DB06272, DB15614",
DB00170,Menadione,approved; nutraceutical,CC1=CC(=O)C2=CC=CC=C2C1=O,C11H8O2,,"Antifibrinolytic Agents, Blood and Blood Forming Organs, Coagulants, Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP1A2 Inducers (strength unknown), Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 CYP2A6 Inhibitors, Cytochrome P-450 CYP2A6 Inhibitors (strength unknown), Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (strength unknown), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (strength unknown), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A5 Inhibitors, Cytochrome P-450 CYP3A5 Inhibitors (strength unknown), Cytochrome P-450 CYP3A7 Inhibitors, Cytochrome P-450 CYP3A7 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Diet, Food, and Nutrition, Dietary Supplements, Diterpenes, Fibrin Modulating Agents, Food, Hematologic Agents, Hemostatics, Micronutrients, Naphthalenes, Naphthoquinones, Physiological Phenomena, Phytol, Quinones, Supplements, Terpenes, Vitamin K, Vitamins, Vitamins (Fat Soluble)"," Vitamin K-dependent gamma-carboxylase,  Vitamin K epoxide reductase complex subunit 1,  Vitamin K epoxide reductase complex subunit 1-like protein 1,  Prothrombin,  Coagulation factor IX,  Vitamin K-dependent protein C,  Vitamin K-dependent protein S,  Ribosyldihydronicotinamide dehydrogenase [quinone],  NAD(P)H dehydrogenase [quinone] 1, 10. Osteocalcin,  Cytochrome P450 1A2,  Cytochrome P450 2A6,  Cytochrome P450 1B1,  Cytochrome P450 2B6,  Cytochrome P450 2C8,  Cytochrome P450 2C9,  Cytochrome P450 2C19,  Cytochrome P450 2D6,  Cytochrome P450 2E1, 10. Cytochrome P450 3A4, 11. Cytochrome P450 3A5, 12. Cytochrome P450 3A7, 13. Xanthine dehydrogenase/oxidase, 14. Aldehyde oxidase, 15. Methylenetetrahydrofolate reductase, 16. Cytochrome P450 1A1","DB00170, DB07669, DB17048, DB12148, DB13075, DB14936, DB15381",
DB00171,ATP,investigational; nutraceutical,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O,C10H16N5O13P3,,"Adenine Nucleotides, Adenosine Triphosphate, Dietary Supplements, Heterocyclic Compounds, Fused-Ring, Nucleic Acids, Nucleotides, and Nucleosides, Nucleotides, Purine Nucleotides, Purines, Ribonucleotides, Supplements"," Multidrug resistance-associated protein 6,  Multidrug resistance-associated protein 4,  Multidrug resistance-associated protein 1,  Cystic fibrosis transmembrane conductance regulator,  Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform,  Casein kinase II subunit alpha,  Casein kinase II subunit beta,  P2Y purinoceptor 11,  Serine/threonine-protein phosphatase 5, 10. Tyrosine-protein kinase ABL2, 11. ATP-binding cassette sub-family A member 1, 12. Acetyl-coenzyme A synthetase, cytoplasmic, 13. ALK tyrosine kinase receptor, 14. NEDD8-activating enzyme E1 regulatory subunit, 15. 5'-AMP-activated protein kinase catalytic subunit alpha-1, 16. Serine/threonine-protein kinase A-Raf, 17. Serine/threonine-protein kinase receptor R3, 18. Long-chain-fatty-acid--CoA ligase 1, 19. Cytosolic purine 5'-nucleotidase, 20. ATPase ASNA1, 21. ATP-binding cassette sub-family C member 9, 22. RAC-alpha serine/threonine-protein kinase, 23. Beta-adrenergic receptor kinase 1, 24. Apoptotic protease-activating factor 1, 25. Acetyl-coenzyme A synthetase 2-like, mitochondrial, 26. Activin receptor type-1B, 27. Activin receptor type-1, 28. Bile salt export pump, 29. Asparagine synthetase [glutamine-hydrolyzing], 30. Cyclin-dependent kinase 15, 31. ADP/ATP translocase 1, 32. ATP-binding cassette sub-family C member 8, 33. Argininosuccinate synthase, 34. AFG3-like protein 2, 35. Beta-adrenergic receptor kinase 2, 36. Anti-Muellerian hormone type-2 receptor, 37. Activated CDC42 kinase 1, 38. Tyrosine-protein kinase ABL1, 39. Adenylate cyclase type 1, 40. P-glycoprotein 1, 41. ATP-binding cassette sub-family G member 1, 42. Canalicular multispecific organic anion transporter 1,  Adenosine kinase","DB00171, DB01690, DB01717, DB02738, DB02930, DB16833, DB01860, DB03222, DB01842, DB02059, DB00131, DB02363, DB02355, DB03230, DB04554, DB01812, DB03664, DB04366, DB02189, DB03708, DB02098, DB02527, DB03478, DB03755, DB03909, DB04395, DB02694, DB03170, DB01774, DB01829",
DB00172,Proline,nutraceutical,OC(=O)[C@@H]1CCCN1,C5H9NO2,,"Amino Acids, Amino Acids, Cyclic, Amino Acids, Peptides, and Proteins, Dietary Supplements, Imino Acids, Proteinogenic Amino Acids, Supplements"," Pyrroline-5-carboxylate reductase 1, mitochondrial,  Bifunctional glutamate/proline--tRNA ligase,  Sodium- and chloride-dependent neutral and basic amino acid transporter B(0+),  Sodium-dependent proline transporter,  Pyrroline-5-carboxylate reductase 2,  Prolyl 4-hydroxylase subunit alpha-2,  Proline dehydrogenase 1, mitochondrial,  Peptidyl-prolyl cis-trans isomerase H,  Proline synthase co-transcribed bacterial homolog protein, 10. Prolyl 4-hydroxylase subunit alpha-1, 11. Peptidyl-prolyl cis-trans isomerase B, 12. Peptidyl-prolyl cis-trans isomerase F, mitochondrial, 13. Peptidyl-prolyl cis-trans isomerase C, 14. Peptidyl-prolyl cis-trans isomerase A, 15. Peptidyl-prolyl cis-trans isomerase G, 16. Prolyl 3-hydroxylase 1, 17. Pyrroline-5-carboxylate reductase, 18. Probable proline--tRNA ligase, mitochondrial, 19. Prolyl 3-hydroxylase 2, 20. Prolyl 3-hydroxylase 3, 21. Pyrroline-5-carboxylate reductase 3, 22. Trans-L-3-hydroxyproline dehydratase,  Proline dehydrogenase 1, mitochondrial,  Monocarboxylate transporter 10","DB00172, DB02853, DB04284, DB08847, DB03088",
DB00173,Adenine,approved; nutraceutical,NC1=C2NC=NC2=NC=N1,C5H5N5,,"Dietary Supplements, Heterocyclic Compounds, Fused-Ring, Purines, Supplements, UGT1A1 Inhibitors"," Adenine phosphoribosyltransferase,  DNA,  S-methyl-5'-thioadenosine phosphorylase,  Nicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase,  Acetyl-CoA carboxylase 2,  Low molecular weight phosphotyrosine protein phosphatase,  5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase,  Peroxisomal trans-2-enoyl-CoA reductase,  A/G-specific adenine glycosylase, 10. Nucleoside deoxyribosyltransferase-I, 11. SRSF protein kinase 2, 12. Holliday junction ATP-dependent DNA helicase RuvB,  UDP-glucuronosyltransferase 1-1","DB00173, DB03164, DB04104",
DB00174,Asparagine,approved; investigational; nutraceutical,N[C@@H](CC(N)=O)C(O)=O,C4H8N2O3,,"Amino Acids, Amino Acids, Basic, Amino Acids, Diamino, Amino Acids, Neutral, Amino Acids, Peptides, and Proteins, Dietary Supplements, Proteinogenic Amino Acids, Supplements"," Sodium-coupled neutral amino acid transporters (Protein Group),  Neutral amino acid transporter B(0),  Asparagine synthetase [glutamine-hydrolyzing],  Asparagine--tRNA ligase, cytoplasmic,  Isoaspartyl peptidase/L-asparaginase,  Probable asparagine--tRNA ligase, mitochondrial,  Monocarboxylate transporter 10","DB00174, DB03943, DB04527, DB03817, DB04498",
DB00175,Pravastatin,approved,[H][C@]12[C@H](C[C@H](O)C=C1C=C[C@H](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC(O)=O)OC(=O)[C@@H](C)CC,C23H36O7,,"Agents Causing Muscle Toxicity, Anticholesteremic Agents, BCRP/ABCG2 Inhibitors, BCRP/ABCG2 Substrates, BSEP/ABCB11 Substrates, Drugs causing inadvertant photosensitivity, Enzyme Inhibitors, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hypolipidemic Agents, Hypolipidemic Agents Indicated for Hyperlipidemia, Lipid Modifying Agents, Lipid Modifying Agents, Plain, Lipid Regulating Agents, Noxae, OAT1/SLC22A6 inhibitors, OAT3/SLC22A8 Inhibitors, OAT3/SLC22A8 Substrates, OATP1B1/SLCO1B1 Substrates, OATP1B3 substrates, OATP2B1/SLCO2B1 substrates, P-glycoprotein substrates, Photosensitizing Agents, Toxic Actions"," 3-hydroxy-3-methylglutaryl-coenzyme A reductase,  Histone deacetylase 2,  Solute carrier organic anion transporter family member 1B1,  Solute carrier organic anion transporter family member 2B1,  P-glycoprotein 1,  Solute carrier organic anion transporter family member 1A2,  Solute carrier family 22 member 6,  Solute carrier family 22 member 8,  Canalicular multispecific organic anion transporter 1,  Solute carrier family 22 member 11,  ATP-binding cassette sub-family G member 2, 10. Solute carrier family 22 member 7, 11. Monocarboxylate transporter 1, 12. Bile salt export pump, 13. Solute carrier organic anion transporter family member 1B3","DB00175, DB06693, DB03785, DB14714, DB00227, DB00641, DB14648, DB08224, DB18113",
DB00176,Fluvoxamine,approved; investigational,COCCCC\C(=N/OCCN)C1=CC=C(C=C1)C(F)(F)F,C15H21F3N2O2,,"Amines, Anti-Anxiety Agents, Antidepressive Agents, Antidepressive Agents Indicated for Depression, Antidepressive Agents, Second-Generation, BSEP/ABCB11 Substrates, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strong), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (strength unknown), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (strong), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (moderate), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (moderate), Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A7 Inhibitors, Cytochrome P-450 CYP3A7 Inhibitors (moderate), Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Hydroxylamines, Hypoglycemia-Associated Agents, Membrane Transport Modulators, Nervous System, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, Oximes, P-glycoprotein inhibitors, Psychoanaleptics, Psychotropic Drugs, Selective Serotonin Reuptake Inhibitors, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin Modulators, Tranquilizing Agents"," Sodium-dependent serotonin transporter,  Potassium voltage-gated channel subfamily H member 2,  Cytochrome P450 2D6,  Cytochrome P450 1A2,  Cytochrome P450 1A1,  Cytochrome P450 3A4,  Cytochrome P450 3A Subfamily (Protein Group),  Cytochrome P450 2C9,  Cytochrome P450 2C19,  Cytochrome P450 2B6,  P-glycoprotein 1,  Bile salt export pump",DB00176,
DB00177,Valsartan,approved; investigational,CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O,C24H29N5O3,,"Agents Acting on the Renin-Angiotensin System, Agents causing angioedema, Agents causing hyperkalemia, Angiotensin 2 Receptor Blocker, Angiotensin II Antagonists and Calcium Channel Blockers, Angiotensin II Antagonists and Diuretics, Angiotensin II receptor antagonists, Angiotensin II receptor blockers (ARBs) and calcium channel blockers, Angiotensin II receptor blockers (ARBs) and diuretics, Angiotensin II receptor blockers (ARBs), plain, Angiotensin II Type 1 Receptor Blockers, Angiotensin II Type 2 Receptor Blockers, Angiotensin Receptor Antagonists, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Cardiovascular Agents, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Hypotensive Agents, OATP1B1/SLCO1B1 Inhibitors, OATP1B1/SLCO1B1 Substrates, OATP1B3 substrates"," Type-1 angiotensin II receptor,  Cytochrome P450 2C9,  Solute carrier organic anion transporter family member 1B3,  Solute carrier organic anion transporter family member 1B1,  Canalicular multispecific organic anion transporter 1",DB00177,
DB00178,Ramipril,approved,[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC,C23H32N2O5,,"ACE Inhibitors and Calcium Channel Blockers, ACE Inhibitors and Diuretics, Agents Acting on the Renin-Angiotensin System, Agents causing angioedema, Agents causing hyperkalemia, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Cardiovascular Agents, Cholinesterase Inhibitors, Drugs causing inadvertant photosensitivity, Enzyme Inhibitors, Heterocyclic Compounds, Fused-Ring, Hypotensive Agents, Lipid Modifying Agents, Photosensitizing Agents, Protease Inhibitors"," Angiotensin-converting enzyme,  B1 bradykinin receptor,  Cholinesterase,  Solute carrier family 15 member 1,  Solute carrier family 15 member 2","DB00178, DB00519, DB14208, DB14209, DB00584, DB00722, DB09477, DB00790, DB13312, DB14213",
DB00179,Masoprocol,approved; investigational,C[C@@H](CC1=CC(O)=C(O)C=C1)[C@H](C)CC1=CC(O)=C(O)C=C1,C18H22O4,,"Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Antioxidants, Benzene Derivatives, Benzyl Compounds, Biological Factors, Catechols, Compounds used in a research, industrial, or household setting, Cyclooxygenase Inhibitors, Enzyme Inhibitors, Lignans, Lipoxygenase Inhibitors, Peripheral Nervous System Agents, Phenols, Protective Agents, Sensory System Agents"," Arachidonate 5-lipoxygenase,  Sex hormone-binding globulin,  Transient receptor potential cation channel subfamily M member 7","DB00179, DB12226, DB12179, DB14129",
DB00180,Flunisolide,approved; investigational,[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO,C24H31FO6,,"Adrenal Cortex Hormones, Adrenals, Agents to Treat Airway Disease, Anti-Asthmatic Agents, Anti-Inflammatory Agents, Corticosteroid Hormone Receptor Agonists, Corticosteroids, Corticosteroids for Systemic Use, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Substrates, Drugs for Obstructive Airway Diseases, Fused-Ring Compounds, Immunosuppressive Agents, Nasal Preparations, Pregnadienes, Pregnanes, Respiratory System Agents, Steroids, Steroids, Fluorinated"," Glucocorticoid receptor,  Cytochrome P450 3A4,  Corticosteroid-binding globulin","DB00180, DB14662, DB00591, DB01047, DB18738, DB00846, DB01260, DB08973, DB14673, DB01222, DB00288, DB01410, DB14637, DB14657, DB15835, DB15777, DB15821, DB06786, DB06781, DB01384, DB09378, DB14664, DB12553, DB01130, DB08971, DB14652, DB13223, DB12322, DB00223, DB00663",
DB00181,Baclofen,approved,NCC(CC(O)=O)C1=CC=C(Cl)C=C1,C10H12ClNO2,,"Agents Causing Muscle Toxicity, Amino Acids, Amino Acids, Peptides, and Proteins, Aminobutyrates, Butyrates, Central Nervous System Agents, Central Nervous System Depressants, Drugs that are Mainly Renally Excreted, GABA Agents, GABA Agonists, GABA-B Receptor Agonists, Gaba-derivative Skeletal Muscle Relaxants, gamma-Aminobutyric Acid-ergic Agonist, Muscle Relaxants, Muscle Relaxants, Centrally Acting Agents, Muscle Relaxants, Peripherally Acting Agents, Musculo-Skeletal System, Neurotransmitter Agents"," Gamma-aminobutyric acid type B receptor subunit 2,  C-X-C chemokine receptor type 4,  Gamma-aminobutyric acid type B receptor subunit 1","DB00181, DB08891, DB12098, DB13455",
DB00182,Amphetamine,approved; illicit; investigational,CC(N)CC1=CC=CC=C1,C9H13N,,"Adrenergic Agents, Agents producing tachycardia, Agents that produce hypertension, Agents that reduce seizure threshold, Amines, Amphetamines, Autonomic Agents, Benzene Derivatives, Biogenic Amines, Biogenic Monoamines, Catechols, Central Nervous System Agents, Central Nervous System Stimulants, Central Nervous System Stimulation, Centrally Acting Sympathomimetics, Cytochrome P-450 CYP2A6 Inhibitors, Cytochrome P-450 CYP2A6 Inhibitors (weak), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dopamine Agents, Dopamine Uptake Inhibitors, Drugs that are Mainly Renally Excreted, Membrane Transport Modulators, Nervous System, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, Peripheral Nervous System Agents, Phenethylamines, Phenols, Psychoanaleptics, Psychostimulants, Agents Used for ADHD and Nootropics, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Sympathomimetics"," Synaptic vesicular amine transporter,  Sodium-dependent dopamine transporter,  Cocaine- and amphetamine-regulated transcript protein,  Trace amine-associated receptor 1,  Monoamine oxidase (Protein Group),  Sodium-dependent noradrenaline transporter,  Alpha adrenergic receptor (Protein Group),  Beta adrenergic receptor (Protein Group),  Dopamine D2 receptor, 10. Amine oxidase [flavin-containing] B, 11. Sodium-dependent serotonin transporter,  Cytochrome P450 2A6,  Cytochrome P450 2D6,  Solute carrier family 22 member 3,  Solute carrier family 22 member 5","DB00182, DB01576, DB00191, DB02972, DB09250, DB01577, DB09571, DB04484, DB01365, DB13285, DB04325, DB01560, DB07910, DB00752, DB02665, DB09352, DB04410, DB00397, DB01486",
DB00183,Pentagastrin,approved,CSCC[C@H](NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O,C37H49N7O9S,,"Amino Acids, Peptides, and Proteins, Diagnostic Agents, Gastrins, Gastrointestinal Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Oligopeptides, Pentagastrin, antagonists & inhibitors, Peptides, Proteins, Tests for Gastric Secretion"," Gastrin/cholecystokinin type B receptor,  Cholinesterase","DB00183, DB12054, DB12292, DB14806, DB00403, DB11628, DB17503, DB14777, DB00027, DB06645, DB13298, DB11724, DB16146, DB18252, DB12748, DB12777, DB12538, DB05479, DB15314, DB15687, DB09099, DB01284, DB14027, DB18527, DB15194, DB12602, DB14786, DB17536, DB15272, DB17410",
DB00184,Nicotine,approved,CN1CCC[C@H]1C1=CN=CC=C1,C10H14N2,,"Agents producing tachycardia, Alkaloids, Autonomic Agents, Cholinergic Agents, Cholinergic Agonists, Cholinergic Nicotinic Agonist, Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP1A2 Inducers (strength unknown), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2A6 Inhibitors, Cytochrome P-450 CYP2A6 Inhibitors (strength unknown), Cytochrome P-450 CYP2A6 Substrates, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2E1 Inducers, Cytochrome P-450 CYP2E1 Inducers (strength unknown), Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs Used in Addictive Disorders, Drugs Used in Nicotine Dependence, Ganglion Blockers, Ganglionic Stimulants, Miscellaneous Autonomic Drugs, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates, Nervous System, Neurotransmitter Agents, Nicotine, antagonists & inhibitors, Nicotinic Agonists, OCT1 inhibitors, OCT2 Inhibitors, Peripheral Nervous System Agents, Pyridines, Smoking Cessation Agents, Solanaceous Alkaloids"," Neuronal acetylcholine receptor subunit alpha-4,  Neuronal acetylcholine receptor subunit alpha-7,  Neuronal acetylcholine receptor subunit beta-2,  Neuronal acetylcholine receptor subunit alpha-2,  Neuronal acetylcholine receptor subunit alpha-3,  Neuronal acetylcholine receptor subunit alpha-5,  Neuronal acetylcholine receptor subunit alpha-6,  Neuronal acetylcholine receptor subunit alpha-9,  Neuronal acetylcholine receptor subunit alpha-10, 10. Neuronal acetylcholine receptor subunit beta-3, 11. Neuronal acetylcholine receptor subunit beta-4, 12. Cytochrome P450 19A1, 13. Choline O-acetyltransferase,  Cytochrome P450 1A1,  Cytochrome P450 1A2,  Cytochrome P450 2C19,  Cytochrome P450 2C8,  Cytochrome P450 2C9,  Cytochrome P450 2D6,  Cytochrome P450 3A4,  Amine oxidase [flavin-containing] A,  Amine oxidase [flavin-containing] B, 10. Cytochrome P450 2A6, 11. Cytochrome P450 2E1, 12. Cytochrome P450 2A13, 13. Cytochrome P450 2B6,  Solute carrier family 22 member 2,  Solute carrier family 22 member 1,  Solute carrier family 22 member 3,  Solute carrier family 22 member 5,  Solute carrier family 22 member 4",DB00184,
DB00185,Cevimeline,approved,CC1O[C@@]2(CS1)CN1CCC2CC1,C10H17NOS,,"Autonomic Agents, Cholinergic Agents, Cholinergic Agonists, Cholinergic Receptor Agonist, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Muscarinic Agonists, Nervous System, Neurotransmitter Agents, Parasympathomimetics, Peripheral Nervous System Agents, Sulfur Compounds"," Muscarinic acetylcholine receptor M3,  Muscarinic acetylcholine receptor M1,  Cytochrome P450 2D6,  Cytochrome P450 3A4,  Dimethylaniline monooxygenase [N-oxide-forming] 1",DB00185,
DB00186,Lorazepam,approved,OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2,C15H10Cl2N2O2,,"Anti-Anxiety Agents, Anticonvulsants, Antiemetics, Autonomic Agents, Benzazepines, Benzodiazepine hypnotics and sedatives, Benzodiazepines and benzodiazepine derivatives, Benzodiazepinones, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, GABA Agents, GABA Modulators, Gastrointestinal Agents, Heterocyclic Compounds, Fused-Ring, Hypnotics and Sedatives, Muscle Relaxants, Muscle Relaxants, Centrally Acting Agents, Nervous System, Neurotransmitter Agents, Peripheral Nervous System Agents, Psycholeptics, Psychotropic Drugs, Tranquilizing Agents"," GABA(A) Receptor (Protein Group),  GABA(A) Receptor Benzodiazepine Binding Site (Protein Group),  UDP-glucuronosyltransferase 2B15,  Cytochrome P450 3A4","DB00186, DB13872, DB00842, DB01511, DB00231, DB14672, DB14028, DB14671, DB00829, DB13837, DB01489, DB01594, DB13335, DB00628, DB01588, DB00801, DB14715, DB01567",
DB00187,Esmolol,approved; withdrawn,COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1,C16H25NO4,,"Adrenergic Agents, Adrenergic Antagonists, Adrenergic beta-1 Receptor Antagonists, Adrenergic beta-Antagonists, Agents causing hyperkalemia, Alcohols, Amines, Amino Alcohols, Antiarrhythmic agents, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Beta Blocking Agents, Selective, Beta-Blockers (Beta1 Selective), Bradycardia-Causing Agents, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 Substrates, Hypotensive Agents, Neurotransmitter Agents, Potential QTc-Prolonging Agents, Propanols, QTc Prolonging Agents"," Beta-1 adrenergic receptor,  Cytochrome P450 2D6","DB00187, DB00264, DB00335, DB06987, DB13443",
DB00188,Bortezomib,approved; investigational,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O,C19H25BN4O4,,"Acids, Acids, Noncarboxylic, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Boron Compounds, Boronic Acids, Cardiotoxic antineoplastic agents, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (moderate), Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (weak), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Hepatotoxic Agents, Hypotensive Agents, Immunosuppressive Agents, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, OATP1B3 inhibitors, P-glycoprotein substrates, P-glycoprotein substrates with a Narrow Therapeutic Index, Potential QTc-Prolonging Agents, Proteasome Inhibitors, Pyrazines, QTc Prolonging Agents"," Proteasome subunit beta type-5,  Proteasome subunit beta type-1,  Cytochrome P450 3A4,  Cytochrome P450 2C19,  Cytochrome P450 2D6,  Cytochrome P450 1A2,  Cytochrome P450 2C9,  P-glycoprotein 1,  Solute carrier organic anion transporter family member 1B3","DB00188, DB16741",
DB00189,Ethchlorvynol,approved; illicit; withdrawn,CCC(O)(\C=C\Cl)C#C,C7H9ClO,,"Alcohols, Central Nervous System Agents, Central Nervous System Depressants, Chlorohydrins, Hypnotics and Sedatives, Nervous System, Psycholeptics", GABA(A) Receptor (Protein Group),DB00189,
DB00190,Carbidopa,approved,C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O,C10H14N2O4,,"Amines, Anti-Dyskinesia Agents, Anti-Parkinson Drugs, Aromatic Amino Acid Decarboxylase Inhibitors, Aromatic L-amino Acid Decarboxylase Inhibitors, Benzene Derivatives, Biogenic Amines, Biogenic Monoamines, Catecholamines, Catechols, Central Nervous System Agents, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Hydrazines, Phenols", Aromatic-L-amino-acid decarboxylase,"DB00190, DB00968, DB01235, DB03552, DB13313, DB06535, DB16171, DB00765, DB16306, DB06262, DB00135, DB03839, DB13848",
DB00191,Phentermine,approved; illicit,CC(C)(N)CC1=CC=CC=C1,C10H15N,,"Adrenergic Agents, Agents producing tachycardia, Agents that produce hypertension, Alimentary Tract and Metabolism, Amines, Amphetamines, Anti-Obesity Agents, Antiobesity Preparations, Excl. Diet Products, Appetite Depressants, Appetite Suppression, Autonomic Agents, Central Nervous System Agents, Centrally Acting Antiobesity Products, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Substrates, Increased Sympathetic Activity, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates, Neurotransmitter Agents, Peripheral Nervous System Agents, Phenethylamines, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Sympathomimetic Amine Anorectic, Sympathomimetics"," Sodium-dependent noradrenaline transporter,  Sodium-dependent serotonin transporter,  Sodium-dependent dopamine transporter,  Amine oxidase [flavin-containing] A,  Amine oxidase [flavin-containing] B,  Pro-neuropeptide Y,  Cytochrome P450 3A4","DB00191, DB00182, DB01576, DB01365, DB02972, DB09250, DB01577, DB09571, DB01556, DB04484, DB00752, DB02665, DB13285",
DB00192,Indecainide,approved,CC(C)NCCCC1(C(N)=O)C2=CC=CC=C2C2=CC=CC=C12,C20H24N2O,,, Sodium channel protein type 5 subunit alpha,DB00192,
DB00193,Tramadol,approved; investigational,COC1=CC=CC(=C1)C1(O)CCCCC1CN(C)C,C16H25NO2,,"Agents producing tachycardia, Agents that reduce seizure threshold, Alcohols, Amines, Analgesics, Anticholinergic Agents, Antidepressive Agents, Central Nervous System Agents, Central Nervous System Depressants, Combined Inhibitors of Serotonin/Norepinephrine Reuptake, Cyclohexanes, Cyclohexanols, Cycloparaffins, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Dimethylamines, Drugs that are Mainly Renally Excreted, Muscarinic Antagonists, Narcotics, Nervous System, NMDA Receptor Antagonists, Opiate Agonists, Opioid Agonist, Opioids, Peripheral Nervous System Agents, Sensory System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2C Receptor Antagonists, Serotonin Agents, Serotonin Modulators, Serotonin Receptor Antagonists, UGT1A1 Substrates"," Mu-type opioid receptor,  Sodium-dependent noradrenaline transporter,  Sodium-dependent serotonin transporter,  Sodium channel protein type 2 subunit alpha,  NMDA receptor (Protein Group),  Adenosine receptor A1,  Alpha-2 adrenergic receptors (Protein Group),  5-hydroxytryptamine receptor 2C,  Kappa-type opioid receptor, 10. Delta-type opioid receptor, 11. Neuronal acetylcholine receptor subunit alpha-7, 12. Muscarinic acetylcholine receptor M3, 13. Muscarinic acetylcholine receptor M1, 14. Neurokinin 1 receptor, 15. Transient receptor potential cation channel subfamily V member 1,  Cytochrome P450 2B6,  UDP-glucuronosyltransferase 1-1,  Cytochrome P450 2D6,  Cytochrome P450 3A4","DB00193, DB16100, DB00505, DB00376, DB00387, DB00942",
DB00194,Vidarabine,approved; investigational,NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,C10H13N5O4,,"Anti-Infective Agents, Antiinfectives for Systemic Use, Antimetabolites, Antiviral Agents, Antivirals for Systemic Use, Arabinonucleosides, Carbohydrates, Direct Acting Antivirals, Glycosides, Heterocyclic Compounds, Fused-Ring, Noxae, Nucleic Acids, Nucleotides, and Nucleosides, Nucleosides, Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors, Ophthalmologicals, Purine Nucleosides, Purines, Ribonucleosides, Sensory Organs, Toxic Actions"," DNA polymerase catalytic subunit,  Thymidine kinase,  Thymidine kinase,  Adenosine deaminase","DB00194, DB00640, DB03528, DB12156, DB03716, DB01073, DB04441, DB04440, DB03273, DB02916, DB16075, DB17756, DB02282, DB11933, DB07170, DB04102, DB07052, DB00131, DB02162, DB02373, DB02607, DB03011, DB02947, DB00242, DB01910, DB04853, DB02934, DB03952, DB02753, DB03230",
DB00195,Betaxolol,approved; investigational,CC(C)NCC(O)COC1=CC=C(CCOCC2CC2)C=C1,C18H29NO3,,"Adrenergic Agents, Adrenergic Antagonists, Adrenergic beta-1 Receptor Antagonists, Adrenergic beta-Antagonists, Agents causing hyperkalemia, Alcohols, Amines, Amino Alcohols, Antiarrhythmic agents, Antiglaucoma Preparations and Miotics, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Autonomic Agents, Beta Blocking Agents, Selective, Beta-adrenergic Agents, Beta-Blockers (Beta1 Selective), Bradycardia-Causing Agents, Cardiovascular Agents, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 Substrates, Hypotensive Agents, Neurotransmitter Agents, Ophthalmologicals, Peripheral Nervous System Agents, Phenoxypropanolamines, Propanolamines, Propanols, QTc Prolonging Agents, Sensory Organs, Sympatholytics"," Beta-1 adrenergic receptor,  Beta-2 adrenergic receptor,  Cytochrome P450 2D6,  Cytochrome P450 1A2","DB00195, DB09351, DB00264, DB00335, DB06987, DB13443",
DB00196,Fluconazole,approved; investigational,OC(CN1C=NC=N1)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1,C13H12F2N6O,,"14-alpha Demethylase Inhibitors, Agents causing hyperkalemia, Anti-Infective Agents, Antifungal Agents, Antifungals for Dermatological Use, Antifungals for Topical Use, Antiinfectives for Systemic Use, Antimycotics for Systemic Use, Azole Antifungals, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strong), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (moderate), Cytochrome P-450 CYP3A5 Inhibitors, Cytochrome P-450 CYP3A5 Inhibitors (weak), Cytochrome P-450 Enzyme Inhibitors, Dermatologicals, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Hormone Antagonists, Hormones, Hormone Substitutes, and Hormone Antagonists, Imidazole and Triazole Derivatives, P-glycoprotein inhibitors, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Steroid Synthesis Inhibitors, Triazole and tetrazole derivatives, Triazole Derivatives, Triazoles"," Cytochrome P450 51,  Cytochrome P450 3A5,  Cytochrome P450 3A4,  Cytochrome P450 2C9,  Cytochrome P450 2C19,  P-glycoprotein 1","DB00196, DB09040",
DB00197,Troglitazone,approved; investigational; withdrawn,CC1=C(C)C2=C(CCC(C)(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)O2)C(C)=C1O,C24H27NO5S,,"Alimentary Tract and Metabolism, Benzopyrans, Blood Glucose Lowering Agents, BSEP/ABCB11 Inhibitors, Chromans, Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strength unknown), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (strength unknown), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (moderate), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (moderate), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A5 Inhibitors, Cytochrome P-450 CYP3A5 Inhibitors (strength unknown), Cytochrome P-450 CYP3A7 Inhibitors, Cytochrome P-450 CYP3A7 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs Used in Diabetes, Heterocyclic Compounds, Fused-Ring, OATP1B1/SLCO1B1 Inhibitors, Oral Hypoglycemics, Pyrans, Sulfur Compounds, Thiazoles, Thiazolidinediones, UGT1A1 Substrates, UGT1A3 substrates, UGT1A4 substrates, UGT1A6 Inhibitors, UGT1A6 substrate, UGT1A9 Substrates, UGT2B7 substrates"," Peroxisome proliferator-activated receptor gamma,  Estrogen-related receptor gamma,  Steroid hormone receptor ERR1,  Peroxisome proliferator-activated receptor delta,  Peroxisome proliferator-activated receptor alpha,  Glutathione S-transferase P,  Long-chain-fatty-acid--CoA ligase 4,  Plasminogen activator inhibitor 1,  Equilibrative nucleoside transporter 1,  Cytochrome P450 19A1,  Cytochrome P450 1A1,  Cytochrome P450 2B6,  Cytochrome P450 2C9,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  UDP-glucuronosyltransferase 1-3,  UDP-glucuronosyltransferase 1-4,  UDP-glucuronosyltransferase 1-6, 10. UDP-glucuronosyltransferase 1-7, 11. UDP-glucuronosyltransferase 1-8, 12. UDP-glucuronosyltransferase 1-9, 13. UDP-glucuronosyltransferase 1-10, 14. UDP-glucuronosyltransferase 2B7, 15. UDP-glucuronosyltransferase 2B15, 16. Cytochrome P450 3A4, 17. Cytochrome P450 2C19, 18. UDP-glucuronosyltransferase 1-1, 19. Cytochrome P450 2C8,  Bile salt export pump,  Solute carrier organic anion transporter family member 1B1","DB00197, DB08607, DB14035, DB09201",
DB00198,Oseltamivir,approved,CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1,C16H28N2O4,,"Acetamides, Acetates, Amides, Anti-Infective Agents, Antiinfectives for Systemic Use, Antiviral Agents, Antivirals for Systemic Use, Direct Acting Antivirals, Drugs that are Mainly Renally Excreted, Neuraminidase Inhibitors, OAT3/SLC22A8 Substrates"," Neuraminidase,  Sialidase-1,  Sialidase-2,  Liver carboxylesterase 1,  Multidrug resistance-associated protein 4,  Solute carrier family 15 member 1,  Solute carrier family 22 member 8","DB00198, DB02600",
DB00199,Erythromycin,approved; investigational; vet_approved,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,C37H67NO13,,"Anti-Acne Preparations, Anti-Acne Preparations for Topical Use, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Antiinfectives for Treatment of Acne, BSEP/ABCB11 Inhibitors, BSEP/ABCB11 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (moderate), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Inhibitors, Cytochrome P-450 CYP3A5 Inhibitors (moderate), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Inhibitors, Cytochrome P-450 CYP3A7 Inhibitors (moderate), Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dermatologicals, Enzyme Inhibitors, Erythromycin and similars, Erythromycins, Gastrointestinal Agents, Lactones, Macrolide Antimicrobial, Macrolides, Macrolides, Lincosamides and Streptogramins, Moderate Risk QTc-Prolonging Agents, OATP1B1/SLCO1B1 Inhibitors, OATP1B1/SLCO1B1 Substrates, OATP1B3 inhibitors, OATP1B3 substrates, Ophthalmologicals, P-glycoprotein inhibitors, P-glycoprotein substrates, Protein Synthesis Inhibitors, QTc Prolonging Agents"," 23S ribosomal RNA,  Motilin receptor,  Potassium voltage-gated channel subfamily H member 2,  Cytochrome P450 3A5,  Cytochrome P450 3A4,  Cytochrome P450 3A7,  Solute carrier organic anion transporter family member 1B3,  Bile salt export pump,  P-glycoprotein 1,  Solute carrier organic anion transporter family member 1B1,  Canalicular multispecific organic anion transporter 1,  Solute carrier organic anion transporter family member 1A2","DB00199, DB01211, DB11442, DB13338, DB13179, DB11474, DB00207, DB11416, DB00778, DB00954, DB01321, DB13456, DB13409, DB11383, DB09309, DB15981, DB11554",
DB00200,Hydroxocobalamin,approved,[N+]1=2[Co-3]345([N+]6=C7[C@H]([C@@](CC(=O)N)(C)[C@@]6([C@@]6(N3C(=C(C)C3=[N+]4C(C(C)(C)[C@@H]3CCC(=O)N)=CC3=[N+]5C(=C7C)[C@@](CC(=O)N)([C@@H]3CCC(=O)N)C)[C@@](C)([C@H]6CC(=O)N)CCC(NC[C@@H](C)OP(=O)(O[C@@H]3[C@H](O[C@H](N(C4=CC(=C(C=C14)C)C)C=2)[C@@H]3O)CO)[O-])=O)[H])C)CCC(=O)N)O[H],C62H89CoN13O15P,,"Antianemic Preparations, Antidotes, Blood and Blood Forming Organs, Corrinoids, Drugs that are Mainly Renally Excreted, Hematinics, Hematologic Agents, Heterocyclic Compounds, Fused-Ring, Micronutrients, Nutritional Support, Vitamin B Complex, Vitamin B12 and Folic Acid, Vitamins"," Methionine synthase,  Methylmalonyl-CoA mutase, mitochondrial,  Methylmalonic aciduria type A protein, mitochondrial,  Transcobalamin-1,  Protein amnionless,  Cubilin,  Methylmalonic aciduria and homocystinuria type C protein,  Transcobalamin-2","DB00200, DB03614, DB11191, DB11467, DB03469, DB05168, DB02667, DB00115, DB03317, DB03906, DB04803, DB05735, DB02832, DB02975, DB15673, DB12674, DB02949, DB11641, DB00361, DB16186, DB13013, DB14098, DB09387, DB16312, DB02868, DB17390, DB14092, DB00541, DB12586, DB17385",
DB00201,Caffeine,approved,CN1C=NC2=C1C(=O)N(C)C(=O)N2C,C8H10N4O2,,"Alkaloids, Anorexigenic Agents & Respiratory and CNS Stimulants, BCRP/ABCG2 Inhibitors, Caffeine and Caffeine Containing Products, Central Nervous System Agents, Central Nervous System Stimulants, Central Nervous System Stimulation, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (moderate), Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dermatologicals, Diagnostic Agents, Drugs for Obstructive Airway Diseases, Enzyme Inhibitors, Heterocyclic Compounds, Fused-Ring, Nervous System, Neurotransmitter Agents, Phosphodiesterase Inhibitors, Psychoanaleptics, Psychostimulants, Agents Used for ADHD and Nootropics, Purinergic Agents, Purinergic Antagonists, Purines, Purinones, Respiratory and CNS Stimulants, Tests for Gastric Secretion, Tricarboxylic Acids, Xanthine derivatives"," Adenosine receptor A1,  Adenosine receptor A2a,  Adenosine receptor A2b,  Adenosine receptor A3,  Phosphodiesterase enzymes (Protein Group),  cAMP-specific 3',5'-cyclic phosphodiesterase 4B,  Ryanodine receptor 1,  Cyclic nucleotide phosphodiesterase (Protein Group),  DNA-dependent protein kinase catalytic subunit, 10. Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform, 11. Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform, 12. Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform, 13. Inositol 1,4,5-trisphosphate receptor (Protein Group), 14. Serine-protein kinase ATM,  Cytochrome P450 1A2,  Cytochrome P450 3A4,  Cytochrome P450 2E1,  Cytochrome P450 2C8,  Cytochrome P450 2C9,  Cytochrome P450 1A1,  Cytochrome P450 1B1,  Cytochrome P450 2D6,  ATP-binding cassette sub-family G member 2","DB00201, DB01412, DB00277, DB01223, DB01303, DB13812, DB03293, DB13592, DB13573, DB14132, DB13449, DB01778, DB09273, DB14018, DB00651, DB13634, DB18002, DB00824, DB12406, DB15122, DB07954, DB17930, DB00806, DB09092",
DB00202,Succinylcholine,approved,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,C14H30N2O4,,"Acids, Acyclic, Agents causing hyperkalemia, Amines, Ammonium Compounds, Central Nervous System Depressants, Choline Derivatives, Cholinesterase substrates, Dicarboxylic Acids, Ethanolamines, Muscle Relaxants, Muscle Relaxants, Peripherally Acting Agents, Musculo-Skeletal System, Neuromuscular Agents, Neuromuscular Blocking Agents, Neuromuscular Depolarizing Agents, Neuromuscular Depolarizing Blockade, Neurotoxic agents, Nitrogen Compounds, Onium Compounds, Peripheral Nervous System Agents, Quaternary Ammonium Compounds, Succinates, Trimethyl Ammonium Compounds"," Neuronal Acetylcholine (nACh) Receptor Subunits (Protein Group),  Muscarinic acetylcholine receptor M2,  Muscarinic acetylcholine receptor M3,  Cholinesterase",DB00202,
DB00203,Sildenafil,approved; investigational,CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1,C22H30N6O4S,,"Agents Causing Muscle Toxicity, Amides, Cardiovascular Agents, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (weak), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (weak), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs Used in Erectile Dysfunction, Enzyme Inhibitors, Genitourinary Agents, Heterocyclic Compounds, Fused-Ring, OATP1B1/SLCO1B1 Inhibitors, P-glycoprotein inhibitors, P-glycoprotein substrates, Phosphodiesterase 5 Inhibitors, Phosphodiesterase Inhibitors, Piperazines, Purines, Sulfonamides, Sulfones, Sulfur Compounds, Urological Agents, Urologicals, Vasodilating Agents"," cGMP-specific 3',5'-cyclic phosphodiesterase,  Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma,  Retinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma,  Ornithine decarboxylase,  Programmed cell death 1 ligand 1,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  Cytochrome P450 2C9,  Cytochrome P450 2C19,  Cytochrome P450 2D6,  Cytochrome P450 2E1,  Multidrug resistance-associated protein 4,  Multidrug resistance-associated protein 5,  Multidrug resistance-associated protein 7,  Solute carrier organic anion transporter family member 1B1,  P-glycoprotein 1","DB00203, DB11927, DB06267, DB11902, DB11792, DB08729, DB00862",
DB00204,Dofetilide,approved; investigational,CN(CCOC1=CC=C(NS(C)(=O)=O)C=C1)CCC1=CC=C(NS(C)(=O)=O)C=C1,C19H27N3O5S2,,"Amides, Amines, Antiarrhythmic agents, Antiarrhythmics, Class III, Cardiac Therapy, Cardiovascular Agents, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Substrates, Ethylamines, Highest Risk QTc-Prolonging Agents, Membrane Transport Modulators, Narrow Therapeutic Index Drugs, OCT2 Substrates, OCT2 Substrates with a Narrow Therapeutic Index, Potassium Channel Blockers, QTc Prolonging Agents, Sulfones, Sulfur Compounds"," Potassium voltage-gated channel subfamily H member 2,  Potassium channel subfamily K member 2,  ATP-sensitive inward rectifier potassium channel 12,  Cytochrome P450 3A4,  Solute carrier family 22 member 2",DB00204,
DB00205,Pyrimethamine,approved; investigational; vet_approved,CCC1=C(C(N)=NC(N)=N1)C1=CC=C(Cl)C=C1,C12H13ClN4,,"Anti-Infective Agents, Antibiotics for Pneumocystis Pneumonia, Antimalarial diaminopyrimidines, Antimalarials, Antiparasitic Agents, Antiparasitic Products, Insecticides and Repellents, Antiprotozoals, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (weak), Cytochrome P-450 Enzyme Inhibitors, Enzyme Inhibitors, Folic Acid Antagonists, MATE 1 Inhibitors, MATE 2 Inhibitors, MATE inhibitors, Pyrimidines"," Dihydrofolate reductase,  Bifunctional dihydrofolate reductase-thymidylate synthase,  Beta-hexosaminidase subunit beta,  Cytochrome P450 2C8,  Multidrug and toxin extrusion protein 1,  Multidrug and toxin extrusion protein 2","DB00205, DB07577, DB04655, DB07244",
DB00206,Reserpine,approved; investigational; withdrawn,[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2,C33H40N2O9,,"Adrenergic Agents, Adrenergic Uptake Inhibitors, Alkaloids, Antiadrenergic Agents, Centrally Acting, Antidepressive Agents, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Antipsychotic Agents, BSEP/ABCB11 Inhibitors, Cardiovascular Agents, Catecholamine-depleting Sympatholytic, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A5 Inducers, Cytochrome P-450 CYP3A5 Inducers (strength unknown), Cytochrome P-450 Enzyme Inducers, Decreased Sympathetic Activity, Drugs that are Mainly Renally Excreted, Gastrointestinal Acidifying Agents, Heterocyclic Compounds, Fused-Ring, Hypotensive Agents, Indole Alkaloids, Indoles, Indolizidines, Indolizines, Membrane Transport Modulators, Neurotoxic agents, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, OATP1B1/SLCO1B1 Inhibitors, OCT1 inhibitors, OCT2 Substrates, Organic Anion Transporting Polypeptide 2B1 Inhibitors, P-glycoprotein inducers, P-glycoprotein inhibitors, P-glycoprotein substrates, Psychotropic Drugs, Secologanin Tryptamine Alkaloids, Tranquilizing Agents"," Synaptic vesicular amine transporter,  Chromaffin granule amine transporter,  Baculoviral IAP repeat-containing protein 5,  Cytochrome P450 3A5,  P-glycoprotein 1,  Solute carrier family 22 member 1,  Bile salt export pump,  Canalicular multispecific organic anion transporter 1,  Solute carrier family 22 member 2,  Solute carrier organic anion transporter family member 1B1,  Solute carrier organic anion transporter family member 2B1","DB00206, DB01089, DB13631, DB13575, DB01180, DB11530, DB01392, DB15949, DB13374, DB00541, DB02868, DB17390, DB00570, DB12131, DB00309, DB01967, DB12586, DB05168, DB11641, DB12674, DB11467, DB00361, DB12755, DB00200, DB02191, DB11191, DB13793, DB04877, DB15096, DB03614",
DB00207,Azithromycin,approved,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,C38H72N2O12,,"Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs causing inadvertant photosensitivity, Experimental Unapproved Treatments for COVID-19, Lactones, Macrolide Antimicrobial, Macrolides, Macrolides, Lincosamides and Streptogramins, Moderate Risk QTc-Prolonging Agents, Ophthalmologicals, P-glycoprotein inhibitors, P-glycoprotein substrates, Photosensitizing Agents, Polyketides, QTc Prolonging Agents"," 23S ribosomal RNA,  Protein-arginine deiminase type-4,  Cytochrome P450 3A4,  P-glycoprotein 1,  Canalicular multispecific organic anion transporter 1","DB00207, DB11416, DB11474, DB00199, DB01211, DB11442, DB00954, DB13338, DB13179, DB11471, DB00778, DB11470, DB01321, DB13456, DB13409, DB13540",
DB00208,Ticlopidine,approved,ClC1=CC=CC=C1CN1CCC2=C(C1)C=CS2,C14H14ClNS,,"Antiplatelet agents, Blood and Blood Forming Organs, Cardiovascular Agents, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (moderate), Cytochrome P-450 CYP2B6 Inhibitors (strong), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (moderate), Cytochrome P-450 CYP2C19 Inhibitors (strong), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (weak), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (weak), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (weak), Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Decreased Platelet Aggregation, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Fibrin Modulating Agents, Hematologic Agents, Heterocyclic Compounds, Fused-Ring, Neurotransmitter Agents, Platelet Aggregation Inhibitors Excl. Heparin, Purinergic Agents, Purinergic Antagonists, Purinergic P2 Receptor Antagonists, Purinergic P2Y Receptor Antagonists, Pyridines, Sulfur Compounds, Thienopyridines, Thiophenes"," P2Y purinoceptor 12,  Cytochrome P450 2C19,  Cytochrome P450 2D6,  Myeloperoxidase,  Cytochrome P450 2C9,  Cytochrome P450 2C8,  Cytochrome P450 1A2,  Cytochrome P450 2B6,  Cytochrome P450 2E1","DB00208, DB00758",
DB00209,Trospium,approved,[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1)[N+]21CCCC1,C25H30NO3,,"Acids, Carbocyclic, Agents producing tachycardia, Alimentary Tract and Metabolism, Anticholinergic Agents, Autonomic Agents, Aza Compounds, Azabicyclo Compounds, Cholinergic Agents, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 Enzyme Inhibitors, Diphenylacetic Acids, Drugs for Functional Gastrointestinal Disorders, Drugs for Urinary Frequency and Incontinence, Genito Urinary System and Sex Hormones, Genitourinary Agents, Hydroxy Acids, Muscarinic Antagonists, Neurotransmitter Agents, Parasympatholytics, Peripheral Nervous System Agents, Phenylacetates, Tropanes, Urological Agents, Urologicals"," Muscarinic acetylcholine receptor M3,  Muscarinic acetylcholine receptor M1,  Cytochrome P450 2D6","DB00209, DB02161, DB11181, DB00725, DB00332, DB00424, DB00572, DB13833, DB11785, DB16896, DB00747, DB11315, DB13542, DB00462, DB09300, DB12086, DB12278, DB08978, DB16011, DB13369, DB09271, DB13507, DB13844, DB04843, DB00771, DB15968",
DB00210,Adapalene,approved,COC1=C(C=C(C=C1)C1=CC2=C(C=C1)C=C(C=C2)C(O)=O)C12CC3CC(CC(C3)C1)C2,C28H28O3,,"Anti-Acne Preparations, Anti-Acne Preparations for Topical Use, Anti-Inflammatory Agents, Dermatologicals, Misc. Skin and Mucous Membrane Agents, Naphthalenes, Retinoids, Retinoids for Topical Use in Acne"," Retinoic acid receptor beta,  Retinoic acid receptor gamma,  Retinoic acid receptor RXR-beta,  Retinoic acid receptor RXR-gamma,  Retinoic acid receptor RXR-alpha,  Transcription factor AP-1,  Toll-like receptor 2,  Retinoic acid receptor alpha,  Aspartate aminotransferase, cytoplasmic",DB00210,
DB00211,Midodrine,approved,COC1=CC(C(O)CNC(=O)CN)=C(OC)C=C1,C12H18N2O4,,"Adrenergic Agents, Adrenergic Agonists, Adrenergic alpha-1 Receptor Agonists, Adrenergic alpha-Agonists, Adrenergic and Dopaminergic Agents, Agents producing tachycardia, Agents that produce hypertension, Alcohols, Amines, Amino Alcohols, Autonomic Agents, Bradycardia-Causing Agents, Cardiac Stimulants Excl. Cardiac Glycosides, Cardiac Therapy, Cardiovascular Agents, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 Substrates, Ethanolamines, Neurotransmitter Agents, Peripheral Nervous System Agents, Sympathomimetics, Vasoconstrictor Agents"," Alpha-1A adrenergic receptor,  Alpha-1B adrenergic receptor,  Alpha-1D adrenergic receptor,  Cytochrome P450 2D6,  Solute carrier family 15 member 1",DB00211,
DB00212,Remikiren,experimental,CC(C)(C)S(=O)(=O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC1CCCCC1)[C@@H](O)[C@@H](O)C1CC1,C33H50N4O6S,,"Agents Acting on the Renin-Angiotensin System, Antihypertensive Agents, Cardiovascular Agents, Enzyme Inhibitors, Protease Inhibitors, Renin Inhibitors", Renin,"DB00212, DB03395, DB13742, DB06260, DB18634",
DB00213,Pantoprazole,approved,COC1=C(OC)C(CS(=O)C2=NC3=C(N2)C=C(OC(F)F)C=C3)=NC=C1,C16H15F2N3O4S,,"2-Pyridinylmethylsulfinylbenzimidazoles, Acid Reducers, Alimentary Tract and Metabolism, Anti-Ulcer Agents, BCRP/ABCG2 Inhibitors, BCRP/ABCG2 Substrates, Benzimidazoles, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (weak), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord), Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Gastric Acid Lowering Agents, Gastrointestinal Agents, Heterocyclic Compounds, Fused-Ring, OAT3/SLC22A8 Inhibitors, OATP1B1/SLCO1B1 Inhibitors, P-glycoprotein inhibitors, P-glycoprotein substrates, Proton Pump Inhibitors, Proton-pump Inhibitors, Pyridines, Sulfoxides, Sulfur Compounds"," Potassium-transporting ATPase alpha chain 1,  N(G),N(G)-dimethylarginine dimethylaminohydrolase 1,  Cytochrome P450 2C19,  Cytochrome P450 3A4,  P-glycoprotein 1,  ATP-binding cassette sub-family G member 2,  Solute carrier family 22 member 8","DB00213, DB00338, DB00736",
DB00214,Torasemide,approved,CC(C)NC(=O)NS(=O)(=O)C1=C(NC2=CC=CC(C)=C2)C=CN=C1,C16H20N4O3S,,"Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Cardiovascular Agents, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Diuretics, High-Ceiling Diuretics, Hyperglycemia-Associated Agents, Hypotensive Agents, Increased Diuresis at Loop of Henle, Membrane Transport Modulators, Natriuretic Agents, Non Potassium Sparing Diuretics, OATP1B1/SLCO1B1 Substrates, Ototoxic agents, Pyridines, Sodium Potassium Chloride Symporter Inhibitors, Sulfonamides, Sulfones, Sulfur Compounds"," Solute carrier family 12 member 2,  Solute carrier family 12 member 1,  Cytochrome P450 2C8,  Cytochrome P450 2C9,  Serum albumin,  Solute carrier organic anion transporter family member 1B1",DB00214,
DB00215,Citalopram,approved,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1,C20H21FN2O,,"Amines, Antidepressive Agents, Antidepressive Agents Indicated for Depression, Antidepressive Agents, Second-Generation, Benzofurans, Central Nervous System Agents, Central Nervous System Depressants, Combined Inhibitors of Serotonin/Norepinephrine Reuptake, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (weak), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (weak), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (weak), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Heterocyclic Compounds, Fused-Ring, Highest Risk QTc-Prolonging Agents, Hypoglycemia-Associated Agents, Monoamine Oxidase A Substrates, Nervous System, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, Nitriles, P-glycoprotein inhibitors, P-glycoprotein substrates, Propylamines, Psychoanaleptics, Psychotropic Drugs, QTc Prolonging Agents, Selective Serotonin Reuptake Inhibitors, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT2 Receptor Antagonists, Serotonin Agents, Serotonin Modulators, Serotonin Receptor Antagonists, Vasodilating Agents"," Sodium-dependent serotonin transporter,  Histamine H1 receptor,  Cytochrome P450 3A4,  Cytochrome P450 2C19,  Cytochrome P450 2D6,  Cytochrome P450 1A2,  Amine oxidase [flavin-containing] A,  Amine oxidase [flavin-containing] B,  Aldehyde oxidase,  P-glycoprotein 1","DB00215, DB01175, DB09190",
DB00216,Eletriptan,approved; investigational,CN1CCC[C@@H]1CC1=CNC2=C1C=C(CCS(=O)(=O)C1=CC=CC=C1)C=C2,C22H26N2O2S,,"Agents that produce hypertension, Amines, Analgesics, Antidepressive Agents, Antimigraine Preparations, Biogenic Amines, Biogenic Monoamines, Central Nervous System Depressants, Cytochrome P-450 CYP2A6 Inducers, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Substrates, Heterocyclic Compounds, Fused-Ring, Indoles, Nervous System, Neurotransmitter Agents, P-glycoprotein substrates, Selective Serotonin 5-HT1 Receptor Agonists, Selective Serotonin Agonists, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 1b Receptor Agonists, Serotonin 1d Receptor Agonists, Serotonin 5-HT1 Receptor Agonists, Serotonin Agents, Serotonin Modulators, Serotonin Receptor Agonists, Serotonin-1b and Serotonin-1d Receptor Agonist, Triptans"," 5-hydroxytryptamine receptor 1D,  5-hydroxytryptamine receptor 1B,  5-hydroxytryptamine receptor 1F,  5-hydroxytryptamine receptor 1A,  Cytochrome P450 2D6,  Cytochrome P450 2C9,  Cytochrome P450 2C19,  Cytochrome P450 2A6,  Prostaglandin G/H synthase 1,  Cytochrome P450 3A4,  P-glycoprotein 1",DB00216,
DB00217,Bethanidine,approved,CN\C(NCC1=CC=CC=C1)=N/C,C10H15N3,,"Adrenergic Agents, Adrenergic Agonists, Adrenergic alpha-2 Receptor Agonists, Adrenergic alpha-Agonists, Agents producing tachycardia, Agents that produce hypertension, Amidines, Antiadrenergic Agents, Peripherally Acting, Antihypertensive Agents, Autonomic Agents, Cardiovascular Agents, Guanidine Derivatives, Guanidines, Neurotransmitter Agents, Peripheral Nervous System Agents, Sympatholytics"," ATP-sensitive inward rectifier potassium channel 1,  Alpha-2 adrenergic receptors (Protein Group),  Beta adrenergic receptor (Protein Group)",DB00217,
DB00218,Moxifloxacin,approved; investigational,[H][C@]12CN(C[C@@]1([H])NCCC2)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1OC)C(O)=O,C21H24FN3O4,,"Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (moderate), Cytochrome P-450 Enzyme Inhibitors, Enzyme Inhibitors, Fluoroquinolone Antibacterial, Fluoroquinolones, Heterocyclic Compounds, Fused-Ring, Moderate Risk QTc-Prolonging Agents, Ophthalmologicals, QTc Prolonging Agents, Quinolines, Quinolone Antimicrobial, Quinolones, Sensory Organs, Topoisomerase II Inhibitors, Topoisomerase Inhibitors"," DNA gyrase subunit A,  DNA topoisomerase 4 subunit A,  DNA topoisomerase 2-alpha,  Serum paraoxonase/arylesterase 1,  Cytochrome P450 1A2","DB00218, DB01044, DB06600, DB11453, DB01137, DB01165, DB03034, DB11393, DB01208, DB11847, DB09047, DB11443, DB06771, DB13261, DB11404, DB00537, DB00365, DB00978, DB14025, DB12447, DB16219, DB00487, DB01059, DB04576, DB11892, DB11426, DB01405, DB11511, DB11491, DB11774",
DB00219,Oxyphenonium,approved,CC[N+](C)(CC)CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1,C21H34NO3,,"Agents producing tachycardia, Alimentary Tract and Metabolism, Amines, Anticholinergic Agents, Autonomic Agents, Cholinergic Agents, Drugs for Functional Gastrointestinal Disorders, Muscarinic Antagonists, Mydriatics, Neurotransmitter Agents, Onium Compounds, Parasympatholytics, Peripheral Nervous System Agents, Quaternary Ammonium Compounds, Synthetic Anticholinergics, Quaternary Ammonium Compounds", Muscarinic acetylcholine receptor M1,"DB00219, DB00986, DB00979, DB11504, DB13497, DB01062, DB00383, DB11186, DB16287, DB09023, DB13181",
DB00220,Nelfinavir,approved,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C,C32H45N3O4S,,"Anti-HIV Agents, Anti-Infective Agents, Anti-Retroviral Agents, Antiinfectives for Systemic Use, Antiviral Agents, Antivirals for Systemic Use, BCRP/ABCG2 Inhibitors, BSEP/ABCB11 Substrates, Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (strength unknown), Cytochrome P-450 CYP2C19 Inducers, Cytochrome P-450 CYP2C19 Inducers (strength unknown), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C9 Inducers, Cytochrome P-450 CYP2C9 Inducers (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strong), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Inhibitors, Cytochrome P-450 CYP3A5 Inhibitors (strong), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Inhibitors, Cytochrome P-450 CYP3A7 Inhibitors (strong), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Direct Acting Antivirals, Enzyme Inhibitors, Heterocyclic Compounds, Fused-Ring, HIV Protease Inhibitors, Hyperglycemia-Associated Agents, Isoquinolines, OATP1B1/SLCO1B1 Inhibitors, OATP1B3 inhibitors, OCT1 inhibitors, Organic Anion Transporting Polypeptide 2B1 Inhibitors, P-glycoprotein inducers, P-glycoprotein inhibitors, P-glycoprotein substrates, Potential QTc-Prolonging Agents, Protease Inhibitors, QTc Prolonging Agents, UGT1A1 Inducers, Viral Protease Inhibitors"," HIV-1 protease,  Cytochrome P450 3A4,  Cytochrome P450 3A7,  Cytochrome P450 3A5,  Cytochrome P450 2B6,  Cytochrome P450 2C19,  UDP-glucuronosyltransferase 1-1,  Cytochrome P450 2C9,  Cytochrome P450 2D6,  Serum albumin,  Alpha-1-acid glycoprotein 1,  P-glycoprotein 1,  Solute carrier family 22 member 1,  Solute carrier organic anion transporter family member 1A2,  ATP-binding cassette sub-family G member 2,  Solute carrier organic anion transporter family member 1B1,  Solute carrier organic anion transporter family member 1B3,  Solute carrier organic anion transporter family member 2B1,  Bile salt export pump",DB00220,
DB00221,Isoetharine,approved,CCC(NC(C)C)C(O)C1=CC(O)=C(O)C=C1,C13H21NO3,,"Adrenergic Agents, Adrenergic Agonists, Adrenergic beta-2 Receptor Agonists, Adrenergic beta-Agonists, Adrenergics for Systemic Use, Adrenergics, Inhalants, Agents producing tachycardia, Agents that produce hypertension, Alcohols, Amines, Amino Alcohols, Anti-Asthmatic Agents, Autonomic Agents, Bronchodilator Agents, Drugs for Obstructive Airway Diseases, Neurotransmitter Agents, Peripheral Nervous System Agents, Respiratory System Agents, Selective Beta 2-adrenergic Agonists"," Beta-1 adrenergic receptor,  Beta-2 adrenergic receptor","DB00221, DB01064, DB13559, DB01288, DB06707, DB01102, DB06814, DB00867, DB00668, DB06152, DB00816, DB11610, DB08957, DB00871, DB00610, DB08985",
DB00222,Glimepiride,approved,CCC1=C(C)CN(C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O,C24H34N4O5S,,"Alimentary Tract and Metabolism, Amides, Blood Glucose Lowering Agents, BSEP/ABCB11 Substrates, Cardiovascular Agents, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 Substrates, Drugs Used in Diabetes, Hypoglycemia-Associated Agents, Immunosuppressive Agents, Insulin Secretagogues, Oral Hypoglycemics, Sulfones, Sulfonylureas, Sulfur Compounds"," ATP-sensitive inward rectifier potassium channel 11,  ATP-sensitive inward rectifier potassium channel 1,  ATP-binding cassette sub-family C member 8,  Cytochrome P450 2C9,  Bile salt export pump",DB00222,
DB00223,Diflorasone,approved,[H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,C22H28F2O5,,"Adrenal Cortex Hormones, Anti-Inflammatory Agents, Corticosteroid Hormone Receptor Agonists, Corticosteroids, Corticosteroids, Dermatological Preparations, Corticosteroids, Potent (Group III), Dermatologicals, Fused-Ring Compounds, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Immunosuppressive Agents, Pregnadienes, Pregnadienetriols, Pregnanes, Steroids, Steroids, Fluorinated", Glucocorticoid receptor,"DB00223, DB00663, DB09095, DB12553, DB00596, DB01384, DB09378, DB00443, DB01234, DB11522, DB13491, DB00324, DB08971, DB13728, DB00620, DB08970, DB13223, DB00547, DB14664, DB11750, DB06781, DB13867, DB14637, DB14657, DB14640, DB14649, DB15777, DB15821, DB00687, DB14669",
DB00224,Indinavir,approved,CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12,C36H47N5O4,,"Agents Causing Muscle Toxicity, Anti-HIV Agents, Anti-Infective Agents, Anti-Retroviral Agents, Antiinfectives for Systemic Use, Antiviral Agents, Antivirals for Systemic Use, BSEP/ABCB11 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strong), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Inhibitors, Cytochrome P-450 CYP3A5 Inhibitors (weak), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Inhibitors, Cytochrome P-450 CYP3A7 Inhibitors (weak), Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Direct Acting Antivirals, Enzyme Inhibitors, HIV Protease Inhibitors, Hyperglycemia-Associated Agents, OATP1B1/SLCO1B1 Inhibitors, OCT1 inhibitors, Organic Anion Transporting Polypeptide 2B1 Inhibitors, P-glycoprotein inducers, P-glycoprotein inhibitors, P-glycoprotein substrates, Protease Inhibitors, Pyridines, UGT1A1 Inhibitors, Viral Protease Inhibitors"," Human immunodeficiency virus type 1 protease,  Cytochrome P450 2D6,  UDP-glucuronosyltransferase 1-1,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  P-glycoprotein 1,  Solute carrier family 22 member 1,  Multidrug resistance-associated protein 1,  Solute carrier organic anion transporter family member 1A2,  Solute carrier organic anion transporter family member 1B1,  Canalicular multispecific organic anion transporter 1,  Solute carrier organic anion transporter family member 2B1,  Bile salt export pump","DB00224, DB01721, DB02009, DB02704",
DB00225,Gadodiamide,approved; investigational,[Gd+3].CNC(=O)CN(CCN(CCN(CC([O-])=O)CC(=O)NC)CC([O-])=O)CC([O-])=O,C16H26GdN5O8,,"Acetates, Acids, Acyclic, Amines, Compounds used in a research, industrial, or household setting, Contrast Media, Coordination Complexes, Diagnostic Uses of Chemicals, Drugs that are Mainly Renally Excreted, Injections, Intravenous, Magnetic Resonance Contrast Activity, Magnetic Resonance Imaging Contrast Media, Miscellaneous Therapeutic Agents, Other Diagnostics, Paramagnetic Contrast Agent, Paramagnetic Contrast Media, Polyamines",,"DB00225, DB00538, DB04229, DB00789, DB14007, DB09425, DB00974, DB02810, DB13404, DB14600, DB14598, DB14599, DB09132",
DB00226,Guanadrel,approved,NC(N)=NCC1COC2(CCCCC2)O1,C10H19N3O2,,"Adrenergic Antagonists, Amidines, Antihypertensive Agents, Cardiovascular Agents", Sodium-dependent noradrenaline transporter,DB00226,
DB00227,Lovastatin,approved; investigational,[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC,C24H36O5,,"Agents Causing Muscle Toxicity, Anticholesteremic Agents, BSEP/ABCB11 Substrates, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Substrates, Drugs causing inadvertant photosensitivity, Enzyme Inhibitors, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hypolipidemic Agents, Hypolipidemic Agents Indicated for Hyperlipidemia, Lipid Modifying Agents, Lipid Regulating Agents, OATP1B1/SLCO1B1 Inhibitors, OATP1B1/SLCO1B1 Substrates, P-glycoprotein inhibitors, Photosensitizing Agents, UGT1A1 Substrates, UGT1A3 substrates, UGT2B7 substrates"," 3-hydroxy-3-methylglutaryl-coenzyme A reductase,  Integrin alpha-L,  Histone deacetylase 2,  Cytochrome P450 3A4,  Serum paraoxonase/lactonase 3,  Cytochrome P450 2C8,  UDP-glucuronosyltransferase 1-1,  UDP-glucuronosyltransferase 1-3,  UDP-glucuronosyltransferase 2B7,  Cytochrome P450 2C19,  Serum albumin,  P-glycoprotein 1,  Solute carrier organic anion transporter family member 1A2,  Solute carrier organic anion transporter family member 1B1,  Canalicular multispecific organic anion transporter 1,  Bile salt export pump,  Solute carrier organic anion transporter family member 2B1,  Solute carrier organic anion transporter family member 1B3","DB00227, DB00641, DB06693, DB14648, DB03785, DB14714, DB00175, DB08224",
DB00228,Enflurane,approved; investigational; vet_approved,FC(F)OC(F)(F)C(F)Cl,C3H2ClF5O,,"Agents that reduce seizure threshold, Anesthetics, Anesthetics, General, Anesthetics, Inhalation, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 Substrates, Ethers, Methyl Ethers, Nervous System"," GABA(A) Receptor (Protein Group),  Voltage-dependent calcium channel (Protein Group),  Glycine receptor subunit alpha-1,  Voltage-gated Potassium Channels (Protein Group),  Calcium-transporting ATPase type 2C member 1,  Glutamate (NMDA) receptor (Protein Group),  Sarcoplasmic/endoplasmic reticulum calcium ATPase 1,  Cytochrome P450 2E1,  Serum albumin",DB00228,
DB00229,Cefotiam,approved; investigational,[H][C@]12SCC(CSC3=NN=NN3CCN(C)C)=C(N1C(=O)[C@H]2NC(=O)CC1=CSC(N)=N1)C(O)=O,C18H23N9O4S3,,"Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, beta-Lactams, Cephalosporins, Heterocyclic Compounds, Fused-Ring, Lactams, Nephrotoxic agents, OAT1/SLC22A6 inhibitors, OAT1/SLC22A6 Substrates, OAT3/SLC22A8 Inhibitors, OAT3/SLC22A8 Substrates, Second-Generation Cephalosporins, Sulfur Compounds, Thiazines"," Penicillin-binding protein 1A,  Solute carrier family 22 member 6,  Solute carrier family 22 member 8","DB00229, DB00267, DB00923, DB01326, DB01212, DB01328, DB00535, DB14725, DB13504, DB13821, DB00671, DB01329, DB01327, DB00430, DB00274, DB13461, DB09062, DB01413, DB13470, DB01416, DB11485, DB13266, DB00493, DB01330, DB11505, DB01415, DB01066, DB00438, DB01332, DB13638",
DB00230,Pregabalin,approved; investigational,CC(C)C[C@H](CN)CC(O)=O,C8H17NO2,,"Acids, Acyclic, Agents causing angioedema, Amino Acids, Amino Acids, Peptides, and Proteins, Aminobutyrates, Analgesics, Anti-Anxiety Agents, Anticonvulsants, Bradycardia-Causing Agents, Butyrates, Central Nervous System Agents, Central Nervous System Depressants, Drugs that are Mainly Renally Excreted, Gabapentinoids, Hypoglycemia-Associated Agents, Membrane Transport Modulators, Miscellaneous Anticonvulsants, Muscle Relaxants, Muscle Relaxants, Centrally Acting Agents, Nervous System, Peripheral Nervous System Agents, Potential QTc-Prolonging Agents, Psychotropic Drugs, QTc Prolonging Agents, Sensory System Agents, Tranquilizing Agents, Vasodilating Agents"," Voltage-dependent calcium channel subunit alpha-2/delta-1,  Excitatory amino acid transporter 3,  Large neutral amino acids transporter small subunit 1","DB00230, DB15264, DB12032, DB00996, DB02878, DB02941",
DB00231,Temazepam,approved; investigational,CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1,C16H13ClN2O2,,"Anti-Anxiety Agents, Benzazepines, Benzodiazepine hypnotics and sedatives, Benzodiazepines and benzodiazepine derivatives, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, GABA Agents, GABA Modulators, Heterocyclic Compounds, Fused-Ring, Hypnotics and Sedatives, Muscle Relaxants, Muscle Relaxants, Centrally Acting Agents, Psychotropic Drugs, Tranquilizing Agents"," GABA(A) Receptor (Protein Group),  GABA(A) Receptor Benzodiazepine Binding Site (Protein Group),  Cytochrome P450 3A4,  Cytochrome P450 2B6,  Cytochrome P450 2C9","DB00231, DB00842, DB13872, DB00829, DB00186, DB13837, DB14671, DB13335, DB01489, DB01594, DB14672, DB14028, DB00801, DB01567, DB01588, DB01511, DB00690, DB00628, DB13437",
DB00232,Methyclothiazide,withdrawn,CN1C(CCl)NC2=CC(Cl)=C(C=C2S1(=O)=O)S(N)(=O)=O,C9H11Cl2N3O4S2,,"Benzothiadiazines, Diuretics, Drugs causing inadvertant photosensitivity, Heterocyclic Compounds, Fused-Ring, Hyperglycemia-Associated Agents, Hypotensive Agents, Increased Diuresis, Membrane Transport Modulators, Natriuretic Agents, Photosensitizing Agents, Sodium Chloride Symporter Inhibitors, Sulfonamides, Sulfones, Sulfur Compounds, Thiazides"," Solute carrier family 12 member 1,  Carbonic anhydrase 1,  Carbonic anhydrase 2,  Carbonic anhydrase 4","DB00232, DB01021, DB08645, DB01324, DB15861, DB13430, DB13532, DB13989, DB00999, DB00606",
DB00233,Aminosalicylic acid,approved,NC1=CC(O)=C(C=C1)C(O)=O,C7H7NO3,,"Acids, Carbocyclic, Aminobenzoates, Aminosalicylic Acid and Derivatives, Aminosalicylic Acids, Anti-Bacterial Agents, Anti-Infective Agents, Antiinfectives for Systemic Use, Antimycobacterials, Benzene Derivatives, Benzoates, Drugs for Treatment of Tuberculosis, Hydroxy Acids, Hydroxybenzoates, Methemoglobinemia Associated Agents, para-Aminobenzoates, Phenols, Salicylates"," Prostaglandin G/H synthase 2,  Inhibitor of nuclear factor kappa-B kinase subunit alpha,  Arachidonate 5-lipoxygenase,  Group IIE secretory phospholipase A2,  Myeloperoxidase","DB00233, DB00244, DB00936, DB02839, DB01397, DB02362, DB14006, DB01401",
DB00234,Reboxetine,approved; experimental,[H][C@@]1(CNCCO1)[C@H](OC1=CC=CC=C1OCC)C1=CC=CC=C1,C19H23NO3,,"Adrenergic Agents, Adrenergic Uptake Inhibitors, Antidepressive Agents, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Membrane Transport Modulators, Morpholines, Nervous System, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, Oxazines, P-glycoprotein inhibitors, Psychoanaleptics, Psychotropic Drugs"," Sodium-dependent noradrenaline transporter,  Cytochrome P450 3A4,  Cytochrome P450 2D6,  P-glycoprotein 1","DB00234, DB12395, DB09186",
DB00235,Milrinone,approved,CC1=C(C=C(C#N)C(=O)N1)C1=CC=NC=C1,C12H9N3O,,"Amines, Aminopyridines, Cardiac Stimulants Excl. Cardiac Glycosides, Cardiac Therapy, Cardiotonic Agents, Cardiovascular Agents, Compounds used in a research, industrial, or household setting, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Hematologic Agents, Phosphodiesterase 3 Inhibitors, Phosphodiesterase Inhibitors, Protective Agents, Pyridines, Vasodilating Agents"," cGMP-inhibited 3',5'-cyclic phosphodiesterase A",DB00235,
DB00236,Pipobroman,approved,BrCCC(=O)N1CCN(CC1)C(=O)CCBr,C10H16Br2N2O2,,"Alkylating Drugs, Antineoplastic Agents, Antineoplastic Agents, Alkylating, Antineoplastic and Immunomodulating Agents, Noxae, Piperazines, Toxic Actions", DNA,DB00236,
DB00237,Butabarbital,approved; illicit,CCC(C)C1(CC)C(=O)NC(=O)NC1=O,C10H16N2O3,,"Anticholinergic Agents, Anticonvulsants, Barbiturates, Central Nervous System Agents, Central Nervous System Depressants, Drugs that are Mainly Renally Excreted, Hypnotics and Sedatives, Nervous System, Nicotinic Antagonists, Psycholeptics, Pyrimidines, Pyrimidinones"," GABA(A) Receptor (Protein Group),  Neuronal Acetylcholine (nACh) Receptor Subunits (Protein Group),  Glutamate receptor 1,  Glutamate receptor 2,  Glutamate receptor 3,  Glutamate receptor 4,  Glutamate receptor ionotropic, kainate 1,  Glutamate receptor ionotropic, kainate 2,  Glutamate receptor ionotropic, kainate 3, 10. Glutamate receptor ionotropic, kainate 4, 11. Glutamate receptor ionotropic, kainate 5,  Serum albumin,  Solute carrier family 2, facilitated glucose transporter member 1","DB00237, DB00312, DB01353, DB00306, DB01351, DB01483, DB13770, DB00418, DB01352, DB00241, DB00463, DB13577",
DB00238,Nevirapine,approved,CC1=C2NC(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1,C15H14N4O,,"Anti-HIV Agents, Anti-Infective Agents, Anti-Retroviral Agents, Antiinfectives for Systemic Use, Antiviral Agents, Antivirals for Systemic Use, Antivirals used in combination for the treatment of HIV infections, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (weak), Cytochrome P-450 CYP2A6 Substrates, Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strong), Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C9 Inducers, Cytochrome P-450 CYP2C9 Inducers (strength unknown), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (weak), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Direct Acting Antivirals, Enzyme Inhibitors, Hepatotoxic Agents, Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor, Inducers of Drug Clearance, Non-Nucleoside Reverse Transcriptase Inhibitors, Nonnucleoside Reverse Transcriptase Inhibitors, Nucleic Acid Synthesis Inhibitors, OCT1 inhibitors, Pyridines, Reverse Transcriptase Inhibitors"," Reverse transcriptase/RNaseH,  Cytochrome P450 2D6,  Cytochrome P450 1A2,  Cytochrome P450 3A7,  Cytochrome P450 3A4,  Cytochrome P450 2B6,  Cytochrome P450 3A5,  Cytochrome P450 2C9,  Cytochrome P450 2A6,  Serum albumin,  Solute carrier family 22 member 1","DB00238, DB08665",
DB00239,Oxiconazole,approved,ClC1=CC(Cl)=C(CO\N=C(/CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1,C18H13Cl4N3O,,"Anti-Infective Agents, Antifungal Agents, Antifungals for Dermatological Use, Antifungals for Topical Use, Azole Antifungals, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Substrates, Dermatologicals, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Imidazole and Triazole Derivatives, Imidazole Derivatives"," Cytochrome P450 51,  Lanosterol synthase,  Nuclear receptor subfamily 1 group I member 2,  Cytochrome P450 3A4,  Cytochrome P450 2C19",DB00239,
DB00240,Alclometasone,approved,[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])[C@H](Cl)CC2=CC(=O)C=C[C@]12C,C22H29ClO5,,"Adrenal Cortex Hormones, Anti-Inflammatory Agents, Corticosteroid Hormone Receptor Agonists, Corticosteroids, Corticosteroids, Dermatological Preparations, Corticosteroids, Moderately Potent (Group II), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Dermatologicals, Fused-Ring Compounds, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Immunosuppressive Agents, Ophthalmologicals, Pregnadienes, Pregnadienetriols, Pregnanes, Sensory Organs, Steroids"," Glucocorticoid receptor,  Cytochrome P450 3A4,  Corticosteroid-binding globulin","DB00240, DB00764, DB00860, DB00959, DB14221, DB00838, DB00394, DB13208, DB00896, DB13856, DB15970, DB14652, DB14631",
DB00241,Butalbital,approved; illicit,CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O,C11H16N2O3,,"Anticholinergic Agents, Anticonvulsants, Barbiturates, Central Nervous System Depressants, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 Enzyme Inducers, Hypnotics and Sedatives, Methemoglobinemia Associated Agents, Nervous System, Nicotinic Antagonists, Psycholeptics, Pyrimidines, Pyrimidinones"," Gamma-aminobutyric acid receptor subunit alpha-2,  Gamma-aminobutyric acid receptor subunit alpha-3,  Gamma-aminobutyric acid receptor subunit alpha-4,  Gamma-aminobutyric acid receptor subunit alpha-5,  Gamma-aminobutyric acid receptor subunit alpha-6,  GABA(A) Receptor (Protein Group),  Gamma-aminobutyric acid receptor subunit alpha-1,  Neuronal acetylcholine receptor subunit alpha-4,  Neuronal acetylcholine receptor subunit alpha-7, 10. Glutamate receptor 2, 11. Glutamate receptor ionotropic, kainate 2","DB00241, DB00306, DB00418, DB13577, DB01352, DB01353, DB13253, DB00237, DB01351, DB13770, DB00312, DB01483",
DB00242,Cladribine,approved; investigational,NC1=C2N=CN([C@H]3C[C@H](O)[C@@H](CO)O3)C2=NC(Cl)=N1,C10H12ClN5O3,,"2-Chloroadenosine, Agents Causing Muscle Toxicity, Antimetabolites, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Substrates, Cardiotoxic antineoplastic agents, Deoxyadenosines, Deoxyribonucleosides, Heterocyclic Compounds, Fused-Ring, Immunologic Factors, Immunosuppressive Agents, Myelosuppressive Agents, Nucleic Acids, Nucleotides, and Nucleosides, Nucleosides, Purine Analogues, Purine Antimetabolite, Purine Nucleosides, Purines, Ribonucleosides, Selective Immunosuppressants"," Ribonucleoside-diphosphate reductase large subunit,  Ribonucleoside-diphosphate reductase subunit M2,  Ribonucleoside-diphosphate reductase subunit M2 B,  DNA,  DNA polymerase alpha catalytic subunit,  DNA polymerase epsilon catalytic subunit A,  DNA polymerase epsilon subunit 2,  DNA polymerase epsilon subunit 3,  DNA polymerase epsilon subunit 4, 10. Purine nucleoside phosphorylase,  Deoxycytidine kinase,  ATP-binding cassette sub-family G member 2,  Solute carrier family 28 member 3","DB00242, DB02103, DB00631, DB16075, DB17756, DB00194, DB00640, DB03528, DB07170, DB02947, DB04102, DB12156, DB03716, DB01073, DB04441, DB15653, DB06843, DB02916, DB03273, DB11933, DB02607, DB02282, DB02373, DB00131, DB03011, DB07052, DB04440, DB03735, DB01910, DB04853",
DB00243,Ranolazine,approved; investigational,COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC2=C(C)C=CC=C2C)CC1,C24H33N3O4,,"Acetamides, Antianginal Agents, BSEP/ABCB11 Substrates, Cardiac Therapy, Cardiovascular Agents, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (weak), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, MATE 1 Inhibitors, MATE 2 Inhibitors, MATE inhibitors, Membrane Transport Modulators, Miscellaneous Cardiac Drugs, Moderate Risk QTc-Prolonging Agents, OCT2 Inhibitors, P-glycoprotein inhibitors, P-glycoprotein substrates, Piperazines, QTc Prolonging Agents, Sodium Channel Blockers, Vasodilating Agents"," Sodium channel protein (Protein Group),  Inward rectifier potassium channel (Protein Group),  Voltage gated L-type calcium channel (Protein Group),  Alpha-1 adrenergic receptors (Protein Group),  Beta-1 adrenergic receptor,  Cytochrome P450 3A4,  Cytochrome P450 2D6,  Alpha-1-acid glycoprotein 1,  Bile salt export pump,  P-glycoprotein 1,  Multidrug and toxin extrusion protein 1,  Multidrug and toxin extrusion protein 2",DB00243,
DB00244,Mesalazine,approved,NC1=CC(C(O)=O)=C(O)C=C1,C7H7NO3,,"Agents causing hyperkalemia, Agents that produce hypertension, Aminosalicylate, Aminosalicylic Acids, Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Benzene Derivatives, Hydroxybenzoates, Intestinal Antiinflammatory Agents, Nephrotoxic agents, OATP1B1/SLCO1B1 Substrates, OATP1B3 substrates, OATP2B1/SLCO2B1 substrates, Phenols, Salicylates"," Prostaglandin G/H synthase 2,  Prostaglandin G/H synthase 1,  Arachidonate 5-lipoxygenase,  Peroxisome proliferator-activated receptor gamma,  Inhibitor of nuclear factor kappa-B kinase subunit alpha,  Inhibitor of nuclear factor kappa-B kinase subunit beta,  Nitric oxide synthase, inducible,  Arylamine N-acetyltransferase 1,  Solute carrier organic anion transporter family member 1B1,  Solute carrier organic anion transporter family member 1B3,  Solute carrier organic anion transporter family member 2B1","DB00244, DB00233, DB02054, DB00936, DB01250, DB01397, DB02839",
DB00245,Benzatropine,approved,[H][C@]12CC[C@]([H])(C[C@@]([H])(C1)OC(C1=CC=CC=C1)C1=CC=CC=C1)N2C,C21H25NO,,"Agents producing tachycardia, Alkaloids, Anti-Dyskinesia Agents, Anti-Parkinson Drugs, Anticholinergic Agents, Aza Compounds, Central Nervous System Agents, Cholinergic Agents, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 Substrates, Dopamine Agents, Dopamine Uptake Inhibitors, Drugs that are Mainly Renally Excreted, Ethers of Tropine or Tropine Derivatives, Histamine Antagonists, Histamine H1 Antagonists, Histamine Receptor Antagonists, Membrane Transport Modulators, Muscarinic Antagonists, Nervous System, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, Peripheral Nervous System Agents, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Tropanes"," Muscarinic acetylcholine receptor M1,  Sodium-dependent dopamine transporter,  Histamine H1 receptor,  Sodium-dependent serotonin transporter,  Sodium-dependent noradrenaline transporter,  Serum albumin","DB00245, DB13468, DB00283, DB01146, DB07494, DB13466",
DB00246,Ziprasidone,approved,ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1,C21H21ClN4OS,,"Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Agents that produce hypertension, Anticholinergic Agents, Antidepressive Agents, Antipsychotic Agents, Antipsychotic Agents (Second Generation [Atypical]), Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (moderate), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dopamine Agents, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Highest Risk QTc-Prolonging Agents, Histamine Antagonists, Histamine H1 Antagonists, Hyperglycemia-Associated Agents, Indole Derivatives, Muscarinic Antagonists, Nervous System, Neurotoxic agents, Neurotransmitter Agents, Psycholeptics, Psychotropic Drugs, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT1 Receptor Agonists, Serotonin 5-HT1 Receptor Antagonists, Serotonin 5-HT1D Receptor Antagonists, Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2A Receptor Antagonists, Serotonin 5-HT2C Receptor Antagonists, Serotonin Agents, Serotonin Receptor Agonists, Serotonin Receptor Antagonists, Sulfur Compounds, Tranquilizing Agents"," Dopamine D2 receptor,  5-hydroxytryptamine receptor 2A,  5-hydroxytryptamine receptor 1A,  5-hydroxytryptamine receptor 1D,  5-hydroxytryptamine receptor 2C,  Dopamine D1 receptor,  Dopamine D5 receptor,  Dopamine D3 receptor,  Dopamine D4 receptor, 10. 5-hydroxytryptamine receptor 1B, 11. 5-hydroxytryptamine receptor 1E, 12. 5-hydroxytryptamine receptor 6, 13. 5-hydroxytryptamine receptor 7, 14. Histamine H1 receptor, 15. Alpha-1A adrenergic receptor, 16. Alpha-1B adrenergic receptor, 17. Alpha-2A adrenergic receptor, 18. Alpha-2B adrenergic receptor, 19. Alpha-2C adrenergic receptor, 20. Muscarinic acetylcholine receptor M1, 21. Muscarinic acetylcholine receptor M2, 22. Muscarinic acetylcholine receptor M3, 23. Muscarinic acetylcholine receptor M4, 24. Muscarinic acetylcholine receptor M5, 25. 5-hydroxytryptamine 3 receptor (Protein Group), 26. 5-hydroxytryptamine receptor 5A,  Cytochrome P450 3A4,  Aldehyde oxidase,  Serum albumin,  Alpha-1-acid glycoprotein 1,  P-glycoprotein 1",DB00246,
DB00247,Methysergide,approved,[H][C@@]12CC3=CN(C)C4=C3C(=CC=C4)C1=C[C@H](CN2C)C(=O)NC(CC)CO,C21H27N3O2,,"Agents that produce hypertension, Alkaloids, Analgesics, Antidepressive Agents, Antimigraine Preparations, Cardiovascular Agents, Central Nervous System Depressants, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Substrates, Ergolines, Ergot Alkaloids and Derivatives, Heterocyclic Compounds, Fused-Ring, Lysergic Acid, Nervous System, Neurotransmitter Agents, Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2A Receptor Antagonists, Serotonin 5-HT2C Receptor Antagonists, Serotonin Agents, Serotonin Receptor Antagonists, Vasoconstrictor Agents"," 5-hydroxytryptamine receptor 2B,  5-hydroxytryptamine receptor 2C,  5-hydroxytryptamine receptor 2A,  5-hydroxytryptamine receptor 1A,  5-hydroxytryptamine receptor 7,  5-hydroxytryptamine receptor 1B,  5-hydroxytryptamine receptor 1F,  5-hydroxytryptamine receptor 1E,  Cytochrome P450 3A4","DB00247, DB00353, DB01253, DB04829, DB00589, DB00696",
DB00248,Cabergoline,approved,[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC,C26H37N5O2,,"Agents that produce hypertension, Alkaloids, Anti-Dyskinesia Agents, Anti-Parkinson Drugs, Antidepressive Agents, Antineoplastic Agents, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dopamine Agents, Dopamine Agonists, Ergolines, Ergot Alkaloids and Derivatives, Ergot-derivative Dopamine Receptor Agonists, Genito Urinary System and Sex Hormones, Heterocyclic Compounds, Fused-Ring, Narrow Therapeutic Index Drugs, Nervous System, Neurotransmitter Agents, P-glycoprotein substrates, P-glycoprotein substrates with a Narrow Therapeutic Index, Prolactine Inhibitors, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT1 Receptor Agonists, Serotonin 5-HT2 Receptor Agonists, Serotonin Agents, Serotonin Modulators, Serotonin Receptor Agonists"," Dopamine D2 receptor,  5-hydroxytryptamine receptor 2B,  Dopamine D3 receptor,  5-hydroxytryptamine receptor 2A,  Alpha-2B adrenergic receptor,  5-hydroxytryptamine receptor 1D,  Dopamine D4 receptor,  Alpha-2A adrenergic receptor,  5-hydroxytryptamine receptor 1A, 10. Alpha-2C adrenergic receptor, 11. Dopamine D5 receptor, 12. Dopamine D1 receptor, 13. 5-hydroxytryptamine receptor 1B, 14. 5-hydroxytryptamine receptor 2C, 15. 5-hydroxytryptamine receptor 7, 16. Alpha-1A adrenergic receptor, 17. Alpha-1B adrenergic receptor, 18. Alpha-1D adrenergic receptor, 19. Beta-1 adrenergic receptor, 20. Beta-2 adrenergic receptor, 21. D(1) dopamine receptor (Protein Group),  Cytochrome P450 3A4,  P-glycoprotein 1","DB00248, DB13399, DB13520, DB01186",
DB00249,Idoxuridine,approved; investigational,OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(I)C(=O)NC1=O,C9H11IN2O5,,"Anti-Infective Agents, Antiinfectives for Systemic Use, Antiviral Agents, Antivirals for Systemic Use, Deoxyribonucleosides, Deoxyuridine, Dermatologicals, Direct Acting Antivirals, Enzyme Inhibitors, Nucleic Acid Synthesis Inhibitors, Nucleic Acids, Nucleotides, and Nucleosides, Nucleoside Analog Antiviral, Nucleosides, Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors, Ophthalmologicals, Pyrimidine Nucleosides, Pyrimidines, Sensory Organs"," DNA,  Thymidine kinase","DB00249, DB02256, DB15427, DB06485, DB02324, DB03274, DB01265, DB04485, DB02745, DB00322, DB12028, DB13421, DB13030, DB03800, DB03448, DB03312, DB13776, DB01629, DB06683, DB14913, DB08432, DB01643, DB00432, DB03761, DB03413, DB03685, DB02714, DB02805, DB12947, DB12901",
DB00250,Dapsone,approved; investigational,NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1,C12H12N2O2S,,"Anti-Acne Preparations, Anti-Acne Preparations for Topical Use, Anti-Bacterial Agents, Anti-Infective Agents, Antibiotics for Pneumocystis Pneumonia, Antiinfectives for Systemic Use, Antimalarials, Antimycobacterials, Antiparasitic Agents, Antiprotozoals, Cytochrome P-450 CYP2C18 Substrates, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Inducers, Cytochrome P-450 CYP2C9 Inducers (strength unknown), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Substrates, Dermatologicals, Drugs causing inadvertant photosensitivity, Drugs for Treatment of Lepra, Enzyme Inhibitors, Folic Acid Antagonists, Leprostatic Agents, Methemoglobinemia Associated Agents, Miscellaneous Antimycobacterials, Miscellaneous Local Anti-infectives, Photosensitizing Agents, Sulfones, Sulfur Compounds"," Inactive dihydropteroate synthase 2,  Dihydropteroate synthase 1,  Myeloperoxidase,  Cytochrome P450 2C18,  Cytochrome P450 2C9,  Cytochrome P450 2E1,  Cytochrome P450 3A4,  Dimethylaniline monooxygenase [N-oxide-forming] 3,  Prostaglandin G/H synthase 1,  Prostaglandin G/H synthase 2,  Cytochrome P450 2C8, 10. Cytochrome P450 2C19, 11. Arylamine N-acetyltransferase 2, 12. Cytochrome P450 3A5, 13. Cytochrome P450 3A7",DB00250,
DB00251,Terconazole,approved,CC(C)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=NC=N3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1,C26H31Cl2N5O3,,"Anti-Infective Agents, Antifungal Agents, Antifungal Agents (Vaginal), Azole Antifungals, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Triazole Derivatives", Cytochrome P450 51,"DB00251, DB01167, DB01026, DB05667",
DB00252,Phenytoin,approved; vet_approved,O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1,C15H12N2O2,,"Agents Causing Muscle Toxicity, Anti-epileptic Agent, Anticonvulsants, Central Nervous System Agents, Central Nervous System Depressants, COMT Substrates, Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP1A2 Inducers (strength unknown), Cytochrome P-450 CYP2A6 Substrates, Cytochrome P-450 CYP2A6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strength unknown), Cytochrome P-450 CYP2B6 Inducers (strong), Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C18 Substrates, Cytochrome P-450 CYP2C18 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C19 Inducers, Cytochrome P-450 CYP2C19 Inducers (moderate), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 CYP2C8 Inducers (strong), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C9 Inducers, Cytochrome P-450 CYP2C9 Inducers (strength unknown), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inducers (strong), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strong), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Inducers, Cytochrome P-450 CYP3A5 Inducers (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A7 Inducers, Cytochrome P-450 CYP3A7 Inducers (weak), Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Decreased Central Nervous System Disorganized Electrical Activity, Enzyme Inducing Antiepileptic Drugs, Hydantoins, Hyperglycemia-Associated Agents, Imidazoles, Imidazolidines, Inducers of Drug Clearance, Membrane Transport Modulators, Methemoglobinemia Associated Agents, Narrow Therapeutic Index Drugs, Nervous System, P-glycoprotein substrates, P-glycoprotein substrates with a Narrow Therapeutic Index, Phenytoin and Prodrugs, Sodium Channel Blockers, Thyroxine-binding globulin substrates, UGT1A1 Inducers, UGT1A1 Substrates, UGT1A1 Substrates with a Narrow Therapeutic Index, UGT1A4 substrates, UGT1A6 Inhibitors, UGT1A6 substrate, UGT1A6 Substrates with a Narrow Therapeutic Index, UGT1A9 Inhibitors, UGT1A9 Substrates, UGT1A9 Substrates with a Narrow Therapeutic Index, Voltage-Gated Sodium Channel Blockers"," Sodium channel protein type 5 subunit alpha,  Sodium channel protein type 1 subunit alpha,  Potassium voltage-gated channel subfamily H member 2,  Voltage-dependent L-type calcium channel (Protein Group),  Sodium channel protein type 2 subunit alpha,  Sodium channel protein type 8 subunit alpha,  Nuclear receptor subfamily 1 group I member 2,  Sodium channel subunit beta-1,  Sodium channel protein type 3 subunit alpha, 10. GABA(A) Receptor (Protein Group),  Cytochrome P450 2C9,  Cytochrome P450 2C19,  Cytochrome P450 2C8,  Cytochrome P450 2B6,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  Cytochrome P450 11B1, mitochondrial,  UDP-glucuronosyltransferase 1-1, 10. UDP-glucuronosyltransferase 1-6, 11. UDP-glucuronosyltransferase 1-9, 12. Cytochrome P450 1A2, 13. Cytochrome P450 2A6, 14. Cytochrome P450 2D6, 15. Cytochrome P450 2E1, 16. Epoxide hydrolase 1, 17. UDP-glucuronosyltransferase 1-4, 18. Catechol O-methyltransferase, 19. NAD(P)H dehydrogenase [quinone] 1, 20. Cytochrome P450 2C18,  Serum albumin,  Thyroxine-binding globulin,  Solute carrier organic anion transporter family member 1C1,  P-glycoprotein 1,  Canalicular multispecific organic anion transporter 1","DB00252, DB00532, DB00754, DB13396, DB13276",
DB00253,Medrysone,approved,[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C,C22H32O3,,"Adrenal Cortex Hormones, Anti-Inflammatory Agents, Corticosteroid Hormone Receptor Agonists, Corticosteroids, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Inducers, Cytochrome P-450 CYP3A5 Inducers (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Substrates, Fused-Ring Compounds, Glucocorticoids, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hyperglycemia-Associated Agents, Immunosuppressive Agents, OAT3/SLC22A8 Substrates, Ophthalmologicals, P-glycoprotein substrates, Pregnanes, Pregnenes, Sensory Organs, Steroids, Thyroxine-binding globulin inhibitors"," Glucocorticoid receptor,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Corticosteroid-binding globulin,  Solute carrier organic anion transporter family member 1A2,  P-glycoprotein 1,  Solute carrier family 22 member 8","DB00253, DB04652, DB04630, DB00741, DB13710, DB13230, DB14570, DB00624, DB01471, DB01543, DB01564, DB05830, DB06710, DB07768, DB11429, DB12787, DB13169, DB13533, DB14093, DB18000, DB09091, DB14584, DB01481, DB01572, DB01485, DB01500, DB01540, DB00367, DB00717, DB09389",
DB00254,Doxycycline,approved; investigational; vet_approved,[H][C@@]12[C@@H](C)C3=CC=CC(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O,C22H24N2O8,,"Agents that produce neuromuscular block (indirect), Alimentary Tract and Metabolism, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives and Antiseptics for Local Oral Treatment, Antiinfectives for Systemic Use, Antiparasitic Agents, Antiprotozoals, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Drugs causing inadvertant photosensitivity, Drugs that are Mainly Renally Excreted, Naphthacenes, OAT1/SLC22A6 inhibitors, Photosensitizing Agents, Stomatological Preparations, Tetracyclines"," Cytochrome P450 3A4,  Serum albumin,  Solute carrier family 22 member 6,  ATP-binding cassette sub-family B member 5","DB00254, DB00595, DB00759, DB00931, DB09550, DB09093, DB00256, DB01301, DB13092, DB00618, DB01017, DB00453, DB12035, DB00560, DB12455, DB12329, DB15040, DB11647, DB13264, DB11691",
DB00255,Diethylstilbestrol,approved; investigational; withdrawn,CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1,C18H20O2,,"Adrenal Cortex Hormones, Antineoplastic Agents, Hormonal, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Inhibitors, Benzene Derivatives, Benzylidene Compounds, BSEP/ABCB11 Substrates, Carcinogens, COMT Substrates, Contraceptive Agents, Female, Contraceptive Agents, Male, Contraceptives, Postcoital, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strong), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Endocrine Therapy, Estrogen Contraceptives, Estrogens, Estrogens, Non-Steroidal, Genito Urinary System and Sex Hormones, Hormonal Contraceptives for Systemic Use, Hormones, Hormones and Related Agents, Hormones, Hormone Substitutes, and Hormone Antagonists, Noxae, OATP1B1/SLCO1B1 Inhibitors, OATP2B1/SLCO2B1 substrates, P-glycoprotein substrates, Sex Hormones and Modulators of the Genital System, Stilbenes, Stilbestrols, Synthetic Estrogens, Plain, Thyroxine-binding globulin inducers, Toxic Actions"," Estrogen receptor beta,  Estrogen receptor alpha,  Estrogen-related receptor gamma,  Steroid hormone receptor ERR1,  Steroid hormone receptor ERR2,  Nuclear receptor coactivator 2,  Nuclear receptor subfamily 1 group I member 2,  Androgen receptor,  Sex hormone-binding globulin,  Cytochrome P450 3A4,  Cytochrome P450 2C8,  Cytochrome P450 2C9,  Cytochrome P450 2E1,  Catechol O-methyltransferase,  Cytochrome P450 19A1,  Transthyretin,  ATP-binding cassette sub-family G member 2,  P-glycoprotein 1,  Solute carrier organic anion transporter family member 1B1,  Solute carrier organic anion transporter family member 2B1,  Bile salt export pump",DB00255,
DB00256,Lymecycline,approved; investigational,[H][C@@]12C[C@@]3([H])C(C(=O)C4=C(O)C=CC=C4[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(=O)NCNCCCC[C@H](N)C(O)=O)=C(O)[C@H]2N(C)C,C29H38N4O10,,"Agents that produce neuromuscular block (indirect), Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Naphthacenes, Tetracyclines", 30S ribosomal protein S4,"DB00256, DB01301, DB00759, DB09550, DB00595, DB09093, DB00453, DB00254, DB00618, DB00931, DB13092, DB01017, DB12035, DB13264, DB12455, DB00560, DB15040, DB12329, DB11647, DB05168, DB00361, DB11691, DB03469, DB11191, DB03614, DB00200, DB11467, DB12674, DB11641",
DB00257,Clotrimazole,approved; vet_approved,ClC1=CC=CC=C1C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1,C22H17ClN2,,"Anti-Infective Agents, Anti-Infective Agents, Local, Antifungal Agents, Antifungal Agents (Vaginal), Antifungals for Dermatological Use, Antifungals for Topical Use, Antiinfectives and Antiseptics for Local Oral Treatment, Azole Antifungals, BSEP/ABCB11 Inhibitors, BSEP/ABCB11 Substrates, Cytochrome P-450 CYP2A6 Inhibitors, Cytochrome P-450 CYP2A6 Inhibitors (strong), Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strength unknown), Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (strong), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (moderate), Cytochrome P-450 CYP2C8 Inhibitors (strong), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (moderate), Cytochrome P-450 CYP2C9 Inhibitors (strong), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (moderate), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inducers (strong), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A7 Inducers, Cytochrome P-450 CYP3A7 Inducers (strong), Cytochrome P-450 CYP3A7 Inducers (weak), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dermatologicals, Enzyme Inhibitors, Gynecological Antiinfectives and Antiseptics, Hormone Antagonists, Hormones, Hormone Substitutes, and Hormone Antagonists, Imidazole and Triazole Derivatives, Imidazole Derivatives, Imidazoles, OATP1B1/SLCO1B1 Inhibitors, OATP1B1/SLCO1B1 Substrates, OATP1B3 inducers, P-glycoprotein inducers, P-glycoprotein inhibitors, P-glycoprotein substrates, Steroid Synthesis Inhibitors, Stomatological Preparations"," Cytochrome P450 51,  Intermediate conductance calcium-activated potassium channel protein 4,  Ergosterol,  Nuclear receptor subfamily 1 group I member 2,  Hydroxycarboxylic acid receptor 2,  Cytochrome P450 2C8,  Cytochrome P450 3A4,  Cytochrome P450 2B6,  Cytochrome P450 2D6,  Cytochrome P450 2A6,  Cytochrome P450 2C9,  Cytochrome P450 2E1,  Cytochrome P450 3A7,  P-glycoprotein 1,  Bile salt export pump,  Solute carrier organic anion transporter family member 1B1,  Solute carrier organic anion transporter family member 1B3",DB00257,
DB00258,Calcium acetate,approved; investigational,[Ca++].CC([O-])=O.CC([O-])=O,C4H6CaO4,,"Acids, Acyclic, Alimentary Tract and Metabolism, Arylsulfonates, Arylsulfonic Acids, Benzene Derivatives, Calcium Salts, Chelating Agents, Compounds used in a research, industrial, or household setting, Drugs for Treatment of Hyperkalemia and Hyperphosphatemia, Fatty Acids, Fatty Acids, Volatile, Lipids, Minerals, Phosphate Binder, Phosphate-removing Agents, Sequestering Agents, Sulfonic Acids, Sulfur Acids, Sulfur Compounds", Phosphate,"DB00258, DB03166, DB14511, DB15111, DB09395, DB09409, DB13996, DB14487, DB14498, DB14518",
DB00259,Sulfanilamide,approved,NC1=CC=C(C=C1)S(N)(=O)=O,C6H8N2O2S,,"Amides, Amines, Aniline Compounds, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Benzene Derivatives, Benzenesulfonamides, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 Enzyme Inhibitors, Dermatologicals, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Methemoglobinemia Associated Agents, Short-Acting Antibacterial Sulfonamides, Sulfanilamides, Sulfonamide Antibacterial, Sulfonamides, Sulfonamides and trimethoprim, Sulfones, Sulfur Compounds", Dihydropteroate synthase,"DB00259, DB04203",
DB00260,Cycloserine,approved,N[C@@H]1CONC1=O,C3H6N2O2,,"Amino Acids, Amino Acids, Neutral, Amino Acids, Peptides, and Proteins, Anti-Bacterial Agents, Anti-Infective Agents, Anti-Infective Agents, Urinary, Antibiotics, Antitubercular, Antiinfectives for Systemic Use, Antimetabolites, Antimycobacterials, Drugs for Treatment of Tuberculosis, Isoxazoles, Neurotoxic agents, Noxae, Oxazoles, Oxazolidinones, Toxic Actions"," D-alanine--D-alanine ligase A,  Alanine racemase,  Aromatic-L-amino-acid decarboxylase,  Proton-coupled amino acid transporter 2","DB00260, DB17627",
DB00261,Anagrelide,approved,ClC1=CC=C2N=C3NC(=O)CN3CC2=C1Cl,C10H7Cl2N3O,,"Agents producing tachycardia, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Antiplatelet agents, Cardiovascular Agents, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (weak), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Decreased Platelet Production, Hematologic Agents, Heterocyclic Compounds, Fused-Ring, Highest Risk QTc-Prolonging Agents, Narrow Therapeutic Index Drugs, Phosphodiesterase 3 Inhibitors, Phosphodiesterase Inhibitors, Platelet-reducing Agents, QTc Prolonging Agents, Thrombocytosis"," cGMP-inhibited 3',5'-cyclic phosphodiesterase A,  Cytochrome P450 1A2",DB00261,
DB00262,Carmustine,approved; investigational,ClCCNC(=O)N(CCCl)N=O,C5H9Cl2N3O2,,"Alkylating Activity, Alkylating Drugs, Amides, Antineoplastic Agents, Antineoplastic Agents, Alkylating, Antineoplastic and Immunomodulating Agents, Cardiotoxic antineoplastic agents, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Immunosuppressive Agents, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, Nitroso Compounds, Nitrosourea Compounds, Nitrosoureas, Noxae, Toxic Actions"," RNA,  Glutathione reductase, mitochondrial,  DNA",DB00262,
DB00263,Sulfisoxazole,approved; vet_approved,CC1=NOC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1C,C11H13N3O3S,,"Amides, Amines, Aniline Compounds, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Benzene Derivatives, Benzenesulfonamides, Blood Glucose Lowering Agents, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Drugs causing inadvertant photosensitivity, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Hypoglycemia-Associated Agents, Moderate Risk QTc-Prolonging Agents, Ophthalmologicals, Photosensitizing Agents, QTc Prolonging Agents, Sensory Organs, Short-Acting Antibacterial Sulfonamides, Sulfanilamides, Sulfonamide Antibacterial, Sulfonamides, Sulfonamides and trimethoprim, Sulfones, Sulfur Compounds"," Dihydropteroate synthase,  Cytochrome P450 2C9","DB00263, DB14033",
DB00264,Metoprolol,approved; investigational,COCCC1=CC=C(OCC(O)CNC(C)C)C=C1,C15H25NO3,,"Adrenergic Agents, Adrenergic Antagonists, Adrenergic beta-1 Receptor Antagonists, Adrenergic beta-Antagonists, Agents causing hyperkalemia, Alcohols, Amines, Amino Alcohols, Antiarrhythmic agents, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Beta blocking agents and calcium channel blockers, Beta Blocking Agents and Thiazides, Beta Blocking Agents, Selective, Beta Blocking Agents, Selective, and Thiazides, Beta-Blockers (Beta1 Selective), Bradycardia-Causing Agents, Cardiovascular Agents, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs causing inadvertant photosensitivity, Drugs that are Mainly Renally Excreted, Hypotensive Agents, OCT2 Inhibitors, Photosensitizing Agents, Propanolamines"," Beta-1 adrenergic receptor,  Beta-2 adrenergic receptor,  Beta adrenergic receptor (Protein Group),  Cytochrome P450 3A4,  Cytochrome P450 2D6,  Serum albumin,  Solute carrier family 22 member 2","DB00264, DB00195, DB09351, DB00335, DB06987, DB13443, DB00187, DB00612, DB13777, DB00866",
DB00265,Crotamiton,approved,CCN(C(=O)C=CC)C1=CC=CC=C1C,C13H17NO,,"Agrochemicals, Amines, Aniline Compounds, Antipruritics, Benzene Derivatives, Compounds used in a research, industrial, or household setting, Pesticides, Scabicides and Pediculicides, Toxic Actions",,DB00265,
DB00266,Dicoumarol,approved,OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2,C19H12O6,,"4-Hydroxycoumarins, Anticoagulants, Benzopyrans, Blood and Blood Forming Organs, Coumarins, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Substrates, Enzyme Inhibitors, Fibrinolytic Agents, Hematologic Agents, Heterocyclic Compounds, Fused-Ring, Narrow Therapeutic Index Drugs, Pyrans, Uncoupling Agents, Vitamin K Antagonists"," Vitamin K epoxide reductase complex subunit 1,  NAD(P)H dehydrogenase [quinone] 1,  Quinone oxidoreductase,  Cytochrome P450 2C9,  Cytochrome P450 2C6,  Cytochrome P450 2C11,  Serum albumin","DB00266, DB00946, DB08663, DB08662, DB08735, DB08736, DB08794, DB00682, DB08496, DB14055, DB12823",
DB00267,Cefmenoxime,approved,[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O,C16H17N9O5S3,,"Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, beta-Lactams, Cephalosporins, Heterocyclic Compounds, Fused-Ring, Lactams, Nephrotoxic agents, Ophthalmologicals, Otologicals, Sensory Organs, Sulfur Compounds, Thiazines, Third-Generation Cephalosporins"," Peptidoglycan synthase FtsI,  Penicillin-binding protein 1A","DB00267, DB01212, DB13504, DB00229, DB00535, DB00671, DB01413, DB01416, DB00493, DB11505, DB13470, DB01332, DB11485, DB00438, DB01066, DB14879, DB01326, DB13682, DB01328, DB00430, DB00274, DB14725, DB01329, DB09062, DB00923, DB01330, DB13461, DB13638, DB01327, DB04918",
DB00268,Ropinirole,approved; investigational,CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1,C16H24N2O,,"Anti-Dyskinesia Agents, Anti-Parkinson Agents (Dopamine Agonist), Anti-Parkinson Drugs, Central Nervous System Agents, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 Substrates, Dopamine Agents, Dopamine Agonists, Heterocyclic Compounds, Fused-Ring, Hypotensive Agents, Nervous System, Neurotransmitter Agents, Nonergot-derivative Dopamine Receptor Agonists"," Dopamine D3 receptor,  Dopamine D2 receptor,  Dopamine D4 receptor,  Alpha adrenergic receptor (Protein Group),  Cytochrome P450 1A2",DB00268,
DB00269,Chlorotrianisene,investigational; withdrawn,COC1=CC=C(C=C1)C(Cl)=C(C1=CC=C(OC)C=C1)C1=CC=C(OC)C=C1,C23H21ClO3,,"Antineoplastic Agents, Antineoplastic Agents, Hormonal, Benzene Derivatives, Benzylidene Compounds, Estrogens, Estrogens, Non-Steroidal, Genito Urinary System and Sex Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Natural and Semisynthetic Estrogens, Plain, Sex Hormones and Modulators of the Genital System, Stilbenes"," Estrogen receptor alpha,  Cytochrome P450 19A1","DB00269, DB00882, DB06735",
DB00270,Isradipine,approved; investigational,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OC(C)C,C19H21N3O5,,"Agents causing hyperkalemia, Antiarrhythmic agents, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Bradycardia-Causing Agents, BSEP/ABCB11 Substrates, Calcium Channel Blockers, Calcium Channel Blockers (Dihydropyridine), Calcium-Regulating Hormones and Agents, Cardiovascular Agents, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (moderate), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dihydropyridine Derivatives, Dihydropyridines, Drugs that are Mainly Renally Excreted, Hypotensive Agents, Membrane Transport Modulators, P-glycoprotein inhibitors, Potential QTc-Prolonging Agents, Pyridines, QTc Prolonging Agents, Selective Calcium Channel Blockers With Mainly Vascular Effects, Vasodilating Agents"," Voltage-dependent L-type calcium channel subunit alpha-1C,  Voltage-dependent calcium channel subunit alpha-2/delta-1,  Voltage-dependent L-type calcium channel subunit beta-2,  Voltage-dependent T-type calcium channel subunit alpha-1H,  Voltage-dependent calcium channel subunit alpha-2/delta-2,  Voltage-dependent L-type calcium channel subunit alpha-1D,  Voltage-dependent L-type calcium channel subunit alpha-1S,  Cytochrome P450 3A4,  Bile salt export pump","DB00270, DB09234, DB01023, DB01054, DB00401, DB00393, DB09236",
DB00271,Diatrizoate,approved; vet_approved,CC(=O)NC1=C(I)C(C(O)=O)=C(I)C(NC(C)=O)=C1I,C11H9I3N2O4,,"Acids, Carbocyclic, Alcohols, Amino Sugars, Benzene Derivatives, Benzoates, Carbohydrates, Compounds used in a research, industrial, or household setting, Contrast Media, Diagnostic Uses of Chemicals, Drugs that are Mainly Renally Excreted, Hexosamines, Iodinated Contrast Agents, Iodobenzoates, Radiographic Contrast Agent, Roentgenography, Sugar Alcohols, Triiodobenzoic Acids, Watersoluble, Nephrotropic, High Osmolar X-Ray Contrast Media, X-Ray Contrast Activity, X-Ray Contrast Media, Iodinated",,"DB00271, DB09346, DB09347, DB13741, DB04711, DB08945, DB13539",
DB00272,Betazole,approved,NCCC1=CC=NN1,C5H9N3,,"Diagnostic Agents, Gastrointestinal Agents, Histamine Agents, Histamine Agonists, Neurotransmitter Agents, Pyrazoles, Tests for Gastric Secretion", Histamine H2 receptor,DB00272,
DB00273,Topiramate,approved,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,C12H21NO8S,,"Alimentary Tract and Metabolism, Anti-Obesity Agents, Anticonvulsants, Antiobesity Preparations, Excl. Diet Products, Carbohydrates, Central Nervous System Agents, Central Nervous System Depressants, Centrally Acting Antiobesity Products, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (strength unknown), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Inducers (weak), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Decreased Central Nervous System Disorganized Electrical Activity, Drugs that are Mainly Renally Excreted, Enzyme Inducing Antiepileptic Drugs, Hexoses, Ketoses, Miscellaneous Anticonvulsants, Monosaccharides, Nervous System, Neuroprotective Agents, P-glycoprotein substrates"," Gamma-aminobutyric acid receptor subunit alpha-1,  Voltage-gated sodium channel alpha subunit (Protein Group),  Kainate receptors (Protein Group),  Carbonic anhydrase 2,  Carbonic anhydrase 4,  Voltage gated L-type calcium channel (Protein Group),  Carbonic anhydrase 1,  Carbonic anhydrase 3,  Voltage-dependent R-type calcium channel (Protein Group),  Cytochrome P450 3A4,  Cytochrome P450 2C19,  Serum albumin,  P-glycoprotein 1,  5'-AMP-activated protein kinase (Protein Group)","DB00273, DB02894",
DB00274,Cefmetazole,approved; investigational,[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)CSCC#N)OC)C(O)=O,C15H17N7O5S3,,"Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, beta-Lactams, Cephalosporins, Cephamycins, Heterocyclic Compounds, Fused-Ring, Lactams, Nephrotoxic agents, Second-Generation Cephalosporins, Sulfur Compounds, Thiazines"," Penicillin binding protein 2a,  Penicillin-binding protein 1A,  Penicillin-binding protein 1B,  Peptidoglycan synthase FtsI,  D-alanyl-D-alanine carboxypeptidase DacA,  D-alanyl-D-alanine carboxypeptidase DacC,  Serum albumin,  Solute carrier family 15 member 1,  Solute carrier family 15 member 2","DB00274, DB09062, DB01330, DB13638, DB01326, DB14725, DB00923, DB01329, DB00229, DB00267, DB01328, DB00430, DB13821, DB01327, DB01331, DB01212, DB13266, DB13778, DB13470, DB00671, DB11935, DB00535, DB13504, DB01416, DB11485, DB00493, DB11505, DB05735, DB14879, DB00567",
DB00275,Olmesartan,approved; investigational,CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O,C24H26N6O3,,"Agents Acting on the Renin-Angiotensin System, Agents causing hyperkalemia, Angiotensin 2 Receptor Blocker, Angiotensin II Antagonists and Calcium Channel Blockers, Angiotensin II receptor antagonists, Angiotensin II receptor blockers (ARBs) and calcium channel blockers, Angiotensin II receptor blockers (ARBs) and diuretics, Angiotensin II receptor blockers (ARBs), plain, Angiotensin Receptor Antagonists, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, BSEP/ABCB11 Inhibitors, Cardiovascular Agents, Hypotensive Agents, Imidazoles, OATP1B1/SLCO1B1 Substrates, OATP1B3 substrates, Tetrazoles"," Type-1 angiotensin II receptor,  Canalicular multispecific organic anion transporter 1,  Solute carrier organic anion transporter family member 1B3,  Solute carrier organic anion transporter family member 1B1,  Bile salt export pump",DB00275,
DB00276,Amsacrine,approved; investigational,COC1=C(NC2=C3C=CC=CC3=NC3=CC=CC=C23)C=CC(NS(C)(=O)=O)=C1,C21H19N3O3S,,"Acridines, Aminoacridines, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Cardiotoxic antineoplastic agents, Compounds used in a research, industrial, or household setting, Heterocyclic Compounds, Fused-Ring, Immunosuppressive Agents, Indicators and Reagents, Intercalating Agents, Laboratory Chemicals, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, P-glycoprotein inhibitors"," DNA,  DNA topoisomerase 2-alpha,  Potassium voltage-gated channel subfamily H member 2,  Alpha-1-acid glycoprotein 1,  Serum albumin,  P-glycoprotein 1",DB00276,
DB00277,Theophylline,approved,CN1C2=C(NC=N2)C(=O)N(C)C1=O,C7H8N4O2,,"Agents that reduce seizure threshold, Alkaloids, Anti-Asthmatic Agents, Autonomic Agents, Bronchodilator Agents, Cardiovascular Agents, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Substrates, Drugs for Obstructive Airway Diseases, Enzyme Inhibitors, Heterocyclic Compounds, Fused-Ring, Narrow Therapeutic Index Drugs, Neurotransmitter Agents, Peripheral Nervous System Agents, Phosphodiesterase 5 Inhibitors, Phosphodiesterase Inhibitors, Purinergic Agents, Purinergic Antagonists, Purinergic P1 Receptor Antagonists, Purines, Purinones, Respiratory Smooth Muscle Relaxants, Respiratory System Agents, Vasodilating Agents, Xanthine derivatives, Xanthines and Adrenergics"," Adenosine receptor A1,  Adenosine receptor A2a,  Adenosine receptor A2b,  cAMP-specific 3',5'-cyclic phosphodiesterase 4B,  cGMP-specific 3',5'-cyclic phosphodiesterase,  cAMP-specific 3',5'-cyclic phosphodiesterase 4A,  cGMP-inhibited 3',5'-cyclic phosphodiesterase A,  Histone deacetylase 2,  Copine-1, 10. Minor histocompatibility antigen H13, 11. Nodal modulator 1, 12. Poly [ADP-ribose] polymerase 1, 13. Protein RIC-3, 14. Tubulin monoglycylase TTLL3,  Cytochrome P450 1A1,  Cytochrome P450 1B1,  Cytochrome P450 2D6,  Cytochrome P450 1A2,  Adenosine deaminase,  Cytochrome P450 2E1,  Cytochrome P450 3A4,  Solute carrier family 22 member 7","DB00277, DB01223, DB01303, DB13812, DB00201, DB01412, DB03293, DB14132, DB01778, DB14018, DB00824, DB07954, DB13592, DB13573, DB13449, DB02134, DB09273, DB08844",
DB00278,Argatroban,approved; investigational,C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)C1=CC=CC2=C1NCC(C)C2,C23H36N6O5S,,"Amides, Amino Acids, Amino Acids, Basic, Amino Acids, Diamino, Amino Acids, Essential, Amino Acids, Peptides, and Proteins, Anticoagulants, Antithrombins, Blood and Blood Forming Organs, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Substrates, Enzyme Inhibitors, Hematologic Agents, Narrow Therapeutic Index Drugs, Piperidines, Protease Inhibitors, Serine Protease Inhibitors, Sulfones, Sulfur Compounds, Thrombin Inhibitors"," Prothrombin,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Serum albumin,  alpha1-acid glycoprotein (Protein Group)",DB00278,
DB00279,Liothyronine,approved; vet_approved,N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C=C2)C(I)=C1)C(O)=O,C15H12I3NO4,,"Agents used to treat hypothyroidism, Drugs that are Mainly Renally Excreted, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, l-Triiodothyronine, OAT3/SLC22A8 Inhibitors, OATP1B1/SLCO1B1 Substrates, OATP1B3 substrates, P-glycoprotein inducers, Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins, Thyroid Products, Thyronines, Thyroxine-binding globulin substrates, Triiodothyronine, UGT1A1 Substrates"," Thyroid hormone receptor alpha,  Thyroid hormone receptor beta,  Proliferating cell nuclear antigen,  UDP-glucuronosyltransferase 1-1,  Transthyretin,  Thyroxine-binding globulin,  Serum albumin,  Solute carrier organic anion transporter family member 1A2,  Solute carrier organic anion transporter family member 1B1,  Solute carrier organic anion transporter family member 1B3,  Solute carrier organic anion transporter family member 4C1,  Sodium/bile acid cotransporter,  Solute carrier organic anion transporter family member 1C1,  Solute carrier organic anion transporter family member 4A1,  Solute carrier family 22 member 8,  Monocarboxylate transporter 10, 10. P-glycoprotein 1, 11. Large neutral amino acids transporter small subunit 1","DB00279, DB00451, DB00509, DB12425, DB01583, DB12629, DB03374, DB01758",
DB00280,Disopyramide,approved,CC(C)N(CCC(C(N)=O)(C1=CC=CC=C1)C1=NC=CC=C1)C(C)C,C21H29N3O,,"Agents producing tachycardia, Antiarrhythmic agents, Antiarrhythmics, Class I, Antiarrhythmics, Class Ia, Anticholinergic Agents, Blood Glucose Lowering Agents, Cardiac Therapy, Cardiovascular Agents, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Highest Risk QTc-Prolonging Agents, Hypoglycemia-Associated Agents, Membrane Transport Modulators, Muscarinic Antagonists, Negative Inotrope, OCT1 inhibitors, OCT2 Inhibitors, Pyridines, QTc Prolonging Agents, Sodium Channel Blockers, Voltage-Gated Sodium Channel Blockers"," Sodium channel protein type 5 subunit alpha,  Muscarinic acetylcholine receptor M1,  Muscarinic acetylcholine receptor M2,  Muscarinic acetylcholine receptor M3,  Potassium voltage-gated channel subfamily D member 2,  Potassium voltage-gated channel subfamily D member 3,  Potassium voltage-gated channel subfamily H member 2,  Alpha-1-acid glycoprotein 2,  Cytochrome P450 1A2,  Cytochrome P450 3A4,  Alpha-1-acid glycoprotein 1,  Solute carrier family 22 member 1,  Solute carrier family 22 member 2","DB00280, DB01620, DB09555, DB01114, DB13679",
DB00281,Lidocaine,approved; vet_approved,CCN(CC)CC(=O)NC1=C(C)C=CC=C1C,C14H22N2O,,"Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use, Agents that reduce seizure threshold, Amides, Amines, Analgesics and Anesthetics, Anesthetics, Anesthetics for Topical Use, Anesthetics, Local, Anilides, Aniline Compounds, Antiarrhythmic agents, Antiarrhythmics, Class I, Antiarrhythmics, Class Ib, Antipruritics and Local Anesthetics, Antipruritics, Incl. Antihistamines, Anesthetics, Etc., Cardiac Therapy, Cardiovascular Agents, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (moderate), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2A6 Substrates, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C18 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dermatologicals, Local Anesthesia, Local Anesthetics (Amide), Membrane Transport Modulators, Methemoglobinemia Associated Agents, Nervous System, Neuraxial Anesthetics, Ophthalmologicals, Otologicals, P-glycoprotein inhibitors, Peripheral Nervous System Agents, Sensory System Agents, Sodium Channel Blockers, Throat Preparations, Vasoprotectives, Voltage-Gated Sodium Channel Blockers"," Sodium channel protein type 10 subunit alpha,  Sodium channel protein type 9 subunit alpha,  Sodium channel protein type 5 subunit alpha,  Epidermal growth factor receptor,  Sodium channel protein type 4 subunit alpha,  Alpha-1-acid glycoprotein 1,  Alpha-1-acid glycoprotein 2,  Cytochrome P450 3A4,  Cytochrome P450 2D6,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  Cytochrome P450 1A2,  Cytochrome P450 2C9,  Cytochrome P450 2C8,  Cytochrome P450 2A6,  Cytochrome P450 2B6,  Solute carrier family 22 member 5,  P-glycoprotein 1","DB00281, DB18588, DB00750, DB08987, DB13082, DB01056",
DB00282,Pamidronic acid,approved,NCCC(O)(P(O)(O)=O)P(O)(O)=O,C3H11NO7P2,,"Agents Causing Muscle Toxicity, Antineoplastic Agents, Bisphosphonates, Bone Density Conservation Agents, Drugs Affecting Bone Structure and Mineralization, Drugs for Treatment of Bone Diseases, Musculo-Skeletal System, Nephrotoxic agents, Organophosphonates, Organophosphorus Compounds"," Farnesyl pyrophosphate synthase,  Hydroxylapatite,  Geranylgeranyl pyrophosphate synthase,  Caspase-3,  Caspase-9","DB00282, DB00630, DB09411",
DB00283,Clemastine,approved; investigational,CN1CCC[C@@H]1CCO[C@](C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1,C21H26ClNO,,"Aminoalkyl Ethers, Anti-Allergic Agents, Antihistamines for Systemic Use, Antihistamines for Topical Use, Antipruritics, Antipruritics, Incl. Antihistamines, Anesthetics, Etc., Central Nervous System Depressants, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Dermatologicals, Highest Risk QTc-Prolonging Agents, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Neurotransmitter Agents, Pyrrolidines, QTc Prolonging Agents"," Histamine H1 receptor,  Cytochrome P450 2D6","DB00283, DB00245, DB13468, DB01146",
DB00284,Acarbose,approved; investigational,[H]C(=O)[C@H](O)[C@@H](O)[C@]([H])(O[C@@]1([H])O[C@H](CO)[C@@]([H])(O[C@H]2O[C@H](C)[C@@H](N[C@@]3([H])C=C(CO)[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O)[C@H](O)CO,C25H43NO18,,"Alimentary Tract and Metabolism, Blood Glucose Lowering Agents, Carbohydrates, Drugs that are Mainly Renally Excreted, Drugs Used in Diabetes, Enzyme Inhibitors, Glycoside Hydrolase Inhibitors, Hypoglycemia-Associated Agents, Oligosaccharides, Oral Hypoglycemics, Polysaccharides, Trisaccharides"," Maltase-glucoamylase, intestinal,  Sucrase-isomaltase, intestinal,  Pancreatic alpha-amylase,  Lysosomal alpha-glucosidase","DB00284, DB02889, DB03495, DB03617, DB03971, DB04439, DB04453, DB04618, DB02218, DB03269, DB04164",
DB00285,Venlafaxine,approved,COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1,C17H27NO2,,"Agents producing tachycardia, Agents that reduce seizure threshold, Amines, Antidepressive Agents, Antidepressive Agents Indicated for Depression, Antidepressive Agents, Second-Generation, BCRP/ABCG2 Inducers, Central Nervous System Agents, Central Nervous System Depressants, Combined Inhibitors of Serotonin/Norepinephrine Reuptake, Cyclohexanes, Cyclohexanols, Cycloparaffins, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Ethylamines, Hexanols, Hypoglycemia-Associated Agents, Membrane Transport Modulators, Nervous System, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, Norepinephrine Uptake Inhibitors, P-glycoprotein inhibitors, P-glycoprotein substrates, Phenethylamines, Potential QTc-Prolonging Agents, Psychoanaleptics, Psychotropic Drugs, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin and Noradrenaline Reuptake Inhibitors, Serotonin Modulators"," Sodium-dependent serotonin transporter,  Sodium-dependent noradrenaline transporter,  Sodium-dependent dopamine transporter,  Cytochrome P450 2D6,  Cytochrome P450 3A4,  Cytochrome P450 2C9,  Cytochrome P450 2C19,  P-glycoprotein 1,  ATP-binding cassette sub-family G member 2","DB00285, DB06700, DB15052",
DB00286,Conjugated estrogens,approved,,,,"Agents causing angioedema, BCRP/ABCG2 Substrates, COMT Substrates, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (weak), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Estradiol Congeners, Estrogens, Estrogens, Conjugated (USP), Genito Urinary System and Sex Hormones, Gonadal Hormones, Gonadal Steroid Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Natural and Semisynthetic Estrogens, Plain, OAT3/SLC22A8 Inhibitors, OAT3/SLC22A8 Substrates, OATP1B1/SLCO1B1 Inhibitors, OATP1B1/SLCO1B1 Substrates, OATP1B3 substrates, OATP2B1/SLCO2B1 substrates, P-glycoprotein substrates, Sex Hormones and Modulators of the Genital System, Thyroxine-binding globulin inducers"," Estrogen receptor beta,  Estrogen receptor alpha,  Cytochrome P450 3A4,  Cytochrome P450 1A2,  Catechol O-methyltransferase,  Thyroxine-binding globulin,  Sex hormone-binding globulin,  Serum albumin,  Canalicular multispecific organic anion transporter 2,  Multidrug resistance-associated protein 4,  Multidrug resistance-associated protein 1,  Solute carrier organic anion transporter family member 1A2,  Sodium/bile acid cotransporter,  Solute carrier family 22 member 10,  Solute carrier family 22 member 8,  Solute carrier organic anion transporter family member 1C1,  Solute carrier organic anion transporter family member 1B1, 10. Solute carrier organic anion transporter family member 2B1, 11. P-glycoprotein 1, 12. Solute carrier family 22 member 6, 13. Organic solute transporter subunit alpha, 14. Organic solute transporter subunit beta, 15. Canalicular multispecific organic anion transporter 1, 16. Solute carrier organic anion transporter family member 4A1, 17. ATP-binding cassette sub-family C member 11, 18. Solute carrier organic anion transporter family member 1B3, 19. Solute carrier family 22 member 11, 20. Solute carrier organic anion transporter family member 3A1, 21. ATP-binding cassette sub-family G member 2",,
DB00287,Travoprost,approved,CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(=C1)C(F)(F)F,C26H35F3O6,,"Antiglaucoma Preparations and Miotics, Antihypertensive Agents, Eicosanoids, Fatty Acids, Fatty Acids, Unsaturated, Inflammation Mediators, Lipids, Ophthalmics, Ophthalmologicals, Prostaglandin analogs reducing intraocular pressure (IOP), Prostaglandins, Prostaglandins F, Synthetic, Prostaglandins, Synthetic", Prostaglandin F2-alpha receptor,"DB00287, DB11519, DB11507, DB11411",
DB00288,Amcinonide,approved,[H][C@@]12C[C@H]3OC4(CCCC4)O[C@@]3(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,C28H35FO7,,"Adrenal Cortex Hormones, Anti-Inflammatory Agents, Corticosteroid Hormone Receptor Agonists, Corticosteroids, Corticosteroids, Dermatological Preparations, Corticosteroids, Potent (Group III), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Inducers, Cytochrome P-450 CYP3A5 Inducers (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Substrates, Dermatologicals, Fused-Ring Compounds, Glucocorticoids, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hyperglycemia-Associated Agents, Immunosuppressive Agents, Pregnadienes, Pregnanes, Steroids, Steroids, Fluorinated, Thyroxine-binding globulin inhibitors"," Glucocorticoid receptor,  Annexin A1,  Cytochrome P450 3A4,  Cytochrome P450 3A5","DB00288, DB18737, DB01047, DB01410, DB00591, DB14662, DB01222, DB00180, DB01260, DB14673, DB14640, DB14649, DB01130, DB06781, DB14634, DB06786, DB01013, DB00846, DB14664, DB13664, DB15835, DB14643, DB12322, DB08973, DB00620, DB14637, DB14657, DB14632, DB11487, DB15999",
DB00289,Atomoxetine,approved,CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1,C17H21NO,,"Adrenergic Agents, Agents producing tachycardia, Agents that produce hypertension, Amines, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Membrane Transport Modulators, Miscellaneous Central Nervous System Agents, Nervous System, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, Norepinephrine Reuptake Inhibitor, Norepinephrine Uptake Inhibitors, Potential QTc-Prolonging Agents, Propylamines, Psychostimulants, Agents Used for ADHD and Nootropics, QTc Prolonging Agents"," Sodium-dependent noradrenaline transporter,  Sodium-dependent serotonin transporter,  NMDA receptor (Protein Group),  G protein-activated inward rectifier potassium channel 1,  Kappa-type opioid receptor,  Cytochrome P450 2C19,  Cytochrome P450 2D6,  Serum albumin,  alpha1-acid glycoprotein (Protein Group),  High affinity immunoglobulin gamma Fc receptor I","DB00289, DB09186, DB00472, DB08472, DB08544, DB06731",
DB00290,Bleomycin,approved; investigational,[H][C@](C)(NC(=O)[C@@]([H])(NC(=O)C1=NC(=NC(N)=C1C)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)[C@@]([H])(OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)C1=CNC=N1)[C@@H](O)[C@H](C)C(=O)N[C@]([H])(C(=O)NCCC1=NC(=CS1)C1=NC(=CS1)C(=O)NCCC[S+](C)C)[C@@]([H])(C)O,C55H84N17O21S3,,"Amino Acids, Peptides, and Proteins, Antibiotics, Antineoplastic, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Carbohydrates, Cardiotoxic antineoplastic agents, Cytoprotective Agent, Cytotoxic Antibiotics and Related Substances, Drugs that are Mainly Renally Excreted, Glycoconjugates, Glycopeptides, Immunosuppressive Agents, Narrow Therapeutic Index Drugs, Peptides"," DNA,  DNA ligase 1,  DNA ligase 3,  Bleomycin hydrolase","DB00290, DB12992, DB13013, DB11467, DB11191, DB05168, DB03469, DB02975, DB05735, DB03614, DB00200, DB15673, DB03317, DB03906, DB12674, DB04803, DB02667, DB11641, DB00361, DB02868, DB15657, DB02832, DB12755, DB00115, DB17390, DB16186, DB00541, DB12586, DB02949, DB16312",
DB00291,Chlorambucil,approved,OC(=O)CCCC1=CC=C(C=C1)N(CCCl)CCCl,C14H19Cl2NO2,,"Agents that reduce seizure threshold, Alkylating Activity, Alkylating Drugs, Antineoplastic Agents, Antineoplastic Agents, Alkylating, Antineoplastic and Immunomodulating Agents, Hydrocarbons, Halogenated, Immunosuppressive Agents, Mustard Compounds, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, Nitrogen Mustard Analogues, Nitrogen Mustard Compounds, Noxae, Toxic Actions"," DNA,  Glutathione S-transferase P,  Glutathione S-transferases (Cytosolic) (Protein Group),  Solute carrier organic anion transporter family member 1A2","DB00291, DB01042",
DB00292,Etomidate,approved,CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1,C14H16N2O2,,"Adrenergic Agonists, Adrenergic alpha-2 Receptor Agonists, Adrenergic alpha-Agonists, Agents producing tachycardia, Agents that produce hypertension, Anesthetics, Anesthetics, General, Anesthetics, Intravenous, Central Nervous System Agents, Central Nervous System Depressants, Drugs that are Mainly Renally Excreted, Hypnotics and Sedatives, Imidazoles, Nervous System"," Gamma-aminobutyric acid receptor subunit alpha-1,  Alpha-2B adrenergic receptor,  GABA(A) Receptor (Protein Group),  Cytochrome P450 11B1, mitochondrial,  Cytochrome P450 11B2, mitochondrial,  Solute carrier family 2, facilitated glucose transporter member 1","DB00292, DB13021, DB15411",
DB00293,Raltitrexed,approved; investigational,CN(CC1=CC2=C(NC(C)=NC2=O)C=C1)C1=CC=C(S1)C(=O)N[C@@H](CCC(O)=O)C(O)=O,C21H22N4O6S,,"Antimetabolites, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Enzyme Inhibitors, Folic Acid Analogues, Folic Acid Antagonists, Heterocyclic Compounds, Fused-Ring, Immunosuppressive Agents, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, Noxae, Sulfur Compounds, Thymidylate Synthase, antagonists & inhibitors, Toxic Actions"," Thymidylate synthase,  Folylpolyglutamate synthase, mitochondrial","DB00293, DB03541",
DB00294,Etonogestrel,approved; investigational,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],C22H28O2,,"Adrenal Cortex Hormones, Combination Contraceptives (with Estrogen and derivatives), Contraceptive Agents, Female, Contraceptive Agents, Hormonal, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Fused-Ring Compounds, Genito Urinary System and Sex Hormones, Hormonal Contraceptives for Systemic Use, Hyperglycemia-Associated Agents, Intravaginal Contraceptives, Norpregnanes, Norpregnenes, Norsteroids, Progesterone Congeners, Progestins, Reproductive Control Agents, Sex Hormones and Modulators of the Genital System, Steroids"," Progesterone receptor,  Cytochrome P450 3A4,  Serum albumin,  Sex hormone-binding globulin","DB00294, DB00367, DB00717, DB09389, DB06730, DB00624, DB01471, DB01543, DB01564, DB05830, DB06710, DB07768, DB11429, DB12787, DB13169, DB13533, DB14093, DB13710, DB13230, DB14570, DB00253, DB14584, DB00304, DB04652, DB18000, DB04630, DB01481, DB01572, DB00741, DB01540",
DB00295,Morphine,approved; investigational,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O,C17H19NO3,,"Alkaloids, Analgesics, Anesthetics, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Heterocyclic Compounds, Fused-Ring, High-risk opioids, Hypotensive Agents, Narcotics, Natural Opium Alkaloids, Nervous System, Neuraxial Anesthetics, Opiate Agonists, Opiate Alkaloids, Opioid Agonist, Opioids, P-glycoprotein substrates, Peripheral Nervous System Agents, Phenanthrenes, Sensory System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, UGT1A1 Substrates, UGT1A3 substrates, UGT2B7 substrates"," Mu-type opioid receptor,  Kappa-type opioid receptor,  Delta-type opioid receptor,  Lymphocyte antigen 96,  Cytochrome P450 2C8,  Cytochrome P450 3A4,  UDP-glucuronosyltransferase 2B7,  UDP-glucuronosyltransferase 1-1,  UDP-glucuronosyltransferase 1-8,  UDP-glucuronosyltransferase 2B15,  UDP-glucuronosyltransferase 2B4,  UDP-glucuronosyltransferase 1-3,  Serum albumin,  P-glycoprotein 1","DB00295, DB00318, DB01477, DB01466, DB11490, DB09209, DB01573, DB01480, DB01497, DB01568, DB01469, DB01452, DB01565, DB01512, DB01551, DB00844, DB06409, DB15341, DB00921, DB01450, DB01548, DB14146, DB06230, DB16072, DB16117, DB13454, DB09049, DB00704, DB01192, DB06800",
DB00296,Ropivacaine,approved,CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C,C17H26N2O,,"Amides, Amines, Anesthetics, Anesthetics, Local, Anilides, Aniline Compounds, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Hypotensive Agents, Local Anesthesia, Local Anesthetics (Amide), Methemoglobinemia Associated Agents, Nervous System, Neuraxial Anesthetics, Peripheral Nervous System Agents, Sensory System Agents"," Sodium channel protein type 10 subunit alpha,  Cytochrome P450 1A2,  Cytochrome P450 3A4,  Cytochrome P450 2B6,  Alpha-1-acid glycoprotein 1","DB00296, DB00297, DB01002, DB00961, DB08987, DB00750, DB13082",
DB00297,Bupivacaine,approved; investigational,CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C,C18H28N2O,,"Agents that reduce seizure threshold, Amides, Amines, Anesthetics, Anesthetics, Local, Anilides, Aniline Compounds, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Hypotensive Agents, Local Anesthesia, Local Anesthetics (Amide), Methemoglobinemia Associated Agents, Nervous System, Neuraxial Anesthetics, Peripheral Nervous System Agents, Sensory System Agents"," Sodium channel protein type 10 subunit alpha,  Prostaglandin E2 receptor EP1 subtype,  Cytochrome P450 2C19,  Cytochrome P450 2D6,  Cytochrome P450 3A4","DB00296, DB00297, DB01002, DB00961, DB08987, DB00750, DB13082",
DB00298,Dapiprazole,approved,CC1=CC=CC=C1N1CCN(CCC2=NN=C3CCCCN23)CC1,C19H27N5,,"Adrenergic Agents, Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Agents that produce hypertension, Antiglaucoma Preparations and Miotics, Antipsychotic Agents, Central Nervous System Agents, Central Nervous System Depressants, Neurotoxic agents, Neurotransmitter Agents, Ophthalmics, Ophthalmologicals, Sensory Organs, Tranquilizing Agents"," Alpha-1A adrenergic receptor,  Alpha-1D adrenergic receptor,  Alpha-1B adrenergic receptor","DB00298, DB09195",
DB00299,Penciclovir,approved,NC1=NC(=O)C2=C(N1)N(CCC(CO)CO)C=N2,C10H15N5O3,,"Anti-Infective Agents, Antiinfectives for Systemic Use, Antiviral Agents, Antivirals for Systemic Use, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 Substrates, Dermatologicals, Direct Acting Antivirals, Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor, Heterocyclic Compounds, Fused-Ring, Nucleic Acid Synthesis Inhibitors, Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors, Purines, Purinones, Reverse Transcriptase Inhibitors"," DNA polymerase catalytic subunit,  Thymidine kinase","DB00299, DB12531, DB06575, DB02495, DB17733, DB15651, DB04260, DB00426, DB00442, DB02489, DB00824",
DB00300,Tenofovir disoproxil,approved; investigational,[H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C,C19H30N5O10P,,"Anti-HIV Agents, Anti-Infective Agents, Anti-Retroviral Agents, Antiinfectives for Systemic Use, Antiviral Agents, Antivirals for Systemic Use, Antivirals used in combination for the treatment of HIV infections, Direct Acting Antivirals, Drugs that are Mainly Renally Excreted, Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor, Heterocyclic Compounds, Fused-Ring, Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor, Nephrotoxic agents, Nucleoside and Nucleotide Reverse Transcriptase Inhibitors, OAT1/SLC22A6 Substrates, OAT3/SLC22A8 Substrates, Organophosphorus Compounds, P-glycoprotein inhibitors, P-glycoprotein substrates, Purines, Reverse Transcriptase Inhibitors, Tenofovir and prodrugs"," Reverse transcriptase/RNaseH,  DNA polymerase/reverse transcriptase,  Adenylate kinase 2, mitochondrial,  Adenylate kinase 4, mitochondrial,  Nucleoside diphosphokinase (Protein Group),  Creatine Kinases (Protein Group),  Solute carrier family 22 member 6,  Solute carrier family 22 member 8,  Multidrug resistance-associated protein 7,  Multidrug resistance-associated protein 4,  Canalicular multispecific organic anion transporter 1,  P-glycoprotein 1","DB00300, DB00718, DB14126, DB02222, DB14925, DB05020, DB13868, DB08843",
DB00301,Flucloxacillin,approved; investigational,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1F)C(O)=O,C19H17ClFN3O5S,,"Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Beta-Lactam Antibacterials, Beta-Lactamase Resistant Penicillins, beta-Lactams, BSEP/ABCB11 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Substrates, Heterocyclic Compounds, Fused-Ring, Lactams, Penicillins, Sulfur Compounds"," Penicillin-binding protein 1A,  Cytochrome P450 3A4,  Bile salt export pump","DB00301, DB00485, DB01147, DB00713, DB09319, DB00739, DB00948, DB01061, DB13506",
DB00302,Tranexamic acid,approved,NC[C@H]1CC[C@@H](CC1)C(O)=O,C8H15NO2,,"Acids, Carbocyclic, Amino Acids, Amino Acids, Peptides, and Proteins, Antifibrinolytic Agents, Blood and Blood Forming Organs, Coagulants, Cyclohexanecarboxylic Acids, Cyclohexanes, Cycloparaffins, Decreased Fibrinolysis, Fibrin Modulating Agents, Hematologic Agents, Hemostatics", Plasminogen,"DB00302, DB00996, DB15264, DB12032, DB02878",
DB00303,Ertapenem,approved; investigational,[H][C@]12[C@@H](C)C(S[C@]3([H])CN[C@@]([H])(C3)C(=O)NC3=CC=CC(=C3)C(O)=O)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O,C22H25N3O7S,,"Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, beta-Lactams, Carbapenems, Drugs that are Mainly Renally Excreted, Heterocyclic Compounds, Fused-Ring, Lactams, Penem Antibacterial, Sulfur Compounds"," Penicillin-binding protein 1A,  Penicillin-binding protein 1B,  Penicillin-binding protein 2,  Penicillin-binding protein 2,  Peptidoglycan synthase FtsI,  Peptidoglycan synthase FtsI,  D-alanyl-D-alanine carboxypeptidase DacB,  D-alanyl-D-alanine carboxypeptidase DacC,  Dipeptidase 1,  Serum albumin","DB00303, DB00760, DB06211, DB16840, DB13028, DB01598, DB12587, DB05735, DB11191",
DB00304,Desogestrel,approved,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H],C22H30O,,"Adrenal Cortex Hormones, Combination Contraceptives (with Estrogen and derivatives), Contraceptive Agents, Female, Contraceptive Agents, Hormonal, Contraceptives, Oral, Contraceptives, Oral, Hormonal, Contraceptives, Oral, Synthetic, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Fused-Ring Compounds, Genito Urinary System and Sex Hormones, Hormonal Contraceptives for Systemic Use, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hyperglycemia-Associated Agents, Norpregnanes, Norpregnenes, Norsteroids, Progestin Contraceptives, Progestins, Progestogens and Estrogens, Sequential Preparations, Reproductive Control Agents, Sex Hormones and Modulators of the Genital System, Steroids, UGT1A1 Inducers"," Progesterone receptor,  Estrogen receptor alpha,  Cytochrome P450 3A4,  Cytochrome P450 2C9,  UDP-glucuronosyltransferase 1-1,  Serum albumin,  Sex hormone-binding globulin","DB00304, DB12474, DB13866, DB00294, DB01493, DB01431, DB00367, DB00717, DB09389, DB03696, DB05212, DB09070, DB09371",
DB00305,Mitomycin,approved,[H][C@]12CN3C4=C([C@@H](COC(N)=O)[C@@]3(OC)[C@@]1([H])N2)C(=O)C(N)=C(C)C4=O,C15H18N4O5,,"Alkylating Activity, Alkylating Drugs, Antibiotics, Antineoplastic, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Azirines, Cardiotoxic antineoplastic agents, Compounds used in a research, industrial, or household setting, Cross-Linking Reagents, Cytotoxic Antibiotics and Related Substances, Enzyme Inhibitors, Heterocyclic Compounds, Fused-Ring, Immunosuppressive Agents, Indicators and Reagents, Indolequinones, Indoles, Mitomycins, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, Noxae, Nucleic Acid Synthesis Inhibitors, Toxic Actions"," DNA,  NADPH--cytochrome P450 reductase","DB00305, DB06478, DB15372",
DB00306,Talbutal,approved; illicit,CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O,C11H16N2O3,,"Anticholinergic Agents, Barbiturates, Plain, Central Nervous System Depressants, Hypnotics and Sedatives, Nervous System, Nicotinic Antagonists, Psycholeptics, Pyrimidines, Pyrimidinones"," Gamma-aminobutyric acid receptor subunit alpha-2,  Gamma-aminobutyric acid receptor subunit alpha-3,  Gamma-aminobutyric acid receptor subunit alpha-4,  Gamma-aminobutyric acid receptor subunit alpha-5,  Gamma-aminobutyric acid receptor subunit alpha-6,  GABA(A) Receptor (Protein Group),  Gamma-aminobutyric acid receptor subunit alpha-1,  Neuronal acetylcholine receptor subunit alpha-4,  Neuronal acetylcholine receptor subunit alpha-7, 10. Glutamate receptor 2, 11. Glutamate receptor ionotropic, kainate 2","DB00306, DB00418, DB01352, DB00241, DB00237, DB13577, DB13770, DB00312, DB13253, DB01353, DB01351, DB01483, DB13229",
DB00307,Bexarotene,approved; investigational,CC1=CC2=C(C=C1C(=C)C1=CC=C(C=C1)C(O)=O)C(C)(C)CCC2(C)C,C24H28O2,,"Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Compounds used in a research, industrial, or household setting, Cyclohexanes, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (moderate), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (moderate), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Immunosuppressive Agents, Myelosuppressive Agents, Naphthalenes, Retinoids, Retinoids for cancer treatment, Tetrahydronaphthalenes"," Retinoic acid receptor RXR-alpha,  Retinoic acid receptor RXR-beta,  Retinoic acid receptor RXR-gamma,  Cytochrome P450 2C8,  Cytochrome P450 3A4","DB00307, DB02877, DB03466",
DB00308,Ibutilide,approved,CCCCCCCN(CC)CCCC(O)C1=CC=C(NS(C)(=O)=O)C=C1,C20H36N2O3S,,"Amides, Antiarrhythmic agents, Antiarrhythmics, Class III, Cardiac Therapy, Cardiovascular Agents, Drugs that are Mainly Renally Excreted, Highest Risk QTc-Prolonging Agents, QTc Prolonging Agents, Sulfones, Sulfur Compounds"," Voltage-dependent L-type calcium channel subunit alpha-1C,  Voltage-dependent L-type calcium channel subunit beta-1,  Potassium voltage-gated channel subfamily H member 2,  Voltage-dependent calcium channel subunit alpha-2/delta-1,  Voltage-dependent calcium channel gamma-1 subunit,  Potassium channel subfamily K member 1,  Potassium channel subfamily K member 6,  Potassium voltage-gated channel subfamily H member 6,  Potassium voltage-gated channel subfamily H member 7, 10. ATP-sensitive inward rectifier potassium channel 11",DB00308,
DB00309,Vindesine,approved; investigational,[H][C@@]12N3CC[C@@]11C4=CC(=C(OC)C=C4N(C)[C@@]1([H])[C@](O)([C@H](O)[C@]2(CC)C=CC3)C(N)=O)[C@]1(C[C@@]2([H])CN(C[C@](O)(CC)C2)CCC2=C1NC1=C2C=CC=C1)C(=O)OC,C43H55N5O7,,"Alkaloids, Antimitotic Agents, Antineoplastic Agents, Antineoplastic Agents, Phytogenic, Antineoplastic and Immunomodulating Agents, Cardiotoxic antineoplastic agents, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Substrates, Heterocyclic Compounds, Fused-Ring, Immunosuppressive Agents, Indole Alkaloids, Indoles, Indolizidines, Indolizines, Mitosis Modulators, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, Secologanin Tryptamine Alkaloids, Tubulin Modulators, Vinca Alkaloids"," Tubulin beta-1 chain,  Cytochrome P450 3A4","DB00309, DB00570, DB00541, DB17390, DB02868, DB12586, DB11641, DB00361, DB05168, DB11191, DB03614, DB00200, DB04877, DB11467, DB04803, DB16312, DB03469, DB12674, DB16186, DB05735, DB03317, DB02832, DB00615, DB03906, DB12755, DB13013, DB02667, DB02949, DB15413, DB15673",
DB00310,Chlorthalidone,approved,NS(=O)(=O)C1=C(Cl)C=CC(=C1)C1(O)NC(=O)C2=CC=CC=C12,C14H11ClN2O4S,,"Amides, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Benzene Derivatives, Benzenesulfonamides, Benzophenones, Cardiovascular Agents, Diuretics, Drugs causing inadvertant photosensitivity, Heterocyclic Compounds, Fused-Ring, Hyperglycemia-Associated Agents, Hypotensive Agents, Imides, Increased Diuresis, Isoindoles, Ketones, Low-Ceiling Diuretics and Potassium-Sparing Agents, Low-Ceiling Diuretics, Excl. Thiazides, Membrane Transport Modulators, Natriuretic Agents, Non Potassium Sparing Diuretics, Photosensitizing Agents, Phthalimides, Sodium Chloride Symporter Inhibitors, Sulfonamides, Sulfones, Sulfur Compounds, Thiazide-like Diuretic"," Carbonic anhydrase 1,  Solute carrier family 12 member 1,  Serum albumin","DB00310, DB08046",
DB00311,Ethoxzolamide,withdrawn,CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O,C9H10N2O3S2,,"Amides, Benzothiazoles, Carbonic Anhydrase Inhibitors, Diuretics, Enzyme Inhibitors, Heterocyclic Compounds, Fused-Ring, Natriuretic Agents, OAT1/SLC22A6 inhibitors, Sulfonamides, Sulfones, Sulfur Compounds, Thiazoles"," Carbonic anhydrase 2,  Carbonic anhydrase 4,  Carbonic anhydrase 7,  Carbonic anhydrase 1,  Carbonic anhydrase 3,  Solute carrier family 22 member 6","DB00311, DB08765",
DB00312,Pentobarbital,approved; investigational; vet_approved,CCCC(C)C1(CC)C(=O)NC(=O)NC1=O,C11H18N2O3,,"Adjuvants, Anesthesia, Anticholinergic Agents, Anticonvulsants, Barbiturates, Barbiturates, Plain, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2A6 Inducers, Cytochrome P-450 CYP2A6 Inducers (strong), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inducers (strong), Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strong), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, GABA Agents, GABA Modulators, Hypnotics and Sedatives, Nervous System, Neurotransmitter Agents, Nicotinic Antagonists, Psycholeptics, Pyrimidines, Pyrimidinones"," Gamma-aminobutyric acid receptor subunit alpha-1,  Gamma-aminobutyric acid receptor subunit alpha-2,  Gamma-aminobutyric acid receptor subunit alpha-3,  Gamma-aminobutyric acid receptor subunit alpha-4,  Gamma-aminobutyric acid receptor subunit alpha-5,  Gamma-aminobutyric acid receptor subunit alpha-6,  GABA(A) Receptor (Protein Group),  Neuronal acetylcholine receptor subunit alpha-4,  Neuronal acetylcholine receptor subunit alpha-7, 10. Glutamate receptor 2, 11. Glutamate receptor ionotropic, kainate 2, 12. NMDA receptor (Protein Group), 13. Nuclear receptor subfamily 1 group I member 2,  Cytochrome P450 2C19,  Cytochrome P450 2A6,  Cytochrome P450 3A4","DB00312, DB01353, DB00237, DB01351, DB00418, DB13770, DB00306, DB01483, DB00241, DB01352, DB00463, DB13577",
DB00313,Valproic acid,approved; investigational,CCCC(CCC)C(O)=O,C8H16O2,,"Acids, Acyclic, Anti-epileptic Agent, Anticonvulsants, Antimanic Agents, Antineoplastic Agents, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 CYP2A6 Substrates, Cytochrome P-450 CYP2A6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (weak), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (moderate), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Decreased Central Nervous System Disorganized Electrical Activity, Drugs causing inadvertant photosensitivity, Enzyme Inhibitors, Fatty Acid Derivatives, Fatty Acids, Fatty Acids, Volatile, GABA Agents, Hepatotoxic Agents, Highest Risk QTc-Prolonging Agents, Histone Deacetylase Inhibitors, Lipids, Methemoglobinemia Associated Agents, Miscellaneous Anticonvulsants, Mood Stabilizer, Narrow Therapeutic Index Drugs, Nervous System, Neurotransmitter Agents, OAT1/SLC22A6 inhibitors, OAT3/SLC22A8 Inhibitors, OAT3/SLC22A8 Substrates, OAT3/SLC22A8 Substrates with a Narrow Therapeutic Index, Organic Anion Transporting Polypeptide 2B1 Inhibitors, Pentanoic Acids, Photosensitizing Agents, Psychotropic Drugs, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Tranquilizing Agents, UGT1A1 Inhibitors, UGT1A1 Substrates, UGT1A1 Substrates with a Narrow Therapeutic Index, UGT1A3 substrates, UGT1A3 Substrates with a Narrow Therapeutic Index, UGT1A4 substrates, UGT1A6 substrate, UGT1A6 Substrates with a Narrow Therapeutic Index, UGT1A9 Substrates, UGT1A9 Substrates with a Narrow Therapeutic Index, UGT2B7 substrates, UGT2B7 Substrates with a Narrow Therapeutic Index, Valerates"," Histone deacetylase 9,  Short/branched chain specific acyl-CoA dehydrogenase, mitochondrial,  2-oxoglutarate dehydrogenase, mitochondrial,  Succinate-semialdehyde dehydrogenase, mitochondrial,  Sodium channel protein (Protein Group),  Histone deacetylase 2,  Peroxisome proliferator-activated receptor alpha,  Peroxisome proliferator-activated receptor delta,  Peroxisome proliferator-activated receptor gamma, 10. Histone deacetylase (Protein Group), 11. Cyclin-dependent kinase inhibitor 1, 12. Hepatocyte growth factor, 13. Ornithine decarboxylase, 14. Programmed cell death 1 ligand 1,  Cytochrome P450 2A6,  Cytochrome P450 2B6,  Cytochrome P450 2C9,  Cytochrome P450 3A5,  Prostaglandin G/H synthase 1,  Cytochrome P450 1A2,  Cytochrome P450 2C19,  Cytochrome P450 3A4,  UDP-glucuronosyltransferase 1-4, 10. UDP-glucuronosyltransferase 1-8, 11. UDP-glucuronosyltransferase 1-10, 12. UDP-glucuronosyltransferase 1-6, 13. UDP-glucuronosyltransferase 1-3, 14. UDP-glucuronosyltransferase 2B7, 15. UDP-glucuronosyltransferase 2B15, 16. UDP-glucuronosyltransferase 1-9, 17. UDP-glucuronosyltransferase 1-1,  Serum albumin,  Solute carrier family 22 member 6,  Solute carrier family 22 member 8,  Solute carrier family 22 member 5,  Monocarboxylate transporter 1,  Solute carrier family 22 member 7,  Solute carrier organic anion transporter family member 2B1","DB00313, DB13910, DB03993, DB05343, DB02406, DB03741, DB17706, DB01856, DB02938, DB08368, DB11936",
DB00314,Capreomycin,approved,[H][C@@]1(CCN=C(N)N1)[C@]1([H])NC(=O)\C(NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC1=O)=C/NC(N)=O.[H][C@@]1(CCN=C(N)N1)[C@]1([H])NC(=O)\C(NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC1=O)=C/NC(N)=O,C50H88N28O15,,"Agents that produce neuromuscular block (indirect), Amino Acids, Peptides, and Proteins, Aminoglycoside Antibacterials, Anti-Bacterial Agents, Anti-Infective Agents, Antibiotics, Antitubercular, Antiinfectives for Systemic Use, Antimycobacterials, Drugs for Treatment of Tuberculosis, Drugs that are Mainly Renally Excreted, Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index, Enzyme Inhibitors, Narrow Therapeutic Index Drugs, Nephrotoxic agents, Peptides, Peptides, Cyclic, Protein Synthesis Inhibitors", 16S/23S rRNA (cytidine-2'-O)-methyltransferase TlyA,"DB00314, DB08993, DB06827",
DB00315,Zolmitriptan,approved; investigational,CN(C)CCC1=CNC2=CC=C(C[C@H]3COC(=O)N3)C=C12,C16H21N3O2,,"Agents that produce hypertension, Amines, Analgesics, Antidepressive Agents, Antimigraine Preparations, Biogenic Amines, Biogenic Monoamines, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 Substrates, Heterocyclic Compounds, Fused-Ring, Indoles, Monoamine Oxidase A Substrates, Nervous System, Neurotransmitter Agents, Oxazoles, Selective Serotonin 5-HT1 Receptor Agonists, Selective Serotonin Agonists, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 1b Receptor Agonists, Serotonin 1d Receptor Agonists, Serotonin 5-HT1 Receptor Agonists, Serotonin Agents, Serotonin Modulators, Serotonin Receptor Agonists, Serotonin-1b and Serotonin-1d Receptor Agonist, Triptans"," 5-hydroxytryptamine receptor 1B,  5-hydroxytryptamine receptor 1D,  5-hydroxytryptamine receptor 1F,  5-hydroxytryptamine receptor 1E,  5-hydroxytryptamine receptor 7,  5-hydroxytryptamine receptor 1A,  5-hydroxytryptamine receptor 2A,  5-hydroxytryptamine receptor 2B,  Cytochrome P450 1A2,  Amine oxidase [flavin-containing] A,  P-glycoprotein 1",DB00315,
DB00316,Acetaminophen,approved,CC(=O)NC1=CC=C(O)C=C1,C8H9NO2,,"Acetaminophen and Prodrugs, Amides, Amines, Analgesics, Analgesics, Non-Narcotic, Anilides, Aniline Compounds, Antipyretics, Central Nervous System Agents, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2A6 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (weak), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Methemoglobinemia Associated Agents, Miscellaneous Analgesics and Antipyretics, Nervous System, P-glycoprotein inhibitors, P-glycoprotein substrates, Sensory System Agents, UGT1A1 Substrates, UGT1A6 substrate, UGT1A9 Substrates"," Prostaglandin G/H synthase 2,  Prostaglandin G/H synthase 1,  Prostaglandin E synthase 3,  Transient receptor potential cation channel subfamily V member 1,  Cytochrome P450 2E1,  Cytochrome P450 1A2,  Cytochrome P450 3A4,  Cytochrome P450 2D6,  Cytochrome P450 2A6,  UDP-glucuronosyltransferase 1-6,  UDP-glucuronosyltransferase 1-1,  UDP-glucuronosyltransferase 1-9,  UDP-glucuronosyltransferase 2B15, 10. Sulfotransferase 1A1, 11. Sulfotransferase 1A3/1A4, 12. Arylamine N-acetyltransferase 2, 13. Fatty-acid amide hydrolase 1, 14. Glutathione S-transferase P, 15. Glutathione S-transferase Mu 1,  Serum albumin,  P-glycoprotein 1","DB00316, DB15885, DB03783, DB08792",
DB00317,Gefitinib,approved; investigational,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1,C22H24ClFN4O3,,"Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Inhibitors, BCRP/ABCG2 Substrates, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Enzyme Inhibitors, Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, Heterocyclic Compounds, Fused-Ring, Kinase Inhibitor, P-glycoprotein inhibitors, P-glycoprotein substrates, Protein Kinase Inhibitors, Quinazolines, Tyrosine Kinase Inhibitors"," Epidermal growth factor receptor,  Cytochrome P450 3A5,  Cytochrome P450 1A1,  Cytochrome P450 2C9,  Cytochrome P450 2C19,  Cytochrome P450 3A4,  Cytochrome P450 2D6,  Serum albumin,  Alpha-1-acid glycoprotein 1,  P-glycoprotein 1,  ATP-binding cassette sub-family G member 2","DB00317, DB12183, DB12114, DB05424, DB11973, DB12174, DB11963, DB08916, DB14795, DB05294, DB00530, DB11737, DB17170, DB03365, DB02984, DB07249",
DB00318,Codeine,approved; illicit,[H][C@]12C=C[C@H](O)[C@@H]3OC4=C5C(C[C@H]1N(C)CC[C@@]235)=CC=C4OC,C18H21NO3,,"Alkaloids, Analgesics, Antitussive Agents, Central Nervous System Agents, Central Nervous System Depressants, Cough and Cold Preparations, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Heterocyclic Compounds, Fused-Ring, Morphinans, Morphine Derivatives, Narcotics, Natural Opium Alkaloids, Nervous System, OAT1/SLC22A6 inhibitors, OCT1 inhibitors, OCT1 substrates, Opiate Agonists, Opiate Alkaloids, Opioid Agonist, Opioids, Opium Alkaloids and Derivatives, Phenanthrenes, Respiratory System Agents, Sensory System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, UGT2B7 substrates"," Mu-type opioid receptor,  Kappa-type opioid receptor,  Delta-type opioid receptor,  Cytochrome P450 2D6,  Cytochrome P450 3A4,  UDP-glucuronosyltransferase 2B7,  UDP-glucuronosyltransferase 2B4,  Solute carrier family 22 member 1","DB00318, DB01477, DB01466, DB00295, DB11490, DB09209, DB01573, DB01568, DB01480, DB01497, DB01469, DB01452, DB01551, DB06409, DB01565, DB01512, DB00844, DB15341, DB14146, DB16072, DB00921, DB01450, DB01548, DB16117, DB13454, DB06230, DB09049, DB00497, DB13458, DB01538",
DB00319,Piperacillin,approved,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=CC=C1)C(O)=O,C23H27N5O7S,,"Agents that produce neuromuscular block (indirect), Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Beta-Lactam Antibacterials, beta-Lactams, Drugs that are Mainly Renally Excreted, Extended-spectrum Penicillins, Heterocyclic Compounds, Fused-Ring, Lactams, OAT1/SLC22A6 inhibitors, OAT3/SLC22A8 Substrates, Penicillin G, Penicillins, Penicillins With Extended Spectrum, Sulfur Compounds"," Penicillin-binding protein 3,  Penicillin-binding protein 2B,  Penicillin-binding protein 2a,  Penicillin-binding protein 1b,  Solute carrier family 22 member 6,  Solute carrier family 22 member 8","DB00319, DB01061, DB00739, DB00415, DB00948, DB01053, DB13836, DB01060, DB00578, DB08795, DB13816, DB01604, DB13739, DB08559, DB07806, DB09320, DB01607, DB13506, DB01602, DB13693, DB13814, DB13686, DB12127, DB00417, DB09319, DB01603, DB01000, DB03658, DB00607, DB13337",
DB00320,Dihydroergotamine,approved; investigational,[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O,C33H37N5O5,,"Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Agents that produce hypertension, Alkaloids, Analgesics, Antidepressive Agents, Antimigraine Preparations, Cardiovascular Agents, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dopamine Agents, Dopamine Agonists, Ergot Alkaloids and Derivatives, Ergot-derivative Dopamine Receptor Agonists, Ergotamine Derivative, Ergotamines, Heterocyclic Compounds, Fused-Ring, Narrow Therapeutic Index Drugs, Nervous System, Neurotransmitter Agents, P-glycoprotein inhibitors, Peripheral Nervous System Agents, Sensory System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT1 Receptor Agonists, Serotonin 5-HT2 Receptor Agonists, Serotonin Agents, Serotonin Modulators, Serotonin Receptor Agonists, Sympatholytic (Adrenergic Blocking) Agents, Vasoconstrictor Agents"," 5-hydroxytryptamine receptor 1B,  5-hydroxytryptamine receptor 1D,  5-hydroxytryptamine receptor 1F,  Alpha-2A adrenergic receptor,  5-hydroxytryptamine receptor 1A,  5-hydroxytryptamine receptor 1E,  5-hydroxytryptamine receptor 2A,  5-hydroxytryptamine receptor 2B,  5-hydroxytryptamine receptor 2C, 10. Alpha-1 adrenergic receptors (Protein Group), 11. Alpha-2 adrenergic receptors (Protein Group), 12. Dopamine D2 receptor, 13. Dopamine D3 receptor, 14. Dopamine D4 receptor, 15. 5-hydroxytryptamine receptor 4, 16. Beta-3 adrenergic receptor,  Cytochrome P450 3A4,  P-glycoprotein 1","DB00320, DB13345, DB11273, DB11274, DB11275, DB00696, DB01200, DB12538, DB12755, DB00080, DB12076, DB02868, DB04911, DB04431, DB04111, DB12586, DB17390, DB13928, DB06663, DB00541, DB00570, DB02792, DB00200, DB05735, DB00361, DB06402, DB00309, DB11191, DB00512, DB16144",
DB00321,Amitriptyline,approved,CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12,C20H23N,,"Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Adrenergic Uptake Inhibitors, Agents producing tachycardia, Agents that produce hypertension, Agents that reduce seizure threshold, Analgesics, Analgesics, Non-Narcotic, Anticholinergic Agents, Antidepressive Agents, Antidepressive Agents Indicated for Depression, Antidepressive Agents, Tricyclic, Central Nervous System Agents, Central Nervous System Depressants, Combined Inhibitors of Serotonin/Norepinephrine Reuptake, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (strength unknown), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (moderate), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Histamine Antagonists, Histamine H1 Antagonists, Membrane Transport Modulators, Moderate Risk QTc-Prolonging Agents, Muscarinic Antagonists, Narrow Therapeutic Index Drugs, Neurotoxic agents, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, Non-Selective Monoamine Reuptake Inhibitors, P-glycoprotein substrates, P-glycoprotein substrates with a Narrow Therapeutic Index, Psychotropic Drugs, QTc Prolonging Agents, Sensory System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2A Receptor Antagonists, Serotonin 5-HT2C Receptor Antagonists, Serotonin Agents, Serotonin Modulators, Serotonin Receptor Antagonists, Tertiary amine tricyclic antidepressants, Tricyclics and Other Norepinephrine-reuptake Inhibitors, UGT1A1 Inhibitors, UGT1A4 substrates"," Sodium-dependent noradrenaline transporter,  Sodium-dependent serotonin transporter,  5-hydroxytryptamine receptor 2A,  5-hydroxytryptamine receptor 1A,  Delta-type opioid receptor,  Kappa-type opioid receptor,  High affinity nerve growth factor receptor,  BDNF/NT-3 growth factors receptor,  Alpha-1A adrenergic receptor, 10. Alpha-1D adrenergic receptor, 11. Alpha-2A adrenergic receptor, 12. Histamine H1 receptor, 13. Potassium voltage-gated channel subfamily KQT member 2, 14. Potassium voltage-gated channel subfamily A member 1, 15. Histamine H2 receptor, 16. Histamine H4 receptor, 17. Sigma non-opioid intracellular receptor 1, 18. 5-hydroxytryptamine receptor 2C, 19. Alpha-1B adrenergic receptor, 20. 5-hydroxytryptamine receptor 7, 21. 5-hydroxytryptamine receptor 1D, 22. Mu-type opioid receptor, 23. 5-hydroxytryptamine receptor 1B, 24. 5-hydroxytryptamine receptor 6, 25. Potassium voltage-gated channel subfamily KQT member 3, 26. 5-hydroxytryptamine receptor 1C, 27. Muscarinic acetylcholine receptor (Protein Group), 28. HERG human cardiac K+ channel (Protein Group),  Cytochrome P450 2D6,  Cytochrome P450 1A2,  Cytochrome P450 2C19,  Cytochrome P450 2C9,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 2B6,  Cytochrome P450 2C8,  UDP-glucuronosyltransferase 2B10, 10. UDP-glucuronosyltransferase 1-4, 11. Glutathione S-transferases (Cytosolic) (Protein Group),  Serum albumin,  Alpha-1-acid glycoprotein 1,  P-glycoprotein 1","DB00321, DB00540, DB13114, DB13384",
DB00322,Floxuridine,approved,OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(F)C(=O)NC1=O,C9H11FN2O5,,"Antimetabolites, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strong), Cytochrome P-450 Enzyme Inhibitors, Deoxyribonucleosides, Deoxyuridine, Drugs that are Mainly Renally Excreted, Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index, Immunosuppressive Agents, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, Noxae, Nucleic Acids, Nucleotides, and Nucleosides, Nucleosides, Pyrimidine Analogues, Pyrimidine Nucleosides, Pyrimidines, Thyroxine-binding globulin inducers, Toxic Actions"," Thymidylate synthase,  Thymidine phosphorylase,  Cytochrome P450 2C9,  Thyroxine-binding globulin","DB00322, DB01629, DB12947, DB02256, DB03761, DB03274, DB02745, DB01265, DB04485, DB13030, DB00249, DB12028, DB09256, DB09327, DB03800, DB03448, DB12957, DB13421, DB03312, DB06683, DB14913, DB00432, DB15427, DB03413, DB03685, DB02714, DB02805, DB02324, DB01643, DB11998",
DB00323,Tolcapone,approved; withdrawn,CC1=CC=C(C=C1)C(=O)C1=CC(=C(O)C(O)=C1)[N+]([O-])=O,C14H11NO5,,"Anti-Dyskinesia Agents, Anti-Parkinson Drugs, Benzene Derivatives, Benzophenones, Central Nervous System Agents, Central Nervous System Depressants, COMT Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Dopamine Agents, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Hypotensive Agents, Ketones, Nervous System, Nitro Compounds, Nitrophenols, Phenols"," Catechol O-methyltransferase,  Cytochrome P450 2C9","DB00323, DB14849, DB07462",
DB00324,Fluorometholone,approved; investigational,[H][C@@]12CC[C@](O)(C(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C,C22H29FO4,,"Adrenal Cortex Hormones, Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use, Anti-Acne Preparations, Anti-Acne Preparations for Topical Use, Anti-Allergic Agents, Anti-Inflammatory Agents, Corticosteroid Hormone Receptor Agonists, Corticosteroids, Corticosteroids, Dermatological Preparations, Corticosteroids, Moderately Potent (Group II), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Inducers, Cytochrome P-450 CYP3A5 Inducers (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Substrates, Dermatologicals, Fused-Ring Compounds, Glucocorticoids, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hyperglycemia-Associated Agents, Immunosuppressive Agents, Ophthalmologicals, Pregnadienediols, Pregnadienes, Pregnanes, Sensory Organs, Steroids, Steroids, Fluorinated, Thyroxine-binding globulin inhibitors, Vasoprotectives"," Glucocorticoid receptor,  Cytochrome P450 3A5,  Cytochrome P450 3A4,  Corticosteroid-binding globulin","DB00324, DB00443, DB01234, DB11522, DB13491, DB00547, DB00620, DB08970, DB11750, DB00223, DB00663, DB09095, DB12553, DB14640, DB14649, DB00596, DB14669, DB00687, DB01384, DB09378, DB08971, DB13158, DB14634, DB00860, DB00959, DB13223, DB13728, DB01185, DB14664, DB00896",
DB00325,Nitroprusside,approved; investigational,O=N[Fe--](C#N)(C#N)(C#N)(C#N)C#N,C5FeN6O,,"Anions, Antihypertensive Agents, Arteriolar Smooth Muscle, Agents Acting On, Cardiovascular Agents, Compounds used in a research, industrial, or household setting, Cyanides, Direct Vasodilators, Drugs that are Mainly Renally Excreted, Electrolytes, Ferric Compounds, Ferricyanides, Hypotensive Agents, Indicators and Reagents, Ions, Iron Compounds, Laboratory Chemicals, Methemoglobinemia Associated Agents, Nitrates and Nitrites, Nitric Oxide Donors, Nitroferricyanide Derivatives, Nitrogen Compounds, Vasodilating Agents, Vasodilation"," Atrial natriuretic peptide receptor 1,  Cytochrome P450 1A1",DB00325,
DB00326,Calcium glucoheptonate,approved,[Ca++].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O,C14H26CaO16,,"Acids, Acyclic, Alimentary Tract and Metabolism, Calcium Salts, Carbohydrates, Hydroxy Acids, Mineral Supplements, Supplements",,"DB00326, DB11126, DB13962, DB04304, DB13180, DB03212, DB03603, DB11141, DB11246, DB11248, DB13620, DB13749, DB14488, DB14528, DB02807, DB03303, DB03489, DB03237, DB01914, DB11735, DB12907, DB12970",
DB00327,Hydromorphone,approved; illicit,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O,C17H19NO3,,"Alkaloids, Analgesics, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Heterocyclic Compounds, Fused-Ring, High-risk opioids, Morphinans, Morphine Derivatives, Narcotics, Natural Opium Alkaloids, Nervous System, Opiate Agonists, Opiate Alkaloids, Opioid Agonist, Opioids, Peripheral Nervous System Agents, Phenanthrenes, Semi-synthetic Opioids, Sensory System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, UGT1A3 substrates, UGT2B7 substrates"," Mu-type opioid receptor,  Delta-type opioid receptor,  Kappa-type opioid receptor,  UDP-glucuronosyltransferase 1-3,  UDP-glucuronosyltransferase 2B7,  Cytochrome P450 2C9,  Serum albumin","DB00327, DB00956, DB00704, DB01192, DB06800, DB00497, DB01183, DB04509, DB01531, DB01565, DB01551, DB06230, DB01512, DB00844, DB00921, DB01450, DB01548, DB16072, DB15341, DB16117, DB14146, DB01538, DB09049, DB01480, DB01497, DB00295, DB00318, DB13471, DB01477, DB01466",
DB00328,Indomethacin,approved; investigational,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O,C19H16ClNO4,,"Acetic Acid Derivatives and Related Substances, Agents causing hyperkalemia, Agents that produce hypertension, Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Antigout Preparations, Antiinflammatory and Antirheumatic Products, Antiinflammatory and Antirheumatic Products, Non-Steroids, Antiinflammatory Preparations, Non-Steroids for Topical Use, Antirheumatic Agents, BSEP/ABCB11 Substrates, Cardiac Therapy, Cardiovascular Agents, Central Nervous System Agents, Cyclooxygenase Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (strength unknown), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Enzyme Inhibitors, Heterocyclic Compounds, Fused-Ring, Hypoglycemia-Associated Agents, Immunosuppressive Agents, Indoles, Musculo-Skeletal System, Myelosuppressive Agents, Nephrotoxic agents, Non COX-2 selective NSAIDS, OAT1/SLC22A6 inhibitors, OAT1/SLC22A6 Substrates, OAT3/SLC22A8 Inhibitors, OAT3/SLC22A8 Substrates, OATP1B1/SLCO1B1 Inhibitors, Ophthalmologicals, Other Nonsteroidal Anti-inflammatory Agents, P-glycoprotein inhibitors, P-glycoprotein substrates, Peripheral Nervous System Agents, Sensory Organs, Sensory System Agents, Tocolytic Agents, Topical Products for Joint and Muscular Pain, UGT1A1 Inhibitors, UGT1A1 Substrates, UGT1A9 Substrates, UGT2B7 Inhibitors, UGT2B7 substrates"," Prostaglandin G/H synthase 2,  Phospholipase A2, membrane associated,  Prostaglandin G/H synthase 1,  Prostaglandin reductase 2,  Peroxisome proliferator-activated receptor gamma,  Lactoylglutathione lyase,  Prostaglandin D2 receptor 2,  Peroxisome proliferator-activated receptor alpha,  Aldo-keto reductase family 1 member C3, 10. Interferon-induced, double-stranded RNA-activated protein kinase, 11. Human Cyclooxygenases (Protein Group),  Cytochrome P450 2C19,  Cytochrome P450 2C9,  Liver carboxylesterase 1,  UDP-glucuronosyltransferase 1-9,  UDP-glucuronosyltransferase 1-1,  UDP-glucuronosyltransferase 2B7,  Serum albumin,  Canalicular multispecific organic anion transporter 2,  Multidrug resistance-associated protein 4,  Multidrug resistance-associated protein 6,  P-glycoprotein 1,  Multidrug resistance-associated protein 1,  Solute carrier organic anion transporter family member 1A2,  Solute carrier family 22 member 6,  Solute carrier family 22 member 8,  Canalicular multispecific organic anion transporter 1, 10. ATP-binding cassette sub-family C member 11, 11. Solute carrier family 22 member 11, 12. Sodium/bile acid cotransporter, 13. Solute carrier family 22 member 7, 14. Solute carrier organic anion transporter family member 1B1, 15. Bile salt export pump","DB00328, DB13783, DB07983, DB03121, DB13308, DB07981, DB07984, DB02504, DB13527, DB02936, DB11909, DB05737",
DB00330,Ethambutol,approved,CC[C@@H](CO)NCCN[C@@H](CC)CO,C10H24N2O2,,"Amines, Anti-Bacterial Agents, Anti-Infective Agents, Antiinfectives for Systemic Use, Antimycobacterials, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (weak), Cytochrome P-450 CYP2A6 Inhibitors, Cytochrome P-450 CYP2A6 Inhibitors (weak), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (weak), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (weak), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (weak), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (weak), Cytochrome P-450 Enzyme Inhibitors, Diamines, Drugs for Treatment of Tuberculosis, Drugs that are Mainly Renally Excreted, Ethylenediamines, Polyamines"," Probable arabinosyltransferase C,  Probable arabinosyltransferase B,  Probable arabinosyltransferase A,  Cytochrome P450 1A2,  Cytochrome P450 2E1,  Cytochrome P450 2C19,  Cytochrome P450 2D6,  Cytochrome P450 2A6,  Cytochrome P450 2C9,  Cytochrome P450 3A4",DB00330,
DB00331,Metformin,approved,CN(C)C(=N)NC(N)=N,C4H11N5,,"Alimentary Tract and Metabolism, Amidines, Biguanides, Blood Glucose Lowering Agents, Drugs that are Mainly Renally Excreted, Drugs Used in Diabetes, Guanidines, MATE 1 Substrates, MATE 2 Substrates, MATE substrates, OCT1 substrates, OCT2 Inhibitors, OCT2 Substrates, Oral Hypoglycemics"," Electron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial,  5'-AMP-activated protein kinase subunit beta-1,  Glycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic,  Solute carrier family 22 member 1,  Solute carrier family 22 member 2,  Solute carrier family 22 member 3,  Multidrug and toxin extrusion protein 1,  Equilibrative nucleoside transporter 4,  Multidrug and toxin extrusion protein 2",DB00331,
DB00332,Ipratropium,approved; experimental,[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(CO)C1=CC=CC=C1)[N+]2(C)C(C)C,C20H30NO3,,"Adrenergics, Inhalants, Agents producing tachycardia, Agents to Treat Airway Disease, Alkaloids, Anti-Asthmatic Agents, Anticholinergic Agents, Antimuscarinics Antispasmodics, Atropine Derivatives, Autonomic Agents, Aza Compounds, Azabicyclo Compounds, Belladonna Alkaloids, Bronchodilator Agents, Cholinergic Agents, Drugs for Obstructive Airway Diseases, Muscarinic Antagonists, Nasal Preparations, Neurotransmitter Agents, Peripheral Nervous System Agents, Respiratory System Agents, Solanaceous Alkaloids, Tropanes"," Muscarinic acetylcholine receptor M3,  Muscarinic acetylcholine receptor M1,  Muscarinic acetylcholine receptor M2,  Serum albumin,  alpha1-acid glycoprotein (Protein Group),  Solute carrier family 22 member 5,  Solute carrier family 22 member 4","DB00332, DB00424, DB00572, DB13833, DB11785, DB16896, DB00209, DB00747, DB11315, DB02161, DB11181, DB00462, DB09300, DB12086, DB00725, DB08978, DB09271, DB15968",
DB00333,Methadone,approved,CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1,C21H27NO,,"Analgesics, Anticholinergic Agents, Antidepressive Agents, Antitussive Agents, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strength unknown), Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C18 Substrates, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Diphenylpropylamine Derivatives, Drugs that are Mainly Renally Excreted, Drugs Used in Addictive Disorders, Drugs Used in Opioid Dependence, High-risk opioids, Ketones, Moderate Risk QTc-Prolonging Agents, Narcotics, Nervous System, Nicotinic Antagonists, NMDA Receptor Antagonists, Opiate Agonists, Opioid Agonist, Opioids, P-glycoprotein inhibitors, Peripheral Nervous System Agents, QTc Prolonging Agents, Respiratory System Agents, Sensory System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin Modulators, Thyroxine-binding globulin inducers"," Mu-type opioid receptor,  NMDA receptor (Protein Group),  Delta-type opioid receptor,  Neuronal acetylcholine receptor subunit alpha-7,  5-hydroxytryptamine receptor 3A,  Neuronal acetylcholine receptor subunit alpha-3,  Neuronal acetylcholine receptor subunit alpha-4,  Neuronal acetylcholine receptor subunit beta-2,  Cytochrome P450 3A4,  Cytochrome P450 2C19,  Cytochrome P450 3A7,  Cytochrome P450 2D6,  Cytochrome P450 2B6,  Cytochrome P450 2C8,  Cytochrome P450 19A1,  Cytochrome P450 1A2,  Cytochrome P450 2C18, 10. Cytochrome P450 2C9, 11. Cytochrome P450 3A Subfamily (Protein Group), 12. UDP-glucuronosyltransferase 2B4,  Alpha-1-acid glycoprotein 1,  Serum albumin,  P-glycoprotein 1","DB00333, DB13515, DB15198, DB01491, DB11609, DB15597, DB13436, DB13361, DB01498",
DB00334,Olanzapine,approved; investigational,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2,C17H20N4S,,"Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Agents producing tachycardia, Anticholinergic Agents, Antidepressive Agents, Antiemetics, Antipsychotic Agents, Antipsychotic Agents (Second Generation [Atypical]), Autonomic Agents, Benzazepines, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (weak), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (weak), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (weak), Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Diazepines, Oxazepines, Thiazepines and Oxepines, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Gastrointestinal Agents, Heterocyclic Compounds, Fused-Ring, Histamine Antagonists, Histamine H1 Antagonists, Histamine H2 Antagonists, Hyperglycemia-Associated Agents, Hypotensive Agents, Muscarinic Antagonists, Nervous System, Neurotransmitter Agents, P-glycoprotein substrates, Peripheral Nervous System Agents, Potential QTc-Prolonging Agents, Psycholeptics, Psychotropic Drugs, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2A Receptor Antagonists, Serotonin 5-HT2C Receptor Antagonists, Serotonin Agents, Serotonin Receptor Antagonists, Tranquilizing Agents, UGT1A4 substrates"," 5-hydroxytryptamine receptor 2A,  Dopamine D2 receptor,  Dopamine D1 receptor,  Dopamine D5 receptor,  Dopamine D3 receptor,  Dopamine D4 receptor,  5-hydroxytryptamine receptor 2C,  5-hydroxytryptamine receptor 3A,  5-hydroxytryptamine receptor 6, 10. Histamine H1 receptor, 11. Alpha-1A adrenergic receptor, 12. Alpha-1B adrenergic receptor, 13. Muscarinic acetylcholine receptor M1, 14. Muscarinic acetylcholine receptor M2, 15. Muscarinic acetylcholine receptor M3, 16. Muscarinic acetylcholine receptor M4, 17. D(1) dopamine receptor (Protein Group), 18. Beta adrenergic receptor (Protein Group), 19. 5-hydroxytryptamine receptor 1 (Protein Group), 20. GABA(A) Receptor Benzodiazepine Binding Site (Protein Group),  Cytochrome P450 1A2,  Cytochrome P450 2D6,  Dimethylaniline monooxygenase [N-oxide-forming] 3,  Cytochrome P450 2C19,  Cytochrome P450 2C9,  UDP-glucuronosyltransferase 1-4,  Cytochrome P450 3A4,  Cytochrome P450 3A Subfamily (Protein Group),  Serum albumin,  Alpha-1-acid glycoprotein 1,  P-glycoprotein 1",DB00334,
DB00335,Atenolol,approved,CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1,C14H22N2O3,,"Adrenergic Agents, Adrenergic Antagonists, Adrenergic beta-1 Receptor Antagonists, Adrenergic beta-Antagonists, Agents causing hyperkalemia, Alcohols, Amines, Amino Alcohols, Antiarrhythmic agents, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Autonomic Agents, Beta blocking agents and calcium channel blockers, Beta Blocking Agents and Thiazides, Beta Blocking Agents, Selective, Beta Blocking Agents, Selective, and Thiazides, Beta-Blockers (Beta1 Selective), Bradycardia-Causing Agents, BSEP/ABCB11 Substrates, Cardiovascular Agents, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 Substrates, Hypotensive Agents, Peripheral Nervous System Agents, QTc shortening agents, Sympatholytics"," Beta-1 adrenergic receptor,  Beta-2 adrenergic receptor,  Cytochrome P450 2D6,  Serum albumin,  Bile salt export pump","DB00335, DB06987, DB13443, DB00264, DB00187, DB00195, DB09351",
DB00336,Nitrofural,approved; investigational; vet_approved; withdrawn,NC(=O)N\N=C\C1=CC=C(O1)[N+]([O-])=O,C6H6N4O4,,"Agents Against Leishmaniasis and Trypanosomiasis, Anti-Infective Agents, Antiparasitic Products, Insecticides and Repellents, Antiprotozoals, Antiseptics and Disinfectants, Blood and Blood Forming Organs, Blood Substitutes and Perfusion Solutions, Dermatologicals, Furans, Irrigating Solutions, Medicated Dressings, Medicated Dressings With Antiinfectives, Nitro Compounds, Nitrofuran Derivatives, Nitrofurans, Ophthalmologicals, Otologicals, Sensory Organs"," Glutathione reductase,  Xanthine dehydrogenase/oxidase","DB00336, DB00698, DB13855",
DB00337,Pimecrolimus,approved; investigational,[H][C@]1(CC[C@H](Cl)[C@@H](C1)OC)\C=C(/C)[C@@]1([H])OC(=O)[C@]2([H])CCCCN2C(=O)C(=O)[C@]2(O)O[C@@]([H])([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC)C(=O)C[C@H](O)[C@H]1C)OC,C43H68ClNO11,,"Agents for Dermatitis, Excluding Corticosteroids, Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Calcineurin Inhibitor Immunosuppressant, Calcineurin Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Dermatologicals, Enzyme Inhibitors, Immunologic Factors, Immunosuppressive Agents, Lactones, Misc. Skin and Mucous Membrane Agents, Peptidylprolyl Isomerase, antagonists & inhibitors, Peripheral Nervous System Agents, Sensory System Agents"," Serine/threonine-protein kinase mTOR,  Peptidyl-prolyl cis-trans isomerase FKBP1A,  Cytochrome P450 3A4","DB00337, DB00864, DB03621, DB01590, DB15527, DB06287, DB00877, DB06233",
DB00338,Omeprazole,approved; investigational; vet_approved,COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C,C17H19N3O3S,,"2-Pyridinylmethylsulfinylbenzimidazoles, Acid Reducers, Alimentary Tract and Metabolism, Anti-Ulcer Agents, BCRP/ABCG2 Inhibitors, Benzimidazoles, Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP1A2 Inducers (strength unknown), Cytochrome P-450 CYP2C18 Substrates, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (weak), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord), Enzyme Inhibitors, Gastric Acid Lowering Agents, Gastrointestinal Agents, Heterocyclic Compounds, Fused-Ring, P-glycoprotein inhibitors, P-glycoprotein substrates, Proton Pump Inhibitors, Proton-pump Inhibitors, Pyridines, Sulfoxides, Sulfur Compounds"," Potassium-transporting ATPase alpha chain 1,  Aryl hydrocarbon receptor,  Cytochrome P450 1A1,  Cytochrome P450 1A2,  Cytochrome P450 1B1,  Cytochrome P450 2C8,  Cytochrome P450 2C9,  Cytochrome P450 2C18,  Cytochrome P450 2D6,  Cytochrome P450 3A4,  Cytochrome P450 2C19,  ATP-binding cassette sub-family G member 2,  Canalicular multispecific organic anion transporter 2,  P-glycoprotein 1","DB00338, DB00736, DB01129, DB13762, DB00448, DB05351, DB17144, DB00213, DB11964, DB13135",
DB00339,Pyrazinamide,approved; investigational,NC(=O)C1=NC=CN=C1,C5H5N3O,,"Anti-Bacterial Agents, Anti-Infective Agents, Antiinfectives for Systemic Use, Antimycobacterials, Drugs causing inadvertant photosensitivity, Drugs for Treatment of Tuberculosis, Drugs that are Mainly Renally Excreted, Hepatotoxic Agents, Photosensitizing Agents, Pyrazines"," Fatty acid synthetase,  Aldehyde oxidase,  Xanthine dehydrogenase/oxidase",DB00339,
DB00340,Metixene,approved,CN1CCCC(CC2C3=CC=CC=C3SC3=CC=CC=C23)C1,C20H23NS,,"Agents producing tachycardia, Anti-Parkinson Drugs, Anticholinergic Agents, Heterocyclic Compounds, Fused-Ring, Muscarinic Antagonists, Nervous System, Sulfur Compounds, Tertiary Amines, Xanthenes", Muscarinic acetylcholine receptor (Protein Group),DB00340,
DB00341,Cetirizine,approved,OC(=O)COCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1,C21H25ClN2O3,,"Anti-Allergic Agents, Antihistamines for Systemic Use, Central Nervous System Depressants, Decongestants and Antiallergics, Drugs that are Mainly Renally Excreted, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Histamine H1 Antagonists, Non-Sedating, Ophthalmologicals, P-glycoprotein inhibitors, P-glycoprotein substrates, Piperazine Derivatives, Piperazines, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Sensory Organs"," Histamine H1 receptor,  P-glycoprotein 1","DB00341, DB06282, DB00557, DB08936, DB00737, DB00354",
DB00342,Terfenadine,approved; withdrawn,CC(C)(C)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,C32H41NO2,,"Anticholinergic Agents, Antihistamines for Systemic Use, Benzene Derivatives, Benzhydryl Compounds, BSEP/ABCB11 Substrates, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strong), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Highest Risk QTc-Prolonging Agents, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Histamine H1 Antagonists, Non-Sedating, Muscarinic Antagonists, Neurotransmitter Agents, P-glycoprotein inhibitors, P-glycoprotein substrates, Piperidines, QTc Prolonging Agents"," Histamine H1 receptor,  Muscarinic acetylcholine receptor M3,  Muscarinic acetylcholine receptor M1,  Muscarinic acetylcholine receptor M5,  Muscarinic acetylcholine receptor M4,  Muscarinic acetylcholine receptor M2,  Potassium voltage-gated channel subfamily H member 2,  Cytochrome P450 3A4,  Cytochrome P450 3A7,  Cytochrome P450 2D6,  Cytochrome P450 3A5,  Cytochrome P450 2C8,  Cytochrome P450 2J2,  alpha1-acid glycoprotein (Protein Group),  Serum albumin,  P-glycoprotein 1,  Bile salt export pump","DB00342, DB01231, DB00950, DB09076",
DB00343,Diltiazem,approved; investigational,COC1=CC=C(C=C1)[C@@H]1SC2=C(C=CC=C2)N(CCN(C)C)C(=O)[C@@H]1OC(C)=O,C22H26N2O4S,,"Agents causing hyperkalemia, Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use, Antiarrhythmic agents, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Benzazepines, Benzothiazepine Derivatives, Bradycardia-Causing Agents, Calcium Channel Blockers, Calcium Channel Blockers (Nondihydropyridine), Calcium-Regulating Hormones and Agents, Cardiovascular Agents, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (moderate), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (moderate), Cytochrome P-450 CYP3A4 Inhibitors (strong), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Inhibitors, Cytochrome P-450 CYP3A5 Inhibitors (moderate), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Inhibitors, Cytochrome P-450 CYP3A7 Inhibitors (moderate), Cytochrome P-450 CYP3A7 Inhibitors (strong), Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs causing inadvertant photosensitivity, Heterocyclic Compounds, Fused-Ring, Hypotensive Agents, Membrane Transport Modulators, Miscellaneous Calcium-channel Blocking Agents, Moderate Risk QTc-Prolonging Agents, Negative Inotrope, P-glycoprotein inhibitors, P-glycoprotein substrates, Photosensitizing Agents, QTc Prolonging Agents, Selective Calcium Channel Blockers With Direct Cardiac Effects, Vasodilating Agents, Vasoprotectives"," Voltage-dependent L-type calcium channel subunit alpha-1C,  Voltage-dependent calcium channel gamma-1 subunit,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  Cytochrome P450 2C19,  Cytochrome P450 2D6,  Cytochrome P450 2C8,  Serum albumin,  Alpha-1-acid glycoprotein 1,  P-glycoprotein 1",DB00343,
DB00344,Protriptyline,approved,CNCCCC1C2=CC=CC=C2C=CC2=CC=CC=C12,C19H21N,,"Adrenergic Agents, Adrenergic Uptake Inhibitors, Agents that produce hypertension, Agents that reduce seizure threshold, Antidepressive Agents, Antidepressive Agents Indicated for Depression, Antidepressive Agents, Tricyclic, Benzocycloheptenes, Central Nervous System Agents, Central Nervous System Depressants, Combined Inhibitors of Serotonin/Norepinephrine Reuptake, Dibenzocycloheptenes, Membrane Transport Modulators, Narrow Therapeutic Index Drugs, Nervous System, Neurotoxic agents, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, Non-Selective Monoamine Reuptake Inhibitors, P-glycoprotein inhibitors, Potential QTc-Prolonging Agents, Psychoanaleptics, Psychotropic Drugs, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin Modulators"," Sodium-dependent noradrenaline transporter,  Sodium-dependent serotonin transporter,  P-glycoprotein 1",DB00344,
DB00345,Aminohippuric acid,approved; investigational,NC1=CC=C(C=C1)C(=O)NCC(O)=O,C9H10N2O3,,"Acids, Carbocyclic, Amides, Aminobenzoates, Aminohippuric Acids, Benzamides and benzamide derivatives, Benzene Derivatives, Benzoates, Compounds used in a research, industrial, or household setting, Diagnostic Agents, Hippurates, Indicators and Reagents, Keto Acids, Laboratory Chemicals, OAT1/SLC22A6 inhibitors, OAT1/SLC22A6 Substrates, OAT3/SLC22A8 Inhibitors, OAT3/SLC22A8 Substrates, OATP1B1/SLCO1B1 Inhibitors, OCT2 Inhibitors, para-Aminobenzoates, Tests for Renal Function and Ureteral Injuries"," Solute carrier family 22 member 2,  Solute carrier family 22 member 5,  Solute carrier family 22 member 6,  Solute carrier family 22 member 8,  Canalicular multispecific organic anion transporter 1,  Solute carrier family 22 member 4,  Solute carrier family 22 member 11,  Solute carrier organic anion transporter family member 3A1,  Multidrug resistance-associated protein 1, 10. Monocarboxylate transporter 1, 11. Solute carrier family 22 member 7","DB00345, DB16842, DB08508, DB07069",
DB00346,Alfuzosin,approved; investigational,COC1=CC2=C(C=C1OC)C(N)=NC(=N2)N(C)CCCNC(=O)C1CCCO1,C19H27N5O4,,"Adrenergic Agents, Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Drugs Used in Benign Prostatic Hypertrophy, Genito Urinary System and Sex Hormones, Genitourinary Agents, Heterocyclic Compounds, Fused-Ring, Neurotransmitter Agents, P-glycoprotein substrates, Peripheral alpha-1 blockers, Potential QTc-Prolonging Agents, Prostatic Hyperplasia, QTc Prolonging Agents, Selective Alfa-1-adrenergic Blocking Agents, Urological Agents, Urologicals"," Alpha-1 adrenergic receptors (Protein Group),  Alpha-1A adrenergic receptor,  Alpha-1B adrenergic receptor,  Alpha-1D adrenergic receptor,  Cytochrome P450 3A4,  Serum albumin,  Alpha-1-acid glycoprotein 1,  P-glycoprotein 1","DB00346, DB01162, DB12230, DB00590",
DB00347,Trimethadione,approved,CN1C(=O)OC(C)(C)C1=O,C6H9NO3,,"Agents causing hyperkalemia, Anti-epileptic Agent, Antiarrhythmic agents, Anticonvulsants, Bradycardia-Causing Agents, Calcium Channel Blockers, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Decreased Central Nervous System Disorganized Electrical Activity, Nervous System, Oxazoles, Oxazolidine Derivatives, Potential QTc-Prolonging Agents, QTc Prolonging Agents"," Voltage-dependent T-type calcium channel subunit alpha-1G,  Cytochrome P450 2E1,  Cytochrome P450 3A4,  Cytochrome P450 2C8,  Cytochrome P450 2C9,  Cytochrome P450 2C19","DB00347, DB13799, DB00617",
DB00348,Nitisinone,approved; investigational,[O-][N+](=O)C1=C(C=CC(=C1)C(F)(F)F)C(=O)C1C(=O)CCCC1=O,C14H10F3NO5,,"4-Hydroxyphenyl-Pyruvate Dioxygenase Inhibitor, 4-Hydroxyphenylpyruvate Dioxygenase, antagonists & inhibitors, Acids, Carbocyclic, Alimentary Tract and Metabolism, Benzene Derivatives, Benzoates, Cyclohexanes, Cycloparaffins, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 Enzyme Inhibitors, Enzyme Inhibitors, Hydroxyphenylpyruvate Dioxygenase Inhibitors, Ketones, Other Miscellaneous Therapeutic Agents, Various Alimentary Tract and Metabolism Products", 4-hydroxyphenylpyruvate dioxygenase,DB00348,
DB00349,Clobazam,approved; illicit,CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O,C16H13ClN2O2,,"Anti-Anxiety Agents, Anticonvulsants, Benzazepines, Benzodiazepines and benzodiazepine derivatives, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C18 Substrates, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (weak), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Inducers (weak), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, GABA Agents, GABA Agonists, GABA-A Receptor Agonists, Heterocyclic Compounds, Fused-Ring, Nervous System, Neurotransmitter Agents, P-glycoprotein substrates, Psycholeptics, Psychotropic Drugs, Tranquilizing Agents, UGT1A4 Inhibitors, UGT1A6 Inhibitors"," GABA(A) Receptor (Protein Group),  GABA(A) Receptor Benzodiazepine Binding Site (Protein Group),  Cytochrome P450 1A2,  Cytochrome P450 2B6,  Cytochrome P450 2D6,  Cytochrome P450 2C8,  Cytochrome P450 2C9,  Cytochrome P450 2C18,  Cytochrome P450 2C19,  Cytochrome P450 3A5,  Cytochrome P450 3A4, 10. Cytochrome P450 3A7, 11. UDP-glucuronosyltransferase 1-1, 12. UDP-glucuronosyltransferase 1-4, 13. UDP-glucuronosyltransferase 1-6, 14. UDP-glucuronosyltransferase 2B4,  Serum albumin,  Alpha-1-acid glycoprotein 1,  P-glycoprotein 1","DB00349, DB17092",
DB00350,Minoxidil,approved; investigational,NC1=CC(=NC(N)=[N+]1[O-])N1CCCCC1,C9H15N5O,,"Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Arteriolar Smooth Muscle, Agents Acting On, Arteriolar Vasodilation, Arteriolar Vasodilator, Cardiovascular Agents, Dermatologicals, Direct Vasodilators, Hypotensive Agents, Misc. Skin and Mucous Membrane Agents, Piperidines, Potassium Channel Opener, Pyrimidine Derivatives, Pyrimidines, UGT1A1 Substrates, Vasodilating Agents"," ATP-sensitive inward rectifier potassium channel 1,  Renin,  Prostaglandin G/H synthase 1,  UDP-glucuronosyltransferase 1-1",DB00350,
DB00351,Megestrol acetate,approved; investigational; vet_approved,[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C,C24H32O4,,"Adrenal Cortex Hormones, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Antineoplastic and Immunomodulating Agents, Appetite Stimulants, Central Nervous System Agents, Central Nervous System Stimulants, Combination Contraceptives (with Estrogen and derivatives), Contraceptive Agents, Female, Contraceptive Agents, Hormonal, Contraceptives, Oral, Contraceptives, Oral, Hormonal, Contraceptives, Oral, Synthetic, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Endocrine Therapy, Fused-Ring Compounds, Genito Urinary System and Sex Hormones, Hormonal Contraceptives for Systemic Use, Hormones and Related Agents, Hyperglycemia-Associated Agents, Megestrol, P-glycoprotein inhibitors, Pregnadien Derivatives, Pregnadienes, Pregnanes, Progestin Contraceptives, Progestins, Progestogens and Estrogens, Sequential Preparations, Reproductive Control Agents, Sex Hormones and Modulators of the Genital System, Steroids"," Progesterone receptor,  Glucocorticoid receptor,  Cytochrome P450 3A4,  P-glycoprotein 1","DB00351, DB13981, DB14659, DB12221, DB15903, DB04839, DB00603, DB11440, DB11636, DB12499, DB14583, DB06789, DB14677, DB14660, DB11529, DB05288, DB06780, DB13958, DB09015, DB01134, DB01420, DB14539, DB01380, DB08804, DB13640, DB13943, DB13944, DB13946, DB16001, DB16002",
DB00352,Tioguanine,approved,NC1=NC(=S)C2=C(N1)N=CN2,C5H5N5S,,"Antimetabolites, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Heterocyclic Compounds, Fused-Ring, Immunosuppressive Agents, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, Noxae, Purine Analogues, Purines, Thiopurine Analogs, Toxic Actions"," DNA,  Hypoxanthine-guanine phosphoribosyltransferase,  Multidrug resistance-associated protein 4","DB00352, DB01033",
DB00353,Methylergometrine,approved,[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO,C20H25N3O2,,"Agents that produce hypertension, Alkaloids, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dopamine Antagonists, Ergolines, Ergonovine, Ergot Alkaloids and Derivatives, Genito Urinary System and Sex Hormones, Heterocyclic Compounds, Fused-Ring, Reproductive Control Agents, Uterotonic agents"," Dopamine D1 receptor,  5-hydroxytryptamine receptor 2B,  Cytochrome P450 3A4","DB00353, DB01253, DB04829, DB00247, DB00589, DB00696",
DB00354,Buclizine,approved,CC(C)(C)C1=CC=C(CN2CCN(CC2)C(C2=CC=CC=C2)C2=CC=C(Cl)C=C2)C=C1,C28H33ClN2,,"Agents producing tachycardia, Anticholinergic Agents, Antihistamines for Systemic Use, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Muscarinic Antagonists, Neurotransmitter Agents, Piperazine Derivatives, Potential QTc-Prolonging Agents, QTc Prolonging Agents"," Histamine H1 receptor,  Muscarinic acetylcholine receptor M1","DB00354, DB08936, DB00737, DB15979, DB00557, DB00341, DB06282, DB01176",
DB00355,Aztreonam,approved,C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(=O)O)\C2=CSC([NH3+])=N2)C(=O)N1S([O-])(=O)=O,C13H17N5O8S2,,"Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, beta-Lactams, Drugs that are Mainly Renally Excreted, Heterocyclic Compounds, Fused-Ring, Lactams, Monobactam Antibacterial, Monobactams, Sulfur Compounds"," Penicillin-binding protein 3,  Beta-lactamase,  Beta-lactamase Toho-1","DB00355, DB13553",
DB00356,Chlorzoxazone,approved,ClC1=CC2=C(OC(=O)N2)C=C1,C7H4ClNO2,,"Benzoxazoles and derivatives, Central Nervous System Agents, Central Nervous System Depressants, Centrally-mediated Muscle Relaxation, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2A6 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (weak), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Heterocyclic Compounds, Fused-Ring, Muscle Relaxants, Muscle Relaxants, Centrally Acting Agents, Musculo-Skeletal System, Oxazol, Thiazine, and Triazine Derivatives, Peripheral Nervous System Agents"," Calcium-activated potassium channel subunit alpha-1,  Cytochrome P450 2E1,  Cytochrome P450 1A1,  Cytochrome P450 1A2,  Cytochrome P450 2A6,  Cytochrome P450 3A4,  Cytochrome P450 2D6",DB00356,
DB00357,Aminoglutethimide,approved; investigational,CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1,C13H16N2O2,,"Antineoplastic Agents, Antineoplastic Agents, Hormonal, Antineoplastic and Immunomodulating Agents, Aromatase Inhibitors, Cytochrome P-450 CYP2C19 Inducers, Cytochrome P-450 CYP2C19 Inducers (strength unknown), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 Enzyme Inducers, Endocrine Therapy, Enzyme Inhibitors, Estrogen Antagonists, Hormone Antagonists, Hormone Antagonists and Related Agents, Hormones, Hormone Substitutes, and Hormone Antagonists, Narrow Therapeutic Index Drugs, Piperidines, Piperidones, Steroid Synthesis Inhibitors"," Cholesterol side-chain cleavage enzyme, mitochondrial,  Cytochrome P450 19A1,  Cytochrome P450 3A4,  Cytochrome P450 2C19","DB00357, DB01437, DB13413, DB08997",
DB00358,Mefloquine,approved; investigational,OC(C1CCCCN1)C1=CC(=NC2=C1C=CC=C2C(F)(F)F)C(F)(F)F,C17H16F6N2O,,"Agents Causing Muscle Toxicity, Agents that reduce seizure threshold, Aminoquinolines, Anti-Infective Agents, Antimalarial methanolquinolines, Antimalarials, Antiparasitic Agents, Antiparasitic Products, Insecticides and Repellents, Antiprotozoals, Cholinesterase Inhibitors, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Heterocyclic Compounds, Fused-Ring, P-glycoprotein inhibitors, P-glycoprotein substrates, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Quinolines"," Fe(II)-protoporphyrin IX,  Adenosine receptor A2a,  Cytochrome P450 19A1,  Acetylcholinesterase,  Cholinesterase,  Cytochrome P450 3A4,  P-glycoprotein 1",DB00358,
DB00359,Sulfadiazine,approved; investigational; vet_approved,NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=N1,C10H10N4O2S,,"Amides, Amines, Aniline Compounds, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Antiparasitic Agents, Antiprotozoals, Benzene Derivatives, Benzenesulfonamides, Blood Glucose Lowering Agents, Coccidiostats, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Hypoglycemia-Associated Agents, Intermediate-Acting Antibacterial Sulfonamides, Methemoglobinemia Associated Agents, Sulfanilamides, Sulfonamide Antibacterial, Sulfonamides, Sulfonamides and trimethoprim, Sulfones, Sulfur Compounds"," Dihydropteroate synthetase,  Cytochrome P450 2C8,  Cytochrome P450 3A4,  Cytochrome P450 2C9","DB00359, DB05245, DB13320, DB06821, DB01581, DB01582, DB11547, DB01382",
DB00360,Sapropterin,approved; investigational,[H][C@@]1(CNC2=C(N1)C(=O)NC(N)=N2)[C@@H](O)[C@H](C)O,C9H15N5O3,,"Alimentary Tract and Metabolism, Amines, BCRP/ABCG2 Inhibitors, Coenzymes, Dietary Supplements, Enzymes and Coenzymes, Ethylamines, Heterocyclic Compounds, Fused-Ring, Nitric Oxide Synthase, Other Miscellaneous Therapeutic Agents, P-glycoprotein inhibitors, Phenethylamines, Phenylalanine Hydroxylase Activator, Phenylalanine Hydroxylase Activators, Pteridines, Pterins, Supplements, Various Alimentary Tract and Metabolism Products"," Phenylalanine-4-hydroxylase,  Nitric oxide synthase, endothelial,  Tyrosine 3-monooxygenase,  Tryptophan 5-hydroxylase 1,  Prostaglandin G/H synthase 2,  P-glycoprotein 1","DB00360, DB03918, DB12575",
DB00361,Vinorelbine,approved; investigational,[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC,C45H54N4O8,,"Alkaloids, Antimitotic Agents, Antineoplastic Agents, Antineoplastic Agents, Phytogenic, Antineoplastic and Immunomodulating Agents, Cardiotoxic antineoplastic agents, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Heterocyclic Compounds, Fused-Ring, Immunosuppressive Agents, Indole Alkaloids, Indoles, Indolizidines, Indolizines, Mitosis Modulators, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, Neurotoxic agents, Secologanin Tryptamine Alkaloids, Tubulin Modulators, Vinca Alkaloids"," Tubulin beta chain,  Cytochrome P450 2D6,  Cytochrome P450 3A4","DB00361, DB11641, DB12586, DB17390, DB00541, DB00570, DB00309, DB05168, DB02868, DB11191, DB00200, DB03614, DB11467, DB03469, DB04803, DB05735, DB03906, DB12674, DB02832, DB03317, DB16186, DB02667, DB16312, DB17385, DB00615, DB02949, DB15673, DB00115, DB11476, DB13013",
DB00362,Anidulafungin,approved; investigational,[H][C@]1(NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)[C@H](C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C1=O)NC(=O)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CC=C(OCCCCC)C=C1)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@@H](C)O,C58H73N7O17,,"Amino Acids, Peptides, and Proteins, Anti-Infective Agents, Antifungal Agents, Antiinfectives for Systemic Use, Antimycotics for Systemic Use, Echinocandin Antifungal, Echinocandins, Peptides, Peptides, Cyclic"," 1,3-beta-glucan synthase component FKS1","DB00362, DB05128, DB01141",
DB00363,Clozapine,approved,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12,C18H19ClN4,,"Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Agents producing tachycardia, Agents that produce hypertension, Agents that reduce seizure threshold, Anticholinergic Agents, Antidepressive Agents, Antipsychotic Agents, Antipsychotic Agents (Second Generation [Atypical]), Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2A6 Substrates, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (strength unknown), Cytochrome P-450 CYP2C19 Inhibitors (weak), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (moderate), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Diazepines, Oxazepines, Thiazepines and Oxepines, Dibenzazepines, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Drugs causing inadvertant photosensitivity, Drugs that are Mainly Renally Excreted, GABA Agents, GABA Antagonists, Heterocyclic Compounds, Fused-Ring, Histamine Antagonists, Histamine H1 Antagonists, Hyperglycemia-Associated Agents, Hypotensive Agents, Moderate Risk QTc-Prolonging Agents, Muscarinic Antagonists, Nervous System, Neurotoxic agents, Neurotransmitter Agents, OCT1 substrates, P-glycoprotein substrates, Photosensitizing Agents, Psycholeptics, Psychotropic Drugs, QTc Prolonging Agents, Serotonin 5-HT1 Receptor Antagonists, Serotonin 5-HT1A Receptor Antagonists, Serotonin 5-HT1D Receptor Antagonists, Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2A Receptor Antagonists, Serotonin 5-HT2C Receptor Antagonists, Serotonin Agents, Serotonin Receptor Antagonists, Tranquilizing Agents, UGT1A4 substrates"," Dopamine D1 receptor,  Dopamine D2 receptor,  Dopamine D3 receptor,  Dopamine D4 receptor,  Dopamine D5 receptor,  5-hydroxytryptamine receptor 1A,  5-hydroxytryptamine receptor 1B,  5-hydroxytryptamine receptor 1D,  5-hydroxytryptamine receptor 1E, 10. 5-hydroxytryptamine receptor 2A, 11. 5-hydroxytryptamine receptor 3A, 12. 5-hydroxytryptamine receptor 2C, 13. 5-hydroxytryptamine receptor 6, 14. 5-hydroxytryptamine receptor 7, 15. Alpha-2C adrenergic receptor, 16. Histamine H1 receptor, 17. Histamine H4 receptor, 18. Alpha-1A adrenergic receptor, 19. Alpha-1B adrenergic receptor, 20. Alpha-2A adrenergic receptor, 21. Alpha-2B adrenergic receptor, 22. Muscarinic acetylcholine receptor M1, 23. Muscarinic acetylcholine receptor M2, 24. Muscarinic acetylcholine receptor M3, 25. Muscarinic acetylcholine receptor M4, 26. Muscarinic acetylcholine receptor M5, 27. Neuron-specific vesicular protein calcyon, 28. Glutathione S-transferase P, 29. Gamma-aminobutyric acid type B receptor subunit 1, 30. Gamma-aminobutyric acid type B receptor subunit 2, 31. Gamma-aminobutyric acid receptor subunit alpha-1, 32. Gamma-aminobutyric acid receptor subunit beta-1, 33. Gamma-aminobutyric acid receptor subunit gamma-1,  Cytochrome P450 1A2,  Cytochrome P450 2D6,  Cytochrome P450 2C9,  Cytochrome P450 3A4,  Cytochrome P450 2C19,  Cytochrome P450 2A6,  Cytochrome P450 2C8,  Dimethylaniline monooxygenase [N-oxide-forming] 3,  UDP-glucuronosyltransferase 1-4, 10. Cytochrome P450 1A1,  Alpha-1-acid glycoprotein 1,  Serum albumin,  P-glycoprotein 1,  Solute carrier family 22 member 1,  Solute carrier family 22 member 2,  Solute carrier family 22 member 3","DB00363, DB05766",
DB00364,Sucralfate,approved,O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@](COS(=O)(=O)O[Al](O)O)(O[C@H]2O[C@H](COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@H]2OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O,C12H35Al9O55S8,,"Alimentary Tract and Metabolism, Aluminium Compounds, Aluminum Complex, Anti-Ulcer Agents, Carbohydrates, Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord), Drugs that are Mainly Renally Excreted, Gastric Cytoprotectants, Gastrointestinal Agents, Glycosides, Metal cations, Metal divalent cations, Organometallic Compounds, Protectants, Sulfur Compounds, Thioglycosides"," Pepsin A-5,  Fibroblast growth factor 2,  Pro-epidermal growth factor","DB00364, DB01901, DB00686, DB02879",
DB00365,Grepafloxacin,approved; investigational; withdrawn,CC1CN(CCN1)C1=C(F)C(C)=C2C(=O)C(=CN(C3CC3)C2=C1)C(O)=O,C19H22FN3O3,,"Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Enzyme Inhibitors, Fluoroquinolones, Heterocyclic Compounds, Fused-Ring, Highest Risk QTc-Prolonging Agents, OAT1/SLC22A6 Substrates, OCT2 Inhibitors, P-glycoprotein inhibitors, P-glycoprotein substrates, QTc Prolonging Agents, Quinolines, Quinolones, Topoisomerase II Inhibitors, Topoisomerase Inhibitors"," DNA gyrase subunit A,  DNA topoisomerase 4 subunit A,  Cytochrome P450 1A2,  Cytochrome P450 3A4,  P-glycoprotein 1,  Multidrug resistance-associated protein 1,  Solute carrier family 22 member 6,  Solute carrier family 22 member 2,  Solute carrier family 22 member 5,  Canalicular multispecific organic anion transporter 1","DB00365, DB00537, DB11404, DB11393, DB01208, DB00978, DB11443, DB01059, DB00487, DB04576, DB06771, DB01044, DB14025, DB11453, DB13261, DB01405, DB11491, DB11511, DB12447, DB16219, DB09047, DB00218, DB13772, DB11847, DB01137, DB01165, DB03034, DB06600",
DB00366,Doxylamine,approved; vet_approved,CN(C)CCOC(C)(C1=CC=CC=C1)C1=CC=CC=N1,C17H22N2O,,"Agents producing tachycardia, Aminoalkyl Ethers, Anticholinergic Agents, Antiemetics, Antihistamines for Systemic Use, Autonomic Agents, Central Nervous System Agents, Central Nervous System Depressants, Ethanolamine Derivatives, Gastrointestinal Agents, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Histamine Receptor Antagonists, Muscarinic Antagonists, Neurotransmitter Agents, Peripheral Nervous System Agents, Potential QTc-Prolonging Agents, Pyridines, QTc Prolonging Agents"," Histamine H1 receptor,  Nuclear receptor subfamily 1 group I member 3,  Muscarinic acetylcholine receptor (Protein Group),  CYP2B protein,  Serum albumin","DB00366, DB00748",
DB00367,Levonorgestrel,approved; investigational,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],C21H28O2,,"Adrenal Cortex Hormones, Combination Contraceptives (with Estrogen and derivatives), Contraceptive Agents, Female, Contraceptive Agents, Hormonal, Contraceptives, Oral, Contraceptives, Oral, Synthetic, Contraceptives, Postcoital, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Substrates, Fused-Ring Compounds, Genito Urinary System and Sex Hormones, Hormonal Contraceptives for Systemic Use, Hyperglycemia-Associated Agents, Inhibit Ovum Fertilization, Norpregnanes, Norpregnenes, Norsteroids, Progestin Contraceptives, Progestin-containing Intrauterine Device, Progestins, Progestogens and Estrogens, Sequential Preparations, Reproductive Control Agents, Sex Hormones and Modulators of the Genital System, Steroids"," Progesterone receptor,  3-oxo-5-alpha-steroid 4-dehydrogenase 1,  Estrogen receptor alpha,  Androgen receptor,  Sex hormone-binding globulin,  Glucocorticoid receptor,  Cytochrome P450 3A5,  Cytochrome P450 3A4","DB00367, DB00717, DB09389, DB00294, DB00624, DB01471, DB01543, DB01564, DB05830, DB06710, DB07768, DB11429, DB12787, DB13169, DB13533, DB14093, DB13710, DB13230, DB14570, DB06730, DB14584, DB00253, DB18000, DB01481, DB01572, DB04652, DB09070, DB09371, DB01500, DB01540",
DB00368,Norepinephrine,approved,NC[C@H](O)C1=CC(O)=C(O)C=C1,C8H11NO3,,"Adrenergic Agents, Adrenergic Agonists, Adrenergic alpha-1 Receptor Agonists, Adrenergic alpha-2 Receptor Agonists, Adrenergic alpha-Agonists, Adrenergic and Dopaminergic Agents, Adrenergic beta-1 Receptor Agonists, Adrenergic beta-2 Receptor Agonists, Adrenergic beta-3 Receptor Agonists, Adrenergic beta-Agonists, Agents producing tachycardia, Agents that produce hypertension, Alcohols, Alpha-and Beta-adrenergic Agonists, Amines, Amino Alcohols, Autonomic Agents, Benzene Derivatives, Biogenic Amines, Biogenic Monoamines, Cardiac Stimulants Excl. Cardiac Glycosides, Cardiac Therapy, Cardiovascular Agents, Catecholamines, Catechols, COMT Substrates, Epinephrine and similars, Ethanolamines, Neurotransmitter Agents, Norepinephrine, antagonists & inhibitors, OCT1 substrates, OCT2 Inhibitors, OCT2 Substrates, Peripheral Nervous System Agents, Phenols, Sympathomimetics, Vasoconstrictor Agents"," Alpha-1A adrenergic receptor,  Alpha-1B adrenergic receptor,  Alpha-1D adrenergic receptor,  Alpha-2A adrenergic receptor,  Alpha-2B adrenergic receptor,  Alpha-2C adrenergic receptor,  Beta-1 adrenergic receptor,  Beta-2 adrenergic receptor,  Beta-3 adrenergic receptor, 10. Phenylalanine-4-hydroxylase, 11. Synaptic vesicular amine transporter, 12. Chromaffin granule amine transporter,  Sodium-dependent noradrenaline transporter,  Solute carrier family 22 member 2,  Solute carrier family 22 member 3,  Solute carrier family 22 member 5,  Solute carrier family 22 member 1,  POU domain, class 5, transcription factor 1","DB00368, DB00668, DB13378, DB06707, DB00988, DB01064, DB13251, DB00388, DB08985, DB08957, DB00610, DB13494, DB13917, DB09203",
DB00369,Cidofovir,approved,NC1=NC(=O)N(C[C@@H](CO)OCP(O)(O)=O)C=C1,C8H14N3O6P,,"Anti-Infective Agents, Antiinfectives for Systemic Use, Antiviral Agents, Antivirals for Systemic Use, Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor, Cytosine, Direct Acting Antivirals, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Nephrotoxic agents, Nucleic Acid Synthesis Inhibitors, Nucleosides and Nucleotides, Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors, OAT1/SLC22A6 inhibitors, OAT1/SLC22A6 Substrates, Organophosphonates, Organophosphorus Compounds, Pyrimidines, Pyrimidinones"," DNA polymerase catalytic subunit,  Thymidine phosphorylase,  Solute carrier family 22 member 6","DB00369, DB12151",
DB00370,Mirtazapine,approved,CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1,C17H19N3,,"Adrenergic Agents, Adrenergic alpha-2 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Agents that produce hypertension, Anti-Anxiety Agents, Antidepressive Agents, Antidepressive Agents Indicated for Depression, Antidepressive Agents, Second-Generation, Antidepressive Agents, Tetracyclic, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (weak), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Heterocyclic Compounds, Fused-Ring, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Miscellaneous Antidepressants, Nervous System, Neurotransmitter Agents, Potential QTc-Prolonging Agents, Psychoanaleptics, Psychotropic Drugs, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2A Receptor Antagonists, Serotonin 5-HT2C Receptor Antagonists, Serotonin 5-HT3 Receptor Antagonists, Serotonin Agents, Serotonin Modulators, Serotonin Receptor Antagonists, Tranquilizing Agents"," 5-hydroxytryptamine receptor 2A,  5HT3 serotonin receptor,  Alpha-2A adrenergic receptor,  Alpha-1 adrenergic receptors (Protein Group),  5-hydroxytryptamine receptor 2C,  Kappa-type opioid receptor,  Histamine H1 receptor,  Cytochrome P450 3A4,  Cytochrome P450 2D6,  Cytochrome P450 1A2,  Sodium-dependent serotonin transporter","DB00370, DB06678, DB06148",
DB00371,Meprobamate,approved; illicit,CCCC(C)(COC(N)=O)COC(N)=O,C9H18N2O4,,"Acids, Acyclic, Anti-Anxiety Agents, Carbamates, Central Nervous System Agents, Central Nervous System Depressants, Hypnotics and Sedatives, Muscle Relaxants, Muscle Relaxants, Centrally Acting Agents, Nervous System, Peripheral Nervous System Agents, Psycholeptics, Psychotropic Drugs, Tranquilizing Agents"," GABA(A) Receptor (Protein Group),  Gamma-aminobutyric acid receptor subunit alpha-1,  Gamma-aminobutyric acid receptor subunit alpha-2,  Gamma-aminobutyric acid receptor subunit alpha-3,  Gamma-aminobutyric acid receptor subunit alpha-4,  Gamma-aminobutyric acid receptor subunit alpha-5,  Gamma-aminobutyric acid receptor subunit alpha-6","DB00371, DB06797",
DB00372,Thiethylperazine,approved; withdrawn,CCSC1=CC2=C(SC3=CC=CC=C3N2CCCN2CCN(C)CC2)C=C1,C22H29N3S2,,"Antiemetics, Antihistamines for Systemic Use, Antipsychotic Agents, Autonomic Agents, Central Nervous System Agents, Central Nervous System Depressants, Dopamine Agents, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Drugs that are Mainly Renally Excreted, Gastrointestinal Agents, Heterocyclic Compounds, Fused-Ring, Neurotoxic agents, Neurotransmitter Agents, Peripheral Nervous System Agents, Phenothiazine Derivatives, Phenothiazines, Piperazines, Sulfur Compounds", Dopamine D2 receptor,"DB00372, DB12710, DB00679, DB00933, DB00420, DB15596, DB00433, DB00831, DB01246, DB01622, DB13784, DB13591, DB00392, DB00902, DB00850, DB01063, DB00623",
DB00373,Timolol,approved,[H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1,C13H24N4O3S,,"Adrenergic Antagonists, Adrenergic beta-Antagonists, Agents causing hyperkalemia, Alcohols, Amines, Amino Alcohols, Antiarrhythmic agents, Antiglaucoma Preparations and Miotics, Antihypertensive Agents, Beta Blocking Agents and Thiazides, Beta Blocking Agents, Non-Selective, Beta Blocking Agents, Non-Selective, and Thiazides, Bradycardia-Causing Agents, Cardiovascular Agents, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, EENT Drugs, Miscellaneous, Hypotensive Agents, Morpholines, Ophthalmologicals, Oxazines, P-glycoprotein substrates, Potential QTc-Prolonging Agents, Propanolamines, Propanols, QTc Prolonging Agents, Sulfur Compounds, Thiadiazoles, Thiazoles"," Beta-1 adrenergic receptor,  Beta-2 adrenergic receptor,  Lysozyme,  Cytochrome P450 2C19,  Cytochrome P450 2D6,  P-glycoprotein 1",DB00373,
DB00374,Treprostinil,approved; investigational,[H][C@]12C[C@@H](O)[C@H](CC[C@@H](O)CCCCC)[C@@]1([H])CC1=C(C2)C(OCC(O)=O)=CC=C1,C23H34O5,,"Antihypertensive Agents, Autacoids, Biological Factors, Blood and Blood Forming Organs, Cardiovascular Agents, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 Substrates, Eicosanoids, Fatty Acids, Fatty Acids, Unsaturated, Inflammation Mediators, Lipids, Platelet Aggregation Inhibitors Excl. Heparin, Potential QTc-Prolonging Agents, Prostacyclin Analogues, Prostacycline Vasodilator, Prostaglandins, Prostaglandins I, QTc Prolonging Agents, Vasodilating Agents, Vasodilation"," Prostacyclin receptor,  Prostaglandin E2 receptor EP2 subtype,  Prostaglandin D2 receptor,  Peroxisome proliferator-activated receptor delta,  P2Y purinoceptor 12,  Cytochrome P450 2C8,  Cytochrome P450 2C9",DB00374,
DB00375,Colestipol,approved,,,,"Amines, Anion Exchange Resins, Bile Acid Sequestrants, Bile-acid Binding Activity, Compounds used in a research, industrial, or household setting, Hypolipidemic Agents, Hypolipidemic Agents Indicated for Hyperlipidemia, Lipid Modifying Agents, Lipid Modifying Agents, Plain, Lipid Regulating Agents, Macromolecular Substances, Non-statin Hypolipidemic Agents Indicated for Hyperlipidemia, Polyamines, Polymers, Sequestering Agents",,,
DB00376,Trihexyphenidyl,approved,OC(CCN1CCCCC1)(C1CCCCC1)C1=CC=CC=C1,C20H31NO,,"Agents producing tachycardia, Anti-Dyskinesia Agents, Anti-Parkinson Drugs, Anticholinergic Agents, Central Nervous System Agents, Cholinergic Agents, Muscarinic Antagonists, Nervous System, Neurotransmitter Agents, Piperidines, Tertiary Amines"," Muscarinic acetylcholine receptor M1,  Muscarinic acetylcholine receptor M2,  Muscarinic acetylcholine receptor M3,  Muscarinic acetylcholine receptor M4,  Muscarinic acetylcholine receptor M5,  Serum albumin","DB00376, DB00387, DB00942, DB00505, DB13713, DB00810, DB00193, DB13642, DB13566",
DB00377,Palonosetron,approved; investigational,[H][C@]12CCCC3=C1C(=CC=C3)C(=O)N(C2)[C@@H]1CN2CCC1CC2,C19H24N2O,,"Alimentary Tract and Metabolism, Antidepressive Agents, Antiemetic Serotonin 5-HT3 Receptor Antagonists, Antiemetics, Antiemetics and Antinauseants, Autonomic Agents, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Gastrointestinal Agents, Heterocyclic Compounds, Fused-Ring, Isoquinolines, Neurotransmitter Agents, Peripheral Nervous System Agents, Quinuclidines, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 3 Receptor Antagonists, Serotonin 5-HT3 Receptor Antagonists, Serotonin Agents, Serotonin Receptor Antagonists"," 5-hydroxytryptamine receptor 3A,  Cytochrome P450 2D6,  Cytochrome P450 3A4,  Cytochrome P450 1A2",DB00377,
DB00378,Dydrogesterone,approved; investigational; withdrawn,[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@@]12C,C21H28O2,,"Adrenal Cortex Hormones, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Fused-Ring Compounds, Genito Urinary System and Sex Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Pregnadien Derivatives, Pregnadienes, Pregnanes, Progestins, Progestogens and Estrogens, Sequential Preparations, Sex Hormones and Modulators of the Genital System, Steroids"," Progesterone receptor,  Cytochrome P450 3A4","DB00378, DB09124, DB13602, DB13857, DB11636, DB11529, DB13129, DB09015, DB00396, DB01434, DB01536, DB13528, DB00990",
DB00379,Mexiletine,approved; investigational,CC(N)COC1=C(C)C=CC=C1C,C11H17NO,,"Amines, Antiarrhythmic agents, Antiarrhythmics, Class I, Antiarrhythmics, Class Ib, Benzene Derivatives, Cardiac Therapy, Cardiovascular Agents, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (moderate), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Membrane Transport Modulators, Phenols, Phenyl Ethers, Propylamines, Sodium Channel Blockers, Voltage-Gated Sodium Channel Blockers"," Sodium channel protein type 5 subunit alpha,  Aryl hydrocarbon receptor,  Cytochrome P450 2B6,  Cytochrome P450 2E1,  Cytochrome P450 3A4,  Cytochrome P450 1A2,  Cytochrome P450 2D6","DB00379, DB07129",
DB00380,Dexrazoxane,approved; withdrawn,C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1,C11H16N4O4,,"Cardiotonic Agents, Cardiovascular Agents, Compounds used in a research, industrial, or household setting, Cytoprotective Agent, Detoxifying Agents for Antineoplastic Treatment, Diketopiperazines, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Immunosuppressive Agents, Miscellaneous Therapeutic Agents, Myelosuppressive Agents, Piperazines, Protective Agents, Topoisomerase II Inhibitors, Topoisomerase Inhibitors"," DNA topoisomerase 2-alpha,  DNA topoisomerase 2-beta",DB00380,
DB00381,Amlodipine,approved,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,C20H25ClN2O5,,"ACE Inhibitors and Calcium Channel Blockers, Agents causing hyperkalemia, Angiotensin II Antagonists and Calcium Channel Blockers, Angiotensin II receptor blockers (ARBs) and calcium channel blockers, Antianginal Agents, Antiarrhythmic agents, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Bradycardia-Causing Agents, Calcium Channel Blockers, Calcium Channel Blockers (Dihydropyridine), Calcium Channel Blockers and Diuretics, Calcium-Regulating Hormones and Agents, Cardiovascular Agents, Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (strength unknown), Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (strength unknown), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (moderate), Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Inhibitors (weak), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Inhibitors, Cytochrome P-450 CYP3A5 Inhibitors (weak), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dihydropyridine Derivatives, Dihydropyridines, Hypotensive Agents, Membrane Transport Modulators, P-glycoprotein inhibitors, P-glycoprotein substrates, Pyridines, Selective Calcium Channel Blockers With Mainly Vascular Effects, Vasodilating Agents"," Voltage-dependent L-type calcium channel subunit alpha-1C,  Voltage-dependent T-type calcium channel subunit alpha-1I,  Voltage-dependent N-type calcium channel subunit alpha-1B,  Voltage-dependent L-type calcium channel subunit beta-1,  Voltage-dependent calcium channel subunit alpha-2/delta-3,  Carbonic anhydrase 1,  Sphingomyelin phosphodiesterase,  Voltage-dependent N-type calcium channel (Protein Group),  Cytochrome P450 3A4,  Cytochrome P450 1A1,  Cytochrome P450 2B6,  Cytochrome P450 3A5,  Cytochrome P450 2C8,  Cytochrome P450 2D6,  Cytochrome P450 2C19,  Cytochrome P450 2C9,  P-glycoprotein 1","DB00381, DB09237, DB01023, DB04920",
DB00382,Tacrine,approved; investigational; withdrawn,NC1=C2CCCCC2=NC2=CC=CC=C12,C13H14N2,,"Acridines, Agents Causing Muscle Toxicity, Aminoacridines, Anti-Dementia Drugs, Autonomic Agents, Central Nervous System Agents, Cholinergic Agents, Cholinesterase Inhibitors, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 Substrates, Enzyme Inhibitors, Heterocyclic Compounds, Fused-Ring, Nervous System, Neurotransmitter Agents, Nootropic Agents, P-glycoprotein substrates, Parasympathomimetics, Peripheral Nervous System Agents, Psychoanaleptics"," Cholinesterase,  Acetylcholinesterase,  Liver carboxylesterase 1,  Cytochrome P450 1A2,  P-glycoprotein 1","DB00382, DB03672, DB04616, DB04617, DB07940",
DB00383,Oxyphencyclimine,approved,CN1CCCN=C1COC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1,C20H28N2O3,,"Agents producing tachycardia, Alimentary Tract and Metabolism, Anticholinergic Agents, Drugs for Functional Gastrointestinal Disorders, Muscarinic Antagonists, Synthetic Anticholinergics, Esters With Tertiary Amino Group"," Muscarinic acetylcholine receptor M3,  Muscarinic acetylcholine receptor M1,  Muscarinic acetylcholine receptor M2","DB00383, DB00219",
DB00384,Triamterene,approved,NC1=NC(N)=C2N=C(C(N)=NC2=N1)C1=CC=CC=C1,C12H11N7,,"Agents causing hyperkalemia, Cardiovascular Agents, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 Substrates, Decreased Renal K+ Excretion, Diuretics, Drugs causing inadvertant photosensitivity, Epithelial Sodium Channel Blockers, Heterocyclic Compounds, Fused-Ring, Hypotensive Agents, Increased Diuresis, Membrane Transport Modulators, Natriuretic Agents, Nephrotoxic agents, Photosensitizing Agents, Potassium-Sparing Diuretics, Pteridines, Sodium Channel Blockers"," Amiloride-sensitive sodium channel subunit gamma,  Amiloride-sensitive sodium channel subunit alpha,  Amiloride-sensitive sodium channel subunit beta,  Amiloride-sensitive sodium channel subunit delta,  Cytochrome P450 1A2","DB00384, DB05552",
DB00385,Valrubicin,approved,[H][C@@]1(C[C@@](O)(CC2=C(O)C3=C(C(O)=C12)C(=O)C1=C(OC)C=CC=C1C3=O)C(=O)COC(=O)CCCC)O[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1,C34H36F3NO13,,"Anthracycline Topoisomerase Inhibitor, Anthracyclines, Anthracyclines and Related Substances, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Carbohydrates, Cytotoxic Antibiotics and Related Substances, Enzyme Inhibitors, Glycosides, Naphthacenes, Topoisomerase II Inhibitors, Topoisomerase Inhibitors"," DNA,  DNA topoisomerase 2-alpha","DB00385, DB00445, DB00694, DB00997, DB11616, DB17149, DB12410, DB01177, DB05706, DB13103, DB01806, DB03219, DB06420, DB03199, DB04131, DB11617, DB11618, DB06013, DB06263, DB12755, DB17273, DB17390, DB03933, DB00541, DB00570",
DB00387,Procyclidine,approved,OC(CCN1CCCC1)(C1CCCCC1)C1=CC=CC=C1,C19H29NO,,"Agents producing tachycardia, Anti-Dyskinesia Agents, Anti-Parkinson Drugs, Anticholinergic Agents, Central Nervous System Agents, Cholinergic Agents, Muscarinic Antagonists, Nervous System, Neurotransmitter Agents, Pyrrolidines, Tertiary Amines"," Muscarinic acetylcholine receptor M3,  Muscarinic acetylcholine receptor M1,  Muscarinic acetylcholine receptor M2,  Muscarinic acetylcholine receptor M4","DB00387, DB00376, DB00942, DB00505, DB13713, DB00810, DB00193, DB13642",
DB00388,Phenylephrine,approved,CNC[C@H](O)C1=CC(O)=CC=C1,C9H13NO2,,"Adrenergic Agents, Adrenergic Agonists, Adrenergic alpha-1 Receptor Agonists, Adrenergic alpha-Agonists, Adrenergic and Dopaminergic Agents, Agents producing tachycardia, Agents that produce hypertension, Alcohols, Amines, Amino Alcohols, Autonomic Agents, Cardiac Stimulants Excl. Cardiac Glycosides, Cardiac Therapy, Cardiotonic Agents, Cardiovascular Agents, Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP1A2 Inducers (strength unknown), Cytochrome P-450 Enzyme Inducers, Decongestants and Antiallergics, Ethanolamines, Monoamine Oxidase A Substrates, Mydriatics, Mydriatics and Cycloplegics, Nasal Decongestants, Nasal Decongestants for Systemic Use, Nasal Preparations, Neurotransmitter Agents, Ophthalmologicals, Peripheral Nervous System Agents, Protective Agents, Respiratory System Agents, Sensory Organs, Sympathomimetic (Adrenergic) Agents, Sympathomimetics, Sympathomimetics Excl. Antiglaucoma Preparations, Sympathomimetics Used as Decongestants, Sympathomimetics, Plain, Vasoconstrictor Agents"," Alpha-1A adrenergic receptor,  Alpha-1B adrenergic receptor,  Alpha-1D adrenergic receptor,  Amine oxidase [flavin-containing] A,  Amine oxidase [flavin-containing] B,  Sulfotransferase 1A3/1A4,  Cytochrome P450 1A2","DB00388, DB08985, DB00668, DB13378, DB00816, DB00871, DB01064, DB00368, DB09203, DB13917, DB08957, DB00610, DB13494, DB01288",
DB00389,Carbimazole,approved; investigational,CCOC(=O)N1C=CN(C)C1=S,C7H10N2O2S,,"Agents Causing Muscle Toxicity, Antithyroid agents, Hormone Antagonists, Hormones, Hormone Substitutes, and Hormone Antagonists, Imidazoles, Sulfur-Containing Imidazole Derivatives, Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins, Thyroid Products"," Thyroid peroxidase,  Cytochrome P450 19A1",DB00389,
DB00390,Digoxin,approved,[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1,C41H64O14,,"Agents causing hyperkalemia, Antiarrhythmic agents, Bradycardia-Causing Agents, BSEP/ABCB11 Substrates, BSEP/ABCB11 Substrates with a Narrow Therapeutic Index, Carbohydrates, Cardanolides, Cardenolides, Cardiac Glycosides, Cardiac Therapy, Cardiotonic Agents, Cardiovascular Agents, Compounds used in a research, industrial, or household setting, Digitalis Glycosides, Digoxin and derivatives, Digoxin, immunology, Drugs that are Mainly Renally Excreted, Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index, Fused-Ring Compounds, Glycosides, Narrow Therapeutic Index Drugs, OATP1B1/SLCO1B1 Inhibitors, OATP1B1/SLCO1B1 Substrates, P-glycoprotein inducers, P-glycoprotein inhibitors, P-glycoprotein substrates, P-glycoprotein substrates with a Narrow Therapeutic Index, Potential QTc-Prolonging Agents, Protective Agents, QTc Prolonging Agents"," Sodium/potassium-transporting ATPase subunit alpha-1,  Cholesterol side-chain cleavage enzyme, mitochondrial,  P-glycoprotein 1,  Solute carrier organic anion transporter family member 4C1,  Bile salt export pump,  Solute carrier organic anion transporter family member 1A2,  Organic solute transporter subunit alpha,  Organic solute transporter subunit beta,  Solute carrier organic anion transporter family member 1B1","DB00390, DB01396, DB13401, DB01078, DB00511, DB13691, DB01092, DB13467, DB13240, DB13756, DB13537, DB12843, DB03671, DB06569, DB04177, DB15532, DB14081, DB12025, DB06748, DB06749, DB14815",
DB00391,Sulpiride,approved; investigational,CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O,C15H23N3O4S,,"Acids, Carbocyclic, Amides, Antidepressive Agents, Antidepressive Agents, Second-Generation, Antipsychotic Agents, BCRP/ABCG2 Substrates, Benzamides and benzamide derivatives, Benzene Derivatives, Benzoates, Central Nervous System Agents, Central Nervous System Depressants, Cholinesterase Inhibitors, Dopamine Agents, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, MATE 1 Substrates, MATE 2 Substrates, MATE substrates, Moderate Risk QTc-Prolonging Agents, Nervous System, Neurotoxic agents, Neurotransmitter Agents, OCT1 substrates, OCT2 Substrates, P-glycoprotein substrates, Psycholeptics, Psychotropic Drugs, QTc Prolonging Agents, Tranquilizing Agents"," Dopamine D2 receptor,  Dopamine D3 receptor,  Carbonic anhydrase 2,  Carbonic anhydrase 3,  Dopamine D4 receptor,  Cholinesterase,  Serum albumin,  Solute carrier family 22 member 1,  Solute carrier family 22 member 2,  Multidrug and toxin extrusion protein 1,  Multidrug and toxin extrusion protein 2,  Solute carrier family 22 member 3,  P-glycoprotein 1,  ATP-binding cassette sub-family G member 2","DB00391, DB16021, DB13523, DB13273, DB06288, DB13025",
DB00392,Profenamine,approved,CCN(CC)C(C)CN1C2=CC=CC=C2SC2=CC=CC=C12,C19H24N2S,,"Adrenergic Agents, Adrenergic Antagonists, Agents producing tachycardia, Anti-Parkinson Drugs, Anticholinergic Agents, Cholinergic Agents, Cholinesterase Inhibitors, Heterocyclic Compounds, Fused-Ring, Histamine Agents, Muscarinic Antagonists, Nervous System, Neurotransmitter Agents, NMDA Receptor Antagonists, Sulfur Compounds, Tertiary Amines"," Muscarinic acetylcholine receptor M1,  Glutamate receptor ionotropic, NMDA 3A,  Muscarinic acetylcholine receptor M2,  Cholinesterase","DB00392, DB01069, DB13420, DB13840, DB15596, DB15978, DB13672, DB12710, DB00420, DB01246, DB01615, DB00433, DB00777, DB00372, DB00902, DB13784",
DB00393,Nimodipine,approved; investigational,COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C,C21H26N2O7,,"Agents causing hyperkalemia, Antiarrhythmic agents, Antihypertensive Agents, Bradycardia-Causing Agents, Calcium Channel Blockers, Calcium Channel Blockers (Dihydropyridine), Calcium-Regulating Hormones and Agents, Cardiovascular Agents, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Dihydropyridine Derivatives, Dihydropyridines, Hypotensive Agents, Membrane Transport Modulators, Moderate Risk QTc-Prolonging Agents, Nicotinic Acids, P-glycoprotein inhibitors, Pyridines, QTc Prolonging Agents, Selective Calcium Channel Blockers With Mainly Vascular Effects, Vasodilating Agents"," Voltage-dependent L-type calcium channel subunit alpha-1C,  Voltage-dependent L-type calcium channel subunit alpha-1D,  Voltage-dependent L-type calcium channel subunit alpha-1F,  Voltage-dependent L-type calcium channel subunit alpha-1S,  Voltage-dependent L-type calcium channel subunit beta-1,  Voltage-dependent L-type calcium channel subunit beta-2,  Voltage-dependent L-type calcium channel subunit beta-3,  Voltage-dependent L-type calcium channel subunit beta-4,  Mineralocorticoid receptor, 10. Aryl hydrocarbon receptor,  Cytochrome P450 3A4","DB00393, DB09240, DB01054, DB09232, DB06712, DB09239, DB14068, DB00622, DB00528, DB09227, DB09231, DB09233, DB09230, DB09238, DB00401, DB09229, DB01115, DB09236, DB01023, DB00270",
DB00394,Beclomethasone dipropionate,approved; investigational,[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,C28H37ClO7,,"Adrenal Cortex Hormones, Adrenals, Agents to Treat Airway Disease, Alimentary Tract and Metabolism, Anti-Asthmatic Agents, Anti-Inflammatory Agents, Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents, BCRP/ABCG2 Inhibitors, Corticosteroid Hormone Receptor Agonists, Corticosteroids, Corticosteroids Acting Locally, Corticosteroids, Dermatological Preparations, Corticosteroids, Potent (Group III), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Inducers, Cytochrome P-450 CYP3A5 Inducers (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Substrates, Dermatologicals, Drugs for Obstructive Airway Diseases, Fused-Ring Compounds, Glucocorticoids, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hyperglycemia-Associated Agents, Immunosuppressive Agents, Intestinal Antiinflammatory Agents, Nasal Preparations, OATP1B1/SLCO1B1 Inhibitors, OATP1B3 inhibitors, P-glycoprotein inducers, P-glycoprotein substrates, Pregnadienes, Pregnadienetriols, Pregnanes, Respiratory System Agents, Steroids, Steroids, Chlorinated, Thyroxine-binding globulin inhibitors"," Glucocorticoid receptor,  Cytochrome P450 3A5,  Cytochrome P450 3A4,  Corticosteroid-binding globulin,  P-glycoprotein 1,  ATP-binding cassette sub-family G member 2,  Solute carrier organic anion transporter family member 1B1,  Solute carrier organic anion transporter family member 1B3","DB00394, DB14221, DB14643, DB14632, DB15999, DB14653, DB14633, DB14644, DB14652, DB15566, DB00240, DB00764, DB01130, DB14538, DB14543, DB01013, DB14540, DB14544, DB01410, DB06781, DB14512, DB14637, DB14657, DB14640, DB14649, DB14541, DB14625, DB14646, DB15777, DB14545",
DB00395,Carisoprodol,approved,CCCC(C)(COC(N)=O)COC(=O)NC(C)C,C12H24N2O4,,"Carbamates, Carbamic Acid Esters, Central Nervous System Agents, Central Nervous System Depressants, Centrally-mediated Muscle Relaxation, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 Substrates, Muscle Relaxants, Muscle Relaxants, Centrally Acting Agents, Musculo-Skeletal System"," Gamma-aminobutyric acid receptor subunit alpha-1,  Gamma-aminobutyric acid receptor subunit beta-2,  Gamma-aminobutyric acid receptor subunit gamma-2,  Gamma-aminobutyric acid receptor subunit alpha-5,  Gamma-aminobutyric acid receptor subunit alpha-3,  Cytochrome P450 2C19",DB00395,
DB00396,Progesterone,approved; vet_approved,[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,C21H30O2,,"Adrenal Cortex Hormones, BCRP/ABCG2 Inducers, BCRP/ABCG2 Inhibitors, BSEP/ABCB11 Inhibitors, Corpus Luteum Hormones, Cytochrome P-450 CYP2A6 Inducers, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (strength unknown), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Inhibitors, Cytochrome P-450 CYP3A7 Inhibitors (strength unknown), Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Fused-Ring Compounds, Genito Urinary System and Sex Hormones, Gonadal Hormones, Gonadal Steroid Hormones, Hormonal Contraceptives for Systemic Use, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hyperglycemia-Associated Agents, OATP1B1/SLCO1B1 Inhibitors, OATP1B3 inducers, OCT1 inhibitors, OCT2 Inhibitors, P-glycoprotein inducers, P-glycoprotein inhibitors, P-glycoprotein substrates, Pregnanes, Pregnenediones, Pregnenes, Progesterone and Derivatives, Progesterone, antagonists & inhibitors, Progestin-containing Intrauterine Device, Progestins, Sex Hormones and Modulators of the Genital System, Steroids"," Progesterone receptor,  Mineralocorticoid receptor,  Estrogen receptor alpha,  Steroid 17-alpha-hydroxylase/17,20 lyase,  Kappa-type opioid receptor,  Alpha-1-acid glycoprotein 1,  Glucocorticoid receptor,  Androgen receptor,  Sex hormone-binding globulin, 10. Estrogen receptor beta,  Steroid 17-alpha-hydroxylase/17,20 lyase,  Cytochrome P450 1A1,  Cytochrome P450 1B1,  Cytochrome P450 2A6,  Cytochrome P450 2D6,  Cytochrome P450 2C19,  Cytochrome P450 2C9,  Cytochrome P450 3A5,  Cytochrome P450 3A4, 10. Cytochrome P450 3A7,  P-glycoprotein 1,  Solute carrier family 22 member 2,  Solute carrier family 22 member 1,  Solute carrier family 22 member 3,  Bile salt export pump,  Multidrug resistance-associated protein 1,  Sodium/bile acid cotransporter,  Solute carrier organic anion transporter family member 1B1,  ATP-binding cassette sub-family G member 2, 10. Solute carrier organic anion transporter family member 1B3","DB00396, DB01434, DB01536, DB01451, DB13391, DB15977, DB13710, DB13230, DB14570, DB00624, DB01471, DB01543, DB01564, DB05830, DB06710, DB07768, DB11429, DB12787, DB13169, DB13533, DB14093, DB01443, DB01456, DB08905, DB00253, DB18000, DB14584, DB04652, DB07373, DB12194",
DB00397,Phenylpropanolamine,approved; vet_approved; withdrawn,CC(N)C(O)C1=CC=CC=C1,C9H13NO,,"Adrenergic Agents, Adrenergic Agonists, Adrenergic alpha-Agonists, Adrenergic beta-2 Receptor Agonists, Adrenergic beta-Agonists, Agents producing tachycardia, Agents that produce hypertension, Agents that reduce seizure threshold, Alcohols, Amines, Amino Alcohols, Anti-Obesity Agents, Appetite Depressants, Autonomic Agents, Cardiovascular Agents, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates, Nasal Decongestants, Nasal Decongestants for Systemic Use, Nasal Preparations, Neurotransmitter Agents, Peripheral Nervous System Agents, Propanolamines, Propanols, Respiratory System Agents, Sympathomimetics, Vasoconstrictor Agents"," Dopamine D1 receptor,  Beta-1 adrenergic receptor,  Beta-2 adrenergic receptor,  Alpha-2 adrenergic receptors (Protein Group),  Amine oxidase [flavin-containing] A","DB00397, DB01486, DB00852, DB01364, DB14752, DB11278, DB11587, DB04484, DB00610, DB11610, DB00182, DB01576",
DB00398,Sorafenib,approved; investigational,CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1,C21H16ClF3N4O3,,"Amides, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Inhibitors, BCRP/ABCG2 Substrates, Benzene Derivatives, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (moderate), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (strength unknown), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2C8 Inhibitors (strong), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strong), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Immunosuppressive Agents, Kinase Inhibitor, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, Nicotinic Acids, OATP1B1/SLCO1B1 Inhibitors, P-glycoprotein inhibitors, P-glycoprotein substrates, P-glycoprotein substrates with a Narrow Therapeutic Index, Phenylurea Compounds, Potential QTc-Prolonging Agents, Protein Kinase Inhibitors, Pyridines, QTc Prolonging Agents, Tyrosine Kinase Inhibitors, UGT1A1 Inhibitors, UGT1A9 Inhibitors, UGT1A9 Substrates, UGT1A9 Substrates with a Narrow Therapeutic Index"," Serine/threonine-protein kinase B-raf,  RAF proto-oncogene serine/threonine-protein kinase,  Vascular endothelial growth factor receptor 3,  Vascular endothelial growth factor receptor 2,  Vascular endothelial growth factor receptor 1,  Receptor-type tyrosine-protein kinase FLT3,  Platelet-derived growth factor receptor beta,  Mast/stem cell growth factor receptor Kit,  Fibroblast growth factor receptor 1, 10. Proto-oncogene tyrosine-protein kinase receptor Ret,  Cytochrome P450 3A4,  Cytochrome P450 2C9,  Cytochrome P450 2C8,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  Cytochrome P450 2B6,  Cytochrome P450 1A2,  Cytochrome P450 2C19,  Cytochrome P450 2D6, 10. UDP-glucuronosyltransferase 1-9, 11. UDP-glucuronosyltransferase 1-1,  P-glycoprotein 1,  ATP-binding cassette sub-family G member 2,  Multidrug resistance-associated protein 4,  Canalicular multispecific organic anion transporter 1,  RalA-binding protein 1,  Solute carrier organic anion transporter family member 1B1","DB00398, DB15414, DB08896, DB06938",
DB00399,Zoledronic acid,approved,OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O,C5H10N2O7P2,,"Bisphosphonates, Bone Density Conservation Agents, Drugs Affecting Bone Structure and Mineralization, Drugs for Treatment of Bone Diseases, Imidazoles, Musculo-Skeletal System, Organophosphonates, Organophosphorus Compounds"," Geranylgeranyl pyrophosphate synthase,  Hydroxylapatite,  Farnesyl pyrophosphate synthase,  Multidrug resistance-associated protein 1","DB00399, DB16907",
DB00400,Griseofulvin,approved; investigational; vet_approved,COC1=CC(OC)=C(Cl)C2=C1C(=O)[C@]1(O2)[C@H](C)CC(=O)C=C1OC,C17H17ClO6,,"Anti-Infective Agents, Antifungal Agents, Antifungals for Dermatological Use, Antifungals for Systemic Use, Antifungals for Topical Use, Benzofurans, Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP1A2 Inducers (strength unknown), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 Enzyme Inducers, Decreased Mitosis, Dermatologicals, Heterocyclic Compounds, Fused-Ring, Microtubule Inhibition, Tubulin Inhibiting Agent"," Tubulin beta chain,  Keratin, type I cytoskeletal 12,  Cytochrome P450 1A2,  Cytochrome P450 3A4",DB00400,
DB00401,Nisoldipine,approved,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OCC(C)C,C20H24N2O6,,"Agents causing hyperkalemia, Antiarrhythmic agents, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Bradycardia-Causing Agents, Calcium Channel Blockers, Calcium Channel Blockers (Dihydropyridine), Calcium-Regulating Hormones and Agents, Cardiovascular Agents, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Substrates, Decreased Blood Pressure, Dihydropyridine Derivatives, Dihydropyridines, Drugs causing inadvertant photosensitivity, Drugs that are Mainly Renally Excreted, Hypotensive Agents, Membrane Transport Modulators, P-glycoprotein inhibitors, Photosensitizing Agents, Pyridines, Selective Calcium Channel Blockers With Mainly Vascular Effects, Vasodilating Agents"," Voltage-dependent L-type calcium channel subunit alpha-1C,  Voltage-dependent calcium channel subunit alpha-2/delta-1,  Voltage-dependent L-type calcium channel subunit beta-2,  Voltage-dependent L-type calcium channel subunit alpha-1D,  Voltage-dependent L-type calcium channel subunit alpha-1S,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  P-glycoprotein 1","DB00401, DB09229, DB01115, DB01054, DB09240, DB00393, DB09239, DB14068, DB06712, DB09232, DB00622, DB00528, DB01023, DB09227, DB09231, DB09234, DB09238, DB00270",
DB00402,Eszopiclone,approved; investigational,CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1,C17H17ClN6O3,,"Benzodiazepine hypnotics and sedatives, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Drugs causing inadvertant photosensitivity, Drugs that are Mainly Renally Excreted, Hypnotics (Nonbenzodiazepine), Hypnotics and Sedatives, Miscellaneous Anxiolytics Sedatives and Hypnotics, Muscle Relaxants, Muscle Relaxants, Centrally Acting Agents, Nervous System, Photosensitizing Agents, Piperazines, Psycholeptics, Pyrazines, Pyridines, Zopiclone and prodrugs"," Gamma-aminobutyric acid receptor subunit alpha-1,  GABA(A) Receptor (Protein Group),  Gamma-aminobutyric acid receptor subunit alpha-2,  Gamma-aminobutyric acid receptor subunit alpha-3,  Gamma-aminobutyric acid receptor subunit alpha-5,  Cytochrome P450 3A4,  Cytochrome P450 2C8","DB00402, DB01198",
DB00403,Ceruletide,approved,[H][C@](NC(=O)[C@H](CC1=CC=C(OS(O)(=O)=O)C=C1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCC(=O)N1)([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O,C58H73N13O21S2,,"Amino Acids, Peptides, and Proteins, Diagnostic Agents, Oligopeptides, Peptides, Tests for Bile Duct Patency", Cholecystokinin receptor type A,"DB00403, DB14806, DB17503, DB16146, DB15272, DB05479, DB15314, DB01284, DB13298, DB12777, DB15687, DB14786, DB14027, DB18527, DB15194, DB12054, DB14777, DB13928, DB12292, DB00183, DB13925, DB14554, DB15494, DB17969, DB04931, DB13985, DB15873, DB17160, DB17278, DB11975",
DB00404,Alprazolam,approved; illicit; investigational,CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12,C17H13ClN4,,"Amines, Anti-Anxiety Agents, Benzazepines, Benzene Derivatives, Benzodiazepines and benzodiazepine derivatives, Biogenic Amines, Biogenic Monoamines, Catechols, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Ethanolamines, GABA Agents, GABA Modulators, Heterocyclic Compounds, Fused-Ring, Hypnotics and Sedatives, Nervous System, Neurotransmitter Agents, Psycholeptics, Psychotropic Drugs, Tranquilizing Agents, Triazolobenzodiazepines"," GABA(A) Receptor (Protein Group),  GABA(A) Receptor Benzodiazepine Binding Site (Protein Group),  Cytochrome P450 3A7,  Cytochrome P450 3A4,  Cytochrome P450 2C9,  Cytochrome P450 3A5,  Serum albumin,  alpha1-acid glycoprotein (Protein Group)","DB00404, DB01215, DB00897, DB00546, DB14716, DB14717, DB14718",
DB00405,Dexbrompheniramine,approved,CN(C)CC[C@@H](C1=CC=C(Br)C=C1)C1=CC=CC=N1,C16H19BrN2,,"Antihistamines for Systemic Use, Central Nervous System Depressants, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Neurotransmitter Agents, Potential QTc-Prolonging Agents, Pyridines, QTc Prolonging Agents, Substituted Alkylamines", Histamine H1 receptor,"DB00405, DB00835, DB01620, DB01114, DB13679, DB09555",
DB00406,Gentian violet cation,approved,CN(C)C1=CC=C(C=C1)C(C1=CC=C(C=C1)N(C)C)=C1C=CC(C=C1)=[N+](C)C,C25H30N3,,"Amines, Aniline Compounds, Anti-Infective Agents, Anti-Infective Agents, Local, Antifungals for Dermatological Use, Antifungals for Topical Use, Dermatologicals, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Miscellaneous Antifungals"," DNA,  Solute carrier family 22 member 1","DB00406, DB03895, DB11279",
DB00407,Ardeparin,approved; investigational; withdrawn,,,,"Agents causing hyperkalemia, Anticoagulants, Carbohydrates, Cardiovascular Agents, Fibrin Modulating Agents, Glycosaminoglycans, Hematologic Agents, Heparin (Low Molecular Weight), Heparin and similars, Polysaccharides"," Antithrombin-III,  Heparin cofactor 2",,
DB00408,Loxapine,approved,CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2,C18H18ClN3O,,"Antidepressive Agents, Antipsychotic Agents, Antipsychotic Agents (First Generation [Typical]), Central Nervous System Agents, Central Nervous System Depressants, Diazepines, Oxazepines, Thiazepines and Oxepines, Dibenzoxazepines, Dopamine Agents, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Drugs causing inadvertant photosensitivity, Heterocyclic Compounds, Fused-Ring, Miscellaneous Antipsychotics, Nervous System, Neurotoxic agents, Neurotransmitter Agents, P-glycoprotein inhibitors, Photosensitizing Agents, Psycholeptics, Psychotropic Drugs, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2A Receptor Antagonists, Serotonin 5-HT2C Receptor Antagonists, Serotonin Agents, Serotonin Receptor Antagonists, Tranquilizing Agents"," 5-hydroxytryptamine receptor 2A,  Dopamine D2 receptor,  5-hydroxytryptamine receptor 2C,  5-hydroxytryptamine receptor 1A,  5-hydroxytryptamine receptor 1B,  5-hydroxytryptamine receptor 1D,  5-hydroxytryptamine receptor 1E,  5-hydroxytryptamine receptor 3A,  5-hydroxytryptamine receptor 5A, 10. 5-hydroxytryptamine receptor 6, 11. 5-hydroxytryptamine receptor 7, 12. Alpha-1A adrenergic receptor, 13. Alpha-1B adrenergic receptor, 14. Alpha-2A adrenergic receptor, 15. Alpha-2B adrenergic receptor, 16. Alpha-2C adrenergic receptor, 17. Beta-1 adrenergic receptor, 18. Muscarinic acetylcholine receptor M1, 19. Muscarinic acetylcholine receptor M2, 20. Muscarinic acetylcholine receptor M3, 21. Muscarinic acetylcholine receptor M4, 22. Muscarinic acetylcholine receptor M5, 23. D(1) dopamine receptor (Protein Group), 24. Dopamine D3 receptor, 25. Dopamine D4 receptor, 26. Dopamine D5 receptor, 27. Histamine H1 receptor, 28. Histamine H2 receptor, 29. Histamine H4 receptor, 30. Sodium-dependent serotonin transporter, 31. Sodium-dependent noradrenaline transporter, 32. Sodium-dependent dopamine transporter, 33. Dopamine D1 receptor","DB00408, DB00543, DB15092",
DB00409,Remoxipride,approved; withdrawn,CCN1CCC[C@H]1CNC(=O)C1=C(OC)C=CC(Br)=C1OC,C16H23BrN2O3,,"Acids, Carbocyclic, Amides, Antipsychotic Agents, Benzamides and benzamide derivatives, Benzene Derivatives, Benzoates, Bromobenzoates, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dopamine Agents, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Nervous System, Neurotoxic agents, Neurotransmitter Agents, Psycholeptics, Psychotropic Drugs, Tranquilizing Agents"," Dopamine D2 receptor,  Dopamine D4 receptor,  Dopamine D3 receptor,  5-hydroxytryptamine receptor 2A,  Sigma non-opioid intracellular receptor 1,  Cytochrome P450 2D6,  Cytochrome P450 1A2,  Cytochrome P450 2B1,  Cytochrome P450 3A Subfamily (Protein Group),  alpha1-acid glycoprotein (Protein Group)","DB00409, DB12518, DB09018",
DB00410,Mupirocin,approved; investigational; vet_approved,C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]1CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O,C26H44O9,,"Anti-Bacterial Agents, Anti-Infective Agents, Antibiotics for Topical Use, Dermatologicals, Enzyme Inhibitors, Epoxy Compounds, Ethers, Ethers, Cyclic, Fatty Acids, Lipids, Nasal Preparations, Protein Synthesis Inhibitors, Pyrans, RNA Synthetase Inhibitor Antibacterial, RNA Synthetase Inhibitors", Isoleucine--tRNA ligase,"DB00410, DB12843",
DB00411,Carbamoylcholine,approved,C[N+](C)(C)CCOC(N)=O,C6H15N2O2,,"Alcohols, Amines, Amino Alcohols, Ammonium Compounds, Analgesics, Analgesics, Non-Narcotic, Antiglaucoma Preparations and Miotics, Autonomic Agents, Cardiotonic Agents, Cardiovascular Agents, Central Nervous System Agents, Choline Esters, Cholinergic Agents, Cholinergic Agonists, Cholinergic Receptor Agonist, Compounds used in a research, industrial, or household setting, Ethanolamines, Miotics, Nervous System, Neurotransmitter Agents, Nitrogen Compounds, Onium Compounds, Ophthalmologicals, Parasympathomemetic (Cholinergic) Agents, Parasympathomimetics, Peripheral Nervous System Agents, Protective Agents, Quaternary Ammonium Compounds, Sensory Organs, Sensory System Agents, Trimethyl Ammonium Compounds"," Muscarinic acetylcholine receptor M1,  Muscarinic acetylcholine receptor M2,  Neuronal acetylcholine receptor subunit alpha-2,  Muscarinic acetylcholine receptor M3,  Muscarinic acetylcholine receptor M4,  Cytosolic phospholipase A2,  Acetylcholinesterase","DB00411, DB01019",
DB00412,Rosiglitazone,approved; investigational,CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1,C18H19N3O3S,,"Alimentary Tract and Metabolism, Blood Glucose Lowering Agents, BSEP/ABCB11 Substrates, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strength unknown), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (moderate), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Drugs Used in Diabetes, Hypoglycemia-Associated Agents, NTCP Inhibitors, OATP1B1/SLCO1B1 Inhibitors, Oral Hypoglycemics, Peroxisome Proliferator Receptor gamma Agonist, Peroxisome Proliferator-activated Receptor Activity, Sulfur Compounds, Thiazoles, Thiazolidinediones, Vasodilating Agents"," Peroxisome proliferator-activated receptor gamma,  Long-chain-fatty-acid--CoA ligase 4,  Peroxisome proliferator-activated receptor alpha,  Peroxisome proliferator-activated receptor delta,  Retinoic acid receptor RXR-alpha,  Retinoic acid receptor RXR-beta,  Retinoic acid receptor RXR-gamma,  Prostaglandin G/H synthase 1,  Cytochrome P450 1A2,  Cytochrome P450 2D6,  Cytochrome P450 3A4,  Cytochrome P450 2B6,  Cytochrome P450 2E1,  Cytochrome P450 2C8,  Cytochrome P450 2C9,  Serum albumin,  Solute carrier organic anion transporter family member 1B1,  Bile salt export pump,  Sodium/bile acid cotransporter","DB00412, DB09198, DB09201",
DB00413,Pramipexole,approved; investigational,CCCN[C@H]1CCC2=C(C1)SC(N)=N2,C10H17N3S,,"Anti-Dyskinesia Agents, Anti-Parkinson Agents (Dopamine Agonist), Anti-Parkinson Drugs, Antioxidants, Benzothiazoles, Biological Factors, Central Nervous System Agents, Dopamine Agents, Dopamine Agonists, Drugs that are Mainly Renally Excreted, Heterocyclic Compounds, Fused-Ring, Hypotensive Agents, Nervous System, Neurotransmitter Agents, Nonergot-derivative Dopamine Receptor Agonists, OCT1 substrates, OCT2 Substrates, Restless Legs Syndrome, Sulfur Compounds, Thiazoles"," Dopamine D3 receptor,  Dopamine D2 receptor,  Dopamine D4 receptor,  5-hydroxytryptamine receptor 1A,  Alpha-2A adrenergic receptor,  Solute carrier family 22 member 2,  Solute carrier family 22 member 1,  Solute carrier family 22 member 3","DB00413, DB15130",
DB00414,Acetohexamide,approved; investigational; withdrawn,CC(=O)C1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1,C15H20N2O4S,,"Alimentary Tract and Metabolism, Amides, Benzene Derivatives, Benzenesulfonamides, Blood Glucose Lowering Agents, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 Substrates, Drugs Used in Diabetes, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Insulin Secretagogues, Oral Hypoglycemics, Sulfonamides, Sulfones, Sulfonylureas, Sulfur Compounds"," ATP-sensitive inward rectifier potassium channel 1,  Cytochrome P450 2C9,  Carbonyl reductase [NADPH] 1,  Serum albumin","DB00414, DB01124, DB13675, DB08962",
DB00415,Ampicillin,approved; vet_approved,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O,C16H19N3O4S,,"Amides, Aminopenicillins, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Beta-Lactam Antibacterials, beta-Lactams, Drugs that are Mainly Renally Excreted, Heterocyclic Compounds, Fused-Ring, Lactams, Ophthalmologicals, Penicillin G, Penicillins, Penicillins With Extended Spectrum, Sensory Organs, Sulfur Compounds"," Penicillin-binding protein 2a,  Penicillin-binding protein 1b,  Penicillin-binding protein 3,  Penicillin-binding protein 1A,  Penicillin-binding protein 2B,  Solute carrier family 15 member 1,  Solute carrier family 15 member 2,  Angiopoietin-1 receptor,  Serum albumin,  Solute carrier family 22 member 5,  Solute carrier family 15 member 1,  Solute carrier family 15 member 2,  Monocarboxylate transporter 1","DB00415, DB01053, DB13836, DB01060, DB08795, DB00578, DB01604, DB08559, DB13739, DB00319, DB13816, DB01061, DB09320, DB01607, DB00739, DB13506, DB01602, DB07806, DB03658, DB00417, DB13686, DB01000, DB13693, DB13337, DB03550, DB03820, DB12127, DB00895, DB13660, DB09319",
DB00416,Metocurine iodide,approved; withdrawn,[I-].[I-].[H][C@@]12CC3=CC=C(OC4=C5C(CC[N+](C)(C)[C@]5([H])CC5=CC(OC6=C(OC)C=C(CC[N+]1(C)C)C2=C6)=C(OC)C=C5)=CC(OC)=C4OC)C=C3,C40H48I2N2O6,,"Alkaloids, Amines, Anticholinergic Agents, Benzylisoquinolines, Central Nervous System Depressants, Heterocyclic Compounds, Fused-Ring, Isoquinolines, Neuromuscular Agents, Neuromuscular Blocking Agents, Neuromuscular-Blocking Agents (Nondepolarizing), Nicotinic Antagonists, Onium Compounds, Peripheral Nervous System Agents, Quaternary Ammonium Compounds, Tetrahydroisoquinolines", Neuronal acetylcholine receptor subunit alpha-2,"DB00416, DB01199, DB01336, DB14066, DB18146, DB16824, DB12093, DB01135, DB13692, DB01226",
DB00417,Phenoxymethylpenicillin,approved; vet_approved,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)COC1=CC=CC=C1)C(O)=O,C16H18N2O5S,,"Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Aza Compounds, Azabicyclo Compounds, Beta-Lactam Antibacterials, Beta-Lactamase Sensitive Penicillins, beta-Lactams, Heterocyclic Compounds, Fused-Ring, Lactams, Natural Penicillins, Penicillin G, Penicillins, Sulfur Compounds"," MecA PBP2' (penicillin binding protein 2'),  Penicillin-binding protein 1A,  D-alanyl-D-alanine carboxypeptidase DacB,  Penicillin acylase,  Solute carrier family 15 member 1","DB00417, DB13337, DB13660, DB01053, DB01060, DB00415, DB03550, DB03820, DB01000, DB00578, DB13506, DB13836, DB01603, DB09320, DB13686, DB08559, DB08795, DB13739, DB00607, DB13300, DB13816, DB13693, DB01607, DB01604, DB00319, DB09319, DB00739, DB01061, DB01602, DB03658",
DB00418,Secobarbital,approved; vet_approved,CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O,C12H18N2O3,,"Adjuvants, Adjuvants, Anesthesia, Anticholinergic Agents, Anticonvulsants, Barbiturates, Barbiturates, Plain, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP1A2 Inducers (strength unknown), Cytochrome P-450 CYP2C19 Inducers, Cytochrome P-450 CYP2C19 Inducers (strength unknown), Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 CYP2C8 Inducers (strong), Cytochrome P-450 CYP2C9 Inducers, Cytochrome P-450 CYP2C9 Inducers (strength unknown), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 Enzyme Inducers, Drugs that are Mainly Renally Excreted, GABA Agents, GABA Modulators, Hypnotics and Sedatives, Nervous System, Neurotransmitter Agents, Nicotinic Antagonists, Psycholeptics, Pyrimidines, Pyrimidinones"," Gamma-aminobutyric acid receptor subunit alpha-2,  Gamma-aminobutyric acid receptor subunit alpha-3,  Gamma-aminobutyric acid receptor subunit alpha-4,  Gamma-aminobutyric acid receptor subunit alpha-5,  Gamma-aminobutyric acid receptor subunit alpha-6,  Gamma-aminobutyric acid receptor subunit alpha-1,  Neuronal acetylcholine receptor subunit alpha-4,  Neuronal acetylcholine receptor subunit alpha-7,  Glutamate receptor 2, 10. Glutamate receptor ionotropic, kainate 2, 11. NMDA receptor (Protein Group),  Cytochrome P450 1A2,  Cytochrome P450 2C19,  Cytochrome P450 2C8,  Cytochrome P450 2C9","DB00418, DB00306, DB13770, DB00241, DB00312, DB01352, DB01353, DB00237, DB01351, DB13577, DB13253, DB01154",
DB00419,Miglustat,approved,CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO,C10H21NO4,,"Alimentary Tract and Metabolism, Alkaloids, Anti-HIV Agents, Anti-Infective Agents, Carbohydrates, Enzyme Inhibitors, Enzyme Stabilizer, Gaucher Disease, Glucosylceramide Synthase Inhibitor, Glucosylceramide Synthase Inhibitors, Glycoside Hydrolase Inhibitors, Imines, Imino Pyranoses, Imino Sugars, Other Miscellaneous Therapeutic Agents, Piperidines, Various Alimentary Tract and Metabolism Products", Ceramide glucosyltransferase,"DB00419, DB14872, DB17619, DB00491, DB08283, DB17804, DB01816, DB03206, DB03955, DB05018, DB02034, DB04878",
DB00420,Promazine,approved; vet_approved,CN(C)CCCN1C2=CC=CC=C2SC2=CC=CC=C12,C17H20N2S,,"Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Agents producing tachycardia, Agents that produce hypertension, Amino Acids, Amino Acids, Branched-Chain, Amino Acids, Peptides, and Proteins, Anticholinergic Agents, Antidepressive Agents, Antiemetics, Antipsychotic Agents, Antipsychotic Agents (First Generation [Typical]), Autonomic Agents, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dopamine Agents, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Gastrointestinal Agents, Heterocyclic Compounds, Fused-Ring, Histamine Antagonists, Histamine H1 Antagonists, Moderate Risk QTc-Prolonging Agents, Muscarinic Antagonists, Nervous System, Neurotoxic agents, Neurotransmitter Agents, Peripheral Nervous System Agents, Phenothiazines, Phenothiazines With Aliphatic Side-Chain, Psycholeptics, Psychotropic Drugs, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2A Receptor Antagonists, Serotonin 5-HT2C Receptor Antagonists, Serotonin Agents, Serotonin Receptor Antagonists, Sulfur Compounds, Tranquilizing Agents"," Dopamine D2 receptor,  5-hydroxytryptamine receptor 2A,  5-hydroxytryptamine receptor 2C,  Alpha-1A adrenergic receptor,  Muscarinic acetylcholine receptor M1,  Histamine H1 receptor,  Cytochrome P450 1A2,  Cytochrome P450 3A4,  Cytochrome P450 2C9,  Cytochrome P450 2D6,  Cytochrome P450 2C19","DB00420, DB01246, DB12710, DB15596, DB00477, DB00902, DB13382, DB01069, DB13420, DB13820, DB01071, DB00392, DB11517, DB00433, DB09000, DB00508, DB13784, DB00372, DB13840, DB00850, DB11447, DB15978, DB01614, DB00679, DB00831, DB01403, DB13672",
DB00421,Spironolactone,approved,[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O,C24H32O4S,,"Agents causing hyperkalemia, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, BSEP/ABCB11 Substrates, Cardiovascular Agents, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (moderate), Cytochrome P-450 Enzyme Inhibitors, Diuretics, Fused-Ring Compounds, Hormone Antagonists, Hormones, Hormone Substitutes, and Hormone Antagonists, Hypotensive Agents, Lactones, Mineralocorticoid (Aldosterone) Receptor Antagonists, Mineralocorticoid Receptor Antagonists, Natriuretic Agents, P-glycoprotein inducers, Potassium-Sparing Diuretics, Pregnanes, Pregnenes, Steroids"," Mineralocorticoid receptor,  Glucocorticoid receptor,  Androgen receptor,  Progesterone receptor,  Estrogen receptor (Protein Group),  Nuclear receptor subfamily 1 group I member 2,  Voltage-dependent L-type calcium channel (Protein Group),  Cytochrome P450 11B1, mitochondrial,  Cytochrome P450 2C8,  Cytochrome P450 11B2, mitochondrial,  Serum albumin,  alpha1-acid glycoprotein (Protein Group),  Canalicular multispecific organic anion transporter 1,  P-glycoprotein 1,  Solute carrier organic anion transporter family member 1A2,  Bile salt export pump","DB00421, DB08804, DB13943, DB13944, DB13946, DB16001, DB16002, DB16141, DB01395",
DB00422,Methylphenidate,approved; investigational,COC(=O)C(C1CCCCN1)C1=CC=CC=C1,C14H19NO2,,"Acids, Carbocyclic, Agents that produce hypertension, Agents that reduce seizure threshold, Central Nervous System Agents, Central Nervous System Stimulants, Central Nervous System Stimulation, Centrally Acting Sympathomimetics, Dopamine Agents, Dopamine Uptake Inhibitors, Heterocyclic Compounds, Fused-Ring, Membrane Transport Modulators, Methylphenidate and isomer, Nervous System, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, Phenylacetates, Piperidines, Psychoanaleptics, Psychostimulants, Agents Used for ADHD and Nootropics, Respiratory and CNS Stimulants"," Sodium-dependent dopamine transporter,  5-hydroxytryptamine receptor 1A,  Sodium-dependent noradrenaline transporter,  Carboxylesterase","DB00422, DB06701",
DB00423,Methocarbamol,approved; vet_approved,COC1=C(OCC(O)COC(N)=O)C=CC=C1,C11H15NO5,,"Acids, Acyclic, Benzene Derivatives, Carbamates, Carbamic Acid Esters, Catechols, Central Nervous System Agents, Central Nervous System Depressants, Centrally-mediated Muscle Relaxation, Ethers, Methyl Ethers, Muscle Relaxants, Muscle Relaxants, Centrally Acting Agents, Musculo-Skeletal System, Peripheral Nervous System Agents, Phenols, Phenyl Ethers, Phenylcarbamates", Carbonic anhydrase 1,"DB00423, DB14656, DB00874",
DB00424,Hyoscyamine,approved,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)C1=CC=CC=C1,C17H23NO3,,"Adjuvants, Anesthesia, Agents producing tachycardia, Alimentary Tract and Metabolism, Alkaloids, Anti-Asthmatic Agents, Antiarrhythmic agents, Anticholinergic Agents, Atropine Derivatives, Autonomic Agents, Aza Compounds, Azabicyclo Compounds, Belladonna Alkaloids, Belladonna Alkaloids, Tertiary Amines, Belladonna and Derivatives, Plain, Bronchodilator Agents, Cardiovascular Agents, Central Nervous System Agents, Cholinergic Agents, Drugs for Functional Gastrointestinal Disorders, Muscarinic Antagonists, Mydriatics, Neurotransmitter Agents, Parasympatholytics, Peripheral Nervous System Agents, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Respiratory System Agents, Solanaceous Alkaloids, Tropanes"," Muscarinic acetylcholine receptor M1,  Muscarinic acetylcholine receptor M2,  Muscarinic acetylcholine receptor M3,  Muscarinic acetylcholine receptor M4,  Adenylate cyclase type 1","DB00424, DB00572, DB13833, DB00332, DB11785, DB16896, DB00209, DB00747, DB11315, DB02161, DB11181, DB00462, DB09300, DB12086, DB00725, DB08978, DB09271, DB15968",
DB00425,Zolpidem,approved,CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1,C19H21N3O,,"Benzodiazepine hypnotics and sedatives, Central Nervous System Agents, Central Nervous System Depressants, Central Nervous System Depression, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, GABA Agents, GABA Agonists, GABA-A Receptor Agonists, gamma-Aminobutyric Acid A Receptor Positive Modulator, gamma-Aminobutyric Acid-ergic Agonist, Hypnotics (Nonbenzodiazepine), Hypnotics and Sedatives, Miscellaneous Anxiolytics Sedatives and Hypnotics, Nervous System, Neurotransmitter Agents, Psycholeptics, Pyridines, Sleep Aids, Pharmaceutical"," Gamma-aminobutyric acid receptor subunit alpha-1,  Gamma-aminobutyric acid receptor subunit alpha-2,  Gamma-aminobutyric acid receptor subunit alpha-3,  Gamma-aminobutyric acid receptor subunit gamma-2,  Cytochrome P450 2C9,  Cytochrome P450 2C19,  Cytochrome P450 2D6,  Cytochrome P450 3A4,  Cytochrome P450 1A2",DB00425,
DB00426,Famciclovir,approved; investigational,CC(=O)OCC(CCN1C=NC2=CN=C(N)N=C12)COC(C)=O,C14H19N5O4,,"Anti-Infective Agents, Antiinfectives for Systemic Use, Antiviral Agents, Antivirals for Systemic Use, Direct Acting Antivirals, Enzyme Inhibitors, Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor, Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor, Heterocyclic Compounds, Fused-Ring, Nucleic Acid Synthesis Inhibitors, Nucleosides and Nucleotides, Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors, Ophthalmologicals, Purines, Sensory Organs"," DNA polymerase catalytic subunit,  Aldehyde oxidase","DB00426, DB00299, DB06575",
DB00427,Triprolidine,approved,CC1=CC=C(C=C1)C(=C/CN1CCCC1)\C1=CC=CC=N1,C19H22N2,,"Anti-Allergic Agents, Antihistamines for Systemic Use, Central Nervous System Depressants, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Neurotransmitter Agents, Potential QTc-Prolonging Agents, Pyridines, QTc Prolonging Agents"," Histamine H1 receptor,  Serum albumin","DB00427, DB09488",
DB00428,Streptozocin,approved; investigational,CN(N=O)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O,C8H15N3O7,,"Alkylating Activity, Alkylating Drugs, Amides, Antibiotics, Antineoplastic, Antineoplastic Agents, Antineoplastic Agents, Alkylating, Antineoplastic and Immunomodulating Agents, Carbohydrates, Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP1A2 Inducers (strength unknown), Cytochrome P-450 CYP2E1 Inducers, Cytochrome P-450 CYP2E1 Inducers (strength unknown), Cytochrome P-450 Enzyme Inducers, Glycosides, Immunosuppressive Agents, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, Nitroso Compounds, Nitrosourea Compounds, Nitrosoureas, P-glycoprotein inducers"," O-GlcNAcase BT_4395,  DNA,  Solute carrier family 2, facilitated glucose transporter member 2,  Bifunctional protein NCOAT,  Cytochrome P450 1A1,  Cytochrome P450 1A2,  Cytochrome P450 2E1,  P-glycoprotein 1","DB00428, DB13832, DB03109, DB03567, DB03740",
DB00429,Carboprost tromethamine,approved,NC(CO)(CO)CO.CCCCC[C@](C)(O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O,C25H47NO8,,"Abortifacient Agents, Abortifacient Agents, Nonsteroidal, Alcohols, Autacoids, Biological Factors, Eicosanoids, Fatty Acids, Fatty Acids, Unsaturated, Genito Urinary System and Sex Hormones, Glycols, Inflammation Mediators, Lipids, Pharmaceutical Preparations, Propylene Glycols, Prostaglandins, Prostaglandins F, Synthetic, Prostaglandins, Synthetic, Reproductive Control Agents, Uterotonic agents", Prostaglandin E2 receptor EP1 subtype,"DB00429, DB01160, DB12789, DB00917, DB11454, DB01088, DB00770",
DB00430,Cefpiramide,approved,[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@@]2([H])NC(=O)[C@H](NC(=O)C1=C(O)C=C(C)N=C1)C1=CC=C(O)C=C1)C(O)=O,C25H24N8O7S2,,"Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, beta-Lactams, Cephalosporins, Heterocyclic Compounds, Fused-Ring, Lactams, Nephrotoxic agents, Sulfur Compounds, Thiazines, Third-Generation Cephalosporins"," Peptidoglycan synthase FtsI,  Penicillin-binding protein 1B,  Penicillin-binding protein 1A,  Penicillin-binding protein 1B,  D-alanyl-D-alanine carboxypeptidase DacC,  Penicillin-binding protein 1A,  Penicillin binding protein 2a,  Serum albumin","DB00430, DB01329, DB00923, DB01326, DB13266, DB14725, DB00267, DB01328, DB00229, DB00274, DB09062, DB01330, DB01212, DB13638, DB13778, DB05735, DB13499, DB01327, DB13821, DB01140, DB01150, DB14879, DB13470, DB00567, DB00671, DB00535, DB11485, DB13682, DB13504, DB00438",
DB00431,Lindane,approved; withdrawn,Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl,C6H6Cl6,,"Agents that reduce seizure threshold, Agrochemicals, Antiparasitic Products, Insecticides and Repellents, Chlorine Containing Products, Compounds used in a research, industrial, or household setting, Ectoparasiticides, Incl. Scabicides, Ectoparasiticides, Incl. Scabicides, Insecticides and Repellents, Hydrocarbons, Chlorinated, Hydrocarbons, Halogenated, Insecticides, Pesticides, Toxic Actions"," Gamma-aminobutyric acid receptor subunit beta-1,  Glycine receptor subunit alpha-1,  Glycine receptor subunit alpha-2,  Glycine receptor subunit alpha-3,  Glycine receptor subunit beta,  Gamma-aminobutyric acid receptor subunit beta-3,  Gamma-aminobutyric acid receptor subunit rho-1,  Progesterone receptor,  Estrogen receptor alpha, 10. Nuclear receptor subfamily 1 group I member 2",DB00431,
DB00432,Trifluridine,approved; investigational,OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(C(=O)NC1=O)C(F)(F)F,C10H11F3N2O5,,"Anti-Infective Agents, Antimetabolites, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Antiviral Agents, Deoxyribonucleosides, Drugs that are Mainly Renally Excreted, Immunosuppressive Agents, Noxae, Nucleic Acid Synthesis Inhibitors, Nucleic Acids, Nucleotides, and Nucleosides, Nucleoside Analog Antiviral, Nucleoside Metabolic Inhibitor, Nucleosides, OAT1/SLC22A6 inhibitors, OAT1/SLC22A6 Substrates, OAT3/SLC22A8 Substrates, Ophthalmologicals, Pyrimidine Analogues, Pyrimidine Nucleosides, Pyrimidines, Sensory Organs, Toxic Actions"," DNA,  Thymidylate synthase,  Thymidine kinase, cytosolic,  Thymidine phosphorylase,  Serum albumin,  Solute carrier family 22 member 6,  Sodium/nucleoside cotransporter 1,  Equilibrative nucleoside transporter 1,  Equilibrative nucleoside transporter 2","DB00432, DB01265, DB04485, DB13421, DB03312, DB06683, DB14913, DB11998, DB02256, DB12606, DB08432, DB01643, DB08596, DB08661, DB03274, DB13030, DB02745, DB06198, DB14930, DB04205, DB03846, DB03150, DB04438, DB00495, DB04243, DB03103, DB00322, DB12028, DB02980, DB00249",
DB00433,Prochlorperazine,approved; vet_approved,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1,C20H24ClN3S,,"Antiemetics, Antipsychotic Agents, Antipsychotic Agents (First Generation [Typical]), Autonomic Agents, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Substrates, Dopamine Agents, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Drugs causing inadvertant photosensitivity, Gastrointestinal Agents, Heterocyclic Compounds, Fused-Ring, Moderate Risk QTc-Prolonging Agents, Nervous System, Neurotoxic agents, Neurotransmitter Agents, Peripheral Nervous System Agents, Phenothiazines, Phenothiazines With Piperazine Structure, Photosensitizing Agents, Psycholeptics, Psychotropic Drugs, QTc Prolonging Agents, Schizophrenia, Sulfur Compounds, Tranquilizing Agents"," Dopamine D2 receptor,  Histamine H1 receptor,  Alpha-1 adrenergic receptors (Protein Group),  Alpha-2 adrenergic receptors (Protein Group),  Cytochrome P450 2D6","DB00433, DB00850, DB13382, DB00477, DB12710, DB13557, DB14651, DB00420, DB01246, DB13784, DB15596, DB00902, DB00372, DB00831, DB00392, DB00623, DB01069, DB13420, DB01071",
DB00434,Cyproheptadine,approved,CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=CC=CC=C12,C21H21N,,"Agents producing tachycardia, Agents that reduce seizure threshold, Anti-Allergic Agents, Anticholinergic Agents, Antidepressive Agents, Antihistamines for Systemic Use, Antipruritics, Benzocycloheptenes, Central Nervous System Depressants, Dermatologicals, Dibenzocycloheptenes, Drugs causing inadvertant photosensitivity, Gastrointestinal Agents, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Miscellaneous Derivatives, Muscarinic Antagonists, Neurotransmitter Agents, OCT1 inhibitors, Photosensitizing Agents, Piperidines, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2A Receptor Antagonists, Serotonin 5-HT2C Receptor Antagonists, Serotonin Agents, Serotonin Receptor Antagonists, UGT1A3 substrates, UGT1A4 substrates"," Histamine H1 receptor,  5-hydroxytryptamine receptor 2A,  5-hydroxytryptamine receptor 2C,  Histamine H2 receptor,  5-hydroxytryptamine receptor 2B,  Muscarinic acetylcholine receptor M1,  Muscarinic acetylcholine receptor M2,  Muscarinic acetylcholine receptor M3,  5-hydroxytryptamine receptor 7,  UDP-glucuronosyltransferase 1-3,  UDP-glucuronosyltransferase 1-4,  UDP-glucuronosyltransferase 2B10,  Serum albumin,  Solute carrier family 22 member 1","DB00434, DB00924, DB13720",
DB00435,Nitric Oxide,approved,[N]=O,NO,,"Anti-Asthmatic Agents, Antioxidants, Autonomic Agents, Bronchodilator Agents, Cardiovascular Agents, Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Drugs that are Mainly Renally Excreted, Endothelium-Dependent Relaxing Factors, Free Radical Scavengers, Free Radicals, Gases, Gasotransmitters, Hypotensive Agents, Methemoglobinemia Associated Agents, Neurotransmitter Agents, Nitrates and Nitrites, Nitrogen Compounds, Nitrogen Oxides, Oxides, Oxygen Compounds, Peripheral Nervous System Agents, Reactive Nitrogen Species, Respiratory System Agents, Vasodilating Agents, Vasodilation"," Guanylate cyclase soluble subunit alpha-2,  Metallothionein-1A,  Indoleamine 2,3-dioxygenase 1,  Nitric oxide synthase, endothelial,  Aldehyde dehydrogenase, mitochondrial,  Cytochrome P450 1A2,  Cytochrome P450 2B6,  Cytochrome P450 3A4",DB00435,
DB00436,Bendroflumethiazide,approved,NS(=O)(=O)C1=CC2=C(NC(CC3=CC=CC=C3)NS2(=O)=O)C=C1C(F)(F)F,C15H14F3N3O4S2,,"Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Benzothiadiazines, Bradycardia-Causing Agents, Cardiovascular Agents, Diuretics, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Heterocyclic Compounds, Fused-Ring, Hyperglycemia-Associated Agents, Hypotensive Agents, Increased Diuresis, Low-Ceiling Diuretics and Potassium-Sparing Agents, Membrane Transport Modulators, Natriuretic Agents, Sodium Chloride Symporter Inhibitors, Sulfonamides, Sulfones, Sulfur Compounds, Thiazides"," Solute carrier family 12 member 3,  Calcium-activated potassium channel subunit alpha-1,  Carbonic anhydrase 1,  Carbonic anhydrase 2,  Carbonic anhydrase 4,  Thiopurine S-methyltransferase","DB00436, DB00774, DB08303, DB15861, DB13430, DB13532",
DB00437,Allopurinol,approved,OC1=NC=NC2=C1C=NN2,C5H4N4O,,"Antigout Preparations, Antimetabolites, Antioxidants, BCRP/ABCG2 Substrates, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Free Radical Scavengers, Heterocyclic Compounds, Fused-Ring, Musculo-Skeletal System, OAT3/SLC22A8 Substrates, Preparations Inhibiting Uric Acid Production, Protective Agents, Purines, Uricosuric Agents, Xanthine Oxidase Inhibitors"," Xanthine dehydrogenase/oxidase,  Aldehyde oxidase,  Xanthine dehydrogenase/oxidase,  Solute carrier family 22 member 8,  Solute carrier family 22 member 7,  ATP-binding cassette sub-family G member 2,  Solute carrier family 22 member 2",DB00437,
DB00438,Ceftazidime,approved,[O-]C(=O)C1=C(CS[C@]2([H])[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C3=CSC(N)=N3)C(=O)N12)C[N+]1=CC=CC=C1,C22H22N6O7S2,,"Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, beta Lactam Antibiotics, beta-Lactams, Cephalosporins, Drugs that are Mainly Renally Excreted, Heterocyclic Compounds, Fused-Ring, Lactams, Nephrotoxic agents, OAT1/SLC22A6 inhibitors, Sulfur Compounds, Thiazines, Third-Generation Cephalosporins"," Peptidoglycan synthase FtsI,  Penicillin-binding protein 1A,  Penicillin-binding protein 1B,  Penicillin-binding protein 2,  Beta-lactamase Toho-1,  Serum albumin,  Solute carrier family 22 member 6","DB00438, DB00671, DB01413, DB13682, DB13504, DB14879, DB01416, DB00493, DB00535, DB00267, DB11505, DB11485, DB01332, DB01212, DB09050, DB01066, DB13667, DB13470, DB13499, DB04918, DB05735, DB11385, DB13461, DB09008, DB14733, DB00229, DB06590, DB01415, DB00430, DB03530",
DB00439,Cerivastatin,approved; withdrawn,COCC1=C(C2=CC=C(F)C=C2)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C(C(C)C)N=C1C(C)C,C26H34FNO5,,"Agents Causing Muscle Toxicity, Anticholesteremic Agents, BCRP/ABCG2 Substrates, BSEP/ABCB11 Substrates, Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strength unknown), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Enzyme Inhibitors, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hypolipidemic Agents, Hypolipidemic Agents Indicated for Hyperlipidemia, Lipid Modifying Agents, Lipid Modifying Agents, Plain, Lipid Regulating Agents, OATP1B1/SLCO1B1 Inhibitors, OATP1B1/SLCO1B1 Substrates, P-glycoprotein substrates, UGT1A1 Substrates"," 3-hydroxy-3-methylglutaryl-coenzyme A reductase,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  Cytochrome P450 2C8,  Cytochrome P450 2D6,  Cytochrome P450 2C9,  Cytochrome P450 2B6,  UDP-glucuronosyltransferase 1-1,  P-glycoprotein 1,  Canalicular multispecific organic anion transporter 1,  ATP-binding cassette sub-family G member 2,  Solute carrier organic anion transporter family member 1B1,  Bile salt export pump","DB00439, DB08860",
DB00440,Trimethoprim,approved; vet_approved,COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC,C14H18N4O3,,"Agents causing hyperkalemia, Agents Causing Muscle Toxicity, Anti-Infective Agents, Anti-Infective Agents, Urinary, Antibacterials for Systemic Use, Antibiotics for Pneumocystis Pneumonia, Antiinfectives for Systemic Use, Antimycobacterials, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (moderate), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs causing inadvertant photosensitivity, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Folic Acid Antagonists, MATE 1 Inhibitors, MATE 1 Substrates, MATE 2 Inhibitors, MATE 2 Substrates, MATE inhibitors, MATE substrates, OCT2 Inhibitors, P-glycoprotein inducers, P-glycoprotein inhibitors, P-glycoprotein substrates, Photosensitizing Agents, Pyrimidines, Renal Agents, Sulfonamides and trimethoprim, Trimethoprim and Derivatives"," Dihydrofolate reductase,  Cytochrome P450 2C9,  Cytochrome P450 3A4,  Cytochrome P450 1A2,  Cytochrome P450 2C8,  P-glycoprotein 1,  Multidrug and toxin extrusion protein 1,  Multidrug and toxin extrusion protein 2","DB00440, DB03125, DB15976, DB13795, DB02809",
DB00441,Gemcitabine,approved,NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F,C9H11F2N3O4,,"Antimetabolites, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Carbohydrates, Cytidine Deaminase Substrates, Deoxycytidine, Deoxyribonucleosides, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Glycosides, Immunosuppressive Agents, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, Noxae, Nucleic Acid Synthesis Inhibitors, Nucleic Acids, Nucleotides, and Nucleosides, Nucleoside Metabolic Inhibitor, Nucleosides, P-glycoprotein substrates, P-glycoprotein substrates with a Narrow Therapeutic Index, Pyrimidine Analogues, Pyrimidine Nucleosides, Pyrimidines, Ribonucleosides, Ribonucleotide Reductases, antagonists & inhibitors, Toxic Actions"," DNA,  Ribonucleoside-diphosphate reductase large subunit,  Thymidylate synthase,  UMP-CMP kinase,  Thymidine kinase 2, mitochondrial,  UMP-CMP kinase,  Nucleoside diphosphate kinase A,  Cytidine deaminase,  Deoxycytidine kinase,  P-glycoprotein 1,  Multidrug resistance-associated protein 7,  Equilibrative nucleoside transporter 1,  Sodium/nucleoside cotransporter 1,  Equilibrative nucleoside transporter 2,  Solute carrier family 28 member 3","DB00441, DB12901, DB12564, DB02594, DB12906, DB16407, DB13030, DB13776, DB12045, DB12383, DB00987, DB02097, DB12957, DB14808, DB11667, DB13921, DB00943, DB06683, DB14913, DB15427, DB15660, DB06433, DB03798, DB06656, DB06187, DB03155, DB04603, DB02883, DB02456, DB03403",
DB00442,Entecavir,approved; investigational,NC1=NC(=O)C2=C(N1)N(C=N2)[C@H]1C[C@H](O)[C@@H](CO)C1=C,C12H15N5O3,,"Anti-Infective Agents, Antiinfectives for Systemic Use, Antiviral Agents, Antivirals for Systemic Use, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 Substrates, Direct Acting Antivirals, Hepatitis B virus, Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor, Heterocyclic Compounds, Fused-Ring, Nucleoside and Nucleotide Reverse Transcriptase Inhibitors, Nucleoside Reverse Transcriptase Inhibitors, Nucleosides and Nucleotides, Purines, Purinones", DNA,"DB00442, DB12531, DB17733, DB00299, DB06575, DB15651",
DB00443,Betamethasone,approved; vet_approved,[H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,C22H29FO5,,"Adrenal Cortex Hormones, Adrenals, Agents Causing Muscle Toxicity, Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use, Alimentary Tract and Metabolism, Anti-Inflammatory Agents, Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents, Corticosteroid Hormone Receptor Agonists, Corticosteroids, Corticosteroids Acting Locally, Corticosteroids for Systemic Use, Corticosteroids for Systemic Use, Plain, Corticosteroids, Dermatological Preparations, Corticosteroids, Potent (Group III), Cytochrome P-450 CYP2A6 Inducers, Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strength unknown), Cytochrome P-450 CYP2C19 Inducers, Cytochrome P-450 CYP2C19 Inducers (strength unknown), Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 CYP2C8 Inducers (strength unknown), Cytochrome P-450 CYP2C9 Inducers, Cytochrome P-450 CYP2C9 Inducers (strength unknown), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Inducers, Cytochrome P-450 CYP3A5 Inducers (weak), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Substrates, Dermatologicals, Drugs for Obstructive Airway Diseases, Fused-Ring Compounds, Glucocorticoids, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hyperglycemia-Associated Agents, Immunosuppressive Agents, Intestinal Antiinflammatory Agents, Nasal Preparations, Ophthalmological and Otological Preparations, Ophthalmologicals, Otologicals, P-glycoprotein substrates, Pregnadienes, Pregnadienetriols, Pregnanes, Respiratory System Agents, Steroids, Steroids, Fluorinated, Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins, Thyroxine-binding globulin inhibitors, Vasoprotectives"," Glucocorticoid receptor,  Cytochrome P450 19A1,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  Cytochrome P450 2A6,  Cytochrome P450 1B1,  Cytochrome P450 2B6,  Cytochrome P450 2C8,  Cytochrome P450 2C9,  Cytochrome P450 2C19, 10. Cytochrome P450 3A4,  Serum albumin,  Corticosteroid-binding globulin,  P-glycoprotein 1","DB00443, DB01234, DB11522, DB13491, DB00324, DB00620, DB00547, DB08970, DB11750, DB00223, DB00663, DB09095, DB12553, DB14640, DB14649, DB14669, DB00687, DB01384, DB09378, DB00596, DB14634, DB00860, DB00959, DB08971, DB13728, DB13158, DB13223, DB01185, DB13208, DB14664",
DB00444,Teniposide,approved,[H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(O)C(OC)=C1)C1=C(C=C3OCOC3=C1)[C@H]2O[C@]1([H])O[C@]2([H])CO[C@H](O[C@@]2([H])[C@H](O)[C@H]1O)C1=CC=CS1,C32H32O13S,,"Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Substrates, Carbohydrates, Cardiotoxic antineoplastic agents, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Inhibitors (weak), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Enzyme Inhibitors, Glucosides, Glycosides, Immunosuppressive Agents, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, Neurotoxic agents, Podophyllotoxin Derivatives, Topoisomerase II Inhibitors, Topoisomerase Inhibitors"," DNA topoisomerase 2-alpha,  Cytochrome P450 3A5,  Cytochrome P450 2C19,  Cytochrome P450 2C9,  Cytochrome P450 3A4,  Multidrug resistance-associated protein 6,  ATP-binding cassette sub-family G member 2","DB00444, DB00773, DB17255, DB01179, DB09094, DB12802",
DB00445,Epirubicin,approved,COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O,C27H29NO11,,"Anthracycline Topoisomerase Inhibitor, Anthracyclines, Anthracyclines and Related Substances, Antibiotics, Antineoplastic, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Carbohydrates, Cardiotoxic antineoplastic agents, Cytotoxic Antibiotics and Related Substances, Enzyme Inhibitors, Glycosides, Hepatotoxic Agents, Immunosuppressive Agents, Myelosuppressive Agents, Naphthacenes, Narrow Therapeutic Index Drugs, Topoisomerase II Inhibitors, Topoisomerase Inhibitors, UGT2B7 substrates, UGT2B7 Substrates with a Narrow Therapeutic Index"," DNA,  DNA topoisomerase 2-alpha,  UDP-glucuronosyltransferase 2B7,  Cytosolic phospholipase A2,  Multidrug resistance-associated protein 1","DB00445, DB00694, DB00997, DB11616, DB17149, DB01177, DB12410, DB05706, DB13103, DB00385, DB06420, DB04131, DB01806, DB06263, DB03219, DB11618, DB03199, DB06013, DB11617, DB12755, DB17273",
DB00446,Chloramphenicol,approved; vet_approved; withdrawn,OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O,C11H12Cl2N2O5,,"Alcohols, Amphenicols, Anti-Acne Preparations, Anti-Acne Preparations for Topical Use, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antibiotics for Topical Use, Antiinfectives for Systemic Use, Antiinfectives for Treatment of Acne, Benzene Derivatives, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (strong), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A5 Inhibitors, Cytochrome P-450 CYP3A5 Inhibitors (strength unknown), Cytochrome P-450 CYP3A7 Inhibitors, Cytochrome P-450 CYP3A7 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Dermatologicals, Enzyme Inhibitors, Genito Urinary System and Sex Hormones, Glycols, Gynecological Antiinfectives and Antiseptics, Immunosuppressive Agents, Myelosuppressive Agents, Nitro Compounds, Nitrobenzenes, OAT1/SLC22A6 inhibitors, Ophthalmological and Otological Preparations, Ophthalmologicals, Otologicals, Propylene Glycols, Protein Synthesis Inhibitors, Sensory Organs"," 50S ribosomal protein L16,  Dr hemagglutinin structural subunit,  Complement decay-accelerating factor,  Chloramphenicol acetyltransferase 3,  Chloramphenicol acetyltransferase,  Chloramphenicol 3-O phosphotransferase,  Cytochrome P450 2C19,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  Solute carrier family 22 member 6","DB00446, DB02608, DB04411, DB07492, DB07565, DB13294, DB14658",
DB00447,Loracarbef,approved; investigational; withdrawn,N[C@@H](C(=O)N[C@H]1[C@H]2CCC(Cl)=C(N2C1=O)C(O)=O)C1=CC=CC=C1,C16H16ClN3O4,,"Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, beta-Lactams, Cephalosporins, Heterocyclic Compounds, Fused-Ring, Lactams, Nephrotoxic agents, Second-Generation Cephalosporins, Sulfur Compounds, Thiazines"," Penicillin-binding protein 3,  Penicillin-binding protein 1A,  Solute carrier family 15 member 1,  Solute carrier family 15 member 2","DB00447, DB04293",
DB00448,Lansoprazole,approved; investigational,CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1,C16H14F3N3O2S,,"Acid Reducers, Alimentary Tract and Metabolism, Anti-Ulcer Agents, BCRP/ABCG2 Inhibitors, Benzimidazoles, Cytochrome P-450 CYP2C18 Substrates, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (strong), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Inducers, Cytochrome P-450 CYP2C9 Inducers (strength unknown), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord), Gastric Acid Lowering Agents, Gastrointestinal Agents, Heterocyclic Compounds, Fused-Ring, Inhibition Gastric Acid Secretion, OAT3/SLC22A8 Inhibitors, P-glycoprotein inhibitors, P-glycoprotein substrates, Proton Pump Inhibitors, Proton-pump Inhibitors, Pyridines, Sulfoxides, Sulfur Compounds"," Potassium-transporting ATPase alpha chain 1,  Microtubule-associated protein tau,  Cytochrome P450 1A1,  Cytochrome P450 1B1,  Cytochrome P450 2C8,  Cytochrome P450 2C9,  Cytochrome P450 2C18,  Cytochrome P450 2D6,  Cytochrome P450 3A4,  Cytochrome P450 2C19,  ATP-binding cassette sub-family G member 2,  P-glycoprotein 1,  Solute carrier family 22 member 8,  Solute carrier family 22 member 1,  Solute carrier family 22 member 2,  Solute carrier family 22 member 3","DB00448, DB05351, DB17144, DB01129, DB13762, DB00338, DB00736, DB11964",
DB00449,Dipivefrin,approved,CNCC(O)C1=CC(OC(=O)C(C)(C)C)=C(OC(=O)C(C)(C)C)C=C1,C19H29NO5,,"Adrenergic Agents, Adrenergic Agonists, Adrenergic alpha-1 Receptor Agonists, Adrenergic alpha-2 Receptor Agonists, Adrenergic alpha-Agonists, Adrenergic beta-1 Receptor Agonists, Adrenergic beta-2 Receptor Agonists, Adrenergic beta-3 Receptor Agonists, Adrenergic beta-Agonists, Alcohols, Amines, Amino Alcohols, Antiglaucoma Preparations and Miotics, Benzene Derivatives, Biogenic Amines, Biogenic Monoamines, Catecholamines, Catechols, Cholinesterase substrates, Ethanolamines, Mydriatics, Neurotransmitter Agents, Ophthalmics, Ophthalmologicals, Phenols, Sensory Organs, Sympathomimetics in Glaucoma Therapy"," Alpha-1A adrenergic receptor,  Alpha-2A adrenergic receptor,  Beta-2 adrenergic receptor,  Cholinesterase,  Acetylcholinesterase","DB00449, DB13316, DB00901",
DB00450,Droperidol,approved; vet_approved,FC1=CC=C(C=C1)C(=O)CCCN1CCC(=CC1)N1C(=O)NC2=CC=CC=C12,C22H22FN3O2,,"Adjuvants, Anesthesia, Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Agents that produce hypertension, Antiemetics, Antipsychotic Agents, Antipsychotic Agents (First Generation [Typical]), Autonomic Agents, Benzimidazoles, Butyrophenone Derivatives, Butyrophenones, Central Nervous System Agents, Central Nervous System Depressants, Dopamine Agents, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Gastrointestinal Agents, Heterocyclic Compounds, Fused-Ring, Ketones, Miscellaneous Anxiolytics Sedatives and Hypnotics, Moderate Risk QTc-Prolonging Agents, Nervous System, Neurotoxic agents, Neurotransmitter Agents, Peripheral Nervous System Agents, Psycholeptics, Psychotropic Drugs, QTc Prolonging Agents, Tranquilizing Agents"," Alpha-1A adrenergic receptor,  Dopamine D2 receptor","DB00450, DB01100",
DB00451,Levothyroxine,approved,N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O,C15H11I4NO4,,"Agents used to treat hypothyroidism, Amino Acids, Amino Acids, Aromatic, Amino Acids, Cyclic, Amino Acids, Peptides, and Proteins, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (moderate), Cytochrome P-450 Enzyme Inhibitors, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Narrow Therapeutic Index Drugs, OATP1B1/SLCO1B1 Inhibitors, OATP1B3 inhibitors, Organic Anion Transporting Polypeptide 2B1 Inhibitors, P-glycoprotein inducers, Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins, Thyroid Products, Thyroxine-binding globulin substrates, UGT1A1 Substrates, UGT1A1 Substrates with a Narrow Therapeutic Index"," Integrin alpha-V,  Integrin beta-3,  Thyroid hormone receptor alpha,  Thyroid hormone receptor beta,  UDP-glucuronosyltransferase 1-1,  P-glycoprotein 1,  Cytochrome P450 2C8,  Transthyretin,  Thyroxine-binding globulin,  Serum albumin,  Solute carrier organic anion transporter family member 1C1,  Monocarboxylate transporter 8,  P-glycoprotein 1,  Solute carrier organic anion transporter family member 1A2,  Solute carrier organic anion transporter family member 1B1,  Solute carrier organic anion transporter family member 4A1,  Large neutral amino acids transporter small subunit 1,  Solute carrier organic anion transporter family member 2B1","DB00279, DB00451, DB00509, DB12425, DB01583, DB12629, DB03374, DB01758",
DB00452,Framycetin,approved,NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O,C23H46N6O13,,"Agents that produce neuromuscular block (indirect), Aminoglycoside Antibacterials, Anti-Bacterial Agents, Anti-Infective Agents, Carbohydrates, Dermatologicals, Glycosides, Medicated Dressings, Medicated Dressings With Antiinfectives, Nasal Preparations, Nephrotoxic agents, Ophthalmologicals, Sensory Organs"," 16S ribosomal RNA,  30S ribosomal protein S12,  C-X-C chemokine receptor type 4","DB00452, DB01421, DB04728, DB03615, DB15080, DB17631, DB16951, DB13673, DB00684, DB13270, DB04717, DB01172, DB04808, DB04718, DB04263, DB04729, DB17884, DB07341, DB11520, DB03779, DB00798, DB13274, DB04626, DB04679, DB04678, DB03618, DB00919, DB04226",
DB00453,Clomocycline,experimental,[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(=O)NCO)=C(O)[C@H]2N(C)C)C(=O)C1=C(C(Cl)=CC=C1O)[C@@]3(C)O,C23H25ClN2O9,,"Agents that produce neuromuscular block (indirect), Anti-Bacterial Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Naphthacenes, Tetracyclines"," 30S ribosomal protein S4,  30S ribosomal protein S9,  16S ribosomal RNA","DB00453, DB09093, DB00618, DB00759, DB13092, DB09550, DB00595, DB00256, DB01301, DB00254, DB00931, DB01017, DB12035, DB12455, DB00560, DB12329, DB15040, DB13264, DB11647, DB11691, DB05168, DB11191, DB03469, DB03614, DB00361, DB00200, DB12674, DB11467, DB02832",
DB00454,Meperidine,approved,CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1,C15H21NO2,,"Adjuvants, Adjuvants, Anesthesia, Agents that reduce seizure threshold, Analgesics, Antidepressive Agents, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP1A2 Inducers (strength unknown), Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, High-risk opioids, Isonipecotic Acids, Narcotics, Nervous System, NMDA Receptor Antagonists, Opiate Agonists, Opioid Agonist, Opioids, P-glycoprotein substrates, Peripheral Nervous System Agents, Phenylpiperidine opioids, Piperidines, Sensory System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin Modulators"," Kappa-type opioid receptor,  Glutamate receptor ionotropic, NMDA 1,  Glutamate receptor ionotropic, NMDA 2B,  Glutamate receptor ionotropic, NMDA 2A,  Glutamate receptor ionotropic, NMDA 2C,  Glutamate receptor ionotropic, NMDA 2D,  Muscarinic acetylcholine receptor (Protein Group),  Mu-type opioid receptor,  Sodium-dependent dopamine transporter, 10. Sodium-dependent noradrenaline transporter, 11. Sodium-dependent serotonin transporter, 12. Liver carboxylesterase 1,  Cytochrome P450 3A4,  Cytochrome P450 2C19,  Cytochrome P450 2B6,  Cytochrome P450 2D6,  Cytochrome P450 1A2,  Serum albumin,  Alpha-1-acid glycoprotein 1,  P-glycoprotein 1","DB00454, DB01505, DB01081, DB01475, DB13605, DB01518, DB08988, DB00913, DB01464, DB01501",
DB00455,Loratadine,approved; investigational,CCOC(=O)N1CCC(CC1)=C1C2=C(CCC3=C1N=CC=C3)C=C(Cl)C=C2,C22H23ClN2O2,,"Anti-Allergic Agents, Antihistamines for Systemic Use, Antipruritics, Benzocycloheptenes, BSEP/ABCB11 Substrates, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (weak), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (moderate), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (weak), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dermatologicals, Dibenzocycloheptenes, Histamine Antagonists, Histamine H1 Antagonists, Histamine H1 Antagonists, Non-Sedating, Loratadine and derivatives, Neurotransmitter Agents, P-glycoprotein inhibitors, P-glycoprotein substrates, Piperidines, Potential QTc-Prolonging Agents, QTc Prolonging Agents"," Histamine H1 receptor,  Potassium voltage-gated channel subfamily H member 2,  Cytochrome P450 3A4,  Cytochrome P450 2D6,  Cytochrome P450 1A1,  Cytochrome P450 2C19,  Cytochrome P450 2C8,  Cytochrome P450 1A2,  Cytochrome P450 2B6,  Cytochrome P450 2C9,  Cytochrome P450 3A5, 10. UDP-glucuronosyltransferase 2B10, 11. UDP-glucuronosyltransferase 1-1, 12. UDP-glucuronosyltransferase 1-3, 13. UDP-glucuronosyltransferase 2B15,  P-glycoprotein 1,  Bile salt export pump","DB00455, DB00967, DB11614, DB00719",
DB00456,Cefalotin,approved; investigational; vet_approved,[H][C@@]1(NC(=O)CC2=CC=CS2)C(=O)N2C(C(O)=O)=C(COC(C)=O)CS[C@]12[H],C16H16N2O6S2,,"Agents that reduce seizure threshold, Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, beta-Lactams, Cephalosporins, First-Generation Cephalosporins, Heterocyclic Compounds, Fused-Ring, Lactams, Nephrotoxic agents, OAT1/SLC22A6 inhibitors, OAT3/SLC22A8 Inhibitors, Sulfur Compounds, Thiazines"," D-alanyl-D-alanine carboxypeptidase,  Penicillin-binding protein 1A,  Penicillin-binding protein 1b,  Penicillin-binding protein 3,  Penicillin-binding protein 2a,  Penicillin-binding protein 2B,  Penicillin-binding protein 1A,  Beta-lactamase,  Serum albumin,  Solute carrier family 22 member 5,  Solute carrier family 15 member 1,  Solute carrier family 15 member 2,  Solute carrier family 22 member 6,  Solute carrier family 22 member 8,  Solute carrier family 22 member 11,  Solute carrier family 22 member 7","DB00456, DB00689, DB01414, DB03313, DB01331, DB01139, DB09008, DB11592, DB00567, DB01140, DB01112, DB13461, DB00493, DB11385, DB03938, DB01150, DB01416, DB02247, DB04133, DB01326, DB01333, DB11505, DB03450, DB13504, DB00535, DB00833, DB13499, DB01328, DB01413, DB13266",
DB00457,Prazosin,approved,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1,C19H21N5O4,,"Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Alpha-Adrenoreceptor Antagonists and Diuretics, Antiadrenergic Agents, Peripherally Acting, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, BCRP/ABCG2 Substrates, Cardiovascular Agents, Heterocyclic Compounds, Fused-Ring, Hypotensive Agents, OCT1 inhibitors, OCT1 substrates, OCT2 Substrates, P-glycoprotein inhibitors, P-glycoprotein substrates, Peripheral alpha-1 blockers, Quinazolines, Vasodilating Agents"," Alpha-1A adrenergic receptor,  Alpha-1B adrenergic receptor,  Alpha-1D adrenergic receptor,  Potassium voltage-gated channel subfamily H member 2,  Alpha-2A adrenergic receptor,  Alpha-2B adrenergic receptor,  Alpha-1 adrenergic receptors (Protein Group),  Alpha-1-acid glycoprotein 1,  Solute carrier family 22 member 1,  Solute carrier family 22 member 3,  P-glycoprotein 1,  ATP-binding cassette sub-family G member 2","DB00457, DB12230, DB01162, DB00590, DB09206",
DB00458,Imipramine,approved,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,C19H24N2,,"Adrenergic Agents, Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Adrenergic Uptake Inhibitors, Agents producing tachycardia, Agents that produce hypertension, Agents that reduce seizure threshold, Anticholinergic Agents, Antidepressive Agents, Antidepressive Agents Indicated for Depression, Antidepressive Agents, Tricyclic, Central Nervous System Agents, Central Nervous System Depressants, Combined Inhibitors of Serotonin/Norepinephrine Reuptake, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (moderate), Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C18 Substrates, Cytochrome P-450 CYP2C18 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (strength unknown), Cytochrome P-450 CYP2C19 Inhibitors (strong), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dibenzazepines, Drugs that are Mainly Renally Excreted, Heterocyclic Compounds, Fused-Ring, Histamine Antagonists, Histamine H1 Antagonists, Hypotensive Agents, Membrane Transport Modulators, Moderate Risk QTc-Prolonging Agents, Muscarinic Antagonists, Narrow Therapeutic Index Drugs, Nervous System, Neurotoxic agents, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, Non-Selective Monoamine Reuptake Inhibitors, OCT2 Inhibitors, P-glycoprotein substrates, P-glycoprotein substrates with a Narrow Therapeutic Index, Psychoanaleptics, Psychotropic Drugs, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2A Receptor Antagonists, Serotonin 5-HT2C Receptor Antagonists, Serotonin Agents, Serotonin Modulators, Serotonin Receptor Antagonists, Tertiary amine tricyclic antidepressants, Tricyclics and Other Norepinephrine-reuptake Inhibitors"," Sodium-dependent noradrenaline transporter,  Sodium-dependent serotonin transporter,  5-hydroxytryptamine receptor 2A,  Histamine H1 receptor,  Alpha-1A adrenergic receptor,  Alpha-1D adrenergic receptor,  Muscarinic acetylcholine receptor M1,  Muscarinic acetylcholine receptor M2,  Muscarinic acetylcholine receptor M3, 10. Muscarinic acetylcholine receptor M4, 11. Muscarinic acetylcholine receptor M5, 12. Potassium voltage-gated channel subfamily D member 2, 13. Potassium voltage-gated channel subfamily D member 3, 14. 5-hydroxytryptamine receptor 2C, 15. Alpha-1B adrenergic receptor, 16. 5-hydroxytryptamine receptor 7, 17. D(1) dopamine receptor (Protein Group), 18. Dopamine D2 receptor, 19. Potassium voltage-gated channel subfamily H member 2, 20. Sodium-dependent dopamine transporter, 21. 5-hydroxytryptamine receptor 1A, 22. 5-hydroxytryptamine receptor 6, 23. Potassium voltage-gated channel subfamily H member 1, 24. Alpha-1-acid glycoprotein 2,  Cytochrome P450 2C19,  Cytochrome P450 2D6,  Cytochrome P450 1A2,  Cytochrome P450 3A4,  Cytochrome P450 3A7,  Cytochrome P450 2B6,  Cytochrome P450 2C18,  Cytochrome P450 2E1,  Alpha-1-acid glycoprotein 1,  Serum albumin,  P-glycoprotein 1,  Solute carrier family 22 member 2,  Solute carrier family 22 member 3,  Solute carrier family 22 member 4","DB00458, DB01151, DB00726, DB13782, DB01242, DB13411",
DB00459,Acitretin,approved,COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1,C21H26O3,,"Alkenes, Antipsoriatics, Antipsoriatics for Systemic Use, Biological Factors, Carotenoids, Cyclohexanes, Cyclohexenes, Cycloparaffins, Dermatologicals, Drugs causing inadvertant photosensitivity, Hepatotoxic Agents, Hydrocarbons, Acyclic, Keratolytic Agents, Misc. Skin and Mucous Membrane Agents, Photosensitizing Agents, Pigments, Biological, Polyenes, Retinoids, Retinoids for Treatment of Psoriasis, Terpenes"," Retinoic acid receptor RXR-alpha,  Retinoic acid receptor alpha,  Retinoic acid receptor beta,  Retinoic acid receptor gamma,  Retinoic acid receptor RXR-beta,  Retinoic acid receptor RXR-gamma,  Retinol-binding protein 1,  Serum albumin","DB00459, DB00926, DB08455, DB13368",
DB00460,Verteporfin,approved; investigational,COC(=O)CCC1=C2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(CCC(O)=O)=C5C)C(C=C)=C4C)C2=CC=C([C@@H](C(=O)OC)[C@@]32C)C(=O)OC)=C1C,C41H42N4O8,,"Antineovascularisation Agents, Dermatologicals, EENT Drugs, Miscellaneous, Heterocyclic Compounds, Fused-Ring, Ocular Vascular Disorder Agents, Ophthalmologicals, Photoabsorption, Photoenhancer, Photosensitizing Activity, Photosensitizing Agents, Porphyrins, Radiation-Sensitizing Agents, Sensory Organs",,"DB00460, DB04980, DB06659, DB04506, DB02133, DB01853",
DB00461,Nabumetone,approved,COC1=CC2=C(C=C1)C=C(CCC(C)=O)C=C2,C15H16O2,,"Agents causing hyperkalemia, Agents that produce hypertension, Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Antiinflammatory and Antirheumatic Products, Antiinflammatory and Antirheumatic Products, Non-Steroids, Antirheumatic Agents, Butanones, COX-2 Inhibitors, Cyclooxygenase Inhibitors, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 Substrates, Drugs causing inadvertant photosensitivity, Enzyme Inhibitors, Ketones, Musculo-Skeletal System, Nephrotoxic agents, Other Nonsteroidal Anti-inflammatory Agents, Photosensitizing Agents, Selective Cyclooxygenase 2 Inhibitors (NSAIDs)"," Prostaglandin G/H synthase 2,  Prostaglandin G/H synthase 1,  Myeloperoxidase,  Cytochrome P450 1A2,  Cytochrome P450 2C9,  Corticosteroid 11-beta-dehydrogenase isozyme 1,  Aldo-keto reductase family 1 member C1,  Aldo-keto reductase family 1 member C2,  Aldo-keto reductase family 1 member C4,  Serum albumin",DB00461,
DB00462,Methscopolamine bromide,approved,[Br-].[H][C@@]12O[C@]1([H])[C@H]1C[C@H](C[C@@H]2[N+]1(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1,C18H24BrNO4,,"Agents producing tachycardia, Alkaloids, Anticholinergic Agents, Autonomic Agents, Aza Compounds, Azabicyclo Compounds, Muscarinic Antagonists, Parasympatholytics, Peripheral Nervous System Agents, Scopolamine Derivatives, Tropanes"," Muscarinic acetylcholine receptor M2,  Muscarinic acetylcholine receptor M1,  Muscarinic acetylcholine receptor M3","DB00462, DB09300, DB12086, DB00747, DB11315, DB09271, DB11785, DB16896, DB00332, DB00424, DB00572, DB13833, DB00209, DB00725, DB02161, DB11181, DB15968, DB08978, DB13825",
DB00463,Metharbital,withdrawn,CCC1(CC)C(=O)NC(=O)N(C)C1=O,C9H14N2O3,,"Anticholinergic Agents, Anticonvulsants, Barbiturates and Derivatives, Central Nervous System Depressants, Nervous System, Nicotinic Antagonists, Pyrimidines, Pyrimidinones"," Gamma-aminobutyric acid receptor subunit alpha-2,  Gamma-aminobutyric acid receptor subunit alpha-3,  Gamma-aminobutyric acid receptor subunit alpha-4,  Gamma-aminobutyric acid receptor subunit alpha-5,  Gamma-aminobutyric acid receptor subunit alpha-6,  GABA(A) Receptor (Protein Group),  Gamma-aminobutyric acid receptor subunit alpha-1,  Neuronal acetylcholine receptor subunit alpha-4,  Neuronal acetylcholine receptor subunit alpha-7, 10. Glutamate receptor 2, 11. Glutamate receptor ionotropic, kainate 2","DB00463, DB01483, DB00237, DB01353, DB13577, DB01351, DB13229, DB00312, DB01352",
DB00464,Sodium tetradecyl sulfate,approved; investigational,[Na+].CCCCC(CC)CCC(CC(C)C)OS([O-])(=O)=O,C14H29NaO4S,,"Acids, Alcohols, Alkanesulfonates, Alkanesulfonic Acids, Antivaricose Therapy, Cardiovascular Agents, Compounds used in a research, industrial, or household setting, Fatty Alcohols, Lipids, Pharmaceutical Preparations, Pharmaceutical Solutions, Sclerosing Agents for Local Injection, Sclerosing Solutions, Solutions, Sulfonic Acids, Sulfur Acids, Sulfur Compounds, Surface-Active Agents, Vasoprotectives"," Vitamin K-dependent protein S,  Vitamin K-dependent protein C","DB00464, DB11328, DB00815, DB03967",
DB00465,Ketorolac,approved,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,C15H13NO3,,"Acetic Acid Derivatives and Related Substances, Agents causing hyperkalemia, Agents that produce hypertension, Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Antiinflammatory and Antirheumatic Products, Antiinflammatory and Antirheumatic Products, Non-Steroids, Antirheumatic Agents, Cyclooxygenase Inhibitors, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 Substrates, Drugs causing inadvertant photosensitivity, Enzyme Inhibitors, Heterocyclic Compounds, Fused-Ring, Musculo-Skeletal System, Mydriatics, Mydriatics and Cycloplegics, Nephrotoxic agents, Non COX-2 selective NSAIDS, Ophthalmologicals, Other Nonsteroidal Anti-inflammatory Agents, Photosensitizing Agents, Sensory Organs, Sympathomimetics Excl. Antiglaucoma Preparations, UGT2B7 substrates"," Prostaglandin G/H synthase 2,  Prostaglandin G/H synthase 1,  UDP-glucuronosyltransferase 2B7,  Cytochrome P450 2C8,  Cytochrome P450 2C9","DB00465, DB00500",
DB00466,Picrotoxin,experimental,[H][C@@]12OC(=O)[C@@]34OC3C[C@@](O)(C3[C@@H](C1OC3=O)C(C)=C)[C@@]24C.[H][C@@]12C[C@@]3(O)C4[C@@H](C(OC4=O)[C@@]4([H])OC(=O)[C@]1(O2)[C@@]34C)C(C)(C)O,C30H34O13,,"Antidotes, Biological Factors, Biological Products, Central Nervous System Agents, Central Nervous System Stimulants, Complex Mixtures, Compounds used in a research, industrial, or household setting, Convulsants, Cyclohexanes, Cycloparaffins, GABA Agents, GABA Antagonists, GABA-A Receptor Antagonists, Lactones, Neurotransmitter Agents, Pharmaceutical Preparations, Plant Extracts, Plant Preparations, Protective Agents, Sesquiterpenes, Stimulants, Terpenes, Toxins, Biological"," Gamma-aminobutyric acid receptor subunit rho-1,  Gamma-aminobutyric acid receptor subunit alpha-1,  Glycine receptor subunit alpha-2,  Glycine receptor subunit alpha-3,  Glycine receptor subunit alpha-1,  Cytochrome P450 1A1,  Glutamine synthetase",DB00466,
DB00467,Enoxacin,approved; investigational,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1,C15H17FN4O3,,"Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strong), Cytochrome P-450 Enzyme Inhibitors, Enzyme Inhibitors, Fluoroquinolones, Heterocyclic Compounds, Fused-Ring, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Quinolines, Quinolones, Topoisomerase II Inhibitors, Topoisomerase Inhibitors"," DNA gyrase subunit A,  DNA topoisomerase 4 subunit A,  DNA topoisomerase 2-alpha,  Cytochrome P450 1A2","DB00467, DB01155, DB16850, DB12479, DB00685, DB09335",
DB00468,Quinine,approved,[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12,C20H24N2O2,,"Agents that produce neuromuscular block (indirect), Agents that reduce seizure threshold, Alkaloids, Analgesics, Analgesics, Non-Narcotic, Anti-Infective Agents, Antimalarial methanolquinolines, Antimalarials, Antiparasitic Agents, Antiparasitic Products, Insecticides and Repellents, Antiprotozoals, Blood Glucose Lowering Agents, Central Nervous System Agents, Central Nervous System Depressants, Cinchona Alkaloids, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (strength unknown), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (moderate), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Herbs (Hypotensive Properties), Heterocyclic Compounds, Fused-Ring, Highest Risk QTc-Prolonging Agents, Hypoglycemia-Associated Agents, Methemoglobinemia Associated Agents, Muscle Relaxants, Muscle Relaxants, Centrally Acting Agents, Musculo-Skeletal System, Neuromuscular Agents, OATP1B1/SLCO1B1 Inhibitors, OCT1 inhibitors, OCT1 substrates, OCT2 Inhibitors, P-glycoprotein inhibitors, P-glycoprotein substrates, Peripheral Nervous System Agents, QTc Prolonging Agents, Quinolines, Quinuclidines, Sensory System Agents"," Fe(II)-protoporphyrin IX,  Platelet glycoprotein IX,  Intermediate conductance calcium-activated potassium channel protein 4,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 1A1,  Cytochrome P450 2D6,  Cytochrome P450 1A2,  Cytochrome P450 2C8,  Cytochrome P450 2C9,  Cytochrome P450 2C19,  Cytochrome P450 2E1, 10. Cytochrome P450 3A7,  Solute carrier family 22 member 2,  Solute carrier family 22 member 1,  Solute carrier family 22 member 5,  P-glycoprotein 1,  Solute carrier organic anion transporter family member 1A2,  Solute carrier family 22 member 4,  Solute carrier organic anion transporter family member 1B1","DB00468, DB00908, DB13718, DB15300, DB16831, DB01346",
DB00469,Tenoxicam,approved,CN1C(C(=O)NC2=CC=CC=N2)=C(O)C2=C(C=CS2)S1(=O)=O,C13H11N3O4S2,,"Agents causing hyperkalemia, Agents that produce hypertension, Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Antiinflammatory and Antirheumatic Products, Antiinflammatory and Antirheumatic Products, Non-Steroids, Antirheumatic Agents, Cyclooxygenase Inhibitors, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 Substrates, Enzyme Inhibitors, Musculo-Skeletal System, Nephrotoxic agents, Non COX-2 selective NSAIDS, OAT3/SLC22A8 Inhibitors, Other Nonsteroidal Anti-inflammatory Agents, Oxicams, Peripheral Nervous System Agents, Sensory System Agents, Sulfur Compounds, Thiazines"," Prostaglandin G/H synthase 2,  Prostaglandin G/H synthase 1,  Cytochrome P450 2C9,  Solute carrier family 22 member 8","DB00469, DB06725, DB00554, DB15883, DB16877, DB08942",
DB00470,Dronabinol,approved; illicit,[H][C@@]12C=C(C)CC[C@@]1([H])C(C)(C)OC1=C2C(O)=CC(CCCCC)=C1,C21H30O2,,"Agents producing tachycardia, Alimentary Tract and Metabolism, Analgesics, Analgesics, Non-Narcotic, Antiemetics and Antinauseants, BCRP/ABCG2 Inhibitors, Cannabinoid Receptor Agonists, Cannabinoids and similars, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 CYP2A6 Inhibitors, Cytochrome P-450 CYP2A6 Inhibitors (strength unknown), Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (strength unknown), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (strength unknown), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C9 Inducers, Cytochrome P-450 CYP2C9 Inducers (strength unknown), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Inhibitors, Cytochrome P-450 CYP3A5 Inhibitors (weak), Cytochrome P-450 CYP3A7 Inhibitors, Cytochrome P-450 CYP3A7 Inhibitors (weak), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Hallucinogens, Hormones, Hormone Substitutes, and Hormone Antagonists, Miscellaneous Antiemetics, Neurotransmitter Agents, P-glycoprotein inhibitors, Peripheral Nervous System Agents, Psychotropic Drugs, Sensory System Agents, Terpenes, UGT1A1 Substrates, UGT1A3 substrates, UGT1A9 Substrates"," Cannabinoid receptor 1,  Cannabinoid receptor 2,  Cytochrome P450 1A1,  Cytochrome P450 1A2,  Cytochrome P450 1B1,  Cytochrome P450 2A6,  Cytochrome P450 2C9,  Cytochrome P450 2B6,  Cytochrome P450 2C19,  Cytochrome P450 2D6,  Cytochrome P450 2J2, 10. Cytochrome P450 3A4, 11. Cytochrome P450 3A5, 12. Cytochrome P450 3A7, 13. Liver carboxylesterase 1, 14. Prostaglandin G/H synthase 1, 15. UDP-glucuronosyltransferase 1-1, 16. UDP-glucuronosyltransferase 1-3, 17. UDP-glucuronosyltransferase 1-9, 18. UDP-glucuronosyltransferase 1-10,  ATP-binding cassette sub-family G member 2,  P-glycoprotein 1,  Multidrug resistance-associated protein 1","DB00470, DB11755, DB14011, DB06444, DB12193, DB18537, DB18539, DB18540, DB18541, DB18542, DB00486",
DB00471,Montelukast,approved,OC(=O)CC1(CC1)CS[C@H](CCC1=CC=CC=C1C(O)(C)C)C1=CC=CC(\C=C\C2=NC3=C(C=CC(Cl)=C3)C=C2)=C1,C35H36ClNO3S,,"Acids, Acyclic, Agents Causing Muscle Toxicity, Agents to Treat Airway Disease, Anions, Anti-Asthmatic Agents, Cycloparaffins, Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2A6 Substrates, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs for Obstructive Airway Diseases, Electrolytes, Fatty Acids, Fatty Acids, Volatile, Heterocyclic Compounds, Fused-Ring, Hormone Antagonists, Hormones, Hormone Substitutes, and Hormone Antagonists, Hydrogen Sulfide, Ions, Leukotriene Antagonists, Leukotriene Modifiers, Lipids, OATP2B1/SLCO2B1 substrates, Respiratory System Agents, Sulfur Compounds"," Cysteinyl leukotriene receptor 1,  Arachidonate 5-lipoxygenase,  Prostaglandin G/H synthase 1,  Cytochrome P450 2A6,  Cytochrome P450 3A4,  Cytochrome P450 2C9,  Cytochrome P450 2C8,  Solute carrier organic anion transporter family member 2B1",DB00471,
DB00472,Fluoxetine,approved; vet_approved,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1,C17H18F3NO,,"Agents that reduce seizure threshold, Amines, Anticholinergic Agents, Antidepressive Agents, Antidepressive Agents Indicated for Depression, Antidepressive Agents, Second-Generation, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (strong), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (moderate), Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strong), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (weak), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Enzyme Inhibitors, Highest Risk QTc-Prolonging Agents, Hypoglycemia-Associated Agents, Membrane Transport Modulators, Nervous System, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, Nicotinic Antagonists, P-glycoprotein inhibitors, Propylamines, Psychoanaleptics, Psychotropic Drugs, QTc Prolonging Agents, Selective Serotonin Reuptake Inhibitors, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2C Receptor Antagonists, Serotonin Agents, Serotonin Modulators, Serotonin Receptor Antagonists, Vasodilating Agents"," Sodium-dependent serotonin transporter,  5-hydroxytryptamine receptor 2C,  Neuronal acetylcholine receptor subunit alpha-2,  Neuronal acetylcholine receptor subunit alpha-3,  Neuronal acetylcholine receptor subunit beta-4,  Cyclin-dependent kinases regulatory subunit 1,  Potassium voltage-gated channel subfamily H member 2,  Cytochrome P450 2B6,  Cytochrome P450 3A5,  Cytochrome P450 2C9,  Cytochrome P450 2D6,  CYP2B protein,  Cytochrome P450 1A2,  Cytochrome P450 3A4,  Cytochrome P450 2C19,  Serum albumin,  Alpha-1-acid glycoprotein 1,  P-glycoprotein 1","DB00472, DB08472, DB08544, DB06731, DB00289, DB09186",
DB00473,Hexylcaine,approved; withdrawn,CC(CNC1CCCCC1)OC(=O)C1=CC=CC=C1,C16H23NO2,,"Amines, Cyclohexanes, Cycloparaffins"," Sodium channel protein type 5 subunit alpha,  Sodium channel protein type 10 subunit alpha","DB00473, DB09088",
DB00474,Methohexital,approved,CCC#CC(C)C1(CC=C)C(=O)NC(=O)N(C)C1=O,C14H18N2O3,,"Anesthetics, Anesthetics, General, Anesthetics, Intravenous, Anticonvulsants, Barbiturates, Barbiturates, Plain, Central Nervous System Agents, Central Nervous System Depressants, Hypnotics and Sedatives, Nervous System, Psycholeptics, Pyrimidines, Pyrimidinones", Gamma-aminobutyric acid receptor subunit alpha-1,"DB00474, DB13229, DB01352",
DB00475,Chlordiazepoxide,approved; illicit; investigational,CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1,C16H14ClN3O,,"Adjuvants, Anesthesia, Anti-Anxiety Agents, Benzazepines, Benzodiazepines and benzodiazepine derivatives, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Substrates, Cytosine Nucleotides, GABA Agents, GABA Modulators, Heterocyclic Compounds, Fused-Ring, Hypnotics and Sedatives, Nervous System, Neurotransmitter Agents, Nucleic Acids, Nucleotides, and Nucleosides, Nucleotides, Psycholeptics, Psychotropic Drugs, Pyrimidine Nucleotides, Pyrimidines, Ribonucleotides, Tranquilizing Agents"," GABA(A) Receptor (Protein Group),  GABA(A) Receptor Benzodiazepine Binding Site (Protein Group),  Cytochrome P450 3A4","DB00475, DB16062",
DB00476,Duloxetine,approved,CNCC[C@H](OC1=CC=CC2=CC=CC=C12)C1=CC=CS1,C18H19NOS,,"Agents producing tachycardia, Analgesics, Antidepressive Agents, Antidepressive Agents Indicated for Depression, Central Nervous System Agents, Central Nervous System Depressants, Combined Inhibitors of Serotonin/Norepinephrine Reuptake, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (strength unknown), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Inhibitors (weak), Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Hypoglycemia-Associated Agents, Membrane Transport Modulators, Nervous System, Neurotransmitter Uptake Inhibitors, Norepinephrine Uptake Inhibitors, P-glycoprotein inhibitors, Peripheral Nervous System Agents, Psychoanaleptics, Psychotropic Drugs, Selective Serotonin Reuptake Inhibitors, Sensory System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin and Noradrenaline Reuptake Inhibitors, Serotonin Modulators, Sulfur Compounds, Thiophenes"," Sodium-dependent serotonin transporter,  Sodium-dependent noradrenaline transporter,  Sodium-dependent dopamine transporter,  Cytochrome P450 2D6,  Cytochrome P450 2C9,  Cytochrome P450 3A4,  Cytochrome P450 1A2,  Cytochrome P450 2B6,  Cytochrome P450 2C19,  Serum albumin,  alpha1-acid glycoprotein (Protein Group),  P-glycoprotein 1",DB00476,
DB00477,Chlorpromazine,approved; investigational; vet_approved,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2,C17H19ClN2S,,"Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Agents producing tachycardia, Agents that produce hypertension, Agents that reduce seizure threshold, Anticholinergic Agents, Antidepressive Agents, Antiemetics, Antipsychotic Agents, Antipsychotic Agents (First Generation [Typical]), Autonomic Agents, BSEP/ABCB11 Inhibitors, Central Nervous System Agents, Central Nervous System Depressants, Cholinesterase Inhibitors, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dopamine Agents, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Drugs causing inadvertant photosensitivity, Drugs that are Mainly Renally Excreted, Gastrointestinal Agents, Heterocyclic Compounds, Fused-Ring, Histamine Antagonists, Histamine H1 Antagonists, Hyperglycemia-Associated Agents, Hypotensive Agents, Moderate Risk QTc-Prolonging Agents, Muscarinic Antagonists, Nervous System, Neurotoxic agents, Neurotransmitter Agents, P-glycoprotein inhibitors, P-glycoprotein substrates, Peripheral Nervous System Agents, Phenothiazines, Phenothiazines With Aliphatic Side-Chain, Photosensitizing Agents, Psycholeptics, Psychotropic Drugs, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT1 Receptor Antagonists, Serotonin 5-HT1A Receptor Antagonists, Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2A Receptor Antagonists, Serotonin Agents, Serotonin Receptor Antagonists, Sulfur Compounds, Tranquilizing Agents"," Dopamine D2 receptor,  Dopamine D1 receptor,  5-hydroxytryptamine receptor 1A,  5-hydroxytryptamine receptor 2A,  Alpha-1A adrenergic receptor,  Alpha-1B adrenergic receptor,  Histamine H1 receptor,  Potassium voltage-gated channel subfamily H member 2,  D(1) dopamine receptor (Protein Group), 10. Dopamine D3 receptor, 11. Dopamine D4 receptor, 12. Dopamine D5 receptor, 13. 5-hydroxytryptamine receptor 2C, 14. 5-hydroxytryptamine 2 receptor (Protein Group), 15. Alpha-1 adrenergic receptors (Protein Group), 16. Alpha-2 adrenergic receptors (Protein Group), 17. Muscarinic acetylcholine receptor M1, 18. Muscarinic acetylcholine receptor M3, 19. Sphingomyelin phosphodiesterase, 20. Calmodulin, 21. alpha1-acid glycoprotein (Protein Group), 22. 5-hydroxytryptamine receptor 6, 23. 5-hydroxytryptamine receptor 7, 24. Histamine H4 receptor,  Cytochrome P450 2D6,  Cytochrome P450 1A2,  Cytochrome P450 2E1,  Cytochrome P450 3A4,  Cholinesterase,  Serum albumin,  P-glycoprotein 1,  Bile salt export pump","DB00477, DB13382, DB00433, DB00850, DB00420, DB01246, DB13557, DB12710, DB15596, DB00902, DB14651, DB13820, DB01071, DB09000, DB01069, DB13420",
DB00478,Rimantadine,approved; investigational,CC(N)C12CC3CC(CC(C3)C1)C2,C12H21N,,"Adamantanes, Anti-Infective Agents, Antiinfectives for Systemic Use, Antiviral Agents, Bridged-Ring Compounds, Cyclic Amines, Cycloparaffins, Enzyme Inhibitors, Influenza A M2 Protein Inhibitor, M2 Protein Inhibitors, Nucleic Acid Synthesis Inhibitors", Matrix protein 2,"DB00478, DB00915, DB01043, DB04926, DB02435",
DB00479,Amikacin,approved; investigational; vet_approved,NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O,C22H43N5O13,,"Aminoglycoside Antibacterials, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Drugs that are Mainly Renally Excreted, Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index, Glycosides, Narrow Therapeutic Index Drugs, Nephrotoxic agents", 30S ribosomal protein S12,"DB00479, DB06696, DB13540, DB16339, DB04096, DB12232, DB04679, DB03618, DB02397, DB04678, DB03013, DB04194, DB08818, DB17689, DB04426, DB04226, DB03296, DB14932, DB12615, DB04718, DB01172, DB04717, DB11520",
DB00480,Lenalidomide,approved,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,C13H13N3O3,,"Acids, Carbocyclic, Angiogenesis Inhibitors, Angiogenesis Modulating Agents, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Drugs that are Mainly Renally Excreted, Growth Inhibitors, Growth Substances, Heterocyclic Compounds, Fused-Ring, Imides, Immunologic Factors, Immunosuppressive Agents, Isoindoles, Myelosuppressive Agents, P-glycoprotein substrates, Phthalic Acids, Phthalimides, Piperidines, Piperidones, Thalidomide Analog"," Protein cereblon,  Tumor necrosis factor ligand superfamily member 11,  Cadherin-5,  Prostaglandin G/H synthase 2,  P-glycoprotein 1","DB00480, DB08910, DB17419, DB01041, DB18115",
DB00481,Raloxifene,approved; investigational,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2,C28H27NO4S,,"BCRP/ABCG2 Substrates, Benzene Derivatives, Benzylidene Compounds, Bone Density Conservation Agents, Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (strong), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Estrogen Agonist-antagonists, Estrogen Agonist/Antagonist, Estrogen Antagonists, Estrogen Receptor Modulators, Genito Urinary System and Sex Hormones, Hormone Antagonists, Hormones, Hormone Substitutes, and Hormone Antagonists, OATP1B1/SLCO1B1 Substrates, OATP1B3 substrates, P-glycoprotein substrates, Selective Estrogen Receptor Modulators, Sex Hormones and Modulators of the Genital System, Stilbenes, UGT1A1 Substrates"," Estrogen receptor alpha,  Estrogen receptor beta,  Serpin B9,  Trefoil factor 1,  Cytochrome P450 2B6,  Cytochrome P450 2C8,  Aldehyde oxidase,  Cytochrome P450 19A1,  Cytochrome P450 3A4,  UDP-glucuronosyltransferase 1-1,  UDP-glucuronosyltransferase 1-10,  UDP-glucuronosyltransferase 1-8,  Serum albumin,  Alpha-1-acid glycoprotein 1,  Solute carrier organic anion transporter family member 1B1,  Solute carrier organic anion transporter family member 1B3,  P-glycoprotein 1,  ATP-binding cassette sub-family G member 2,  Canalicular multispecific organic anion transporter 1,  Canalicular multispecific organic anion transporter 2,  Multidrug resistance-associated protein 4",DB00481,
DB00482,Celecoxib,approved; investigational,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F,C17H14F3N3O2S,,"Agents causing hyperkalemia, Agents that produce hypertension, Amides, Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Antiinflammatory and Antirheumatic Products, Antiinflammatory and Antirheumatic Products, Non-Steroids, Antineoplastic and Immunomodulating Agents, Antirheumatic Agents, BCRP/ABCG2 Substrates, Benzene Derivatives, Benzenesulfonamides, BSEP/ABCB11 Inhibitors, Central Nervous System Agents, COX-2 Inhibitors, Cyclooxygenase Inhibitors, Cyclooxygenase-2 (COX-2) Inhibitors, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs causing inadvertant photosensitivity, Enzyme Inhibitors, Genito Urinary System and Sex Hormones, Methemoglobinemia Associated Agents, Musculo-Skeletal System, Nephrotoxic agents, P-glycoprotein substrates, Peripheral Nervous System Agents, Photosensitizing Agents, Pyrazoles, Selective Cyclooxygenase 2 Inhibitors (NSAIDs), Sensory System Agents, Sulfonamides, Sulfones, Sulfur Compounds"," Prostaglandin G/H synthase 2,  Carbonic anhydrase 2,  Carbonic anhydrase 3,  Cadherin-11,  3-phosphoinositide-dependent protein kinase 1,  Sialidase-1,  Cytochrome P450 3A4,  Cytochrome P450 2C9,  Cytochrome P450 2D6,  Cytochrome P450 2C8,  Prostaglandin G/H synthase 2,  Multidrug resistance-associated protein 4,  Bile salt export pump,  P-glycoprotein 1,  ATP-binding cassette sub-family G member 2","DB00482, DB14059, DB03477, DB11395",
DB00483,Gallamine triethiodide,approved,[I-].[I-].[I-].CC[N+](CC)(CC)CCOC1=CC=CC(OCC[N+](CC)(CC)CC)=C1OCC[N+](CC)(CC)CC,C30H60I3N3O3,,"Agents producing tachycardia, Amines, Anticholinergic Agents, Central Nervous System Depressants, Cholinergic Agents, Cholinesterase Inhibitors, Muscarinic Antagonists, Neuromuscular Agents, Neuromuscular Blocking Agents, Neuromuscular-Blocking Agents (Nondepolarizing), Neurotransmitter Agents, Nicotinic Antagonists, Onium Compounds, Peripheral Nervous System Agents, Quaternary Ammonium Compounds"," Muscarinic acetylcholine receptor M2,  Acetylcholinesterase,  Neuronal acetylcholine receptor subunit alpha-2,  Muscarinic acetylcholine receptor M1,  Muscarinic acetylcholine receptor M5","DB00483, DB13584",
DB00484,Brimonidine,approved,BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12,C11H10BrN5,,"Adrenergic Agents, Adrenergic Agonists, Adrenergic alpha-2 Receptor Agonists, Adrenergic alpha-Agonists, Antiglaucoma Preparations and Miotics, Cardiovascular Agents, Central Nervous System Depressants, Decongestants and Antiallergics, Dermatologicals, Heterocyclic Compounds, Fused-Ring, Hypotensive Agents, Misc. Skin and Mucous Membrane Agents, Ophthalmologicals, Quinoxalines, Sensory Organs, Sympathomimetics in Glaucoma Therapy, Sympathomimetics Used as Decongestants"," Alpha-2A adrenergic receptor,  Alpha-2B adrenergic receptor,  Alpha-2C adrenergic receptor,  Aldehyde oxidase",DB00484,
DB00485,Dicloxacillin,approved; investigational; vet_approved,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl)C(O)=O,C19H17Cl2N3O5S,,"Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Beta-Lactam Antibacterials, Beta-Lactamase Resistant Penicillins, beta-Lactams, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 Enzyme Inducers, Heterocyclic Compounds, Fused-Ring, Lactams, Penicillins, Sulfur Compounds"," Penicillin-binding protein 3,  Penicillin-binding protein 1b,  Penicillin-binding protein 2a,  Penicillin-binding protein 3,  Penicillin-binding protein 1A,  Penicillin-binding protein 2B,  Cytochrome P450 3A4,  Serum albumin,  Solute carrier family 15 member 1,  Solute carrier family 15 member 2","DB00485, DB01147, DB00301, DB00713, DB01061, DB00739, DB00319, DB09319, DB13836, DB00578, DB00948, DB13506, DB01603, DB01604, DB00415, DB00607, DB01607",
DB00486,Nabilone,approved; investigational,[H][C@@]12CC(=O)CC[C@@]1([H])C(C)(C)OC1=CC(=CC(O)=C21)C(C)(C)CCCCCC,C24H36O3,,"Agents producing tachycardia, Alimentary Tract and Metabolism, Antiemetics, Antiemetics and Antinauseants, Autonomic Agents, Cannabinoids and similars, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (moderate), Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (moderate), Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (weak), Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (weak), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs causing inadvertant photosensitivity, Gastrointestinal Agents, Hypotensive Agents, Miscellaneous Antiemetics, Peripheral Nervous System Agents, Photosensitizing Agents, Psychotropic Drugs, Terpenes, Tranquilizing Agents"," Cannabinoid receptor 2,  Cannabinoid receptor 1,  Cytochrome P450 2C9,  Cytochrome P450 3A4,  Cytochrome P450 2C8,  Cytochrome P450 2E1,  Cytochrome P450 2J2","DB00486, DB06444, DB00470, DB11755, DB12193, DB07933, DB14011",
DB00487,Pefloxacin,approved,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCN(C)CC1,C17H20FN3O3,,"Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Enzyme Inhibitors, Fluoroquinolones, Heterocyclic Compounds, Fused-Ring, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Quinolines, Quinolones, Topoisomerase II Inhibitors, Topoisomerase Inhibitors"," DNA topoisomerase 4 subunit A,  DNA gyrase subunit A,  DNA topoisomerase 2-alpha,  DNA topoisomerase 1,  Cytochrome P450 1A2","DB00487, DB01059, DB11404, DB00537, DB04576, DB00978, DB11393, DB01208, DB00365, DB11511, DB11491, DB11443, DB01405, DB14025, DB13772, DB06771, DB01044, DB11453, DB12447, DB16219, DB01137, DB01165, DB03034, DB13261, DB09047, DB00218",
DB00488,Altretamine,approved,CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C,C9H18N6,,"Alkylating Activity, Alkylating Drugs, Antineoplastic Agents, Antineoplastic Agents, Alkylating, Antineoplastic and Immunomodulating Agents, Immunosuppressive Agents, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, Noxae, Toxic Actions, Triazines", DNA,"DB00488, DB14031",
DB00489,Sotalol,approved,CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1,C12H20N2O3S,,"Adrenergic Agents, Adrenergic Antagonists, Adrenergic beta-Antagonists, Agents causing hyperkalemia, Alcohols, Amines, Amino Alcohols, Antiarrhythmic agents, Autonomic Agents, Beta Blocking Agents and Thiazides, Beta Blocking Agents, Non-Selective, Beta Blocking Agents, Non-Selective, and Thiazides, Bradycardia-Causing Agents, Cardiac Rhythm Alteration, Cardiovascular Agents, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Substrates, Ethanolamines, Highest Risk QTc-Prolonging Agents, Hypotensive Agents, Narrow Therapeutic Index Drugs, Neurotransmitter Agents, Peripheral Nervous System Agents, QTc Prolonging Agents, Sympatholytics"," Beta-1 adrenergic receptor,  Beta-2 adrenergic receptor,  Potassium voltage-gated channel subfamily H member 2,  Cytochrome P450 2D6",DB00489,
DB00490,Buspirone,approved; investigational,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1,C21H31N5O2,,"Agents that produce hypertension, Antidepressive Agents, Azaspirodecanedione Derivatives, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Substrates, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Drugs that are Mainly Renally Excreted, Miscellaneous Anxiolytics Sedatives and Hypnotics, Nervous System, Neurotransmitter Agents, P-glycoprotein inhibitors, Piperazines, Psycholeptics, Pyrimidines, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Spiro Compounds, Tranquilizing Agents"," 5-hydroxytryptamine receptor 1A,  Dopamine D2 receptor,  Dopamine D3 receptor,  Dopamine D4 receptor,  Alpha-1 adrenergic receptors (Protein Group),  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  Cytochrome P450 2D6,  Serum albumin,  Alpha-1-acid glycoprotein 1,  P-glycoprotein 1","DB00490, DB12184, DB12833",
DB00491,Miglitol,approved,OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO,C8H17NO5,,"Alimentary Tract and Metabolism, Alkaloids, Blood Glucose Lowering Agents, Carbohydrates, Drugs Used in Diabetes, Enzyme Inhibitors, Glycoside Hydrolase Inhibitors, Hypoglycemia-Associated Agents, Imines, Imino Pyranoses, Imino Sugars, Oral Hypoglycemics, Piperidines"," Lysosomal alpha-glucosidase,  Neutral alpha-glucosidase AB,  Neutral alpha-glucosidase C,  Maltase-glucoamylase, intestinal,  Pancreatic alpha-amylase","DB00491, DB00419, DB14872, DB17619, DB08283, DB17804, DB03206, DB03955, DB05018, DB01816, DB02034, DB04878",
DB00492,Fosinopril,approved,CCC(=O)O[C@@H](OP(=O)(CCCCC1=CC=CC=C1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C,C30H46NO7P,,"ACE Inhibitors and Diuretics, Agents Acting on the Renin-Angiotensin System, Agents causing angioedema, Agents causing hyperkalemia, Amino Acids, Amino Acids, Cyclic, Amino Acids, Peptides, and Proteins, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Cardiovascular Agents, Drugs causing inadvertant photosensitivity, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Hypotensive Agents, Imino Acids, Organophosphorus Compounds, Phosphinic Acids, Photosensitizing Agents, Protease Inhibitors"," Angiotensin-converting enzyme,  Solute carrier family 15 member 1,  Solute carrier family 15 member 2","DB00492, DB14207",
DB00493,Cefotaxime,approved,[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O,C16H17N5O7S2,,"Agents that reduce seizure threshold, Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, beta-Lactams, Cephalosporins, Heterocyclic Compounds, Fused-Ring, Lactams, Nephrotoxic agents, OAT1/SLC22A6 inhibitors, OAT3/SLC22A8 Inhibitors, Sulfur Compounds, Thiazines, Third-Generation Cephalosporins"," Penicillin-binding protein 1b,  Penicillin-binding protein 2a,  Penicillin-binding protein 3,  Penicillin-binding protein 1A,  Penicillin-binding protein 2B,  Solute carrier family 22 member 6,  Solute carrier family 22 member 8,  Solute carrier family 22 member 11,  Solute carrier family 22 member 7, 10. Solute carrier family 15 member 1, 11. Serum albumin, 12. Beta-lactamase, 13. Solute carrier family 15 member 2,  Solute carrier family 15 member 1,  Solute carrier family 15 member 2,  Solute carrier family 22 member 6,  Solute carrier family 22 member 8,  Solute carrier family 22 member 11,  Solute carrier family 22 member 7","DB00493, DB01416, DB13504, DB11505, DB00535, DB01413, DB00671, DB01332, DB00267, DB11485, DB13461, DB00438, DB01066, DB01212, DB14879, DB13470, DB13682, DB01112, DB00456, DB00689, DB01414, DB00229, DB03313, DB01139, DB01415, DB04918, DB13667, DB01331, DB09050, DB14733",
DB00494,Entacapone,approved; investigational,CCN(CC)C(=O)C(=C\C1=CC(=C(O)C(O)=C1)[N+]([O-])=O)\C#N,C14H15N3O5,,"Anti-Dyskinesia Agents, Anti-Parkinson Drugs, Benzene Derivatives, Central Nervous System Agents, Central Nervous System Depressants, COMT Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 Enzyme Inhibitors, Dopamine Agents, Enzyme Inhibitors, Nervous System, Phenols, UGT1A9 Substrates"," Catechol O-methyltransferase,  Cytochrome P450 2D6,  Catechol O-methyltransferase,  UDP-glucuronosyltransferase 1-9",DB00494,
DB00495,Zidovudine,approved,CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O,C10H13N5O4,,"Agents Causing Muscle Toxicity, Anti-HIV Agents, Anti-Infective Agents, Anti-Retroviral Agents, Antiinfectives for Systemic Use, Antimetabolites, Antiviral Agents, Antivirals for Systemic Use, Antivirals used in combination for the treatment of HIV infections, BCRP/ABCG2 Substrates, Cytochrome P-450 CYP2A6 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Deoxyribonucleosides, Dideoxynucleosides, Direct Acting Antivirals, Enzyme Inhibitors, Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor, Immunosuppressive Agents, Myelosuppressive Agents, Noxae, Nucleic Acid Synthesis Inhibitors, Nucleic Acids, Nucleotides, and Nucleosides, Nucleoside and Nucleotide Reverse Transcriptase Inhibitors, Nucleoside Reverse Transcriptase Inhibitors, Nucleosides, OAT1/SLC22A6 Substrates, OAT3/SLC22A8 Inhibitors, OAT3/SLC22A8 Substrates, P-glycoprotein substrates, Pyrimidine Nucleosides, Pyrimidines, Reverse Transcriptase Inhibitors, Toxic Actions, UGT1A1 Inducers, UGT1A1 Substrates, UGT2B7 substrates"," Reverse transcriptase/RNaseH,  Telomerase reverse transcriptase,  Cytochrome P450 2A6,  Cytochrome P450 2C9,  Cytochrome P450 3A4,  Thymidine kinase, cytosolic,  UDP-glucuronosyltransferase 2B7,  UDP-glucuronosyltransferase 1-1,  Serum albumin,  Solute carrier family 22 member 2,  Solute carrier family 22 member 6,  Solute carrier family 22 member 7,  Solute carrier family 22 member 8,  Solute carrier family 22 member 11,  Sodium/nucleoside cotransporter 1,  Equilibrative nucleoside transporter 2,  P-glycoprotein 1,  Multidrug resistance-associated protein 4, 10. Multidrug resistance-associated protein 5, 11. ATP-binding cassette sub-family G member 2","DB00495, DB17759, DB03666, DB04542, DB03233, DB01265, DB04485, DB13421, DB03312, DB06683, DB14913, DB06198, DB14930, DB00432, DB03150, DB12423, DB08596, DB08661, DB12606, DB01643, DB02256, DB11998, DB08432, DB03274, DB04205, DB03846, DB03195, DB08651, DB04438, DB13030",
DB00496,Darifenacin,approved; investigational,NC(=O)C([C@@H]1CCN(CCC2=CC3=C(OCC3)C=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1,C28H30N2O2,,"Agents producing tachycardia, Anticholinergic Agents, Cholinergic Agents, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs for Urinary Frequency and Incontinence, Genito Urinary System and Sex Hormones, Genitourinary Agents, Heterocyclic Compounds, Fused-Ring, Muscarinic Antagonists, Neurotransmitter Agents, Urological Agents, Urologicals"," Muscarinic acetylcholine receptor M3,  Muscarinic acetylcholine receptor M1,  Muscarinic acetylcholine receptor M2,  Muscarinic acetylcholine receptor M4,  Muscarinic acetylcholine receptor M5,  Cytochrome P450 3A4,  Cytochrome P450 2D6",DB00496,
DB00497,Oxycodone,approved; illicit; investigational,COC1=C2O[C@H]3C(=O)CC[C@@]4(O)[C@H]5CC(C=C1)=C2[C@@]34CCN5C,C18H21NO4,,"Alkaloids, Analgesics, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Substrates, Heterocyclic Compounds, Fused-Ring, Morphinans, Morphine Derivatives, Narcotics, Natural Opium Alkaloids, Nervous System, Opiate Agonists, Opiate Alkaloids, Opioid Agonist, Opioids, Peripheral Nervous System Agents, Phenanthrenes, Semi-synthetic Opioids, Sensory System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"," Mu-type opioid receptor,  Kappa-type opioid receptor,  Delta-type opioid receptor,  Cytochrome P450 2D6,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Serum albumin,  alpha1-acid glycoprotein (Protein Group)","DB00497, DB00704, DB01192, DB06800, DB01183, DB04509, DB00956, DB00327, DB06230, DB01512, DB00844, DB14146, DB15341, DB01551, DB09049, DB01565, DB01531, DB16117, DB16072, DB00921, DB01450, DB01548, DB01538, DB13471, DB01480, DB01497, DB01469, DB00318, DB01477, DB01466",
DB00498,Phenindione,approved; investigational,O=C1C(C(=O)C2=CC=CC=C12)C1=CC=CC=C1,C15H10O2,,"Anticoagulants, Blood and Blood Forming Organs, Hematologic Agents, Indans, Indenes, Narrow Therapeutic Index Drugs, Vitamin K Antagonists", Vitamin K epoxide reductase complex subunit 1,"DB00498, DB13136, DB13275, DB01125, DB13545, DB13347",
DB00499,Flutamide,approved; investigational,CC(C)C(=O)NC1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F,C11H11F3N2O3,,"Amides, Amines, Androgen Receptor Antagonists, Androgen Receptor Inhibitors, Anilides, Aniline Compounds, Antiandrogens, Antiandrogens, non-steroidal, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Antineoplastic and Immunomodulating Agents, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Endocrine Therapy, Hormone Antagonists, Hormone Antagonists and Related Agents, Hormones, Hormone Substitutes, and Hormone Antagonists, Methemoglobinemia Associated Agents"," Androgen receptor,  Aryl hydrocarbon receptor,  Nuclear receptor subfamily 1 group I member 2,  Cytochrome P450 1A1,  Cytochrome P450 1B1,  Cytochrome P450 3A5,  Cytochrome P450 1A2,  Cytochrome P450 3A4,  Multidrug resistance-associated protein 1","DB00499, DB07454",
DB00500,Tolmetin,approved,CN1C(CC(O)=O)=CC=C1C(=O)C1=CC=C(C)C=C1,C15H15NO3,,"Acetic Acid Derivatives and Related Substances, Agents causing hyperkalemia, Agents that produce hypertension, Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Antiinflammatory and Antirheumatic Products, Antiinflammatory and Antirheumatic Products, Non-Steroids, Antiinflammatory Preparations, Non-Steroids for Topical Use, Antirheumatic Agents, Cyclooxygenase Inhibitors, Enzyme Inhibitors, Musculo-Skeletal System, Nephrotoxic agents, Non COX-2 selective NSAIDS, OAT1/SLC22A6 inhibitors, Peripheral Nervous System Agents, Sensory System Agents, Topical Products for Joint and Muscular Pain"," Prostaglandin G/H synthase 2,  Prostaglandin G/H synthase 1,  Tryptophan 2,3-dioxygenase,  Myeloperoxidase,  Serum albumin,  Solute carrier family 22 member 6","DB00500, DB04828, DB00465, DB16088",
DB00501,Cimetidine,approved; investigational,CN\C(NCCSCC1=C(C)NC=N1)=N\C#N,C10H16N6S,,"Acid Reducers, Adjuvants, Agents Causing Muscle Toxicity, Alimentary Tract and Metabolism, Amidines, Anti-Ulcer Agents, BSEP/ABCB11 Inhibitors, Chemically-Induced Disorders, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (weak), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (strength unknown), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (weak), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (weak), Cytochrome P-450 CYP3A5 Inhibitors, Cytochrome P-450 CYP3A5 Inhibitors (moderate), Cytochrome P-450 CYP3A5 Inhibitors (weak), Cytochrome P-450 CYP3A7 Inhibitors, Cytochrome P-450 CYP3A7 Inhibitors (moderate), Cytochrome P-450 Enzyme Inhibitors, Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord), Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Gastric Acid Lowering Agents, Gastrointestinal Agents, Guanidines, Histamine Agents, Histamine Antagonists, Histamine H2 Antagonists, Imidazoles, MATE 1 Inhibitors, MATE 1 Substrates, MATE 2 Inhibitors, MATE 2 Substrates, MATE inhibitors, MATE substrates, Neurotransmitter Agents, OAT1/SLC22A6 inhibitors, OAT1/SLC22A6 Substrates, OAT3/SLC22A8 Inhibitors, OAT3/SLC22A8 Substrates, OCT1 inhibitors, OCT1 substrates, OCT2 Inhibitors, OCT2 Substrates, P-glycoprotein inducers, P-glycoprotein substrates"," Histamine H2 receptor,  Cytochrome P450 11B1, mitochondrial,  Cytochrome P450 2C8,  Cytochrome P450 2C9,  Cytochrome P450 2E1,  Dimethylaniline monooxygenase [N-oxide-forming] 3,  Dimethylaniline monooxygenase [N-oxide-forming] 1,  Cytochrome P450 1A2,  Cytochrome P450 2D6,  Cytochrome P450 2C19, 10. Cytochrome P450 3A4, 11. Cytochrome P450 3A5,  Serum albumin,  P-glycoprotein 1,  Solute carrier family 22 member 2,  Solute carrier family 22 member 1,  Solute carrier family 22 member 3,  Solute carrier family 22 member 5,  Solute carrier family 22 member 6,  Solute carrier family 22 member 8,  Multidrug and toxin extrusion protein 1,  Solute carrier family 22 member 4, 10. Solute carrier family 22 member 11, 11. Solute carrier family 22 member 7, 12. Bile salt export pump, 13. Multidrug and toxin extrusion protein 2","DB00501, DB08805",
DB00502,Haloperidol,approved,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1,C21H23ClFNO2,,"Agents that reduce seizure threshold, Anti-Dyskinesia Agents, Antiemetics, Antipsychotic Agents, Antipsychotic Agents (First Generation [Typical]), Autonomic Agents, Butyrophenone Derivatives, Butyrophenones, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (moderate), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dopamine Agents, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Drugs causing inadvertant photosensitivity, Drugs that are Mainly Renally Excreted, Gastrointestinal Agents, Hyperglycemia-Associated Agents, Ketones, Moderate Risk QTc-Prolonging Agents, Nervous System, Neurotoxic agents, Neurotransmitter Agents, NMDA Receptor Antagonists, P-glycoprotein inhibitors, P-glycoprotein substrates, Peripheral Nervous System Agents, Photosensitizing Agents, Psycholeptics, Psychotropic Drugs, QTc Prolonging Agents, Tranquilizing Agents, UGT1A9 Substrates"," 5-hydroxytryptamine receptor 2C,  Dopamine D2 receptor,  5-hydroxytryptamine receptor 2A,  Dopamine D3 receptor,  Melanin-concentrating hormone receptor 1,  Synaptic vesicular amine transporter,  Sigma non-opioid intracellular receptor 1,  Histamine H1 receptor,  Muscarinic acetylcholine receptor M3, 10. Alpha-1A adrenergic receptor, 11. Alpha-2A adrenergic receptor, 12. Alpha-2B adrenergic receptor, 13. Alpha-2C adrenergic receptor, 14. 5-hydroxytryptamine receptor 1A, 15. 5-hydroxytryptamine receptor 6, 16. 5-hydroxytryptamine receptor 7, 17. Glutamate receptor ionotropic, NMDA 2B, 18. Dopamine D1 receptor,  Carbonyl reductase [NADPH] 1,  UDP-glucuronosyltransferase 1-9,  Cytochrome P450 2C19,  Cytochrome P450 2C9,  Cytochrome P450 1A1,  Cytochrome P450 1A2,  Cytochrome P450 2D6,  Cytochrome P450 3A5,  Cytochrome P450 3A4, 10. Cytochrome P450 3A7,  P-glycoprotein 1","DB00502, DB13554, DB12401, DB13552, DB13791, DB00836",
DB00503,Ritonavir,approved; investigational,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,C37H48N6O5S2,,"Acids, Acyclic, Agents Causing Muscle Toxicity, Anti-HIV Agents, Anti-Infective Agents, Anti-Retroviral Agents, Antiinfectives for Systemic Use, Antiviral Agents, Antivirals for Systemic Use, Antivirals for treatment of HCV infections, Antivirals used in combination for the treatment of HIV infections, BCRP/ABCG2 Inhibitors, BCRP/ABCG2 Substrates, BSEP/ABCB11 Inhibitors, BSEP/ABCB11 Substrates, Chemically-Induced Disorders, Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP1A2 Inducers (strength unknown), Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (weak), Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (strength unknown), Cytochrome P-450 CYP2C19 Inducers, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (strength unknown), Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 CYP2C8 Inducers (strength unknown), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (moderate), Cytochrome P-450 CYP2C8 Inhibitors (strong), Cytochrome P-450 CYP2C9 Inducers, Cytochrome P-450 CYP2C9 Inducers (weak), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strong), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Inhibitors, Cytochrome P-450 CYP3A5 Inhibitors (strong), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Inhibitors, Cytochrome P-450 CYP3A7 Inhibitors (strong), Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Direct Acting Antivirals, Enzyme Inhibitors, Experimental Unapproved Treatments for COVID-19, HIV Protease Inhibitors, Hyperglycemia-Associated Agents, OATP1B1/SLCO1B1 Inhibitors, OATP1B3 inhibitors, Organic Anion Transporting Polypeptide 2B1 Inhibitors, P-glycoprotein inducers, P-glycoprotein inhibitors, P-glycoprotein substrates, Potential QTc-Prolonging Agents, Protease Inhibitors, QTc Prolonging Agents, Sulfur Compounds, Thiazoles, Treatments for Hepatitis C, UDP Glucuronosyltransferases Inducers, UGT1A1 Inducers, Viral Protease Inhibitors"," Human immunodeficiency virus type 1 protease,  Nuclear receptor subfamily 1 group I member 2,  Cytochrome P450 3A4,  Cytochrome P450 2D6,  Cytochrome P450 2C9,  Cytochrome P450 2C19,  Cytochrome P450 2B6,  Cytochrome P450 2C8,  Cytochrome P450 1A2,  Cytochrome P450 3A5,  Cytochrome P450 3A7, 10. UDP-glucuronosyltransferases (UGTs) (Protein Group),  Serum albumin,  Alpha-1-acid glycoprotein 1,  P-glycoprotein 1,  Multidrug resistance-associated protein 1,  Solute carrier organic anion transporter family member 1A2,  Canalicular multispecific organic anion transporter 1,  ATP-binding cassette sub-family G member 2,  Solute carrier organic anion transporter family member 1B1,  Solute carrier organic anion transporter family member 2B1,  Bile salt export pump,  Solute carrier organic anion transporter family member 1B3","DB00503, DB09065",
DB00504,Levallorphan,approved,[H][C@@]12CCCC[C@@]11CCN(CC=C)[C@@H]2CC2=C1C=C(O)C=C2,C19H25NO,,"Alkaloids, Central Nervous System Agents, Heterocyclic Compounds, Fused-Ring, Morphinans, Opiate Alkaloids, Opioid Antagonists, Peripheral Nervous System Agents, Phenanthrenes, Sensory System Agents", Mu-type opioid receptor,"DB00504, DB00854, DB14682, DB00652, DB13606, DB00514, DB13810, DB00611, DB01209",
DB00505,Tridihexethyl,withdrawn,CC[N+](CC)(CC)CCC(O)(C1CCCCC1)C1=CC=CC=C1,C21H36NO,,"Agents producing tachycardia, Alimentary Tract and Metabolism, Amines, Ammonium Compounds, Anticholinergic Agents, Drugs for Functional Gastrointestinal Disorders, Muscarinic Antagonists, Nitrogen Compounds, Onium Compounds, Synthetic Anticholinergics, Quaternary Ammonium Compounds"," Muscarinic acetylcholine receptor M3,  Muscarinic acetylcholine receptor M1,  Muscarinic acetylcholine receptor M2","DB00505, DB00376, DB00387, DB00942, DB13713, DB00810, DB00193",
DB00507,Nitazoxanide,approved; investigational; vet_approved,CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O,C12H9N3O5S,,"Anti-Infective Agents, Antiparasitic Agents, Antiparasitic Products, Insecticides and Repellents, Antiprotozoals, Sulfur Compounds", Pyruvate-flavodoxin oxidoreductase,DB00507,
DB00508,Triflupromazine,approved; vet_approved,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(C=C2)C(F)(F)F,C18H19F3N2S,,"Agents producing tachycardia, Anticholinergic Agents, Antidepressive Agents, Antiemetics, Antipsychotic Agents, Autonomic Agents, Central Nervous System Agents, Central Nervous System Depressants, Cholinesterase Inhibitors, Dopamine Agents, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Gastrointestinal Agents, Heterocyclic Compounds, Fused-Ring, Muscarinic Antagonists, Nervous System, Neurotoxic agents, Neurotransmitter Agents, P-glycoprotein inhibitors, Peripheral Nervous System Agents, Phenothiazines, Phenothiazines With Aliphatic Side-Chain, Psycholeptics, Psychotropic Drugs, Serotonin 5-HT2 Receptor Antagonists, Serotonin Agents, Serotonin Receptor Antagonists, Sulfur Compounds, Tranquilizing Agents"," Dopamine D2 receptor,  Dopamine D1 receptor,  5-hydroxytryptamine receptor 2B,  Muscarinic acetylcholine receptor M1,  Muscarinic acetylcholine receptor M2,  Cholinesterase,  P-glycoprotein 1","DB00508, DB00831, DB00623, DB11517, DB09000, DB01614, DB00420, DB01246, DB01608, DB11540, DB12710, DB01063, DB00902, DB13213, DB01038, DB15596",
DB00509,Dextrothyroxine,approved; investigational,N[C@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O,C15H11I4NO4,,"Amino Acids, Amino Acids, Aromatic, Amino Acids, Cyclic, Amino Acids, Peptides, and Proteins, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Lipid Modifying Agents, Lipid Modifying Agents, Plain"," Thyroid hormone receptor alpha,  Thyroid hormone receptor beta,  Thyroid peroxidase,  Solute carrier organic anion transporter family member 1B1,  Solute carrier organic anion transporter family member 1C1,  Solute carrier organic anion transporter family member 4A1,  Solute carrier organic anion transporter family member 4C1,  Large neutral amino acids transporter small subunit 1","DB00279, DB00451, DB00509, DB12425, DB01583, DB12629, DB03374, DB01758",
DB00511,Acetyldigitoxin,approved,[H][C@@]1(CC[C@]2(O)[C@]3([H])CC[C@]4([H])C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](OC(C)=O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)C1=CC(=O)OC1,C43H66O14,,"Antiarrhythmic agents, Carbohydrates, Cardanolides, Cardenolides, Cardiac Glycosides, Cardiac Therapy, Cardiotonic Agents, Cardiovascular Agents, Compounds used in a research, industrial, or household setting, Digitalis Glycosides, Enzyme Inhibitors, Fused-Ring Compounds, Glycosides, Protective Agents, Steroids", Sodium/potassium-transporting ATPase subunit alpha-1,"DB00511, DB13691, DB13467, DB00390, DB01396, DB13401, DB01078, DB13240, DB01092, DB13756, DB13537, DB12843, DB06569, DB15774, DB15907, DB15532, DB03671, DB14081, DB01410, DB12025, DB04177, DB06748, DB06749, DB15136",
DB00512,Vancomycin,approved,CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(N)[C@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2,C66H75Cl2N9O24,,"Agents that produce neuromuscular block (indirect), Alimentary Tract and Metabolism, Amino Acids, Peptides, and Proteins, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents, Antiinfectives for Systemic Use, Carbohydrates, Drugs that are Mainly Renally Excreted, Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index, Glycoconjugates, Glycopeptide Antibacterials, Glycopeptides, Intestinal Antiinfectives, Narrow Therapeutic Index Drugs, Nephrotoxic agents, Ophthalmologicals, Peptides, Sensory Organs"," Serum albumin,  alpha1-acid glycoprotein (Protein Group),  Histamine H1 receptor","DB00512, DB04529, DB06402, DB04431, DB04911, DB04111, DB02792, DB06149, DB05735, DB04952, DB05168, DB11191, DB11467, DB05109, DB16186, DB00200, DB12674, DB03614, DB02975, DB12755, DB16312, DB13013, DB02868, DB03469, DB15673, DB11691, DB03933, DB03906, DB18365, DB01200",
DB00513,Aminocaproic acid,approved; investigational,NCCCCCC(O)=O,C6H13NO2,,"Acids, Acyclic, Amino Acids, Amino Acids, Peptides, and Proteins, Aminocaproates, Antifibrinolytic Agents, Blood and Blood Forming Organs, Caproates, Coagulants, Decreased Fibrinolysis, Fibrin Modulating Agents, Hematologic Agents, Hemostatics"," Plasminogen,  Tissue-type plasminogen activator,  Apolipoprotein(a),  Aldehyde oxidase","DB00513, DB00123, DB03252, DB03134, DB04419, DB15458, DB03590, DB02068, DB04235, DB01715",
DB00514,Dextromethorphan,approved,[H][C@]12CCCC[C@]11CCN(C)[C@H]2CC2=C1C=C(OC)C=C2,C18H25NO,,"Alkaloids, Anticholinergic Agents, Antidepressive Agents, Antitussive Agents, Central Nervous System Agents, Central Nervous System Depressants, Combined Inhibitors of Serotonin/Norepinephrine Reuptake, Cough and Cold Preparations, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Substrates, Excitatory Amino Acid Agents, Excitatory Amino Acid Antagonists, Heterocyclic Compounds, Fused-Ring, Morphinans, Nervous System, Neurotransmitter Agents, Nicotinic Antagonists, NMDA Receptor Antagonists, Opiate Alkaloids, Opioids, Opium Alkaloids and Derivatives, Phenanthrenes, Respiratory System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin Modulators, Sigma-1 Agonist, Sigma-1 Receptor Agonists, UGT2B17 substrates, UGT2B7 substrates, Uncompetitive N-methyl-D-aspartate Receptor Antagonist, Uncompetitive NMDA Receptor Antagonists"," Sigma non-opioid intracellular receptor 1,  Glutamate receptor ionotropic, NMDA 3A,  Neuronal acetylcholine receptor subunit alpha-2,  Sodium-dependent serotonin transporter,  Membrane-associated progesterone receptor component 1,  Neuronal acetylcholine receptor subunit alpha-3,  Neuronal acetylcholine receptor subunit alpha-4,  Neuronal acetylcholine receptor subunit beta-4,  Neuronal acetylcholine receptor subunit beta-2, 10. Neuronal acetylcholine receptor subunit alpha-7, 11. Mu-type opioid receptor, 12. Delta-type opioid receptor, 13. Kappa-type opioid receptor, 14. NADPH oxidase (Protein Group), 15. Sodium-dependent noradrenaline transporter,  Cytochrome P450 2D6,  Cytochrome P450 3A4,  Cytochrome P450 3A7,  Cytochrome P450 2B6,  Cytochrome P450 2C19,  Cytochrome P450 2C9,  UDP-glucuronosyltransferase 2B4,  UDP-glucuronosyltransferase 2B7,  UDP-glucuronosyltransferase 2B15, 10. UDP-glucuronosyltransferase 2B17","DB00514, DB00854, DB14682, DB13606, DB00504, DB00652, DB13810, DB00611, DB01209, DB01547",
DB00515,Cisplatin,approved,[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H],Cl2H6N2Pt,,"Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Substrates, Cardiotoxic antineoplastic agents, Chlorine Compounds, Cholinesterase Inhibitors, Compounds used in a research, industrial, or household setting, Cross-Linking Reagents, Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Drugs that are Mainly Renally Excreted, Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index, Immunosuppressive Agents, Indicators and Reagents, Laboratory Chemicals, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, Nephrotoxic agents, Nitrogen Compounds, OCT2 Inhibitors, OCT2 Substrates, OCT2 Substrates with a Narrow Therapeutic Index, Platinum Compounds, Radiation-Sensitizing Agents"," DNA,  DNA-3-methyladenine glycosylase,  Alpha-2-macroglobulin,  Serotransferrin,  Copper transport protein ATOX1,  Myeloperoxidase,  Xanthine dehydrogenase/oxidase,  Cytochrome P450 4A11,  Prostaglandin G/H synthase 2,  Arylamine N-acetyltransferase,  Cytochrome P450 2C9,  Cytochrome P450 2B6,  Cholinesterase,  Glutathione S-transferase theta-1, 10. Metallothionein-1A, 11. Metallothionein-2, 12. Superoxide dismutase [Cu-Zn], 13. Glutathione S-transferase P, 14. NAD(P)H dehydrogenase [quinone] 1, 15. Glutathione S-transferase Mu 1,  Serum albumin,  Canalicular multispecific organic anion transporter 2,  Multidrug resistance-associated protein 5,  Canalicular multispecific organic anion transporter 1,  Solute carrier family 22 member 2,  High affinity copper uptake protein 1,  Probable low affinity copper uptake protein 2,  Multidrug resistance-associated protein 6,  Copper-transporting ATPase 2,  Copper-transporting ATPase 1, 10. ATP-binding cassette sub-family G member 2",DB00515,
DB00516,Bentoquatam,approved,,,,"Aluminium Compounds, Aluminum Silicates, Dermatologicals, Metal cations, Metal divalent cations, Minerals, Oxides, Oxygen Compounds, Silicates, Silicon Compounds",,,
DB00517,Anisotropine methylbromide,approved,[Br-].CCCC(CCC)C(=O)O[C@H]1CC2CCC(C1)[N+]2(C)C,C17H32BrNO2,,"Agents producing tachycardia, Alkaloids, Anticholinergic Agents, Aza Compounds, Azabicyclo Compounds, Cholinergic Agents, Muscarinic Antagonists, Neurotransmitter Agents"," Muscarinic acetylcholine receptor M1,  Muscarinic acetylcholine receptor M2,  Muscarinic acetylcholine receptor M3",DB00517,
DB00518,Albendazole,approved; vet_approved,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,C12H15N3O2S,,"Acids, Acyclic, Anthelmintics, Anti-Infective Agents, Anticestodal Agents, Antihelminthic, Antimitotic Agents, Antinematodal Agents, Antiparasitic Agents, Antiparasitic Products, Insecticides and Repellents, Antiplatyhelmintic Agents, Benzimidazole Derivatives, Benzimidazoles, Carbamates, Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP1A2 Inducers (strong), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Substrates, Heterocyclic Compounds, Fused-Ring, Mitosis Modulators, P-glycoprotein substrates, Tubulin Modulators"," Tubulin beta-2 chain,  Tubulin alpha-1A chain,  Tubulin beta-4B chain,  Fumarate reductase flavoprotein subunit,  Cytochrome P450 1A1,  Cytochrome P450 1A2,  Cytochrome P450 3A4,  Cytochrome P450 2C19,  P-glycoprotein 1","DB00518, DB13871, DB11410, DB11446",
DB00519,Trandolapril,approved,[H][C@@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O,C24H34N2O5,,"ACE Inhibitors and Calcium Channel Blockers, Agents Acting on the Renin-Angiotensin System, Agents causing angioedema, Agents causing hyperkalemia, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Cardiovascular Agents, Enzyme Inhibitors, Heterocyclic Compounds, Fused-Ring, Hypotensive Agents, Protease Inhibitors"," Angiotensin-converting enzyme,  Liver carboxylesterase 1,  Solute carrier family 15 member 1,  Solute carrier family 15 member 2","DB00519, DB00178, DB14209, DB14208, DB00584, DB00790, DB00722, DB09477, DB14213, DB13312",
DB00520,Caspofungin,approved,[H][C@@]12C[C@@H](O)CN1C(=O)[C@@H](NC(=O)[C@]([H])(C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]1[C@@H](O)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@@H](C)O,C52H88N10O15,,"Amino Acids, Peptides, and Proteins, Anti-Infective Agents, Antifungal Agents, Antiinfectives for Systemic Use, Antimycotics for Systemic Use, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Echinocandin Antifungal, Echinocandins, Enzyme Inhibitors, Lipids, Lipopeptides, OAT1/SLC22A6 inhibitors, OATP1B1/SLCO1B1 Inhibitors, OATP1B1/SLCO1B1 Substrates, OATP1B3 substrates, P-glycoprotein inhibitors, Peptides, Peptides, Cyclic"," 1,3-beta-glucan synthase component FKS1,  Cytochrome P450 3A4,  Solute carrier family 22 member 1,  P-glycoprotein 1,  Solute carrier family 22 member 6,  Solute carrier organic anion transporter family member 1B1,  Solute carrier organic anion transporter family member 1B3",DB00520,
DB00521,Carteolol,approved,CC(C)(C)NCC(O)COC1=CC=CC2=C1CCC(=O)N2,C16H24N2O3,,"Adrenergic Agents, Adrenergic Antagonists, Adrenergic beta-Antagonists, Agents causing hyperkalemia, Alcohols, Amines, Amino Alcohols, Antiarrhythmic agents, Antiglaucoma Preparations and Miotics, Antihypertensive Agents, Autonomic Agents, Beta Blocking Agents, Non-Selective, Bradycardia-Causing Agents, Cardiovascular Agents, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 Substrates, Heterocyclic Compounds, Fused-Ring, Hypotensive Agents, Negative Inotrope, Neurotransmitter Agents, Ophthalmologicals, Peripheral Nervous System Agents, Phenoxypropanolamines, Potential QTc-Prolonging Agents, Propanolamines, Propanols, QTc Prolonging Agents, Quinolines, Quinolones, Sensory Organs, Sympatholytics"," Beta-2 adrenergic receptor,  Beta-1 adrenergic receptor,  Cytochrome P450 2D6","DB00521, DB17770",
DB00522,Bentiromide,investigational; withdrawn,OC(=O)C1=CC=C(NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)C2=CC=CC=C2)C=C1,C23H20N2O5,,"Acids, Carbocyclic, Aminobenzoates, Benzene Derivatives, Benzoates, Compounds used in a research, industrial, or household setting, Diagnostic Agents, Indicators and Reagents, Laboratory Chemicals, Pancreatic Function Tests, Tests for Pancreatic Function", Serine protease hepsin,DB00522,
DB00523,Alitretinoin,approved; investigational,C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O,C20H28O2,,"Agents for Dermatitis, Excluding Corticosteroids, Alkenes, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Biological Factors, Carotenoids, Cyclohexanes, Cyclohexenes, Cycloparaffins, Dermatologicals, Diterpenes, Hydrocarbons, Acyclic, Misc. Skin and Mucous Membrane Agents, P-glycoprotein substrates, Pigments, Biological, Polyenes, Retinoids, Retinoids for cancer treatment, Terpenes, Vitamin A, Vitamins, Vitamins (Fat Soluble)"," Retinoic acid receptor alpha,  Retinoic acid receptor RXR-alpha,  Retinoic acid receptor beta,  Retinoic acid receptor RXR-beta,  Retinoic acid receptor gamma,  Retinoic acid receptor RXR-gamma,  Insulin-like growth factor-binding protein 3,  Pregnancy-specific beta-1-glycoprotein 5,  Cytochrome P450 26C1,  Cellular retinoic acid-binding protein 2,  Cellular retinoic acid-binding protein 1,  P-glycoprotein 1","DB00523, DB00755, DB00982, DB00162, DB08467, DB02699, DB06755, DB08127, DB12112, DB16291",
DB00524,Metolazone,approved,CC1NC2=CC(Cl)=C(C=C2C(=O)N1C1=CC=CC=C1C)S(N)(=O)=O,C16H16ClN3O3S,,"Amides, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Cardiovascular Agents, Diuretics, Drugs that are Mainly Renally Excreted, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Heterocyclic Compounds, Fused-Ring, Hyperglycemia-Associated Agents, Hypotensive Agents, Increased Diuresis, Low-Ceiling Diuretics and Potassium-Sparing Agents, Low-Ceiling Diuretics, Excl. Thiazides, Membrane Transport Modulators, Natriuretic Agents, Non Potassium Sparing Diuretics, Quinazolines, Quinazolinones, Sodium Chloride Symporter Inhibitors, Sulfonamides, Sulfones, Sulfur Compounds, Thiazide-like Diuretic", Solute carrier family 12 member 3,"DB00524, DB13708, DB01325",
DB00525,Tolnaftate,approved; investigational; vet_approved,CN(C(=S)OC1=CC2=CC=CC=C2C=C1)C1=CC=CC(C)=C1,C19H17NOS,,"Acids, Acyclic, Anti-Infective Agents, Antifungal Agents, Antifungals for Dermatological Use, Antifungals for Topical Use, Carbamates, Dermatologicals, Naphthalenes, Sulfur Compounds, Thiocarbamates", Squalene monooxygenase,DB00525,
DB00526,Oxaliplatin,approved; investigational,[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1,C8H14N2O4Pt,,"Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Substrates, Coordination Complexes, Immunosuppressive Agents, Moderate Risk QTc-Prolonging Agents, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, OCT2 Substrates, OCT2 Substrates with a Narrow Therapeutic Index, Platinum Compounds, QTc Prolonging Agents"," DNA,  Glutathione S-transferase theta-1,  Metallothionein-1A,  Metallothionein-2,  Myeloperoxidase,  Superoxide dismutase [Cu-Zn],  Glutathione S-transferase P,  Glutathione S-transferase Mu 1,  NAD(P)H dehydrogenase [quinone] 1,  Serum albumin,  Solute carrier family 22 member 2,  High affinity copper uptake protein 1,  Solute carrier family 22 member 3,  ATP-binding cassette sub-family G member 2,  Canalicular multispecific organic anion transporter 1,  Copper-transporting ATPase 2,  Copper-transporting ATPase 1",DB00526,
DB00527,Cinchocaine,approved; vet_approved,CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC,C20H29N3O2,,"Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use, Amides, Analgesics and Anesthetics, Anesthetics, Anesthetics for Topical Use, Anesthetics, Local, Antipruritics and Local Anesthetics, Antipruritics, Incl. Antihistamines, Anesthetics, Etc., Cell-mediated Immunity, Central Nervous System Agents, Central Nervous System Depressants, Cholinesterase Inhibitors, Dermatologicals, Heterocyclic Compounds, Fused-Ring, Increased Histamine Release, Local Anesthetics (Amide), Nervous System, Ophthalmologicals, Otologicals, Peripheral Nervous System Agents, Quinolines, Sensory Organs, Sensory System Agents, Standardized Chemical Allergen, Vasoprotectives"," Sodium channel protein type 5 subunit alpha,  Sodium channel protein type 10 subunit alpha,  Calmodulin,  Cholinesterase",DB00527,
DB00528,Lercanidipine,approved; investigational,COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=C1,C36H41N3O6,,"ACE Inhibitors and Calcium Channel Blockers, Agents causing hyperkalemia, Agents Causing Muscle Toxicity, Angiotensin II receptor blockers (ARBs) and calcium channel blockers, Antiarrhythmic agents, Antihypertensive Agents, Bradycardia-Causing Agents, Calcium Channel Blockers, Calcium-Regulating Hormones and Agents, Cardiovascular Agents, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dihydropyridine Derivatives, Hypotensive Agents, Membrane Transport Modulators, Pyridines, Selective Calcium Channel Blockers With Mainly Vascular Effects, Vasodilating Agents"," Voltage-dependent calcium channel gamma-1 subunit,  Cytochrome P450 2D6,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 3A7","DB00528, DB09231, DB09239, DB14068, DB00622, DB09227, DB01054, DB00393, DB09230, DB09238, DB09240, DB06712, DB09232, DB09233, DB00401, DB09229",
DB00529,Foscarnet,approved,OC(=O)P(O)(O)=O,CH3O5P,,"Acetates, Acids, Acyclic, Anti-Infective Agents, Anti-Retroviral Agents, Antiinfectives for Systemic Use, Antiviral Agents, Antivirals for Systemic Use, Chelating Activity, Direct Acting Antivirals, Enzyme Inhibitors, Nephrotoxic agents, Nucleic Acid Synthesis Inhibitors, OAT1/SLC22A6 inhibitors, Organophosphonates, Organophosphorus Compounds, Phosphonic Acid Derivatives, Potential QTc-Prolonging Agents, Pyrophosphate Analog DNA Polymerase Inhibitor, QTc Prolonging Agents, Reverse Transcriptase Inhibitors"," DNA polymerase catalytic subunit,  DNA polymerase catalytic subunit,  Solute carrier family 22 member 6,  Monocarboxylate transporter 1",DB00529,
DB00530,Erlotinib,approved; investigational,COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2,C22H23N3O4,,"Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Inhibitors, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strong), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Enzyme Inhibitors, Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, Heterocyclic Compounds, Fused-Ring, Highest Risk QTc-Prolonging Agents, Kinase Inhibitor, Narrow Therapeutic Index Drugs, Organic Anion Transporting Polypeptide 2B1 Inhibitors, P-glycoprotein inhibitors, P-glycoprotein substrates, P-glycoprotein substrates with a Narrow Therapeutic Index, Protein Kinase Inhibitors, QTc Prolonging Agents, Quinazolines, Tyrosine Kinase Inhibitors, UGT1A1 Inhibitors"," Nuclear receptor subfamily 1 group I member 2,  Epidermal growth factor receptor,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 1A2,  Cytochrome P450 1A1,  Cytochrome P450 2D6,  Cytochrome P450 2C8,  Cytochrome P450 1B1,  UDP-glucuronosyltransferase 1-1,  Epidermal growth factor receptor,  Serum albumin,  Alpha-1-acid glycoprotein 1,  ATP-binding cassette sub-family G member 2,  P-glycoprotein 1,  Solute carrier organic anion transporter family member 2B1","DB00530, DB11737, DB12174, DB03365, DB02984, DB02848, DB17170, DB00317",
DB00531,Cyclophosphamide,approved; investigational,ClCCN(CCCl)P1(=O)NCCCO1,C7H15Cl2N2O2P,,"Alkylating Activity, Alkylating Drugs, Antineoplastic Agents, Antineoplastic Agents, Alkylating, Antineoplastic and Immunomodulating Agents, Antirheumatic Agents, Cardiotoxic antineoplastic agents, Cytochrome P-450 CYP2A6 Substrates, Cytochrome P-450 CYP2A6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strength unknown), Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C18 Substrates, Cytochrome P-450 CYP2C18 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 CYP2C8 Inducers (strength unknown), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Substrates, Hydrocarbons, Halogenated, Immunologic Factors, Immunosuppressive Agents, Methemoglobinemia Associated Agents, Mustard Compounds, Mutagens, Myeloablative Agonists, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, Neurotoxic agents, Nitrogen Mustard Analogues, Nitrogen Mustard Compounds, Noxae, Organophosphorus Compounds, Phosphoramide Mustards, Phosphoramides, Toxic Actions"," DNA,  Nuclear receptor subfamily 1 group I member 2,  Cytochrome P450 2C9,  Cytochrome P450 3A4,  Cytochrome P450 2B6,  Cytochrome P450 2C19,  Cytochrome P450 2A6,  Cytochrome P450 2C18,  Cytochrome P450 3A5,  Cytochrome P450 2C8","DB00531, DB12902, DB01181, DB12727",
DB00532,Mephenytoin,approved; investigational; withdrawn,CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1,C12H14N2O2,,"Anti-epileptic Agent, Anticonvulsants, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (strength unknown), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Decreased Central Nervous System Disorganized Electrical Activity, Hydantoins, Imidazoles, Imidazolidines, Nervous System, Thyroxine-binding globulin substrates"," Sodium channel protein type 5 subunit alpha,  Nuclear receptor subfamily 1 group I member 2,  Cytochrome P450 2C19,  Cytochrome P450 2B6,  Cytochrome P450 1A2,  Cytochrome P450 2D6,  Cytochrome P450 2C8,  Cytochrome P450 2C9,  Thyroxine-binding globulin","DB00532, DB00252, DB00754, DB13396, DB13276",
DB00533,Rofecoxib,approved; investigational; withdrawn,CS(=O)(=O)C1=CC=C(C=C1)C1=C(C(=O)OC1)C1=CC=CC=C1,C17H14O4S,,"Agents causing hyperkalemia, Agents that produce hypertension, Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Antiinflammatory and Antirheumatic Products, Antiinflammatory and Antirheumatic Products, Non-Steroids, Antirheumatic Agents, COX-2 Inhibitors, Cyclooxygenase Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strong), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (weak), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Enzyme Inhibitors, Musculo-Skeletal System, Nephrotoxic agents, Peripheral Nervous System Agents, Selective Cyclooxygenase 2 Inhibitors (NSAIDs), Sensory System Agents, Sulfur Compounds"," Prostaglandin G/H synthase 2,  Elastin,  Prostaglandin G/H synthase 1,  Cytochrome P450 2C8,  Cytochrome P450 2C9,  Cytochrome P450 3A4,  Cytochrome P450 1A2,  Multidrug resistance-associated protein 4",DB00533,
DB00534,Chlormerodrin,approved; withdrawn,COC(CNC(N)=O)C[Hg]Cl,C5H11ClHgN2O2,,"Alkylmercury Compounds, Organomercury Compounds, Organometallic Compounds"," Solute carrier family 12 member 1,  Succinate-semialdehyde dehydrogenase, mitochondrial","DB00534, DB09406",
DB00535,Cefdinir,approved,[H][C@]12SCC(C=C)=C(N1C(=O)[C@H]2NC(=O)C(=N/O)\C1=CSC(N)=N1)C(O)=O,C14H13N5O5S2,,"Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Aza Compounds, Azabicyclo Compounds, beta Lactam Antibiotics, beta-Lactams, Cephalosporins, Drugs that are Mainly Renally Excreted, Heterocyclic Compounds, Fused-Ring, Lactams, OAT1/SLC22A6 Substrates, OAT3/SLC22A8 Substrates, Sulfur Compounds, Thiazines, Third-Generation Cephalosporins"," Penicillin-binding protein 2,  PBP3,  Myeloperoxidase,  Solute carrier family 22 member 5,  Solute carrier family 15 member 1,  Solute carrier family 15 member 2,  Solute carrier family 22 member 6,  Solute carrier family 22 member 8","DB00535, DB13504, DB00671, DB01416, DB00493, DB01413, DB01332, DB01066, DB00267, DB11485, DB11505, DB00438, DB01212, DB13470, DB13461, DB00229, DB14879, DB13682, DB04918, DB01415, DB01150, DB13667, DB00567, DB11592, DB14733, DB00689, DB01112, DB01326, DB00430, DB01140",
DB00536,Guanidine,approved,NC(N)=N,CH5N3,,"Acetylcholine Releasing Agent, Amidines, Guanidines, Increased Acetylcholine Activity, MATE 1 Substrates, MATE 2 Substrates, MATE substrates, OAT3/SLC22A8 Inhibitors, OCT1 inhibitors, OCT2 Inhibitors"," Aldehyde dehydrogenase, mitochondrial,  Ribonuclease pancreatic,  DNA,  Disks large homolog 4,  Lysozyme,  Guanidinoacetate N-methyltransferase,  Arginase,  Solute carrier family 22 member 2,  Solute carrier family 22 member 1,  Solute carrier family 22 member 3,  Solute carrier family 22 member 5,  Solute carrier family 22 member 8,  Solute carrier family 22 member 4,  Multidrug and toxin extrusion protein 1,  Multidrug and toxin extrusion protein 2",DB00536,
DB00537,Ciprofloxacin,approved; investigational,OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O,C17H18FN3O3,,"Agents Causing Muscle Toxicity, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Chemically-Induced Disorders, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strong), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (moderate), Cytochrome P-450 CYP3A5 Inhibitors, Cytochrome P-450 CYP3A5 Inhibitors (moderate), Cytochrome P-450 CYP3A7 Inhibitors, Cytochrome P-450 CYP3A7 Inhibitors (moderate), Cytochrome P-450 Enzyme Inhibitors, Drugs causing inadvertant photosensitivity, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Fluoroquinolone Antibacterial, Fluoroquinolones, Heterocyclic Compounds, Fused-Ring, MATE 1 Inhibitors, MATE 1 Substrates, MATE 2 Inhibitors, MATE inhibitors, MATE substrates, Moderate Risk QTc-Prolonging Agents, Ophthalmological and Otological Preparations, Ophthalmologicals, Otologicals, P-glycoprotein substrates, Photosensitizing Agents, QTc Prolonging Agents, Quinolines, Quinolone Antimicrobial, Quinolones, Sensory Organs, Topoisomerase II Inhibitors, Topoisomerase Inhibitors"," DNA topoisomerase 4 subunit A,  DNA gyrase subunit A,  DNA topoisomerase 2-alpha,  Potassium voltage-gated channel subfamily H member 2,  DNA gyrase subunit A,  DNA topoisomerase 4 subunit A,  DNA topoisomerase 4 subunit B,  DNA gyrase subunit A,  Multidrug resistance protein MdtK, 10. Gyrase A, 11. DNA gyrase subunit A,  Cytochrome P450 1A2,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  Serum albumin,  P-glycoprotein 1,  Multidrug and toxin extrusion protein 1,  Multidrug and toxin extrusion protein 2","DB00537, DB11404, DB01059, DB00487, DB11393, DB01208, DB00978, DB04576, DB00365, DB11443, DB14025, DB06771, DB01044, DB11491, DB11511, DB11453, DB01405, DB12447, DB16219, DB13261, DB13772, DB09047, DB00218, DB01137, DB01165, DB03034, DB11847, DB06600, DB08972",
DB00538,Gadoversetamide,approved; investigational,[Gd+3].COCCNC(=O)CN(CCN(CCN(CC([O-])=O)CC(=O)NCCOC)CC([O-])=O)CC([O-])=O,C20H34GdN5O10,,"Compounds used in a research, industrial, or household setting, Contrast Media, Diagnostic Uses of Chemicals, Gadolinium-based Contrast Agent, Magnetic Resonance Contrast Activity, Magnetic Resonance Imaging Contrast Media, Other Diagnostics, Paramagnetic Contrast Agent, Paramagnetic Contrast Media",,"DB00538, DB00225, DB04229",
DB00539,Toremifene,approved; investigational,CN(C)CCOC1=CC=C(C=C1)C(=C(\CCCl)C1=CC=CC=C1)\C1=CC=CC=C1,C26H28ClNO,,"Anti-Estrogens, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Antineoplastic and Immunomodulating Agents, Benzene Derivatives, Benzylidene Compounds, Bone Density Conservation Agents, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Endocrine Therapy, Estrogen Agonist/Antagonist, Estrogen Receptor Modulators, Highest Risk QTc-Prolonging Agents, Hormone Antagonists, Hormone Antagonists and Related Agents, Hormones, Hormone Substitutes, and Hormone Antagonists, P-glycoprotein inhibitors, P-glycoprotein substrates, QTc Prolonging Agents, Selective Estrogen Receptor Modulators, Stilbenes"," Estrogen receptor alpha,  Sex hormone-binding globulin,  Cytochrome P450 1A1,  Cytochrome P450 3A4,  P-glycoprotein 1","DB00539, DB00675, DB04468, DB04938, DB06640, DB15641, DB00882, DB06735",
DB00540,Nortriptyline,approved,CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12,C19H21N,,"Adrenergic Agents, Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Adrenergic Uptake Inhibitors, Agents producing tachycardia, Agents that produce hypertension, Agents that reduce seizure threshold, Anticholinergic Agents, Antidepressive Agents, Antidepressive Agents Indicated for Depression, Antidepressive Agents, Tricyclic, Benzocycloheptenes, Central Nervous System Agents, Central Nervous System Depressants, Combined Inhibitors of Serotonin/Norepinephrine Reuptake, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dibenzocycloheptenes, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Histamine Antagonists, Histamine H1 Antagonists, Membrane Transport Modulators, Muscarinic Antagonists, Narrow Therapeutic Index Drugs, Nervous System, Neurotoxic agents, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, Non-Selective Monoamine Reuptake Inhibitors, P-glycoprotein substrates, P-glycoprotein substrates with a Narrow Therapeutic Index, Potential QTc-Prolonging Agents, Psychoanaleptics, Psychotropic Drugs, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT1 Receptor Antagonists, Serotonin 5-HT1A Receptor Antagonists, Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2A Receptor Antagonists, Serotonin 5-HT2C Receptor Antagonists, Serotonin Agents, Serotonin Modulators, Serotonin Receptor Antagonists, Tricyclics and Other Norepinephrine-reuptake Inhibitors"," Sodium-dependent noradrenaline transporter,  Sodium-dependent serotonin transporter,  5-hydroxytryptamine receptor 2A,  5-hydroxytryptamine receptor 1A,  Histamine H1 receptor,  Alpha-1A adrenergic receptor,  Alpha-1D adrenergic receptor,  5-hydroxytryptamine receptor 2C,  Alpha-1B adrenergic receptor, 10. Alpha-2 adrenergic receptors (Protein Group), 11. Beta adrenergic receptor (Protein Group), 12. Dopamine D2 receptor, 13. Sigma receptor (Protein Group), 14. 5-hydroxytryptamine receptor 1C, 15. Muscarinic acetylcholine receptor (Protein Group),  Cytochrome P450 2D6,  Cytochrome P450 3A4,  Cytochrome P450 1A2,  Cytochrome P450 2C19,  Cytochrome P450 3A5,  Cytochrome P450 2E1,  Serum albumin,  Alpha-1-acid glycoprotein 1,  Sodium-dependent noradrenaline transporter,  P-glycoprotein 1","DB00540, DB00321, DB13114, DB13384",
DB00541,Vincristine,approved; investigational,[H][C@@]12N3CC[C@@]11C4=C(C=C(OC)C(=C4)[C@]4(C[C@H]5C[N@](C[C@](O)(CC)C5)CCC5=C4NC4=CC=CC=C54)C(=O)OC)N(C=O)[C@@]1([H])[C@](O)([C@H](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OC,C46H56N4O10,,"Agents Causing Muscle Toxicity, Alkaloids, Antimitotic Agents, Antineoplastic Agents, Antineoplastic Agents, Phytogenic, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Substrates, BSEP/ABCB11 Substrates, BSEP/ABCB11 Substrates with a Narrow Therapeutic Index, Cardiotoxic antineoplastic agents, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Substrates, Heterocyclic Compounds, Fused-Ring, Immunosuppressive Agents, Indole Alkaloids, Indoles, Indolizidines, Indolizines, Mitosis Modulators, Narrow Therapeutic Index Drugs, Neurotoxic agents, OATP1B1/SLCO1B1 Inhibitors, OATP1B3 inhibitors, P-glycoprotein inducers, P-glycoprotein inhibitors, P-glycoprotein substrates, P-glycoprotein substrates with a Narrow Therapeutic Index, Secologanin Tryptamine Alkaloids, Tubulin Modulators, Vinca Alkaloids"," Tubulin beta chain,  Tubulin alpha-4A chain,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  P-glycoprotein 1,  Canalicular multispecific organic anion transporter 2,  Solute carrier family 22 member 3,  Multidrug resistance-associated protein 1,  Multidrug resistance-associated protein 7,  Canalicular multispecific organic anion transporter 1,  Bile salt export pump,  ATP-binding cassette sub-family G member 2,  RalA-binding protein 1, 10. Solute carrier organic anion transporter family member 1B1, 11. Solute carrier organic anion transporter family member 1B3","DB00541, DB00570, DB17390, DB12586, DB00309, DB02868, DB11641, DB00361, DB05168, DB11191, DB11467, DB00200, DB03614, DB04803, DB03469, DB05735, DB12674, DB16186, DB16312, DB02832, DB03317, DB03906, DB04877, DB00615, DB15673, DB17385, DB13013, DB02949, DB02667, DB12755",
DB00542,Benazepril,approved; investigational,[H][C@@]1(CCC2=CC=CC=C2N(CC(O)=O)C1=O)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC,C24H28N2O5,,"ACE Inhibitors and Calcium Channel Blockers, ACE Inhibitors and Diuretics, Agents Acting on the Renin-Angiotensin System, Agents causing angioedema, Agents causing hyperkalemia, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Cardiovascular Agents, Decreased Blood Pressure, Drugs causing inadvertant photosensitivity, Enzyme Inhibitors, Heterocyclic Compounds, Fused-Ring, Hypotensive Agents, Photosensitizing Agents, Protease Inhibitors"," Angiotensin-converting enzyme,  Methylenetetrahydrofolate reductase,  Solute carrier family 15 member 1,  Solute carrier family 15 member 2","DB00542, DB14125, DB05796, DB15356",
DB00543,Amoxapine,approved,ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1,C17H16ClN3O,,"Adrenergic Agents, Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Adrenergic Uptake Inhibitors, Agents producing tachycardia, Agents that produce hypertension, Agents that reduce seizure threshold, Anticholinergic Agents, Antidepressive Agents, Antidepressive Agents Indicated for Depression, Antidepressive Agents, Tetracyclic, Antidepressive Agents, Tricyclic, Antipsychotic Agents, Central Nervous System Agents, Central Nervous System Depressants, Combined Inhibitors of Serotonin/Norepinephrine Reuptake, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dibenzoxazepines, Dopamine Agents, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Heterocyclic Compounds, Fused-Ring, Histamine Antagonists, Histamine H1 Antagonists, Membrane Transport Modulators, Muscarinic Antagonists, Narrow Therapeutic Index Drugs, Nervous System, Neurotoxic agents, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, Non-Selective Monoamine Reuptake Inhibitors, P-glycoprotein inhibitors, Potential QTc-Prolonging Agents, Psychoanaleptics, Psychotropic Drugs, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT1 Receptor Antagonists, Serotonin 5-HT1A Receptor Antagonists, Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2A Receptor Antagonists, Serotonin 5-HT2C Receptor Antagonists, Serotonin Agents, Serotonin Modulators, Serotonin Receptor Antagonists"," Sodium-dependent serotonin transporter,  Sodium-dependent noradrenaline transporter,  Dopamine D2 receptor,  Dopamine D1 receptor,  Alpha-2A adrenergic receptor,  Alpha-1A adrenergic receptor,  Muscarinic acetylcholine receptor M1,  Gamma-aminobutyric acid receptor subunit alpha-1,  5-hydroxytryptamine receptor 2A, 10. 5-hydroxytryptamine receptor 2C, 11. 5-hydroxytryptamine receptor 6, 12. 5-hydroxytryptamine receptor 7, 13. Dopamine D3 receptor, 14. Dopamine D4 receptor, 15. Histamine H1 receptor, 16. Alpha-1 adrenergic receptors (Protein Group), 17. Muscarinic acetylcholine receptor (Protein Group), 18. 5-hydroxytryptamine receptor 2B, 19. 5-hydroxytryptamine receptor 3A, 20. 5-hydroxytryptamine receptor 1A, 21. 5-hydroxytryptamine receptor 1B, 22. Alpha-2 adrenergic receptors (Protein Group), 23. Histamine H4 receptor, 24. GABA(A) Receptor (Protein Group), 25. Sodium-dependent dopamine transporter,  Cytochrome P450 2D6,  Alpha-1-acid glycoprotein 1","DB00408, DB00543, DB15092",
DB00544,Fluorouracil,approved,FC1=CNC(=O)NC1=O,C4H3FN2O2,,"Antimetabolites, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Substrates, Cardiotoxic antineoplastic agents, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2A6 Substrates, Cytochrome P-450 CYP2A6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs causing inadvertant photosensitivity, Fluoropyrimidines, Fluorouracil and prodrugs, Immunologic Factors, Immunosuppressive Agents, Misc. Skin and Mucous Membrane Agents, Moderate Risk QTc-Prolonging Agents, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, Noxae, Nucleic Acid Synthesis Inhibitors, Nucleoside Metabolic Inhibitor, Photosensitizing Agents, Pyrimidine Analogues, Pyrimidines, Pyrimidinones, QTc Prolonging Agents, Thyroxine-binding globulin inducers, Toxic Actions"," DNA,  RNA,  Thymidylate synthase,  Dihydropyrimidine dehydrogenase [NADP(+)],  Uridine phosphorylase 1,  Uridine phosphorylase 2,  Cytochrome P450 2A6,  Cytochrome P450 2C8,  Methylenetetrahydrofolate reductase,  Thymidylate synthase,  Uridine 5'-monophosphate synthase,  Amidophosphoribosyltransferase, 10. Cytochrome P450 1A2, 11. Thymidine phosphorylase, 12. Cytochrome P450 2C9,  Serum albumin,  Thyroxine-binding globulin,  Solute carrier family 22 member 7,  Equilibrative nucleoside transporter 1,  ATP-binding cassette sub-family G member 2,  Canalicular multispecific organic anion transporter 2,  Multidrug resistance-associated protein 4,  Multidrug resistance-associated protein 5","DB00544, DB03419, DB16345",
DB00545,Pyridostigmine,approved; investigational,CN(C)C(=O)OC1=C[N+](C)=CC=C1,C9H13N2O2,,"Cholinergic Agents, Cholinesterase Inhibitors, Cholinesterase substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (weak), Cytochrome P-450 Enzyme Inducers, Enzyme Inhibitors, Nervous System, Neurotransmitter Agents, Parasympathomemetic (Cholinergic) Agents, Parasympathomimetics, Pyridines, Pyridinium Compounds"," Cholinesterase,  Acetylcholinesterase,  Acetylcholinesterase,  Cholinesterase,  Cytochrome P450 3A4","DB00545, DB13694",
DB00546,Adinazolam,experimental,CN(C)CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12,C19H18ClN5,,"Anti-Anxiety Agents, Antidepressive Agents, Benzazepines, Benzodiazepines and benzodiazepine derivatives, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Heterocyclic Compounds, Fused-Ring, Nervous System, Psycholeptics, Psychotropic Drugs, Triazolobenzodiazepines"," GABA(A) Receptor (Protein Group),  GABA(A) Receptor Benzodiazepine Binding Site (Protein Group),  Cytochrome P450 3A4,  Cytochrome P450 2C19","DB00546, DB00404, DB00897, DB01215, DB14716, DB14717, DB14718",
DB00547,Desoximetasone,approved,[H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,C22H29FO4,,"Adrenal Cortex Hormones, Anti-Inflammatory Agents, Corticosteroid Hormone Receptor Agonists, Corticosteroids, Corticosteroids, Dermatological Preparations, Corticosteroids, Potent (Group III), Dermatologicals, Fused-Ring Compounds, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Immunosuppressive Agents, Pregnadienediols, Pregnadienes, Pregnadienetriols, Pregnanes, Steroids, Steroids, Fluorinated", Glucocorticoid receptor,"DB00547, DB00324, DB00443, DB01234, DB11522, DB13491, DB00620, DB08970, DB11750, DB09095, DB00223, DB00663, DB12553, DB14640, DB14649, DB00596, DB08971, DB14669, DB00687, DB13158, DB01384, DB09378, DB00896, DB00860, DB00959, DB13223, DB14634, DB14664, DB13728, DB01185",
DB00548,Azelaic acid,approved,OC(=O)CCCCCCCC(O)=O,C9H16O4,,"Acids, Acyclic, Anti-Acne Preparations, Anti-Acne Preparations for Topical Use, Decreased Protein Synthesis, Decreased Sebaceous Gland Activity, Dermatologicals, Drugs that are Mainly Renally Excreted, Misc. Skin and Mucous Membrane Agents"," Thioredoxin reductase,  3-oxo-5-beta-steroid 4-dehydrogenase,  3-oxo-5-alpha-steroid 4-dehydrogenase 2,  Tyrosinase,  DNA polymerase I","DB00548, DB02448, DB03017, DB03193, DB03500, DB03600, DB03704, DB03796, DB04519, DB07645, DB08231, DB16857, DB11290, DB14077, DB01856, DB02938, DB16084, DB01631, DB05343, DB11117, DB02405, DB08171, DB15678, DB02242, DB02260, DB04039, DB04560, DB02406, DB02767, DB07930",
DB00549,Zafirlukast,approved; investigational,COC1=CC(=CC=C1CC1=CN(C)C2=C1C=C(NC(=O)OC1CCCC1)C=C2)C(=O)NS(=O)(=O)C1=CC=CC=C1C,C31H33N3O6S,,"Acids, Acyclic, Agents to Treat Airway Disease, Amides, Anti-Asthmatic Agents, Carbamates, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 CYP1A2 Inhibitors (strong), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (moderate), Cytochrome P-450 CYP2C19 Inhibitors (strong), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2C8 Inhibitors (strong), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (weak), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs for Obstructive Airway Diseases, Heterocyclic Compounds, Fused-Ring, Hormone Antagonists, Hormones, Hormone Substitutes, and Hormone Antagonists, Leukotriene Antagonists, Leukotriene Modifiers, NTCP Inhibitors, Respiratory System Agents, Sulfones, Sulfur Compounds"," Cysteinyl leukotriene receptor 1,  Cytochrome P450 2C9,  Cytochrome P450 2C8,  Prostaglandin G/H synthase 1,  Cytochrome P450 3A4,  Cytochrome P450 1A2,  Cytochrome P450 2C19,  Cytochrome P450 2D6,  ATP-binding cassette sub-family G member 2,  Sodium/bile acid cotransporter","DB00549, DB16227",
DB00550,Propylthiouracil,approved; investigational,CCCC1=CC(=O)NC(=S)N1,C7H10N2OS,,"Agents Causing Muscle Toxicity, Antimetabolites, Antithyroid agents, Hormone Antagonists, Hormones, Hormone Substitutes, and Hormone Antagonists, Immunosuppressive Agents, Myelosuppressive Agents, Noxae, Pyrimidines, Pyrimidinones, Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins, Thiouracil, Thiouracils, Thyroid Hormone Synthesis Inhibitor, Thyroid Hormone Synthesis Inhibitors, Thyroid Products, Toxic Actions"," Thyroid peroxidase,  Myeloperoxidase,  Dopamine beta-hydroxylase,  Cytochrome P450 1A1","DB00550, DB13644",
DB00551,Acetohydroxamic acid,approved,CC(=O)NO,C2H5NO2,,"Amines, Enzyme Inhibitors, Genito Urinary System and Sex Hormones, Hydroxy Acids, Hydroxylamines, Urease Inhibitor, Urease Inhibitors, Urologicals"," Urease subunit alpha,  Macrophage metalloelastase","DB00551, DB02736",
DB00552,Pentostatin,approved; investigational,OC[C@H]1O[C@H](C[C@@H]1O)N1C=NC2=C1N=CNC[C@H]2O,C11H16N4O4,,"Adenosine Deaminase Inhibitors, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Cancer immunotherapy, Cardiotoxic antineoplastic agents, Coformycin, Deoxyribonucleosides, Drugs that are Mainly Renally Excreted, Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index, Enzyme Inhibitors, Formycins, Immunosuppressive Agents, Immunotherapy, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, Nucleic Acid Synthesis Inhibitors, Nucleic Acids, Nucleotides, and Nucleosides, Nucleoside Metabolic Inhibitor, Nucleosides, Pyrimidine Nucleosides, Pyrimidines", Adenosine deaminase,DB00552,
DB00553,Methoxsalen,approved,COC1=C2OC(=O)C=CC2=CC2=C1OC=C2,C12H8O4,,"Antipsoriatics, Antipsoriatics for Systemic Use, Antipsoriatics for Topical Use, Benzopyrans, Coloring Agents, Compounds used in a research, industrial, or household setting, Cross-Linking Reagents, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 CYP2A6 Inhibitors, Cytochrome P-450 CYP2A6 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Dermatologicals, Drugs that are Mainly Renally Excreted, Furocoumarins, Heterocyclic Compounds, Fused-Ring, Indicators and Reagents, Laboratory Chemicals, Photoabsorption, Photoactivated Radical Generator, Photosensitizing Activity, Photosensitizing Agents, Photosensitizing Agents for Phototherapy, Psoralens for Systemic Use, Psoralens for Topical Use, Pyrans, Radiation-Sensitizing Agents"," DNA,  Cytochrome P450 1A1,  Cytochrome P450 2A13,  Cytochrome P450 2A6,  Cytochrome P450 1A2","DB00553, DB12216, DB18665",
DB00554,Piroxicam,approved; investigational,CN1C(C(=O)NC2=NC=CC=C2)=C(O)C2=C(C=CC=C2)S1(=O)=O,C15H13N3O4S,,"Agents causing hyperkalemia, Agents that produce hypertension, Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Antiinflammatory and Antirheumatic Products, Antiinflammatory and Antirheumatic Products, Non-Steroids, Antiinflammatory Preparations, Non-Steroids for Topical Use, Antirheumatic Agents, Cyclooxygenase Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs causing inadvertant photosensitivity, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Musculo-Skeletal System, Nephrotoxic agents, Non COX-2 selective NSAIDS, OAT1/SLC22A6 inhibitors, OAT3/SLC22A8 Inhibitors, Ophthalmologicals, Organic Anion Transporting Polypeptide 2B1 Inhibitors, Other Nonsteroidal Anti-inflammatory Agents, Oxicams, Peripheral Nervous System Agents, Photosensitizing Agents, Sensory Organs, Sensory System Agents, Sulfur Compounds, Thiazines, Topical Products for Joint and Muscular Pain"," Prostaglandin G/H synthase 2,  Prostaglandin G/H synthase 1,  Cytochrome P450 2C8,  Cytochrome P450 2C9,  Serum albumin,  Solute carrier family 22 member 6,  Solute carrier family 22 member 8,  Solute carrier family 22 member 11,  Solute carrier organic anion transporter family member 2B1","DB00554, DB15883, DB16877, DB08942, DB00814, DB00469, DB06725",
DB00555,Lamotrigine,approved; investigational,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,C9H7Cl2N5,,"Agents causing hyperkalemia, Agents producing tachycardia, Anti-epileptic Agent, Antiarrhythmic agents, Anticholinergic Agents, Anticonvulsants, Bradycardia-Causing Agents, Calcium Channel Blockers, Calcium-Regulating Hormones and Agents, Central Nervous System Agents, Central Nervous System Depressants, Decreased Central Nervous System Disorganized Electrical Activity, Drugs causing inadvertant photosensitivity, Drugs that are Mainly Renally Excreted, Membrane Transport Modulators, Miscellaneous Anticonvulsants, Mood Stabilizer, Muscarinic Antagonists, Nervous System, OCT1 substrates, OCT2 Inhibitors, P-glycoprotein inhibitors, P-glycoprotein substrates, Photosensitizing Agents, Potential QTc-Prolonging Agents, Psychotropic Drugs, QTc Prolonging Agents, Sodium Channel Blockers, Tranquilizing Agents, Triazines, UGT1A1 Inducers, UGT1A1 Substrates, UGT1A3 substrates, UGT1A4 substrates"," Voltage-dependent R-type calcium channel subunit alpha-1E (CACNA1E),  Voltage-gated sodium channel alpha subunit (Protein Group),  Adenosine receptor A1,  Adenosine receptor A2a,  Alpha-1A adrenergic receptor,  Alpha-2A adrenergic receptor,  Beta-1 adrenergic receptor,  D(1) dopamine receptor (Protein Group),  Dopamine D2 receptor, 10. GABA(A) Receptor (Protein Group), 11. GABA(A) Receptor Benzodiazepine Binding Site (Protein Group), 12. Histamine H1 receptor, 13. Kappa-type opioid receptor, 14. Acetylcholine receptor subunit alpha, 15. 5-hydroxytryptamine receptor 2A, 16. 5-hydroxytryptamine receptor 3A, 17. Glutamate receptor 1,  Dihydrofolate reductase,  UDP-glucuronosyltransferases (UGTs) (Protein Group),  Serum albumin,  P-glycoprotein 1,  Solute carrier family 22 member 2,  Solute carrier family 22 member 1",DB00555,
DB00556,Perflutren,approved,FC(F)(F)C(F)(F)C(F)(F)F,C3F8,,"Amino Acids, Peptides, and Proteins, Compounds used in a research, industrial, or household setting, Contrast Media, Diagnostic Uses of Chemicals, Hydrocarbons, Fluorinated, Hydrocarbons, Halogenated, Microspheres, Moderate Risk QTc-Prolonging Agents, Other Diagnostics, Proteins, QTc Prolonging Agents, Ultrasound Contrast Activity, Ultrasound Contrast Media",,"DB00556, DB13117, DB12821",
DB00557,Hydroxyzine,approved,OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1,C21H27ClN2O2,,"Anti-Anxiety Agents, Antipruritics, Central Nervous System Depressants, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dermatologicals, Diphenylmethane Derivatives, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Histamine Receptor Antagonists, Miscellaneous Anxiolytics Sedatives and Hypnotics, Nervous System, Neurotransmitter Agents, P-glycoprotein substrates, Piperazines, Potential QTc-Prolonging Agents, Psycholeptics, QTc Prolonging Agents"," Histamine H1 receptor,  Potassium voltage-gated channel subfamily H member 2,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 2D6,  Serum albumin,  P-glycoprotein 1","DB00557, DB00341, DB06282, DB08936, DB00737, DB00354, DB15979",
DB00558,Zanamivir,approved; investigational,[H][C@]1(OC(=C[C@H](N=C(N)N)[C@H]1NC(C)=O)C(O)=O)[C@H](O)[C@H](O)CO,C12H20N4O7,,"Acids, Acyclic, Amidines, Amino Sugars, Anti-Infective Agents, Antiinfectives for Systemic Use, Antiviral Agents, Antivirals for Systemic Use, Carbohydrates, Direct Acting Antivirals, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Guanidines, Hydroxy Acids, Neuraminic Acids, Neuraminidase Inhibitors, Pyrans, Sialic Acids, Sugar Acids"," Neuraminidase,  Neuraminidase,  Sialidase-2","DB00558, DB03321, DB12791, DB11888, DB03991, DB04227",
DB00559,Bosentan,approved; investigational,COC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)N=C(N=C1OCCO)C1=NC=CC=N1,C27H29N5O6S,,"Amides, Antihypertensive Agents, Antihypertensives for Pulmonary Arterial Hypertension, Benzene Derivatives, Benzenesulfonamides, BSEP/ABCB11 Inhibitors, Cardiovascular Agents, Cytochrome P-450 CYP2C9 Inducers, Cytochrome P-450 CYP2C9 Inducers (moderate), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (moderate), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Substrates, Endothelin Receptor Antagonists, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Hepatotoxic Agents, OATP1B1/SLCO1B1 Substrates, Pyrimidines, Sulfonamides, Sulfones, Sulfur Compounds, Vasodilating Agents"," Endothelin B receptor,  Endothelin-1 receptor,  Cytochrome P450 3A4,  Cytochrome P450 2C9,  Bile salt export pump","DB00559, DB06558, DB06677",
DB00560,Tigecycline,approved,[H][C@@]12CC3=C(C(O)=C(NC(=O)CNC(C)(C)C)C=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2,C29H39N5O8,,"Agents that produce neuromuscular block (indirect), Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Enzyme Inhibitors, Glycylcyclines, Naphthacenes, Protein Synthesis Inhibitors, Tetracyclines"," 16S ribosomal RNA,  30S ribosomal protein S9,  30S ribosomal protein S12,  30S ribosomal protein S13,  30S ribosomal protein S14,  30S ribosomal protein S19","DB00560, DB15040, DB12329, DB01017, DB12455, DB00254, DB00759, DB09550, DB00595, DB00931, DB12035, DB00256, DB01301, DB09093, DB00453, DB00618, DB13092, DB13264, DB11647, DB11191, DB05168, DB12674, DB03614, DB03469, DB00200, DB00361, DB11467, DB05109, DB15413, DB11641",
DB00561,Doxapram,approved; vet_approved,CCN1CC(CCN2CCOCC2)C(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,C24H30N2O2,,"Agents that produce hypertension, Central Nervous System Agents, Central Nervous System Stimulants, Increased Medullary Respiratory Drive, Pyrrolidines, Pyrrolidinones, Respiratory System Agents"," Potassium channel subfamily K member 3,  Potassium channel subfamily K member 9","DB00561, DB01529, DB13413, DB04896, DB08918",
DB00562,Benzthiazide,approved,NS(=O)(=O)C1=CC2=C(C=C1Cl)N=C(CSCC1=CC=CC=C1)NS2(=O)=O,C15H14ClN3O4S3,,"Diuretics, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Heterocyclic Compounds, Fused-Ring, Hyperglycemia-Associated Agents, Sodium Chloride Symporter Inhibitors, Stimulants, Sulfonamides, Sulfones, Sulfur Compounds, Thiazides"," Solute carrier family 12 member 3,  Carbonic anhydrase (Protein Group),  Carbonic anhydrase 1,  Carbonic anhydrase 2,  Carbonic anhydrase 4,  Carbonic anhydrase 9,  Carbonic anhydrase 12",DB00562,
DB00563,Methotrexate,approved,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O,C20H22N8O5,,"Abortifacient Agents, Abortifacient Agents, Nonsteroidal, Agents Causing Muscle Toxicity, Antimetabolites, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Antirheumatic Agents, BCRP/ABCG2 Substrates, Biological Factors, Cancer immunotherapy, Cardiotoxic antineoplastic agents, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Substrates, Dermatologicals, Drugs causing inadvertant photosensitivity, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Folic Acid Analogues, Folic Acid Antagonists, Hepatotoxic Agents, Heterocyclic Compounds, Fused-Ring, Immunologic Factors, Immunosuppressive Agents, Immunotherapy, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, Nephrotoxic agents, Noxae, Nucleic Acid Synthesis Inhibitors, OAT1/SLC22A6 inhibitors, OAT3/SLC22A8 Inhibitors, OAT3/SLC22A8 Substrates, OAT3/SLC22A8 Substrates with a Narrow Therapeutic Index, OATP1B1/SLCO1B1 Substrates, OATP1B3 substrates, P-glycoprotein substrates, P-glycoprotein substrates with a Narrow Therapeutic Index, Photosensitizing Agents, Pigments, Biological, Pteridines, Pterins, Reproductive Control Agents, Toxic Actions"," Thymidylate synthase,  Bifunctional purine biosynthesis protein PURH,  Dihydrofolate reductase,  Dihydrofolate reductase,  Aldehyde oxidase,  Methylenetetrahydrofolate reductase,  6-phosphogluconate dehydrogenase, decarboxylating,  Folylpolyglutamate synthase, mitochondrial,  Thymidylate synthase,  Bifunctional purine biosynthesis protein PURH,  Gamma-glutamyl hydrolase,  Cytochrome P450 3A4, 10. Carboxypeptidase G2,  Serum albumin,  Canalicular multispecific organic anion transporter 2,  Multidrug resistance-associated protein 4,  Multidrug resistance-associated protein 1,  Solute carrier family 22 member 6,  Multidrug resistance-associated protein 7,  Solute carrier family 22 member 8,  Canalicular multispecific organic anion transporter 1,  P-glycoprotein 1,  Solute carrier organic anion transporter family member 1A2, 10. Monocarboxylate transporter 1, 11. ATP-binding cassette sub-family C member 11, 12. Solute carrier organic anion transporter family member 1B3, 13. Solute carrier family 22 member 11, 14. Solute carrier organic anion transporter family member 1C1, 15. Solute carrier organic anion transporter family member 3A1, 16. ATP-binding cassette sub-family G member 2, 17. Solute carrier family 22 member 7, 18. Proton-coupled folate transporter, 19. Solute carrier organic anion transporter family member 1B1, 20. Solute carrier organic anion transporter family member 4C1, 21. Folate transporter 1, 22. Folate receptor alpha, 23. Folate receptor beta, 24. Solute carrier family 15 member 1, 25. Proton-coupled amino acid transporter 1","DB00563, DB08878, DB07765, DB16620, DB06178, DB07689, DB00158, DB06813",
DB00564,Carbamazepine,approved; investigational,NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12,C15H12N2O,,"Analgesics, Analgesics, Non-Narcotic, Anticonvulsants, Antimanic Agents, Carboxamide Derivatives, Cardiovascular Agents, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP1A2 Inducers (strong), Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strong), Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C19 Inducers, Cytochrome P-450 CYP2C19 Inducers (moderate), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (strength unknown), Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 CYP2C8 Inducers (strength unknown), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C9 Inducers, Cytochrome P-450 CYP2C9 Inducers (strength unknown), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inducers (strong), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strong), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Inducers, Cytochrome P-450 CYP3A5 Inducers (strength unknown), Cytochrome P-450 CYP3A5 Inducers (strong), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Decreased Central Nervous System Disorganized Electrical Activity, Dibenzazepines, Drugs that are Mainly Renally Excreted, Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index, Enzyme Inducing Antiepileptic Drugs, Heterocyclic Compounds, Fused-Ring, Immunosuppressive Agents, Inducers of Drug Clearance, Membrane Transport Modulators, Miscellaneous Anticonvulsants, Mood Stabilizer, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, P-glycoprotein inducers, P-glycoprotein substrates, Peripheral Nervous System Agents, Psychotropic Drugs, Sensory System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Sodium Channel Blockers, Thyroxine-binding globulin substrates, UGT1A1 Inducers, UGT1A6 inducer, UGT2B7 substrates, UGT2B7 Substrates with a Narrow Therapeutic Index"," Voltage-gated sodium channel alpha subunit (Protein Group),  Neuronal acetylcholine receptor subunit alpha-4,  Nuclear receptor subfamily 1 group I member 2,  Cytochrome P450 3A4,  Cytochrome P450 2C8,  Cytochrome P450 1A2,  Cytochrome P450 2C9,  Cytochrome P450 2C19,  Cytochrome P450 2B6,  Cytochrome P450 3A5,  UDP-glucuronosyltransferase 2B7,  UDP-glucuronosyltransferase 1-1, 10. UDP-glucuronosyltransferase 1-6, 11. UDP-glucuronosyltransferase 1-7,  P-glycoprotein 1,  RalA-binding protein 1,  Canalicular multispecific organic anion transporter 1",DB00564,
DB00565,Cisatracurium,approved; investigational,COC1=CC2=C(C=C1OC)[C@@H](CC1=CC(OC)=C(OC)C=C1)[N@@+](C)(CCC(=O)OCCCCCOC(=O)CC[N@@+]1(C)CCC3=C(C=C(OC)C(OC)=C3)[C@H]1CC1=CC(OC)=C(OC)C=C1)CC2,C53H72N2O12,,"Anticholinergic Agents, Benzylisoquinolines, Central Nervous System Depressants, Heterocyclic Compounds, Fused-Ring, Isoquinolines, Muscle Relaxants, Muscle Relaxants, Peripherally Acting Agents, Musculo-Skeletal System, Neuromuscular Agents, Neuromuscular Blocking Agents, Neuromuscular Nondepolarizing Blockade, Neuromuscular-Blocking Agents (Nondepolarizing), Nicotinic Antagonists, Peripheral Nervous System Agents"," Neuronal Acetylcholine (nACh) Receptor Subunits (Protein Group),  Acetylcholine receptor subunit alpha,  Muscarinic acetylcholine receptor M2","DB00565, DB00732, DB01226, DB01135, DB12093, DB13692, DB05710, DB11915, DB13393, DB12779, DB04844, DB12161, DB00767, DB16905",
DB00566,Succimer,approved,OC(=O)[C@@H](S)[C@@H](S)C(O)=O,C4H6O4S2,,"Acids, Acyclic, Antidotes, Chelating Agents, Compounds used in a research, industrial, or household setting, Dicarboxylic Acids, Lead Chelating Activity, Lead Chelator, Protective Agents, Sequestering Agents, Succinates, Sulfhydryl Compounds, Sulfur Compounds"," Lead,  Mercury,  Cadmium,  Arsenic","DB00566, DB14089, DB09436, DB09276",
DB00567,Cephalexin,approved; investigational; vet_approved,[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O,C16H17N3O4S,,"Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Aza Compounds, Azabicyclo Compounds, beta-Lactams, Cephalosporins, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, First-Generation Cephalosporins, Heterocyclic Compounds, Fused-Ring, Lactams, MATE 1 Substrates, MATE substrates, Nephrotoxic agents, OAT1/SLC22A6 inhibitors, OAT1/SLC22A6 Substrates, OAT3/SLC22A8 Inhibitors, OAT3/SLC22A8 Substrates, Sulfur Compounds, Thiazines"," Penicillin-binding protein 3,  Penicillin-binding protein 2a,  Penicillin-binding protein 1b,  Penicillin-binding protein 2B,  Penicillin-binding protein 1A,  Serum albumin,  Solute carrier family 22 member 5,  Solute carrier family 15 member 1,  Solute carrier family 15 member 2,  Solute carrier family 22 member 6,  Multidrug and toxin extrusion protein 1,  Solute carrier family 22 member 8","DB00567, DB01140, DB01150, DB00689, DB00833, DB01326, DB13266, DB03938, DB01333, DB00923, DB01414, DB00456, DB14107, DB14725, DB09008, DB01329, DB03313, DB01139, DB01328, DB11385, DB11592, DB00229, DB13461, DB13504, DB00535, DB13499, DB00430, DB13821, DB01112, DB11367",
DB00568,Cinnarizine,approved; investigational,C(\C=C\C1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1,C26H28N2,,"Agents causing hyperkalemia, Antiarrhythmic agents, Antivertigo Preparations, Bradycardia-Causing Agents, Calcium Channel Blockers, Calcium-Regulating Hormones and Agents, Cardiovascular Agents, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2A6 Substrates, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Membrane Transport Modulators, Moderate Risk QTc-Prolonging Agents, Nervous System, Neurotransmitter Agents, Piperazines, QTc Prolonging Agents, Vasodilating Agents"," Histamine H1 receptor,  Voltage-dependent L-type calcium channel subunit alpha-1C,  Voltage-dependent L-type calcium channel subunit alpha-1D,  Voltage-dependent L-type calcium channel subunit alpha-1F,  Voltage-dependent L-type calcium channel subunit alpha-1S,  Voltage-dependent T-type calcium channel subunit alpha-1G,  Voltage-dependent T-type calcium channel subunit alpha-1H,  Voltage-dependent T-type calcium channel subunit alpha-1I,  Dopamine D2 receptor, 10. D(1) dopamine receptor (Protein Group), 11. Muscarinic acetylcholine receptor (Protein Group),  Cytochrome P450 2D6,  Cytochrome P450 2C9,  Cytochrome P450 1A2,  Cytochrome P450 2B6,  Cytochrome P450 2A6,  Cytochrome P450 1A1,  Cytochrome P450 3A4,  Serum albumin","DB00568, DB04841, DB01176",
DB00569,Fondaparinux,approved; investigational,CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS(O)(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3NS(O)(=O)=O)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O,C31H53N3O49S8,,"Anticoagulants, Antithrombins, Blood and Blood Forming Organs, Carbohydrates, Cardiovascular Agents, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Factor Xa Inhibitors, Fibrin Modulating Agents, Hematologic Agents, Indirect factor Xa inhibitors, Miscellaneous Anticoagulants, Oligosaccharides, Polysaccharides, Protease Inhibitors, Serine Protease Inhibitors"," Coagulation factor X,  Antithrombin-III","DB00569, DB02322, DB03959, DB06406, DB02353, DB15880",
DB00570,Vinblastine,approved,[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@@](CC)([C@@H](OC(C)=O)[C@]2(O)C(=O)OC)[C@@]13[H])[C@]1(C[C@@]2([H])CN(C[C@](O)(CC)C2)CCC2=C1NC1=C2C=CC=C1)C(=O)OC,C46H58N4O9,,"Alkaloids, Antimitotic Agents, Antineoplastic Agents, Antineoplastic Agents, Phytogenic, Antineoplastic and Immunomodulating Agents, BSEP/ABCB11 Inhibitors, BSEP/ABCB11 Substrates, BSEP/ABCB11 Substrates with a Narrow Therapeutic Index, Cardiotoxic antineoplastic agents, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Heterocyclic Compounds, Fused-Ring, Immunosuppressive Agents, Indole Alkaloids, Indoles, Indolizidines, Indolizines, Mitosis Modulators, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, OATP1B1/SLCO1B1 Inhibitors, P-glycoprotein inducers, P-glycoprotein inhibitors, P-glycoprotein substrates, P-glycoprotein substrates with a Narrow Therapeutic Index, Secologanin Tryptamine Alkaloids, Tubulin Modulators, Vinca Alkaloids"," Tubulin alpha-1A chain,  Tubulin beta chain,  Tubulin delta chain,  Tubulin gamma-1 chain,  Tubulin epsilon chain,  Transcription factor AP-1,  Cytochrome P450 2D6,  Cytochrome P450 3A4,  P-glycoprotein 1,  Multidrug resistance-associated protein 1,  Canalicular multispecific organic anion transporter 1,  Multidrug resistance-associated protein 6,  Bile salt export pump,  Solute carrier organic anion transporter family member 1B1","DB00570, DB00541, DB17390, DB12586, DB00309, DB11641, DB00361, DB02868, DB05168, DB11191, DB00200, DB11467, DB03614, DB03469, DB04803, DB05735, DB16312, DB12674, DB02832, DB16186, DB03317, DB04877, DB03906, DB00615, DB12755, DB15673, DB02949, DB13013, DB17385, DB02667",
DB00571,Propranolol,approved; investigational,CC(C)NCC(O)COC1=CC=CC2=C1C=CC=C2,C16H21NO2,,"Adrenergic Agents, Adrenergic Antagonists, Adrenergic beta-Antagonists, Agents causing hyperkalemia, Alcohols, Amines, Amino Alcohols, Antiarrhythmic agents, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Beta Blocking Agents and Thiazides, Beta Blocking Agents, Non-Selective, Beta Blocking Agents, Non-Selective, and Thiazides, Bradycardia-Causing Agents, Cardiovascular Agents, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Hypotensive Agents, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates, Naphthalenes, Negative Inotrope, Neurotransmitter Agents, OCT2 Inhibitors, P-glycoprotein inhibitors, P-glycoprotein substrates, Phenoxypropanolamines, Propanolamines, Propanols, QTc Prolonging Agents, Vasodilating Agents"," Beta-1 adrenergic receptor,  Beta-2 adrenergic receptor,  Beta-3 adrenergic receptor,  5-hydroxytryptamine receptor 1A,  5-hydroxytryptamine receptor 1B,  Cytochrome P450 1A1,  Amine oxidase [flavin-containing] A,  Cytochrome P450 1A2,  Cytochrome P450 2D6,  Cytochrome P450 2C19,  Cytochrome P450 3A5,  Cytochrome P450 3A4,  Cytochrome P450 3A7,  Alpha-1-acid glycoprotein 1,  Serum albumin,  Solute carrier family 22 member 2,  P-glycoprotein 1","DB00571, DB03322, DB13777",
DB00572,Atropine,approved; vet_approved,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1,C17H23NO3,,"Adjuvants, Anesthesia, Agents producing tachycardia, Agents that produce hypertension, Alimentary Tract and Metabolism, Alkaloids, Anti-Asthmatic Agents, Antiarrhythmic agents, Anticholinergic Agents, Antimuscarinics Antispasmodics, Autonomic Agents, Aza Compounds, Azabicyclo Compounds, Belladonna Alkaloids, Belladonna Alkaloids, Tertiary Amines, Belladonna and Derivatives, Plain, Bronchodilator Agents, BSEP/ABCB11 Substrates, Cardiovascular Agents, Central Nervous System Agents, Cholinergic Agents, Drugs for Functional Gastrointestinal Disorders, Moderate Risk QTc-Prolonging Agents, Muscarinic Antagonists, Mydriatics, Mydriatics and Cycloplegics, Neurotransmitter Agents, Ophthalmologicals, Parasympatholytics, Peripheral Nervous System Agents, QTc Prolonging Agents, Respiratory System Agents, Sensory Organs, Solanaceous Alkaloids, Tropanes"," Muscarinic acetylcholine receptor M1,  Muscarinic acetylcholine receptor M2,  Muscarinic acetylcholine receptor M3,  Muscarinic acetylcholine receptor M4,  Muscarinic acetylcholine receptor M5,  Glycine receptor subunit alpha-1,  Neuronal acetylcholine receptor subunit alpha-4,  Neuronal acetylcholine receptor subunit beta-2,  Alpha-1-acid glycoprotein 1,  Bile salt export pump","DB00424, DB00572, DB13833, DB00332, DB11785, DB16896, DB00209, DB00747, DB11315, DB02161, DB11181, DB00462, DB09300, DB12086, DB00725, DB08978, DB09271, DB15968",
DB00573,Fenoprofen,approved,CC(C(O)=O)C1=CC(OC2=CC=CC=C2)=CC=C1,C15H14O3,,"Acids, Carbocyclic, Agents causing hyperkalemia, Agents that produce hypertension, Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Antiinflammatory and Antirheumatic Products, Antiinflammatory and Antirheumatic Products, Non-Steroids, Antirheumatic Agents, Cyclooxygenase Inhibitors, Enzyme Inhibitors, Musculo-Skeletal System, Nephrotoxic agents, Non COX-2 selective NSAIDS, Peripheral Nervous System Agents, Phenylpropionates, Propionates, Sensory System Agents"," Prostaglandin G/H synthase 2,  Peroxisome proliferator-activated receptor alpha,  Peroxisome proliferator-activated receptor gamma,  Prostaglandin G/H synthase 1,  Serum albumin",DB00573,
DB00574,Fenfluramine,approved; illicit; investigational; withdrawn,CCNC(C)CC1=CC=CC(=C1)C(F)(F)F,C12H16F3N,,"Alimentary Tract and Metabolism, Amines, Anticonvulsants, Antidepressive Agents, Antiobesity Preparations, Excl. Diet Products, Central Nervous System Depressants, Centrally Acting Antiobesity Products, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Ethylamines, Membrane Transport Modulators, Nervous System, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, Phenethylamines, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT2 Receptor Agonists, Serotonin Agents, Serotonin Receptor Agonists, Stimulants"," Sodium-dependent serotonin transporter,  5-hydroxytryptamine receptor 1D,  5-hydroxytryptamine receptor 2C,  Sigma non-opioid intracellular receptor 1,  5-hydroxytryptamine receptor 2A,  5-hydroxytryptamine receptor 2B,  5-hydroxytryptamine receptor 1A,  Cytochrome P450 1A2,  Cytochrome P450 2B6,  Cytochrome P450 2C9,  Cytochrome P450 2C19,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 2D6","DB00574, DB01191",
DB00575,Clonidine,approved,ClC1=CC=CC(Cl)=C1NC1=NCCN1,C9H9Cl2N3,,"Adrenergic Agents, Adrenergic Agonists, Adrenergic alpha-1 Receptor Agonists, Adrenergic alpha-2 Receptor Agonists, Adrenergic alpha-Agonists, Agents producing tachycardia, Agents that produce hypertension, Analgesics, Anesthetics, Anesthetics, General, Antiadrenergic Agents, Centrally Acting, Antiglaucoma Preparations and Miotics, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Antimigraine Preparations, Autonomic Agents, Bradycardia-Causing Agents, Cardiovascular Agents, Central alpha-2 Adrenergic Agonist, Central Alpha-agonists, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Substrates, Hypotensive Agents, Imidazoles, Imidazoline Receptor Agonists, Imidazolines, Narrow Therapeutic Index Drugs, Nervous System, Neurotransmitter Agents, Ophthalmologicals, Peripheral Nervous System Agents, Sensory Organs, Sensory System Agents, Sympatholytics, Sympathomimetics in Glaucoma Therapy"," Alpha-2B adrenergic receptor,  Alpha-2C adrenergic receptor,  Alpha-2A adrenergic receptor,  Alpha-1A adrenergic receptor,  Alpha-1B adrenergic receptor,  Alpha-1D adrenergic receptor,  Cytochrome P450 1A2,  Cytochrome P450 3A4,  Cytochrome P450 1A1,  Cytochrome P450 3A5,  Cytochrome P450 2D6,  Serum albumin,  Solute carrier family 22 member 3,  Solute carrier family 22 member 5,  Solute carrier family 22 member 4","DB00575, DB00964, DB13429",
DB00576,Sulfamethizole,approved; investigational; vet_approved,CC1=NN=C(NS(=O)(=O)C2=CC=C(N)C=C2)S1,C9H10N4O2S2,,"Amides, Amines, Aniline Compounds, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Benzene Derivatives, Benzenesulfonamides, Blood and Blood Forming Organs, Blood Substitutes and Perfusion Solutions, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Dermatologicals, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Irrigating Solutions, Ophthalmologicals, Sensory Organs, Short-Acting Antibacterial Sulfonamides, Sulfanilamides, Sulfathiazoles, Sulfonamide Antibacterial, Sulfonamides, Sulfonamides and trimethoprim, Sulfones, Sulfur Compounds, Thiazoles"," Dihydropteroate synthase,  Cytochrome P450 2C9,  Serum albumin",DB00576,
DB00577,Valaciclovir,approved; investigational,CC(C)[C@H](N)C(=O)OCCOCN1C=NC2=C1NC(N)=NC2=O,C13H20N6O4,,"Acyclovir and prodrug, Amino Acids, Amino Acids, Branched-Chain, Amino Acids, Peptides, and Proteins, Anti-Infective Agents, Antiinfectives for Systemic Use, Antiviral Agents, Antivirals for Systemic Use, Direct Acting Antivirals, Drugs that are Mainly Renally Excreted, Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor, Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor, Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor, Heterocyclic Compounds, Fused-Ring, Nephrotoxic agents, Nucleic Acid Synthesis Inhibitors, Nucleosides and Nucleotides, Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors, OAT3/SLC22A8 Substrates, Prodrugs, Purines, Purinones"," Thymidine kinase,  DNA polymerase catalytic subunit,  Guanylate kinase,  Thymidine kinase,  Solute carrier family 15 member 1,  Solute carrier family 15 member 2,  Solute carrier family 22 member 8,  Solute carrier family 22 member 6,  Sodium- and chloride-dependent neutral and basic amino acid transporter B(0+),  Ileal sodium/bile acid cotransporter","DB00577, DB01610, DB00787, DB01004, DB17744",
DB00578,Carbenicillin,approved; investigational,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C(C(O)=O)C1=CC=CC=C1)C(O)=O,C17H18N2O6S,,"Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Beta-Lactam Antibacterials, beta-Lactams, Heterocyclic Compounds, Fused-Ring, Lactams, OAT1/SLC22A6 inhibitors, Penicillin G, Penicillins, Penicillins With Extended Spectrum, Sulfur Compounds"," Penicillin-binding protein (Protein Group),  Beta-lactamase Toho-1,  Cytosolic phospholipase A2,  Solute carrier family 22 member 6","DB00578, DB01053, DB00415, DB13506, DB13836, DB01607, DB01060, DB08795, DB08559, DB13739, DB09320, DB01604, DB09319, DB00319, DB13816, DB13693, DB01061, DB01000, DB00417, DB13686, DB00739, DB03820, DB07806, DB00895, DB03550, DB01602, DB13337, DB13660, DB13300, DB12343",
DB00579,Mazindol,approved; investigational,OC1(N2CCN=C2C2=CC=CC=C12)C1=CC=C(Cl)C=C1,C16H13ClN2O,,"Adrenergic Agents, Adrenergic Uptake Inhibitors, Alimentary Tract and Metabolism, Anorexigenic Agents & Respiratory and Cerebral Stimulants, Miscellaneous, Anorexigenic Agents & Respiratory and CNS Stimulants, Antidepressive Agents, Antiobesity Preparations, Excl. Diet Products, Central Nervous System Agents, Central Nervous System Depressants, Central Nervous System Stimulants, Centrally Acting Antiobesity Products, Combined Inhibitors of Serotonin/Norepinephrine Reuptake, Dopamine Agents, Dopamine Uptake Inhibitors, Heterocyclic Compounds, Fused-Ring, Isoindoles, Membrane Transport Modulators, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin Modulators"," Sodium-dependent noradrenaline transporter,  Sodium-dependent dopamine transporter,  Sodium-dependent serotonin transporter,  Synaptic vesicular amine transporter",DB00579,
DB00580,Valdecoxib,approved; investigational; withdrawn,CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O,C16H14N2O3S,,"Agents causing hyperkalemia, Agents that produce hypertension, Amides, Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Antiinflammatory and Antirheumatic Products, Antiinflammatory and Antirheumatic Products, Non-Steroids, Antirheumatic Agents, Benzene Derivatives, COX-2 Inhibitors, Cyclooxygenase Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (weak), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Enzyme Inhibitors, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Musculo-Skeletal System, Nephrotoxic agents, Peripheral Nervous System Agents, Selective Cyclooxygenase 2 Inhibitors (NSAIDs), Sensory System Agents, Sulfonamides, Sulfones, Sulfur Compounds, UGT1A9 Substrates"," Prostaglandin G/H synthase 2,  Carbonic anhydrase 2,  Carbonic anhydrase 3,  UDP-glucuronosyltransferase 1-9,  Cytochrome P450 2C9,  Cytochrome P450 3A4","DB00580, DB08439",
DB00581,Lactulose,approved,OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O,C12H22O11,,"Acidifying Activity, Alimentary Tract and Metabolism, Ammonia Detoxicants, Carbohydrates, Disaccharides, Drugs for Constipation, Gastrointestinal Agents, Laxatives, Osmotic Activity, Osmotic Laxatives, Stimulation Large Intestine Fluid/Electrolyte Secretion", Evolved beta-galactosidase subunit alpha,"DB00581, DB11602, DB15146, DB15379, DB04116, DB01687, DB01697, DB01909, DB02061, DB02065, DB02717, DB02743, DB03277, DB03281, DB03323, DB03995, DB04248, DB04465, DB04681, DB15617, DB02686, DB03279, DB02357, DB07633, DB02645, DB02695, DB04141, DB12942, DB16867, DB04664",
DB00582,Voriconazole,approved,C[C@@H](C1=NC=NC=C1F)[C@](O)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1,C16H14F3N5O,,"14-alpha Demethylase Inhibitors, Anti-Infective Agents, Antifungal Agents, Antiinfectives for Systemic Use, Antimycotics for Systemic Use, Azole Antifungals, Chemically-Induced Disorders, Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (moderate), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (weak), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (weak), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (moderate), Cytochrome P-450 CYP3A4 Inhibitors (strong), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Inhibitors, Cytochrome P-450 CYP3A5 Inhibitors (strong), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Inhibitors, Cytochrome P-450 CYP3A7 Inhibitors (strong), Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs causing inadvertant photosensitivity, Enzyme Inhibitors, Photosensitizing Agents, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Steroid Synthesis Inhibitors, Triazole and tetrazole derivatives, Triazole Derivatives, Triazoles"," Cytochrome P450 51,  Dimethylaniline monooxygenase [N-oxide-forming] 1,  Dimethylaniline monooxygenase [N-oxide-forming] 3,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  Cytochrome P450 2C19,  Cytochrome P450 3A4,  Cytochrome P450 2C9,  Cytochrome P450 2B6,  Prostaglandin G/H synthase 1",DB00582,
DB00583,Levocarnitine,approved; investigational,C[N+](C)(C)C[C@H](O)CC([O-])=O,C7H15NO3,,"Alimentary Tract and Metabolism, Amines, Amino Acids and Derivatives, Caloric Agents, Carnitine Analog, Dietary Supplements, Drugs that are Mainly Renally Excreted, OAT3/SLC22A8 Substrates, OATP1B1/SLCO1B1 Inhibitors, Quaternary Ammonium Compounds, Supplements, Trimethyl Ammonium Compounds"," Xanthine dehydrogenase/oxidase,  Liver carboxylesterase 1,  Myeloperoxidase,  Carnitine O-palmitoyltransferase 1, liver isoform,  Solute carrier family 22 member 4,  Solute carrier family 22 member 5,  Carnitine O-acetyltransferase,  Mitochondrial carnitine/acylcarnitine carrier protein CACL,  Mitochondrial carnitine/acylcarnitine carrier protein, 10. Peroxisomal carnitine O-octanoyltransferase, 11. Carnitine O-palmitoyltransferase 2, mitochondrial,  Solute carrier family 22 member 4,  Solute carrier organic anion transporter family member 1B1,  Solute carrier family 22 member 5,  Solute carrier family 22 member 16,  Solute carrier family 22 member 8","DB00583, DB02648",
DB00584,Enalapril,approved; vet_approved,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O,C20H28N2O5,,"ACE Inhibitors and Calcium Channel Blockers, ACE Inhibitors and Diuretics, Agents Acting on the Renin-Angiotensin System, Agents causing angioedema, Agents causing hyperkalemia, Agents Causing Muscle Toxicity, Amino Acids, Peptides, and Proteins, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Cardiovascular Agents, Decreased Blood Pressure, Dipeptides, Drugs causing inadvertant photosensitivity, Enzyme Inhibitors, Hypotensive Agents, OAT1/SLC22A6 inhibitors, OAT3/SLC22A8 Inhibitors, OATP1B1/SLCO1B1 Substrates, Oligopeptides, P-glycoprotein inhibitors, Peptides, Photosensitizing Agents, Protease Inhibitors"," Angiotensin-converting enzyme,  Serum albumin,  P-glycoprotein 1,  Solute carrier family 15 member 1,  Solute carrier family 22 member 6,  Solute carrier family 22 member 8,  Solute carrier family 22 member 7,  Solute carrier organic anion transporter family member 1A2","DB00584, DB09477, DB00178, DB00722, DB00519, DB14208, DB14209, DB13312, DB01340",
DB00585,Nizatidine,approved,CNC(NCCSCC1=CSC(CN(C)C)=N1)=C[N+]([O-])=O,C12H21N5O2S2,,"Acid Reducers, Agents Causing Muscle Toxicity, Alimentary Tract and Metabolism, Anti-Ulcer Agents, Cholinesterase Inhibitors, Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord), Gastric Acid Lowering Agents, Gastrointestinal Agents, Histamine Agents, Histamine Antagonists, Histamine H2 Antagonists, Neurotransmitter Agents, P-glycoprotein substrates, Sulfur Compounds, Thiazoles"," Histamine H2 receptor,  Cholinesterase,  P-glycoprotein 1",DB00585,
DB00586,Diclofenac,approved; vet_approved,OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl,C14H11Cl2NO2,,"Acetic Acid Derivatives and Related Substances, Acids, Carbocyclic, Agents causing angioedema, Agents causing hyperkalemia, Agents that produce hypertension, Amines, Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Antiinflammatory and Antirheumatic Products, Antiinflammatory and Antirheumatic Products, Non-Steroids, Antiinflammatory Preparations, Non-Steroids for Topical Use, Antimigraine Agents, Miscellaneous, Antirheumatic Agents, BSEP/ABCB11 Substrates, Central Nervous System Agents, Cyclooxygenase Inhibitors, Cyclooxygenase-2 (COX-2) Inhibitors, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C18 Substrates, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Decreased Prostaglandin Production, Dermatologicals, Drugs causing inadvertant photosensitivity, Enzyme Inhibitors, Ethylamines, Musculo-Skeletal System, Nephrotoxic agents, Non COX-2 selective NSAIDS, OAT1/SLC22A6 inhibitors, OAT3/SLC22A8 Inhibitors, OATP1B1/SLCO1B1 Inhibitors, Ophthalmologicals, Other Nonsteroidal Anti-inflammatory Agents, P-glycoprotein inducers, Peripheral Nervous System Agents, Phenylacetates, Photosensitizing Agents, Sensory Organs, Sensory System Agents, Topical Products for Joint and Muscular Pain, UDP Glucuronosyltransferases Inhibitors, UGT1A1 Substrates, UGT1A3 substrates, UGT1A9 Substrates, UGT2B17 Inhibitors, UGT2B7 substrates"," Prostaglandin G/H synthase 2,  Prostaglandin G/H synthase 1,  Cytochrome P450 2C9,  Cytochrome P450 2C19,  Cytochrome P450 1A2,  Cytochrome P450 2C8,  UDP-glucuronosyltransferase 2B7,  Cytochrome P450 3A4,  Cytochrome P450 2B6,  Cytochrome P450 2C18,  Cytochrome P450 2E1, 10. UDP-glucuronosyltransferase 1-3, 11. UDP-glucuronosyltransferase 1-9, 12. UDP-glucuronosyltransferase 2B4, 13. Arachidonate 5-lipoxygenase, 14. Phospholipase A2, membrane associated,  Transthyretin,  Serum albumin,  Solute carrier family 22 member 6,  Multidrug resistance-associated protein 4,  Multidrug resistance-associated protein 1,  Solute carrier family 22 member 8,  Solute carrier family 22 member 11,  Solute carrier organic anion transporter family member 1C1,  Solute carrier organic anion transporter family member 1B1,  Bile salt export pump,  Sodium channel protein type 4 subunit alpha, 10. Acid-sensing ion channel 1, 11. Potassium voltage-gated channel subfamily KQT member 2, 12. Potassium voltage-gated channel subfamily KQT member 3, 13. P-glycoprotein 1","DB00586, DB06736, DB01283",
DB00587,Cinalukast,experimental,CCC(CC)(CC(=O)NC1=CC(\C=C\C2=NC(=CS2)C2CCC2)=CC=C1)C(O)=O,C23H28N2O3S,,Sulfur Compounds, Cysteinyl leukotriene receptor 1,DB00587,
DB00588,Fluticasone propionate,approved,[H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,C25H31F3O5S,,"Adrenal Cortex Hormones, Adrenals, Agents to Treat Airway Disease, Androstadienes, Androstanes, Androstenes, Anti-Allergic Agents, Anti-Asthmatic Agents, Anti-Inflammatory Agents, Autonomic Agents, Bronchodilator Agents, Central Nervous System Depressants, Corticosteroids, Corticosteroids, Dermatological Preparations, Corticosteroids, Potent (Group III), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strong), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Inhibitors, Cytochrome P-450 CYP3A5 Inhibitors (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dermatologicals, Fused-Ring Compounds, Glucocorticoids, Immunosuppressive Agents, OATP1B1/SLCO1B1 Inhibitors, P-glycoprotein substrates, Peripheral Nervous System Agents, Respiratory System Agents, Steroids, Thyroxine-binding globulin inhibitors"," Glucocorticoid receptor,  Progesterone receptor,  Cytosolic phospholipase A2,  Mineralocorticoid receptor,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  Cytochrome P450 2C8,  Cytochrome P450 3A4,  Solute carrier organic anion transporter family member 1B1,  Corticosteroid-binding globulin,  P-glycoprotein 1,  Solute carrier organic anion transporter family member 1B1","DB00588, DB13867, DB06781, DB08906, DB14664, DB12322, DB01013, DB18737, DB15777, DB14637, DB14657, DB01047, DB15821, DB14640, DB14649, DB00591, DB00223, DB00663, DB14634, DB09095, DB00596",
DB00589,Lisuride,approved; investigational,[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@@H](CN2C)NC(=O)N(CC)CC,C20H26N4O,,"Agents that produce hypertension, Alkaloids, Analgesics, Anti-Dyskinesia Agents, Anti-Parkinson Drugs, Antidepressive Agents, Antimigraine Preparations, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Dopamine Agents, Dopamine Agonists, Dopamine Antagonists, Ergolines, Ergot Alkaloids and Derivatives, Ergot-derivative Dopamine Receptor Agonists, Genito Urinary System and Sex Hormones, Heterocyclic Compounds, Fused-Ring, Nervous System, Neurotransmitter Agents, Prolactine Inhibitors, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT1 Receptor Agonists, Serotonin 5-HT2 Receptor Antagonists, Serotonin Agents, Serotonin Receptor Agonists, Serotonin Receptor Antagonists"," Dopamine D2 receptor,  Dopamine D3 receptor,  Dopamine D4 receptor,  5-hydroxytryptamine receptor 2A,  5-hydroxytryptamine receptor 2C,  Dopamine D1 receptor,  Dopamine D5 receptor,  5-hydroxytryptamine receptor 1A,  5-hydroxytryptamine receptor 1D, 10. 5-hydroxytryptamine receptor 2B, 11. 5-hydroxytryptamine receptor 1B, 12. Alpha-2A adrenergic receptor, 13. Alpha-2B adrenergic receptor, 14. Alpha-2C adrenergic receptor, 15. 5-hydroxytryptamine receptor 7,  Cytochrome P450 3A4","DB00589, DB04829, DB01253, DB00353, DB00247",
DB00590,Doxazosin,approved,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=CC=CC=C2O1,C23H25N5O5,,"Adrenergic Agents, Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Antiadrenergic Agents, Peripherally Acting, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Cardiovascular Agents, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Substrates, Drugs Used in Benign Prostatic Hypertrophy, Genito Urinary System and Sex Hormones, Heterocyclic Compounds, Fused-Ring, Hypotensive Agents, Neurotransmitter Agents, OCT1 inhibitors, P-glycoprotein inhibitors, Peripheral alpha-1 blockers, Quinazolines, Urologicals"," Alpha-1A adrenergic receptor,  Alpha-1D adrenergic receptor,  HERG human cardiac K+ channel (Protein Group),  Alpha-1B adrenergic receptor,  Cytochrome P450 3A4,  Cytochrome P450 2C19,  Cytochrome P450 2C9,  Cytochrome P450 2D6,  P-glycoprotein 1,  Solute carrier family 22 member 1","DB00590, DB01162, DB12230, DB00346, DB00457",
DB00591,Fluocinolone acetonide,approved; investigational; vet_approved,[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO,C24H30F2O6,,"Adrenal Cortex Hormones, Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use, Anti-Inflammatory Agents, Corticosteroid Hormone Receptor Agonists, Corticosteroids, Corticosteroids, Dermatological Preparations, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Substrates, Dermatologicals, Drugs that are Mainly Renally Excreted, Fused-Ring Compounds, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Immunosuppressive Agents, Ophthalmologicals, Otologicals, Pregnadienes, Pregnanes, Steroids, Steroids, Fluorinated, Vasoprotectives"," Glucocorticoid receptor,  Annexin A1,  Annexin A2,  Annexin A3,  Annexin A4,  Annexin A5,  Phospholipase A2,  Cytochrome P450 3A4,  Corticosteroid-binding globulin","DB00591, DB01047, DB18738, DB00180, DB14662, DB00288, DB00846, DB14673, DB06781, DB01260, DB06786, DB08973, DB14664, DB01222, DB12553, DB01410, DB12322, DB00223, DB00663, DB14637, DB14657, DB14640, DB14649, DB09095, DB15835, DB00596, DB15777, DB14634, DB13728, DB15821",
DB00592,Piperazine,approved; vet_approved,C1CNCCN1,C4H10N2,,"Anthelmintics, Anti-Infective Agents, Antinematodal Agents, Antiparasitic Agents, Antiparasitic Products, Insecticides and Repellents, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 Substrates, Hyperglycemia-Associated Agents, Piperazine and Derivatives, Piperazines"," Gamma-aminobutyric acid receptor subunit beta-3,  Cytochrome P450 2D6","DB00592, DB06824",
DB00593,Ethosuximide,approved,CCC1(C)CC(=O)NC1=O,C7H11NO2,,"Agents causing hyperkalemia, Anti-epileptic Agent, Antiarrhythmic agents, Anticonvulsants, Bradycardia-Causing Agents, Calcium Channel Blockers, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Decreased Central Nervous System Disorganized Electrical Activity, Imides, Nervous System, Potential QTc-Prolonging Agents, Pyrrolidines, Pyrrolidinones, QTc Prolonging Agents, Succinimide Derivatives, Succinimides"," Voltage-dependent T-type calcium channel subunit alpha-1G,  Cytochrome P450 3A Subfamily (Protein Group),  Cytochrome P450 3A4,  Cytochrome P450 2E1","DB00593, DB13740",
DB00594,Amiloride,approved,NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N,C6H8ClN7O,,"Acid Sensing Ion Channel Blockers, Agents causing hyperkalemia, Cardiovascular Agents, Decreased Renal K+ Excretion, Diuretics, Epithelial Sodium Channel Blockers, Hypotensive Agents, Increased Diuresis, Membrane Transport Modulators, Natriuretic Agents, OCT2 Inhibitors, Potassium-Sparing Diuretics, Pyrazines, Sodium Channel Blockers"," Amiloride-sensitive sodium channel subunit alpha,  Amiloride-sensitive sodium channel subunit beta,  Amiloride-sensitive sodium channel subunit gamma,  Amiloride-sensitive sodium channel subunit delta,  Amiloride-sensitive amine oxidase [copper-containing],  Acid-sensing ion channel 2,  Acid-sensing ion channel 1,  Sodium/hydrogen exchanger 1,  Urokinase-type plasminogen activator,  Amiloride-sensitive amine oxidase [copper-containing],  Amiloride-sensitive amine oxidase [copper-containing],  Solute carrier family 22 member 2,  Solute carrier family 22 member 4",DB00594,
DB00595,Oxytetracycline,approved; investigational; vet_approved,[H][C@@]12[C@@H](O)[C@@]3([H])C(C(=O)C4=C(C=CC=C4O)[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C,C22H24N2O9,,"Agents that produce neuromuscular block (indirect), Alimentary Tract and Metabolism, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antibiotics for Topical Use, Antiinfectives and Antiseptics for Local Oral Treatment, Antiinfectives for Systemic Use, Dermatologicals, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Naphthacenes, OAT1/SLC22A6 inhibitors, OAT3/SLC22A8 Inhibitors, OAT3/SLC22A8 Substrates, Ophthalmologicals, Sensory Organs, Stomatological Preparations, Tetracyclines"," 30S ribosomal protein S9,  30S ribosomal protein S4,  16S ribosomal RNA,  Serum albumin,  Solute carrier family 22 member 6,  Solute carrier family 22 member 8,  Solute carrier family 22 member 11,  Solute carrier family 22 member 7","DB00595, DB00759, DB00254, DB09550, DB00931, DB09093, DB00256, DB01301, DB00618, DB00453, DB13092, DB01017, DB12035, DB12455, DB00560, DB15040, DB12329, DB13264, DB11647, DB11691, DB05168, DB12674",
DB00596,Ulobetasol,approved,[H][C@@]12C[C@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,C22H27ClF2O4,,"Adrenal Cortex Hormones, Anti-Inflammatory Agents, Antipsoriatics, Antipsoriatics for Topical Use, Cardiovascular Agents, Corticosteroid Hormone Receptor Agonists, Corticosteroids, Corticosteroids, Dermatological Preparations, Corticosteroids, Potent (Group III), Dermatologicals, Fused-Ring Compounds, Immunosuppressive Agents, Pregnadienes, Pregnadienetriols, Pregnanes, Steroids, Steroids, Fluorinated, Vasoconstrictor Agents"," Glucocorticoid receptor,  Corticosteroid-binding globulin","DB00596, DB00223, DB00663, DB09095, DB11750, DB12553, DB13728, DB01384, DB09378, DB00324, DB08971, DB00443, DB01234, DB11522, DB13491, DB13223, DB00547, DB14664, DB08970, DB00838, DB00620, DB13158, DB13867, DB01013, DB06781, DB14637, DB14657, DB14652, DB15777, DB15821",
DB00597,Gadoteridol,approved; investigational,[Gd+3].CC(O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1,C17H29GdN4O7,,"Compounds used in a research, industrial, or household setting, Contrast Media, Diagnostic Uses of Chemicals, Drugs that are Mainly Renally Excreted, Elements, Lanthanoid Series Elements, Magnetic Resonance Contrast Activity, Magnetic Resonance Imaging Contrast Media, Metals, Metals, Rare Earth, Other Diagnostics, Paramagnetic Contrast Agent, Paramagnetic Contrast Media",,"DB00597, DB09132, DB00789, DB14007, DB09425, DB00974, DB13404, DB14600, DB14598, DB14599",
DB00598,Labetalol,approved,CC(CCC1=CC=CC=C1)NCC(O)C1=CC(C(N)=O)=C(O)C=C1,C19H24N2O3,,"Adrenergic Agents, Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Adrenergic beta-Antagonists, Agents causing hyperkalemia, Agents producing tachycardia, Alcohols, Alpha and Beta Blocking Agents, Alpha and Beta Blocking Agents and Thiazides, Amides, Amines, Amino Alcohols, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Autonomic Agents, Beta Blocking Agents and Thiazides, Bradycardia-Causing Agents, Cardiovascular Agents, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Ethanolamines, Hypotensive Agents, Negative Inotrope, Neurotransmitter Agents, Peripheral alpha-1 blockers, Peripheral Nervous System Agents, Salicylamides, Sympathomimetics, UGT1A1 Substrates, UGT1A9 Substrates, UGT2B7 substrates, Vasodilating Agents"," Beta-1 adrenergic receptor,  Beta-2 adrenergic receptor,  Alpha-1 adrenergic receptors (Protein Group),  Cytochrome P450 2D6,  Cytochrome P450 2C19,  UDP-glucuronosyltransferase 1-1,  UDP-glucuronosyltransferase 2B7,  UDP-glucuronosyltransferase 1-9,  Serum albumin,  alpha1-acid glycoprotein (Protein Group),  ATP-binding cassette sub-family B member 5","DB00598, DB11541",
DB00599,Thiopental,approved; vet_approved,CCCC(C)C1(CC)C(=O)NC(=S)NC1=O,C11H18N2O2S,,"Anesthetics, Anesthetics, General, Anesthetics, Intravenous, Anticholinergic Agents, Anticonvulsants, Barbiturates, Barbiturates, Plain, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, GABA Agents, GABA Modulators, Hypnotics and Sedatives, Hypotensive Agents, Narrow Therapeutic Index Drugs, Nervous System, Neurotransmitter Agents, Nicotinic Antagonists, Psycholeptics, Pyrimidines, Pyrimidinones, Thiobarbiturates"," Gamma-aminobutyric acid receptor subunit alpha-1,  Gamma-aminobutyric acid receptor subunit alpha-2,  Gamma-aminobutyric acid receptor subunit alpha-3,  Gamma-aminobutyric acid receptor subunit alpha-4,  Gamma-aminobutyric acid receptor subunit alpha-5,  Gamma-aminobutyric acid receptor subunit alpha-6,  Neuronal acetylcholine receptor subunit alpha-4,  Neuronal acetylcholine receptor subunit alpha-7,  Glutamate receptor 2, 10. Glutamate receptor ionotropic, kainate 2, 11. Fatty-acid amide hydrolase 1, 12. Muscarinic acetylcholine receptor M3,  Cytochrome P450 3A Subfamily (Protein Group),  Cytochrome P450 2C19","DB00599, DB01154",
DB00600,Monobenzone,approved,OC1=CC=C(OCC2=CC=CC=C2)C=C1,C13H12O2,,"alpha-Galactosidase, antagonists & inhibitors, Benzene Derivatives, Depigmenting Agents, Dermatologicals, Melanin Synthesis Inhibitors, Phenols", Tyrosinase,DB00600,
DB00601,Linezolid,approved; investigational,CC(=O)NC[C@H]1CN(C(=O)O1)C1=CC(F)=C(C=C1)N1CCOCC1,C16H20FN3O4,,"Acetamides, Acetates, Acids, Acyclic, Agents that produce hypertension, Agents that reduce seizure threshold, Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antidepressive Agents, Antiinfectives for Systemic Use, Central Nervous System Depressants, Enzyme Inhibitors, Immunosuppressive Agents, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates, Monoamine Oxidase Inhibitors, Myelosuppressive Agents, OAT1/SLC22A6 inhibitors, OAT3/SLC22A8 Inhibitors, Oxazolidinone Antibacterial, Oxazolidinones, Protein Synthesis Inhibitors, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin Modulators"," 23S ribosomal RNA,  Amine oxidase [flavin-containing] B,  Amine oxidase [flavin-containing] A,  Serum albumin,  Solute carrier family 22 member 6,  Solute carrier family 22 member 8","DB00601, DB11905",
DB00602,Ivermectin,approved; investigational; vet_approved,[H][C@@]12OC\C3=C/C=C/[C@H](C)[C@H](O[C@H]4C[C@H](OC)[C@@H](O[C@H]5C[C@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)\C(C)=C\C[C@]4([H])C[C@@]([H])(C[C@]5(CC[C@H](C)[C@]([H])(O5)C(C)C)O4)OC(=O)[C@]([H])(C=C(C)[C@H]1O)[C@@]23O.[H][C@@]12OC\C3=C/C=C/[C@H](C)[C@H](O[C@H]4C[C@H](OC)[C@@H](O[C@H]5C[C@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)\C(C)=C\C[C@]4([H])C[C@@]([H])(C[C@]5(CC[C@H](C)[C@]([H])(O5)[C@@H](C)CC)O4)OC(=O)[C@]([H])(C=C(C)[C@H]1O)[C@@]23O,C95H146O28,,"Agents Causing Muscle Toxicity, Agrochemicals, Anthelmintics, Anti-Infective Agents, Antinematodal Agents, Antiparasitic Agents, Antiparasitic Products, Insecticides and Repellents, Avermectines, BCRP/ABCG2 Substrates, Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Dermatologicals, Insecticides, Lactones, OATP1B1/SLCO1B1 Inhibitors, OATP1B3 inhibitors, P-glycoprotein inducers, P-glycoprotein inhibitors, P-glycoprotein substrates, Pediculicides, Pesticides, Polyketides, Scabicides and Pediculicides, Toxic Actions"," Cytochrome P450 3A4,  Cytochrome P450 2D6,  Cytochrome P450 2E1,  P-glycoprotein 1,  Multidrug resistance-associated protein 1,  Canalicular multispecific organic anion transporter 1,  ATP-binding cassette sub-family G member 2,  Solute carrier organic anion transporter family member 1B1,  Solute carrier organic anion transporter family member 1B3","DB00602, DB11400, DB11405, DB11431, DB11459, DB11531, DB02169, DB01780, DB11752, DB06569, DB15774, DB15907, DB14062, DB17240",
DB00603,Medroxyprogesterone acetate,approved; investigational,[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C,C24H34O4,,"Adrenal Cortex Hormones, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Antineoplastic and Immunomodulating Agents, Combination Contraceptives (with Estrogen and derivatives), Contraceptive Agents, Female, Contraceptive Agents, Hormonal, Contraceptive Agents, Male, Contraceptives, Oral, Contraceptives, Oral, Hormonal, Contraceptives, Oral, Synthetic, Corpus Luteum Hormones, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (moderate), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Endocrine Therapy, Fused-Ring Compounds, Genito Urinary System and Sex Hormones, Gonadal Hormones, Gonadal Steroid Hormones, Hormonal Contraceptives for Systemic Use, Hormones, Hormones and Related Agents, Hormones, Hormone Substitutes, and Hormone Antagonists, Hydroxyprogesterones, Hyperglycemia-Associated Agents, P-glycoprotein inhibitors, Pregnanes, Pregnen (4) Derivatives, Pregnenediones, Pregnenes, Progesterone and Derivatives, Progesterone Congeners, Progestin Contraceptives, Progestins, Progestogens and Estrogens, Sequential Preparations, Reproductive Control Agents, Sex Hormones and Modulators of the Genital System, Steroids"," Progesterone receptor,  Estrogen receptor alpha,  P-glycoprotein 1,  GABA(A) Receptor (Protein Group),  Cytochrome P450 3A4,  Cytochrome P450 2C8,  3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2,  Cytochrome P450 2C9,  Cytochrome P450 3A1,  Serum albumin,  P-glycoprotein 1","DB00603, DB11440, DB06789, DB14677, DB12499, DB06780, DB13958, DB14583, DB01134, DB01420, DB08804, DB13943, DB13944, DB13946, DB16001, DB16002, DB16141, DB14539, DB08308, DB08619, DB13640, DB01380, DB01395, DB14540, DB14538, DB14544, DB13185, DB14543, DB14541, DB15984",
DB00604,Cisapride,approved; investigational; withdrawn,CO[C@H]1CN(CCCOC2=CC=C(F)C=C2)CC[C@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC,C23H29ClFN3O4,,"Acids, Carbocyclic, Alimentary Tract and Metabolism, Amides, Aminobenzoates, Anti-Ulcer Agents, Antidepressive Agents, Benzamides and benzamide derivatives, Benzene Derivatives, Benzoates, Central Nervous System Depressants, Chlorobenzoates, Cytochrome P-450 CYP2A6 Substrates, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (moderate), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strong), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs for Functional Gastrointestinal Disorders, Gastrointestinal Agents, Highest Risk QTc-Prolonging Agents, Neurotransmitter Agents, para-Aminobenzoates, Piperidines, Propulsives, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin Receptor Agonists"," 5-hydroxytryptamine receptor 4,  5-hydroxytryptamine receptor 3A,  5-hydroxytryptamine receptor 2A,  Potassium voltage-gated channel subfamily H member 2,  Cytochrome P450 2A6,  Cytochrome P450 2B6,  Cytochrome P450 2C19,  Cytochrome P450 2C8,  Cytochrome P450 2C9,  Cytochrome P450 2D6,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 3A7","DB00604, DB06422, DB13511, DB05542, DB11675, DB06480, DB04917",
DB00605,Sulindac,approved; investigational,CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(C=C1)S(C)=O,C20H17FO3S,,"Acetic Acid Derivatives and Related Substances, Agents causing hyperkalemia, Agents that produce hypertension, Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Antiinflammatory and Antirheumatic Products, Antiinflammatory and Antirheumatic Products, Non-Steroids, Antirheumatic Agents, Cyclooxygenase Inhibitors, Drugs causing inadvertant photosensitivity, Enzyme Inhibitors, Indenes, Musculo-Skeletal System, Nephrotoxic agents, Non COX-2 selective NSAIDS, OAT1/SLC22A6 inhibitors, Other Nonsteroidal Anti-inflammatory Agents, Peripheral Nervous System Agents, Photosensitizing Agents, Sensory System Agents"," Prostaglandin G/H synthase 2,  Prostaglandin G/H synthase 1,  Aldose reductase,  Mitogen-activated protein kinase 3,  Peroxisome proliferator-activated receptor delta,  Prostaglandin D2 receptor 2,  Aldo-keto reductase family 1 member B10,  Cytochrome P450 1A1,  Serum albumin,  Solute carrier family 22 member 6","DB00605, DB06246",
DB00606,Cyclothiazide,approved,NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C1CC2CC1C=C2,C14H16ClN3O4S2,,"Antihypertensive Agents, Cardiovascular Agents, Diuretics, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Heterocyclic Compounds, Fused-Ring, Hyperglycemia-Associated Agents, Natriuretic Agents, OAT1/SLC22A6 inhibitors, Receptors, AMPA, Sulfonamides, Sulfones, Sulfur Compounds, Thiazides"," Sodium/potassium-transporting ATPase subunit gamma,  Carbonic anhydrase (Protein Group),  Carbonic anhydrase 1,  Carbonic anhydrase 2,  Secreted frizzled-related protein 4,  Solute carrier family 22 member 6","DB00606, DB13430, DB13532, DB15861, DB01021, DB08645, DB08303, DB00232, DB13989",
DB00607,Nafcillin,approved; investigational,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(OCC)C=CC2=CC=CC=C12)C(O)=O,C21H22N2O5S,,"Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Beta-Lactam Antibacterials, Beta-Lactamase Resistant Penicillins, beta-Lactams, Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP1A2 Inducers (strength unknown), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (moderate), Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 Enzyme Inducers, Heterocyclic Compounds, Fused-Ring, Lactams, OAT1/SLC22A6 inhibitors, Penicillins, Sulfur Compounds"," Penicillin-binding protein 1b,  Penicillin-binding protein 2B,  Penicillin-binding protein 2a,  Penicillin-binding protein 3,  Penicillin-binding protein 1A,  Cytochrome P450 1A2,  Cytochrome P450 3A4,  Serum albumin,  Solute carrier family 22 member 6","DB00607, DB01603, DB00417, DB01060, DB13337, DB13816, DB00415, DB13506, DB01000, DB01053, DB13660, DB08795, DB00739, DB00319, DB09320, DB03550, DB03820, DB08559, DB13836, DB00578, DB01604, DB13739, DB01061, DB09319, DB12127, DB01602, DB00713, DB01607, DB13814, DB13693",
DB00608,Chloroquine,approved; investigational; vet_approved,CCN(CC)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12,C18H26ClN3,,"Agents Causing Muscle Toxicity, Agents that produce neuromuscular block (indirect), Agents that reduce seizure threshold, alpha-Galactosidase, antagonists & inhibitors, Amebicides, Aminoquinolines, Analgesics, Analgesics, Non-Narcotic, Anti-Infective Agents, Anti-Inflammatory Agents, Antimalarials, Antinematodal Agents, Antiparasitic Agents, Antiparasitic Products, Insecticides and Repellents, Antiprotozoals, Antirheumatic Agents, Biguanides, Central Nervous System Agents, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs causing inadvertant photosensitivity, Drugs that are Mainly Renally Excreted, Experimental Unapproved Treatments for COVID-19, Filaricides, Heterocyclic Compounds, Fused-Ring, Methemoglobinemia Associated Agents, Moderate Risk QTc-Prolonging Agents, P-glycoprotein inhibitors, P-glycoprotein substrates, Peripheral Nervous System Agents, Photosensitizing Agents, QTc Prolonging Agents, Quinolines, Sensory System Agents, Tumor Necrosis Factor Blockers"," Glutathione S-transferase A2,  Tumor necrosis factor,  Toll-like receptor 9,  Glutathione S-transferase,  High mobility group protein B1,  Glutathione S-transferase Mu 1,  Angiotensin-converting enzyme 2,  Cytochrome P450 2C8,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 2D6,  Cytochrome P450 1A1,  Serum albumin,  alpha1-acid glycoprotein (Protein Group),  P-glycoprotein 1","DB00608, DB01611, DB01103, DB02240, DB17749, DB17778, DB13941",
DB00609,Ethionamide,approved,CCC1=NC=CC(=C1)C(N)=S,C8H10N2S,,"Anti-Bacterial Agents, Anti-Infective Agents, Antiinfectives for Systemic Use, Antimycobacterials, Drugs causing inadvertant photosensitivity, Drugs for Treatment of Tuberculosis, Fatty Acid Synthesis Inhibitors, Hypolipidemic Agents, Isonicotinic Acids, Photosensitizing Agents, Pyridines, Thiocarbamide Derivatives"," Enoyl-[acyl-carrier-protein] reductase [NADH],  Catalase-peroxidase","DB00609, DB12667",
DB00610,Metaraminol,approved; investigational,C[C@H](N)[C@H](O)C1=CC(O)=CC=C1,C9H13NO2,,"Adrenergic Agents, Adrenergic Agonists, Adrenergic alpha-1 Receptor Agonists, Adrenergic alpha-Agonists, Adrenergic and Dopaminergic Agents, Agents producing tachycardia, Agents that produce hypertension, Alcohols, Amines, Amino Alcohols, Autonomic Agents, Cardiac Stimulants Excl. Cardiac Glycosides, Cardiac Therapy, Cardiovascular Agents, Neurotransmitter Agents, Peripheral Nervous System Agents, Propanolamines, Propanols, Sympathomimetics, Vasoconstrictor Agents", Alpha-1A adrenergic receptor,"DB00610, DB06707, DB13378, DB13703, DB00368, DB00388, DB00397, DB01486, DB00221, DB00723, DB06262, DB08985",
DB00611,Butorphanol,approved; illicit; vet_approved,[H][C@@]12CC3=C(C=C(O)C=C3)[C@]3(CCCC[C@@]13O)CCN2CC1CCC1,C21H29NO2,,"Alkaloids, Analgesics, Antitussive Agents, Central Nervous System Agents, Central Nervous System Depressants, Heterocyclic Compounds, Fused-Ring, Mixed Agonist / Antagonist Opioids, Morphinan Derivatives, Morphinans, Narcotics, Nervous System, Opiate Alkaloids, Opiate Partial Agonists, Opioid Agonist/Antagonist, Opioid Antagonists, Opioids, Peripheral Nervous System Agents, Phenanthrenes, Respiratory System Agents, Sensory System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"," Kappa-type opioid receptor,  Delta-type opioid receptor,  Mu-type opioid receptor","DB00611, DB01547, DB00854, DB14682, DB00514, DB13606, DB00504, DB12543, DB15241, DB00652",
DB00612,Bisoprolol,approved,CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1,C18H31NO4,,"Adrenergic Agents, Adrenergic Antagonists, Adrenergic beta-1 Receptor Antagonists, Adrenergic beta-Antagonists, Agents causing hyperkalemia, Alcohols, Amines, Amino Alcohols, Antiarrhythmic agents, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Autonomic Agents, Beta blocking agents and calcium channel blockers, Beta Blocking Agents and Thiazides, Beta Blocking Agents, Selective, Beta Blocking Agents, Selective, and Thiazides, Beta-Blockers (Beta1 Selective), Bradycardia-Causing Agents, Cardiovascular Agents, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Hypotensive Agents, Neurotransmitter Agents, P-glycoprotein inhibitors, P-glycoprotein substrates, Peripheral Nervous System Agents, Phenoxypropanolamines, Propanolamines, Propanols, Sympatholytics"," Beta-1 adrenergic receptor,  Beta-2 adrenergic receptor,  Cytochrome P450 3A4,  P-glycoprotein 1","DB00612, DB00264, DB13777",
DB00613,Amodiaquine,approved; investigational,CCN(CC)CC1=C(O)C=CC(NC2=C3C=CC(Cl)=CC3=NC=C2)=C1,C20H22ClN3O,,"Aminoquinolines, Anti-Infective Agents, Antimalarials, Antiparasitic Agents, Antiparasitic Products, Insecticides and Repellents, Antiprotozoals, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Heterocyclic Compounds, Fused-Ring, P-glycoprotein inhibitors, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Quinolines"," Fe(II)-protoporphyrin IX,  Histamine N-methyltransferase,  Cytochrome P450 2C8,  Cytochrome P450 1A1,  Cytochrome P450 1B1,  Cytochrome P450 2D6,  Cytochrome P450 2C9,  P-glycoprotein 1","DB00613, DB16249",
DB00614,Furazolidone,experimental; vet_approved,[O-][N+](=O)C1=CC=C(O1)\C=N\N1CCOC1=O,C8H7N3O5,,"Agents that produce hypertension, Agents that reduce seizure threshold, Anti-Infective Agents, Anti-Infective Agents, Local, Anti-Infective Agents, Urinary, Antidepressive Agents, Antiparasitic Agents, Antiparasitic Products, Insecticides and Repellents, Antiprotozoals, Antitrichomonal Agents, Central Nervous System Depressants, Enzyme Inhibitors, Furans, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates, Monoamine Oxidase Inhibitors, Nitro Compounds, Nitrofurans, Nitroimidazole Derivatives, Oxazoles, Oxazolidinones, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"," DNA,  Amine oxidase [flavin-containing] A,  Amine oxidase [flavin-containing] B","DB00614, DB13724, DB16567",
DB00615,Rifabutin,approved; investigational,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21,C46H62N4O11,,"Alimentary Tract and Metabolism, Anti-Bacterial Agents, Anti-Infective Agents, Antibiotics, Antitubercular, Antiinfectives for Systemic Use, Antimycobacterials, Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (weak), Cytochrome P-450 CYP2C19 Inducers, Cytochrome P-450 CYP2C19 Inducers (moderate), Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 CYP2C8 Inducers (weak), Cytochrome P-450 CYP2C9 Inducers, Cytochrome P-450 CYP2C9 Inducers (strength unknown), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Inducers (weak), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Substrates, Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord), Drugs for Treatment of Tuberculosis, Heterocyclic Compounds, Fused-Ring, Lactams, Macrocyclic, P-glycoprotein inducers, Rifamycin Antimycobacterial, Rifamycins"," DNA-directed RNA polymerase subunit alpha,  DNA-directed RNA polymerase subunit beta,  DNA-directed RNA polymerase subunit beta',  Heat shock protein HSP 90-alpha,  Endoplasmin,  Cytochrome P450 2C19,  Cytochrome P450 2B6,  Cytochrome P450 2C8,  Cytochrome P450 2C9,  Cytochrome P450 3A4,  P-glycoprotein 1","DB00615, DB04220, DB11191, DB11467, DB03614, DB05168, DB00200, DB02975, DB03469, DB13013, DB04803, DB12674, DB05735, DB16312, DB16186, DB15673, DB12586, DB00361, DB02868, DB17390, DB00541, DB03317, DB11641, DB03906, DB00570, DB02832, DB17385, DB02667, DB00309, DB00115",
DB00616,Candoxatril,experimental,COCCOC[C@H](CC1(CCCC1)C(=O)N[C@H]1CC[C@H](CC1)C(O)=O)C(=O)OC1=CC2=C(CCC2)C=C1,C29H41NO7,,"Acids, Acyclic, Antihypertensive Agents, Cardiovascular Agents, Enzyme Inhibitors, Fatty Acids, Fatty Acids, Volatile, Indenes, Lipids, Neprilysin, antagonists & inhibitors, Prodrugs, Protease Inhibitors"," Neprilysin,  Angiotensin-converting enzyme",DB00616,
DB00617,Paramethadione,approved,CCC1(C)OC(=O)N(C)C1=O,C7H11NO3,,"Anticonvulsants, Central Nervous System Depressants, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Nervous System, Oxazolidine Derivatives"," Voltage-dependent T-type calcium channel subunit alpha-1I,  Cytochrome P450 2E1,  Cytochrome P450 3A4,  Cytochrome P450 2C9,  Cytochrome P450 2C8","DB00617, DB00347, DB13799",
DB00618,Demeclocycline,approved,[H][C@]12C[C@@]3([H])[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C(=O)C1=C([C@H]2O)C(Cl)=CC=C1O,C21H21ClN2O8,,"Agents that produce neuromuscular block (indirect), Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antibiotics for Topical Use, Antiinfectives for Systemic Use, Dermatologicals, Drugs causing inadvertant photosensitivity, Naphthacenes, Photosensitizing Agents, Tetracyclines", Vasopressin V2 receptor,"DB00618, DB09093, DB00453, DB00759, DB13092, DB09550, DB00595, DB00256, DB01301, DB00931, DB00254, DB01017, DB12035, DB12455, DB00560, DB12329, DB15040, DB11647, DB13264, DB11691, DB11191, DB05168",
DB00619,Imatinib,approved,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,C29H31N7O,,"Amides, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Bcr-Abl Tyrosine Kinase Inhibitors, BCRP/ABCG2 Inhibitors, BCRP/ABCG2 Substrates, Benzamides and benzamide derivatives, Benzene Derivatives, BSEP/ABCB11 Substrates, Cancer immunotherapy, Cardiotoxic antineoplastic agents, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (moderate), Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Inhibitors, Cytochrome P-450 CYP3A5 Inhibitors (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Inhibitors, Cytochrome P-450 CYP3A7 Inhibitors (strength unknown), Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs causing inadvertant photosensitivity, Enzyme Inhibitors, Highest Risk QTc-Prolonging Agents, Immunosuppressive Agents, Immunotherapy, Kinase Inhibitor, Myelosuppressive Agents, OATP1B3 substrates, OCT1 substrates, OCT2 Inhibitors, P-glycoprotein inhibitors, P-glycoprotein substrates, Photosensitizing Agents, Piperazines, Protein Kinase Inhibitors, Pyrimidines, QTc Prolonging Agents, Tyrosine Kinase Inhibitors, UDP Glucuronosyltransferases Inhibitors, UGT2B17 Inhibitors"," Breakpoint cluster region protein,  Mast/stem cell growth factor receptor Kit,  Proto-oncogene tyrosine-protein kinase receptor Ret,  High affinity nerve growth factor receptor,  Macrophage colony-stimulating factor 1 receptor,  Platelet-derived growth factor receptor alpha,  Epithelial discoidin domain-containing receptor 1,  Tyrosine-protein kinase ABL1,  Platelet-derived growth factor receptor beta, 10. Discoidin domain-containing receptor 2,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  Cytochrome P450 1A2,  Cytochrome P450 2C9,  Cytochrome P450 2D6,  Cytochrome P450 2C19,  Cytochrome P450 2C8,  Serum albumin,  Alpha-1-acid glycoprotein 1,  Solute carrier family 22 member 1,  P-glycoprotein 1,  Solute carrier family 22 member 2,  ATP-binding cassette sub-family G member 2,  ATP-binding cassette sub-family A member 3,  Bile salt export pump,  Canalicular multispecific organic anion transporter 1,  Multidrug resistance-associated protein 1,  Solute carrier family 22 member 5, 10. Solute carrier organic anion transporter family member 1B3, 11. Multidrug resistance-associated protein 4, 12. Solute carrier organic anion transporter family member 1A2","DB00619, DB04739, DB03878, DB11904, DB11851, DB04868, DB11830, DB08221",
DB00620,Triamcinolone,approved; vet_approved,[H][C@@]12C[C@@H](O)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,C21H27FO6,,"Adrenal Cortex Hormones, Adrenals, Agents Causing Muscle Toxicity, Agents to Treat Airway Disease, Alimentary Tract and Metabolism, Anti-Inflammatory Agents, Corticosteroid Hormone Receptor Agonists, Corticosteroids, Corticosteroids for Local Oral Treatment, Corticosteroids for Systemic Use, Corticosteroids for Systemic Use, Plain, Corticosteroids, Dermatological Preparations, Corticosteroids, Moderately Potent (Group II), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Inducers, Cytochrome P-450 CYP3A5 Inducers (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Inducers, Cytochrome P-450 CYP3A7 Inducers (strength unknown), Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Substrates, Dermatologicals, Drugs for Obstructive Airway Diseases, Enzyme Inhibitors, Fused-Ring Compounds, Glucocorticoids, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hyperglycemia-Associated Agents, Immunologic Factors, Immunosuppressive Agents, Nasal Preparations, Ophthalmologicals, Pregnadienes, Pregnanes, Protein-Lysine 6-Oxidase, antagonists & inhibitors, Sensory Organs, Steroids, Steroids, Fluorinated, Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins, Thyroxine-binding globulin inhibitors, Vasoprotectives"," Glucocorticoid receptor,  Cytochrome P450 3A4,  Prostaglandin G/H synthase 2,  Cholinesterase,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  Corticosteroid-binding globulin,  Serum albumin","DB00620, DB00443, DB01234, DB11522, DB13491, DB00324, DB08970, DB00547, DB12553, DB11750, DB00223, DB00663, DB09095, DB14640, DB14649, DB14669, DB00687, DB01384, DB09378, DB00596, DB14634, DB00860, DB00959, DB13728, DB08971, DB13158, DB13223, DB14664, DB13208, DB01185",
DB00621,Oxandrolone,approved; investigational,[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)OC[C@]12C,C19H30O3,,"Alimentary Tract and Metabolism, Anabolic Agents, Anabolic Agents for Systemic Use, Anabolic Steroids, Androgens, Androstan Derivatives, Androstanes, Androstanols, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Fused-Ring Compounds, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Steroids, Thyroxine-binding globulin inhibitors"," Androgen receptor,  Cytochrome P450 2C9","DB00621, DB14655, DB13951, DB08510, DB14665",
DB00622,Nicardipine,approved; investigational,COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1,C26H29N3O6,,"Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Agents causing hyperkalemia, Agents producing tachycardia, Antiarrhythmic agents, Anticholinergic Agents, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Bradycardia-Causing Agents, BSEP/ABCB11 Substrates, Calcium Channel Blockers, Calcium Channel Blockers (Dihydropyridine), Calcium-Regulating Hormones and Agents, Cardiovascular Agents, Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strength unknown), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (strength unknown), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (moderate), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Inhibitors (strong), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (moderate), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Inhibitors, Cytochrome P-450 CYP3A5 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dihydropyridine Derivatives, Dihydropyridines, Hypotensive Agents, Membrane Transport Modulators, Muscarinic Antagonists, OATP1B1/SLCO1B1 Inhibitors, P-glycoprotein inhibitors, P-glycoprotein substrates, Potential QTc-Prolonging Agents, Pyridines, QTc Prolonging Agents, Selective Calcium Channel Blockers With Mainly Vascular Effects, Vasodilating Agents"," Voltage-dependent L-type calcium channel subunit alpha-1C,  Voltage-dependent L-type calcium channel subunit beta-2,  Voltage-dependent calcium channel subunit alpha-2/delta-1,  Voltage-dependent L-type calcium channel subunit alpha-1D,  Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A,  Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B,  Alpha-1A adrenergic receptor,  Alpha-1B adrenergic receptor,  Alpha-1D adrenergic receptor, 10. Muscarinic acetylcholine receptor M1, 11. Muscarinic acetylcholine receptor M2, 12. Muscarinic acetylcholine receptor M3, 13. Muscarinic acetylcholine receptor M4, 14. Muscarinic acetylcholine receptor M5, 15. Calmodulin, 16. Voltage-dependent calcium channel (Protein Group), 17. Voltage-dependent T-type calcium channel subunit alpha-1G, 18. Voltage-dependent T-type calcium channel subunit alpha-1H, 19. Voltage-dependent T-type calcium channel subunit alpha-1I,  Cytochrome P450 3A4,  Cytochrome P450 2D6,  Cytochrome P450 2C19,  Cytochrome P450 2C8,  Cytochrome P450 2B6,  Cytochrome P450 2E1,  Cytochrome P450 3A5,  Cytochrome P450 2C9,  P-glycoprotein 1,  Solute carrier organic anion transporter family member 1B1,  Bile salt export pump","DB00622, DB09227, DB09231, DB09238, DB00528, DB01054, DB09230, DB09240, DB09239, DB14068, DB00393, DB06712, DB09232, DB00401, DB09233, DB09229, DB09235, DB01115",
DB00623,Fluphenazine,approved,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1,C22H26F3N3OS,,"Agents that reduce seizure threshold, Antipsychotic Agents, Antipsychotic Agents (First Generation [Typical]), Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (weak), Cytochrome P-450 Enzyme Inhibitors, Delayed-Action Preparations, Dopamine Agents, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Drugs causing inadvertant photosensitivity, Heterocyclic Compounds, Fused-Ring, Nervous System, Neurotoxic agents, Neurotransmitter Agents, P-glycoprotein inhibitors, Phenothiazines, Phenothiazines With Piperazine Structure, Photosensitizing Agents, Psycholeptics, Psychotropic Drugs, Sulfur Compounds, Tranquilizing Agents"," Dopamine D2 receptor,  Dopamine D1 receptor,  Calmodulin,  Androgen receptor,  5-hydroxytryptamine receptor 2A,  5-hydroxytryptamine receptor 2C,  Cytochrome P450 2E1,  Cytochrome P450 2D6,  P-glycoprotein 1","DB00623, DB00831, DB00508, DB01063, DB01038, DB13784, DB12710, DB11517, DB13213, DB09000, DB00850, DB01614, DB01608, DB11540, DB00433, DB00372",
DB00624,Testosterone,approved; investigational,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,C19H28O2,,"3-Oxoandrosten (4) Derivatives, Anabolic Steroids, Androgens, Androgens and Estrogens, Androstanes, Androstenes, Androstenols, BCRP/ABCG2 Substrates, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Fused-Ring Compounds, Genito Urinary System and Sex Hormones, Gonadal Hormones, Gonadal Steroid Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, OAT3/SLC22A8 Inducers, OATP1B3 substrates, P-glycoprotein inhibitors, Sex Hormones and Modulators of the Genital System, Steroids, Testosterone and derivatives, Testosterone Congeners, Thyroxine-binding globulin inhibitors"," Androgen receptor,  Estrogen receptor alpha,  Mineralocorticoid receptor,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  Cytochrome P450 3A43,  Cytochrome P450 19A1,  Amine oxidase [flavin-containing] A,  Cholesterol side-chain cleavage enzyme, mitochondrial,  Cytochrome P450 1A1,  Cytochrome P450 1B1, 10. Cytochrome P450 2A13, 11. Cytochrome P450 2B6, 12. Cytochrome P450 2C19, 13. Cytochrome P450 2C9, 14. Cytochrome P450 2C8,  Serum albumin,  Sex hormone-binding globulin,  Solute carrier family 22 member 8,  Solute carrier family 22 member 7,  Sodium/bile acid cotransporter,  ATP-binding cassette sub-family G member 2,  Solute carrier organic anion transporter family member 1B3","DB00624, DB01471, DB01543, DB01564, DB05830, DB06710, DB07768, DB11429, DB12787, DB13169, DB13533, DB14093, DB13710, DB13230, DB14570, DB01481, DB01572, DB00253, DB18000, DB00367, DB00717, DB09389, DB14584, DB04652, DB01485, DB01500, DB01540, DB04630, DB00741, DB13089",
DB00625,Efavirenz,approved; investigational,FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1,C14H9ClF3NO2,,"Anti-Infective Agents, Anti-Retroviral Agents, Antiinfectives for Systemic Use, Antiviral Agents, Antivirals for Systemic Use, Antivirals used in combination for the treatment of HIV infections, BSEP/ABCB11 Substrates, Central Nervous System Depressants, Cycloparaffins, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strength unknown), Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C19 Inducers, Cytochrome P-450 CYP2C19 Inducers (strength unknown), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (moderate), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (moderate), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (moderate), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (moderate), Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strong), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Inducers, Cytochrome P-450 CYP3A5 Inducers (moderate), Cytochrome P-450 CYP3A7 Inducers, Cytochrome P-450 CYP3A7 Inducers (moderate), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Direct Acting Antivirals, Enzyme Inhibitors, Heterocyclic Compounds, Fused-Ring, Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor, Hydrocarbons, Acyclic, Inducers of Drug Clearance, Moderate Risk QTc-Prolonging Agents, Non-Nucleoside Reverse Transcriptase Inhibitors, Nonnucleoside Reverse Transcriptase Inhibitors, Nucleic Acid Synthesis Inhibitors, OCT1 inhibitors, Oxazines, QTc Prolonging Agents, Reverse Transcriptase Inhibitors, UGT1A1 Inducers"," Reverse transcriptase/RNaseH,  Cytochrome P450 2C19,  Cytochrome P450 2C9,  Cytochrome P450 2B6,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  Cytochrome P450 1A2,  Cytochrome P450 2D6,  Cytochrome P450 2C8, 10. UDP-glucuronosyltransferase 1-1,  Serum albumin,  Bile salt export pump,  Solute carrier family 22 member 1",DB00625,
DB00626,Bacitracin,approved; vet_approved,CC[C@H](C)[C@H](N)C1=N[C@@H](CS1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H]1CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(O)=O)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC1=O)[C@@H](C)CC,C66H103N17O16S,,"Acids, Carbocyclic, Amino Acids, Peptides, and Proteins, Anti-Bacterial Agents, Anti-Infective Agents, Anti-Infective Agents, Local, Antibacterials for Systemic Use, Antibiotics for Topical Use, Antiinfectives for Systemic Use, Bacitracins, Benzene Derivatives, Benzoates, Decreased Cell Wall Synthesis & Repair, Dermatologicals, Hydroxy Acids, Hydroxybenzoates, Nephrotoxic agents, Peptides, Peptides, Cyclic, Phenols, Throat Preparations"," C55-isoprenyl pyrophosphate,  Insulin-degrading enzyme,  Alpha-2-macroglobulin,  Bacitracin transport ATP-binding protein BcrA,  Bacitracin transport permease protein BCRB,  Bacitracin transport permease protein BcrC","DB00626, DB06260, DB18634, DB15366, DB13742, DB13298, DB05724, DB01284, DB05479, DB15314, DB15355, DB15687, DB01278, DB11724, DB12631, DB14027, DB15194, DB13928, DB04931",
DB00627,Niacin,approved; investigational; nutraceutical,OC(=O)C1=CN=CC=C1,C6H5NO2,,"Agents Causing Muscle Toxicity, Cardiovascular Agents, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Diet, Food, and Nutrition, Food, Growth Substances, Hyperglycemia-Associated Agents, Hypolipidemic Agents, Hypolipidemic Agents Indicated for Hyperlipidemia, Lipid Modifying Agents, Lipid Modifying Agents, Plain, Lipid Regulating Agents, Micronutrients, Miscellaneous Antilipemic Agents, Nicotinic Acid and Derivatives, Nicotinic Acids, Non-statin Hypolipidemic Agents Indicated for Hyperlipidemia, Noxae, Organic Anion Transporting Polypeptide 2B1 Inhibitors, Peripheral Vasodilators, Physiological Phenomena, Pyridines, Thyroxine-binding globulin inhibitors, Toxic Actions, Vasodilating Agents, Vitamin B Complex, Vitamins"," Hydroxycarboxylic acid receptor 3,  Hydroxycarboxylic acid receptor 2,  Nicotinate-nucleotide pyrophosphorylase [carboxylating],  Nicotinamide N-methyltransferase,  Cytochrome P450 2D6,  Cytochrome P450 3A4,  Cytochrome P450 2E1,  Thyroxine-binding globulin,  Solute carrier family 22 member 5,  Solute carrier organic anion transporter family member 2B1,  Monocarboxylate transporter 1,  Sodium-coupled monocarboxylate transporter 1,  Monocarboxylate transporter 4","DB00627, DB13576, DB14529, DB13882, DB04145, DB15905",
DB00628,Clorazepic acid,approved; illicit,OC(=O)C1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2,C16H11ClN2O3,,"Anti-Anxiety Agents, Anticonvulsants, Benzazepines, Benzodiazepines and benzodiazepine derivatives, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, GABA Agents, GABA Modulators, Heterocyclic Compounds, Fused-Ring, Nervous System, Neurotransmitter Agents, Psycholeptics, Psychotropic Drugs, Tranquilizing Agents"," GABA(A) Receptor (Protein Group),  GABA(A) Receptor Benzodiazepine Binding Site (Protein Group),  Cytochrome P450 3A4","DB00628, DB01545, DB14028, DB00829, DB01511, DB13335, DB01588, DB00842, DB00801, DB01567, DB00231, DB00690, DB00186, DB13872, DB13837, DB01594",
DB00629,Guanabenz,approved; investigational,NC(N)=NN=CC1=C(Cl)C=CC=C1Cl,C8H8Cl2N4,,"Adrenergic Agents, Adrenergic Agonists, Adrenergic alpha-2 Receptor Agonists, Adrenergic alpha-Agonists, Agents producing tachycardia, Agents that produce hypertension, Amidines, Antihypertensive Agents, Cardiovascular Agents, Central alpha-2 Adrenergic Agonist, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 Substrates, Guanidines, Neurotransmitter Agents"," Alpha-2A adrenergic receptor,  Alpha-2B adrenergic receptor,  Cytochrome P450 1A2",DB00629,
DB00630,Alendronic acid,approved,NCCCC(O)(P(O)(O)=O)P(O)(O)=O,C4H13NO7P2,,"Agents Causing Muscle Toxicity, Bisphosphonates, Bone Density Conservation Agents, Drugs Affecting Bone Structure and Mineralization, Drugs for Treatment of Bone Diseases, Musculo-Skeletal System, Organophosphonates, Organophosphorus Compounds"," Farnesyl pyrophosphate synthase,  Hydroxylapatite,  Tyrosine-protein phosphatase non-receptor type 4,  Receptor-type tyrosine-protein phosphatase S,  Receptor-type tyrosine-protein phosphatase epsilon,  V-type proton ATPase catalytic subunit A","DB00630, DB00282, DB11620",
DB00631,Clofarabine,approved; investigational,[H][C@]1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C=NC2=C(N)N=C(Cl)N=C12,C10H11ClFN5O3,,"Adenine Nucleotides, Antimetabolites, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Arabinonucleosides, BCRP/ABCG2 Substrates, Drugs that are Mainly Renally Excreted, Heterocyclic Compounds, Fused-Ring, Hypotensive Agents, Immunosuppressive Agents, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, Noxae, Nucleic Acid Synthesis Inhibitors, Nucleic Acids, Nucleotides, and Nucleosides, Nucleoside Metabolic Inhibitor, Nucleosides, Nucleotides, OAT3/SLC22A8 Substrates, OAT3/SLC22A8 Substrates with a Narrow Therapeutic Index, OCT2 Substrates with a Narrow Therapeutic Index, Purine Analogues, Purine Nucleotides, Purines, Ribonucleotides, Toxic Actions"," DNA,  DNA polymerase alpha catalytic subunit,  Ribonucleoside-diphosphate reductase large subunit,  Deoxycytidine kinase,  ATP-binding cassette sub-family G member 2","DB00631, DB00242, DB02103, DB16075, DB07170, DB03716, DB00194, DB00640, DB03528, DB02947, DB04102, DB17756, DB12156, DB01073, DB04441, DB07052, DB02282, DB02916, DB15653, DB02373, DB03273, DB06843, DB11933, DB02523, DB01752, DB02162, DB02607, DB03011, DB01910, DB07413",
DB00632,Docosanol,approved; investigational,CCCCCCCCCCCCCCCCCCCCCCO,C22H46O,,"Alcohols, Anti-Infective Agents, Antiviral Agents, Dermatologicals, Lipids"," Envelope glycoprotein GP350,  Envelope glycoprotein GP340","DB00632, DB03143, DB06894, DB09494, DB11220, DB12452, DB15953, DB02210, DB01637, DB07171, DB14134",
DB00633,Dexmedetomidine,approved; vet_approved,C[C@H](C1=CNC=N1)C1=C(C)C(C)=CC=C1,C13H16N2,,"Adrenergic Agents, Adrenergic Agonists, Adrenergic alpha-2 Receptor Agonists, Adrenergic alpha-Agonists, Agents producing tachycardia, Agents that produce hypertension, Analgesics, Analgesics, Non-Narcotic, Anesthetics, Anesthetics, General, Bradycardia-Causing Agents, Central alpha-2 Adrenergic Agonist, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Hypnotics and Sedatives, Hypotensive Agents, Imidazoles, Miscellaneous Anxiolytics Sedatives and Hypnotics, Nervous System, Neurotransmitter Agents, Peripheral Nervous System Agents, Psycholeptics, Sensory System Agents"," Alpha-2A adrenergic receptor,  Cytochrome P450 2E1,  Cytochrome P450 1A2,  Cytochrome P450 1A1,  Cytochrome P450 2D6","DB00633, DB11428, DB11556, DB12143",
DB00634,Sulfacetamide,approved,CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1,C8H10N2O3S,,"Amides, Amines, Aniline Compounds, Anti-Acne Preparations, Anti-Acne Preparations for Topical Use, Anti-Bacterial Agents, Anti-Infective Agents, Anti-Infective Agents, Local, Anti-Infective Agents, Urinary, Antiinfectives for Treatment of Acne, Dermatologicals, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Ophthalmologicals, Sensory Organs, Sulfanilamides, Sulfonamide Antibacterial, Sulfonamides, Sulfones, Sulfur Compounds"," Dihydropteroate synthase,  Dihydropteroate synthase type-1,  Folic acid synthesis protein FOL1","DB00634, DB13214, DB09355",
DB00635,Prednisone,approved; vet_approved,[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,C21H26O5,,"Adrenal Cortex Hormones, Adrenals, Alimentary Tract and Metabolism, Anti-Inflammatory Agents, Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Corticosteroid Hormone Receptor Agonists, Corticosteroids, Corticosteroids Acting Locally, Corticosteroids for Systemic Use, Corticosteroids for Systemic Use, Plain, Cytochrome P-450 CYP2A6 Inducers, Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strength unknown), Cytochrome P-450 CYP2C19 Inducers, Cytochrome P-450 CYP2C19 Inducers (strength unknown), Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 CYP2C8 Inducers (strength unknown), Cytochrome P-450 CYP2C9 Inducers, Cytochrome P-450 CYP2C9 Inducers (strength unknown), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Inducers, Cytochrome P-450 CYP3A5 Inducers (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Fused-Ring Compounds, Glucocorticoids, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hyperglycemia-Associated Agents, Immunosuppressive Agents, Intestinal Antiinflammatory Agents, P-glycoprotein inducers, P-glycoprotein inhibitors, P-glycoprotein substrates, Prednisolone and Prodrugs, Pregnadienediols, Pregnadienes, Pregnanes, Steroids, Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins, Thyroxine-binding globulin inhibitors"," Glucocorticoid receptor,  Cytochrome P450 2C19,  Cytochrome P450 3A5,  Cytochrome P450 3A Subfamily (Protein Group),  Cytochrome P450 2A6,  Cytochrome P450 1B1,  Cytochrome P450 2B6,  Cytochrome P450 2C8,  Cytochrome P450 2C9,  Corticosteroid 11-beta-dehydrogenase isozyme 1, 10. Cytochrome P450 3A4,  Serum albumin,  Corticosteroid-binding globulin,  P-glycoprotein 1,  Solute carrier organic anion transporter family member 1A2","DB00635, DB09383, DB12952, DB00860, DB00959, DB00896, DB15970, DB14681, DB13208, DB14625, DB14646, DB01541, DB13586, DB15114, DB12081, DB07373, DB12194, DB01569, DB13158, DB13230, DB14570, DB00547",
DB00636,Clofibrate,approved; investigational,CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1,C12H15ClO3,,"Acids, Acyclic, Agents Causing Muscle Toxicity, Anticholesteremic Agents, Benzene Derivatives, Butyrates, Clofibric Acid, Cytochrome P-450 CYP2A6 Inhibitors, Cytochrome P-450 CYP2A6 Inhibitors (strength unknown), Cytochrome P-450 CYP2E1 Inducers, Cytochrome P-450 CYP2E1 Inducers (strength unknown), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Ethers, Fibric Acids, Hypolipidemic Agents, Isobutyrates, Lipid Modifying Agents, Lipid Modifying Agents, Plain, Lipid Regulating Agents, Phenols, Phenyl Ethers, Thyroxine-binding globulin inducers"," Peroxisome proliferator-activated receptor alpha,  Cytochrome P450 1A1,  Cytochrome P450 4A11,  Cytochrome P450 3A4,  Glutathione S-transferase A2,  Cytochrome P450 2E1,  Thyroxine-binding globulin","DB00636, DB13433, DB13780, DB13849, DB13918",
DB00637,Astemizole,approved; withdrawn,COC1=CC=C(CCN2CCC(CC2)NC2=NC3=CC=CC=C3N2CC2=CC=C(F)C=C2)C=C1,C28H31FN4O,,"Anti-Allergic Agents, Antihistamines for Systemic Use, Benzimidazoles, BSEP/ABCB11 Substrates, BSEP/ABCB11 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Heterocyclic Compounds, Fused-Ring, Highest Risk QTc-Prolonging Agents, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Histamine H1 Antagonists, Non-Sedating, Narrow Therapeutic Index Drugs, Neurotransmitter Agents, P-glycoprotein inhibitors, QTc Prolonging Agents"," Histamine H1 receptor,  Potassium voltage-gated channel subfamily H member 2,  Potassium voltage-gated channel subfamily H member 1,  Microtubule-associated protein tau,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  Cytochrome P450 2D6,  Cytochrome P450 2J2,  P-glycoprotein 1,  Bile salt export pump","DB00637, DB06457, DB12523",
DB00639,Butoconazole,approved,ClC1=CC=C(CCC(CN2C=CN=C2)SC2=C(Cl)C=CC=C2Cl)C=C1,C19H17Cl3N2S,,"Anti-Infective Agents, Antifungal Agents, Antifungal Agents (Vaginal), Azole Antifungals, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Imidazole Derivatives", Ergosterol,DB00639,
DB00640,Adenosine,approved; investigational,NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1,C10H13N5O4,,"Adenosine, antagonists & inhibitors, Agents producing tachycardia, Alkenes, Analgesics, Antiarrhythmic agents, Antiarrhythmics, Class V, Biological Factors, Carbohydrates, Cardiac Therapy, Cardiovascular Agents, Central Nervous System Agents, Cyclohexanes, Cyclohexenes, Cycloparaffins, Glycosides, Heterocyclic Compounds, Fused-Ring, Hydrocarbons, Acyclic, Miscellaneous Cardiac Drugs, Miscellaneous Therapeutic Agents, Moderate Risk QTc-Prolonging Agents, Neurotransmitter Agents, Nucleic Acids, Nucleotides, and Nucleosides, Nucleosides, Peripheral Nervous System Agents, Polyenes, Purine Nucleosides, Purinergic Agents, Purinergic Agonists, Purinergic P1 Receptor Agonists, Purines, QTc Prolonging Agents, Ribonucleosides, Sensory System Agents, Terpenes, Vasodilating Agents"," Adenosine receptor A1,  Adenosine receptor A2a,  Adenosine receptor A2b,  Adenosine receptor A3,  Adenylate kinase isoenzyme 1,  Nucleoside diphosphate kinase A,  Nucleoside diphosphate kinase B,  Purine nucleoside phosphorylase,  Xanthine dehydrogenase/oxidase,  Adenosine deaminase,  Adenosine kinase,  Serum albumin,  Equilibrative nucleoside transporter 1,  Equilibrative nucleoside transporter 2,  Equilibrative nucleoside transporter 3,  Equilibrative nucleoside transporter 4,  Sodium/nucleoside cotransporter 1,  Sodium/nucleoside cotransporter 2,  Gap junction alpha-1 protein,  Solute carrier family 28 member 3","DB00194, DB00640, DB03528, DB12156, DB03716, DB01073, DB04441, DB04440, DB03273, DB02916, DB16075, DB17756, DB02282, DB11933, DB07170, DB04102, DB07052, DB00131, DB02162, DB02373, DB02607, DB03011, DB02947, DB00242, DB01910, DB04853, DB02934, DB03952, DB02753, DB03230",
DB00641,Simvastatin,approved,[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC,C25H38O5,,"Agents Causing Muscle Toxicity, Anticholesteremic Agents, BSEP/ABCB11 Substrates, Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strength unknown), Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (weak), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs causing inadvertant photosensitivity, Enzyme Inhibitors, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hypolipidemic Agents, Hypolipidemic Agents Indicated for Hyperlipidemia, Lipid Modifying Agents, Lipid Modifying Agents, Plain, Lipid Regulating Agents, Naphthalenes, Noxae, OATP1B1/SLCO1B1 Inhibitors, OATP1B1/SLCO1B1 Substrates, P-glycoprotein inhibitors, P-glycoprotein substrates, Photosensitizing Agents, UGT1A1 Substrates, UGT1A3 substrates, UGT2B7 substrates"," 3-hydroxy-3-methylglutaryl-coenzyme A reductase,  Integrin alpha-L,  Histone deacetylase 2,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 2C8,  Cytochrome P450 2C9,  Cytochrome P450 2D6,  Cytochrome P450 2B6,  UDP-glucuronosyltransferase 1-1,  UDP-glucuronosyltransferase 1-3,  UDP-glucuronosyltransferase 2B7, 10. Cytochrome P450 2C19, 11. Cocaine esterase, 12. Liver carboxylesterase 1,  P-glycoprotein 1,  Solute carrier organic anion transporter family member 1A2,  Solute carrier organic anion transporter family member 1B1,  Canalicular multispecific organic anion transporter 1,  Bile salt export pump,  Solute carrier organic anion transporter family member 2B1,  Solute carrier organic anion transporter family member 1B3","DB00227, DB00641, DB06693, DB14648, DB03785, DB14714, DB00175, DB08224",
DB00642,Pemetrexed,approved; investigational,NC1=NC(=O)C2=C(NC=C2CCC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N1,C20H21N5O6,,"Amino Acids, Amino Acids, Acidic, Amino Acids, Dicarboxylic, Amino Acids, Peptides, and Proteins, Antimetabolites, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index, Enzyme Inhibitors, Folic Acid Analogues, Folic Acid Antagonists, Glutamates, Heterocyclic Compounds, Fused-Ring, Immunosuppressive Agents, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, Nucleic Acid Synthesis Inhibitors, OAT3/SLC22A8 Substrates, OAT3/SLC22A8 Substrates with a Narrow Therapeutic Index"," Thymidylate synthase,  Bifunctional purine biosynthesis protein PURH,  Dihydrofolate reductase,  Trifunctional purine biosynthetic protein adenosine-3,  Equilibrative nucleoside transporter 1,  Deoxycytidine kinase,  Serum albumin,  Solute carrier family 22 member 8,  Folate transporter 1,  Proton-coupled folate transporter,  ATP-binding cassette sub-family G member 2,  Multidrug resistance-associated protein 5,  Solute carrier family 22 member 6,  Solute carrier family 22 member 11","DB00642, DB02223, DB08131, DB03038",
DB00643,Mebendazole,approved; vet_approved,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C1=CC=CC=C1,C16H13N3O3,,"Acids, Acyclic, Anthelmintics, Anti-Infective Agents, Antihelminthic, Antimitotic Agents, Antinematodal Agents, Antiparasitic Agents, Antiparasitic Products, Insecticides and Repellents, Benzimidazole Derivatives, Benzimidazoles, Carbamates, Heterocyclic Compounds, Fused-Ring, Mitosis Modulators, Tubulin Modulators"," Tubulin alpha-1A chain,  Tubulin beta-4B chain,  Cytochrome P450 1A1,  Cytochrome P450 3A Subfamily (Protein Group)","DB00643, DB08974, DB08313, DB13465",
DB00644,Gonadorelin,approved; investigational; vet_approved,CC(C)CC(NC(=O)CNC(=O)C(CC1=CC=C(O)C=C1)NC(=O)C(CO)NC(=O)C(CC1=CNC2=CC=CC=C12)NC(=O)C(CC1=CN=CN1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(N)=O,C55H75N17O13,,"Adrenal Cortex Hormones, Amino Acids, Peptides, and Proteins, Diagnostic Agents, Gonadotropin-releasing hormone agonist, Gonadotropin-Releasing Hormone, agonists, Gonadotropin-Releasing Hormone, antagonists & inhibitors, Gonadotropins and Antigonadotropins, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hypothalamic Hormones, Nerve Tissue Proteins, Neuropeptides, Oligopeptides, Peptide Hormones, Peptides, Pituitary and Hypothalamic Hormones and Analogues, Pituitary Function, Pituitary Hormone-Releasing Hormones, Proteins, Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins, Tests for Fertility Disturbances"," Gonadotropin-releasing hormone receptor,  Putative gonadotropin-releasing hormone II receptor","DB00644, DB00007, DB06825, DB11510, DB00666, DB18169, DB06719, DB00014, DB04931, DB06788, DB14027, DB15194, DB05479, DB15314, DB11700, DB01284, DB13298, DB15687, DB13928, DB14803, DB11724, DB06763, DB12631, DB14777, DB15272, DB17938, DB12199, DB14786, DB16013, DB16146",
DB00645,Dyclonine,approved,CCCCOC1=CC=C(C=C1)C(=O)CCN1CCCCC1,C18H27NO2,,"Anesthetics, Anesthetics, Local, Central Nervous System Agents, Central Nervous System Depressants, Ketones, Nervous System, Peripheral Nervous System Agents, Sensory System Agents, Throat Preparations", Sodium channel protein type 10 subunit alpha,DB00645,
DB00646,Nystatin,approved; vet_approved,[H][C@]12C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)\C=C\C=C\C=C\C=C\CC\C=C\C=C\[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]1C(O)=O)O2,C47H75NO17,,"Alimentary Tract and Metabolism, Anti-Infective Agents, Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents, Antifungal Agents, Antifungal Agents (Vaginal), Antifungals for Dermatological Use, Antifungals for Topical Use, Compounds used in a research, industrial, or household setting, Dermatologicals, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Intestinal Antiinfectives, Ionophores, Lactones, Membrane Transport Modulators, OATP1B1/SLCO1B1 Inhibitors, OATP1B3 inhibitors, Polyene Antifungal, Polyenes, Polyketides"," Ergosterol,  Solute carrier organic anion transporter family member 1B1,  Solute carrier organic anion transporter family member 1B3","DB00646, DB00681, DB00826, DB01152, DB15981, DB06145, DB01321, DB13456, DB13409",
DB00647,Dextropropoxyphene,approved; illicit; investigational; withdrawn,CCC(=O)O[C@@](CC1=CC=CC=C1)([C@H](C)CN(C)C)C1=CC=CC=C1,C22H29NO2,,"Acids, Acyclic, Agents that reduce seizure threshold, Analgesics, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Diphenylpropylamine Derivatives, High-risk opioids, Narcotics, Nervous System, Opioid Agonist, Opioids, Peripheral Nervous System Agents, Propionates, Sensory System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"," Mu-type opioid receptor,  Delta-type opioid receptor,  Kappa-type opioid receptor,  Liver carboxylesterase 1,  NMDA receptor (Protein Group),  Cytochrome P450 2D6,  Cytochrome P450 3A4,  Cytochrome P450 3A Subfamily (Protein Group),  UDP-glucuronosyltransferase 2B4","DB00647, DB06793, DB01473, DB13160, DB01499, DB01552, DB01542, DB01478",
DB00648,Mitotane,approved,ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl,C14H10Cl4,,"Adrenal Cytotoxic Agents, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Antineoplastic and Immunomodulating Agents, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inducers (strong), Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strong), Cytochrome P-450 CYP3A5 Inducers, Cytochrome P-450 CYP3A5 Inducers (strong), Cytochrome P-450 CYP3A7 Inducers, Cytochrome P-450 CYP3A7 Inducers (strong), Cytochrome P-450 Enzyme Inducers, Hydrocarbons, Chlorinated, Hydrocarbons, Halogenated, Narrow Therapeutic Index Drugs, P-glycoprotein inhibitors, Thyroxine-binding globulin inducers"," Cytochrome P450 11B1, mitochondrial,  Estrogen receptor alpha,  Progesterone receptor,  Androgen receptor,  Adrenodoxin, mitochondrial,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  Thyroxine-binding globulin,  Sex hormone-binding globulin,  Corticosteroid-binding globulin,  P-glycoprotein 1","DB00648, DB12117, DB13424",
DB00649,Stavudine,approved; investigational,CC1=CN([C@@H]2O[C@H](CO)C=C2)C(=O)NC1=O,C10H12N2O4,,"Agents Causing Muscle Toxicity, Anti-HIV Agents, Anti-Infective Agents, Anti-Retroviral Agents, Antiinfectives for Systemic Use, Antimetabolites, Antiviral Agents, Antivirals for Systemic Use, Antivirals used in combination for the treatment of HIV infections, Deoxyribonucleosides, Dideoxynucleosides, Direct Acting Antivirals, Enzyme Inhibitors, Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor, Neurotoxic agents, Noxae, Nucleic Acid Synthesis Inhibitors, Nucleic Acids, Nucleotides, and Nucleosides, Nucleoside and Nucleotide Reverse Transcriptase Inhibitors, Nucleoside Reverse Transcriptase Inhibitors, Nucleosides, OAT1/SLC22A6 Substrates, Pyrimidine Nucleosides, Pyrimidines, Reverse Transcriptase Inhibitors, Toxic Actions"," Reverse transcriptase/RNaseH,  Serum albumin,  Solute carrier family 22 member 6,  Sodium/nucleoside cotransporter 1","DB00649, DB12074, DB04672, DB02569, DB02887",
DB00650,Leucovorin,approved,[H]C(=O)N1C(CNC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNC2=C1C(=O)NC(N)=N2,C20H23N7O7,,"Antidotes, Coenzymes, Compounds used in a research, industrial, or household setting, Detoxifying Agents for Antineoplastic Treatment, Enzymes and Coenzymes, Folate Analog, Folic Acid and Derivatives, Formyltetrahydrofolates, Heterocyclic Compounds, Fused-Ring, Micronutrients, OAT3/SLC22A8 Inhibitors, OAT3/SLC22A8 Substrates, Protective Agents, Pteridines, Pterins, Tetrahydrofolates, Vitamin B Complex, Vitamins", Solute carrier family 22 member 8,"DB00650, DB03256, DB11596, DB04789, DB11256, DB02067, DB00116, DB02031, DB12676, DB17113, DB02800, DB02301, DB02358",
DB00651,Dyphylline,approved,CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O,C10H14N4O4,,"Anti-Asthmatic Agents, Autonomic Agents, Bronchodilator Agents, Cardiovascular Agents, Drugs for Obstructive Airway Diseases, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Heterocyclic Compounds, Fused-Ring, Peripheral Nervous System Agents, Phosphodiesterase Inhibitors, Purines, Purinones, Respiratory System Agents, Vasodilating Agents, Xanthine derivatives, Xanthines and Adrenergics"," cAMP-specific 3',5'-cyclic phosphodiesterase 4B,  cAMP-specific 3',5'-cyclic phosphodiesterase 4A,  cAMP-specific 3',5'-cyclic phosphodiesterase 4C,  cAMP-specific 3',5'-cyclic phosphodiesterase 4D,  Adenosine receptor A1,  Adenosine receptor A2a","DB00651, DB13449, DB09092, DB13573, DB09273, DB18002, DB13592, DB00201, DB06479, DB13634, DB01412, DB12406, DB15122, DB13636, DB13842, DB13812, DB00806, DB02290, DB03022, DB03812, DB03973, DB02135, DB02711, DB01223, DB07954",
DB00652,Pentazocine,approved; vet_approved,CC1C2CC3=C(C=C(O)C=C3)C1(C)CCN2CC=C(C)C,C19H27NO,,"Adjuvants, Anesthesia, Agents that reduce seizure threshold, Alkaloids, Analgesics, Benzomorphan Derivatives, Benzomorphans, Central Nervous System Agents, Central Nervous System Depressants, Heterocyclic Compounds, Fused-Ring, Mixed Agonist / Antagonist Opioids, Morphinans, Narcotics, Nervous System, Opiate Alkaloids, Opiate Partial Agonists, Opioid Antagonists, Opioids, P-glycoprotein substrates, Partial Opioid Agonist/Antagonist, Peripheral Nervous System Agents, Phenanthrenes, Sensory System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"," Sigma non-opioid intracellular receptor 1,  Mu-type opioid receptor,  Kappa-type opioid receptor,  P-glycoprotein 1","DB00652, DB00504, DB13606, DB00854, DB14682, DB00514, DB13810, DB00611",
DB00653,Magnesium sulfate,approved; investigational; vet_approved,[Mg++].[O-]S([O-])(=O)=O,MgO4S,,"Agents causing hyperkalemia, Agents that produce neuromuscular block (indirect), Alimentary Tract and Metabolism, Analgesics, Anesthetics, Antiarrhythmic agents, Anticonvulsants, Blood and Blood Forming Organs, Blood Substitutes and Perfusion Solutions, Bradycardia-Causing Agents, Calcium Channel Blockers, Calcium-Regulating Hormones and Agents, Cardiovascular Agents, Central Nervous System Agents, Central Nervous System Depressants, Dermatologicals, Diagnostic Agents, Drugs for Constipation, Electrolyte Solutions, I.V. Solution Additives, Laxatives, Laxatives, magnesium containing, Magnesium Compounds, Magnesium Salts, Membrane Transport Modulators, Metal cations, Metal divalent cations, Mineral Supplements, Miscellaneous Anticonvulsants, Osmotic Laxatives, Peripheral Nervous System Agents, Replacement Preparations, Reproductive Control Agents, Sensory System Agents, Sulfates, Sulfur Acids, Sulfur Compounds, Sulfuric Acids, Tests for Bile Duct Patency, Tocolytic Agents, Vasodilating Agents", Voltage-dependent L-type calcium channel (Protein Group),"DB00653, DB08938, DB11309, DB14546, DB06778, DB09322, DB09472, DB11150, DB11171, DB11239, DB13257, DB14180, DB14499, DB14530, DB15533, DB15760, DB09087, DB14015",
DB00654,Latanoprost,approved; investigational,CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1,C26H40O5,,"Antiglaucoma Preparations and Miotics, Antihypertensive Agents, Autacoids, Biological Factors, Compounds used in a research, industrial, or household setting, Eicosanoids, Fatty Acids, Fatty Acids, Unsaturated, Lipids, OAT1/SLC22A6 inhibitors, OAT3/SLC22A8 Inhibitors, Ophthalmic Solutions, Ophthalmologicals, Pharmaceutical Preparations, Pharmaceutical Solutions, Prostaglandin analogs reducing intraocular pressure (IOP), Prostaglandins, Prostaglandins F, Synthetic, Prostaglandins, Synthetic, Sensory Organs, Solutions"," Prostaglandin F2-alpha receptor,  Solute carrier organic anion transporter family member 2A1,  Solute carrier family 22 member 6,  Solute carrier family 22 member 8","DB00654, DB11660",
DB00655,Estrone,approved,[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,C18H22O2,,"17-Ketosteroids, Adrenal Cortex Hormones, BCRP/ABCG2 Inhibitors, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Substrates, Estradiol Congeners, Estranes, Estrenes, Estrogens, Fused-Ring Compounds, Genito Urinary System and Sex Hormones, Gonadal Hormones, Gonadal Steroid Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Ketosteroids, Natural and Semisynthetic Estrogens, Plain, OAT3/SLC22A8 Substrates, OATP1B1/SLCO1B1 Inhibitors, Organic Anion Transporting Polypeptide 2B1 Inhibitors, P-glycoprotein inducers, P-glycoprotein substrates, Sex Hormones and Modulators of the Genital System, Steroids, Thyroxine-binding globulin inducers"," Estrogen receptor alpha,  Estrogen receptor beta,  Androgen receptor,  Cytochrome P450 19A1,  Sex hormone-binding globulin,  Cytochrome P450 3A4,  Cytochrome P450 1B1,  Cytochrome P450 2B6,  Cytochrome P450 2C9,  Cytochrome P450 2E1,  Cytochrome P450 3A5,  Cytochrome P450 1A2,  Cytochrome P450 1A1,  Serum albumin,  Solute carrier organic anion transporter family member 2B1,  P-glycoprotein 1,  Solute carrier organic anion transporter family member 1A2,  ATP-binding cassette sub-family G member 2,  Solute carrier organic anion transporter family member 1B1,  Solute carrier family 22 member 8","DB00655, DB00783, DB04573, DB07702, DB07706, DB04574, DB00977, DB12235, DB07707, DB13954, DB13386, DB15690, DB13956, DB02342",
DB00656,Trazodone,approved; investigational,ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1,C19H22ClN5O,,"Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Agents that produce hypertension, Agents that reduce seizure threshold, Anti-Anxiety Agents, Antidepressive Agents, Antidepressive Agents Indicated for Depression, Antidepressive Agents, Second-Generation, Antidepressive Agents, Triazolopyridine, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Histamine Antagonists, Histamine H1 Antagonists, Membrane Transport Modulators, Nervous System, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, P-glycoprotein inducers, Peripheral alpha-1 blockers, Piperazines, Potential QTc-Prolonging Agents, Psychoanaleptics, Psychotropic Drugs, Pyridines, Pyridones, QTc Prolonging Agents, Selective Serotonin Reuptake Inhibitors, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT1 Receptor Antagonists, Serotonin 5-HT1A Receptor Antagonists, Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2A Receptor Antagonists, Serotonin Agents, Serotonin antagonist and reuptake inhibitors (SARIs), Serotonin Modulators, Serotonin Receptor Antagonists, Tranquilizing Agents"," 5-hydroxytryptamine receptor 2A,  5-hydroxytryptamine receptor 2C,  Sodium-dependent serotonin transporter,  5-hydroxytryptamine receptor 1A,  Histamine H1 receptor,  Alpha-1A adrenergic receptor,  Alpha-2A adrenergic receptor,  5-hydroxytryptamine receptor 1C,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  Cytochrome P450 2D6,  P-glycoprotein 1",DB00656,
DB00657,Mecamylamine,approved; investigational,CNC1(C)C2CCC(C2)C1(C)C,C11H21N,,"Agents that produce neuromuscular block (indirect), Antiadrenergic Agents, Ganglion-Blocking, Anticholinergic Agents, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Autonomic Agents, Bridged-Ring Compounds, Cardiovascular Agents, Cholinergic Agents, Decreased Autonomic Ganglionic Activity, Drugs that are Mainly Renally Excreted, Ganglion Blockers, Hypotensive Agents, Neurotransmitter Agents, Nicotinic Antagonists, Norbornanes, Peripheral Nervous System Agents, Secondary and Tertiary Amines"," Neuronal acetylcholine receptor subunit alpha-2,  Neuronal acetylcholine receptor subunit alpha-7,  Neuronal acetylcholine receptor subunit alpha-4,  Neuronal acetylcholine receptor subunit beta-2","DB00657, DB11807, DB06714, DB08999, DB02409, DB01074",
DB00658,Sevelamer,approved,NCC=C.ClCC1CO1,C6H12ClNO,,"Amines, Bile Acid Sequestrants, Chelating Agents, Compounds used in a research, industrial, or household setting, Drugs for Treatment of Hyperkalemia and Hyperphosphatemia, Lipid Regulating Agents, Phosphate Binder, Phosphate Chelating Activity, Phosphate-removing Agents, Polyamines, Polystyrene Sulfonates, Sequestering Agents", Phosphate,DB00658,
DB00659,Acamprosate,approved; investigational,CC(=O)NCCCS(O)(=O)=O,C5H11NO4S,,"Alcohol Deterrents, Central Nervous System Agents, Drugs Used in Addictive Disorders, Drugs Used in Alcohol Dependence, Hydrocarbons, Acyclic, Miscellaneous Central Nervous System Agents, Nervous System, OAT1/SLC22A6 inhibitors, OAT3/SLC22A8 Substrates, Sulfonic Acids, Sulfur Acids, Sulfur Compounds"," Glutamate (NMDA) receptor (Protein Group),  Metabotropic glutamate receptor 5,  Gamma-aminobutyric acid type B receptor subunit 1,  Solute carrier family 22 member 6","DB00659, DB02618",
DB00660,Metaxalone,approved,CC1=CC(OCC2CNC(=O)O2)=CC(C)=C1,C12H15NO3,,"Central Nervous System Depressants, Centrally-mediated Muscle Relaxation, Drugs that are Mainly Renally Excreted, Muscle Relaxants, Muscle Relaxants, Centrally Acting Agents, Oxazoles, Peripheral Nervous System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome",,"DB00660, DB13754",
DB00661,Verapamil,approved,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1,C27H38N2O4,,"ACE Inhibitors and Calcium Channel Blockers, Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Amines, Antiarrhythmic agents, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Bradycardia-Causing Agents, Calcium Channel Blockers, Calcium Channel Blockers (Nondihydropyridine), Cardiovascular Agents, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C18 Substrates, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (weak), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (moderate), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Inhibitors, Cytochrome P-450 CYP3A5 Inhibitors (moderate), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Hypotensive Agents, MATE 1 Inhibitors, MATE 2 Inhibitors, MATE inhibitors, Membrane Transport Modulators, Miscellaneous Calcium-channel Blocking Agents, Negative Inotrope, OATP1B1/SLCO1B1 Inhibitors, OCT1 inhibitors, OCT1 substrates, P-glycoprotein inhibitors, P-glycoprotein substrates, Phenylalkylamine Derivatives, Selective Calcium Channel Blockers With Direct Cardiac Effects, Vasodilating Agents, Verapamil and analogues"," Voltage-dependent L-type calcium channel subunit alpha-1C,  Voltage-dependent N-type calcium channel subunit alpha-1B,  Voltage-dependent P/Q-type calcium channel subunit alpha-1A,  ATP-sensitive inward rectifier potassium channel 11,  Voltage-dependent T-type calcium channel subunit alpha-1G,  Voltage-dependent T-type calcium channel subunit alpha-1H,  Potassium voltage-gated channel subfamily H member 2,  Sodium-dependent serotonin transporter,  Alpha-1A adrenergic receptor, 10. Alpha-1B adrenergic receptor, 11. Alpha-1D adrenergic receptor, 12. Voltage-dependent calcium channel (Protein Group), 13. P-glycoprotein 1,  Cytochrome P450 3A4,  Cytochrome P450 1A2,  Cytochrome P450 2C8,  Cytochrome P450 2C9,  Cytochrome P450 2C18,  Cytochrome P450 3A5,  Cytochrome P450 2B6,  Cytochrome P450 2C19,  Cytochrome P450 2D6, 10. Cytochrome P450 2E1,  Serum albumin,  Alpha-1-acid glycoprotein 1,  P-glycoprotein 1,  Solute carrier family 22 member 1,  Solute carrier family 22 member 4,  Solute carrier family 22 member 5,  Canalicular multispecific organic anion transporter 2,  Solute carrier organic anion transporter family member 1B1,  Solute carrier organic anion transporter family member 1A2,  Multidrug resistance-associated protein 1,  Multidrug resistance-associated protein 4, 10. Multidrug resistance-associated protein 7, 11. Multidrug and toxin extrusion protein 1, 12. Multidrug and toxin extrusion protein 2","DB00661, DB14063, DB06669, DB12923, DB12605",
DB00662,Trimethobenzamide,approved; investigational,COC1=CC(=CC(OC)=C1OC)C(=O)NCC1=CC=C(OCCN(C)C)C=C1,C21H28N2O5,,"Acids, Carbocyclic, Amides, Aminoalkyl Ethers, Antiemetics, Antihistamines for Systemic Use, Autonomic Agents, Benzene Derivatives, Benzoates, Central Nervous System Agents, Central Nervous System Depressants, Emesis Suppression, Gastrointestinal Agents, Peripheral Nervous System Agents",,"DB00662, DB04924, DB08989",
DB00663,Flumethasone,approved; vet_approved,[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,C22H28F2O5,,"Adrenal Cortex Hormones, Anti-Inflammatory Agents, Corticosteroids, Corticosteroids, Dermatological Preparations, Corticosteroids, Moderately Potent (Group II), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Dermatologicals, Fused-Ring Compounds, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Immunosuppressive Agents, Otologicals, Pregnadienes, Pregnadienetriols, Pregnanes, Sensory Organs, Steroids, Steroids, Fluorinated"," Glucocorticoid receptor,  Cytochrome P450 3A4,  Corticosteroid-binding globulin","DB00223, DB00663, DB09095, DB12553, DB00596, DB01384, DB09378, DB00443, DB01234, DB11522, DB13491, DB00324, DB08971, DB13728, DB00620, DB08970, DB13223, DB00547, DB14664, DB11750, DB06781, DB13867, DB14637, DB14657, DB14640, DB14649, DB15777, DB15821, DB00687, DB14669",
DB00664,Sulfametopyrazine,approved; withdrawn,COC1=NC=CN=C1NS(=O)(=O)C1=CC=C(N)C=C1,C11H12N4O3S,,"Amides, Amines, Aniline Compounds, Anti-Infective Agents, Anti-Infective Agents, Urinary, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Antiparasitic Agents, Antiparasitic Products, Insecticides and Repellents, Antiprotozoals, Benzene Derivatives, Benzenesulfonamides, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Long-Acting Antibacterial Sulfonamides, Sulfanilamides, Sulfonamides, Sulfonamides and trimethoprim, Sulfones, Sulfur Compounds", Dihydropteroate synthetase,DB00664,
DB00665,Nilutamide,approved; investigational,CC1(C)NC(=O)N(C1=O)C1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F,C12H10F3N3O4,,"Androgen Receptor Antagonists, Androgen Receptor Inhibitors, Antiandrogens, Antiandrogens, non-steroidal, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (weak), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Endocrine Therapy, Hormone Antagonists, Hormone Antagonists and Related Agents, Hormones, Hormone Substitutes, and Hormone Antagonists, Imidazoles"," Androgen receptor,  Cytochrome P450 2C19,  NADPH--cytochrome P450 reductase",DB00665,
DB00666,Nafarelin,approved,CC(C)C[C@H](NC(=O)[C@@H](CC1=CC2=C(C=CC=C2)C=C1)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O,C66H83N17O13,,"Adrenal Cortex Hormones, Agents Causing Muscle Toxicity, Amino Acids, Peptides, and Proteins, Fertility Agents, Fertility Agents, Female, Gonadotropin Releasing Hormone Receptor Agonist, Gonadotropin Releasing Hormone Receptor Agonists, Gonadotropin-releasing hormone agonist, Gonadotropins and Antigonadotropins, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hypothalamic Hormones, Nerve Tissue Proteins, Neuropeptides, Oligopeptides, Peptide Hormones, Peptides, Pituitary and Hypothalamic Hormones and Analogues, Pituitary Hormone-Releasing Hormones, Proteins, Reproductive Control Agents, Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins"," Gonadotropin-releasing hormone receptor,  Putative gonadotropin-releasing hormone II receptor","DB00666, DB00007, DB06825, DB11510, DB18169, DB06719, DB00644, DB04931, DB06788, DB14027, DB05479, DB15314, DB15194, DB01284, DB13298, DB15687, DB00014, DB11724, DB13928, DB14803, DB15272, DB11700, DB17938, DB12199, DB16013, DB14786, DB06610, DB14777, DB11720, DB16146",
DB00668,Epinephrine,approved; vet_approved,CNC[C@H](O)C1=CC(O)=C(O)C=C1,C9H13NO3,,"Adrenergic Agents, Adrenergic Agonists, Adrenergic alpha-1 Receptor Agonists, Adrenergic alpha-2 Receptor Agonists, Adrenergic alpha-Agonists, Adrenergic and Dopaminergic Agents, Adrenergic beta-1 Receptor Agonists, Adrenergic beta-2 Receptor Agonists, Adrenergic beta-3 Receptor Agonists, Adrenergic beta-Agonists, Adrenergics, Inhalants, Agents producing tachycardia, Agents that produce hypertension, Alpha-and Beta-adrenergic Agonists, Amines, Anti-Asthmatic Agents, Antiglaucoma Preparations and Miotics, Autonomic Agents, Benzene Derivatives, Biogenic Amines, Biogenic Monoamines, Bronchodilator Agents, Cardiac Stimulants Excl. Cardiac Glycosides, Cardiac Therapy, Cardiovascular Agents, Catecholamines, Catechols, COMT Substrates, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Dental Agents, Drugs for Obstructive Airway Diseases, Epinephrine and similars, Hemostatics, Hyperglycemia-Associated Agents, Local Hemostatics, Mydriatics, Nasal Preparations, Neurotransmitter Agents, OCT1 substrates, OCT2 Inhibitors, OCT2 Substrates, Ophthalmologicals, Peripheral Nervous System Agents, Phenols, Respiratory System Agents, Stomatological Preparations, Sympathomimetic (Adrenergic) Agents, Sympathomimetics, Sympathomimetics in Glaucoma Therapy, Sympathomimetics, Plain, Vasoconstrictor Agents"," Alpha-1A adrenergic receptor,  Alpha-1B adrenergic receptor,  Beta-1 adrenergic receptor,  Beta-2 adrenergic receptor,  Alpha-2A adrenergic receptor,  Alpha-2B adrenergic receptor,  Alpha-1D adrenergic receptor,  Tumor necrosis factor,  Cytochrome P450 2C9,  Cytochrome P450 3A4,  Catechol O-methyltransferase,  Monoamine oxidase (Protein Group),  Solute carrier family 22 member 2,  Solute carrier family 22 member 1","DB00668, DB01064, DB00368, DB00388, DB08985, DB08957, DB13494, DB09203, DB13917, DB13378, DB01102, DB00816, DB00871, DB06707, DB00221, DB01288, DB00988, DB13206, DB11610, DB13251",
DB00669,Sumatriptan,approved; investigational,CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1,C14H21N3O2S,,"Agents that produce hypertension, Amides, Amines, Analgesics, Antidepressive Agents, Antimigraine Preparations, BCRP/ABCG2 Substrates, Biogenic Amines, Biogenic Monoamines, Cardiovascular Agents, Central Nervous System Depressants, Drugs that are Mainly Renally Excreted, Genito Urinary System and Sex Hormones, Heterocyclic Compounds, Fused-Ring, Indoles, Monoamine Oxidase A Substrates, Nervous System, Neurotransmitter Agents, OATP1B1/SLCO1B1 Substrates, P-glycoprotein substrates, Selective Serotonin 5-HT1 Receptor Agonists, Selective Serotonin Agonists, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 1b Receptor Agonists, Serotonin 1d Receptor Agonists, Serotonin 5-HT1 Receptor Agonists, Serotonin Agents, Serotonin Modulators, Serotonin Receptor Agonists, Serotonin-1b and Serotonin-1d Receptor Agonist, Sulfonamides, Sulfones, Sulfur Compounds, Triptans, Tryptamines, Vasoconstrictor Agents"," 5-hydroxytryptamine receptor 1A,  5-hydroxytryptamine receptor 1D,  5-hydroxytryptamine receptor 1B,  5-hydroxytryptamine receptor 1F,  Amine oxidase [flavin-containing] A,  Solute carrier organic anion transporter family member 1A2,  P-glycoprotein 1,  ATP-binding cassette sub-family G member 2,  Solute carrier organic anion transporter family member 1B1","DB00669, DB00918",
DB00670,Pirenzepine,approved,CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1,C19H21N5O2,,"Agents producing tachycardia, Alimentary Tract and Metabolism, Anti-Ulcer Agents, Anticholinergic Agents, Benzazepines, Benzodiazepinones, Cholinergic Agents, Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord), Gastrointestinal Agents, Heterocyclic Compounds, Fused-Ring, Muscarinic Antagonists, Neurotransmitter Agents", Muscarinic acetylcholine receptor M1,DB00670,
DB00671,Cefixime,approved; investigational,[H][C@]12SCC(C=C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OCC(O)=O)\C1=CSC(N)=N1)C(O)=O,C16H15N5O7S2,,"Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, beta Lactam Antibiotics, beta-Lactams, Cephalosporins, Heterocyclic Compounds, Fused-Ring, Lactams, Sulfur Compounds, Thiazines, Third-Generation Cephalosporins"," Penicillin-binding protein (Protein Group),  Penicillin-binding protein 2,  Solute carrier family 15 member 1,  Solute carrier family 15 member 2","DB00671, DB00535, DB13504, DB01416, DB00438, DB01413, DB01066, DB00493, DB01332, DB00267, DB11485, DB11505, DB14879, DB01212, DB13470, DB13682, DB13461, DB00229, DB04918, DB13667, DB01415, DB09050, DB14733, DB01112, DB05735, DB00430, DB13499, DB06590, DB01150, DB03530",
DB00672,Chlorpropamide,approved; investigational,CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1,C10H13ClN2O3S,,"Alimentary Tract and Metabolism, Amides, Benzene Derivatives, Benzenesulfonamides, Blood Glucose Lowering Agents, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Drugs Used in Diabetes, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Hypoglycemia-Associated Agents, Insulin Secretagogues, OAT1/SLC22A6 inhibitors, Oral Hypoglycemics, Sulfonamides, Sulfones, Sulfonylureas, Sulfur Compounds"," ATP-binding cassette sub-family C member 8,  Cytochrome P450 2C9,  Cytochrome P450 2C19,  Prostaglandin G/H synthase 1,  Solute carrier family 15 member 1,  Solute carrier family 15 member 2,  Solute carrier family 22 member 6","DB00672, DB13406, DB01124, DB08484",
DB00673,Aprepitant,approved; investigational,C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F,C23H21F7N4O3,,"Alimentary Tract and Metabolism, Antiemetics, Antiemetics and Antinauseants, Aprepitant and Prodrugs, Autonomic Agents, Central Nervous System Agents, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (weak), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C9 Inducers, Cytochrome P-450 CYP2C9 Inducers (strength unknown), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Inhibitors (weak), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (moderate), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Inhibitors, Cytochrome P-450 CYP3A5 Inhibitors (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Inhibitors, Cytochrome P-450 CYP3A7 Inhibitors (strength unknown), Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Gastrointestinal Agents, Morpholines, Neurokinin 1 Antagonists, Neurokinin-1 Receptor Antagonists, Neurotransmitter Agents, Oxazines, Peripheral Nervous System Agents, Substance P/Neurokinin-1 Receptor Antagonist"," Neurokinin 1 receptor,  Cytochrome P450 3A4,  Cytochrome P450 2C19,  Cytochrome P450 2C9","DB00673, DB06717",
DB00674,Galantamine,approved,[H][C@]12C[C@@H](O)C=C[C@]11CCN(C)CC3=C1C(O2)=C(OC)C=C3,C17H21NO3,,"Alkaloids, Amaryllidaceae Alkaloids, Anti-Dementia Drugs, Autonomic Agents, Benzazepines, Bradycardia-Causing Agents, Central Nervous System Agents, Cholinergic Agents, Cholinesterase Inhibitors, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Enzyme Inhibitors, Heterocyclic Compounds, Fused-Ring, Nervous System, Neurotransmitter Agents, Nootropic Agents, P-glycoprotein inhibitors, Parasympathomemetic (Cholinergic) Agents, Parasympathomimetics, Peripheral Nervous System Agents, Potential QTc-Prolonging Agents, Psychoanaleptics, QTc Prolonging Agents"," Acetylcholinesterase,  Neuronal acetylcholine receptor subunit alpha-7,  Muscle nicotinic acetylcholine receptor,  Cholinesterase,  Cytochrome P450 3A4,  Cytochrome P450 2D6,  P-glycoprotein 1","DB00674, DB02673, DB01568, DB01466, DB00318, DB01477, DB00295, DB09209, DB01573, DB01480, DB01497, DB11490, DB01452, DB01469, DB06230, DB15341",
DB00675,Tamoxifen,approved,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1,C26H29NO,,"Anti-Estrogens, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Substrates, Benzene Derivatives, Benzylidene Compounds, BSEP/ABCB11 Inhibitors, Cardiotoxic antineoplastic agents, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2A6 Substrates, Cytochrome P-450 CYP2A6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (moderate), Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (moderate), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Endocrine Therapy, Estrogen Agonist/Antagonist, Estrogen Antagonists, Estrogen Receptor Modulators, Hormone Antagonists, Hormone Antagonists and Related Agents, Hormones, Hormone Substitutes, and Hormone Antagonists, Narrow Therapeutic Index Drugs, P-glycoprotein inducers, P-glycoprotein inhibitors, P-glycoprotein substrates, P-glycoprotein substrates with a Narrow Therapeutic Index, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Selective Estrogen Receptor Modulators, Stilbenes, Thyroxine-binding globulin inducers, UGT2B17 substrates, UGT2B7 substrates, UGT2B7 Substrates with a Narrow Therapeutic Index"," Estrogen receptor alpha,  Estrogen receptor beta,  Protein kinase C (Protein Group),  Sex hormone-binding globulin,  3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase,  Androgen receptor,  Potassium voltage-gated channel subfamily H member 2,  Nuclear receptor subfamily 1 group I member 2,  Estrogen-related receptor gamma, 10. Mitogen-activated protein kinase 8,  Cytochrome P450 2D6,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  Cytochrome P450 2C9,  Cytochrome P450 2C19,  Cytochrome P450 2B6,  Cytochrome P450 1A1,  Cytochrome P450 1B1, 10. Dimethylaniline monooxygenase [N-oxide-forming] 1, 11. Dimethylaniline monooxygenase [N-oxide-forming] 3, 12. Cytochrome P450 2C8, 13. Liver carboxylesterase 1, 14. Cytochrome P450 19A1, 15. Cytochrome P450 2A6, 16. Cytochrome P450 2E1, 17. UDP-glucuronosyltransferase 1-10, 18. Sulfotransferase 1A1, 19. Bile salt sulfotransferase, 20. Cytochrome P450 1A2, 21. UDP-glucuronosyltransferase 2B7, 22. UDP-glucuronosyltransferase 2B17, 23. Estrogen sulfotransferase,  Serum albumin,  Thyroxine-binding globulin,  P-glycoprotein 1,  ATP-binding cassette sub-family G member 2,  Canalicular multispecific organic anion transporter 1,  Bile salt export pump,  ATP-binding cassette sub-family A member 1","DB00675, DB04468, DB00539, DB15641, DB04938, DB00882, DB06735, DB06640",
DB00676,Benzyl benzoate,approved,O=C(OCC1=CC=CC=C1)C1=CC=CC=C1,C14H12O2,,"Acaricides, Acids, Carbocyclic, Agrochemicals, Antiparasitic Products, Insecticides and Repellents, Benzene Derivatives, Compounds used in a research, industrial, or household setting, Ectoparasiticides, Incl. Scabicides, Ectoparasiticides, Incl. Scabicides, Insecticides and Repellents, Insecticides, Pesticides, Toxic Actions",,"DB00676, DB14176, DB01086, DB13628",
DB00677,Isoflurophate,approved; investigational; withdrawn,CC(C)OP(F)(=O)OC(C)C,C6H14FO3P,,"Cholinergic Agents, Cholinesterase Inhibitors, Enzyme Inhibitors, Neurotransmitter Agents, Ophthalmics, Organofluorophosphonates, Organophosphonates, Organophosphorus Compounds, Protease Inhibitors"," Acetylcholinesterase,  Cholinesterase,  Serotransferrin,  Cholinesterase,  Serum albumin",DB00677,
DB00678,Losartan,approved,CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1,C22H23ClN6O,,"Agents Acting on the Renin-Angiotensin System, Agents causing angioedema, Agents causing hyperkalemia, Angiotensin 2 Receptor Blocker, Angiotensin II receptor antagonists, Angiotensin II receptor blockers (ARBs) and calcium channel blockers, Angiotensin II receptor blockers (ARBs) and diuretics, Angiotensin II receptor blockers (ARBs), plain, Angiotensin II Type 1 Receptor Blockers, Angiotensin II Type 2 Receptor Blockers, Angiotensin Receptor Antagonists, Antiarrhythmic agents, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Benzene Derivatives, Biphenyl Compounds, BSEP/ABCB11 Substrates, Cardiovascular Agents, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (strength unknown), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs causing inadvertant photosensitivity, Hypotensive Agents, Imidazoles, OAT1/SLC22A6 inhibitors, P-glycoprotein inhibitors, P-glycoprotein substrates, Photosensitizing Agents, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Tetrazoles, UGT1A1 Substrates, UGT1A3 substrates, UGT2B17 substrates, UGT2B7 substrates"," Type-1 angiotensin II receptor,  Cytochrome P450 2C9,  Cytochrome P450 3A4,  Cytochrome P450 2C19,  UDP-glucuronosyltransferase 1-1,  UDP-glucuronosyltransferase 1-3,  UDP-glucuronosyltransferase 1-10,  UDP-glucuronosyltransferase 2B7,  UDP-glucuronosyltransferase 2B17,  Cytochrome P450 2C8,  Serum albumin,  P-glycoprotein 1,  Solute carrier family 22 member 6,  Solute carrier family 22 member 12,  Solute carrier family 2, facilitated glucose transporter member 9,  Bile salt export pump",DB00678,
DB00679,Thioridazine,approved; withdrawn,CSC1=CC2=C(SC3=CC=CC=C3N2CCC2CCCCN2C)C=C1,C21H26N2S2,,"Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Agents that produce hypertension, Antidepressive Agents, Antipsychotic Agents, Antipsychotic Agents (First Generation [Typical]), Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strong), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dopamine Agents, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Drugs causing inadvertant photosensitivity, Heterocyclic Compounds, Fused-Ring, Highest Risk QTc-Prolonging Agents, Hypotensive Agents, Nervous System, Neurotoxic agents, Neurotransmitter Agents, Phenothiazines, Phenothiazines With Piperidine Structure, Photosensitizing Agents, Psycholeptics, Psychotropic Drugs, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2A Receptor Antagonists, Serotonin Agents, Serotonin Receptor Antagonists, Sulfur Compounds, Tranquilizing Agents"," Dopamine D2 receptor,  Dopamine D1 receptor,  Alpha-1A adrenergic receptor,  Alpha-1B adrenergic receptor,  5-hydroxytryptamine receptor 2A,  Potassium voltage-gated channel subfamily H member 2,  Cytochrome P450 2E1,  Cytochrome P450 2D6,  Cytochrome P450 2C19","DB00679, DB00933, DB00372, DB13591, DB01071, DB00420, DB12710, DB00902, DB01246",
DB00680,Moricizine,approved; investigational; withdrawn,CCOC(=O)NC1=CC2=C(SC3=CC=CC=C3N2C(=O)CCN2CCOCC2)C=C1,C22H25N3O4S,,"Antiarrhythmic agents, Antiarrhythmics, Class I, Antiarrhythmics, Class Ic, Antipsychotic Agents, Cardiac Therapy, Cardiovascular Agents, Central Nervous System Depressants, Heterocyclic Compounds, Fused-Ring, Membrane Transport Modulators, Morpholines, Neurotoxic agents, Oxazines, Phenothiazines, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Sodium Channel Blockers, Sulfur Compounds, Voltage-Gated Sodium Channel Blockers", Sodium channel protein type 5 subunit alpha,"DB00680, DB13645",
DB00681,Amphotericin B,approved; investigational,[H][C@]12C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]1C(O)=O)O2,C47H73NO17,,"Agents Causing Muscle Toxicity, Agents that reduce seizure threshold, Alimentary Tract and Metabolism, Amebicides, Anti-Bacterial Agents, Anti-Infective Agents, Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents, Antifungal Agents, Antiinfectives and Antiseptics for Local Oral Treatment, Antiinfectives for Systemic Use, Antimycotics for Systemic Use, Antiparasitic Agents, Antiprotozoals, Biomimetic Materials, Carbohydrates, Compounds used in a research, industrial, or household setting, Drug Carriers, Genito Urinary System and Sex Hormones, Glycosides, Gynecological Antiinfectives and Antiseptics, Hypotensive Agents, Intestinal Antiinfectives, Lactones, Lipid-based Polyene Antifungal, Liposomes, Membranes, Artificial, Narrow Therapeutic Index Drugs, Nephrotoxic agents, Pharmaceutical Preparations, Polyene Antifungal, Polyenes, Polyketides, Stomatological Preparations", Ergosterol,"DB00681, DB00646, DB00826, DB01152, DB15981, DB06145, DB01321, DB13456, DB13409",
DB00682,Warfarin,approved,CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2,C19H16O4,,"4-Hydroxycoumarins, Agrochemicals, Anticoagulants, Blood and Blood Forming Organs, Compounds used in a research, industrial, or household setting, Coumarins, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C18 Substrates, Cytochrome P-450 CYP2C18 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (strength unknown), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C9 Inducers, Cytochrome P-450 CYP2C9 Inducers (weak), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (weak), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index, Hematologic Agents, Heterocyclic Compounds, Fused-Ring, Narrow Therapeutic Index Drugs, Pesticides, Pyrans, Rodenticides, Toxic Actions, Vitamin K Antagonists, Vitamin K Inhibitors"," Vitamin K epoxide reductase complex subunit 1,  Nuclear receptor subfamily 1 group I member 2,  Cytochrome P450 2C9,  Cytochrome P450 1A2,  Cytochrome P450 2C19,  Cytochrome P450 3A4,  Cytochrome P450 2C8,  Cytochrome P450 2C18,  Serum albumin,  Alpha-1-acid glycoprotein 1","DB00682, DB08496, DB14055, DB01418, DB00946, DB08735, DB08736, DB08663, DB08662, DB00266",
DB00683,Midazolam,approved; illicit,CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12,C18H13ClFN3,,"Adjuvants, Anesthesia, Anesthetics, Anti-Anxiety Agents, Benzodiazepine hypnotics and sedatives, Benzodiazepines and benzodiazepine derivatives, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, GABA Agents, GABA Modulators, Heterocyclic Compounds, Fused-Ring, Hypnotics and Sedatives, Nervous System, Neurotransmitter Agents, P-glycoprotein substrates, Psycholeptics, Psychotropic Drugs, Tranquilizing Agents, Triazolobenzodiazepines, UGT1A4 substrates, UGT2B7 substrates"," GABA(A) Receptor (Protein Group),  GABA(A) Receptor Benzodiazepine Binding Site (Protein Group),  Adenosine receptor A2a,  Cytochrome P450 3A4,  UDP-glucuronosyltransferase 1-4,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  UDP-glucuronosyltransferase 2B7,  UDP-glucuronosyltransferase 2B4,  Serum albumin,  Alpha-1-acid glycoprotein 1,  P-glycoprotein 1,  Excitatory amino acid transporter 2",DB00683,
DB00684,Tobramycin,approved; investigational,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O,C18H37N5O9,,"Agents that produce neuromuscular block (indirect), Aminoglycoside Antibacterials, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Carbohydrates, Drugs that are Mainly Renally Excreted, Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index, Glycosides, Narrow Therapeutic Index Drugs, Nebramycin, Nephrotoxic agents, Ophthalmologicals, Ototoxic agents, Sensory Organs"," 16S ribosomal RNA,  23S ribosomal RNA","DB00684, DB13270, DB13673, DB01172, DB00452, DB01421, DB04728, DB03615, DB15080, DB17631, DB04808, DB04729, DB17884, DB04263, DB16951, DB04717, DB00798, DB13274, DB03779, DB07341, DB04718, DB07378, DB07357, DB04626, DB11520, DB06696",
DB00685,Trovafloxacin,approved; investigational; withdrawn,[H][C@@]12CN(C[C@]1([H])[C@H]2N)C1=NC2=C(C=C1F)C(=O)C(=CN2C1=C(F)C=C(F)C=C1)C(O)=O,C20H15F3N4O3,,"Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (weak), Cytochrome P-450 Enzyme Inhibitors, Drugs causing inadvertant photosensitivity, Enzyme Inhibitors, Fluoroquinolones, Heterocyclic Compounds, Fused-Ring, Highest Risk QTc-Prolonging Agents, Photosensitizing Agents, QTc Prolonging Agents, Quinolines, Quinolones, Topoisomerase II Inhibitors, Topoisomerase Inhibitors"," DNA gyrase subunit A,  DNA topoisomerase 4 subunit A,  DNA topoisomerase 2-alpha,  Cytochrome P450 1A2","DB00685, DB16850, DB09335, DB01155, DB12479, DB00467, DB11999, DB11943",
DB00686,Pentosan polysulfate,approved,O[C@@H]1CO[C@@H](O[C@@H]2CO[C@@H](O)[C@H](OS(O)(=O)=O)[C@H]2OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O,C10H18O21S4,,"Anticoagulants, Antivaricose Therapy, Carbohydrates, Drugs causing inadvertant photosensitivity, Genito Urinary System and Sex Hormones, Glycosaminoglycans, Hematologic Agents, Miscellaneous Therapeutic Agents, Photosensitizing Agents, Polysaccharides, Sulfur Acids, Sulfur Compounds, Sulfuric Acids, Urologicals, Vasoprotectives"," Fibroblast growth factor 2,  Fibroblast growth factor 1,  Fibroblast growth factor 4","DB00686, DB01901, DB02879, DB06406, DB01981, DB02837, DB00364, DB01818, DB02894",
DB00687,Fludrocortisone,approved; investigational,[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C,C21H29FO5,,"11-Hydroxycorticosteroids, 17-Hydroxycorticosteroids, Adrenal Cortex Hormones, Adrenals, Anti-Inflammatory Agents, Corticosteroids, Corticosteroids for Systemic Use, Corticosteroids for Systemic Use, Plain, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Fused-Ring Compounds, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hydroxycorticosteroids, Hyperglycemia-Associated Agents, Immunosuppressive Agents, Mineralocorticoids, Pregnenes, Steroids, Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins"," Mineralocorticoid receptor,  Glucocorticoid receptor,  Cytochrome P450 3A4,  Corticosteroid 11-beta-dehydrogenase isozyme 2,  Corticosteroid 11-beta-dehydrogenase isozyme 1,  Serum albumin,  Corticosteroid-binding globulin","DB00687, DB01185, DB00443, DB01234, DB11522, DB13491, DB00324, DB00620, DB08970, DB00547, DB00223, DB00663, DB00741, DB13610, DB12553, DB09095, DB11750, DB04652, DB14640, DB14649, DB04630, DB01384, DB09378, DB09091, DB00253, DB00596, DB13728",
DB00688,Mycophenolate mofetil,approved; investigational,COC1=C(C\C=C(/C)CCC(=O)OCCN2CCOCC2)C(O)=C2C(=O)OCC2=C1C,C23H31NO7,,"Agents Causing Muscle Toxicity, Anti-Bacterial Agents, Anti-Infective Agents, Antibiotics, Antineoplastic, Antibiotics, Antitubercular, Antimetabolite Immunosuppressant, BCRP/ABCG2 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Fatty Acids, Immunologic Factors, Immunosuppressive Agents, IMP Dehydrogenase, antagonists & inhibitors, Lipids, Mycophenolic Acid and Prodrugs, OATP1B1/SLCO1B1 Substrates, OATP1B3 substrates, P-glycoprotein substrates, UGT1A1 Substrates, UGT1A6 substrate, UGT1A9 Substrates, UGT2B7 substrates"," Inosine-5'-monophosphate dehydrogenase 1,  Inosine-5'-monophosphate dehydrogenase 2,  6-pyruvoyl tetrahydrobiopterin synthase,  UDP-glucuronosyltransferase 1-7,  UDP-glucuronosyltransferase 1-6,  UDP-glucuronosyltransferase 1-9,  UDP-glucuronosyltransferase 2B7,  UDP-glucuronosyltransferase 1-8,  UDP-glucuronosyltransferase 1-10,  Liver carboxylesterase 1,  Cytochrome P450 3A4,  Cytochrome P450 3A5, 10. Cytochrome P450 2C8, 11. Carboxylic ester hydrolase, 12. UDP-glucuronosyltransferase 1-1,  Solute carrier organic anion transporter family member 1B1,  Solute carrier organic anion transporter family member 1B3,  ATP-binding cassette sub-family G member 2,  P-glycoprotein 1,  Canalicular multispecific organic anion transporter 1","DB00688, DB01024",
DB00689,Cephaloglycin,approved,[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O,C18H19N3O6S,,"Amides, Anti-Bacterial Agents, Anti-Infective Agents, beta-Lactams, Cephalosporins, Heterocyclic Compounds, Fused-Ring, Lactams, Nephrotoxic agents, Sulfur Compounds, Thiazines"," Penicillin-binding protein 1B,  Solute carrier family 22 member 5","DB00689, DB00567, DB01414, DB00456, DB01140, DB03313, DB01139, DB01150, DB00833, DB13461, DB01112, DB01326, DB03938, DB00493, DB01331, DB01333, DB00923, DB13266, DB01416, DB14725, DB11592, DB01329, DB01328, DB09008, DB00535, DB11505, DB11385, DB01415, DB13504, DB00229",
DB00690,Flurazepam,approved; illicit; investigational,CCN(CC)CCN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F,C21H23ClFN3O,,"Anti-Anxiety Agents, Benzazepines, Benzodiazepines and benzodiazepine derivatives, Benzodiazepinones, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2A6 Substrates, Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, GABA Agents, GABA Modulators, Heterocyclic Compounds, Fused-Ring, Hypnotics and Sedatives, Nervous System, Neurotransmitter Agents, OCT2 Inhibitors, P-glycoprotein inhibitors, Psycholeptics, Psychotropic Drugs, Tranquilizing Agents"," GABA(A) Receptor (Protein Group),  GABA(A) Receptor Benzodiazepine Binding Site (Protein Group),  Cytochrome P450 3A4,  Cytochrome P450 2E1,  Cytochrome P450 2A6,  P-glycoprotein 1,  Solute carrier family 22 member 2","DB00690, DB01567, DB13837, DB00829, DB13335, DB01594, DB00801, DB01588, DB01545, DB14028, DB00231, DB00628, DB01589, DB00842, DB01544, DB01511, DB13872, DB13437",
DB00691,Moexipril,approved,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC(OC)=C(OC)C=C2C[C@H]1C(O)=O,C27H34N2O7,,"ACE Inhibitors and Diuretics, Agents Acting on the Renin-Angiotensin System, Agents causing angioedema, Agents causing hyperkalemia, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Cardiovascular Agents, Drugs causing inadvertant photosensitivity, Enzyme Inhibitors, Heterocyclic Compounds, Fused-Ring, Hypotensive Agents, Isoquinolines, Photosensitizing Agents, Potential QTc-Prolonging Agents, Protease Inhibitors, QTc Prolonging Agents"," Angiotensin-converting enzyme,  Solute carrier family 15 member 1,  Solute carrier family 15 member 2","DB00691, DB14210, DB00881, DB14217",
DB00692,Phentolamine,approved,CC1=CC=C(C=C1)N(CC1=NCCN1)C1=CC(O)=CC=C1,C17H19N3O,,"Adrenergic Agents, Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Agents that produce hypertension, Antidotes, Antihypertensive Agents, Cardiovascular Agents, Drugs that are Mainly Renally Excreted, Hypotensive Agents, Imidazoles, Imidazoline Derivatives, Neurotransmitter Agents, Non-selective Alfa-adrenergic Blocking Agents, Peripheral alpha-1 blockers, Peripheral Vasodilators, Sympatholytic (Adrenergic Blocking) Agents, Vasodilating Agents"," Alpha-1 adrenergic receptors (Protein Group),  Alpha-2 adrenergic receptors (Protein Group),  ATP-sensitive inward rectifier potassium channel 11",DB00692,
DB00693,Fluorescein,approved,OC1=CC=C2C(OC3=CC(O)=CC=C3C22OC(=O)C3=C2C=CC=C3)=C1,C20H12O5,,"BSEP/ABCB11 Substrates, Coloring Agents, Colouring Agents, Compounds used in a research, industrial, or household setting, Contrast Media, Diagnostic Agents, Diagnostic Dye, Diagnostic Uses of Chemicals, Fluoresceins, Fluorescent Dyes, Heterocyclic Compounds, Fused-Ring, Indicators and Reagents, Laboratory Chemicals, Luminescent Agents, OAT1/SLC22A6 inhibitors, OAT1/SLC22A6 Substrates, OAT3/SLC22A8 Substrates, Ocular Disorders, Ophthalmologicals, Other Diagnostics, Sensory Organs, Spiro Compounds, Xanthenes"," Ig kappa chain V-II region RPMI 6410,  DNA,  Solute carrier family 22 member 6,  Bile salt export pump,  Multidrug resistance-associated protein 1","DB00693, DB11184, DB07764",
DB00694,Daunorubicin,approved,COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=O,C27H29NO10,,"Anthracycline Topoisomerase Inhibitor, Anthracyclines, Anthracyclines and Related Substances, Antibiotics, Antineoplastic, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Substrates, BSEP/ABCB11 Substrates, BSEP/ABCB11 Substrates with a Narrow Therapeutic Index, Cardiotoxic antineoplastic agents, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Inducers, Cytochrome P-450 CYP3A5 Inducers (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Cytotoxic Antibiotics and Related Substances, Enzyme Inhibitors, Glycosides, Immunosuppressive Agents, Myelosuppressive Agents, Naphthacenes, Narrow Therapeutic Index Drugs, P-glycoprotein inducers, P-glycoprotein inhibitors, P-glycoprotein substrates, P-glycoprotein substrates with a Narrow Therapeutic Index, Topoisomerase II Inhibitors, Topoisomerase Inhibitors"," DNA,  DNA topoisomerase 2-alpha,  DNA topoisomerase 2-beta,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  NADPH--cytochrome P450 reductase,  Cytochrome P450 1B1,  Aldose reductase,  Carbonyl reductase [NADPH] 1,  Carbonyl reductase [NADPH] 3,  P-glycoprotein 1,  Multidrug resistance-associated protein 1,  Multidrug resistance-associated protein 7,  ATP-binding cassette sub-family G member 2,  Multidrug resistance-associated protein 6","DB00445, DB00694, DB00997, DB11616, DB17149, DB01177, DB12410, DB05706, DB13103, DB00385, DB06420, DB04131, DB01806, DB06263, DB03219, DB11618, DB03199, DB06013, DB11617, DB12755, DB17273",
DB00695,Furosemide,approved; vet_approved,NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O,C12H11ClN2O5S,,"Acids, Carbocyclic, Amides, Amines, Aminobenzoates, Aniline Compounds, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Benzene Derivatives, Benzoates, Cardiovascular Agents, Diuretics, Drugs causing inadvertant photosensitivity, Drugs that are Mainly Renally Excreted, High-Ceiling Diuretics, High-Ceiling Diuretics and Potassium-Sparing Agents, Hyperglycemia-Associated Agents, Hypotensive Agents, Increased Diuresis at Loop of Henle, Membrane Transport Modulators, Natriuretic Agents, Nephrotoxic agents, Non Potassium Sparing Diuretics, OAT1/SLC22A6 inhibitors, OAT3/SLC22A8 Inhibitors, Ototoxic agents, Photosensitizing Agents, Sodium Potassium Chloride Symporter Inhibitors, Sulfanilamides, Sulfonamides, Sulfones, Sulfur Compounds, Thyroxine-binding globulin substrates, UGT1A1 Substrates"," Solute carrier family 12 member 1,  Carbonic anhydrase 2,  G-protein coupled receptor 35,  6-phosphogluconate dehydrogenase, decarboxylating,  UDP-glucuronosyltransferase 1-1,  Serum albumin,  Thyroxine-binding globulin,  Solute carrier family 22 member 6,  Solute carrier family 22 member 5,  Solute carrier family 22 member 8,  Canalicular multispecific organic anion transporter 1,  Solute carrier organic anion transporter family member 2A1,  Solute carrier family 22 member 11",DB00695,
DB00696,Ergotamine,approved,[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O,C33H35N5O5,,"Adrenergic Agents, Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Agents that produce hypertension, Alkaloids, Analgesics, Analgesics, Non-Narcotic, Antidepressive Agents, Antimigraine Preparations, Cardiovascular Agents, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Inhibitors (strong), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Ergot Alkaloids and Derivatives, Ergotamine Derivative, Ergotamines, Heterocyclic Compounds, Fused-Ring, Narrow Therapeutic Index Drugs, Nervous System, Neurotransmitter Agents, P-glycoprotein inhibitors, Peripheral Nervous System Agents, Reproductive Control Agents, Sensory System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT1 Receptor Agonists, Serotonin 5-HT2 Receptor Agonists, Serotonin Agents, Serotonin Modulators, Serotonin Receptor Agonists, Sympatholytic (Adrenergic Blocking) Agents, Uterotonic agents, Vasoconstrictor Agents"," 5-hydroxytryptamine receptor 1D,  5-hydroxytryptamine receptor 1B,  5-hydroxytryptamine receptor 2A,  Alpha-1A adrenergic receptor,  Alpha-1B adrenergic receptor,  Alpha-1D adrenergic receptor,  Dopamine D2 receptor,  Alpha-2A adrenergic receptor,  D(1) dopamine receptor (Protein Group), 10. 5-hydroxytryptamine receptor 1A, 11. 5-hydroxytryptamine receptor 1F, 12. 5-hydroxytryptamine receptor 2C, 13. 5-hydroxytryptamine receptor 2B, 14. Alpha-2C adrenergic receptor,  Cytochrome P450 3A4,  P-glycoprotein 1","DB00696, DB01200, DB00320, DB13345, DB11273, DB11274, DB11275, DB00200, DB05735, DB04911, DB11191, DB02868, DB12586, DB03614, DB12674, DB00361, DB04431, DB05168, DB17390, DB00541, DB12755, DB11641, DB04111, DB00570, DB12076, DB06402, DB11467, DB02975, DB02792, DB00309",
DB00697,Tizanidine,approved; investigational,ClC1=C(NC2=NCCN2)C2=NSN=C2C=C1,C9H8ClN5S,,"Adrenergic Agents, Adrenergic Agonists, Adrenergic alpha-2 Receptor Agonists, Adrenergic alpha-Agonists, Agents producing tachycardia, Analgesics, Anticonvulsants, Autonomic Agents, Bradycardia-Causing Agents, Central alpha-2 Adrenergic Agonist, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Substrates, Hypotensive Agents, Imidazoles, Imidazolines, Muscle Relaxants, Muscle Relaxants, Centrally Acting Agents, Musculo-Skeletal System, Narrow Therapeutic Index Drugs, Neuromuscular Agents, Neurotransmitter Agents, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Sensory System Agents"," Nischarin,  Alpha-1 adrenergic receptors (Protein Group),  Alpha-2 adrenergic receptors (Protein Group),  Cytochrome P450 1A2",DB00697,
DB00698,Nitrofurantoin,approved; vet_approved,[O-][N+](=O)C1=CC=C(O1)\C=N\N1CC(=O)NC1=O,C8H6N4O5,,"Agents causing hyperkalemia, Anti-Bacterial Agents, Anti-Infective Agents, Anti-Infective Agents, Urinary, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, BCRP/ABCG2 Substrates, BSEP/ABCB11 Substrates, Drugs that are Mainly Renally Excreted, Furans, Methemoglobinemia Associated Agents, Nitro Compounds, Nitrofuran Antibacterial, Nitrofuran Derivatives, Nitrofurans, P-glycoprotein substrates, Renal Agents, Thyroxine-binding globulin substrates"," Probable pyruvate-flavodoxin oxidoreductase,  Oxygen-insensitive NADPH nitroreductase,  30S ribosomal protein S10,  NADPH--cytochrome P450 reductase,  ATP-binding cassette sub-family G member 2,  Bile salt export pump,  P-glycoprotein 1,  Canalicular multispecific organic anion transporter 1","DB00698, DB13730, DB00336",
DB00699,Nicergoline,approved; investigational,[H][C@@]12CC3=CN(C)C4=CC=CC(=C34)[C@]1(C[C@@H](COC(=O)C1=CN=CC(Br)=C1)CN2C)OC,C24H26BrN3O3,,"Adrenergic Agents, Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Agents that produce hypertension, Alkaloids, Cardiovascular Agents, Central Nervous System Agents, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 Substrates, Ergolines, Ergot Alkaloids and Derivatives, Heterocyclic Compounds, Fused-Ring, Neurotransmitter Agents, Nootropic Agents, Peripheral Vasodilators, Vasodilating Agents"," Alpha-1A adrenergic receptor,  Cytochrome P450 2D6",DB00699,
DB00700,Eplerenone,approved,[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)C[C@H]1O[C@@]11[C@@]2([H])[C@@H](CC2=CC(=O)CC[C@]12C)C(=O)OC,C24H30O6,,"Agents causing hyperkalemia, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Cardiovascular Agents, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Substrates, Diuretics, Fused-Ring Compounds, Hormone Antagonists, Hormones, Hormone Substitutes, and Hormone Antagonists, Hypotensive Agents, Lactones, Mineralocorticoid (Aldosterone) Receptor Antagonists, Mineralocorticoid Receptor Antagonists, Natriuretic Agents, Potassium-Sparing Diuretics, Pregnanes, Pregnenes, Steroids"," Mineralocorticoid receptor,  Cytochrome P450 11B2, mitochondrial,  Cytochrome P450 3A4,  Cytochrome P450 3A5","DB00700, DB08547, DB14544, DB14543, DB14540, DB14538, DB14545, DB14541, DB02329, DB08308, DB08619, DB01395, DB04376, DB06789, DB14677, DB08804, DB13943, DB13944, DB13946, DB16001, DB16002, DB16141, DB14539, DB17045, DB13185, DB01420, DB13640",
DB00701,Amprenavir,approved; investigational,CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1,C25H35N3O6S,,"Acids, Acyclic, Amides, Amprenavir and Prodrugs, Anti-HIV Agents, Anti-Infective Agents, Anti-Retroviral Agents, Antibiotics, Antitubercular, Antiinfectives for Systemic Use, Antiviral Agents, Antivirals for Systemic Use, Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (weak), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Inhibitors (strong), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Direct Acting Antivirals, Drugs for Treatment of Tuberculosis, Enzyme Inhibitors, HIV Protease Inhibitors, OATP1B1/SLCO1B1 Inhibitors, P-glycoprotein inducers, P-glycoprotein substrates, Protease Inhibitors, Sulfones, Sulfur Compounds, Viral Protease Inhibitors"," Human immunodeficiency virus type 1 protease,  Cytochrome P450 2B6,  Cytochrome P450 2C19,  Cytochrome P450 2C9,  Cytochrome P450 2D6,  Cytochrome P450 3A5,  Cytochrome P450 3A4,  P-glycoprotein 1,  Multidrug resistance-associated protein 1,  Solute carrier organic anion transporter family member 1B1","DB00701, DB01264, DB01319, DB08223, DB05961, DB04887",
DB00702,Icodextrin,approved; investigational,,,,"Biopolymers, Carbohydrates, Compounds used in a research, industrial, or household setting, Dialysis Solutions, Glucans, Macromolecular Substances, Pharmaceutical Preparations, Pharmaceutical Solutions, Polymers, Polysaccharides, Solutions", Pancreatic alpha-amylase,,
DB00703,Methazolamide,approved,CN1N=C(S\C1=N\C(C)=O)S(N)(=O)=O,C5H8N4O3S2,,"Antiglaucoma Preparations and Miotics, Carbonic Anhydrase Inhibitors, Cardiovascular Agents, Diuretics, Drugs causing inadvertant photosensitivity, Enzyme Inhibitors, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Hypotensive Agents, Natriuretic Agents, OAT1/SLC22A6 inhibitors, Ophthalmologicals, Photosensitizing Agents, Sensory Organs, Sulfonamides, Sulfur Compounds, Thiadiazoles, Thiazoles"," Carbonic anhydrase 1,  Carbonic anhydrase 4,  Carbonic anhydrase 2,  Carbonic anhydrase 7,  Carbonic anhydrase 3,  Solute carrier family 22 member 6",DB00703,
DB00704,Naltrexone,approved; investigational; vet_approved,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]1(O)CCC2=O,C20H23NO4,,"Agents Causing Muscle Toxicity, Alcohol Deterrents, Alimentary Tract and Metabolism, Alkaloids, Analgesics, Antiobesity Preparations, Excl. Diet Products, Central Nervous System Agents, Centrally Acting Antiobesity Products, Drugs Used in Addictive Disorders, Drugs Used in Alcohol Dependence, Hepatotoxic Agents, Heterocyclic Compounds, Fused-Ring, Morphinans, Natural Opium Alkaloids, Nervous System, Opiate Alkaloids, Opiate Antagonists, Opioid Antagonists, Opioids, Peripheral Nervous System Agents, Phenanthrenes, Sensory System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, UGT1A1 Substrates"," Mu-type opioid receptor,  Kappa-type opioid receptor,  Delta-type opioid receptor,  Sigma non-opioid intracellular receptor 1,  UDP-glucuronosyltransferase 1-1","DB00704, DB01192, DB06800, DB00497, DB01183, DB04509, DB00327, DB00956, DB06230, DB01512, DB00844, DB14146, DB15341, DB01565, DB09049, DB01551, DB01531, DB00921, DB01450, DB01548, DB16117, DB16072, DB13471, DB01538, DB01480, DB01497, DB00295, DB01469, DB00318, DB01477",
DB00705,Delavirdine,approved,CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2,C22H28N6O3S,,"Anti-HIV Agents, Anti-Infective Agents, Anti-Retroviral Agents, Antiinfectives for Systemic Use, Antiviral Agents, Antivirals for Systemic Use, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (strong), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strong), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strong), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Inhibitors, Cytochrome P-450 CYP3A5 Inhibitors (strength unknown), Cytochrome P-450 CYP3A7 Inhibitors, Cytochrome P-450 CYP3A7 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Direct Acting Antivirals, Enzyme Inhibitors, Heterocyclic Compounds, Fused-Ring, Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor, Indoles, Non-Nucleoside Reverse Transcriptase Inhibitors, Nonnucleoside Reverse Transcriptase Inhibitors, Nucleic Acid Synthesis Inhibitors, Piperazines, Reverse Transcriptase Inhibitors"," Reverse transcriptase/RNaseH,  Cytochrome P450 3A4,  Cytochrome P450 2D6,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  Cytochrome P450 2C9,  Cytochrome P450 2C19","DB00705, DB12264",
DB00706,Tamsulosin,approved; investigational,CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC(=C(OC)C=C1)S(N)(=O)=O,C20H28N2O5S,,"Adrenergic Agents, Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Amides, Benzene Derivatives, Benzenesulfonamides, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Drugs Used in Benign Prostatic Hypertrophy, Genito Urinary System and Sex Hormones, Genitourinary Agents, Gynecological Antiinfectives and Antiseptics, Hypotensive Agents, Neurotransmitter Agents, Peripheral alpha-1 blockers, Selective Alfa-1-adrenergic Blocking Agents, Sulfonamides, Sulfones, Sulfur Compounds, Urological Agents, Urologicals"," Alpha-1A adrenergic receptor,  Alpha-1D adrenergic receptor,  Alpha-1B adrenergic receptor,  Cytochrome P450 2D6,  Cytochrome P450 3A4,  Alpha-1-acid glycoprotein 1",DB00706,
DB00707,Porfimer sodium,approved; investigational,,,,"Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Biological Factors, Dermatologicals, Hematoporphyrin Derivative, Hematoporphyrins, Heterocyclic Compounds, Fused-Ring, Photoabsorption, Photoactivated Radical Generator, Photosensitizing Activity, Photosensitizing Agents, Photosensitizing Agents for Phototherapy, Pigments, Biological, Porphyrins, Radiation-Sensitizing Agents, Sensitizers Used in Photodynamic/radiation Therapy"," Low-density lipoprotein receptor,  High affinity immunoglobulin gamma Fc receptor I",,
DB00708,Sufentanil,approved; investigational,CCC(=O)N(C1=CC=CC=C1)C1(COC)CCN(CCC2=CC=CS2)CC1,C22H30N2O2S,,"Adjuvants, Anesthesia, Agents that produce hypertension, Analgesics, Anesthetics, Anesthetics, General, Anesthetics, Intravenous, Bradycardia-Causing Agents, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Fentanyl and fentanyl analogues, High-risk opioids, Hypotensive Agents, Narcotics, Nervous System, Neuraxial Anesthetics, Opiate Agonists, Opioid Agonist, Opioid Anesthetics, Opioids, Opioids, Anilidopiperidine, Peripheral Nervous System Agents, Phenylpiperidine opioids, Piperidines, Sensory System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"," Mu-type opioid receptor,  Delta-type opioid receptor,  Kappa-type opioid receptor,  Cytochrome P450 3A4","DB00708, DB09180, DB09179, DB01439, DB09170, DB01470, DB01535, DB15360, DB09174",
DB00709,Lamivudine,approved; investigational,NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1,C8H11N3O3S,,"Agents Causing Muscle Toxicity, Anti-HIV Agents, Anti-Infective Agents, Anti-Retroviral Agents, Antiinfectives for Systemic Use, Antiviral Agents, Antivirals for Systemic Use, Antivirals used in combination for the treatment of HIV infections, BCRP/ABCG2 Substrates, Deoxycytidine, Deoxyribonucleosides, Dideoxynucleosides, Direct Acting Antivirals, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor, Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor, Nucleic Acid Synthesis Inhibitors, Nucleic Acids, Nucleotides, and Nucleosides, Nucleoside and Nucleotide Reverse Transcriptase Inhibitors, Nucleoside Reverse Transcriptase Inhibitors, Nucleosides, OAT1/SLC22A6 Substrates, OCT1 substrates, OCT2 Substrates, P-glycoprotein substrates, Pyrimidine Nucleosides, Pyrimidines, Reverse Transcriptase Inhibitors"," Reverse transcriptase/RNaseH,  DNA,  Protein P,  Deoxycytidine kinase,  UMP-CMP kinase,  Phosphoglycerate kinase 1,  Nucleoside diphosphate kinase A,  Nucleoside diphosphate kinase B,  Choline-phosphate cytidylyltransferase A,  Ethanolamine-phosphate cytidylyltransferase,  5'(3')-deoxyribonucleotidase, cytosolic type,  Serum albumin,  Multidrug resistance-associated protein 1,  Solute carrier family 22 member 6,  ATP-binding cassette sub-family G member 2,  Solute carrier family 22 member 1,  Solute carrier family 22 member 2,  Solute carrier family 22 member 3,  P-glycoprotein 1,  Multidrug resistance-associated protein 4,  Canalicular multispecific organic anion transporter 2, 10. Canalicular multispecific organic anion transporter 1",DB00709,
DB00710,Ibandronate,approved; investigational,CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O,C9H23NO7P2,,"Agents Causing Muscle Toxicity, Bisphosphonates, Bone Density Conservation Agents, Drugs Affecting Bone Structure and Mineralization, Drugs for Treatment of Bone Diseases, Musculo-Skeletal System, Organophosphonates, Organophosphorus Compounds, Potential QTc-Prolonging Agents, QTc Prolonging Agents"," Hydroxylapatite,  Geranylgeranyl pyrophosphate synthase,  Farnesyl pyrophosphate synthase",DB00710,
DB00711,Diethylcarbamazine,approved; investigational; vet_approved,CCN(CC)C(=O)N1CCN(C)CC1,C10H21N3O,,"Acids, Acyclic, Anthelmintics, Anti-Infective Agents, Antihelminthic, Antinematodal Agents, Antiparasitic Agents, Antiparasitic Products, Insecticides and Repellents, Carbamates, Cholinesterase Inhibitors, Enzyme Inhibitors, Filaricides, Lipoxygenase Inhibitors, Piperazine and Derivatives, Piperazines"," Arachidonate 5-lipoxygenase,  Prostaglandin G/H synthase 1,  Cholinesterase",DB00711,
DB00712,Flurbiprofen,approved; investigational,CC(C(O)=O)C1=CC(F)=C(C=C1)C1=CC=CC=C1,C15H13FO2,,"Acids, Acyclic, Agents causing hyperkalemia, Agents that produce hypertension, Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Antiinflammatory and Antirheumatic Products, Antiinflammatory and Antirheumatic Products, Non-Steroids, Antiinflammatory Preparations, Non-Steroids for Topical Use, Antirheumatic Agents, Benzene Derivatives, Biphenyl Compounds, Central Nervous System Agents, Cyclooxygenase Inhibitors, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 Substrates, Drugs causing inadvertant photosensitivity, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Musculo-Skeletal System, Nephrotoxic agents, Non COX-2 selective NSAIDS, OAT1/SLC22A6 inhibitors, Ophthalmologicals, Other Nonsteroidal Anti-inflammatory Agents, Peripheral Nervous System Agents, Photosensitizing Agents, Propionates, Sensory Organs, Sensory System Agents, Throat Preparations, Topical Products for Joint and Muscular Pain, UGT1A1 Inhibitors, UGT1A1 Substrates, UGT1A3 substrates, UGT1A9 Substrates, UGT2B7 substrates"," Prostaglandin G/H synthase 2,  Prostaglandin G/H synthase 1,  UDP-glucuronosyltransferase 2B7,  UDP-glucuronosyltransferase 1-1,  UDP-glucuronosyltransferase 1-3,  UDP-glucuronosyltransferase 1-9,  UDP-glucuronosyltransferase 2B4,  Cytochrome P450 2C9,  Serum albumin,  Multidrug resistance-associated protein 4,  Solute carrier family 22 member 6","DB00712, DB05289, DB16159, DB03753, DB16825, DB14938, DB02047",
DB00713,Oxacillin,approved; investigational,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1)C(O)=O,C19H19N3O5S,,"Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Beta-Lactam Antibacterials, Beta-Lactamase Resistant Penicillins, beta-Lactams, Drugs that are Mainly Renally Excreted, Heterocyclic Compounds, Fused-Ring, Lactams, Penicillins, Sulfur Compounds"," Penicillin-binding protein 3,  Penicillin-binding protein 2a,  Penicillin-binding protein 1A,  Penicillin-binding protein 2B,  Penicillin-binding protein 1b,  Penicillin-binding protein 1A,  Solute carrier family 15 member 1,  Penicillin-binding protein 2,  Solute carrier family 15 member 2, 10. Beta-lactamase Toho-1,  Solute carrier family 15 member 1,  Solute carrier family 15 member 2","DB00713, DB00485, DB01147, DB00301, DB00739, DB01603, DB01061, DB00578, DB00319, DB00415, DB13836, DB01060, DB13506, DB09319, DB00607, DB13816, DB01053, DB01607, DB00948, DB08795, DB01604, DB13739, DB08559",
DB00714,Apomorphine,approved; investigational,[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23,C17H17NO2,,"Alkaloids, Anti-Parkinson Agents (Dopamine Agonist), Anti-Parkinson Drugs, Antidepressive Agents, Aporphines, Autonomic Agents, Benzylisoquinolines, Central Nervous System Agents, Central Nervous System Depressants, COMT Substrates, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Substrates, Dopamine Agents, Dopamine Agonists, Drugs Used in Erectile Dysfunction, Emetics, Gastrointestinal Agents, Genito Urinary System and Sex Hormones, Heterocyclic Compounds, Fused-Ring, Hypotensive Agents, Isoquinolines, Nervous System, Neurotransmitter Agents, Nonergot-derivative Dopamine Receptor Agonists, Opiate Agonists, Peripheral Nervous System Agents, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin Receptor Antagonists, Urologicals"," Dopamine D4 receptor,  Dopamine D2 receptor,  Dopamine D3 receptor,  Dopamine D5 receptor,  Dopamine D1 receptor,  Alpha-2C adrenergic receptor,  Alpha-2B adrenergic receptor,  5-hydroxytryptamine receptor 1A,  5-hydroxytryptamine receptor 2A, 10. 5-hydroxytryptamine receptor 2B, 11. 5-hydroxytryptamine receptor 2C, 12. Alpha-2A adrenergic receptor, 13. 5-hydroxytryptamine receptor 1D, 14. 5-hydroxytryptamine receptor 1B,  Catechol O-methyltransferase,  Sulfotransferase 1A1,  Sulfotransferase 1A2,  Sulfotransferase 1A3/1A4,  Estrogen sulfotransferase,  Sulfotransferase family cytosolic 1B member 1,  Cytochrome P450 2B6,  Cytochrome P450 2C8,  Cytochrome P450 3A4, 10. Cytochrome P450 3A5, 11. UDP-glucuronosyltransferases (UGTs) (Protein Group),  Serum albumin,  Synaptic vesicular amine transporter","DB00714, DB16927, DB17202",
DB00715,Paroxetine,approved; investigational,FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1,C19H20FNO3,,"Agents producing tachycardia, Anticholinergic Agents, Antidepressive Agents, Antidepressive Agents Indicated for Depression, Antidepressive Agents, Second-Generation, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (strength unknown), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strong), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs causing inadvertant photosensitivity, Enzyme Inhibitors, Hypoglycemia-Associated Agents, Membrane Transport Modulators, Muscarinic Antagonists, Nervous System, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, P-glycoprotein inhibitors, Photosensitizing Agents, Piperidines, Psychoanaleptics, Psychotropic Drugs, Selective Serotonin Reuptake Inhibitors, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin Modulators"," Sodium-dependent serotonin transporter,  Sodium-dependent noradrenaline transporter,  5-hydroxytryptamine receptor 2A,  Alpha-1 adrenergic receptors (Protein Group),  Alpha-2 adrenergic receptors (Protein Group),  Beta adrenergic receptor (Protein Group),  Dopamine D2 receptor,  Histamine H1 receptor,  Serotonin Receptors (Protein Group), 10. Muscarinic acetylcholine receptor (Protein Group), 11. 5-hydroxytryptamine receptor 2B, 12. D(1) dopamine receptor (Protein Group),  Cytochrome P450 2B6,  Cytochrome P450 1A2,  Cytochrome P450 3A4,  Cytochrome P450 2C19,  Cytochrome P450 2D6,  Cytochrome P450 2C9,  P-glycoprotein 1",DB00715,
DB00716,Nedocromil,approved; investigational,CCCC1=C2N(CC)C(=CC(=O)C2=CC2=C1OC(=CC2=O)C(O)=O)C(O)=O,C19H17NO7,,"4-Quinolones, Anti-Allergic Agents, Anti-Asthmatic Agents, Anti-Inflammatory Agents, Antiallergic Agents, Excl. Corticosteroids, Decongestants and Antiallergics, Decreased Histamine Release, Drugs for Obstructive Airway Diseases, Drugs that are Mainly Renally Excreted, Heterocyclic Compounds, Fused-Ring, Immunologic Factors, Mast Cell Stabilizers, Nasal Preparations, Ophthalmologicals, Quinolines, Quinolones, Respiratory Agents, Miscellaneous, Respiratory System Agents, Sensory Organs"," Cysteinyl leukotriene receptor 1,  Cysteinyl leukotriene receptor 2,  fMet-Leu-Phe receptor,  Prostaglandin D2 receptor,  Heat shock protein HSP 90-alpha",DB00716,
DB00717,Norethisterone,approved,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],C20H26O2,,"Adrenal Cortex Hormones, Anti-Gonadotropin-Releasing Hormones, Combination Contraceptives (with Estrogen and derivatives), Contraceptive Agents, Female, Contraceptive Agents, Hormonal, Contraceptives, Oral, Contraceptives, Oral, Hormonal, Contraceptives, Oral, Synthetic, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2A6 Substrates, Cytochrome P-450 CYP2C19 Inducers, Cytochrome P-450 CYP2C19 Inducers (strength unknown), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Substrates, Estren Derivatives, Fused-Ring Compounds, Genito Urinary System and Sex Hormones, Hormonal Contraceptives for Systemic Use, Hyperglycemia-Associated Agents, Hypothalamic Hormones, Norpregnenes, Norsteroids, P-glycoprotein inhibitors, Pituitary and Hypothalamic Hormones and Analogues, Progestin Contraceptives, Progestins, Progestogens and Estrogens, Sequential Preparations, Reproductive Control Agents, Sex Hormones and Modulators of the Genital System, Steroids, Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins"," Progesterone receptor,  Androgen receptor,  Glucocorticoid receptor,  Cytochrome P450 3A4,  Aldo-keto reductase family 1 member C4,  3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2,  3-oxo-5-alpha-steroid 4-dehydrogenase (Protein Group),  3-oxo-5-beta-steroid 4-dehydrogenase,  Cytochrome P450 2C19,  Cytochrome P450 1A2,  Cytochrome P450 2A6,  Serum albumin,  Sex hormone-binding globulin,  P-glycoprotein 1","DB00367, DB00717, DB09389, DB00294, DB00624, DB01471, DB01543, DB01564, DB05830, DB06710, DB07768, DB11429, DB12787, DB13169, DB13533, DB14093, DB13710, DB13230, DB14570, DB06730, DB14584, DB00253, DB18000, DB01481, DB01572, DB04652, DB09070, DB09371, DB01500, DB01540",
DB00718,Adefovir dipivoxil,approved; investigational,CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C(N)N=CN=C12)OCOC(=O)C(C)(C)C,C20H32N5O8P,,"Anti-Infective Agents, Antiinfectives for Systemic Use, Antiviral Agents, Antivirals for Systemic Use, Direct Acting Antivirals, Enzyme Inhibitors, Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor, Heterocyclic Compounds, Fused-Ring, Nephrotoxic agents, Nucleic Acid Synthesis Inhibitors, Nucleoside and Nucleotide Reverse Transcriptase Inhibitors, Nucleosides and Nucleotides, OAT1/SLC22A6 inhibitors, OAT1/SLC22A6 Substrates, Organophosphorus Compounds, Purines, Reverse Transcriptase Inhibitors"," DNA polymerase/reverse transcriptase,  Adenylate kinase 2, mitochondrial,  Adenylate kinase 4, mitochondrial,  Nucleoside diphosphate kinase A,  Nucleoside diphosphate kinase B,  Solute carrier family 22 member 6,  Multidrug resistance-associated protein 4,  Multidrug resistance-associated protein 5,  Solute carrier family 22 member 3","DB00718, DB00300, DB05020, DB13868, DB08843, DB14126, DB14925, DB02222",
DB00719,Azatadine,approved,CN1CCC(CC1)=C1C2=CC=CC=C2CCC2=C1N=CC=C2,C20H22N2,,"Agents that reduce seizure threshold, Anticholinergic Agents, Antihistamines for Systemic Use, Benzocycloheptenes, Cholinergic Agents, Dibenzocycloheptenes, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Neurotransmitter Agents, Piperidines, Potential QTc-Prolonging Agents, QTc Prolonging Agents", Histamine H1 receptor,"DB00719, DB00967, DB00455, DB11614",
DB00720,Clodronic acid,approved; investigational; vet_approved,OP(O)(=O)C(Cl)(Cl)P(O)(O)=O,CH4Cl2O6P2,,"Bisphosphonates, Bone Density Conservation Agents, Drugs Affecting Bone Structure and Mineralization, Drugs for Treatment of Bone Diseases, Musculo-Skeletal System, Organophosphonates, Organophosphorus Compounds"," Hydroxylapatite,  ADP/ATP translocase 1,  ADP/ATP translocase 2,  ADP/ATP translocase 3,  Prostaglandin G/H synthase 2",DB00720,
DB00721,Procaine,approved; investigational; vet_approved,CCN(CC)CCOC(=O)C1=CC=C(N)C=C1,C13H20N2O2,,"Acids, Carbocyclic, Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use, Agents that reduce seizure threshold, Aminobenzoates, Anesthetics, Anesthetics, Local, Anticholinergic Agents, Antidepressive Agents, Benzene Derivatives, Benzoates, Central Nervous System Agents, Central Nervous System Depressants, Cholinesterase Inhibitors, Cholinesterase substrates, Esters of Aminobenzoic Acid, Local Anesthetics (Ester), Methemoglobinemia Associated Agents, Monoamine Oxidase Inhibitors, Nervous System, Nicotinic Antagonists, NMDA Receptor Antagonists, Ophthalmologicals, para-Aminobenzoates, Peripheral Nervous System Agents, Sensory Organs, Sensory System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Vasoprotectives"," Sodium channel protein type 10 subunit alpha,  Glutamate receptor ionotropic, NMDA 3A,  5-hydroxytryptamine receptor 3A,  Sodium-dependent dopamine transporter,  Neuronal acetylcholine receptor subunit alpha-2,  Calcium-activated potassium channel (Protein Group),  Cytosolic phospholipase A2,  60 kDa lysophospholipase,  Monoamine oxidase (Protein Group), 10. DNA (cytosine-5)-methyltransferase 1, 11. DNA (cytosine-5)-methyltransferase 3A,  Cholinesterase,  Sodium-dependent dopamine transporter,  Sodium-dependent noradrenaline transporter,  Sodium-dependent serotonin transporter","DB00721, DB01161, DB09085, DB01086, DB13578",
DB00722,Lisinopril,approved; investigational,NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O,C21H31N3O5,,"ACE Inhibitors and Calcium Channel Blockers, ACE Inhibitors and Diuretics, Agents Acting on the Renin-Angiotensin System, Agents causing angioedema, Agents causing hyperkalemia, Amino Acids, Peptides, and Proteins, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Cardiotonic Agents, Cardiovascular Agents, Compounds used in a research, industrial, or household setting, Dipeptides, Drugs causing inadvertant photosensitivity, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Hypotensive Agents, Lipid Modifying Agents, Oligopeptides, Peptides, Photosensitizing Agents, Protease Inhibitors, Protective Agents"," Angiotensin-converting enzyme,  Renin,  Solute carrier family 15 member 1,  Solute carrier family 15 member 2","DB00722, DB09477, DB14208, DB00584, DB14209, DB00178, DB00519, DB03090",
DB00723,Methoxamine,approved; investigational,COC1=CC(C(O)C(C)N)=C(OC)C=C1,C11H17NO3,,"Adrenergic Agents, Adrenergic Agonists, Adrenergic alpha-1 Receptor Agonists, Adrenergic alpha-Agonists, Adrenergic and Dopaminergic Agents, Agents producing tachycardia, Agents that produce hypertension, Alcohols, Amines, Amino Alcohols, Autonomic Agents, Cardiac Stimulants Excl. Cardiac Glycosides, Cardiac Therapy, Cardiovascular Agents, Ethylamines, Neurotransmitter Agents, Peripheral Nervous System Agents, Phenethylamines, Propanolamines, Propanols, Sympathomimetics, Vasoconstrictor Agents"," Alpha-1A adrenergic receptor,  Alpha-1D adrenergic receptor,  Alpha-1B adrenergic receptor","DB00723, DB01467, DB01465, DB01528, DB00610",
DB00724,Imiquimod,approved; investigational,CC(C)CN1C=NC2=C1C1=C(C=CC=C1)N=C2N,C14H16N4,,"Adjuvants, Immunologic, Aminoquinolines, Antineoplastic Agents, Cancer immunotherapy, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Dermatologicals, Heterocyclic Compounds, Fused-Ring, Immune Response Modifiers, Immunologic Factors, Immunomodulatory Agents, Immunosuppressive Agents, Immunotherapy, Increased Cytokine Activity, Increased Cytokine Production, Interferon Inducers, Misc. Skin and Mucous Membrane Agents, Quinolines, Toll-Like Receptor Agonists"," Toll-like receptor 7,  Toll-like receptor 8,  Cytochrome P450 3A4","DB00724, DB05680, DB12476, DB06530",
DB00725,Homatropine methylbromide,approved,[Br-].C[N+]1(C)C2CCC1CC(C2)OC(=O)C(O)C1=CC=CC=C1,C17H24BrNO3,,"Agents producing tachycardia, Alimentary Tract and Metabolism, Alkaloids, Anticholinergic Agents, Aza Compounds, Azabicyclo Compounds, Belladonna Alkaloids, Semisynthetic, Quaternary Ammonium Compounds, Belladonna and Derivatives, Plain, Drugs for Functional Gastrointestinal Disorders, Muscarinic Antagonists"," Muscarinic acetylcholine receptor M2,  Muscarinic acetylcholine receptor M1,  Muscarinic acetylcholine receptor M4,  Muscarinic acetylcholine receptor M5,  Muscarinic acetylcholine receptor M3","DB00725, DB02161, DB11181, DB00209, DB00332, DB00424, DB00572, DB13833, DB11785, DB16896, DB00462, DB09300, DB12086, DB00747, DB11315, DB08978, DB16011, DB09271, DB13542, DB12278",
DB00726,Trimipramine,approved,CC(CN(C)C)CN1C2=CC=CC=C2CCC2=CC=CC=C12,C20H26N2,,"Adrenergic Agents, Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Adrenergic Uptake Inhibitors, Agents that produce hypertension, Agents that reduce seizure threshold, Antidepressive Agents, Antidepressive Agents Indicated for Depression, Antidepressive Agents, Tricyclic, Central Nervous System Agents, Central Nervous System Depressants, Combined Inhibitors of Serotonin/Norepinephrine Reuptake, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Substrates, Dibenzazepines, Heterocyclic Compounds, Fused-Ring, Histamine Antagonists, Histamine H1 Antagonists, Membrane Transport Modulators, Narrow Therapeutic Index Drugs, Nervous System, Neurotoxic agents, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, Non-Selective Monoamine Reuptake Inhibitors, P-glycoprotein substrates, P-glycoprotein substrates with a Narrow Therapeutic Index, Potential QTc-Prolonging Agents, Psychoanaleptics, Psychotropic Drugs, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT1 Receptor Antagonists, Serotonin 5-HT1A Receptor Antagonists, Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2C Receptor Antagonists, Serotonin Agents, Serotonin Modulators, Serotonin Receptor Antagonists, Tertiary amine tricyclic antidepressants, Tricyclics and Other Norepinephrine-reuptake Inhibitors"," Sodium-dependent serotonin transporter,  Sodium-dependent noradrenaline transporter,  Sodium-dependent dopamine transporter,  5-hydroxytryptamine receptor 2A,  5-hydroxytryptamine receptor 1A,  Alpha-1A adrenergic receptor,  Alpha-1B adrenergic receptor,  Dopamine D2 receptor,  Alpha-2B adrenergic receptor, 10. Histamine H1 receptor, 11. 5-hydroxytryptamine receptor 2C, 12. 5-hydroxytryptamine receptor 3A, 13. 5-hydroxytryptamine receptor 1D, 14. Alpha-2A adrenergic receptor, 15. D(1) dopamine receptor (Protein Group), 16. Beta adrenergic receptor (Protein Group), 17. Muscarinic acetylcholine receptor (Protein Group), 18. 5-hydroxytryptamine receptor 1C,  Cytochrome P450 2C9,  Cytochrome P450 2D6,  Cytochrome P450 2C19,  P-glycoprotein 1","DB00726, DB00458, DB01151, DB13782, DB01242, DB13411",
DB00727,Nitroglycerin,approved; investigational,[O-][N+](=O)OCC(CO[N+]([O-])=O)O[N+]([O-])=O,C3H5N3O9,,"Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use, Antianginal Agents, Antihypertensive Agents, Cardiac Therapy, Cardiovascular Agents, Compounds used in a research, industrial, or household setting, Explosive Agents, Hypotensive Agents, Methemoglobinemia Associated Agents, Nitrate Vasodilator, Nitrates and Nitrites, Nitro Compounds, Organic Nitrates, Vasodilating Agents, Vasodilation, Vasodilators Used in Cardiac Diseases, Vasoprotectives"," Atrial natriuretic peptide receptor 1,  Aldehyde dehydrogenase, mitochondrial","DB00727, DB01613",
DB00728,Rocuronium,approved,[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](O)[C@H](C[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1,C32H53N2O4,,"Agents producing tachycardia, Androstanes, Androstanols, Anticholinergic Agents, Central Nervous System Depressants, Fused-Ring Compounds, Muscarinic Antagonists, Muscle Relaxants, Muscle Relaxants, Peripherally Acting Agents, Musculo-Skeletal System, Neuromuscular Agents, Neuromuscular Blocking Agents, Neuromuscular Nondepolarizing Blockade, Neuromuscular-Blocking Agents (Nondepolarizing), Nicotinic Antagonists, OCT1 inhibitors, OCT1 substrates, Peripheral Nervous System Agents, Steroids"," Neuronal acetylcholine receptor subunit alpha-2,  Muscarinic acetylcholine receptor M2,  5-hydroxytryptamine receptor 3A,  Solute carrier family 22 member 1,  Solute carrier organic anion transporter family member 1A2","DB00728, DB04834, DB01337, DB01339, DB01338",
DB00730,Thiabendazole,approved; vet_approved,N1C2=CC=CC=C2N=C1C1=CSC=N1,C10H7N3S,,"Anthelmintics, Anti-Infective Agents, Antifungals for Dermatological Use, Antifungals for Topical Use, Antihelminthic, Antinematodal Agents, Antiparasitic Agents, Antiparasitic Products, Insecticides and Repellents, Benzimidazole Derivatives, Benzimidazoles, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dermatologicals, Drugs that are Mainly Renally Excreted, Heterocyclic Compounds, Fused-Ring, Imidazole and Triazole Derivatives, Sulfur Compounds, Thiazoles"," Fumarate reductase flavoprotein subunit,  Cytochrome P450 1A2,  Cytochrome P450 1A1",DB00730,
DB00731,Nateglinide,approved; investigational,CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](CC1=CC=CC=C1)C(O)=O,C19H27NO3,,"Alimentary Tract and Metabolism, Amino Acids, Amino Acids, Aromatic, Amino Acids, Cyclic, Amino Acids, Peptides, and Proteins, Blood Glucose Lowering Agents, Cyclohexanes, Cycloparaffins, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Drugs Used in Diabetes, Glinide, Hypoglycemia-Associated Agents, Insulin Secretagogues, OAT1/SLC22A6 inhibitors, Oral Hypoglycemics, Potassium Channel Blockers, UGT1A9 Substrates"," ATP-binding cassette sub-family C member 8,  Peroxisome proliferator-activated receptor gamma,  Cytochrome P450 2C9,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  Prostaglandin G/H synthase 1,  UDP-glucuronosyltransferase 1-9,  Cytochrome P450 2D6,  Serum albumin,  Alpha-1-acid glycoprotein 1,  Multidrug resistance-associated protein 4,  Monocarboxylate transporter 1,  Solute carrier family 15 member 1,  Solute carrier family 15 member 2,  Solute carrier family 22 member 6","DB00731, DB08275, DB08505",
DB00732,Atracurium besylate,approved,[O-]S(=O)(=O)C1=CC=CC=C1.[O-]S(=O)(=O)C1=CC=CC=C1.COC1=CC2=C(C=C1OC)C(CC1=CC(OC)=C(OC)C=C1)[N+](C)(CCC(=O)OCCCCCOC(=O)CC[N+]1(C)CCC3=C(C=C(OC)C(OC)=C3)C1CC1=CC(OC)=C(OC)C=C1)CC2,C65H82N2O18S2,,"Anticholinergic Agents, Benzylisoquinolines, Central Nervous System Depressants, Cholinergic Agents, Heterocyclic Compounds, Fused-Ring, Isoquinolines, Miscellaneous Skeletal Muscle Relaxants, Neuromuscular Agents, Neuromuscular Blocking Agents, Neuromuscular-Blocking Agents (Nondepolarizing), Neurotransmitter Agents, Nicotinic Antagonists, Peripheral Nervous System Agents", Neuronal acetylcholine receptor subunit alpha-2,"DB00732, DB00565, DB01226, DB01135, DB11915, DB12093, DB05710, DB00767, DB13393, DB13692",
DB00733,Pralidoxime,approved; vet_approved,C[N+]1=C(\C=N\O)C=CC=C1,C7H9N2O,,"Amines, Antidotes, Cholinergic Agents, Cholinesterase Reactivators, Compounds used in a research, industrial, or household setting, Drugs that are Mainly Renally Excreted, Enzyme Reactivators, Hydroxylamines, Neurotransmitter Agents, Oximes, Protective Agents"," Acetylcholinesterase,  Cholinesterase",DB00733,
DB00734,Risperidone,approved; investigational,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1,C23H27FN4O2,,"Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Agents that produce hypertension, Agents that reduce seizure threshold, Antidepressive Agents, Antipsychotic Agents, Antipsychotic Agents (Second Generation [Atypical]), Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dopamine Agents, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Histamine Antagonists, Histamine H1 Antagonists, Hyperglycemia-Associated Agents, Nervous System, Neurotoxic agents, Neurotransmitter Agents, P-glycoprotein substrates, Potential QTc-Prolonging Agents, Psycholeptics, Psychotropic Drugs, Pyrimidines, Pyrimidinones, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT1 Receptor Antagonists, Serotonin 5-HT1A Receptor Antagonists, Serotonin 5-HT1D Receptor Antagonists, Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2A Receptor Antagonists, Serotonin 5-HT2C Receptor Antagonists, Serotonin Agents, Serotonin Receptor Antagonists, Tranquilizing Agents"," 5-hydroxytryptamine receptor 2A,  Dopamine D2 receptor,  Alpha-1B adrenergic receptor,  Alpha-2B adrenergic receptor,  Alpha-1A adrenergic receptor,  Alpha-2C adrenergic receptor,  Histamine H1 receptor,  5-hydroxytryptamine receptor 2C,  5-hydroxytryptamine receptor 1D, 10. 5-hydroxytryptamine receptor 1A, 11. 5-hydroxytryptamine receptor 7, 13. Dopamine D1 receptor,  Cytochrome P450 2D6,  Cytochrome P450 3A4,  Serum albumin,  Alpha-1-acid glycoprotein 1,  P-glycoprotein 1","DB00734, DB01267, DB06229",
DB00735,Naftifine,approved,CN(CC=CC1=CC=CC=C1)CC1=CC=CC2=CC=CC=C12,C21H21N,,"Alkenes, Allyl Compounds, Allylamine Antifungal, Amines, Anti-Infective Agents, Antifungal Agents, Antifungals for Dermatological Use, Antifungals for Topical Use, Dermatologicals, Hydrocarbons, Acyclic", Squalene monooxygenase,"DB00735, DB00857",
DB00736,Esomeprazole,approved; investigational,COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1,C17H19N3O3S,,"2-Pyridinylmethylsulfinylbenzimidazoles, Acid Reducers, Alimentary Tract and Metabolism, Anti-Ulcer Agents, Antiinflammatory and Antirheumatic Products, Antiinflammatory and Antirheumatic Products, Non-Steroids, Benzimidazoles, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (weak), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs causing inadvertant photosensitivity, Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord), Enzyme Inhibitors, Gastric Acid Lowering Agents, Gastrointestinal Agents, Heterocyclic Compounds, Fused-Ring, Musculo-Skeletal System, OAT3/SLC22A8 Inhibitors, P-glycoprotein inhibitors, P-glycoprotein substrates, Photosensitizing Agents, Propionates, Proton Pump Inhibitors, Proton-pump Inhibitors, Pyridines, Sulfoxides, Sulfur Compounds"," Potassium-transporting ATPase alpha chain 1,  N(G),N(G)-dimethylarginine dimethylaminohydrolase 1,  Cytochrome P450 2C19,  Cytochrome P450 3A4,  P-glycoprotein 1,  Solute carrier family 22 member 8","DB00338, DB00736, DB01129, DB13762, DB00448, DB05351, DB17144, DB00213, DB11964, DB13135",
DB00737,Meclizine,approved,CC1=CC(CN2CCN(CC2)C(C2=CC=CC=C2)C2=CC=C(Cl)C=C2)=CC=C1,C25H27ClN2,,"Anti-Allergic Agents, Anticholinergic Agents, Antiemetics, Antihistamines for Systemic Use, Antivertigo Preparations, Autonomic Agents, Benzene Derivatives, Benzhydryl Compounds, Central Nervous System Agents, Central Nervous System Depressants, Cholinergic Agents, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 Substrates, Emesis Suppression, Gastrointestinal Agents, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Neurotransmitter Agents, Peripheral Nervous System Agents, Piperazine Derivatives, Piperazines"," Histamine H1 receptor,  Nuclear receptor subfamily 1 group I member 3,  Cytochrome P450 2D6,  Serum albumin","DB00737, DB08936, DB00354, DB15979, DB00557, DB01176, DB00341, DB06282",
DB00738,Pentamidine,approved; investigational,NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1,C19H24N4O2,,"Agents Against Leishmaniasis and Trypanosomiasis, Agents causing hyperkalemia, Amidines, Anti-Infective Agents, Antibiotics for Pneumocystis Pneumonia, Antifungal Agents, Antiparasitic Agents, Antiparasitic Products, Insecticides and Repellents, Antiprotozoals, Benzamidines, Blood Glucose Lowering Agents, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Substrates, Hyperglycemia-Associated Agents, Hypoglycemia-Associated Agents, Miscellaneous Antiprotozoals, Moderate Risk QTc-Prolonging Agents, Nephrotoxic agents, QTc Prolonging Agents, Trypanocidal Agents"," tRNA (cytosine(38)-C(5))-methyltransferase,  DNA,  Cytochrome P450 2C19,  Cytochrome P450 1A1,  Cytochrome P450 2D6,  Cytochrome P450 3A5,  Cytochrome P450 4A11","DB00738, DB03808, DB13296",
DB00739,Hetacillin,approved; vet_approved; withdrawn,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2N1C(=O)[C@H](NC1(C)C)C1=CC=CC=C1)C(O)=O,C19H23N3O4S,,"Amides, Anti-Bacterial Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Beta-Lactam Antibacterials, beta-Lactams, Heterocyclic Compounds, Fused-Ring, Lactams, Penicillins, Penicillins With Extended Spectrum, Sulfur Compounds"," Penicillin-binding protein 2a,  Penicillin-binding protein 1b,  Penicillin-binding protein 3,  Penicillin-binding protein 1A,  Penicillin-binding protein 2B","DB00739, DB00319, DB01061, DB00415, DB01060, DB01053, DB13836, DB00578, DB00948, DB08795, DB13816, DB01604, DB13739, DB08559, DB01607, DB13506, DB09320, DB13814, DB01602, DB07806, DB13693, DB12127, DB13686, DB01603, DB09319, DB00417, DB00607, DB00713, DB13337, DB12343",
DB00740,Riluzole,approved; investigational,NC1=NC2=C(S1)C=C(OC(F)(F)F)C=C2,C8H5F3N2OS,,"Anticonvulsants, BCRP/ABCG2 Substrates, Benzothiazoles, Central Nervous System Agents, Central Nervous System Depressants, Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 Substrates, Excitatory Amino Acid Agents, Excitatory Amino Acid Antagonists, Heterocyclic Compounds, Fused-Ring, Miscellaneous Central Nervous System Agents, Nervous System, Neuroprotective Agents, Neurotransmitter Agents, Protective Agents, Sulfur Compounds, Thiazoles"," Sodium channel protein type 5 subunit alpha,  Cystine/glutamate transporter,  Cytochrome P450 1A1,  Cytochrome P450 1A2,  ATP-binding cassette sub-family G member 2","DB00740, DB13858",
DB00741,Hydrocortisone,approved; vet_approved,[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,C21H30O5,,"11-Hydroxycorticosteroids, 17-Hydroxycorticosteroids, Adrenal Cortex Hormones, Adrenals, Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use, Alimentary Tract and Metabolism, Anti-Inflammatory Agents, Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents, Corticosteroid Hormone Receptor Agonists, Corticosteroids, Corticosteroids Acting Locally, Corticosteroids for Local Oral Treatment, Corticosteroids for Systemic Use, Corticosteroids for Systemic Use, Plain, Corticosteroids, Dermatological Preparations, Corticosteroids, Weak (Group I), Cytochrome P-450 CYP2A6 Inducers, Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strength unknown), Cytochrome P-450 CYP2C19 Inducers, Cytochrome P-450 CYP2C19 Inducers (strength unknown), Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 CYP2C8 Inducers (strength unknown), Cytochrome P-450 CYP2C9 Inducers, Cytochrome P-450 CYP2C9 Inducers (strength unknown), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Substrates, Dermatologicals, Fused-Ring Compounds, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hydrocortisone and derivatives, Hydroxycorticosteroids, Hyperglycemia-Associated Agents, Immunosuppressive Agents, Intestinal Antiinflammatory Agents, Nasal Preparations, OAT3/SLC22A8 Substrates, Ophthalmological and Otological Preparations, Ophthalmologicals, Otologicals, P-glycoprotein inducers, P-glycoprotein substrates, Pregnanes, Pregnenediones, Pregnenes, Sensory Organs, Steroids, Stomatological Preparations, Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins, Vasoprotectives"," Glucocorticoid receptor,  Annexin A1,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  Cytochrome P450 11B1, mitochondrial,  Cytochrome P450 11B2, mitochondrial,  Cytochrome P450 2C8,  3-oxo-5-beta-steroid 4-dehydrogenase,  3-oxo-5-alpha-steroid 4-dehydrogenase 2,  Corticosteroid 11-beta-dehydrogenase isozyme 2, 10. Corticosteroid 11-beta-dehydrogenase isozyme 1, 11. Cytochrome P450 2A6, 12. Cytochrome P450 1B1, 13. Cytochrome P450 2B6, 14. Cytochrome P450 2C9, 15. Cytochrome P450 2C19,  Sex hormone-binding globulin,  Corticosteroid-binding globulin,  P-glycoprotein 1,  Solute carrier organic anion transporter family member 1A2,  Solute carrier family 22 member 8","DB00741, DB04652, DB04630, DB00253, DB09091, DB13230, DB14570, DB13710, DB18000, DB00624, DB01471, DB01543, DB01564, DB05830, DB06710, DB07768, DB11429, DB12787, DB13169, DB13533, DB14093, DB14584, DB14681, DB01485, DB01500, DB01540, DB00860, DB00959, DB14539, DB16935",
DB00742,Mannitol,approved; investigational,OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,C6H14O6,,"Agents causing hyperkalemia, Alcohols, Alimentary Tract and Metabolism, Blood and Blood Forming Organs, Blood Substitutes and Perfusion Solutions, Carbohydrates, Compounds used in a research, industrial, or household setting, Cough and Cold Preparations, Diagnostic Agents, Diet, Food, and Nutrition, Diuretics, Diuretics, Osmotic, Drugs for Constipation, Drugs that are Mainly Renally Excreted, Expectorants, Flavoring Agents, Food, Food Additives, Food Ingredients, Hypotensive Agents, i.v. Solutions, Increased Diuresis, Irrigating Solutions, Kidney Function, Laxatives, Natriuretic Agents, Nephrotoxic agents, Osmotic Activity, Osmotic Laxatives, P-glycoprotein substrates, Physiological Phenomena, Solutions Producing Osmotic Diuresis, Sugar Alcohols, Sweetening Agents", Mannitol dehydrogenase,"DB00742, DB01638, DB02399, DB03815, DB03106, DB13178, DB15350, DB15908, DB11195, DB14704, DB14108, DB04079",
DB00743,Gadobenic acid,approved; investigational,[Gd+3].OC(=O)CN(CCN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O)C(COCC1=CC=CC=C1)C(O)=O,C22H28GdN3O11,,"Alcohols, Amino Sugars, Carbohydrates, Compounds used in a research, industrial, or household setting, Contrast Media, Diagnostic Uses of Chemicals, Drugs that are Mainly Renally Excreted, Gadolinium-based Contrast Agent, Hexosamines, Magnetic Resonance Contrast Activity, Magnetic Resonance Imaging Contrast Media, Moderate Risk QTc-Prolonging Agents, Other Diagnostics, Paramagnetic Contrast Agent, Paramagnetic Contrast Media, QTc Prolonging Agents, Sugar Alcohols"," Serum albumin,  Canalicular multispecific organic anion transporter 1",DB00743,
DB00744,Zileuton,approved; investigational; withdrawn,CC(N(O)C(N)=O)C1=CC2=CC=CC=C2S1,C11H12N2O2S,,"Agents to Treat Airway Disease, Amides, Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Decreased Leukotriene Production, Enzyme Inhibitors, Hormone Antagonists, Hormones, Hormone Substitutes, and Hormone Antagonists, Leukotriene Antagonists, Lipoxygenase Inhibitors, Peripheral Nervous System Agents, Sensory System Agents, UGT1A9 Substrates"," Arachidonate 5-lipoxygenase,  Prostaglandin G/H synthase 1,  UDP-glucuronosyltransferase 1-9,  Cytochrome P450 2C9,  Cytochrome P450 1A2,  Cytochrome P450 3A4,  Serum albumin",DB00744,
DB00745,Modafinil,approved; investigational,NC(=O)CS(=O)C(C1=CC=CC=C1)C1=CC=CC=C1,C15H15NO2S,,"Benzene Derivatives, Benzhydryl Compounds, Central Nervous System Agents, Central Nervous System Stimulants, Central Nervous System Stimulation, Centrally Acting Sympathomimetics, Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP1A2 Inducers (strength unknown), Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strength unknown), Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (strength unknown), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Inducers, Cytochrome P-450 CYP2C9 Inducers (strength unknown), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (moderate), Cytochrome P-450 CYP3A4 Inducers (weak), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Inducers, Cytochrome P-450 CYP3A5 Inducers (moderate), Cytochrome P-450 CYP3A5 Inducers (weak), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Increased Sympathetic Activity, Nervous System, Psychoanaleptics, Psychostimulants, Agents Used for ADHD and Nootropics, Stimulants, Sympathomimetic-like Agent, Wakefulness-Promoting Agents"," Sodium-dependent dopamine transporter,  Alpha-1B adrenergic receptor,  Cytochrome P450 2C19,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 1A2,  Cytochrome P450 2B6,  Cytochrome P450 2C9,  Cytochrome P450 2D6","DB00745, DB06413, DB08925",
DB00746,Deferoxamine,approved; investigational,CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN,C25H48N6O8,,"Amines, Chelating Agents, Compounds used in a research, industrial, or household setting, Heavy Metal Antagonists, Hydroxamic Acids, Hydroxy Acids, Hydroxylamines, Iron Chelating Activity, Iron Chelating Agents, Sequestering Agents, Siderophores"," Iron,  Aluminum,  Amyloid beta A4 protein,  Xanthine dehydrogenase/oxidase",DB00746,
DB00747,Scopolamine,approved; investigational,CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1,C17H21NO4,,"Adjuvants, Adjuvants, Anesthesia, Agents producing tachycardia, Alimentary Tract and Metabolism, Alkaloids, Anticholinergic Agents, Antiemetics, Antiemetics and Antinauseants, Antimuscarinics Antispasmodics, Autonomic Agents, Aza Compounds, Azabicyclo Compounds, Belladonna Alkaloids, Central Nervous System Agents, Central Nervous System Depressants, Cholinergic Agents, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Gastrointestinal Agents, Hypnotics and Sedatives, Muscarinic Antagonists, Mydriatics, Mydriatics and Cycloplegics, Nervous System, Neurotransmitter Agents, Ophthalmologicals, Peripheral Nervous System Agents, Psycholeptics, Scopolamine Derivatives, Sensory Organs, Solanaceous Alkaloids, Tropanes"," Muscarinic acetylcholine receptor M1,  Muscarinic acetylcholine receptor M2,  Muscarinic acetylcholine receptor M3,  Muscarinic acetylcholine receptor M4,  Muscarinic acetylcholine receptor M5,  Neuronal acetylcholine receptor subunit alpha-4,  Neuronal acetylcholine receptor subunit beta-2,  Sucrase-isomaltase, intestinal,  Cytochrome P450 3A4","DB00747, DB11315, DB00462, DB09300, DB12086, DB09271, DB11785, DB16896, DB00332, DB00424, DB00572, DB13833, DB00209, DB02161, DB11181, DB00725, DB15968, DB08978",
DB00748,Carbinoxamine,approved,CN(C)CCOC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1,C16H19ClN2O,,"Aminoalkyl Ethers, Antihistamines for Systemic Use, Central Nervous System Depressants, Drugs causing inadvertant photosensitivity, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Moderate Risk QTc-Prolonging Agents, Neurotransmitter Agents, Photosensitizing Agents, QTc Prolonging Agents"," Histamine H1 receptor,  alpha1-acid glycoprotein (Protein Group)","DB00748, DB00366, DB04890",
DB00749,Etodolac,approved; investigational; vet_approved,CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1,C17H21NO3,,"Acetic Acid Derivatives and Related Substances, Agents causing hyperkalemia, Agents that produce hypertension, Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Antiinflammatory and Antirheumatic Products, Antiinflammatory and Antirheumatic Products, Non-Steroids, Antirheumatic Agents, COX-2 Inhibitors, Cyclooxygenase Inhibitors, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 Substrates, Drugs causing inadvertant photosensitivity, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Heterocyclic Compounds, Fused-Ring, Indoleacetic Acids, Indoles, Musculo-Skeletal System, Nephrotoxic agents, OAT1/SLC22A6 inhibitors, Other Nonsteroidal Anti-inflammatory Agents, Peripheral Nervous System Agents, Photosensitizing Agents, Selective Cyclooxygenase 2 Inhibitors (NSAIDs), Sensory System Agents, UGT1A3 substrates, UGT1A9 Substrates, UGT2B7 substrates"," Prostaglandin G/H synthase 2,  Prostaglandin G/H synthase 1,  Retinoic acid receptor RXR-alpha,  UDP-glucuronosyltransferase 1-3,  UDP-glucuronosyltransferase 1-10,  UDP-glucuronosyltransferase 2B7,  Cytochrome P450 2C9,  UDP-glucuronosyltransferase 1-9,  Serum albumin,  Solute carrier family 22 member 6",DB00749,
DB00750,Prilocaine,approved,CCCNC(C)C(=O)NC1=CC=CC=C1C,C13H20N2O,,"Amides, Amines, Anesthetics, Anesthetics, Local, Anilides, Aniline Compounds, Central Nervous System Agents, Central Nervous System Depressants, Local Anesthesia, Local Anesthetics (Amide), Methemoglobinemia Associated Agents, Nervous System, Peripheral Nervous System Agents, Sensory System Agents", Sodium channel protein type 5 subunit alpha,"DB00750, DB08987, DB01056, DB00281, DB00961, DB00296, DB00297, DB01002",
DB00751,Epinastine,approved; investigational,NC1=NCC2N1C1=CC=CC=C1CC1=CC=CC=C21,C16H15N3,,"Acid Reducers, Antidepressive Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Decongestants and Antiallergics, Decreased Histamine Release, Heterocyclic Compounds, Fused-Ring, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Histamine H1 Inhibitors, Histamine H2 Antagonists, Neurotransmitter Agents, Ophthalmics, Ophthalmologicals, P-glycoprotein substrates, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Sensory Organs, Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2A Receptor Antagonists, Serotonin Agents, Serotonin Receptor Antagonists"," Histamine H1 receptor,  Histamine H2 receptor,  Alpha-1A adrenergic receptor,  Alpha-2A adrenergic receptor,  5-hydroxytryptamine receptor 2A,  5-hydroxytryptamine receptor 7,  Cytochrome P450 2B6,  Cytochrome P450 2D6,  Cytochrome P450 3A4,  P-glycoprotein 1",DB00751,
DB00752,Tranylcypromine,approved; investigational,NC1CC1C1=CC=CC=C1,C9H11N,,"Agents that produce hypertension, Agents that reduce seizure threshold, Amines, Anti-Anxiety Agents, Antidepressive Agents, Antidepressive Agents Indicated for Depression, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 CYP2A6 Inhibitors, Cytochrome P-450 CYP2A6 Inhibitors (strong), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Enzyme Inhibitors, Hypotensive Agents, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates, Monoamine Oxidase Inhibitors, Monoamine Oxidase Inhibitors, Non-Selective, Nervous System, Propylamines, Psychoanaleptics, Psychotropic Drugs, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin Modulators, Tranquilizing Agents"," Amine oxidase [flavin-containing] B,  Amine oxidase [flavin-containing] A,  Cytochrome P450 2D6,  Cytochrome P450 2C9,  Cytochrome P450 2C19,  Cytochrome P450 1A2,  Cytochrome P450 2A6,  Cytochrome P450 3A4","DB00752, DB02665, DB00182, DB01576, DB00191",
DB00753,Isoflurane,approved; vet_approved,FC(F)OC(Cl)C(F)(F)F,C3H2ClF5O,,"Agents that produce hypertension, Agents that reduce seizure threshold, Anesthetics, Anesthetics, General, Anesthetics, Inhalation, Anticholinergic Agents, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strength unknown), Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Substrates, Ethers, Hydrocarbons, Halogenated, Hypotensive Agents, Methyl Ethers, Nervous System, Nicotinic Antagonists, Potential QTc-Prolonging Agents, QTc Prolonging Agents"," Gamma-aminobutyric acid receptor subunit alpha-1,  Calcium-transporting ATPase type 2C member 1,  Glycine receptor subunit alpha-1,  Glutamate receptor 1,  Potassium voltage-gated channel subfamily A member 1,  GABA(A) Receptor (Protein Group),  ATP synthase subunit delta, mitochondrial,  Calmodulin,  Neuronal acetylcholine receptor subunit alpha-4, 10. Neuronal acetylcholine receptor subunit beta-2,  Cytochrome P450 2B6,  NADH-ubiquinone oxidoreductase chain 1,  Cytochrome P450 2E1,  Serum albumin",DB00753,
DB00754,Ethotoin,approved,CCN1C(=O)NC(C1=O)C1=CC=CC=C1,C11H12N2O2,,"Anti-epileptic Agent, Anticonvulsants, Cardiovascular Agents, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 Enzyme Inducers, Decreased Central Nervous System Disorganized Electrical Activity, Hydantoins, Imidazoles, Imidazolidines, Membrane Transport Modulators, Nervous System, Sodium Channel Blockers, Thyroxine-binding globulin substrates, Voltage-Gated Sodium Channel Blockers"," Sodium channel protein type 5 subunit alpha,  Nuclear receptor subfamily 1 group I member 2,  Thyroxine-binding globulin","DB00754, DB00532, DB00252, DB13396, DB13276",
DB00755,Tretinoin,approved; investigational; nutraceutical,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O,C20H28O2,,"Agents that produce hypertension, Alkenes, Anti-Acne Preparations, Anti-Acne Preparations for Topical Use, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Biological Factors, Cardiotoxic antineoplastic agents, Carotenoids, Cell Stimulants and Proliferants, Cyclohexanes, Cyclohexenes, Cycloparaffins, Cytochrome P-450 CYP2A6 Substrates, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C18 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Substrates, Dermatologicals, Diterpenes, Hydrocarbons, Acyclic, Hypotensive Agents, Immunosuppressive Agents, Keratolytic Agents, Pigments, Biological, Polyenes, Retinoids, Retinoids for cancer treatment, Retinoids for Topical Use in Acne, Terpenes, UGT2B7 substrates, Vitamin A, Vitamins, Vitamins (Fat Soluble)"," Retinoic acid receptor alpha,  Retinoic acid receptor beta,  Retinoic acid receptor gamma,  Retinoic acid receptor RXR-alpha,  Retinoic acid receptor RXR-beta,  Retinoic acid receptor RXR-gamma,  Cellular retinoic acid-binding protein 1,  Retinoic acid receptor responder protein 1,  Retinal dehydrogenase 1, 10. Retinal dehydrogenase 2, 11. Retinoic acid-induced protein 3, 12. Lipocalin-1, 13. Odorant-binding protein 2a, 14. Retinol-binding protein 4, 15. [Pyruvate dehydrogenase [lipoamide]] kinase isozyme 4, mitochondrial, 16. Carcinoembryonic antigen,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  Cytochrome P450 2B6,  Cytochrome P450 2C8,  Cytochrome P450 2C9,  Cytochrome P450 2A6,  Cytochrome P450 2C18,  Cytochrome P450 1A1, 10. Cytochrome P450 4A11, 11. UDP-glucuronosyltransferase 2B7, 12. Cytochrome P450 2E1, 13. Cytochrome P450 26A1,  Serum albumin,  Cellular retinoic acid-binding protein 1,  Cellular retinoic acid-binding protein 2","DB00523, DB00755, DB00982, DB00162, DB08467, DB02699, DB06755, DB08127, DB12112, DB16291",
DB00756,Hexachlorophene,approved; withdrawn,OC1=C(CC2=C(O)C(Cl)=CC(Cl)=C2Cl)C(Cl)=C(Cl)C=C1Cl,C13H6Cl6O2,,"Anti-Infective Agents, Anti-Infective Agents, Local, Antiseptics and Disinfectants, Benzene Derivatives, Chlorobenzenes, Chlorophenols, Dermatologicals, Drugs causing inadvertant photosensitivity, Phenol and Derivatives, Phenols, Photosensitizing Agents"," D-lactate dehydrogenase,  Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial,  Glutamate dehydrogenase 1, mitochondrial,  Estrogen receptor alpha","DB00756, DB11396",
DB00757,Dolasetron,approved; investigational,[H][C@@]1(C[C@@]2([H])C[C@]3([H])C[C@@]([H])(C1)N2CC3=O)OC(=O)C1=CNC2=C1C=CC=C2,C19H20N2O3,,"Alimentary Tract and Metabolism, Antidepressive Agents, Antiemetic Serotonin 5-HT3 Receptor Antagonists, Antiemetics, Antiemetics and Antinauseants, Autonomic Agents, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Gastrointestinal Agents, Heterocyclic Compounds, Fused-Ring, Moderate Risk QTc-Prolonging Agents, Neurotransmitter Agents, Peripheral Nervous System Agents, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 3 Receptor Antagonists, Serotonin 5-HT3 Receptor Antagonists, Serotonin Agents, Serotonin Receptor Antagonists"," 5-hydroxytryptamine receptor 3A,  Cytochrome P450 2C9,  Cytochrome P450 3A4,  Cytochrome P450 2D6","DB00757, DB11699, DB07243",
DB00758,Clopidogrel,approved,[H][C@@](N1CCC2=C(C1)C=CS2)(C(=O)OC)C1=CC=CC=C1Cl,C16H16ClNO2S,,"Antiplatelet agents, Blood and Blood Forming Organs, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (moderate), Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strong), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Decreased Platelet Aggregation, Hematologic Agents, Heterocyclic Compounds, Fused-Ring, Neurotransmitter Agents, OCT1 inhibitors, OCT2 Inhibitors, P-glycoprotein substrates, P2Y12 Platelet Inhibitor, Platelet Aggregation Inhibitors Excl. Heparin, Purinergic Agents, Purinergic Antagonists, Purinergic P2 Receptor Antagonists, Purinergic P2Y Receptor Antagonists, Pyridines, Sulfur Compounds, Thienopyridines, Thiophenes"," P2Y purinoceptor 12,  Cytochrome P450 2C9,  Cytochrome P450 1A2,  Cytochrome P450 2C8,  Liver carboxylesterase 1,  Cytochrome P450 3A4,  Cytochrome P450 2B6,  Cytochrome P450 3A5,  Cytochrome P450 2C19,  Serum albumin,  P-glycoprotein 1,  Solute carrier family 22 member 1,  Solute carrier family 22 member 2","DB00758, DB16349, DB00208",
DB00759,Tetracycline,approved; vet_approved; withdrawn,[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O,C22H24N2O8,,"Agents that produce neuromuscular block (indirect), Alimentary Tract and Metabolism, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antibiotics for Topical Use, Antiinfectives and Antiseptics for Local Oral Treatment, Antiinfectives for Systemic Use, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dermatologicals, Drugs causing inadvertant photosensitivity, Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord), Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Naphthacenes, OAT1/SLC22A6 inhibitors, OAT3/SLC22A8 Inhibitors, OAT3/SLC22A8 Substrates, Ophthalmological and Otological Preparations, Ophthalmologicals, Organic Anion Transporting Polypeptide 2B1 Inhibitors, Otologicals, Photosensitizing Agents, Protein Synthesis Inhibitors, Sensory Organs, Stomatological Preparations, Tetracyclines"," 30S ribosomal protein S7,  30S ribosomal protein S14,  30S ribosomal protein S3,  30S ribosomal protein S8,  30S ribosomal protein S19,  16S ribosomal RNA,  Major prion protein,  Multidrug translocase MdfA,  Protein-arginine deiminase type-4,  Cytochrome P450 3A4,  Serum albumin,  Solute carrier family 22 member 6,  Solute carrier family 22 member 8,  Solute carrier family 22 member 11,  Solute carrier family 22 member 7,  Solute carrier organic anion transporter family member 2B1","DB00759, DB09550, DB00595, DB09093, DB01301, DB00254, DB00256, DB00618, DB00453, DB00931, DB01017, DB13092, DB12035, DB12455, DB00560, DB12329, DB11647, DB15040, DB13264, DB11691",
DB00760,Meropenem,approved; investigational,[H][C@]1([C@@H](C)O)C(=O)N2C(C(O)=O)=C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)[C@H](C)[C@]12[H],C17H25N3O5S,,"Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, beta-Lactams, Carbapenems, Drugs that are Mainly Renally Excreted, Heterocyclic Compounds, Fused-Ring, Lactams, Penem Antibacterial, Sulfur Compounds, Thienamycins"," D-alanyl-D-alanine carboxypeptidase DacB,  Beta-lactamase OXA-10,  Dipeptidase 1","DB00760, DB06211, DB00303, DB01598, DB13028, DB16840, DB12587",
DB00761,Potassium chloride,approved; withdrawn,[Cl-].[K+],ClK,,"Agents causing hyperkalemia, Alimentary Tract and Metabolism, Blood and Blood Forming Organs, Blood Substitutes and Perfusion Solutions, Chlorides, Chlorine Compounds, Drugs that are Mainly Renally Excreted, Electrolyte Solutions, Hemodialysis Solution, I.V. Solution Additives, Mineral Supplements, Minerals, Potassium Compounds, Potassium Salt, Replacement Preparations"," Solute carrier family 12 member 2,  Solute carrier family 12 member 1,  Solute carrier family 12 member 5,  Solute carrier family 12 member 6,  Solute carrier family 12 member 7,  Solute carrier family 12 member 4,  Solute carrier family 12 member 2,  Solute carrier family 12 member 1,  Solute carrier family 12 member 5,  Solute carrier family 12 member 6,  Solute carrier family 12 member 7,  Solute carrier family 12 member 4",DB00761,
DB00762,Irinotecan,approved; investigational,CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12,C33H38N4O6,,"Alkaloids, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Substrates, Cholinesterase substrates, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Enzyme Inhibitors, Immunosuppressive Agents, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, OATP1B1/SLCO1B1 Inhibitors, P-glycoprotein substrates, P-glycoprotein substrates with a Narrow Therapeutic Index, Pharmaceutical Preparations, Topoisomerase 1 (TOP1) inhibitors, Topoisomerase I Inhibitors, Topoisomerase Inhibitors, UGT1A1 Substrates, UGT1A1 Substrates with a Narrow Therapeutic Index, UGT1A9 Substrates, UGT1A9 Substrates with a Narrow Therapeutic Index"," DNA topoisomerase I, mitochondrial,  DNA topoisomerase 1,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  UDP-glucuronosyltransferase 1-1,  UDP-glucuronosyltransferase 1-9,  Human Carboxylesterases (Protein Group),  Serum albumin,  Solute carrier family 22 member 3,  Solute carrier organic anion transporter family member 1B1,  Multidrug resistance-associated protein 1,  ATP-binding cassette sub-family G member 2,  P-glycoprotein 1,  Canalicular multispecific organic anion transporter 1","DB00762, DB05482, DB12385, DB12459, DB05806, DB04690, DB01030, DB12515, DB12222, DB12185, DB16186, DB06721, DB12124, DB12384, DB06159, DB17152, DB16138, DB17385, DB11191, DB11467, DB03614, DB00200, DB05168, DB03469, DB04803, DB13013, DB02975, DB03906, DB12674, DB05735",
DB00763,Methimazole,approved,CN1C=CNC1=S,C4H6N2S,,"Antithyroid agents, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 CYP2A6 Inhibitors, Cytochrome P-450 CYP2A6 Inhibitors (weak), Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (strong), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (weak), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strong), Cytochrome P-450 CYP3A4 Inhibitors (weak), Cytochrome P-450 Enzyme Inhibitors, Drugs that are Mainly Renally Excreted, Hormone Antagonists, Hormones, Hormone Substitutes, and Hormone Antagonists, Imidazoles, Immunosuppressive Agents, Myelosuppressive Agents, Sulfur Compounds, Sulfur-Containing Imidazole Derivatives, Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins, Thyroid Hormone Synthesis Inhibitor, Thyroid Hormone Synthesis Inhibitors, Thyroid Products"," Thyroid peroxidase,  Cytochrome P450 1A2,  Cytochrome P450 2A6,  Cytochrome P450 2B6,  Cytochrome P450 2C19,  Cytochrome P450 2C9,  Cytochrome P450 2D6,  Cytochrome P450 2E1,  Cytochrome P450 3A4,  Dimethylaniline monooxygenase [N-oxide-forming] 3",DB00763,
DB00764,Mometasone,experimental,[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,C22H28Cl2O4,,"Adrenal Cortex Hormones, Adrenals, Anti-Allergic Agents, Anti-Inflammatory Agents, Corticosteroid Hormone Receptor Agonists, Corticosteroids, Corticosteroids, Dermatological Preparations, Corticosteroids, Potent (Group III), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Inducers, Cytochrome P-450 CYP3A5 Inducers (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dermatologicals, Drugs for Obstructive Airway Diseases, Fused-Ring Compounds, Glucocorticoids, Hyperglycemia-Associated Agents, Immunosuppressive Agents, Nasal Preparations, Pregnadienediols, Pregnadienes, Pregnanes, Steroids, Thyroxine-binding globulin inhibitors"," Glucocorticoid receptor,  Progesterone receptor,  Cytochrome P450 2C8,  Cytochrome P450 3A4,  Cytochrome P450 3A5","DB00764, DB00240, DB00838, DB14221, DB00394, DB00860, DB00959, DB13208, DB00896, DB11750, DB14652, DB13856",
DB00765,Metyrosine,approved,C[C@](N)(CC1=CC=C(O)C=C1)C(O)=O,C10H13NO3,,"Amino Acids, Amino Acids, Aromatic, Amino Acids, Cyclic, Amino Acids, Peptides, and Proteins, Antihypertensive Agents, Catecholamine Synthesis Inhibitor, Enzyme Inhibitors, Methyltyrosines, Tyrosine Hydroxylase Inhibitors", Tyrosine 3-monooxygenase,"DB00765, DB16306, DB00135, DB03839, DB00968, DB03978, DB15296, DB00190, DB01235, DB00120, DB02556, DB03552, DB15405, DB03897, DB02685, DB04436, DB13313, DB01758, DB06838",
DB00766,Clavulanic acid,approved; vet_approved,[H][C@@]12CC(=O)N1[C@@H](C(O)=O)\C(O2)=C\CO,C8H9NO5,,"Anti-Bacterial Agents, Anti-Infective Agents, beta-Lactamase Inhibitors, beta-Lactams, Enzyme Inhibitors, Heterocyclic Compounds, Fused-Ring, Lactams", Sodium/glucose cotransporter 1,DB00766,
DB00767,Benzquinamide,withdrawn,CCN(CC)C(=O)C1CN2CCC3=CC(OC)=C(OC)C=C3C2CC1OC(C)=O,C22H32N2O5,,"Agents producing tachycardia, Anticholinergic Agents, Heterocyclic Compounds, Fused-Ring, Histamine Antagonists, Histamine H1 Antagonists, Muscarinic Antagonists, P-glycoprotein inhibitors"," Histamine H1 receptor,  Muscarinic acetylcholine receptor M4,  Muscarinic acetylcholine receptor M1,  Muscarinic acetylcholine receptor M5,  Muscarinic acetylcholine receptor M2,  Muscarinic acetylcholine receptor M3","DB00767, DB11915, DB16905, DB14945, DB04844, DB12161, DB13393, DB12268, DB00565, DB01226, DB00732, DB01135",
DB00768,Olopatadine,approved,CN(C)CC\C=C1\C2=CC=CC=C2COC2=C1C=C(CC(O)=O)C=C2,C21H23NO3,,"Anti-Allergic Agents, Anti-Inflammatory Agents, Antiallergic Agents, Excl. Corticosteroids, Antihistamine Drugs, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Decongestants and Antiallergics, Decreased Histamine Release, Dibenzoxepins, Heterocyclic Compounds, Fused-Ring, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Histamine H1 Antagonists, Non-Sedating, Histamine H1 Inhibitors, Mast Cell Stabilizers, Nasal Preparations, Neurotransmitter Agents, Ophthalmologicals, P-glycoprotein substrates, Peripheral Nervous System Agents, Sensory Organs, Sensory System Agents"," Histamine H1 receptor,  Histamine H2 receptor,  Histamine H3 receptor,  Protein S100-A1,  Protein S100-A12,  Protein S100-B,  Protein S100-A13,  Protein S100-A2,  Cytochrome P450 3A4,  Dimethylaniline monooxygenase [N-oxide-forming] 1,  Dimethylaniline monooxygenase [N-oxide-forming] 3,  Serum albumin,  P-glycoprotein 1","DB00768, DB01142, DB14750",
DB00769,Hydrocortamate,approved,[H][C@@]12CC[C@](O)(C(=O)COC(=O)CN(CC)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,C27H41NO6,,"Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 Enzyme Inducers"," Glucocorticoid receptor,  Cytochrome P450 3A4","DB00769, DB14539, DB14541, DB14545, DB14538, DB14543, DB14540, DB14544, DB12499, DB00603, DB11440, DB01380, DB15566, DB06780, DB14583, DB14632, DB08547, DB06789, DB14677, DB15999, DB14633, DB14644, DB01134, DB05288, DB13958, DB14643",
DB00770,Alprostadil,approved; investigational,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O,C20H34O5,,"Autacoids, Biological Factors, Cardiac Therapy, Cardiovascular Agents, Drugs Used in Erectile Dysfunction, Eicosanoids, Fatty Acids, Fatty Acids, Monounsaturated, Fatty Acids, Unsaturated, Genito Urinary System and Sex Hormones, Genitourinary Agents, Genitourinary Arterial Vasodilation, Hematologic Agents, Inflammation Mediators, Lipids, Miscellaneous Vasodilatating Agents, OAT1/SLC22A6 inhibitors, OAT1/SLC22A6 Substrates, OAT3/SLC22A8 Substrates, OATP2B1/SLCO2B1 substrates, Organic Anion Transporting Polypeptide 2B1 Inhibitors, Prostaglandin E1 Agonist, Prostaglandin Receptor Agonists, Prostaglandins, Prostaglandins E, Prostaglandins, Synthetic, Urological Agents, Urologicals, Vasodilating Agents, Venous Vasodilation"," Prostaglandin E2 receptor EP1 subtype,  Prostaglandin E2 receptor EP2 subtype,  Prostaglandin E2 receptor EP3 subtype,  Prostaglandin E2 receptor EP4 subtype,  Prostaglandin D2 receptor 2,  15-hydroxyprostaglandin dehydrogenase [NAD(+)],  Serum albumin,  Multidrug resistance-associated protein 4,  Multidrug resistance-associated protein 5,  Solute carrier organic anion transporter family member 2A1,  Solute carrier organic anion transporter family member 3A1,  Solute carrier organic anion transporter family member 2B1,  Solute carrier family 22 member 6","DB00770, DB00917, DB09211, DB08964, DB00929, DB07177, DB12789, DB02056, DB01160, DB00429",
DB00771,Clidinium,approved,C[N@@+]12CC[C@@H](CC1)C(C2)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,C22H26NO3,,"Acids, Carbocyclic, Agents producing tachycardia, Alimentary Tract and Metabolism, Anticholinergic Agents, Autonomic Agents, Benzilates, Central Nervous System Depressants, Decreased Parasympathetic Acetylcholine Activity, Digestive/GI System Activity Alteration, Diphenylacetic Acids, Drugs for Functional Gastrointestinal Disorders, GI Motility Alteration, Hydroxy Acids, Muscarinic Antagonists, Parasympatholytics, Peripheral Nervous System Agents, Phenylacetates, Quinuclidines", Muscarinic acetylcholine receptor M1,"DB00771, DB13844, DB04843, DB13351, DB15888, DB13507, DB13369, DB13542, DB09023, DB13181, DB13380, DB16287, DB00209, DB00986, DB01461",
DB00772,Malathion,approved; investigational,CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC,C10H19O6PS2,,"Agrochemicals, Antiparasitic Products, Insecticides and Repellents, Cholinergic Agents, Cholinesterase Inhibitors, Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 Substrates, Ectoparasiticides, Incl. Scabicides, Ectoparasiticides, Incl. Scabicides, Insecticides and Repellents, Enzyme Inhibitors, Insecticides, Neurotransmitter Agents, Organophosphates, Organophosphorus Compounds, Organothiophosphates, Organothiophosphorus Compounds, Pesticides, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Sulfur Compounds, Toxic Actions"," Cholinesterase,  Cytochrome P450 1A2,  Cytochrome P450 2B6",DB00772,
DB00773,Etoposide,approved,[H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(O)C(OC)=C1)C1=CC3=C(OCO3)C=C1[C@H]2O[C@@H]1O[C@]2([H])CO[C@@H](C)O[C@@]2([H])[C@H](O)[C@H]1O,C29H32O13,,"Antineoplastic Agents, Antineoplastic Agents, Phytogenic, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Substrates, Carbohydrates, Cardiotoxic antineoplastic agents, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Enzyme Inhibitors, Glucosides, Glycosides, Immunosuppressive Agents, Myelosuppressive Agents, Naphthalenes, Narrow Therapeutic Index Drugs, P-glycoprotein inhibitors, P-glycoprotein substrates, P-glycoprotein substrates with a Narrow Therapeutic Index, Podophyllotoxin, Podophyllotoxin Derivatives, Tetrahydronaphthalenes, Topoisomerase II Inhibitors, Topoisomerase Inhibitors, UGT1A1 Substrates, UGT1A1 Substrates with a Narrow Therapeutic Index"," DNA topoisomerase 2-alpha,  DNA topoisomerase 2-beta,  Cytochrome P450 1A2,  Cytochrome P450 2E1,  Cytochrome P450 3A5,  UDP-glucuronosyltransferase 1-1,  Glutathione S-transferase theta-1,  Glutathione S-transferase P,  Prostaglandin G/H synthase 2,  Prostaglandin G/H synthase 1,  Cytochrome P450 3A4,  Canalicular multispecific organic anion transporter 2,  Multidrug resistance-associated protein 6,  P-glycoprotein 1,  Multidrug resistance-associated protein 1,  Multidrug resistance-associated protein 7,  Canalicular multispecific organic anion transporter 1,  ATP-binding cassette sub-family G member 2","DB00773, DB00444, DB17255, DB01179, DB09094, DB12802",
DB00774,Hydroflumethiazide,approved; investigational; withdrawn,NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1C(F)(F)F,C8H8F3N3O4S2,,"Amides, Antihypertensive Agents, Benzothiadiazines, Cardiovascular Agents, Diuretics, Drugs causing inadvertant photosensitivity, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Heterocyclic Compounds, Fused-Ring, Hypotensive Agents, Increased Diuresis, Membrane Transport Modulators, Natriuretic Agents, OAT1/SLC22A6 inhibitors, OAT3/SLC22A8 Inhibitors, OAT3/SLC22A8 Substrates, Photosensitizing Agents, Sodium Chloride Symporter Inhibitors, Sulfonamides, Sulfones, Sulfur Compounds, Thiazides"," Solute carrier family 12 member 1,  Carbonic anhydrase 7,  Carbonic anhydrase 9,  Sodium/potassium-transporting ATPase subunit alpha-1,  Calcium-activated potassium channel subunit alpha-1,  Carbonic anhydrase 1,  Carbonic anhydrase 2,  Carbonic anhydrase 4,  Carbonic anhydrase 12,  Serum albumin,  Solute carrier family 22 member 6,  Solute carrier family 22 member 8","DB00774, DB00436, DB00999",
DB00775,Tirofiban,approved,CCCCS(=O)(=O)N[C@@H](CC1=CC=C(OCCCCC2CCNCC2)C=C1)C(O)=O,C22H36N2O5S,,"Amino Acids, Amino Acids, Aromatic, Amino Acids, Cyclic, Amino Acids, Peptides, and Proteins, Antiplatelet agents, Blood and Blood Forming Organs, Cardiovascular Agents, Decreased Platelet Aggregation, Drugs that are Mainly Renally Excreted, Fibrin Modulating Agents, Hematologic Agents, Platelet Aggregation Inhibitors Excl. Heparin"," Integrin alpha-IIb,  Integrin beta-3",DB00775,
DB00776,Oxcarbazepine,approved,NC(=O)N1C2=CC=CC=C2CC(=O)C2=C1C=CC=C2,C15H12N2O2,,"Anti-epileptic Agent, Anticonvulsants, Carboxamide Derivatives, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (strength unknown), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A5 Inducers, Cytochrome P-450 CYP3A5 Inducers (strength unknown), Cytochrome P-450 CYP3A5 Inhibitors, Cytochrome P-450 CYP3A5 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Decreased Central Nervous System Disorganized Electrical Activity, Dibenzazepines, Drugs causing inadvertant photosensitivity, Enzyme Inducing Antiepileptic Drugs, Heterocyclic Compounds, Fused-Ring, Membrane Transport Modulators, Miscellaneous Anticonvulsants, Nervous System, P-glycoprotein inducers, P-glycoprotein substrates, Photosensitizing Agents, Sodium Channel Blockers, Voltage-Gated Sodium Channel Blockers"," Sodium channel protein (Protein Group),  Aldo-keto reductase family 1 member C1,  Aldo-keto reductase family 1 member C2,  Aldo-keto reductase family 1 member C3,  Aldo-keto reductase family 1 member C4,  Carbonyl reductase [NADPH] 1,  Carbonyl reductase [NADPH] 3,  Cytochrome P450 2C19,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Serum albumin,  P-glycoprotein 1",DB00776,
DB00777,Propiomazine,approved,CCC(=O)C1=CC2=C(SC3=CC=CC=C3N2CC(C)N(C)C)C=C1,C20H24N2OS,,"Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Agents producing tachycardia, Agents that produce hypertension, Anticholinergic Agents, Antidepressive Agents, Central Nervous System Depressants, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Heterocyclic Compounds, Fused-Ring, Histamine Antagonists, Histamine H1 Antagonists, Hypnotics and Sedatives, Muscarinic Antagonists, Nervous System, Psycholeptics, Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2A Receptor Antagonists, Serotonin 5-HT2C Receptor Antagonists, Serotonin Agents, Serotonin Receptor Antagonists, Sulfur Compounds"," Histamine H1 receptor,  Muscarinic acetylcholine receptor (Protein Group),  Alpha-1A adrenergic receptor,  Dopamine D2 receptor,  5-hydroxytryptamine receptor 2A,  5-hydroxytryptamine receptor 2C","DB00777, DB01615, DB11540, DB01038, DB13213, DB01614, DB01063, DB11517, DB01069, DB13420, DB00392",
DB00778,Roxithromycin,approved; investigational; withdrawn,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O,C41H76N2O15,,"Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (weak), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Erythromycin and similars, Lactones, Macrolides, Macrolides, Lincosamides and Streptogramins, Moderate Risk QTc-Prolonging Agents, OATP1B1/SLCO1B1 Inhibitors, OATP1B3 inhibitors, Polyketides, QTc Prolonging Agents"," 50S ribosomal protein L10,  P-glycoprotein 1,  Cytochrome P450 2B6,  Cytochrome P450 3A4","DB00778, DB00199, DB01211, DB11442, DB13338, DB00207, DB11416, DB11474, DB13179",
DB00779,Nalidixic acid,approved; investigational,CCN1C=C(C(O)=O)C(=O)C2=C1N=C(C)C=C2,C12H12N2O3,,"4-Quinolones, Agents that reduce seizure threshold, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Drugs causing inadvertant photosensitivity, Enzyme Inhibitors, Fluoroquinolones, Heterocyclic Compounds, Fused-Ring, Moderate Risk QTc-Prolonging Agents, Naphthyridines, OAT1/SLC22A6 inhibitors, Photosensitizing Agents, QTc Prolonging Agents, Quinolines, Quinolones, Topoisomerase II Inhibitors, Topoisomerase Inhibitors"," DNA,  Tryptophan 2,3-dioxygenase,  Cytochrome P450 1A2,  Solute carrier family 22 member 6",DB00779,
DB00780,Phenelzine,approved,NNCCC1=CC=CC=C1,C8H12N2,,"Agents that produce hypertension, Agents that reduce seizure threshold, Antidepressive Agents, Antidepressive Agents Indicated for Depression, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (strength unknown), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2E1 Inducers, Cytochrome P-450 CYP2E1 Inducers (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A5 Inhibitors, Cytochrome P-450 CYP3A5 Inhibitors (strength unknown), Cytochrome P-450 CYP3A7 Inhibitors, Cytochrome P-450 CYP3A7 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Hydrazines, Hypotensive Agents, Monoamine Oxidase A Substrates, Monoamine Oxidase Inhibitors, Monoamine Oxidase Inhibitors, Non-Selective, Nervous System, Psychoanaleptics, Psychotropic Drugs, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin Modulators"," Amine oxidase [flavin-containing] A,  Amine oxidase [flavin-containing] B,  Membrane primary amine oxidase,  4-aminobutyrate aminotransferase, mitochondrial,  Alanine aminotransferase 1,  Alanine aminotransferase 2,  Glutamic acid decarboxylase,  Cytochrome P450 2C19,  Cytochrome P450 2C8,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  Cytochrome P450 2D6,  Cytochrome P450 3A Subfamily (Protein Group),  Amine oxidase [flavin-containing] A,  Amine oxidase [flavin-containing] B, 10. Cytochrome P450 2E1","DB00780, DB04325, DB09250",
DB00782,Propantheline,approved,CC(C)[N+](C)(CCOC(=O)C1C2=CC=CC=C2OC2=CC=CC=C12)C(C)C,C23H30NO3,,"Agents producing tachycardia, Alimentary Tract and Metabolism, Amines, Anti-Ulcer Agents, Anticholinergic Agents, Cholinergic Agents, Drugs for Functional Gastrointestinal Disorders, Drugs that are Mainly Renally Excreted, Gastrointestinal Agents, Heterocyclic Compounds, Fused-Ring, Muscarinic Antagonists, Neurotransmitter Agents, Onium Compounds, Quaternary Ammonium Compounds, Synthetic Anticholinergics, Quaternary Ammonium Compounds, Xanthenes", Muscarinic acetylcholine receptor M1,"DB00782, DB00940",
DB00783,Estradiol,approved; investigational; vet_approved,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,C18H24O2,,"Adrenal Cortex Hormones, Androgens and Estrogens, Anti-Gonadotropin-Releasing Hormones, Antiandrogens and Estrogens, BCRP/ABCG2 Inhibitors, COMT Substrates, Contraceptive Agents, Female, Contraceptives, Oral, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (weak), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Estradiol Congeners, Estradiol, agonists, Estranes, Estrenes, Estrogen Contraceptives, Estrogens, Estrogens, agonists, Fused-Ring Compounds, Genito Urinary System and Sex Hormones, Gonadal Hormones, Gonadal Steroid Hormones, Hormonal Contraceptives for Systemic Use, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hyperglycemia-Associated Agents, Hypothalamic Hormones, Intravaginal Contraceptives, Natural and Semisynthetic Estrogens, Plain, OAT3/SLC22A8 Substrates, OATP1B1/SLCO1B1 Inhibitors, OCT2 Inhibitors, P-glycoprotein substrates, Pituitary and Hypothalamic Hormones and Analogues, Progestogens and Estrogens, Sequential Preparations, Sex Hormones and Modulators of the Genital System, Steroids, Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins, Thyroxine-binding globulin inducers, UGT1A1 Substrates"," Estrogen receptor alpha,  Estrogen receptor beta,  Nuclear receptor subfamily 1 group I member 2,  Neuronal acetylcholine receptor subunit alpha-4,  G-protein coupled estrogen receptor 1,  ATP synthase subunit a,  Beclin-1,  Cytochrome P450 3A4,  Cytochrome P450 1A2,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  UDP-glucuronosyltransferase 1-1,  Cytochrome P450 1A1,  Cytochrome P450 1B1,  Cytochrome P450 2C19,  Cytochrome P450 2C8, 10. Cytochrome P450 2C9, 11. UDP-glucuronosyltransferase 2B15, 12. Catechol O-methyltransferase, 13. UDP-glucuronosyltransferases (UGTs) (Protein Group), 14. Cytochrome P450 19A1,  Sex hormone-binding globulin,  Serum albumin,  Fatty acid-binding protein, intestinal,  Solute carrier family 22 member 2,  Solute carrier family 22 member 3,  Multidrug resistance-associated protein 7,  Solute carrier family 22 member 11,  ATP-binding cassette sub-family G member 2,  Solute carrier organic anion transporter family member 1B1,  P-glycoprotein 1,  Solute carrier family 22 member 8,  Solute carrier organic anion transporter family member 1B3, 10. Solute carrier organic anion transporter family member 1C1","DB00783, DB04573, DB07702, DB07706, DB00977, DB12235, DB13386, DB07707, DB15690, DB02342, DB01357, DB12487, DB13956, DB00655, DB07891, DB13952, DB13954, DB03860, DB13418, DB07678, DB04575, DB06597, DB00947",
DB00784,Mefenamic acid,approved,CC1=C(C)C(NC2=CC=CC=C2C(O)=O)=CC=C1,C15H15NO2,,"Acids, Carbocyclic, Agents causing hyperkalemia, Agents that produce hypertension, Amines, Aminobenzoates, Analgesics, Analgesics, Non-Narcotic, Aniline Compounds, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Antiinflammatory and Antirheumatic Products, Antiinflammatory and Antirheumatic Products, Non-Steroids, Antirheumatic Agents, Benzene Derivatives, Benzoates, Central Nervous System Agents, Cyclooxygenase Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (weak), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (weak), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs causing inadvertant photosensitivity, Enzyme Inhibitors, Fenamates, Musculo-Skeletal System, Nephrotoxic agents, ortho-Aminobenzoates, Other Nonsteroidal Anti-inflammatory Agents, Peripheral Nervous System Agents, Photosensitizing Agents, Sensory System Agents, UGT1A9 Inhibitors, UGT2B7 Inhibitors"," Prostaglandin G/H synthase 2,  Prostaglandin G/H synthase 1,  Cytochrome P450 2C9,  Cytochrome P450 1A2,  UDP-glucuronosyltransferase 1-9,  UDP-glucuronosyltransferase 2B7,  Cytochrome P450 2C8,  Serum albumin","DB00784, DB02266, DB09216, DB00939, DB02179",
DB00785,Cryptenamine,approved,,,,"Alkaloids, Antihypertensive Agents, Cardiovascular Agents, Cevanes, Heterocyclic Compounds, Fused-Ring, Veratrum Alkaloids"," Muscarinic acetylcholine receptor M2,  Beta adrenergic receptor (Protein Group)",,
DB00786,Marimastat,investigational,CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C,C15H29N3O5,,"Amines, Enzyme Inhibitors, Hydroxy Acids, Hydroxylamines, Metalloendopeptidases, antagonists & inhibitors"," Interstitial collagenase,  72 kDa type IV collagenase,  Stromelysin-1,  Matrilysin,  Neutrophil collagenase,  Matrix metalloproteinase-9,  Stromelysin-2,  Stromelysin-3,  Macrophage metalloelastase, 10. Collagenase 3, 11. Matrix metalloproteinase-14, 12. Matrix metalloproteinase-15, 13. Matrix metalloproteinase-16, 14. Matrix metalloproteinase-17, 15. Matrix metalloproteinase-19, 16. Matrix metalloproteinase-20, 17. Matrix metalloproteinase-21, 18. Matrix metalloproteinase-23, 19. Matrix metalloproteinase-24, 20. Matrix metalloproteinase-25, 21. Matrix metalloproteinase-26, 22. Matrix metalloproteinase-27, 23. Matrix metalloproteinase-28","DB00786, DB04310, DB02090",
DB00787,Acyclovir,approved,NC1=NC(=O)C2=C(N1)N(COCCO)C=N2,C8H11N5O3,,"Acyclovir and prodrug, Anti-Infective Agents, Antiinfectives for Systemic Use, Antiviral Agents, Antivirals for Systemic Use, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 Substrates, Dermatologicals, Direct Acting Antivirals, Drugs that are Mainly Renally Excreted, Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor, Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor, Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor, Heterocyclic Compounds, Fused-Ring, MATE 1 Substrates, MATE 2 Substrates, MATE substrates, Nephrotoxic agents, Nucleic Acid Synthesis Inhibitors, Nucleosides and Nucleotides, Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors, OAT1/SLC22A6 inhibitors, OAT1/SLC22A6 Substrates, OAT3/SLC22A8 Inhibitors, OAT3/SLC22A8 Substrates, OCT1 inhibitors, OCT1 substrates, Ophthalmologicals, Purines, Purinones, Sensory Organs"," DNA polymerase catalytic subunit,  DNA polymerase catalytic subunit,  Thymidine kinase,  Guanylate kinase,  Nucleoside diphosphokinase (Protein Group),  Pyruvate Kinases (Protein Group),  Creatine Kinases (Protein Group),  Phosphoglycerate Kinases (Protein Group),  Succinyl-CoA Synthetases (Protein Group),  Phosphoenolpyruvate Carboxykinases (Protein Group),  Adenylosuccinate Synthetases (Protein Group),  Serum albumin,  Solute carrier family 22 member 1,  Solute carrier family 22 member 6,  Solute carrier family 22 member 8,  Ileal sodium/bile acid cotransporter,  Multidrug and toxin extrusion protein 1,  Multidrug and toxin extrusion protein 2","DB00787, DB01004, DB00577, DB01610, DB02489, DB03609",
DB00788,Naproxen,approved; vet_approved,COC1=CC2=C(C=C1)C=C(C=C2)[C@H](C)C(O)=O,C14H14O3,,"Agents causing hyperkalemia, Agents that produce hypertension, Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Antigout Preparations, Antiinflammatory and Antirheumatic Products, Antiinflammatory and Antirheumatic Products, Non-Steroids, Antiinflammatory Preparations, Non-Steroids for Topical Use, Antiinflammatory Products for Vaginal Administration, Antirheumatic Agents, BSEP/ABCB11 Substrates, Central Nervous System Agents, Cyclooxygenase Inhibitors, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 Substrates, Drugs causing inadvertant photosensitivity, Enzyme Inhibitors, Genito Urinary System and Sex Hormones, Musculo-Skeletal System, Naphthaleneacetic Acids, Naphthalenes, Nephrotoxic agents, Non COX-2 selective NSAIDS, OAT1/SLC22A6 inhibitors, Other Nonsteroidal Anti-inflammatory Agents, P-glycoprotein inhibitors, Peripheral Nervous System Agents, Photosensitizing Agents, Propionates, Sensory System Agents, Topical Products for Joint and Muscular Pain, UGT1A1 Substrates, UGT1A3 substrates, UGT1A6 substrate, UGT1A9 Substrates, UGT2B7 substrates"," Prostaglandin G/H synthase 1,  Prostaglandin G/H synthase 2,  Peptostreptococcal albumin-binding protein,  Cytochrome P450 2C8,  UDP-glucuronosyltransferase 2B7,  UDP-glucuronosyltransferase 1-3,  UDP-glucuronosyltransferase 1-6,  UDP-glucuronosyltransferase 1-7,  UDP-glucuronosyltransferase 1-8,  UDP-glucuronosyltransferase 1-9,  UDP-glucuronosyltransferase 1-10,  Cytochrome P450 2C9, 10. Cytochrome P450 1A2,  Serum albumin,  Solute carrier organic anion transporter family member 1A2,  Solute carrier family 22 member 6,  Bile salt export pump,  P-glycoprotein 1,  Solute carrier family 22 member 8","DB00788, DB15877",
DB00789,Gadopentetic acid,approved,[Gd+3].OC(=O)CN(CCN(CCN(CC(O)=O)CC([O-])=O)CC([O-])=O)CC([O-])=O,C14H20GdN3O10,,"Acetates, Acids, Acyclic, Amines, Compounds used in a research, industrial, or household setting, Contrast Media, Coordination Complexes, Diagnostic Uses of Chemicals, Drugs that are Mainly Renally Excreted, Magnetic Resonance Contrast Activity, Magnetic Resonance Imaging Contrast Media, Miscellaneous Therapeutic Agents, Other Diagnostics, Paramagnetic Contrast Agent, Paramagnetic Contrast Media, Polyamines"," 6-phosphogluconate dehydrogenase, decarboxylating","DB00789, DB14007, DB09425, DB00974, DB13404, DB14600, DB14598, DB14599, DB09132, DB00225, DB00597, DB02810",
DB00790,Perindopril,approved,[H][C@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O,C19H32N2O5,,"ACE Inhibitors and Calcium Channel Blockers, ACE Inhibitors and Diuretics, Agents Acting on the Renin-Angiotensin System, Agents causing angioedema, Agents causing hyperkalemia, Alkanes, Amines, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Butanes, Cardiovascular Agents, Cholinesterase Inhibitors, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Heterocyclic Compounds, Fused-Ring, Hydrocarbons, Acyclic, Hypotensive Agents, Indoles, Lipid Modifying Agents, Protease Inhibitors"," Angiotensin-converting enzyme,  Secreted frizzled-related protein 4,  Cholinesterase,  Solute carrier family 15 member 1,  Solute carrier family 15 member 2","DB00790, DB14213, DB00519, DB00178, DB14209, DB14208",
DB00791,Uracil mustard,approved,ClCCN(CCCl)C1=CNC(=O)NC1=O,C8H11Cl2N3O2,,"Alkylating Drugs, Antineoplastic Agents, Antineoplastic Agents, Alkylating, Antineoplastic and Immunomodulating Agents, Hydrocarbons, Halogenated, Mustard Compounds, Narrow Therapeutic Index Drugs, Nitrogen Mustard Compounds, Nitrosoureas, Noxae, Pyrimidines, Pyrimidinones, Toxic Actions", DNA,DB00791,
DB00792,Tripelennamine,approved; vet_approved,CN(C)CCN(CC1=CC=CC=C1)C1=CC=CC=N1,C16H21N3,,"Amines, Aminopyridines, Anti-Allergic Agents, Antihistamines for Systemic Use, Antihistamines for Topical Use, Antipruritics, Incl. Antihistamines, Anesthetics, Etc., Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Dermatologicals, Diamines, Ethylenediamine Derivatives, Ethylenediamines, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Neurotransmitter Agents, Polyamines, Pyridines, Substituted Ethylene Diamines"," Histamine H1 receptor,  Cytochrome P450 2D6,  Serum albumin","DB00792, DB08800, DB06691, DB16022",
DB00793,Haloprogin,approved; withdrawn,ClC1=CC(Cl)=C(Cl)C=C1OCC#CI,C9H4Cl3IO,,"Anti-Infective Agents, Antifungal Agents, Antifungals for Dermatological Use, Antifungals for Topical Use, Benzene Derivatives, Dermatologicals, Ethers, Phenols",,DB00793,
DB00794,Primidone,approved; vet_approved,CCC1(C(=O)NCNC1=O)C1=CC=CC=C1,C12H14N2O2,,"Anti-epileptic Agent, Anticholinergic Agents, Anticonvulsants, Barbiturates, Barbiturates and Derivatives, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP1A2 Inducers (strength unknown), Cytochrome P-450 CYP1A2 Inducers (strong), Cytochrome P-450 CYP2C19 Inducers, Cytochrome P-450 CYP2C19 Inducers (strength unknown), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C9 Inducers, Cytochrome P-450 CYP2C9 Inducers (strength unknown), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2E1 Inducers, Cytochrome P-450 CYP2E1 Inducers (strength unknown), Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inducers (strong), Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Inducers (strong), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Substrates, Decreased Central Nervous System Disorganized Electrical Activity, Enzyme Inducing Antiepileptic Drugs, GABA Agents, GABA Modulators, Hypnotics and Sedatives, Nervous System, Neurotransmitter Agents, Nicotinic Antagonists, Phenobarbital and similars, Psycholeptics, Pyrimidines, Pyrimidinones, UGT1A1 Inducers"," Gamma-aminobutyric acid receptor subunit alpha-2,  Gamma-aminobutyric acid receptor subunit alpha-3,  Gamma-aminobutyric acid receptor subunit alpha-4,  Gamma-aminobutyric acid receptor subunit alpha-5,  Gamma-aminobutyric acid receptor subunit alpha-6,  GABA(A) Receptor (Protein Group),  Gamma-aminobutyric acid receptor subunit alpha-1,  Neuronal acetylcholine receptor subunit alpha-4,  Neuronal acetylcholine receptor subunit alpha-7, 10. Glutamate receptor 2, 11. Glutamate receptor ionotropic, kainate 2,  Cytochrome P450 2C9,  Cytochrome P450 2C19,  Cytochrome P450 2E1,  Cytochrome P450 3A4,  Cytochrome P450 1A2,  UDP-glucuronosyltransferases (UGTs) (Protein Group),  Transient receptor potential cation channel subfamily M member 3","DB00794, DB01174, DB00849, DB13362, DB09001",
DB00795,Sulfasalazine,approved,OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=C1,C18H14N4O5S,,"Agents causing hyperkalemia, Agents that produce hypertension, Alimentary Tract and Metabolism, Amides, Aminosalicylate, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents, Antirheumatic Agents, BCRP/ABCG2 Inhibitors, BCRP/ABCG2 Substrates, Gastrointestinal Agents, Immunosuppressive Agents, Intestinal Antiinflammatory Agents, Methemoglobinemia Associated Agents, Nephrotoxic agents, Non COX-2 selective NSAIDS, NTCP Inhibitors, OATP1B1/SLCO1B1 Inhibitors, OATP1B3 inhibitors, Organic Anion Transporting Polypeptide 2B1 Inhibitors, Salicylates, Sulfonamides, Sulfones, Sulfur Compounds"," Arachidonate 5-lipoxygenase,  Prostaglandin G/H synthase 2,  Prostaglandin G/H synthase 1,  Acetyl-CoA acetyltransferase, mitochondrial,  Phospholipase A2,  Cystine/glutamate transporter,  Nuclear factor NF-kappa-B p105 subunit,  Nuclear factor NF-kappa-B p100 subunit,  Inhibitor of nuclear factor kappa-B kinase subunit beta, 10. Inhibitor of nuclear factor kappa-B kinase subunit alpha, 11. Peroxisome proliferator-activated receptor gamma,  Serum albumin,  ATP-binding cassette sub-family G member 2,  Canalicular multispecific organic anion transporter 1,  Proton-coupled folate transporter,  Solute carrier organic anion transporter family member 1B1,  Solute carrier organic anion transporter family member 1B3,  Solute carrier organic anion transporter family member 2B1,  Sodium/bile acid cotransporter",DB00795,
DB00796,Candesartan cilexetil,approved,CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1,C33H34N6O6,,"Agents Acting on the Renin-Angiotensin System, Agents causing hyperkalemia, Angiotensin 2 Receptor Blocker, Angiotensin II Antagonists and Diuretics, Angiotensin II receptor antagonists, Angiotensin Receptor Antagonists, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Benzene Derivatives, Cardiovascular Agents, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strong), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Heterocyclic Compounds, Fused-Ring, Hypotensive Agents, P-glycoprotein inhibitors, UGT1A3 substrates"," Type-1 angiotensin II receptor,  Cytochrome P450 2C9,  Cytochrome P450 2C8,  UDP-glucuronosyltransferase 1-3,  Prostaglandin G/H synthase 1,  P-glycoprotein 1","DB00796, DB13919, DB08822",
DB00797,Tolazoline,approved; vet_approved,C(C1=NCCN1)C1=CC=CC=C1,C10H12N2,,"Adrenergic Agents, Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Agents that produce hypertension, Antihypertensive Agents, Cardiovascular Agents, Hypotensive Agents, Imidazoles, Imidazoline Derivatives, Imidazolines, Musculo-Skeletal System, Neurotransmitter Agents, Peripheral alpha-1 blockers, Peripheral Vasodilators, Topical Products for Joint and Muscular Pain, Vasodilating Agents"," Alpha-1A adrenergic receptor,  Alpha-2A adrenergic receptor,  Histamine H1 receptor,  Histamine H2 receptor,  Alpha-2C adrenergic receptor,  Alpha-2B adrenergic receptor","DB00797, DB06711, DB06694, DB15881",
DB00798,Gentamicin,approved; vet_approved,[H][C@@]1(CN)CC[C@@H](N)[C@@H](O[C@]2([H])[C@@H](N)C[C@@H](N)[C@H](O[C@@]3([H])OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1.[H][C@]1(CC[C@@H](N)[C@@H](O[C@]2([H])[C@@H](N)C[C@@H](N)[C@H](O[C@@]3([H])OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1)C(C)N.[H][C@]1(CC[C@@H](N)[C@@H](O[C@]2([H])[C@@H](N)C[C@@H](N)[C@H](O[C@@]3([H])OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1)C(C)NC,C60H123N15O21,,"Agents that produce neuromuscular block (indirect), alpha-Galactosidase, antagonists & inhibitors, Aminoglycoside Antibacterials, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antibiotics for Topical Use, Antiinfectives for Systemic Use, Carbohydrates, Dermatologicals, Drugs that are Mainly Renally Excreted, Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index, Enzyme Inhibitors, Gentamicins, Glycosides, Narrow Therapeutic Index Drugs, Nephrotoxic agents, OAT1/SLC22A6 inhibitors, OCT2 Substrates, OCT2 Substrates with a Narrow Therapeutic Index, Ophthalmological and Otological Preparations, Ophthalmologicals, Otologicals, Protein Synthesis Inhibitors, Sensory Organs"," 30S ribosomal protein S12,  16S ribosomal RNA,  23S ribosomal RNA,  NH(3)-dependent NAD(+) synthetase,  Dihydrofolate reductase,  Solute carrier family 22 member 2,  Low-density lipoprotein receptor-related protein 2,  Canalicular multispecific organic anion transporter 1","DB00798, DB13274, DB04729, DB17884, DB04263, DB00684, DB13270, DB13673, DB01172, DB04718, DB00452, DB01421, DB13540, DB04728, DB03615, DB04717, DB15080, DB17631, DB04626, DB04808, DB11520, DB16951, DB12604, DB11512, DB06696, DB00955, DB01082, DB00919",
DB00799,Tazarotene,approved; investigational,CCOC(=O)C1=CN=C(C=C1)C#CC1=CC2=C(SCCC2(C)C)C=C1,C21H21NO2S,,"Antipsoriatics, Antipsoriatics for Topical Use, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 Substrates, Dermatologicals, Keratolytic Agents, Misc. Skin and Mucous Membrane Agents, Noxae, Prodrugs, Pyridines, Retinoids, Teratogens, Toxic Actions"," Retinoic acid receptor alpha,  Retinoic acid receptor RXR-beta,  Retinoic acid receptor gamma,  Retinoic acid receptor beta,  Cytochrome P450 2C8",DB00799,
DB00800,Fenoldopam,approved,OC1=CC=C(C=C1)C1CNCCC2=C(Cl)C(O)=C(O)C=C12,C16H16ClNO3,,"Adrenergic and Dopaminergic Agents, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Benzazepines, Cardiac Stimulants Excl. Cardiac Glycosides, Cardiac Therapy, Cardiovascular Agents, Dopamine Agents, Dopamine Agonists, Dopamine D1 Receptor Agonists, Drugs that are Mainly Renally Excreted, Heterocyclic Compounds, Fused-Ring, Hypotensive Agents, Neurotransmitter Agents, Vasodilating Agents"," Dopamine D5 receptor,  Dopamine D1 receptor,  Alpha-1B adrenergic receptor,  Alpha-1D adrenergic receptor,  Alpha-1A adrenergic receptor,  Alpha-2B adrenergic receptor,  Alpha-2C adrenergic receptor,  Alpha-2A adrenergic receptor",DB00800,
DB00801,Halazepam,approved; illicit; withdrawn,FC(F)(F)CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1,C17H12ClF3N2O,,"Anti-Anxiety Agents, Benzazepines, Benzodiazepines and benzodiazepine derivatives, Central Nervous System Agents, Central Nervous System Depressants, Heterocyclic Compounds, Fused-Ring, Nervous System, Psycholeptics, Psychotropic Drugs, Tranquilizing Agents"," GABA(A) Receptor (Protein Group),  GABA(A) Receptor Benzodiazepine Binding Site (Protein Group)","DB00801, DB00829, DB13335, DB01567, DB14028, DB01588, DB00690, DB00231, DB00842, DB13837, DB01511, DB00628, DB13872, DB13437, DB01594, DB01589, DB14671, DB00186",
DB00802,Alfentanil,approved; illicit,CCN1N=NN(CCN2CCC(COC)(CC2)N(C(=O)CC)C2=CC=CC=C2)C1=O,C21H32N6O3,,"Agents that produce hypertension, Analgesics, Anesthetics, Anesthetics, General, Anesthetics, Intravenous, Bradycardia-Causing Agents, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Substrates, Fentanyl and fentanyl analogues, High-risk opioids, Narcotics, Nervous System, Opiate Agonists, Opioid Agonist, Opioid Anesthetics, Opioids, Opioids, Anilidopiperidine, P-glycoprotein inhibitors, Peripheral Nervous System Agents, Phenylpiperidine opioids, Piperidines, Sensory System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"," Mu-type opioid receptor,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  Alpha-1-acid glycoprotein 1,  Serum albumin,  P-glycoprotein 1","DB00802, DB09172, DB09181",
DB00803,Colistin,approved,CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)C(NC(=O)[C@@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O,C52H98N16O13,,"Agents that produce neuromuscular block (indirect), Alimentary Tract and Metabolism, Amino Acids, Peptides, and Proteins, Aminoglycoside Antibacterials, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents, Antiinfectives for Systemic Use, Antimicrobial Cationic Peptides, Antimicrobial Peptides, Drugs that are Mainly Renally Excreted, Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index, Intestinal Antiinfectives, Lipids, Lipopeptides, Membrane Proteins, Narrow Therapeutic Index Drugs, Nephrotoxic agents, Peptides, Peptides, Cyclic, Polymyxins, Pore Forming Cytotoxic Proteins, Proteins",,"DB00803, DB01111, DB18246, DB00781, DB00091, DB12139, DB13068, DB11801, DB11693",
DB00804,Dicyclomine,approved,CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1,C19H35NO2,,"Acids, Carbocyclic, Agents producing tachycardia, Alimentary Tract and Metabolism, Anticholinergic Agents, Antimuscarinics Antispasmodics, Autonomic Agents, Cholinergic Agents, Cyclohexanecarboxylic Acids, Cyclohexanes, Cycloparaffins, Drugs for Functional Gastrointestinal Disorders, Drugs that are Mainly Renally Excreted, Muscarinic Antagonists, Neurotransmitter Agents, Parasympatholytics, Peripheral Nervous System Agents, Synthetic Anticholinergics, Esters With Tertiary Amino Group"," Muscarinic acetylcholine receptor M1,  Muscarinic acetylcholine receptor M3,  Muscarinic acetylcholine receptor M2","DB00804, DB13678, DB13581",
DB00805,Minaprine,approved,CC1=CC(=NN=C1NCCN1CCOCC1)C1=CC=CC=C1,C17H22N4O,,"Agents that produce hypertension, Agents that reduce seizure threshold, Antidepressive Agents, Central Nervous System Agents, Central Nervous System Depressants, Central Nervous System Stimulants, Cholinesterase Inhibitors, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 Substrates, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates, Monoamine Oxidase Inhibitors, Nervous System, Psychoanaleptics, Psychotropic Drugs, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2A Receptor Antagonists, Serotonin 5-HT2C Receptor Antagonists, Serotonin Agents, Serotonin Receptor Antagonists"," Amine oxidase [flavin-containing] A,  5-hydroxytryptamine receptor 2B,  5-hydroxytryptamine receptor 2A,  5-hydroxytryptamine receptor 2C,  Acetylcholinesterase,  Sodium-dependent serotonin transporter,  Dopamine D1 receptor,  Dopamine D2 receptor,  Muscarinic acetylcholine receptor M1,  Cytochrome P450 2D6",DB00805,
DB00806,Pentoxifylline,approved; investigational,CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C,C13H18N4O3,,"Alkaloids, Antioxidants, Antiplatelet agents, Blood Viscosity Reducer, Cardiovascular Agents, Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 Substrates, Drugs for Obstructive Airway Diseases, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Free Radical Scavengers, Hematologic Activity Alteration, Hematologic Agents, Hemorrheologic Agents, Heterocyclic Compounds, Fused-Ring, Peripheral Vasodilators, Phosphodiesterase 5 Inhibitors, Phosphodiesterase Inhibitors, Protective Agents, Purine Derivatives, Purines, Purinones, Radiation-Protective Agents, Vasodilating Agents, Xanthine derivatives"," Adenosine receptor A2a,  Adenosine receptor A1,  5'-nucleotidase,  Cytochrome P450 1A2","DB00806, DB06479, DB13634, DB12406, DB15122, DB18002, DB13098, DB07954, DB13449, DB00824, DB00201, DB13573, DB00651, DB13592, DB02290, DB03022, DB03812, DB03973, DB02135, DB02711, DB09092, DB01412",
DB00807,Proparacaine,approved; vet_approved,CCCOC1=C(N)C=C(C=C1)C(=O)OCCN(CC)CC,C16H26N2O3,,"Acids, Carbocyclic, Aminobenzoates, Anesthetics, Anesthetics, Local, Benzene Derivatives, Benzoates, Central Nervous System Agents, Central Nervous System Depressants, Ethers, Hydroxy Acids, Hydroxybenzoate Ethers, Hydroxybenzoates, Isomerism, Local Anesthesia, Ophthalmologicals, para-Aminobenzoates, Peripheral Nervous System Agents, Phenols, Phenyl Ethers, Sensory Organs, Sensory System Agents", Sodium channel protein type 10 subunit alpha,"DB00807, DB00892",
DB00808,Indapamide,approved,CC1CC2=CC=CC=C2N1NC(=O)C1=CC(=C(Cl)C=C1)S(N)(=O)=O,C16H16ClN3O3S,,"Amides, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Cardiovascular Agents, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Diuretics, Drugs causing inadvertant photosensitivity, Drugs that are Mainly Renally Excreted, Genito Urinary System and Sex Hormones, Heterocyclic Compounds, Fused-Ring, Hyperglycemia-Associated Agents, Hypotensive Agents, Increased Diuresis, Indoles, Lipid Modifying Agents, Low-Ceiling Diuretics, Excl. Thiazides, Membrane Transport Modulators, Natriuretic Agents, Non Potassium Sparing Diuretics, Photosensitizing Agents, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Sodium Chloride Symporter Inhibitors, Sulfonamides, Sulfones, Sulfur Compounds, Thiazide-like Diuretic"," Solute carrier family 12 member 3,  Cytochrome P450 3A4,  Epoxide hydrolase 1,  alpha1-acid glycoprotein (Protein Group),  Serum albumin","DB00808, DB07467",
DB00809,Tropicamide,approved; investigational,CCN(CC1=CC=NC=C1)C(=O)C(CO)C1=CC=CC=C1,C17H20N2O2,,"Anticholinergic Agents, Autonomic Agents, Cholinergic Agents, Muscarinic Antagonists, Mydriatics, Mydriatics and Cycloplegics, Neurotransmitter Agents, Ophthalmologicals, Peripheral Nervous System Agents, Pyridines, Sensory Organs"," Muscarinic acetylcholine receptor M4,  Muscarinic acetylcholine receptor M1,  Muscarinic acetylcholine receptor M2,  Muscarinic acetylcholine receptor M3",DB00809,
DB00810,Biperiden,approved; investigational,OC(CCN1CCCCC1)(C1CC2CC1C=C2)C1=CC=CC=C1,C21H29NO,,"Agents producing tachycardia, Anti-Dyskinesia Agents, Anti-Parkinson Drugs, Anticholinergic Agents, Autonomic Agents, Aza Compounds, Azabicyclo Compounds, Bridged-Ring Compounds, Central Nervous System Agents, Cholinergic Agents, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Muscarinic Antagonists, Nervous System, Neurotransmitter Agents, Nicotinic Antagonists, Parasympatholytics, Peripheral Nervous System Agents, Piperidines, Tertiary Amines"," Muscarinic acetylcholine receptor M1,  Cytochrome P450 2D6","DB00810, DB00942, DB00387, DB00376, DB00505",
DB00811,Ribavirin,approved,NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,C8H12N4O5,,"Anti-Infective Agents, Antiinfectives for Systemic Use, Antimetabolites, Antiviral Agents, Antivirals for Systemic Use, Antivirals for treatment of HCV infections, Direct Acting Antivirals, Drugs that are Mainly Renally Excreted, Noxae, Nucleic Acids, Nucleotides, and Nucleosides, Nucleoside Analog Antiviral, Nucleosides, Nucleosides and Nucleotides, Ribonucleosides, Toxic Actions, Treatments for Hepatitis C"," Inosine-5'-monophosphate dehydrogenase 1,  RNA-directed RNA polymerase L,  Genome polyprotein,  Inosine-5'-monophosphate dehydrogenase 2,  RNA-directed RNA polymerase catalytic subunit,  Cytosolic purine 5'-nucleotidase,  Adenosine kinase,  Solute carrier family 28 member 3,  Equilibrative nucleoside transporter 1","DB00811, DB06523, DB14663, DB17193, DB06408",
DB00812,Phenylbutazone,approved; vet_approved,CCCCC1C(=O)N(N(C1=O)C1=CC=CC=C1)C1=CC=CC=C1,C19H20N2O2,,"Agents causing hyperkalemia, Agents that produce hypertension, Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Antiinflammatory and Antirheumatic Products, Antiinflammatory and Antirheumatic Products, Non-Steroids, Antiinflammatory Preparations, Non-Steroids for Topical Use, Antirheumatic Agents, Butylpyrazolidines, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Musculo-Skeletal System, Nephrotoxic agents, Non COX-2 selective NSAIDS, OAT1/SLC22A6 inhibitors, OAT3/SLC22A8 Inhibitors, Peripheral Nervous System Agents, Pyrazoles, Pyrazolones, Sensory System Agents, Topical Products for Joint and Muscular Pain"," Prostaglandin G/H synthase 1,  Prostaglandin G/H synthase 2,  Prostacyclin synthase,  Cytochrome P450 3A4,  Cytochrome P450 2C9,  Solute carrier family 22 member 6,  Solute carrier family 22 member 8,  Solute carrier family 22 member 11","DB00812, DB08940, DB13629, DB03585, DB13364, DB13286, DB13232, DB01138",
DB00813,Fentanyl,approved; illicit; investigational; vet_approved,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,C22H28N2O,,"Adjuvants, Adjuvants, Anesthesia, Agents that produce hypertension, Agents that reduce seizure threshold, Analgesics, Anesthetics, Anesthetics, General, Anesthetics, Intravenous, Antidepressive Agents, Bradycardia-Causing Agents, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Fentanyl and fentanyl analogues, High-risk opioids, Narcotics, Nervous System, Neuraxial Anesthetics, Opiate Agonists, Opioid Agonist, Opioid Anesthetics, Opioids, Opioids, Anilidopiperidine, P-glycoprotein inhibitors, Peripheral Nervous System Agents, Phenylpiperidine opioids, Piperidines, Sensory System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin Modulators"," Mu-type opioid receptor,  Delta-type opioid receptor,  Kappa-type opioid receptor,  P-glycoprotein 1,  Cytochrome P450 3A4,  Cytochrome P450 3A7,  Serum albumin,  alpha1-acid glycoprotein (Protein Group),  P-glycoprotein 1","DB00813, DB09173, DB01557, DB09171, DB01571, DB01532, DB01453, DB09177, DB09178, DB09169, DB01570, DB13653, DB09179, DB09182, DB09180, DB01439, DB01470, DB09168",
DB00814,Meloxicam,approved; vet_approved,CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=C(C=CC=C2)S1(=O)=O,C14H13N3O4S2,,"Agents causing hyperkalemia, Agents that produce hypertension, Amides, Analgesics, Analgesics, Non-Narcotic, Anesthetics, Anesthetics, Local, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Antiinflammatory and Antirheumatic Products, Antiinflammatory and Antirheumatic Products, Non-Steroids, Antirheumatic Agents, COX-2 Inhibitors, Cyclooxygenase Inhibitors, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Musculo-Skeletal System, Nephrotoxic agents, Nervous System, Other Nonsteroidal Anti-inflammatory Agents, Oxicams, Peripheral Nervous System Agents, Selective Cyclooxygenase 2 Inhibitors (NSAIDs), Sensory System Agents, Sulfur Compounds, Thiazines, Thiazoles"," Prostaglandin G/H synthase 2,  Prostaglandin G/H synthase 1,  6-phosphogluconate dehydrogenase, decarboxylating,  Cytochrome P450 2C8,  Cytochrome P450 2C9,  Cytochrome P450 3A4,  Serum albumin,  Multidrug resistance-associated protein 4","DB00814, DB00554, DB15883, DB08942, DB16877",
DB00815,Sodium lauryl sulfate,experimental,[Na+].CCCCCCCCCCCCOS([O-])(=O)=O,C12H25NaO4S,,"Alcohols, Alkanesulfonates, Alkanesulfonic Acids, Compounds used in a research, industrial, or household setting, Dodecanol, Fatty Alcohols, Lipids, Sulfones, Sulfonic Acids, Sulfur Acids, Sulfur Compounds, Surface-Active Agents", Serum albumin,"DB00815, DB03967, DB07518, DB00464, DB11328",
DB00816,Orciprenaline,approved,CC(C)NCC(O)C1=CC(O)=CC(O)=C1,C11H17NO3,,"Adrenergic Agents, Adrenergic Agonists, Adrenergic beta-2 Receptor Agonists, Adrenergic beta-Agonists, Adrenergics for Systemic Use, Adrenergics, Inhalants, Agents producing tachycardia, Agents that produce hypertension, Agents to Treat Airway Disease, Alcohols, Amines, Amino Alcohols, Anti-Asthmatic Agents, Autonomic Agents, Benzene Derivatives, Bronchodilator Agents, Catecholamines, Catechols, Drugs for Obstructive Airway Diseases, Ethanolamines, Neurotransmitter Agents, Non-selective Beta-adrenergic Agonists, Peripheral Nervous System Agents, Phenols, Reproductive Control Agents, Respiratory System Agents, Selective Beta 2-adrenergic Agonists, Sympathomimetics, Tocolytic Agents", Beta-2 adrenergic receptor,"DB00816, DB00871, DB08985, DB01064, DB00388, DB01288, DB00668, DB13378, DB13494, DB00221, DB08957",
DB00817,Rosoxacin,approved; investigational,CCN1C=C(C(O)=O)C(=O)C2=C1C=C(C=C2)C1=CC=NC=C1,C17H14N2O3,,"Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Fluoroquinolones, Heterocyclic Compounds, Fused-Ring, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Quinolines"," DNA gyrase subunit B,  DNA topoisomerase 4 subunit A,  Cytochrome P450 1A2","DB00817, DB12924",
DB00818,Propofol,approved; investigational; vet_approved,CC(C)C1=CC=CC(C(C)C)=C1O,C12H18O,,"Agents Causing Muscle Toxicity, Agents that produce hypertension, Agents that reduce seizure threshold, Anesthetics, Anesthetics, General, Anesthetics, Intravenous, Benzene Derivatives, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C18 Substrates, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (weak), Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Hypnotics and Sedatives, Hypotensive Agents, Miscellaneous General Anesthetics, Nervous System, P-glycoprotein inducers, Phenols, Potential QTc-Prolonging Agents, QTc Prolonging Agents, UGT1A1 Inhibitors, UGT1A1 Substrates, UGT1A6 substrate, UGT1A9 Substrates"," Gamma-aminobutyric acid receptor subunit beta-2,  Gamma-aminobutyric acid receptor subunit beta-3,  GABA(A) Receptor (Protein Group),  Sodium channel protein type 4 subunit alpha,  Sodium channel protein type 2 subunit alpha,  Cytochrome P450 2C9,  Cytochrome P450 2B6,  UDP-glucuronosyltransferase 1-8,  UDP-glucuronosyltransferase 1-9,  UDP-glucuronosyltransferase 1-1,  Fatty-acid amide hydrolase 1,  Cytochrome P450 2E1,  Cytochrome P450 1B1,  Cytochrome P450 1A1, 10. Cytochrome P450 1A2, 11. Cytochrome P450 2C18, 12. Cytochrome P450 2C19, 13. Cytochrome P450 2C8, 14. UDP-glucuronosyltransferase 1-6,  Serum albumin,  P-glycoprotein 1","DB00818, DB16863, DB13008, DB02513, DB07726, DB03301, DB16295",
DB00819,Acetazolamide,approved; vet_approved,CC(=O)NC1=NN=C(S1)S(N)(=O)=O,C4H6N4O3S2,,"Anticonvulsants, Antiglaucoma Agents, Antiglaucoma Preparations and Miotics, Carbonic Anhydrase Inhibitors, Cardiovascular Agents, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Diuretics, Drugs causing inadvertant photosensitivity, Enzyme Inhibitors, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Natriuretic Agents, OAT1/SLC22A6 inhibitors, Ophthalmologicals, Photosensitizing Agents, Sensory Organs, Sulfonamides, Sulfur Compounds, Thiadiazoles, Thiazoles"," Carbonic anhydrase 1,  Carbonic anhydrase 2,  Carbonic anhydrase 4,  Carbonic anhydrase 12,  Carbonic anhydrase 14,  Carbonic anhydrase 3,  Carbonic anhydrase 7,  Aquaporin-1,  Cytochrome P450 3A4,  Solute carrier family 22 member 6",DB00819,
DB00820,Tadalafil,approved; investigational,[H][C@]12CC3=C(NC4=CC=CC=C34)[C@H](N1C(=O)CN(C)C2=O)C1=CC2=C(OCO2)C=C1,C22H19N3O4,,"5-alpha Reductase Inhibitors, Antihypertensive Agents, Antihypertensives for Pulmonary Arterial Hypertension, Carbolines, Cardiovascular Agents, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Drugs Used in Benign Prostatic Hypertrophy, Drugs Used in Erectile Dysfunction, Enzyme Inhibitors, Genito Urinary System and Sex Hormones, Genitourinary Agents, Heterocyclic Compounds, Fused-Ring, Indole Alkaloids, Indoles, Phosphodiesterase 5 Inhibitors, Phosphodiesterase Inhibitors, Pyridines, Urological Agents, Urologicals, Vasodilating Agents"," cGMP-specific 3',5'-cyclic phosphodiesterase,  Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A,  Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma,  Cytochrome P450 3A4","DB00820, DB14802, DB15138, DB12306, DB12674, DB06663",
DB00821,Carprofen,approved; vet_approved; withdrawn,CC(C(O)=O)C1=CC2=C(C=C1)C1=C(N2)C=CC(Cl)=C1,C15H12ClNO2,,"Agents causing hyperkalemia, Agents that produce hypertension, Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Antirheumatic Agents, Dermatologicals, Heterocyclic Compounds, Fused-Ring, Indoles, Nephrotoxic agents, OAT1/SLC22A6 inhibitors, Peripheral Nervous System Agents, Photosensitizing Agents, Radiation-Sensitizing Agents, Selective Cyclooxygenase 2 Inhibitors (NSAIDs), Sensory System Agents"," Prostaglandin G/H synthase 2,  Prostaglandin G/H synthase 1,  Solute carrier family 22 member 6",DB00821,
DB00822,Disulfiram,approved,CCN(CC)C(=S)SSC(=S)N(CC)CC,C10H20N2S4,,"Acetyl Aldehyde Dehydrogenase Inhibitors, Acids, Acyclic, Agents that reduce seizure threshold, Alcohol Deterrents, Aldehyde Dehydrogenase Inhibitor, Antiparasitic Products, Insecticides and Repellents, BSEP/ABCB11 Substrates, Carbamates, Central Nervous System Agents, Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Disulfides, Drugs Used in Addictive Disorders, Drugs Used in Alcohol Dependence, Ectoparasiticides, Incl. Scabicides, Ectoparasiticides, Incl. Scabicides, Insecticides and Repellents, Enzyme Inhibitors, Nervous System, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Sulfides, Sulfur Compounds, Sulfur Containing Products, Thiocarbamates"," Dopamine beta-hydroxylase,  Aldehyde dehydrogenase, mitochondrial,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 2E1,  Bile salt export pump","DB00822, DB13245",
DB00823,Ethynodiol diacetate,approved,[H][C@@]12CC[C@@](OC(C)=O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CC[C@H](OC(C)=O)C=C3CC[C@@]21[H],C24H32O4,,"Adrenal Cortex Hormones, Combination Contraceptives (with Estrogen and derivatives), Contraceptive Agents, Female, Contraceptive Agents, Hormonal, Contraceptives, Oral, Contraceptives, Oral, Hormonal, Contraceptives, Oral, Synthetic, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Fused-Ring Compounds, Genito Urinary System and Sex Hormones, Hormonal Contraceptives for Systemic Use, Hyperglycemia-Associated Agents, Norpregnanes, Norpregnenes, Norsteroids, Progestin Contraceptives, Progestins, Reproductive Control Agents, Sex Hormones and Modulators of the Genital System, Steroids"," Progesterone receptor,  Estrogen receptor alpha,  Cytochrome P450 3A4","DB00823, DB14678, DB02703",
DB00824,Enprofylline,approved; experimental,CCCN1C2=C(NC=N2)C(=O)NC1=O,C8H10N4O2,,"Adenosine A2 Receptor Antagonists, Alkaloids, Anti-Asthmatic Agents, Autonomic Agents, Bronchodilator Agents, Heterocyclic Compounds, Fused-Ring, Neurotransmitter Agents, Peripheral Nervous System Agents, Purinergic Agents, Purinergic Antagonists, Purinergic P1 Receptor Antagonists, Purines, Purinones, Respiratory System Agents"," cAMP-specific 3',5'-cyclic phosphodiesterase 4B,  Adenosine receptor A2b,  cAMP-specific 3',5'-cyclic phosphodiesterase 4A,  Adenosine receptor A1,  Adenosine receptor A2a,  Adenosine receptor A3","DB00824, DB07954, DB01223, DB00277, DB01303, DB13812, DB13634, DB01412, DB03293, DB12406, DB15122, DB00201, DB00806, DB13449, DB00299, DB12946, DB13098, DB06479",
DB00825,Levomenthol,approved,CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O,C10H20O,,"Agents causing hyperkalemia, Antiarrhythmic agents, Antipruritics, Antipruritics and Local Anesthetics, Basic Lotions and Liniments, Bradycardia-Causing Agents, Calcium Channel Blockers, Cyclohexanes, Cyclohexanols, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, EENT Drugs, Miscellaneous, Herbs and Natural Products, Other Analgesics, Other Cold and Cough Preparations, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Vasodilating Agents"," Transient receptor potential cation channel subfamily M member 8,  Transient receptor potential cation channel subfamily A member 1,  Transient receptor potential cation channel subfamily V member 3,  Voltage-dependent L-type calcium channel (Protein Group),  Kappa-type opioid receptor,  Cytochrome P450 3A4","DB00825, DB11344, DB14123, DB11288, DB17066, DB13163, DB01479, DB01513, DB01530, DB03882, DB03926, DB01637, DB07171, DB14134",
DB00826,Natamycin,approved,[H][C@@]12C[C@H](O)C[C@]3(O)C[C@H](O)[C@@H](C(O)=O)[C@]([H])(C[C@@H](O[C@]4([H])O[C@H](C)[C@@H](O)[C@H](N)[C@@H]4O)\C=C\C=C\C=C\C=C\C[C@@H](C)OC(=O)\C=C\[C@@]1([H])O2)O3,C33H47NO13,,"Alimentary Tract and Metabolism, Anti-Bacterial Agents, Anti-Infective Agents, Anti-Infective Agents, Local, Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents, Antifungal Agents, Antifungals for Dermatological Use, Antifungals for Topical Use, Antiinfectives and Antiseptics for Local Oral Treatment, Dermatologicals, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Intestinal Antiinfectives, Lactones, Ophthalmologicals, Polyene Antifungal, Polyene Antimicrobial, Sensory Organs, Stomatological Preparations", Ergosterol,"DB00826, DB00681, DB00646, DB01152",
DB00827,Cinoxacin,approved; investigational; withdrawn,CCN1N=C(C(O)=O)C(=O)C2=CC3=C(OCO3)C=C12,C12H10N2O5,,"Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Enzyme Inhibitors, Fluoroquinolones, Heterocyclic Compounds, Fused-Ring, Moderate Risk QTc-Prolonging Agents, OAT1/SLC22A6 inhibitors, QTc Prolonging Agents, Topoisomerase II Inhibitors, Topoisomerase Inhibitors"," DNA gyrase subunit A,  DNA,  Cytochrome P450 1A2,  Solute carrier family 22 member 6",DB00827,
DB00828,Fosfomycin,approved,C[C@@H]1O[C@@H]1P(O)(O)=O,C3H7O4P,,"Anti-Bacterial Agents, Anti-Infective Agents, Anti-Infective Agents, Urinary, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Drugs that are Mainly Renally Excreted, Organophosphonates, Organophosphorus Compounds, Otologicals, Sensory Organs", UDP-N-acetylglucosamine 1-carboxyvinyltransferase,DB00828,
DB00829,Diazepam,approved; illicit; investigational; vet_approved,CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1,C16H13ClN2O,,"Adjuvants, Anesthesia, Anesthetics, Anesthetics, General, Anesthetics, Intravenous, Anti-Anxiety Agents, Anticonvulsants, Autonomic Agents, Benzazepines, Benzodiazepine hypnotics and sedatives, Benzodiazepines and benzodiazepine derivatives, Benzodiazepinones, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C18 Substrates, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (strength unknown), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, GABA Agents, GABA Modulators, Heterocyclic Compounds, Fused-Ring, Hypnotics and Sedatives, Muscle Relaxants, Muscle Relaxants, Centrally Acting Agents, Nervous System, P-glycoprotein substrates, Peripheral Nervous System Agents, Psycholeptics, Psychotropic Drugs, Tranquilizing Agents"," GABA(A) Receptor (Protein Group),  GABA(A) Receptor Benzodiazepine Binding Site (Protein Group),  Cytochrome P450 2C9,  Cytochrome P450 3A7,  Cytochrome P450 3A4,  Cytochrome P450 2C19,  Cytochrome P450 3A5,  Cytochrome P450 2B6,  Prostaglandin G/H synthase 1,  Cytochrome P450 2C18,  Cytochrome P450 2C8,  Serum albumin,  P-glycoprotein 1","DB00829, DB14028, DB13335, DB00801, DB01567, DB00231, DB01588, DB01511, DB13437, DB00842, DB00690, DB00628, DB13872, DB00186, DB13837, DB14671, DB14672, DB01489, DB01594",
DB00830,Phenmetrazine,approved; illicit,CC1NCCOC1C1=CC=CC=C1,C11H15NO,,"Agents producing tachycardia, Agents that produce hypertension, Anti-Obesity Agents, Appetite Depressants, Autonomic Agents, Central Nervous System Agents, Central Nervous System Stimulants, Morpholines, Oxazines, Peripheral Nervous System Agents, Sympathomimetics"," Sodium-dependent noradrenaline transporter,  Sodium-dependent dopamine transporter","DB00830, DB01579",
DB00831,Trifluoperazine,approved; investigational,CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1,C21H24F3N3S,,"Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Agents that produce hypertension, Antiemetics, Antipsychotic Agents, Antipsychotic Agents (First Generation [Typical]), Autonomic Agents, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 Substrates, Dopamine Agents, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Drugs causing inadvertant photosensitivity, Gastrointestinal Agents, Heterocyclic Compounds, Fused-Ring, Nervous System, Neurotoxic agents, Neurotransmitter Agents, P-glycoprotein inhibitors, P-glycoprotein substrates, Peripheral Nervous System Agents, Phenothiazines, Phenothiazines With Piperazine Structure, Photosensitizing Agents, Psycholeptics, Psychotropic Drugs, Sulfur Compounds, Tranquilizing Agents, UGT1A4 substrates"," Dopamine D2 receptor,  Neuron-specific vesicular protein calcyon,  Alpha-1A adrenergic receptor,  Calmodulin,  Troponin C, slow skeletal and cardiac muscles,  Protein S100-A4,  Xanthine dehydrogenase/oxidase,  UDP-glucuronosyltransferase 1-4,  Cytochrome P450 1A2,  P-glycoprotein 1","DB00831, DB00623, DB00508, DB12710, DB01063, DB11517, DB09000, DB13213, DB01038, DB01614, DB01608, DB13784, DB00372, DB00433, DB00420, DB00902, DB01246, DB11540, DB00850",
DB00832,Phensuximide,approved,CN1C(=O)CC(C1=O)C1=CC=CC=C1,C11H11NO2,,"Anticonvulsants, Central Nervous System Depressants, Imides, Nervous System, Pyrrolidines, Pyrrolidinones, Succinimide Derivatives",,"DB00832, DB05246",
DB00833,Cefaclor,approved,[H][C@]12SCC(Cl)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O,C15H14ClN3O4S,,"Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, beta-Lactams, BSEP/ABCB11 Substrates, Cephalosporins, Drugs that are Mainly Renally Excreted, Heterocyclic Compounds, Fused-Ring, Lactams, Nephrotoxic agents, OAT3/SLC22A8 Inhibitors, OAT3/SLC22A8 Substrates, Second-Generation Cephalosporins, Sulfur Compounds, Thiazines"," Penicillin-binding protein 3,  Penicillin-binding protein 1A,  Myeloperoxidase,  Solute carrier family 15 member 1,  Solute carrier family 15 member 2,  Solute carrier family 22 member 8,  Bile salt export pump","DB00833, DB00567, DB01140, DB01150, DB00689, DB13266, DB01326, DB01333, DB00923, DB03938, DB11367, DB01415, DB01329, DB00456, DB01414, DB14725, DB03313, DB01139, DB09008, DB01332, DB01328, DB13461, DB14107, DB11592",
DB00834,Mifepristone,approved; investigational,[H][C@@]12CC[C@@](O)(C#CC)[C@@]1(C)C[C@H](C1=CC=C(C=C1)N(C)C)C1=C3CCC(=O)C=C3CC[C@@]21[H],C29H35NO2,,"Abortifacient Agents, Abortifacient Agents, Steroidal, Adrenal Cortex Hormones, Blood Glucose Lowering Agents, BSEP/ABCB11 Substrates, Contraceptive Agents, Female, Contraceptive Agents, Hormonal, Contraceptives, Oral, Contraceptives, Oral, Synthetic, Contraceptives, Postcoital, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (moderate), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Inhibitors, Cytochrome P-450 CYP3A7 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Estranes, Estrenes, Fused-Ring Compounds, Genito Urinary System and Sex Hormones, Highest Risk QTc-Prolonging Agents, Hormonal Contraceptives for Systemic Use, Hormone Antagonists, Hormones, Hormone Substitutes, and Hormone Antagonists, Hypoglycemia-Associated Agents, Luteolytic Agents, Menstruation-Inducing Agents, OATP1B1/SLCO1B1 Inhibitors, OATP1B3 inhibitors, P-glycoprotein inducers, P-glycoprotein inhibitors, Progestational Hormone Receptor Antagonists, Progesterone Receptor Modulators, Progestin Antagonist, QTc Prolonging Agents, Reproductive Control Agents, Sex Hormones and Modulators of the Genital System, Steroids"," Progesterone receptor,  Glucocorticoid receptor,  Prostate-specific antigen,  Nuclear receptor subfamily 1 group I member 2,  Cytochrome P450 2D6,  Cytochrome P450 2C8,  Cytochrome P450 2C9,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  P-glycoprotein 1,  Multidrug resistance-associated protein 1,  Bile salt export pump,  Solute carrier organic anion transporter family member 1B1,  Solute carrier organic anion transporter family member 1B3","DB00834, DB12637, DB08867, DB15585, DB05253, DB05423, DB06680, DB16221",
DB00835,Brompheniramine,approved,CN(C)CCC(C1=CC=C(Br)C=C1)C1=CC=CC=N1,C16H19BrN2,,"Agents producing tachycardia, Anti-Allergic Agents, Anticholinergic Agents, Antihistamines for Systemic Use, Central Nervous System Depressants, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 Substrates, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Muscarinic Antagonists, Neurotransmitter Agents, Potential QTc-Prolonging Agents, Propylamine Derivatives, Pyridines, QTc Prolonging Agents, Substituted Alkylamines"," Histamine H1 receptor,  Muscarinic acetylcholine receptor M1,  Muscarinic acetylcholine receptor M2,  Muscarinic acetylcholine receptor M3,  Muscarinic acetylcholine receptor M4,  Muscarinic acetylcholine receptor M5","DB00405, DB00835, DB01620, DB01114, DB13679, DB09555",
DB00836,Loperamide,approved,CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1,C29H33ClN2O2,,"Agents causing hyperkalemia, Alimentary Tract and Metabolism, Antiarrhythmic agents, Antidiarrheals, Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents, Antipropulsives, Bradycardia-Causing Agents, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Inhibitors (strong), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Gastrointestinal Agents, Moderate Risk QTc-Prolonging Agents, Opioid Agonist, P-glycoprotein substrates, Piperidines, QTc Prolonging Agents"," Mu-type opioid receptor,  Delta-type opioid receptor,  Kappa-type opioid receptor,  Calmodulin,  Pro-opiomelanocortin,  Voltage-dependent P/Q-type calcium channel subunit alpha-1A,  Potassium voltage-gated channel subfamily H member 2,  Cytochrome P450 3A4,  Cytochrome P450 2C8,  Cytochrome P450 2B6,  Cytochrome P450 2D6,  P-glycoprotein 1","DB00836, DB13759, DB00502",
DB00837,Progabide,experimental,OC(=N)CCCN=C(C1=CC=C(Cl)C=C1)C1=C(O)C=CC(F)=C1,C17H16ClFN2O2,,"Acids, Acyclic, Amino Acids, Amino Acids, Peptides, and Proteins, Aminobutyrates, Anti-Dyskinesia Agents, Anti-Parkinson Drugs, Anticonvulsants, Antidepressive Agents, Butyrates, Central Nervous System Agents, Central Nervous System Depressants, Fatty Acid Derivatives, GABA Agents, GABA Agonists, Nervous System, Neurotransmitter Agents, Psychotropic Drugs"," Gamma-aminobutyric acid receptor subunit alpha-1,  Gamma-aminobutyric acid type B receptor subunit 1",DB00837,
DB00838,Clocortolone,approved,[H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,C22H28ClFO4,,"Adrenal Cortex Hormones, Anti-Inflammatory Agents, Corticosteroid Hormone Receptor Agonists, Corticosteroids, Corticosteroids, Dermatological Preparations, Corticosteroids, Moderately Potent (Group II), Dermatologicals, Fused-Ring Compounds, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Immunosuppressive Agents, Pregnadienediols, Pregnadienes, Pregnanes, Steroids, Steroids, Fluorinated", Glucocorticoid receptor,"DB00838, DB14652, DB14653, DB08971, DB13856, DB13223, DB01384, DB09378, DB00596, DB00764, DB00240, DB09095, DB00223, DB00663, DB12553, DB15777, DB15821, DB14637, DB14657, DB13728, DB11750, DB14664, DB00394, DB08973, DB14221",
DB00839,Tolazamide,approved; investigational,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN1CCCCCC1,C14H21N3O3S,,"Alimentary Tract and Metabolism, Amides, Benzene Derivatives, Benzenesulfonamides, Blood Glucose Lowering Agents, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Drugs Used in Diabetes, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Hypoglycemia-Associated Agents, Insulin Secretagogues, Oral Hypoglycemics, Sulfonamides, Sulfones, Sulfonylureas, Sulfur Compounds"," Sulfonylurea receptor 1, Kir6.2 (Protein Group),  Cytochrome P450 2C9","DB00839, DB01120",
DB00840,Hydroxypropyl cellulose,approved,,,,"Artificial Tears, Biopolymers, Carbohydrates, Compounds used in a research, industrial, or household setting, Demulcent, Demulcent Activity, Glucans, Macromolecular Substances, Ophthalmics, Polymers, Polysaccharides",,,
DB00841,Dobutamine,approved,CC(CCC1=CC=C(O)C=C1)NCCC1=CC(O)=C(O)C=C1,C18H23NO3,,"Adrenergic Agents, Adrenergic Agonists, Adrenergic alpha-1 Receptor Agonists, Adrenergic alpha-Agonists, Adrenergic and Dopaminergic Agents, Adrenergic beta-1 Receptor Agonists, Adrenergic beta-2 Receptor Agonists, Adrenergic beta-Agonists, Agents producing tachycardia, Agents that produce hypertension, Amines, Autonomic Agents, Benzene Derivatives, Cardiac Stimulants Excl. Cardiac Glycosides, Cardiac Therapy, Cardiotonic Agents, Cardiovascular Agents, Catecholamines, Catechols, Compounds used in a research, industrial, or household setting, COMT Substrates, Drugs that are Mainly Renally Excreted, Ethylamines, Neurotransmitter Agents, Peripheral Nervous System Agents, Phenethylamines, Phenols, Protective Agents, Selective Beta 1-adrenergic Agonists, Sympathomimetic (Adrenergic) Agents, Sympathomimetics"," Alpha-1 adrenergic receptors (Protein Group),  Beta-1 adrenergic receptor,  Beta-2 adrenergic receptor,  Estrogen receptor alpha,  Catechol O-methyltransferase","DB00841, DB12313, DB11541, DB06618",
DB00842,Oxazepam,approved,OC1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2,C15H11ClN2O2,,"Anti-Anxiety Agents, Benzazepines, Benzodiazepine hypnotics and sedatives, Benzodiazepines and benzodiazepine derivatives, Benzodiazepinones, Central Nervous System Agents, Central Nervous System Depressants, Drugs that are Mainly Renally Excreted, GABA Agents, GABA Modulators, Heterocyclic Compounds, Fused-Ring, Hypnotics and Sedatives, Nervous System, Neurotransmitter Agents, Psycholeptics, Psychotropic Drugs, Tranquilizing Agents, UGT1A9 Substrates, UGT2B7 substrates"," GABA(A) Receptor (Protein Group),  GABA(A) Receptor Benzodiazepine Binding Site (Protein Group),  UDP-glucuronosyltransferase 2B15,  UDP-glucuronosyltransferase 2B7,  UDP-glucuronosyltransferase 1-9,  Serum albumin","DB00842, DB00231, DB00186, DB13872, DB14028, DB14672, DB00829, DB13837, DB14671, DB01511, DB13335, DB01489, DB01594, DB00801, DB01567, DB00628, DB01588, DB00690",
DB00843,Donepezil,approved,COC1=C(OC)C=C2C(=O)C(CC3CCN(CC4=CC=CC=C4)CC3)CC2=C1,C24H29NO3,,"Anti-Dementia Drugs, BCRP/ABCG2 Substrates, Bradycardia-Causing Agents, Central Nervous System Agents, Central Nervous System Depressants, Cholinergic Agents, Cholinesterase Inhibitors, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Enzyme Inhibitors, Indans, Indenes, Muscle Relaxants, Muscle Relaxants, Centrally Acting Agents, Nervous System, Neurotransmitter Agents, Nootropic Agents, Parasympathomemetic (Cholinergic) Agents, Piperidines, Psychoanaleptics"," Acetylcholinesterase,  5-hydroxytryptamine receptor 2A,  Cholinesterase,  Nitric oxide synthase, brain,  Tumor necrosis factor-inducible gene 6 protein,  Interleukin-1 beta,  Nuclear factor NF-kappa-B (Protein Group),  NMDA receptor (Protein Group),  Cytochrome P450 2D6,  Cytochrome P450 3A4,  Cytochrome P450 2C9,  ATP-binding cassette sub-family G member 2","DB00843, DB07701",
DB00844,Nalbuphine,approved,O[C@H]1CC[C@@]2(O)[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC2CCC2)[C@H]1O5,C21H27NO4,,"Alkaloids, Analgesics, Central Nervous System Agents, Central Nervous System Depressants, Heterocyclic Compounds, Fused-Ring, Mixed Agonist / Antagonist Opioids, Morphinan Derivatives, Morphinans, Narcotics, Nervous System, Opiate Alkaloids, Opiate Partial Agonists, Opioid Agonist/Antagonist, Opioid Antagonists, Opioids, Peripheral Nervous System Agents, Phenanthrenes, Semi-synthetic Opioids, Sensory System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"," Kappa-type opioid receptor,  Mu-type opioid receptor,  Delta-type opioid receptor","DB00844, DB01512, DB01565, DB14146, DB01551, DB00921, DB01450, DB01548, DB09049, DB16072, DB15341, DB01538, DB06230, DB16117, DB00704, DB01192, DB06800, DB01531, DB00497, DB01183, DB04509, DB01480, DB01497, DB00295, DB13471, DB00318, DB00327, DB01477, DB01466, DB01469",
DB00845,Clofazimine,approved; investigational,CC(C)N=C1C=C2N(C3=CC=C(Cl)C=C3)C3=C(C=CC=C3)N=C2C=C1NC1=CC=C(Cl)C=C1,C27H22Cl2N4,,"Anti-Bacterial Agents, Anti-Infective Agents, Anti-Inflammatory Agents, Antiinfectives for Systemic Use, Antimycobacterials, BCRP/ABCG2 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A5 Inhibitors, Cytochrome P-450 CYP3A5 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Drugs causing inadvertant photosensitivity, Drugs for Treatment of Lepra, Heterocyclic Compounds, Fused-Ring, Leprostatic Agents, P-glycoprotein inhibitors, P-glycoprotein substrates, Phenazines, Photosensitizing Agents, Potential QTc-Prolonging Agents, QTc Prolonging Agents"," Peroxisome proliferator-activated receptor gamma,  Potassium voltage-gated channel subfamily A member 3,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 2C8,  Cytochrome P450 2D6,  Serum albumin,  P-glycoprotein 1,  ATP-binding cassette sub-family G member 2,  Multidrug resistance-associated protein 1",DB00845,
DB00846,Flurandrenolide,approved,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO,C24H33FO6,,"Adrenal Cortex Hormones, Anti-Inflammatory Agents, Corticosteroid Hormone Receptor Agonists, Corticosteroids, Corticosteroids, Dermatological Preparations, Corticosteroids, Potent (Group III), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Dermatologicals, Fused-Ring Compounds, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Immunosuppressive Agents, Pregnanes, Pregnenediones, Pregnenes, Steroids, Steroids, Fluorinated"," Glucocorticoid receptor,  Cytochrome P450 3A4,  Corticosteroid-binding globulin","DB00846, DB14673, DB00180, DB14662, DB00591, DB06786, DB01047, DB18738, DB01260, DB00288, DB01222, DB08973, DB01410, DB14637, DB14657",
DB00847,Cysteamine,approved; investigational,NCCS,C2H7NS,,"Alimentary Tract and Metabolism, Amines, Amino Acids and Derivatives, Cystine Depleting Agents, Cystine Disulfide Reduction, EENT Drugs, Miscellaneous, Ethylamines, Mercaptoethylamines, Ophthalmics, Ophthalmologicals, Other Miscellaneous Therapeutic Agents, Sensory Organs, Sulfhydryl Compounds, Sulfur Compounds"," Cystine,  Neuropeptide Y receptor type 2,  Myeloperoxidase,  Serum albumin",DB00847,
DB00848,Levamisole,approved; investigational; vet_approved; withdrawn,C1CN2C[C@@H](N=C2S1)C1=CC=CC=C1,C11H12N2S,,"Adjuvants, Immunologic, Anthelmintics, Anti-Infective Agents, Antinematodal Agents, Antiparasitic Agents, Antiparasitic Products, Insecticides and Repellents, Antirheumatic Agents, Imidazoles, Imidazothiazole Derivatives, Immunologic Factors, Levamisole, analogs & derivatives, Sulfur Compounds, Thiazoles"," Neuronal acetylcholine receptor subunit alpha-3,  Alkaline phosphatase, germ cell type,  Acetylcholine receptor subunit alpha-type unc-38,  Acetylcholine receptor subunit alpha-type unc-63,  Acetylcholine receptor subunit beta-type lev-1,  Acetylcholine receptor subunit beta-type unc-29","DB00848, DB16561",
DB00849,Methylphenobarbital,approved,CCC1(C(=O)NC(=O)N(C)C1=O)C1=CC=CC=C1,C13H14N2O3,,"Anticholinergic Agents, Anticonvulsants, Barbiturates, Barbiturates and Derivatives, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Substrates, GABA Agents, GABA Modulators, Hypnotics and Sedatives, Nervous System, Neurotransmitter Agents, Nicotinic Antagonists, Phenobarbital and similars, Psycholeptics, Pyrimidines, Pyrimidinones"," Gamma-aminobutyric acid receptor subunit alpha-2,  Gamma-aminobutyric acid receptor subunit alpha-3,  Gamma-aminobutyric acid receptor subunit alpha-4,  Gamma-aminobutyric acid receptor subunit alpha-5,  Gamma-aminobutyric acid receptor subunit alpha-6,  Gamma-aminobutyric acid receptor subunit alpha-1,  Neuronal acetylcholine receptor subunit alpha-4,  Neuronal acetylcholine receptor subunit alpha-7,  Glutamate receptor 2, 10. Glutamate receptor ionotropic, kainate 2, 11. Nuclear receptor subfamily 1 group I member 2,  Cytochrome P450 2C19,  Cytochrome P450 2B6","DB00849, DB01174, DB09001, DB00794, DB13362, DB11654",
DB00850,Perphenazine,approved,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1,C21H26ClN3OS,,"Antipsychotic Agents, Antipsychotic Agents (First Generation [Typical]), Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C18 Substrates, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dopamine Agents, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Drugs causing inadvertant photosensitivity, Heterocyclic Compounds, Fused-Ring, Nervous System, Neurotoxic agents, Neurotransmitter Agents, Phenothiazines, Phenothiazines With Piperazine Structure, Photosensitizing Agents, Psycholeptics, Psychotropic Drugs, Sulfur Compounds, Tranquilizing Agents"," Dopamine D2 receptor,  Dopamine D1 receptor,  Calmodulin,  Cytochrome P450 1A2,  Cytochrome P450 2C18,  Cytochrome P450 2C19,  Cytochrome P450 2C8,  Cytochrome P450 2C9,  Cytochrome P450 3A4,  Cytochrome P450 2D6,  Serum albumin","DB00850, DB00433, DB13382, DB13557, DB00477, DB14651, DB12710, DB13784, DB00420, DB00623, DB13840, DB01246, DB15596, DB01063, DB00831, DB00372, DB00902",
DB00851,Dacarbazine,approved; investigational,CN(C)\N=N\C1=C(N=CN1)C(N)=O,C6H10N6O,,"Alkylating Activity, Alkylating Drugs, Antineoplastic Agents, Antineoplastic Agents, Alkylating, Antineoplastic and Immunomodulating Agents, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Imidazoles, Immunosuppressive Agents, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, Noxae, Toxic Actions, Triazenes"," DNA,  DNA polymerase alpha subunit B,  6-phosphogluconate dehydrogenase, decarboxylating,  Cytochrome P450 1A1,  Cytochrome P450 1A2,  Cytochrome P450 2E1",DB00851,
DB00852,Pseudoephedrine,approved,CN[C@@H](C)[C@@H](O)C1=CC=CC=C1,C10H15NO,,"Adrenergic Agonists, Adrenergic alpha-1 Receptor Agonists, Adrenergic alpha-2 Receptor Agonists, Adrenergic alpha-Agonists, Adrenergic beta-Agonists, Agents producing tachycardia, Agents that produce hypertension, Alcohols, Alpha-and Beta-adrenergic Agonists, Amines, Amino Alcohols, Amphetamines, Anti-Asthmatic Agents, Autonomic Agents, Bronchodilator Agents, Cardiovascular Agents, Ethylamines, Hyperglycemia-Associated Agents, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates, Nasal Decongestants, Nasal Decongestants for Systemic Use, Nasal Preparations, Norepinephrine Releasing Agents, Peripheral Nervous System Agents, Phenethylamines, Propanolamines, Propanols, Respiratory System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Sympathomimetic (Adrenergic) Agents, Sympathomimetics, Tumor Necrosis Factor Blockers, Vasoconstrictor Agents"," Sodium-dependent noradrenaline transporter,  Sodium-dependent dopamine transporter,  Alpha-1A adrenergic receptor,  Alpha-2A adrenergic receptor,  Sodium-dependent serotonin transporter,  Beta-2 adrenergic receptor,  Beta-1 adrenergic receptor,  Nuclear factor of activated T-cells, cytoplasmic 1,  Tumor necrosis factor, 10. Nuclear factor NF-kappa-B p105 subunit, 11. activator protein 1 (Protein Group), 12. Interleukin-2,  Amine oxidase [flavin-containing] A,  Serum albumin,  Sodium-dependent noradrenaline transporter,  Sodium-dependent dopamine transporter,  Sodium-dependent serotonin transporter","DB00852, DB01364, DB14752, DB11278, DB11587, DB00397, DB01486, DB11610, DB00867, DB01577, DB09571, DB15902",
DB00853,Temozolomide,approved; investigational,CN1N=NC2=C(N=CN2C1=O)C(N)=O,C6H6N6O2,,"Alkylating Activity, Alkylating Drugs, Antineoplastic Agents, Antineoplastic Agents, Alkylating, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Substrates, Drugs that are Mainly Renally Excreted, Imidazoles, Immunosuppressive Agents, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, Noxae, P-glycoprotein substrates, P-glycoprotein substrates with a Narrow Therapeutic Index, Toxic Actions, Triazenes"," DNA,  Serum albumin,  Alpha-1-acid glycoprotein 1,  P-glycoprotein 1,  ATP-binding cassette sub-family G member 2",DB00853,
DB00854,Levorphanol,approved,[H][C@@]12CCCC[C@@]11CCN(C)[C@@H]2CC2=C1C=C(O)C=C2,C17H23NO,,"Alkaloids, Analgesics, Central Nervous System Agents, Central Nervous System Depressants, Heterocyclic Compounds, Fused-Ring, Morphinans, Narcotics, Opiate Alkaloids, Opioid Agonist, Opioids, Peripheral Nervous System Agents, Phenanthrenes, Sensory System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"," Mu-type opioid receptor,  Delta-type opioid receptor,  Kappa-type opioid receptor","DB00854, DB14682, DB13606, DB00514, DB00504, DB00652, DB13810, DB00611, DB01209, DB12273",
DB00855,Aminolevulinic acid,approved,NCC(=O)CCC(O)=O,C5H9NO3,,"Amino Acids, Amino Acids, Peptides, and Proteins, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Dermatologicals, Enkephalins, Keto Acids, Levulinic Acids, Misc. Skin and Mucous Membrane Agents, Nerve Tissue Proteins, Neuropeptides, Opioid Peptides, Optical Imaging Agent, Peptides, Photosensitizing Agents, Photosensitizing Agents for Phototherapy, Porphyrin Precursor, Proteins, Radiation-Sensitizing Agents, Roentgenography, Sensitizers Used in Photodynamic/radiation Therapy"," Delta-aminolevulinic acid dehydratase,  Solute carrier family 15 member 1,  Solute carrier family 15 member 2","DB00855, DB00992, DB02068, DB02239, DB13800, DB14514",
DB00856,Chlorphenesin,approved; experimental,OCC(O)COC1=CC=C(Cl)C=C1,C9H11ClO3,,"Alcohols, Antifungals for Dermatological Use, Antifungals for Topical Use, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 Enzyme Inducers, Dermatologicals, Glycols, Muscle Relaxants, Muscle Relaxants, Centrally Acting Agents, Peripheral Nervous System Agents, Propylene Glycols"," Cytochrome P450 19A1,  Cytochrome P450 3A4,  Xanthine dehydrogenase/oxidase,  Prostaglandin G/H synthase 2,  Cholinesterase","DB00856, DB11368, DB14656",
DB00857,Terbinafine,approved; investigational; vet_approved,CN(C\C=C\C#CC(C)(C)C)CC1=CC=CC2=CC=CC=C12,C21H25N,,"Agents Causing Muscle Toxicity, Allylamine Antifungal, Allylamines, Anti-Infective Agents, Antifungal Agents, Antifungals for Dermatological Use, Antifungals for Systemic Use, Antifungals for Topical Use, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (weak), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dermatologicals, Enzyme Inhibitors, Naphthalenes"," Squalene monooxygenase,  Squalene monooxygenase,  Prostaglandin G/H synthase 1,  Cytochrome P450 2D6,  Cytochrome P450 2C9,  Cytochrome P450 1A2,  Cytochrome P450 3A4,  Cytochrome P450 2C8,  Cytochrome P450 2C19,  Serum albumin,  alpha1-acid glycoprotein (Protein Group),  ABC multidrug transporter MDR2","DB00857, DB00735",
DB00858,Drostanolone,illicit,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)[C@H](C)C[C@]12C,C20H32O2,,"Androstanes, Fused-Ring Compounds, Steroids"," Androgen receptor,  Cytochrome P450 19A1,  Sex hormone-binding globulin","DB00858, DB02854, DB02901, DB05087, DB07447, DB11859, DB12308, DB12972, DB13587, DB11371, DB06622, DB08956, DB02817, DB16260, DB03619, DB01586, DB02659, DB05990, DB06777, DB11789, DB11622, DB18044, DB16870, DB01530, DB01561, DB03882, DB03926, DB04693, DB07375, DB07557",
DB00859,Penicillamine,approved,[H][C@](N)(C(O)=O)C(C)(C)S,C5H11NO2S,,"Agents Causing Muscle Toxicity, Amino Acids, Amino Acids, Peptides, and Proteins, Amino Acids, Sulfur, Antidotes, Antiinflammatory and Antirheumatic Products, Antirheumatic Agents, Chelating Agents, Compounds used in a research, industrial, or household setting, Heavy Metal Antagonists, Immunosuppressive Agents, Musculo-Skeletal System, Myelosuppressive Agents, OATP1B1/SLCO1B1 Substrates, Penicillamine and Similar Agents, Protective Agents, Sequestering Agents, Specific Antirheumatic Agents, Sulfur Compounds"," Copper,  Solute carrier organic anion transporter family member 1B1","DB00859, DB00161",
DB00860,Prednisolone,approved; vet_approved,[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,C21H28O5,,"Adrenal Cortex Hormones, Adrenals, Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use, Alimentary Tract and Metabolism, Anti-Inflammatory Agents, Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents, Antidotes, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Corticosteroid Hormone Receptor Agonists, Corticosteroids, Corticosteroids Acting Locally, Corticosteroids for Local Oral Treatment, Corticosteroids for Systemic Use, Corticosteroids for Systemic Use, Plain, Corticosteroids, Dermatological Preparations, Corticosteroids, Weak (Group I), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Substrates, Dermatologicals, Fused-Ring Compounds, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hyperglycemia-Associated Agents, Immunosuppressive Agents, Intestinal Antiinflammatory Agents, Nasal Preparations, Ophthalmological and Otological Preparations, Ophthalmologicals, Otologicals, P-glycoprotein substrates, Prednisolone and Prodrugs, Pregnadienes, Pregnadienetriols, Pregnanes, Sensory Organs, Steroids, Stomatological Preparations, Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins, Vasoprotectives"," Glucocorticoid receptor,  Cytochrome P450 3A4,  Corticosteroid-binding globulin,  Serum albumin,  Solute carrier organic anion transporter family member 1A2,  P-glycoprotein 1","DB00860, DB00959, DB13208, DB00896, DB00635, DB09383, DB12952, DB01569, DB00741, DB15114, DB00443, DB01234, DB11522, DB13491, DB15566, DB00240, DB00324, DB01384, DB09378, DB14631, DB00547, DB01541, DB13586, DB00873, DB12081, DB04652, DB00620, DB14632, DB04630, DB15999",
DB00861,Diflunisal,approved; investigational,OC(=O)C1=C(O)C=CC(=C1)C1=C(F)C=C(F)C=C1,C13H8F2O3,,"Agents causing hyperkalemia, Agents that produce hypertension, Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Antirheumatic Agents, Benzene Derivatives, Cyclooxygenase Inhibitors, Drugs causing inadvertant photosensitivity, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Hydroxybenzoates, Nephrotoxic agents, Nervous System, Non COX-2 selective NSAIDS, OAT1/SLC22A6 inhibitors, Other Nonsteroidal Anti-inflammatory Agents, Peripheral Nervous System Agents, Phenols, Photosensitizing Agents, Salicylates, Salicylic Acid and Derivatives, Sensory System Agents, UGT1A9 Inhibitors"," Prostaglandin G/H synthase 2,  Prostaglandin G/H synthase 1,  UDP-glucuronosyltransferase 1-8,  UDP-glucuronosyltransferase 1-9,  Transthyretin,  Serum albumin,  Solute carrier family 22 member 6",DB00861,
DB00862,Vardenafil,approved,CCCC1=NC(C)=C2N1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(CC)CC1,C23H32N6O4S,,"Cardiovascular Agents, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (weak), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (weak), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (weak), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (weak), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs Used in Erectile Dysfunction, Enzyme Inhibitors, Genito Urinary System and Sex Hormones, Genitourinary Agents, Imidazoles, P-glycoprotein inhibitors, P-glycoprotein substrates, Phosphodiesterase 5 Inhibitors, Phosphodiesterase Inhibitors, Piperazines, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Urological Agents, Urologicals, Vasodilating Agents"," cGMP-specific 3',5'-cyclic phosphodiesterase,  Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma,  Retinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 2C9,  Cytochrome P450 2C8,  Cytochrome P450 2C19,  Cytochrome P450 2D6,  P-glycoprotein 1","DB00862, DB00203, DB11927, DB11792, DB11902, DB06267",
DB00863,Ranitidine,approved; withdrawn,CNC(NCCSCC1=CC=C(CN(C)C)O1)=C[N+]([O-])=O,C13H22N4O3S,,"Acid Reducers, Agents Causing Muscle Toxicity, Alimentary Tract and Metabolism, Anti-Ulcer Agents, Cholinesterase Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (weak), Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord), Drugs that are Mainly Renally Excreted, Furans, Gastric Acid Lowering Agents, Gastrointestinal Agents, Histamine Antagonists, Histamine H2 Antagonists, OAT1/SLC22A6 inhibitors, OAT1/SLC22A6 Substrates, OAT3/SLC22A8 Substrates, OCT1 inhibitors, OCT1 substrates, OCT2 Inhibitors, OCT2 Substrates, P-glycoprotein inhibitors, P-glycoprotein substrates"," Histamine H2 receptor,  Acetylcholinesterase,  Cytochrome P450 3A4,  Acetylcholinesterase,  Cytochrome P450 1A2,  Cytochrome P450 2D6,  Solute carrier family 22 member 1,  P-glycoprotein 1,  Solute carrier family 22 member 8,  Solute carrier family 22 member 2",DB00863,
DB00864,Tacrolimus,approved; investigational,CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC,C44H69NO12,,"Agents causing hyperkalemia, Agents Causing Muscle Toxicity, Agents for Dermatitis, Excluding Corticosteroids, Antineoplastic and Immunomodulating Agents, Calcineurin Inhibitor Immunosuppressant, Calcineurin Inhibitors, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (weak), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dermatologicals, Drugs causing inadvertant photosensitivity, Enzyme Inhibitors, Hyperglycemia-Associated Agents, Immunologic Factors, Immunosuppressive Agents, Lactones, Misc. Skin and Mucous Membrane Agents, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, Nephrotoxic agents, OATP1B1/SLCO1B1 Inhibitors, P-glycoprotein inducers, P-glycoprotein inhibitors, P-glycoprotein substrates, P-glycoprotein substrates with a Narrow Therapeutic Index, Photosensitizing Agents, Polyketides, Potential QTc-Prolonging Agents, QTc Prolonging Agents"," Peptidyl-prolyl cis-trans isomerase FKBP1A,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Serum albumin,  Alpha-1-acid glycoprotein 1,  P-glycoprotein 1,  ATP-binding cassette sub-family A member 5,  Solute carrier organic anion transporter family member 1B1","DB00864, DB00337, DB03621, DB01590, DB15527, DB06287, DB00877, DB06233, DB15422",
DB00865,Benzphetamine,approved; illicit,C[C@@H](CC1=CC=CC=C1)N(C)CC1=CC=CC=C1,C17H21N,,"Adrenergic Agents, Adrenergic Agonists, Adrenergic alpha-1 Receptor Agonists, Adrenergic alpha-Agonists, Adrenergic Uptake Inhibitors, Agents producing tachycardia, Agents that produce hypertension, Amines, Amphetamines, Antidepressive Agents, Appetite Suppression, Autonomic Agents, Central Nervous System Agents, Central Nervous System Depressants, Central Nervous System Stimulants, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Dopamine Agents, Dopamine Uptake Inhibitors, Ethylamines, Increased Sympathetic Activity, Membrane Transport Modulators, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, Peripheral Nervous System Agents, Phenethylamines, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Sympathomimetic Amine Anorectic, Sympathomimetics"," Synaptic vesicular amine transporter,  Alpha-2A adrenergic receptor,  Alpha-1A adrenergic receptor,  Sodium-dependent dopamine transporter,  Cytochrome P450 3A4,  Cytochrome P450 2B6,  NADPH--cytochrome P450 reductase","DB00865, DB13561",
DB00866,Alprenolol,experimental; withdrawn,CC(C)NCC(O)COC1=CC=CC=C1CC=C,C15H23NO2,,"Adrenergic Agents, Adrenergic Antagonists, Adrenergic beta-Antagonists, Agents causing hyperkalemia, Alcohols, Amines, Amino Alcohols, Antiarrhythmic agents, Antidepressive Agents, Antihypertensive Agents, Autonomic Agents, Beta Blocking Agents, Non-Selective, Bradycardia-Causing Agents, Cardiovascular Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 Substrates, Neurotransmitter Agents, Peripheral Nervous System Agents, Phenoxypropanolamines, Propanolamines, Propanols, Serotonin 5-HT1 Receptor Antagonists, Serotonin 5-HT1A Receptor Antagonists, Serotonin Agents, Serotonin Receptor Antagonists, Sympatholytics"," Beta-1 adrenergic receptor,  Beta-2 adrenergic receptor,  5-hydroxytryptamine receptor 1A,  Beta-3 adrenergic receptor,  Cytochrome P450 2D6","DB00866, DB01359, DB00264",
DB00867,Ritodrine,approved; investigational,C[C@@H](NCCC1=CC=C(O)C=C1)[C@@H](O)C1=CC=C(O)C=C1,C17H21NO3,,"Adrenergic Agents, Adrenergic Agonists, Adrenergic beta-2 Receptor Agonists, Adrenergic beta-Agonists, Agents producing tachycardia, Agents that produce hypertension, Alcohols, Amines, Amino Alcohols, Autonomic Agents, Ethylamines, Genito Urinary System and Sex Hormones, Neurotransmitter Agents, Peripheral Nervous System Agents, Phenethylamines, Propanolamines, Propanols, Reproductive Control Agents, Sympathomimetics, Sympathomimetics, Labour Repressants, Tocolytic Agents"," Beta-2 adrenergic receptor,  Beta adrenergic receptor (Protein Group),  ATP-sensitive potassium channel (Protein Group),  Calcium transporting ATPases (Protein Group),  Calcium-activated potassium channel (Protein Group),  Myosin light chain kinase, smooth muscle,  Sulfotransferase 1C4,  6-phosphogluconate dehydrogenase, decarboxylating,  Sulfotransferase 1A1,  Sulfotransferase 1A3/1A4,  Sulfotransferase (Protein Group),  Sulfotransferase 1C4","DB00867, DB11610, DB06152, DB01288, DB11541, DB08954, DB13206, DB11587, DB00221, DB08941, DB00852, DB01364, DB09203, DB14752, DB11278, DB01064",
DB00868,Benzonatate,approved,CCCCNC1=CC=C(C=C1)C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC,C30H53NO11,,"Alkanes, Amines, Antitussive Agents, Butanes, Central Nervous System Agents, Cholinesterase substrates, Cough and Cold Preparations, Decreased Tracheobronchial Stretch Receptor Activity, Hydrocarbons, Acyclic, Non-narcotic Antitussive, Respiratory System Agents"," Sodium channel protein type 5 subunit alpha,  Cholinesterase","DB00868, DB09085",
DB00869,Dorzolamide,approved,CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O,C10H16N2O4S3,,"Amides, Antiglaucoma Preparations and Miotics, Antihypertensive Agents, Carbonic Anhydrase Inhibitors, Cardiovascular Agents, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 Substrates, Diuretics, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Intraocular Pressure, drug effects, Ophthalmologicals, Sensory Organs, Sulfonamides, Sulfones, Sulfur Compounds"," Carbonic anhydrase 2,  Carbonic anhydrase 4,  Carbonic anhydrase 1,  Carbonic anhydrase 3,  Cytochrome P450 2C9,  Cytochrome P450 2B1,  Cytochrome P450 2E1,  Cytochrome P450 3A2","DB00869, DB04081",
DB00870,Suprofen,approved; withdrawn,CC(C(O)=O)C1=CC=C(C=C1)C(=O)C1=CC=CS1,C14H12O3S,,"Acids, Carbocyclic, Agents causing hyperkalemia, Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Antiinflammatory and Antirheumatic Products, Antiinflammatory and Antirheumatic Products, Non-Steroids, Antirheumatic Agents, Cyclooxygenase Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Enzyme Inhibitors, Musculo-Skeletal System, Nephrotoxic agents, Non COX-2 selective NSAIDS, Peripheral Nervous System Agents, Phenylpropionates, Propionates, Sensory System Agents, UGT1A1 Substrates, UGT2B7 substrates"," Prostaglandin G/H synthase 1,  Prostaglandin G/H synthase 2,  UDP-glucuronosyltransferase 1-1,  UDP-glucuronosyltransferase 2B7,  Cytochrome P450 2C9,  Serum albumin,  Solute carrier family 22 member 12","DB00870, DB03752, DB01600",
DB00871,Terbutaline,approved,CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1,C12H19NO3,,"Adrenergic Agents, Adrenergic Agonists, Adrenergic beta-2 Receptor Agonists, Adrenergic beta-Agonists, Adrenergics for Systemic Use, Adrenergics, Inhalants, Agents producing tachycardia, Agents that produce hypertension, Agents to Treat Airway Disease, Alcohols, Amines, Amino Alcohols, Anti-Asthmatic Agents, Autonomic Agents, Bronchodilator Agents, Cholinesterase Inhibitors, Drugs for Obstructive Airway Diseases, Drugs that are Mainly Renally Excreted, Ethanolamines, Neurotransmitter Agents, OCT2 Substrates, Peripheral Nervous System Agents, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Reproductive Control Agents, Respiratory System Agents, Selective Beta 2-adrenergic Agonists, Sympathomimetics, Tocolytic Agents"," Beta-2 adrenergic receptor,  Beta-3 adrenergic receptor,  Beta-1 adrenergic receptor,  Sulfotransferase (Protein Group),  UDP-glucuronosyltransferases (UGTs) (Protein Group),  Cholinesterase,  Solute carrier family 22 member 5,  Solute carrier family 22 member 2","DB00871, DB00816, DB08985, DB01064, DB00388, DB01288, DB00668, DB13378, DB13494, DB00221, DB08957",
DB00872,Conivaptan,approved; investigational,CC1=NC2=C(CCN(C(=O)C3=CC=C(NC(=O)C4=CC=CC=C4C4=CC=CC=C4)C=C3)C3=CC=CC=C23)N1,C32H26N4O2,,"Antidiuretic Hormone Receptor Antagonists, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strong), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Diuretics, Heterocyclic Compounds, Fused-Ring, Hypotensive Agents, Narrow Therapeutic Index Drugs, Natriuretic Agents, P-glycoprotein inhibitors"," Vasopressin V1a receptor,  Vasopressin V2 receptor,  Cytochrome P450 3A4,  P-glycoprotein 1",DB00872,
DB14596,Loteprednol etabonate,approved,[H][C@@]12CC[C@](OC(=O)OCC)(C(=O)OCCl)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,C24H31ClO7,,"Adrenal Cortex Hormones, Androstadienes, Androstanes, Androstenes, Anti-Allergic Agents, Corticosteroids, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Fused-Ring Compounds, Immunosuppressive Agents, Steroids"," Glucocorticoid receptor,  Cytochrome P450 3A4,  Serum paraoxonase/arylesterase 1","DB14596, DB01130, DB00873, DB05442, DB01410, DB01260, DB01222",
DB00874,Guaifenesin,approved; investigational; vet_approved,COC1=CC=CC=C1OCC(O)CO,C10H14O4,,"Benzene Derivatives, Catechols, Cough and Cold Preparations, Ethers, Expectorants, Methyl Ethers, Phenols, Phenyl Ethers, Respiratory System Agents", NMDA receptor (Protein Group),"DB00874, DB00423",
DB00875,Flupentixol,approved; investigational; withdrawn,[H]\C(CCN1CCN(CCO)CC1)=C1/C2=CC=CC=C2SC2=C1C=C(C=C2)C(F)(F)F,C23H25F3N2OS,,"Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Agents producing tachycardia, Agents that produce hypertension, Anticholinergic Agents, Antidepressive Agents, Antipsychotic Agents, Antipsychotic Agents (First Generation [Typical]), Central Nervous System Agents, Central Nervous System Depressants, Dopamine Agents, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Drugs causing inadvertant photosensitivity, Heterocyclic Compounds, Fused-Ring, Highest Risk QTc-Prolonging Agents, Muscarinic Antagonists, Nervous System, Neurotoxic agents, Neurotransmitter Agents, P-glycoprotein inhibitors, Photosensitizing Agents, Piperazines, Psycholeptics, Psychotropic Drugs, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2A Receptor Antagonists, Serotonin 5-HT2C Receptor Antagonists, Serotonin Agents, Serotonin Receptor Antagonists, Sulfur Compounds, Thioxanthene Derivatives, Thioxanthenes, Tranquilizing Agents, Xanthenes"," Dopamine D2 receptor,  Dopamine D1 receptor,  5-hydroxytryptamine receptor 2A,  Alpha-1A adrenergic receptor,  Dopamine D3 receptor,  Dopamine D4 receptor,  5-hydroxytryptamine receptor 2C,  Muscarinic acetylcholine receptor M1,  Liver carboxylesterase 1,  Aromatic-L-amino-acid decarboxylase,  P-glycoprotein 1","DB00875, DB01624, DB13841, DB13292",
DB00876,Eprosartan,approved,CCCCC1=NC=C(\C=C(/CC2=CC=CS2)C(O)=O)N1CC1=CC=C(C=C1)C(O)=O,C23H24N2O4S,,"Acids, Acyclic, Agents Acting on the Renin-Angiotensin System, Agents causing angioedema, Agents causing hyperkalemia, Agents Causing Muscle Toxicity, Angiotensin 2 Receptor Blocker, Angiotensin II receptor antagonists, Angiotensin II receptor blockers (ARBs) and diuretics, Angiotensin II receptor blockers (ARBs), plain, Angiotensin II Type 1 Receptor Blockers, Angiotensin Receptor Antagonists, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Cardiovascular Agents, Hypotensive Agents, Sulfur Compounds"," Type-1 angiotensin II receptor,  Canalicular multispecific organic anion transporter 1",DB00876,
DB00877,Sirolimus,approved; investigational,[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC,C51H79NO13,,"Agents causing angioedema, Anti-Bacterial Agents, Anti-Infective Agents, Antibiotics, Antineoplastic, Antifungal Agents, Antineoplastic and Immunomodulating Agents, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Substrates, Decreased Immunologic Activity, Hyperglycemia-Associated Agents, Immunologic Factors, Immunosuppressive Agents, Immunotherapy, Kinase Inhibitor, Lactones, Macrolides, Mammalian target of rapamycin (mTOR) kinase inhibitors, mTOR Inhibitor Immunosuppressant, mTOR Inhibitors, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, OATP1B1/SLCO1B1 Inhibitors, Ophthalmologicals, P-glycoprotein inducers, P-glycoprotein inhibitors, P-glycoprotein substrates, P-glycoprotein substrates with a Narrow Therapeutic Index, Polyketides, Protein Kinase Inhibitors, Selective Immunosuppressants, Sensory Organs, Sirolimus and Prodrugs"," Serine/threonine-protein kinase mTOR,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  Serum albumin,  Alpha-1-acid glycoprotein 1,  Apolipoproteins (Protein Group),  P-glycoprotein 1,  Solute carrier organic anion transporter family member 1B1,  Multidrug and toxin extrusion protein 1","DB00877, DB01590, DB06287, DB15527, DB06233, DB00864, DB00337, DB15422, DB03621",
DB00878,Chlorhexidine,approved; vet_approved; withdrawn,ClC1=CC=C(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC2=CC=C(Cl)C=C2)C=C1,C22H30Cl2N10,,"Alimentary Tract and Metabolism, Amidines, Anti-Infective Agents, Anti-Infective Agents, Local, Antiinfectives and Antiseptics for Local Oral Treatment, Antiseptics and Disinfectants, Biguanides, Biguanides and Amidines, Compounds used in a research, industrial, or household setting, Decreased Cell Wall Integrity, Dental Agents, Dermatologicals, Disinfectants, Guanidines, Household Products, Irrigating Solutions, Medicated Dressings, Medicated Dressings With Antiinfectives, Miscellaneous Anti-infectives, Miscellaneous Local Anti-infectives, Mouthwashes, Mouthwashes and Gargles, Ophthalmological and Otological Preparations, Ophthalmologicals, Otologicals, Sensory Organs, Stomatological Preparations, Throat Preparations", Serum albumin,"DB00878, DB01131, DB12314",
DB00879,Emtricitabine,approved; investigational,NC1=NC(=O)N(C=C1F)[C@@H]1CS[C@H](CO)O1,C8H10FN3O3S,,"Anti-HIV Agents, Anti-Infective Agents, Anti-Retroviral Agents, Antiinfectives for Systemic Use, Antiviral Agents, Antivirals for Systemic Use, Antivirals used in combination for the treatment of HIV infections, Carbohydrates, Deoxycytidine, Deoxyribonucleosides, Dideoxynucleosides, Direct Acting Antivirals, Enzyme Inhibitors, Glycosides, Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor, MATE 1 Substrates, MATE substrates, Nucleic Acid Synthesis Inhibitors, Nucleic Acids, Nucleotides, and Nucleosides, Nucleoside and Nucleotide Reverse Transcriptase Inhibitors, Nucleoside Reverse Transcriptase Inhibitors, Nucleosides, Pyrimidine Nucleosides, Pyrimidines, Reverse Transcriptase Inhibitors, Ribonucleosides"," Reverse transcriptase/RNaseH,  Deoxycytidine kinase,  Serum albumin,  Multidrug and toxin extrusion protein 1","DB00879, DB12753",
DB00880,Chlorothiazide,approved; vet_approved,NS(=O)(=O)C1=C(Cl)C=C2NC=NS(=O)(=O)C2=C1,C7H6ClN3O4S2,,"Antihypertensive Agents, Benzothiadiazines, Cardiovascular Agents, Diuretics, Drugs causing inadvertant photosensitivity, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Heterocyclic Compounds, Fused-Ring, Hyperglycemia-Associated Agents, Hypotensive Agents, Increased Diuresis, Membrane Transport Modulators, Natriuretic Agents, OAT1/SLC22A6 inhibitors, Photosensitizing Agents, Sodium Chloride Symporter Inhibitors, Sulfonamides, Sulfones, Sulfur Compounds, Thiazides"," Solute carrier family 12 member 3,  Carbonic anhydrase 1,  Carbonic anhydrase 2,  Solute carrier family 22 member 6",DB00880,
DB00881,Quinapril,approved; investigational,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC=CC=C2C[C@H]1C(O)=O,C25H30N2O5,,"ACE Inhibitors and Diuretics, Agents Acting on the Renin-Angiotensin System, Agents causing angioedema, Agents causing hyperkalemia, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Cardiovascular Agents, Enzyme Inhibitors, Heterocyclic Compounds, Fused-Ring, Hypotensive Agents, Isoquinolines, OAT3/SLC22A8 Substrates, Protease Inhibitors, Tetrahydroisoquinolines"," Angiotensin-converting enzyme,  Liver carboxylesterase 1,  Serum albumin,  Solute carrier family 15 member 1,  Solute carrier family 15 member 2,  Solute carrier family 22 member 8","DB00881, DB14217, DB00691, DB14210, DB13312",
DB00882,Clomifene,approved; investigational,CCN(CC)CCOC1=CC=C(C=C1)C(=C(Cl)C1=CC=CC=C1)C1=CC=CC=C1,C26H28ClNO,,"Benzene Derivatives, Benzylidene Compounds, Clomiphene, Estrogen Agonist-antagonists, Estrogen Agonist/Antagonist, Estrogen Antagonists, Estrogen Receptor Modulators, Fertility Agents, Fertility Agents, Female, Genito Urinary System and Sex Hormones, Hormone Antagonists, Hormones, Hormone Substitutes, and Hormone Antagonists, Ovulation Stimulants, Synthetic, P-glycoprotein substrates, Reproductive Control Agents, Selective Estrogen Receptor Modulators, Sex Hormones and Modulators of the Genital System, Stilbenes"," Estrogen receptor alpha,  Sex hormone-binding globulin,  Steroid 17-alpha-hydroxylase/17,20 lyase,  P-glycoprotein 1","DB00882, DB06735, DB00269, DB00675, DB04468, DB00539",
DB00883,Isosorbide dinitrate,approved; investigational,[H][C@]12OC[C@H](O[N+]([O-])=O)[C@@]1([H])OC[C@H]2O[N+]([O-])=O,C6H8N2O8,,"Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use, Alcohols, Antianginal Agents, Carbohydrates, Cardiac Therapy, Cardiovascular Agents, Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Hypotensive Agents, Methemoglobinemia Associated Agents, Nitrate Vasodilator, Nitrates and Nitrites, Nitric Oxide Donors, Organic Nitrates, Sugar Alcohols, Vasodilating Agents, Vasodilation, Vasodilators Used in Cardiac Diseases, Vasoprotectives"," Atrial natriuretic peptide receptor 1,  Cytochrome P450 2E1","DB00883, DB01020",
DB00884,Risedronic acid,approved; investigational,OC(CC1=CN=CC=C1)(P(O)(O)=O)P(O)(O)=O,C7H11NO7P2,,"Agents Causing Muscle Toxicity, Bisphosphonates, Bone Density Conservation Agents, Calcium-Regulating Hormones and Agents, Cardiovascular Agents, Drugs Affecting Bone Structure and Mineralization, Drugs for Treatment of Bone Diseases, Membrane Transport Modulators, Musculo-Skeletal System, Organophosphonates, Organophosphorus Compounds, Pyridines"," Hydroxylapatite,  Farnesyl pyrophosphate synthase,  Prostaglandin G/H synthase 2",DB00884,
DB00885,Pemirolast,approved; investigational,CC1=CC=CN2C(=O)C(=CN=C12)C1=NNN=N1,C10H8N6O,,"Decreased Histamine Release, Histamine Agents, Mast Cell Stabilizers, Neurotransmitter Agents, Ophthalmics, Pyrimidines",,DB00885,
DB00886,Omapatrilat,investigational,[H][C@]12CCC[C@H](N1C(=O)[C@H](CCS2)NC(=O)[C@@H](S)CC1=CC=CC=C1)C(O)=O,C19H24N2O4S2,,"Agents Acting on the Renin-Angiotensin System, Agents causing angioedema, Agents causing hyperkalemia, Agents that produce hypertension, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Azepines, Cardiovascular Agents, Enzyme Inhibitors, Metalloendopeptidases, antagonists & inhibitors, Protease Inhibitors, Sulfur Compounds, Thiepins, Vasopeptidase Inhibitors"," Neprilysin,  Angiotensin-converting enzyme",DB00886,
DB00887,Bumetanide,approved,CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O,C17H20N2O5S,,"Acids, Carbocyclic, Agents Causing Muscle Toxicity, Amides, Aminobenzoates, Benzene Derivatives, Benzoates, Cardiovascular Agents, Diuretics, Drugs causing inadvertant photosensitivity, Drugs that are Mainly Renally Excreted, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, High-Ceiling Diuretics, High-Ceiling Diuretics and Potassium-Sparing Agents, Hyperglycemia-Associated Agents, Hypotensive Agents, Increased Diuresis at Loop of Henle, Membrane Transport Modulators, meta-Aminobenzoates, Natriuretic Agents, Nephrotoxic agents, Non Potassium Sparing Diuretics, OAT1/SLC22A6 inhibitors, OAT3/SLC22A8 Inhibitors, OAT3/SLC22A8 Substrates, Photosensitizing Agents, Sodium Potassium Chloride Symporter Inhibitors, Sulfonamides, Sulfones, Sulfur Compounds"," Solute carrier family 12 member 1,  Solute carrier family 12 member 2,  Solute carrier family 12 member 4,  Solute carrier family 12 member 5,  Cystic fibrosis transmembrane conductance regulator,  Prostaglandin G/H synthase 2,  Sodium/bile acid cotransporter,  Solute carrier family 22 member 6,  Solute carrier family 22 member 8,  Solute carrier family 22 member 11,  Solute carrier family 22 member 7,  Solute carrier organic anion transporter family member 1A2","DB00887, DB02925",
DB00888,Mechlorethamine,approved; investigational,CN(CCCl)CCCl,C5H11Cl2N,,"Alkylating Activity, Alkylating Drugs, Antineoplastic Agents, Antineoplastic Agents, Alkylating, Antineoplastic and Immunomodulating Agents, Cardiotoxic antineoplastic agents, Cholinesterase Inhibitors, Compounds used in a research, industrial, or household setting, Hydrocarbons, Halogenated, Immunosuppressive Agents, Irritants, Mustard Compounds, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, Nitrogen Mustard Analogues, Nitrogen Mustard Compounds, Noxae, Poisons, Toxic Actions"," DNA,  Cholinesterase",DB00888,
DB00889,Granisetron,approved; investigational,CN1N=C(C(=O)N[C@@H]2C[C@@H]3CCC[C@H](C2)N3C)C2=C1C=CC=C2,C18H24N4O,,"Alimentary Tract and Metabolism, Antidepressive Agents, Antiemetic Serotonin 5-HT3 Receptor Antagonists, Antiemetics, Antiemetics and Antinauseants, Autonomic Agents, Aza Compounds, Azabicyclo Compounds, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Gastrointestinal Agents, Heterocyclic Compounds, Fused-Ring, Indazoles, Moderate Risk QTc-Prolonging Agents, Neurotransmitter Agents, Peripheral Nervous System Agents, Pyrazoles, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 3 Receptor Antagonists, Serotonin 5-HT3 Receptor Antagonists, Serotonin Agents, Serotonin Receptor Antagonists"," 5-hydroxytryptamine receptor 3A,  Cytochrome P450 3A4,  Cytochrome P450 1A1","DB00889, DB05905, DB05586",
DB00890,Dienestrol,approved; investigational,[H]\C(C)=C(/C(=C(\[H])C)/C1=CC=C(O)C=C1)\C1=CC=C(O)C=C1,C18H18O2,,"Benzene Derivatives, Benzyl Compounds, Benzylidene Compounds, Bibenzyls, Dihydrostilbenoids, Estrogens, Estrogens, Non-Steroidal, Genito Urinary System and Sex Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Phenols, Sex Hormones and Modulators of the Genital System, Stilbenes, Stilbestrols, Synthetic Estrogens, Plain"," Estrogen receptor alpha,  Sex hormone-binding globulin","DB00890, DB14668",
DB00891,Sulfapyridine,approved,NC1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=N1,C11H11N3O2S,,"Amides, Amines, Aniline Compounds, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Benzene Derivatives, Benzenesulfonamides, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Dermatologicals, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Methemoglobinemia Associated Agents, Short-Acting Antibacterial Sulfonamides, Sulfanilamides, Sulfonamides, Sulfonamides and trimethoprim, Sulfones, Sulfur Compounds"," Dihydropteroate synthase type-1,  Cytochrome P450 2C9",DB00891,
DB00892,Oxybuprocaine,approved; investigational,CCCCOC1=CC(=CC=C1N)C(=O)OCCN(CC)CC,C17H28N2O3,,"Acids, Carbocyclic, Aminobenzoates, Anesthetics, Anesthetics for Topical Use, Anesthetics, Local, Antipruritics, Incl. Antihistamines, Anesthetics, Etc., Benzene Derivatives, Benzoates, Central Nervous System Agents, Central Nervous System Depressants, Cholinesterase substrates, Dermatologicals, Local Anesthetics (Ester), Ophthalmologicals, para-Aminobenzoates, Peripheral Nervous System Agents, Sensory Organs, Sensory System Agents"," Sodium channel protein type 10 subunit alpha,  Cholinesterase","DB00892, DB00807",
DB00893,Iron Dextran,approved; vet_approved,,,,"Compounds used in a research, industrial, or household setting, Dextrans, Hematinics, Iron Compounds, Iron Preparations, Parenteral Iron Replacement, Supplements"," Hemoglobin subunit beta,  Hemoglobin subunit alpha,  Ferritin heavy chain,  Ferritin light chain,  Serotransferrin",,
DB00894,Testolactone,approved; investigational,[H][C@@]12CCC3=CC(=O)C=C[C@]3(C)[C@@]1([H])CC[C@]1(C)OC(=O)CC[C@@]21[H],C19H24O3,,"Androstadienes, Androstanes, Androstenes, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Aromatase Inhibitors, Drugs that are Mainly Renally Excreted, Fused-Ring Compounds, Homosteroids, Steroids", Cytochrome P450 19A1,"DB00894, DB14639, DB08804, DB13943, DB13944, DB13946, DB16001, DB16002, DB16141, DB15999, DB14643, DB14632, DB15566, DB01395, DB01420, DB14633, DB14644, DB13640, DB08308, DB08619, DB00873, DB14678, DB13958, DB02329, DB14625, DB14646, DB06789, DB14677, DB13185, DB05442",
DB00895,Benzylpenicilloyl polylysine,approved,,C28H46N6O8S,,"Acetamides, Amides, Anti-Bacterial Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Benzene Derivatives, beta-Lactams, Drug Hypersensitivity, Heterocyclic Compounds, Fused-Ring, Lactams, Penicillins, Sulfur Compounds"," High affinity immunoglobulin epsilon receptor subunit gamma,  High affinity immunoglobulin epsilon receptor subunit alpha","DB00895, DB07806, DB01053, DB00578, DB00415, DB03820, DB01060, DB13836, DB08559, DB03550, DB03658, DB13506, DB13816, DB13693, DB01000, DB13739, DB08795, DB01604, DB01607, DB09320, DB13686, DB09319, DB00417, DB13660, DB00319, DB01061, DB00739, DB13337, DB01602, DB05029",
DB00896,Rimexolone,approved,[H][C@@]12C[C@@H](C)[C@](C)(C(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,C24H34O3,,"Adrenal Cortex Hormones, Anti-Inflammatory Agents, Corticosteroid Hormone Receptor Agonists, Corticosteroids, Corticosteroids for Systemic Use, Plain, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inducers (strong), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strong), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Inducers, Cytochrome P-450 CYP3A5 Inducers (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Substrates, Fused-Ring Compounds, Glucocorticoids, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hyperglycemia-Associated Agents, Immunosuppressive Agents, Ophthalmologicals, Pregnanes, Sensory Organs, Steroids, Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins, Thyroxine-binding globulin inhibitors"," Glucocorticoid receptor,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Corticosteroid-binding globulin","DB00896, DB00860, DB00959, DB13208, DB01541, DB13586, DB00635, DB09383, DB12952, DB01569, DB07373, DB12194, DB00253, DB15114, DB00547, DB04652, DB04630, DB00873, DB00324, DB08971, DB12081, DB00443, DB01234, DB11522, DB13491, DB15566, DB00741, DB00240, DB00764, DB13223",
DB00897,Triazolam,approved; investigational,CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12,C17H12Cl2N4,,"Adjuvants, Anesthesia, Agents Causing Muscle Toxicity, Anti-Anxiety Agents, Benzazepines, Benzodiazepine hypnotics and sedatives, Benzodiazepines and benzodiazepine derivatives, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, GABA Agents, GABA Modulators, Heterocyclic Compounds, Fused-Ring, Hypnotics and Sedatives, Nervous System, Neurotransmitter Agents, Psycholeptics, Psychotropic Drugs, Tranquilizing Agents, Triazolobenzodiazepines"," GABA(A) Receptor (Protein Group),  GABA(A) Receptor Benzodiazepine Binding Site (Protein Group),  Cytochrome P450 3A7,  Cytochrome P450 3A4,  Cytochrome P450 2C8,  Cytochrome P450 3A5","DB00897, DB00404, DB01215, DB00546, DB14716, DB14717",
DB00898,Ethanol,approved,CCO,C2H6O,,"Agents Causing Muscle Toxicity, Alcohols, Anti-Infective Agents, Anti-Infective Agents, Local, Antidotes, Antiseptics and Disinfectants, Central Nervous System Agents, Central Nervous System Depressants, Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (strength unknown), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (weak), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2E1 Inducers, Cytochrome P-450 CYP2E1 Inducers (moderate), Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (weak), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dermatologicals, Miscellaneous Local Anti-infectives, Miscellaneous Therapeutic Agents, Nerve Depressants, Neurotoxic agents, NMDA Receptor Antagonists, Solvents"," Gamma-aminobutyric acid receptor subunit alpha-1,  Glutamate receptor ionotropic, NMDA 3A,  Glycine receptor subunit alpha-1,  Glycine receptor subunit alpha-2,  Voltage-dependent L-type calcium channel subunit beta-1,  5-hydroxytryptamine receptor 3A,  Gamma-aminobutyric acid receptor subunit alpha-2,  Neuronal acetylcholine receptor subunit alpha-10,  Voltage-dependent L-type calcium channel subunit alpha-1C, 10. Gamma-aminobutyric acid receptor subunit alpha-5, 11. Gamma-aminobutyric acid receptor subunit alpha-4, 12. Gamma-aminobutyric acid receptor subunit alpha-3, 13. Glutamate receptor 1, 14. Voltage-dependent calcium channel gamma-1 subunit, 15. Neuronal acetylcholine receptor subunit alpha-2, 16. Gamma-aminobutyric acid receptor subunit alpha-6, 17. Glutamate receptor 2, 18. Glutamate receptor 4, 19. Glutamate receptor 3, 20. Neuronal acetylcholine receptor subunit alpha-4, 21. Neuronal acetylcholine receptor subunit beta-2, 22. G protein-activated inward rectifier potassium channel 1, 23. G protein-activated inward rectifier potassium channel 2, 24. Vascular cell adhesion protein 1, 25. Equilibrative nucleoside transporter 1, 26. G protein-activated inward rectifier potassium channel 4, 27. Neuronal acetylcholine receptor subunit alpha-7, 28. Neuronal acetylcholine receptor subunit alpha-9, 29. Gamma-aminobutyric acid receptor subunit beta-1, 30. Gamma-aminobutyric acid receptor subunit beta-3, 31. Gamma-aminobutyric acid receptor subunit beta-2, 32. Voltage-dependent L-type calcium channel subunit alpha-1S, 33. Voltage-dependent L-type calcium channel subunit alpha-1D, 34. Neuronal acetylcholine receptor subunit beta-4, 35. Neuronal acetylcholine receptor subunit alpha-3, 36. Neuronal acetylcholine receptor subunit alpha-5, 37. Neuronal acetylcholine receptor subunit alpha-6, 38. Neuronal acetylcholine receptor subunit beta-3, 39. Gamma-aminobutyric acid receptor subunit gamma-1, 40. Gamma-aminobutyric acid receptor subunit gamma-3, 41. Gamma-aminobutyric acid receptor subunit epsilon, 42. Gamma-aminobutyric acid receptor subunit pi, 43. Gamma-aminobutyric acid receptor subunit theta, 44. Gamma-aminobutyric acid receptor subunit delta, 45. Equilibrative nucleoside transporter 2, 46. 5-hydroxytryptamine receptor 3E, 47. 5-hydroxytryptamine receptor 3B, 48. 5-hydroxytryptamine receptor 3D, 49. 5-hydroxytryptamine receptor 3C, 50. Voltage-dependent calcium channel gamma-2 subunit, 51. G protein-activated inward rectifier potassium channel 3, 52. Neural cell adhesion molecule L1, 53. Acetylcholinesterase, 54. Alcohol dehydrogenase class 4 mu/sigma chain,  Cytochrome P450 1A1,  Cytochrome P450 1A2,  Cytochrome P450 2B6,  Cytochrome P450 2C9,  Cytochrome P450 2C19,  Cytochrome P450 2E1,  Cytochrome P450 3A4,  Cytochrome P450 4A11,  Alcohol dehydrogenase 1A, 10. Alcohol dehydrogenase 1B, 11. Alcohol dehydrogenase 1C, 12. Alcohol dehydrogenase class-3, 13. Alcohol dehydrogenase 4, 14. Alcohol dehydrogenase class 4 mu/sigma chain, 15. Alcohol dehydrogenase 6, 16. Alcohol dehydrogenase [NADP(+)]","DB00898, DB02325, DB03175",
DB00899,Remifentanil,approved,CCC(=O)N(C1=CC=CC=C1)C1(CCN(CCC(=O)OC)CC1)C(=O)OC,C20H28N2O5,,"Acids, Acyclic, Agents producing tachycardia, Agents that produce hypertension, Analgesics, Anesthetics, Anesthetics, General, Anesthetics, Intravenous, Bradycardia-Causing Agents, Central Nervous System Agents, Central Nervous System Depressants, Fentanyl and fentanyl analogues, High-risk opioids, Hypnotics and Sedatives, Hypotensive Agents, Narcotics, Nervous System, Opiate Agonists, Opioid Agonist, Opioid Anesthetics, Opioids, Opioids, Anilidopiperidine, Peripheral Nervous System Agents, Phenylpiperidine opioids, Piperidines, Propionates, Sensory System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"," Mu-type opioid receptor,  Delta-type opioid receptor,  Kappa-type opioid receptor","DB00899, DB01535, DB15360, DB09174",
DB00900,Didanosine,approved,OC[C@@H]1CC[C@@H](O1)N1C=NC2=C1NC=NC2=O,C10H12N4O3,,"Anti-HIV Agents, Anti-Infective Agents, Anti-Retroviral Agents, Antiinfectives for Systemic Use, Antimetabolites, Antiviral Agents, Antivirals for Systemic Use, Deoxyribonucleosides, Dideoxynucleosides, Direct Acting Antivirals, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Heterocyclic Compounds, Fused-Ring, Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor, Neurotoxic agents, Noxae, Nucleic Acid Synthesis Inhibitors, Nucleic Acids, Nucleotides, and Nucleosides, Nucleoside and Nucleotide Reverse Transcriptase Inhibitors, Nucleoside Reverse Transcriptase Inhibitors, Nucleosides, OAT1/SLC22A6 Substrates, Purine Nucleosides, Purines, Reverse Transcriptase Inhibitors, Ribonucleosides, Toxic Actions"," Reverse transcriptase/RNaseH,  Purine nucleoside phosphorylase,  Serum albumin,  Solute carrier family 22 member 6,  Equilibrative nucleoside transporter 1,  Equilibrative nucleoside transporter 2","DB00900, DB02380, DB04335, DB03609, DB02857, DB17756, DB05973, DB04566, DB04440, DB04457, DB02502, DB03735, DB13156, DB12156, DB02309, DB03493, DB02103, DB03491, DB01972, DB03315, DB00194, DB00640, DB03528, DB02023, DB02753, DB02181, DB07170, DB02934, DB03952, DB03726",
DB00901,Bitolterol,withdrawn,CC1=CC=C(C=C1)C(=O)OC1=C(OC(=O)C2=CC=C(C)C=C2)C=C(C=C1)C(O)CNC(C)(C)C,C28H31NO5,,"Adrenergic Agents, Adrenergic Agonists, Adrenergic beta-2 Receptor Agonists, Adrenergic beta-Agonists, Adrenergics, Inhalants, Agents producing tachycardia, Agents that produce hypertension, Alcohols, Amines, Amino Alcohols, Anti-Asthmatic Agents, Autonomic Agents, Bronchodilator Agents, Drugs for Obstructive Airway Diseases, Neurotransmitter Agents, Peripheral Nervous System Agents, Respiratory System Agents, Selective Beta 2-adrenergic Agonists", Beta-2 adrenergic receptor,"DB00901, DB00449",
DB00902,Methdilazine,approved,CN1CCC(CN2C3=CC=CC=C3SC3=CC=CC=C23)C1,C18H20N2S,,"Agents that reduce seizure threshold, Antihistamines for Systemic Use, Heterocyclic Compounds, Fused-Ring, Histamine Antagonists, Histamine H1 Antagonists, Phenothiazine Derivatives, Sulfur Compounds", Histamine H1 receptor,"DB00902, DB01246, DB01071, DB00420, DB12710, DB13784, DB13820, DB13382, DB11517, DB15596, DB09000, DB00477, DB00433, DB00508, DB00831, DB00679, DB15978, DB01403, DB00372, DB01069, DB13420, DB00850, DB00392",
DB00903,Etacrynic acid,approved; investigational,CCC(=C)C(=O)C1=C(Cl)C(Cl)=C(OCC(O)=O)C=C1,C13H12Cl2O4,,"Acetates, Acids, Acyclic, Agents that produce neuromuscular block (indirect), Aryloxyacetic Acid Derivatives, Diuretics, Enzyme Inhibitors, Glycolates, High-Ceiling Diuretics, Hydroxy Acids, Hyperglycemia-Associated Agents, Hypotensive Agents, Increased Diuresis at Loop of Henle, Natriuretic Agents, Nephrotoxic agents, Non Potassium Sparing Diuretics, OAT1/SLC22A6 inhibitors, Ototoxic agents, Phenoxyacetates, Sodium Potassium Chloride Symporter Inhibitors"," Solute carrier family 12 member 1,  Sodium/potassium-transporting ATPase subunit alpha-1,  Lymphoid enhancer-binding factor 1,  Glutathione S-transferase P,  Glutathione S-transferase A2,  Serum albumin,  Solute carrier family 22 member 6",DB00903,
DB00904,Ondansetron,approved; withdrawn,CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2,C18H19N3O,,"Anti-Anxiety Agents, Antidepressive Agents, Antiemetic Serotonin 5-HT3 Receptor Antagonists, Antiemetics, Antiemetics and Antinauseants, Carbazoles, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Heterocyclic Compounds, Fused-Ring, Imidazoles, Indoles, Moderate Risk QTc-Prolonging Agents, Peripheral Nervous System Agents, Psychotropic Drugs, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 3 Receptor Antagonists, Serotonin 5-HT3 Receptor Antagonists, Serotonin Agents, Serotonin Receptor Antagonists"," 5-hydroxytryptamine receptor 3A,  5-hydroxytryptamine receptor 4,  Mu-type opioid receptor,  5-hydroxytryptamine receptor 1A,  5-hydroxytryptamine receptor 1B,  Cytochrome P450 3A4,  Cytochrome P450 1A2,  Cytochrome P450 2D6,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  Cytochrome P450 2C9,  Cytochrome P450 2E1","DB00904, DB04885, DB09290, DB08557, DB08655",
DB00905,Bimatoprost,approved; investigational,CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1,C25H37NO4,,"Amides, Antiglaucoma Preparations and Miotics, Antihypertensive Agents, Autacoids, Biological Factors, Cardiovascular Agents, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Eicosanoids, Fatty Acids, Fatty Acids, Unsaturated, Inflammation Mediators, Lipids, Ophthalmologicals, Prostaglandin analogs reducing intraocular pressure (IOP), Prostaglandins, Prostaglandins F, Synthetic, Prostaglandins, Synthetic, Sensory Organs"," Prostaglandin F2-alpha receptor,  Prostaglandin E2 receptor EP1 subtype,  Prostaglandin E2 receptor EP3 subtype,  Cytochrome P450 3A4,  Cytochrome P450 3A5",DB00905,
DB00906,Tiagabine,approved; investigational,CC1=C(SC=C1)C(=CCCN1CCC[C@H](C1)C(O)=O)C1=C(C)C=CS1,C20H25NO2S2,,"Anti-epileptic Agent, Anticonvulsants, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Decreased Central Nervous System Disorganized Electrical Activity, Fatty Acid Derivatives, GABA Agents, GABA Uptake Inhibitors, Membrane Transport Modulators, Nervous System, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, Nipecotic Acid and Derivatives, Piperidines, UGT1A1 Substrates"," Sodium- and chloride-dependent GABA transporter 1,  UDP-glucuronosyltransferase 1-1,  Cytochrome P450 3A4",DB00906,
DB00907,Cocaine,approved; illicit,[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C,C17H21NO4,,"Agents producing tachycardia, Agents that reduce seizure threshold, Alkaloids, Analgesics and Anesthetics, Anesthetics, Anesthetics, Local, Anticholinergic Agents, Aza Compounds, Azabicyclo Compounds, Cardiovascular Agents, Central Nervous System Agents, Central Nervous System Stimulants, Cholinesterase substrates, Cocaine, antagonists & inhibitors, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dopamine Agents, Dopamine Uptake Inhibitors, Esters of Benzoic Acid, Highest Risk QTc-Prolonging Agents, Local Anesthetics (Ester), Membrane Transport Modulators, Muscarinic Antagonists, Nervous System, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, OCT2 Inhibitors, Ophthalmologicals, QTc Prolonging Agents, Sensory Organs, Sensory System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Throat Preparations, Tropanes, Vasoconstrictor Agents"," Sodium-dependent dopamine transporter,  Sodium-dependent noradrenaline transporter,  Sodium channel protein (Protein Group),  Sodium-dependent serotonin transporter,  Muscarinic acetylcholine receptor M1,  Muscarinic acetylcholine receptor M2,  Sigma non-opioid intracellular receptor 1,  Liver carboxylesterase 1,  Cytochrome P450 3A4,  Cytochrome P450 2D6,  Cytochrome P450 2C8,  Cholinesterase,  Liver carboxylesterase 1,  alpha1-acid glycoprotein (Protein Group),  Solute carrier family 22 member 2,  Sodium-dependent dopamine transporter","DB00907, DB01515",
DB00908,Quinidine,approved; investigational,[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,C20H24N2O2,,"Adrenergic Agents, Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Agents producing tachycardia, Agents that produce hypertension, Agents that produce neuromuscular block (indirect), Agents that reduce seizure threshold, Alkaloids, Anti-Infective Agents, Antiarrhythmic agents, Antiarrhythmics, Class I, Antiarrhythmics, Class Ia, Anticholinergic Agents, Antimalarials, Antiparasitic Agents, Antiprotozoals, Biological Products, Biopolymers, BSEP/ABCB11 Inhibitors, Carbohydrates, Cardiac Therapy, Cardiovascular Agents, Cholinergic Agents, Cinchona Alkaloids, Complex Mixtures, Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strong), Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (strength unknown), Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 CYP2C8 Inducers (weak), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (weak), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (moderate), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strong), Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (weak), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs causing inadvertant photosensitivity, Drugs that are Mainly Renally Excreted, Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index, Enzyme Inhibitors, Heterocyclic Compounds, Fused-Ring, Highest Risk QTc-Prolonging Agents, Macromolecular Substances, Membrane Transport Modulators, Muscarinic Antagonists, Narrow Therapeutic Index Drugs, Negative Inotrope, Neurotransmitter Agents, OAT3/SLC22A8 Inhibitors, OATP1B1/SLCO1B1 Inhibitors, OCT1 inhibitors, OCT2 Inhibitors, P-glycoprotein inhibitors, P-glycoprotein substrates, P-glycoprotein substrates with a Narrow Therapeutic Index, Pharmaceutical Preparations, Photosensitizing Agents, Plant Extracts, Plant Preparations, Polymers, Polysaccharides, QTc Prolonging Agents, Quinolines, Quinuclidines, Sodium Channel Blockers, Voltage-Gated Sodium Channel Blockers"," Sodium channel protein type 5 subunit alpha,  Potassium channel subfamily K member 1,  Potassium channel subfamily K member 6,  Potassium voltage-gated channel subfamily H member 2,  Alpha-1A adrenergic receptor,  Alpha-1B adrenergic receptor,  Alpha-1D adrenergic receptor,  Cytochrome P450 3A4,  Cytochrome P450 3A7,  Cytochrome P450 2D6,  Cytochrome P450 1A2,  Cytochrome P450 2E1,  Cytochrome P450 1A1,  Cytochrome P450 2B6,  Cytochrome P450 2C9,  Cytochrome P450 2C8,  Serum albumin,  Alpha-1-acid glycoprotein 1,  Solute carrier family 22 member 2,  Solute carrier family 22 member 1,  Solute carrier family 22 member 5,  P-glycoprotein 1,  Solute carrier organic anion transporter family member 1A2,  Solute carrier family 22 member 8,  Canalicular multispecific organic anion transporter 1,  Solute carrier family 22 member 4,  Solute carrier organic anion transporter family member 1B1, 10. Bile salt export pump","DB00468, DB00908, DB13718, DB15300, DB16831, DB01346",
DB00909,Zonisamide,approved; investigational,NS(=O)(=O)CC1=NOC2=CC=CC=C12,C8H8N2O3S,,"Agents causing hyperkalemia, Amides, Anti-epileptic Agent, Antiarrhythmic agents, Anticonvulsants, Bradycardia-Causing Agents, Calcium Channel Blockers, Calcium-Regulating Hormones and Agents, Carbonic Anhydrase Inhibitors, Cardiovascular Agents, Central Nervous System Agents, Central Nervous System Depressants, Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (weak), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Decreased Central Nervous System Disorganized Electrical Activity, Diuretics, Drugs that are Mainly Renally Excreted, Isoxazoles, Membrane Transport Modulators, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates, Nervous System, P-glycoprotein inhibitors, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Sulfonamides, Sulfones, Sulfur Compounds, UGT1A1 Substrates"," Sodium channel protein type 1 subunit alpha,  Sodium channel protein type 2 subunit alpha,  Sodium channel protein type 3 subunit alpha,  Sodium channel protein type 4 subunit alpha,  Sodium channel protein type 5 subunit alpha,  Sodium channel protein type 9 subunit alpha,  Sodium channel protein type 11 subunit alpha,  Sodium channel subunit beta-1,  Sodium channel subunit beta-2, 10. Sodium channel subunit beta-3, 11. Sodium channel subunit beta-4, 12. Voltage-dependent T-type calcium channel subunit alpha-1G, 13. Voltage-dependent T-type calcium channel subunit alpha-1H, 14. Voltage-dependent T-type calcium channel subunit alpha-1I, 15. Carbonic anhydrase 1, 16. Carbonic anhydrase 2, 17. Carbonic anhydrase 3, 18. Carbonic anhydrase 4, 19. Carbonic anhydrase 5A, mitochondrial, 20. Carbonic anhydrase 5B, mitochondrial, 21. Carbonic anhydrase 6, 22. Carbonic anhydrase 7, 23. Carbonic anhydrase-related protein, 24. Carbonic anhydrase 9, 25. Carbonic anhydrase-related protein 10, 26. Carbonic anhydrase-related protein 11, 27. Carbonic anhydrase 12, 28. Carbonic anhydrase 13, 29. Carbonic anhydrase 14, 30. Amine oxidase [flavin-containing] B, 31. Amine oxidase [flavin-containing] A, 32. GABA(A) Receptor Benzodiazepine Binding Site (Protein Group),  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 2C19,  UDP-glucuronosyltransferase 1-1,  Aldehyde oxidase,  P-glycoprotein 1",DB00909,
DB00910,Paricalcitol,approved; investigational,[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1C[C@@H](O)C[C@H](O)C1)[C@H](C)\C=C\[C@H](C)C(C)(C)O,C27H44O3,,"Anti-Parathyroid Agents, Bone Density Conservation Agents, Calcium Homeostasis, Cholestanes, Cholestenes, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Fused-Ring Compounds, Lipids, Membrane Lipids, Secosteroids, Steroids, Sterols, Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins, UGT1A4 substrates, Vitamin D and Analogues, Vitamins, Vitamins (Fat Soluble)"," Vitamin D3 receptor,  1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial,  Cytochrome P450 3A4,  UDP-glucuronosyltransferase 1-4","DB00910, DB01070, DB06410, DB00153, DB04891, DB06117, DB01436, DB13097, DB04038, DB15557, DB02300, DB13689, DB00136, DB00169, DB00146, DB18029, DB18406, DB04258",
DB00911,Tinidazole,approved; investigational,CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O,C8H13N3O4S,,"Alimentary Tract and Metabolism, Alkylating Drugs, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Antiparasitic Agents, Antiparasitic Products, Insecticides and Repellents, Antiprotozoals, Antitrichomonal Agents, BSEP/ABCB11 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord), Drugs that are Mainly Renally Excreted, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Imidazole Derivatives, Imidazoles, Nitro Compounds, Nitroimidazole Antimicrobial, Nitroimidazole Derivatives, Nitroimidazoles, Noxae, Toxic Actions"," DNA,  Cytochrome P450 3A4,  Bile salt export pump",DB00911,
DB00912,Repaglinide,approved; investigational,CCOC1=C(C=CC(CC(=O)N[C@@H](CC(C)C)C2=CC=CC=C2N2CCCCC2)=C1)C(O)=O,C27H36N2O4,,"Acids, Acyclic, Alimentary Tract and Metabolism, Blood Glucose Lowering Agents, BSEP/ABCB11 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Drugs Used in Diabetes, Glinide, Hypoglycemia-Associated Agents, Insulin Secretagogues, Meglitinides, OATP1B1/SLCO1B1 Substrates, Oral Hypoglycemics, Potassium Channel Blockers, Stereoisomerism"," ATP-binding cassette sub-family C member 8,  Peroxisome proliferator-activated receptor gamma,  Histamine H1 receptor,  Cytochrome P450 2C8,  Cytochrome P450 3A4,  Serum albumin,  Solute carrier organic anion transporter family member 1B1,  Bile salt export pump",DB00912,
DB00913,Anileridine,approved; illicit,CCOC(=O)C1(CCN(CCC2=CC=C(N)C=C2)CC1)C1=CC=CC=C1,C22H28N2O2,,"Anesthetics, Anesthetics, General, Nervous System, Opioid Anesthetics, Piperidines", Mu-type opioid receptor,"DB00913, DB00454, DB13605, DB01505, DB01081, DB01475, DB01518, DB08988",
DB00914,Phenformin,approved; investigational; withdrawn,NC(=N)NC(=N)NCCC1=CC=CC=C1,C10H15N5,,"Alimentary Tract and Metabolism, Amidines, Biguanides, Blood Glucose Lowering Agents, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 Substrates, Drugs Used in Diabetes, Guanidines, OCT1 inhibitors, OCT1 substrates, OCT2 Inhibitors, Oral Hypoglycemics"," 5'-AMP-activated protein kinase catalytic subunit alpha-1,  ATP-sensitive inward rectifier potassium channel 8,  Cytochrome P450 2D6,  Solute carrier family 22 member 2,  Solute carrier family 22 member 1",DB00914,
DB00915,Amantadine,approved,NC12CC3CC(CC(C3)C1)C2,C10H17N,,"Adamantane Derivatives, Adamantanes, Analgesics, Analgesics, Non-Narcotic, Anti-Dyskinesia Agents, Anti-Infective Agents, Anti-Parkinson Drugs, Anticholinergic Agents, Antiviral Agents, Bridged-Ring Compounds, Central Nervous System Agents, Dopamine Agents, Drugs that are Mainly Renally Excreted, Influenza A M2 Protein Inhibitor, M2 Protein Inhibitors, Nervous System, Neurotransmitter Agents, Nicotinic Antagonists, NMDA Receptor Antagonists, OCT1 inhibitors, OCT1 substrates, OCT2 Inhibitors, OCT2 Substrates, Peripheral Nervous System Agents, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Sensory System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"," Matrix protein 2,  Glutamate receptor ionotropic, NMDA 3A,  Dopamine D2 receptor,  Neuronal acetylcholine receptor subunit alpha-7,  Neuronal acetylcholine receptor subunit alpha-4,  Neuronal acetylcholine receptor subunit alpha-3,  Aromatic-L-amino-acid decarboxylase,  Amine oxidase [flavin-containing] B,  Solute carrier family 22 member 2,  Solute carrier family 22 member 1","DB00915, DB01043, DB00478, DB04926, DB06714",
DB00916,Metronidazole,approved,CC1=NC=C(N1CCO)[N+]([O-])=O,C6H9N3O3,,"Agents that reduce seizure threshold, Alimentary Tract and Metabolism, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives and Antiseptics for Local Oral Treatment, Antiinfectives for Systemic Use, Antiparasitic Agents, Antiparasitic Products, Insecticides and Repellents, Antiprotozoals, Cytochrome P-450 CYP2A6 Substrates, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dermatologicals, Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord), Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Imidazole Derivatives, Imidazoles, Miscellaneous Antiprotozoals, Miscellaneous Local Anti-infectives, Nitro Compounds, Nitroimidazole Antimicrobial, Nitroimidazole Derivatives, Nitroimidazoles, P-glycoprotein inhibitors, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Stomatological Preparations, UGT1A1 Substrates"," Oxygen-insensitive NADPH nitroreductase,  Cytochrome P450 2C8,  UDP-glucuronosyltransferase 1-1,  Cytochrome P450 2A6,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  Cytochrome P450 2C9,  Cytochrome P450 3A4,  P-glycoprotein 1",DB00916,
DB00917,Dinoprostone,approved,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O,C20H32O5,,"Autacoids, Biological Factors, Dinoprostone, antagonists & inhibitors, Eicosanoids, Fatty Acids, Fatty Acids, Unsaturated, Genito Urinary System and Sex Hormones, Inflammation Mediators, Lipids, OAT1/SLC22A6 inhibitors, OAT1/SLC22A6 Substrates, OAT3/SLC22A8 Inhibitors, OAT3/SLC22A8 Substrates, OATP1B1/SLCO1B1 Substrates, OATP2B1/SLCO2B1 substrates, OCT1 inhibitors, OCT2 Inhibitors, Prostaglandins, Prostaglandins E, Prostaglandins, Synthetic, Reproductive Control Agents, Uterotonic agents"," Prostaglandin E2 receptor EP2 subtype,  Prostaglandin E2 receptor EP1 subtype,  Prostaglandin E2 receptor EP3 subtype,  Prostaglandin E2 receptor EP4 subtype,  Prostaglandin D2 receptor 2,  Solute carrier family 22 member 2,  Multidrug resistance-associated protein 5,  Solute carrier family 22 member 6,  Solute carrier family 22 member 8,  Solute carrier family 22 member 11,  Solute carrier family 22 member 7,  Multidrug resistance-associated protein 4,  Solute carrier organic anion transporter family member 2B1,  Solute carrier organic anion transporter family member 1A2, 10. Organic solute transporter subunit alpha, 11. Organic solute transporter subunit beta, 12. Solute carrier organic anion transporter family member 2A1, 13. Solute carrier organic anion transporter family member 4A1, 14. Solute carrier organic anion transporter family member 1C1, 15. Solute carrier organic anion transporter family member 3A1, 16. Solute carrier organic anion transporter family member 1B1","DB00917, DB00770, DB09211, DB07177, DB08964, DB00929, DB12789, DB02056, DB01160, DB00429",
DB00918,Almotriptan,approved; investigational,CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2,C17H25N3O2S,,"Agents that produce hypertension, Amines, Analgesics, Antidepressive Agents, Antimigraine Preparations, Biogenic Amines, Biogenic Monoamines, Central Nervous System Depressants, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Heterocyclic Compounds, Fused-Ring, Indoles, Migraine Disorders, Monoamine Oxidase A Substrates, Nervous System, Neurotransmitter Agents, Selective Serotonin 5-HT1 Receptor Agonists, Selective Serotonin Agonists, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 1b Receptor Agonists, Serotonin 1d Receptor Agonists, Serotonin 5-HT1 Receptor Agonists, Serotonin Agents, Serotonin Modulators, Serotonin Receptor Agonists, Serotonin-1b and Serotonin-1d Receptor Agonist, Triptans"," 5-hydroxytryptamine receptor 1D,  5-hydroxytryptamine receptor 1B,  Cytochrome P450 3A4,  Cytochrome P450 2D6,  Amine oxidase [flavin-containing] A,  Dimethylaniline monooxygenase [N-oxide-forming] 3,  Cytochrome P450 2C19,  Cytochrome P450 2E1,  Cytochrome P450 2C8","DB00918, DB00669",
DB00919,Spectinomycin,approved; investigational; vet_approved,[H][C@@]12O[C@H](C)CC(=O)[C@]1(O)O[C@]1([H])[C@@H](NC)[C@@H](O)[C@@H](NC)[C@H](O)[C@@]1([H])O2,C14H24N2O7,,"Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Carbohydrates, Dioxanes, Glycosides, Heterocyclic Compounds, Fused-Ring", 30S ribosomal protein S12,"DB00919, DB04626, DB11520, DB01082, DB04717, DB04678, DB04718, DB03618, DB17689, DB11512, DB03013, DB04194, DB04728, DB03615, DB00452, DB01421, DB15080, DB17631, DB00798, DB13274, DB04679",
DB00920,Ketotifen,approved,CN1CCC(CC1)=C1C2=C(SC=C2)C(=O)CC2=CC=CC=C12,C19H19NOS,,"Anti-Allergic Agents, Anti-Asthmatic Agents, Antihistamine Drugs, Antihistamines for Systemic Use, Antipruritics, Decongestants and Antiallergics, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Histamine H1 Inhibitors, Ophthalmologicals, Other Antihistamines, Piperidines, Sensory Organs, Sulfur Compounds, Thiophenes, UGT1A3 substrates, UGT1A4 substrates"," Histamine H1 receptor,  6-phosphogluconate dehydrogenase, decarboxylating,  UDP-glucuronosyltransferase 1-3,  UDP-glucuronosyltransferase 1-4,  UDP-glucuronosyltransferase 2B10","DB00920, DB06153",
DB00921,Buprenorphine,approved; illicit; investigational; vet_approved,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4,C29H41NO4,,"Alkaloids, Analgesics, BCRP/ABCG2 Inhibitors, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2C18 Substrates, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (strength unknown), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (weak), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs Used in Addictive Disorders, Drugs Used in Opioid Dependence, Heterocyclic Compounds, Fused-Ring, Mixed Agonist / Antagonist Opioids, Morphinans, Narcotics, Nervous System, Opiate Agonists, Opiate Alkaloids, Opiate Partial Agonists, Opioid Antagonists, Opioids, Oripavine Derivatives, P-glycoprotein inhibitors, Peripheral Nervous System Agents, Phenanthrenes, Sensory System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, UGT1A1 Substrates, UGT1A9 Substrates"," Kappa-type opioid receptor,  Mu-type opioid receptor,  Delta-type opioid receptor,  Nociceptin receptor,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 2C9,  Cytochrome P450 2C8,  Cytochrome P450 3A7,  Cytochrome P450 2D6,  Cytochrome P450 2C18,  Cytochrome P450 2C19,  P-glycoprotein 1,  ATP-binding cassette sub-family G member 2","DB00921, DB01450, DB01548, DB16072, DB01565, DB01551, DB01512, DB01538, DB00844, DB14146, DB16117, DB09049, DB01531, DB15341, DB01480, DB01497, DB01469, DB06230, DB00497, DB00704, DB01192, DB06800, DB00956, DB00327, DB00318, DB00295, DB01477, DB01466, DB01183, DB04509",
DB00922,Levosimendan,approved; investigational,C[C@@H]1CC(=O)NN=C1C1=CC=C(NN=C(C#N)C#N)C=C1,C14H12N6O,,"Antiarrhythmic agents, Cardiac Stimulants Excl. Cardiac Glycosides, Cardiac Therapy, Cardiotonic Agents, Cardiovascular Agents, Compounds used in a research, industrial, or household setting, Enzyme Inhibitors, Hydrazines, Hydrazones, Hypotensive Agents, Moderate Risk QTc-Prolonging Agents, Phosphodiesterase 3 Inhibitors, Phosphodiesterase Inhibitors, Protective Agents, Pyridazines, QTc Prolonging Agents, Vasodilating Agents"," Troponin C, slow skeletal and cardiac muscles,  ATP-sensitive inward rectifier potassium channel 11,  ATP-sensitive inward rectifier potassium channel 8,  cGMP-inhibited 3',5'-cyclic phosphodiesterase A",DB00922,
DB00923,Ceforanide,approved,[H][C@]12SCC(CSC3=NN=NN3CC(O)=O)=C(N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1CN)C(O)=O,C20H21N7O6S2,,"Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, beta-Lactams, Cephalosporins, Heterocyclic Compounds, Fused-Ring, Lactams, Nephrotoxic agents, Second-Generation Cephalosporins, Sulfur Compounds, Thiazines", Penicillin-binding protein 2,"DB00923, DB01326, DB14725, DB01329, DB00229, DB01328, DB13266, DB13821, DB01327, DB00430, DB00567, DB00274, DB01140, DB01150, DB09062, DB13638, DB00267, DB01330, DB00689, DB13778, DB01212, DB00833, DB13499, DB03938, DB11592, DB01333, DB09008, DB11385, DB00535, DB00456",
DB00924,Cyclobenzaprine,approved,CN(C)CCC=C1C2=CC=CC=C2C=CC2=CC=CC=C12,C20H21N,,"Agents that reduce seizure threshold, Antidepressive Agents, Benzocycloheptenes, Central Nervous System Agents, Central Nervous System Depressants, Centrally-mediated Muscle Relaxation, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Dibenzocycloheptenes, Drugs causing inadvertant photosensitivity, Muscle Relaxants, Muscle Relaxants, Centrally Acting Agents, Musculo-Skeletal System, Neurotoxic agents, Photosensitizing Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2A Receptor Antagonists, Serotonin 5-HT2C Receptor Antagonists, Serotonin Agents, Serotonin Receptor Antagonists, Tranquilizing Agents, UGT1A4 substrates"," 5-hydroxytryptamine receptor 2A,  5-hydroxytryptamine receptor 2B,  5-hydroxytryptamine receptor 2C,  5-hydroxytryptamine receptor 6,  Sodium-dependent serotonin transporter,  Sodium-dependent noradrenaline transporter,  5-hydroxytryptamine receptor 7,  Toll-like receptor 4,  Aldehyde oxidase,  Cytochrome P450 3A4,  Cytochrome P450 1A2,  Cytochrome P450 2D6,  UDP-glucuronosyltransferase 1-4,  UDP-glucuronosyltransferase 2B10,  Serum albumin","DB00924, DB00434, DB13384",
DB00925,Phenoxybenzamine,approved,CC(COC1=CC=CC=C1)N(CCCl)CC1=CC=CC=C1,C18H22ClNO,,"Adrenergic Agents, Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Agents that produce hypertension, Amines, Antihypertensive Agents, Cardiovascular Agents, Ethylamines, Hypotensive Agents, Neurotransmitter Agents, OCT1 inhibitors, OCT2 Inhibitors, Peripheral alpha-1 blockers, Peripheral Vasodilators, Vasodilating Agents"," Alpha-1A adrenergic receptor,  Alpha-2A adrenergic receptor,  Alpha-2C adrenergic receptor,  Alpha-2B adrenergic receptor,  Calmodulin,  Beta-2 adrenergic receptor,  Alpha-1B adrenergic receptor,  Alpha-1D adrenergic receptor,  Solute carrier family 22 member 2,  Solute carrier family 22 member 1,  Solute carrier family 22 member 3","DB00925, DB13462",
DB00926,Etretinate,withdrawn,CCOC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)C(C)=C(OC)C=C1C,C23H30O3,,"Alkenes, Antipsoriatics, Antipsoriatics for Systemic Use, Biological Factors, Carotenoids, Dermatologicals, Drugs causing inadvertant photosensitivity, Hydrocarbons, Acyclic, Keratolytic Agents, Photosensitizing Agents, Pigments, Biological, Polyenes, Retinoids, Retinoids for Treatment of Psoriasis, Terpenes"," Retinoic acid receptor alpha,  Retinoic acid receptor RXR-alpha,  Retinoic acid receptor beta,  Retinoic acid receptor RXR-gamma,  Retinoic acid receptor RXR-beta,  Retinoic acid receptor gamma,  Cytochrome P450 19A1,  Cellular retinoic acid-binding protein 1","DB00926, DB00459, DB08455, DB13368",
DB00927,Famotidine,approved,NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1,C8H15N7O2S3,,"Acid Reducers, Alimentary Tract and Metabolism, Anti-Ulcer Agents, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (weak), Cytochrome P-450 Enzyme Inhibitors, Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord), Gastric Acid Lowering Agents, Gastrointestinal Agents, Histamine Agents, Histamine Antagonists, Histamine H2 Antagonists, MATE 1 Inhibitors, MATE inhibitors, Neurotransmitter Agents, OAT3/SLC22A8 Inhibitors, OAT3/SLC22A8 Substrates, OCT2 Inhibitors, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Sulfur Compounds, Thiazoles"," Histamine H2 receptor,  Cytochrome P450 1A2,  Solute carrier family 22 member 6,  Solute carrier family 22 member 8,  Solute carrier family 22 member 2,  Multidrug and toxin extrusion protein 1",DB00927,
DB00928,Azacitidine,approved; investigational,NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,C8H12N4O5,,"Antimetabolites, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Aza Compounds, Cytidine Deaminase Substrates, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Immunosuppressive Agents, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, Noxae, Nucleic Acid Synthesis Inhibitors, Nucleic Acids, Nucleotides, and Nucleosides, Nucleoside Metabolic Inhibitor, Nucleosides, Pyrimidine Analogues, Pyrimidine Nucleosides, Pyrimidines, Ribonucleosides, Toxic Actions"," DNA (cytosine-5)-methyltransferase 1,  RNA,  DNA,  Cytidine deaminase","DB00928, DB01262",
DB00929,Misoprostol,approved,CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC,C22H38O5,,"Abortifacient Agents, Abortifacient Agents, Nonsteroidal, Alimentary Tract and Metabolism, Anti-Ulcer Agents, Antiinflammatory and Antirheumatic Products, Antiinflammatory and Antirheumatic Products, Non-Steroids, Autacoids, Biological Factors, Drugs causing inadvertant photosensitivity, Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord), Eicosanoids, Fatty Acids, Fatty Acids, Unsaturated, Gastrointestinal Agents, Genito Urinary System and Sex Hormones, Inflammation Mediators, Lipids, Musculo-Skeletal System, Photosensitizing Agents, Propionates, Prostaglandin E1 Analog, Prostaglandins, Prostaglandins E, Synthetic, Prostaglandins, Synthetic, Reproductive Control Agents, Uterotonic agents"," Prostaglandin E2 receptor EP3 subtype,  Prostaglandin E2 receptor EP2 subtype,  Prostaglandin E2 receptor EP1 subtype,  Prostaglandin E2 receptor EP4 subtype","DB00929, DB00770, DB00917, DB07177, DB09211, DB08964",
DB00930,Colesevelam,approved,,,,"Alkenes, Allyl Compounds, Allylamine, Amines, Anticholesteremic Agents, Bile Acid Sequestrants, Bile-acid Binding Activity, Hydrocarbons, Acyclic, Hypolipidemic Agents, Hypolipidemic Agents Indicated for Hyperlipidemia, Lipid Modifying Agents, Lipid Modifying Agents, Plain, Lipid Regulating Agents, Non-statin Hypolipidemic Agents Indicated for Hyperlipidemia",,,
DB00931,Metacycline,approved; investigational,[H][C@@]12[C@@H](O)[C@]3([H])C(=C)C4=C(C(O)=CC=C4)C(=O)C3=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C,C22H22N2O8,,"Agents that produce neuromuscular block (indirect), Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Naphthacenes, Tetracyclines"," 16S ribosomal RNA,  Serum albumin","DB00931, DB13092, DB00595, DB00254, DB00759, DB09550, DB00618, DB01301, DB09093, DB00453, DB00256, DB01017, DB12035, DB00560, DB15040, DB12329, DB12455, DB13264, DB11647, DB11691, DB05168, DB11191, DB12674, DB00361, DB03469, DB03614",
DB00932,Tipranavir,approved; investigational,[H][C@@](CC)(C1=CC(NS(=O)(=O)C2=NC=C(C=C2)C(F)(F)F)=CC=C1)C1=C(O)C[C@@](CCC)(CCC2=CC=CC=C2)OC1=O,C31H33F3N2O5S,,"Amides, Anti-HIV Agents, Anti-Infective Agents, Anti-Retroviral Agents, Antiinfectives for Systemic Use, Antiviral Agents, Antivirals for Systemic Use, BSEP/ABCB11 Inhibitors, BSEP/ABCB11 Substrates, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (weak), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strong), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Direct Acting Antivirals, Drugs causing inadvertant photosensitivity, Enzyme Inhibitors, Hepatotoxic Agents, HIV Protease Inhibitors, Hyperglycemia-Associated Agents, OATP1B1/SLCO1B1 Inhibitors, OATP1B3 inhibitors, Organic Anion Transporting Polypeptide 2B1 Inhibitors, P-glycoprotein inducers, P-glycoprotein inhibitors, P-glycoprotein substrates, Photosensitizing Agents, Protease Inhibitors, Pyrans, Sulfones, Sulfur Compounds, UGT1A1 Inducers"," Human immunodeficiency virus type 1 protease,  Cytochrome P450 2C19,  UDP-glucuronosyltransferase 1-1,  Cytochrome P450 3A4,  Cytochrome P450 2D6,  Bile salt export pump,  Solute carrier organic anion transporter family member 2B1,  Solute carrier organic anion transporter family member 1B1,  Solute carrier organic anion transporter family member 1B3,  P-glycoprotein 1","DB00932, DB15108",
DB00933,Mesoridazine,approved; investigational,CN1CCCCC1CCN1C2=C(SC3=C1C=C(C=C3)S(C)=O)C=CC=C2,C21H26N2OS2,,"Antidepressive Agents, Antipsychotic Agents, Antipsychotic Agents (First Generation [Typical]), Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 Substrates, Dopamine Agents, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Heterocyclic Compounds, Fused-Ring, Moderate Risk QTc-Prolonging Agents, Nervous System, Neurotoxic agents, Neurotransmitter Agents, Phenothiazines, Phenothiazines With Piperidine Structure, Psycholeptics, Psychotropic Drugs, QTc Prolonging Agents, Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2A Receptor Antagonists, Serotonin Agents, Serotonin Receptor Antagonists, Sulfur Compounds, Tranquilizing Agents"," Dopamine D2 receptor,  5-hydroxytryptamine receptor 2A,  Cytochrome P450 2D6","DB00933, DB00679, DB13591, DB00372, DB01071, DB01621",
DB00934,Maprotiline,approved; investigational,CNCCCC12CCC(C3=CC=CC=C13)C1=CC=CC=C21,C20H23N,,"Adrenergic Agents, Adrenergic Uptake Inhibitors, Agents producing tachycardia, Agents that reduce seizure threshold, Anthracenes, Anticholinergic Agents, Antidepressive Agents, Antidepressive Agents Indicated for Depression, Antidepressive Agents, Second-Generation, Antidepressive Agents, Tetracyclic, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Histamine Antagonists, Histamine H1 Antagonists, Membrane Transport Modulators, Muscarinic Antagonists, Nervous System, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, Non-Selective Monoamine Reuptake Inhibitors, Potential QTc-Prolonging Agents, Psychoanaleptics, Psychotropic Drugs, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin Modulators, Tricyclics and Other Norepinephrine-reuptake Inhibitors"," Sodium-dependent noradrenaline transporter,  Histamine H1 receptor,  Muscarinic acetylcholine receptor M1,  Muscarinic acetylcholine receptor M2,  Muscarinic acetylcholine receptor M3,  Muscarinic acetylcholine receptor M4,  Muscarinic acetylcholine receptor M5,  Alpha-1 adrenergic receptors (Protein Group),  5-hydroxytryptamine receptor 2A, 10. 5-hydroxytryptamine receptor 2C, 11. 5-hydroxytryptamine receptor 7, 12. Dopamine D2 receptor, 13. Alpha-2 adrenergic receptors (Protein Group),  Cytochrome P450 1A2,  Cytochrome P450 2D6,  Alpha-1-acid glycoprotein 1","DB00934, DB09307, DB09021, DB09016",
DB00935,Oxymetazoline,approved; investigational,CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C,C16H24N2O,,"Adrenergic Agents, Adrenergic Agonists, Adrenergic alpha-1 Receptor Agonists, Adrenergic alpha-2 Receptor Agonists, Adrenergic alpha-Agonists, Agents producing tachycardia, Agents that produce hypertension, Autonomic Agents, Cardiovascular Agents, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 Substrates, Decongestants and Antiallergics, Dermatologicals, Imidazoles, Increased Sympathetic Activity, Nasal Decongestants, Nasal Preparations, Neurotransmitter Agents, Ophthalmologicals, Peripheral Nervous System Agents, Respiratory System Agents, Sensory Organs, Sympathomimetics, Sympathomimetics Used as Decongestants, Sympathomimetics, Plain, UGT1A9 Substrates, Vasoconstriction, Vasoconstrictor Agents"," Alpha-1A adrenergic receptor,  Alpha-2A adrenergic receptor,  Alpha-2B adrenergic receptor,  Alpha-2C adrenergic receptor,  Alpha-1B adrenergic receptor,  Alpha-1D adrenergic receptor,  5-hydroxytryptamine receptor 1A,  5-hydroxytryptamine receptor 1B,  5-hydroxytryptamine receptor 1D, 10. 5-hydroxytryptamine receptor 1C,  UDP-glucuronosyltransferase 1-9,  Cytochrome P450 2C19","DB00935, DB06694",
DB00936,Salicylic acid,approved; investigational; vet_approved,OC(=O)C1=CC=CC=C1O,C7H6O3,,"Acids, Carbocyclic, Agents causing hyperkalemia, Agents that produce hypertension, Analgesics, Analgesics, Non-Narcotic, Anti-Infective Agents, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Antifungal Agents, Antifungals for Dermatological Use, Antifungals for Topical Use, Benzene Derivatives, Benzoates, Cyclooxygenase Inhibitors, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 Substrates, Dermatologicals, Enzyme Inhibitors, Hydroxy Acids, Hydroxybenzoates, Keratolytic Agents, Nephrotoxic agents, Nervous System, Non COX-2 selective NSAIDS, OAT1/SLC22A6 inhibitors, OAT3/SLC22A8 Inhibitors, OATP2B1/SLCO2B1 substrates, Ophthalmologicals, Peripheral Nervous System Agents, Phenols, Salicylates, Salicylic Acid and Derivatives, Sclerosing Solutions, Sensory Organs, Sensory System Agents"," Prostaglandin G/H synthase 1,  Prostaglandin G/H synthase 2,  Aldo-keto reductase family 1 member C1,  Cytochrome P450 2C9,  Serum albumin,  Solute carrier family 22 member 6,  Solute carrier family 22 member 10,  Solute carrier family 22 member 8,  Solute carrier family 22 member 11,  Solute carrier organic anion transporter family member 2B1,  Monocarboxylate transporter 1,  Solute carrier family 22 member 7","DB00936, DB01397, DB14006, DB01401, DB02839, DB09543, DB11079, DB13860, DB01672, DB04242, DB15576, DB00233, DB00244, DB04641, DB03793",
DB00937,Diethylpropion,approved; illicit,CCN(CC)C(C)C(=O)C1=CC=CC=C1,C13H19NO,,"Agents producing tachycardia, Agents that produce hypertension, Alimentary Tract and Metabolism, Amines, Amphetamines, Anti-Obesity Agents, Antiobesity Preparations, Excl. Diet Products, Appetite Depressants, Appetite Suppression, Central Nervous System Depressants, Centrally Acting Antiobesity Products, Ethylamines, Increased Sympathetic Activity, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Stimulants, Sympathomimetic Amine Anorectic, Sympathomimetics"," Sodium-dependent noradrenaline transporter,  Sodium-dependent dopamine transporter","DB00937, DB15339, DB13108, DB01560, DB13285",
DB00938,Salmeterol,approved,OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1,C25H37NO4,,"Adrenergic Agents, Adrenergic Agonists, Adrenergic beta-2 Receptor Agonists, Adrenergic beta-Agonists, Adrenergics, Inhalants, Agents Causing Muscle Toxicity, Agents producing tachycardia, Agents that produce hypertension, Agents to Treat Airway Disease, Alcohols, Amines, Amino Alcohols, Anti-Asthmatic Agents, Autonomic Agents, Bronchodilator Agents, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strong), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs for Obstructive Airway Diseases, Ethanolamines, Ethylamines, Long-acting beta-adrenoceptor agonists, Neurotransmitter Agents, OCT1 inhibitors, OCT1 substrates, OCT2 Inhibitors, Peripheral Nervous System Agents, Phenethylamines, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Respiratory System Agents, Selective Beta 2-adrenergic Agonists, Sympathomimetic (Adrenergic) Agents"," Beta-2 adrenergic receptor,  Beta-1 adrenergic receptor,  Beta-3 adrenergic receptor,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  Cytochrome P450 2C8,  Serum albumin,  alpha1-acid glycoprotein (Protein Group),  Solute carrier family 22 member 1,  Solute carrier family 22 member 3,  Solute carrier family 22 member 2","DB00938, DB09082, DB01001, DB13139",
DB00939,Meclofenamic acid,approved; vet_approved,CC1=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C(Cl)C=C1,C14H11Cl2NO2,,"Acids, Carbocyclic, Agents causing hyperkalemia, Agents that produce hypertension, Aminobenzoates, Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Antiinflammatory and Antirheumatic Products, Antiinflammatory and Antirheumatic Products, Non-Steroids, Antiinflammatory Preparations, Non-Steroids for Topical Use, Antirheumatic Agents, Benzene Derivatives, Benzoates, Cyclooxygenase Inhibitors, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Fenamates, Musculo-Skeletal System, Nephrotoxic agents, Non COX-2 selective NSAIDS, OAT1/SLC22A6 inhibitors, ortho-Aminobenzoates, Peripheral Nervous System Agents, Sensory System Agents, Thyroxine-binding globulin substrates, Topical Products for Joint and Muscular Pain"," Prostaglandin G/H synthase 1,  Prostaglandin G/H synthase 2,  Arachidonate 5-lipoxygenase,  Potassium voltage-gated channel subfamily KQT member 2,  Potassium voltage-gated channel subfamily KQT member 3,  Thyroxine-binding globulin,  Solute carrier family 22 member 6,  Solute carrier organic anion transporter family member 1C1","DB00939, DB09216, DB00784",
DB00940,Methantheline,approved; investigational,CC[N+](C)(CC)CCOC(=O)C1C2=CC=CC=C2OC2=CC=CC=C12,C21H26NO3,,"Acid Reducers, Agents producing tachycardia, Alimentary Tract and Metabolism, Amines, Anticholinergic Agents, Cholinergic Agents, Drugs for Functional Gastrointestinal Disorders, Gastric Acid Lowering Agents, Histamine Antagonists, Histamine H2 Antagonists, Muscarinic Antagonists, Neurotransmitter Agents, Onium Compounds, Quaternary Ammonium Compounds, Synthetic Anticholinergics, Quaternary Ammonium Compounds"," Histamine H2 receptor,  Muscarinic acetylcholine receptor M2,  Muscarinic acetylcholine receptor M3,  Muscarinic acetylcholine receptor M4,  Muscarinic acetylcholine receptor M5,  Muscarinic acetylcholine receptor M1,  Acetylcholinesterase","DB00940, DB00782",
DB00941,Hexafluronium,approved,C[N+](C)(CCCCCC[N+](C)(C)C1C2=C(C=CC=C2)C2=C1C=CC=C2)C1C2=C(C=CC=C2)C2=C1C=CC=C2,C36H42N2,,"Amines, Anticholinergic Agents, Bis-Trimethylammonium Compounds, Central Nervous System Depressants, Cholinergic Agents, Cholinesterase Inhibitors, Muscle Relaxants, Muscle Relaxants, Peripherally Acting Agents, Musculo-Skeletal System, Neurotransmitter Agents, Nicotinic Antagonists, Onium Compounds, Quaternary Ammonium Compounds", Cholinesterase,DB00941,
DB00942,Cycrimine,approved,OC(CCN1CCCCC1)(C1CCCC1)C1=CC=CC=C1,C19H29NO,,"Agents producing tachycardia, Anticholinergic Agents, Muscarinic Antagonists", Muscarinic acetylcholine receptor M1,"DB00942, DB00387, DB00376, DB00505, DB13713, DB00810, DB13642, DB00193, DB13566",
DB00943,Zalcitabine,approved; investigational,NC1=NC(=O)N(C=C1)[C@H]1CC[C@@H](CO)O1,C9H13N3O3,,"Anti-HIV Agents, Anti-Infective Agents, Anti-Retroviral Agents, Antiinfectives for Systemic Use, Antimetabolites, Antiviral Agents, Antivirals for Systemic Use, Deoxycytidine, Deoxyribonucleosides, Dideoxynucleosides, Direct Acting Antivirals, Enzyme Inhibitors, Noxae, Nucleic Acid Synthesis Inhibitors, Nucleic Acids, Nucleotides, and Nucleosides, Nucleoside and Nucleotide Reverse Transcriptase Inhibitors, Nucleoside Reverse Transcriptase Inhibitors, Nucleosides, OAT1/SLC22A6 Substrates, Pyrimidine Nucleosides, Pyrimidines, Reverse Transcriptase Inhibitors, Toxic Actions"," Reverse transcriptase/RNaseH,  Deoxycytidine kinase,  Serum albumin,  Solute carrier family 22 member 6,  Solute carrier family 22 member 7,  Equilibrative nucleoside transporter 1,  Equilibrative nucleoside transporter 2","DB00943, DB02594, DB00987, DB02097, DB13776, DB02883, DB12383, DB12957, DB13921, DB11667, DB15660, DB03798, DB06433, DB00441, DB06656, DB12901, DB06187, DB03068, DB06485, DB02456, DB03403, DB01961, DB05494, DB02256, DB04603, DB03258, DB03274, DB13920",
DB00944,Demecarium,approved,CN(CCCCCCCCCCN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C,C32H52N4O4,,"Amines, Ammonium Compounds, Antiglaucoma Preparations and Miotics, Cholinergic Agents, Cholinesterase Inhibitors, Enzyme Inhibitors, Neurotransmitter Agents, Nitrogen Compounds, Onium Compounds, Ophthalmologicals, Parasympathomimetics, Sensory Organs"," Acetylcholinesterase,  Cholinesterase","DB00944, DB01400",
DB00945,Acetylsalicylic acid,approved; vet_approved,CC(=O)OC1=CC=CC=C1C(O)=O,C9H8O4,,"Acids, Carbocyclic, Agents causing angioedema, Agents causing hyperkalemia, Agents that produce hypertension, Alimentary Tract and Metabolism, Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Antiinflammatory and Antirheumatic Products, Antiplatelet agents, Antipyretics, Benzene Derivatives, Blood and Blood Forming Organs, Cardiovascular Agents, Cyclooxygenase Inhibitors, Cytochrome P-450 CYP2C19 Inducers, Cytochrome P-450 CYP2C19 Inducers (strength unknown), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Substrates, Decreased Platelet Aggregation, Decreased Prostaglandin Production, Drugs that are Mainly Renally Excreted, Hematologic Agents, Hydroxybenzoates, Musculo-Skeletal System, Nephrotoxic agents, Non COX-2 selective NSAIDS, OAT1/SLC22A6 inhibitors, OAT3/SLC22A8 Inhibitors, P-glycoprotein inducers, P-glycoprotein substrates, Peripheral Nervous System Agents, Platelet Aggregation Inhibitors Excl. Heparin, Salicylates, Salicylic Acid and Derivatives, Sensory System Agents, Stomatological Preparations, UGT1A6 substrate"," Prostaglandin G/H synthase 1,  Prostaglandin G/H synthase 2,  Aldo-keto reductase family 1 member C1,  5'-AMP-activated protein kinase (Protein Group),  Endothelin-1 receptor,  Cellular tumor antigen p53,  78 kDa glucose-regulated protein,  Ribosomal protein S6 kinase alpha-3,  NF-kappa-B inhibitor alpha, 10. Tumor necrosis factor-inducible gene 6 protein, 11. Caspase-1, 12. Caspase-3, 13. Inhibitor of nuclear factor kappa-B kinase subunit beta, 14. Extracellular signal-regulated kinase (ERK) (Protein Group), 15. G1/S-specific cyclin-D1, 16. Myc proto-oncogene protein, 17. Proliferating cell nuclear antigen, 19. Sialidase-1,  Cytochrome P450 2C19,  Cytochrome P450 2C9,  UDP-glucuronosyltransferase 1-6,  Arylamine N-acetyltransferase 2,  Solute carrier family 22 member 6,  P-glycoprotein 1,  Solute carrier family 22 member 8","DB00945, DB13509, DB13612, DB01399, DB13538, DB14130, DB11071, DB13839, DB08814",
DB00946,Phenprocoumon,approved; investigational,CCC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2,C18H16O3,,"4-Hydroxycoumarins, Anticoagulants, Benzopyrans, Blood and Blood Forming Organs, Coumarins, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Substrates, Hematologic Agents, Heterocyclic Compounds, Fused-Ring, Narrow Therapeutic Index Drugs, Pyrans, Vitamin K Antagonists, Vitamin K Inhibitors"," Vitamin K epoxide reductase complex subunit 1,  Cytochrome P450 2C8,  Cytochrome P450 2C9,  Cytochrome P450 3A4,  Serum albumin,  Alpha-1-acid glycoprotein 1","DB00946, DB08663, DB08662, DB00682, DB08496, DB14055, DB08735, DB08736, DB00266, DB01418, DB08794, DB12823",
DB00947,Fulvestrant,approved; investigational,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@@]21[H],C32H47F5O3S,,"Anti-Estrogens, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Antineoplastic and Immunomodulating Agents, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Endocrine Therapy, Estradiol Congeners, Estranes, Estrenes, Estrogen Antagonists, Estrogen Receptor Antagonists, Fused-Ring Compounds, Gonadal Hormones, Gonadal Steroid Hormones, Hormone Antagonists, Hormone Antagonists and Related Agents, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Selective Estrogen Receptor Modulators, Steroids, UGT1A1 Substrates"," Estrogen receptor alpha,  Cytochrome P450 3A4,  UDP-glucuronosyltransferase 1-1","DB00947, DB15690, DB00783, DB04573, DB07702, DB07706, DB00977",
DB00948,Mezlocillin,approved; investigational,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)N1CCN(C1=O)S(C)(=O)=O)C1=CC=CC=C1)C(O)=O,C21H25N5O8S2,,"Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Beta-Lactam Antibacterials, beta-Lactams, Heterocyclic Compounds, Fused-Ring, Lactams, Penicillin G, Penicillins, Penicillins With Extended Spectrum, Sulfur Compounds"," Penicillin-binding protein 1A,  Penicillin-binding protein 3,  Penicillin-binding protein 2","DB00948, DB01061, DB00319, DB00739, DB13816, DB00415, DB01060, DB08559, DB08795, DB13836, DB01053, DB13693, DB01604, DB00578, DB09320, DB13814, DB13739, DB12127, DB01602, DB00713, DB13506, DB00485, DB01147, DB13686, DB09319, DB07806, DB00301",
DB00949,Felbamate,approved,NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,C11H14N2O4,,"Acids, Acyclic, Alcohols, Anti-epileptic Agent, Anticonvulsants, Carbamates, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (moderate), Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (weak), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Decreased Central Nervous System Disorganized Electrical Activity, Excitatory Amino Acid Agents, Excitatory Amino Acid Antagonists, Glycols, Nervous System, Neurotransmitter Agents, NMDA Receptor Antagonists, Phenylcarbamates, Potential QTc-Prolonging Agents, Propylene Glycols, QTc Prolonging Agents"," Glutamate receptor ionotropic, NMDA 2B,  Glutamate receptor ionotropic, NMDA 2A,  Cytochrome P450 2E1,  Cytochrome P450 2C9,  Cytochrome P450 2C19,  Cytochrome P450 3A4",DB00949,
DB00950,Fexofenadine,approved; investigational,CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,C32H39NO4,,"Anti-Allergic Agents, Antihistamines for Systemic Use, Benzene Derivatives, Benzhydryl Compounds, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Histamine H1 Antagonists, Non-Sedating, Neurotransmitter Agents, OAT3/SLC22A8 Substrates, OATP1B1/SLCO1B1 Substrates, OATP1B3 substrates, OATP2B1/SLCO2B1 substrates, P-glycoprotein substrates, Piperidines"," Histamine H1 receptor,  Serum albumin,  alpha1-acid glycoprotein (Protein Group),  P-glycoprotein 1,  Solute carrier organic anion transporter family member 1B1,  Solute carrier organic anion transporter family member 1B3,  Solute carrier organic anion transporter family member 2B1,  Solute carrier organic anion transporter family member 1A2,  Canalicular multispecific organic anion transporter 1,  Canalicular multispecific organic anion transporter 2,  Solute carrier family 22 member 8","DB00950, DB00342, DB01231, DB09076",
DB00951,Isoniazid,approved; investigational,NNC(=O)C1=CC=NC=C1,C6H7N3O,,"Agents Causing Muscle Toxicity, Agents that reduce seizure threshold, Anti-Bacterial Agents, Anti-Infective Agents, Antiinfectives for Systemic Use, Antimycobacterials, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 CYP2A6 Inhibitors, Cytochrome P-450 CYP2A6 Inhibitors (strength unknown), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (strong), Cytochrome P-450 CYP2C19 Inhibitors (weak), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP2E1 Inducers, Cytochrome P-450 CYP2E1 Inducers (strength unknown), Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (moderate), Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (moderate), Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs for Treatment of Tuberculosis, Drugs that are Mainly Renally Excreted, Fatty Acid Synthesis Inhibitors, Hepatotoxic Agents, Hydrazides, Hydrazines, Hyperglycemia-Associated Agents, Hypolipidemic Agents, Isonicotinic Acids, Pyridines, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"," Catalase-peroxidase,  Enoyl-[acyl-carrier-protein] reductase [NADH],  Cytochrome P450 2C8,  Cytochrome P450 1A2,  Cytochrome P450 3A4,  Cytochrome P450 2C19,  Dihydrofolate reductase,  Arylamine N-acetyltransferase 2,  Arylamine N-acetyltransferase,  Cytochrome P450 2A6,  Cytochrome P450 2C8,  Cytochrome P450 2E1,  Cytochrome P450 1A2,  Cytochrome P450 2C9,  Cytochrome P450 2D6,  Cytochrome P450 2C19, 10. Cytochrome P450 3A4,  Serum albumin","DB00951, DB04818",
DB00952,Naratriptan,approved; investigational,CNS(=O)(=O)CCC1=CC2=C(NC=C2C2CCN(C)CC2)C=C1,C17H25N3O2S,,"Agents that produce hypertension, Amines, Analgesics, Antidepressive Agents, Antimigraine Preparations, Biogenic Amines, Biogenic Monoamines, Cardiovascular Agents, Central Nervous System Depressants, Heterocyclic Compounds, Fused-Ring, Indoles, Monoamine Oxidase A Substrates, Nervous System, Neurotransmitter Agents, Selective Serotonin 5-HT1 Receptor Agonists, Selective Serotonin Agonists, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 1b Receptor Agonists, Serotonin 1d Receptor Agonists, Serotonin 5-HT1 Receptor Agonists, Serotonin Agents, Serotonin Modulators, Serotonin Receptor Agonists, Serotonin-1b and Serotonin-1d Receptor Agonist, Triptans, Vasoconstrictor Agents"," 5-hydroxytryptamine receptor 1A,  5-hydroxytryptamine receptor 1D,  5-hydroxytryptamine receptor 1B,  5-hydroxytryptamine receptor 1F,  Amine oxidase [flavin-containing] A",DB00952,
DB00953,Rizatriptan,approved,CN(C)CCC1=CNC2=C1C=C(CN1C=NC=N1)C=C2,C15H19N5,,"Agents that produce hypertension, Amines, Analgesics, Antidepressive Agents, Antimigraine Preparations, Biogenic Amines, Biogenic Monoamines, Central Nervous System Depressants, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Drugs that are Mainly Renally Excreted, Heterocyclic Compounds, Fused-Ring, Indoles, Migraine Disorders, Monoamine Oxidase A Substrates, Nervous System, Neurotransmitter Agents, Selective Serotonin 5-HT1 Receptor Agonists, Selective Serotonin Agonists, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 1b Receptor Agonists, Serotonin 1d Receptor Agonists, Serotonin 5-HT1 Receptor Agonists, Serotonin Agents, Serotonin Modulators, Serotonin Receptor Agonists, Serotonin-1b and Serotonin-1d Receptor Agonist, Triptans"," 5-hydroxytryptamine receptor 1B,  5-hydroxytryptamine receptor 1D,  5-hydroxytryptamine receptor 1A,  5-hydroxytryptamine receptor 1E,  5-hydroxytryptamine receptor 1F,  5-hydroxytryptamine receptor 7,  Amine oxidase [flavin-containing] A,  Cytochrome P450 2D6",DB00953,
DB00954,Dirithromycin,experimental,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O,C42H78N2O14,,"Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Lactones, Macrolides, Macrolides, Lincosamides and Streptogramins, Polyketides"," 23S ribosomal RNA,  Cytochrome P450 3A4","DB00954, DB11474, DB00207, DB11416, DB00199, DB01211, DB13179, DB13338, DB11442",
DB00955,Netilmicin,approved; investigational,CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1O[C@H]1OC[C@](C)(O)[C@H](NC)[C@H]1O,C21H41N5O7,,"Agents that produce neuromuscular block (indirect), Aminoglycoside Antibacterials, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Carbohydrates, Drugs that are Mainly Renally Excreted, Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index, Enzyme Inhibitors, Gentamicins, Glycosides, Narrow Therapeutic Index Drugs, Nephrotoxic agents, Ophthalmologicals, Protein Synthesis Inhibitors, Sensory Organs"," 30S ribosomal protein S12,  16S ribosomal RNA","DB00955, DB12604, DB12615, DB13540, DB00798, DB13274",
DB00956,Hydrocodone,approved; illicit; investigational,[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O,C18H21NO3,,"Alkaloids, Analgesics, Antitussive Agents, Central Nervous System Agents, Central Nervous System Depressants, Cough and Cold Preparations, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Heterocyclic Compounds, Fused-Ring, Morphinans, Morphine Derivatives, Narcotics, Opiate Alkaloids, Opioid Agonist, Opioids, Opium Alkaloids and Derivatives, Peripheral Nervous System Agents, Respiratory System Agents, Semi-synthetic Opioids, Sensory System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"," Mu-type opioid receptor,  Delta-type opioid receptor,  Sigma non-opioid intracellular receptor 1,  Cytochrome P450 2D6,  Cytochrome P450 3A4,  Cytochrome P450 2B6,  Cytochrome P450 2C19","DB00956, DB00327, DB00497, DB00704, DB01192, DB06800, DB01183, DB04509, DB01531, DB01551, DB01565, DB06230, DB01512, DB16072, DB00921, DB01450, DB01548, DB00844, DB15341, DB16117, DB14146, DB01538, DB09049, DB01480, DB01497, DB00318, DB01477, DB01466, DB00295, DB01469",
DB00957,Norgestimate,approved; investigational,[H][C@@]12CC[C@@](OC(C)=O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CC\C(C=C3CC[C@@]21[H])=N/O,C23H31NO3,,"Adrenal Cortex Hormones, Combination Contraceptives (with Estrogen and derivatives), Contraceptive Agents, Female, Contraceptive Agents, Hormonal, Contraceptives, Oral, Contraceptives, Oral, Synthetic, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Substrates, Fused-Ring Compounds, Genito Urinary System and Sex Hormones, Hormonal Contraceptives for Systemic Use, Hyperglycemia-Associated Agents, Norpregnanes, Norpregnenes, Norsteroids, P-glycoprotein inhibitors, Progestin Contraceptives, Progestins, Progestogens and Estrogens, Sequential Preparations, Reproductive Control Agents, Sex Hormones and Modulators of the Genital System, Steroids, UGT1A1 Substrates"," Progesterone receptor,  Estrogen receptor alpha,  Androgen receptor,  Cytochrome P450 3A4,  Cytochrome P450 2B6,  Cytochrome P450 2C9,  UDP-glucuronosyltransferase 1-1,  Serum albumin,  Sex hormone-binding globulin,  Canalicular multispecific organic anion transporter 1,  P-glycoprotein 1","DB00957, DB06713",
DB00958,Carboplatin,approved,[H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H],C6H12N2O4Pt,,"Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Substrates, Compounds used in a research, industrial, or household setting, Coordination Complexes, Cross-Linking Reagents, Drugs that are Mainly Renally Excreted, Immunosuppressive Agents, Indicators and Reagents, Laboratory Chemicals, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, Nephrotoxic agents, Organometallic Compounds, Platinum Compounds"," DNA,  Xanthine dehydrogenase/oxidase,  Myeloperoxidase,  Glutathione S-transferase theta-1,  Metallothionein-1A,  Metallothionein-2,  Superoxide dismutase [Cu-Zn],  Glutathione S-transferase P,  Glutathione S-transferase Mu 1,  NAD(P)H dehydrogenase [quinone] 1,  High affinity copper uptake protein 1,  Probable low affinity copper uptake protein 2,  Copper-transporting ATPase 1,  Copper-transporting ATPase 2,  ATP-binding cassette sub-family G member 2,  Canalicular multispecific organic anion transporter 1",DB00958,
DB00959,Methylprednisolone,approved; vet_approved,[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C,C22H30O5,,"Adrenal Cortex Hormones, Adrenals, Anti-Acne Preparations, Anti-Acne Preparations for Topical Use, Anti-Inflammatory Agents, Antiemetics, Antineoplastic Agents, Autonomic Agents, Central Nervous System Agents, Compounds used in a research, industrial, or household setting, Corticosteroid Hormone Receptor Agonists, Corticosteroids, Corticosteroids for Systemic Use, Corticosteroids for Systemic Use, Plain, Corticosteroids, Dermatological Preparations, Corticosteroids, Weak (Group I), Cytochrome P-450 CYP2A6 Inducers, Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strength unknown), Cytochrome P-450 CYP2C19 Inducers, Cytochrome P-450 CYP2C19 Inducers (strength unknown), Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 CYP2C8 Inducers (strength unknown), Cytochrome P-450 CYP2C9 Inducers, Cytochrome P-450 CYP2C9 Inducers (strength unknown), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Substrates, Dermatologicals, Experimental Unapproved Treatments for COVID-19, Fused-Ring Compounds, Gastrointestinal Agents, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hyperglycemia-Associated Agents, Immunosuppressive Agents, Neuroprotective Agents, Ophthalmological and Otological Preparations, Ophthalmologicals, P-glycoprotein inducers, P-glycoprotein substrates, Peripheral Nervous System Agents, Pregnadienes, Pregnadienetriols, Pregnanes, Protective Agents, Sensory Organs, Steroids, Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins"," Glucocorticoid receptor,  Annexin A1,  20-ketosteroid reductase (20-hydroxysteroid dehydrogenase) (Protein Group),  11beta-hydroxysteroid dehydrogenase (Protein Group),  Cytochrome P450 3A4,  Cytochrome P450 3A Subfamily (Protein Group),  Cytochrome P450 2A6,  Cytochrome P450 1B1,  Cytochrome P450 2B6,  Cytochrome P450 2C8,  Cytochrome P450 2C19, 10. Cytochrome P450 2C9,  Serum albumin,  P-glycoprotein 1","DB00860, DB00959, DB13208, DB00896, DB00635, DB09383, DB12952, DB01569, DB00741, DB15114, DB00443, DB01234, DB11522, DB13491, DB15566, DB00240, DB00324, DB01384, DB09378, DB14631, DB00547, DB01541, DB13586, DB00873, DB12081, DB04652, DB00620, DB14632, DB04630, DB15999",
DB00960,Pindolol,approved; investigational,CC(C)NCC(O)COC1=CC=CC2=C1C=CN2,C14H20N2O2,,"Adrenergic Agents, Adrenergic Antagonists, Adrenergic beta-Antagonists, Agents causing hyperkalemia, Alcohols, Amines, Amino Alcohols, Antidepressive Agents, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Beta Blocking Agents, Non-Selective, Bradycardia-Causing Agents, Cardiovascular Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Hypotensive Agents, Neurotransmitter Agents, OCT2 Substrates, Phenoxypropanolamines, Propanolamines, Propanols, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT1 Receptor Antagonists, Serotonin 5-HT1A Receptor Antagonists, Serotonin Agents, Serotonin Receptor Antagonists, Vasodilating Agents"," Beta-1 adrenergic receptor,  Beta-2 adrenergic receptor,  Beta-3 adrenergic receptor,  5-hydroxytryptamine receptor 1A,  5-hydroxytryptamine receptor 1B,  UDP-glucuronosyltransferases (UGTs) (Protein Group),  Sulfotransferase (Protein Group),  Cytochrome P450 2D6,  alpha1-acid glycoprotein (Protein Group),  Solute carrier family 22 member 2","DB00960, DB07543, DB13530, DB01136",
DB00961,Mepivacaine,approved; vet_approved,CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C,C15H22N2O,,"Amides, Anesthetics, Anesthetics, Local, Central Nervous System Agents, Central Nervous System Depressants, Drugs that are Mainly Renally Excreted, Local Anesthesia, Local Anesthetics (Amide), Methemoglobinemia Associated Agents, Nervous System, Peripheral Nervous System Agents, Piperidines, Sensory System Agents", Sodium channel protein type 10 subunit alpha,"DB00961, DB00296, DB00297, DB01002, DB08987, DB00750, DB13082",
DB00962,Zaleplon,approved; illicit; investigational,CCN(C(C)=O)C1=CC=CC(=C1)C1=CC=NC2=C(C=NN12)C#N,C17H15N5O,,"Acetates, Acids, Acyclic, Amides, Anticonvulsants, Benzodiazepine hypnotics and sedatives, Central Nervous System Agents, Central Nervous System Depressants, Central Nervous System Depression, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, GABA Agents, GABA Agonists, GABA Modulators, GABA-A Receptor Agonists, gamma-Aminobutyric Acid A Receptor Agonist, Hypnotics (Nonbenzodiazepine), Hypnotics and Sedatives, Miscellaneous Anxiolytics Sedatives and Hypnotics, Nervous System, Neurotransmitter Agents, Psycholeptics"," Gamma-aminobutyric acid receptor subunit alpha-1,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  Aldehyde oxidase","DB00962, DB12590",
DB00963,Bromfenac,approved; withdrawn,NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1,C15H12BrNO3,,"Agents causing hyperkalemia, Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Antirheumatic Agents, Benzene Derivatives, Central Nervous System Agents, Cyclooxygenase Inhibitors, Hydrocarbons, Brominated, Hydrocarbons, Halogenated, Ketones, Nephrotoxic agents, Ophthalmologicals, Peripheral Nervous System Agents, Selective Cyclooxygenase 2 Inhibitors (NSAIDs), Sensory Organs, Sensory System Agents"," Prostaglandin G/H synthase 2,  Prostaglandin G/H synthase 1,  Prostaglandin G/H synthase 2","DB00963, DB15911",
DB00964,Apraclonidine,approved,NC1=CC(Cl)=C(NC2=NCCN2)C(Cl)=C1,C9H10Cl2N4,,"Adrenergic Agents, Adrenergic Agonists, Adrenergic alpha-1 Receptor Agonists, Adrenergic alpha-2 Receptor Agonists, Adrenergic alpha-Agonists, Antiglaucoma Preparations and Miotics, EENT Drugs, Miscellaneous, Hypotensive Agents, Imidazoles, Imidazolines, Neurotransmitter Agents, Ophthalmics, Ophthalmologicals, Sensory Organs, Sympathomimetics in Glaucoma Therapy"," Alpha-1A adrenergic receptor,  Alpha-2A adrenergic receptor,  Alpha-2B adrenergic receptor","DB00964, DB00575, DB13429",
DB00965,Ethiodized oil,approved; investigational,,,,"Biological Products, Complex Mixtures, Compounds used in a research, industrial, or household setting, Contrast Media, Diagnostic Uses of Chemicals, Iodinated Contrast Agents, Iodized Oil, Lipids, Non-Watersoluble X-Ray Contrast Media, Oils, Plant Oils, Plant Preparations, Radiographic Contrast Agent, Roentgenography, X-Ray Contrast Activity, X-Ray Contrast Media, Iodinated",,,
DB00966,Telmisartan,approved; investigational,CCCC1=NC2=C(C=C(C=C2C)C2=NC3=CC=CC=C3N2C)N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O,C33H30N4O2,,"Agents Acting on the Renin-Angiotensin System, Agents causing angioedema, Agents causing hyperkalemia, Angiotensin 2 Receptor Blocker, Angiotensin II receptor antagonists, Angiotensin II receptor blockers (ARBs) and calcium channel blockers, Angiotensin II receptor blockers (ARBs) and diuretics, Angiotensin II receptor blockers (ARBs), plain, Angiotensin II Type 1 Receptor Blockers, Angiotensin II Type 2 Receptor Blockers, Angiotensin Receptor Antagonists, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, BCRP/ABCG2 Inhibitors, Benzene Derivatives, Benzimidazoles, Biphenyl Compounds, BSEP/ABCB11 Substrates, Cardiovascular Agents, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Heterocyclic Compounds, Fused-Ring, Hypotensive Agents, P-glycoprotein inhibitors, UGT1A3 substrates"," Peroxisome proliferator-activated receptor gamma,  Type-1 angiotensin II receptor,  Cytochrome P450 2C19,  UDP-glucuronosyltransferase 1-3,  P-glycoprotein 1,  Canalicular multispecific organic anion transporter 1,  ATP-binding cassette sub-family G member 2,  Bile salt export pump",DB00966,
DB00967,Desloratadine,approved; investigational,ClC1=CC2=C(C=C1)C(=C1CCNCC1)C1=C(CC2)C=CC=N1,C19H19ClN2,,"Anticholinergic Agents, Antihistamines for Systemic Use, Benzocycloheptenes, Central Nervous System Depressants, Cholinergic Agents, Dibenzocycloheptenes, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Histamine H1 Antagonists, Non-Sedating, Loratadine and derivatives, Moderate Risk QTc-Prolonging Agents, Neurotransmitter Agents, P-glycoprotein inhibitors, Piperidines, QTc Prolonging Agents"," Histamine H1 receptor,  P-glycoprotein 1","DB00967, DB00719, DB00455, DB11614",
DB00968,Methyldopa,approved,C[C@](N)(CC1=CC=C(O)C(O)=C1)C(O)=O,C10H13NO4,,"Adrenergic Agents, Adrenergic Agonists, Adrenergic alpha-2 Receptor Agonists, Adrenergic alpha-Agonists, Agents Causing Muscle Toxicity, Amines, Amino Acids, Amino Acids, Aromatic, Amino Acids, Cyclic, Amino Acids, Peptides, and Proteins, Antiadrenergic Agents, Centrally Acting, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Aromatic L-amino Acid Decarboxylase Inhibitors, Autonomic Agents, Benzene Derivatives, Bradycardia-Causing Agents, Cardiovascular Agents, Catecholamines, Catechols, Central alpha-2 Adrenergic Agonist, Central Alpha-agonists, COMT Substrates, Dihydroxyphenylalanine, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Hypotensive Agents, Neurotransmitter Agents, Peripheral Nervous System Agents, Phenols, Sympatholytics"," Aromatic-L-amino-acid decarboxylase,  Alpha-2A adrenergic receptor,  Catechol O-methyltransferase,  Aromatic-L-amino-acid decarboxylase,  Sulfotransferase (Protein Group),  Dopamine beta-hydroxylase,  Phenylethanolamine N-methyltransferase,  Serum albumin,  Solute carrier family 15 member 1","DB00968, DB01235, DB00190, DB03552, DB13313, DB00765, DB16306, DB06535, DB06262, DB00135, DB03839, DB13848, DB16171, DB16683, DB17621",
DB00969,Alosetron,approved; withdrawn,CN1C2=C(C3=CC=CC=C13)C(=O)N(CC1=C(C)NC=N1)CC2,C17H18N4O,,"Alimentary Tract and Metabolism, Antidepressive Agents, Antiemetic Serotonin 5-HT3 Receptor Antagonists, Antiemetics, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (moderate), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (moderate), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs for Functional Gastrointestinal Disorders, Gastrointestinal Agents, Heterocyclic Compounds, Fused-Ring, Indole Alkaloids, Indoles, Neurotransmitter Agents, Pyridines, Serotonin 3 Receptor Antagonists, Serotonin 5-HT3 Receptor Antagonists, Serotonin Agents, Serotonin Receptor Antagonists"," 5-hydroxytryptamine receptor 3A,  Cytochrome P450 1A2,  Cytochrome P450 3A4,  Cytochrome P450 2C9,  Cytochrome P450 2E1","DB00969, DB12562, DB13808, DB11725",
DB00970,Dactinomycin,approved; investigational,[H][C@@]12CCCN1C(=O)[C@H](NC(=O)[C@@H](NC(=O)C1=C3N=C4C(OC3=C(C)C=C1)=C(C)C(=O)C(N)=C4C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@]3([H])CCCN3C(=O)[C@H](NC1=O)C(C)C)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C2=O)C(C)C,C62H86N12O16,,"Actinomycin, Actinomycines, Amino Acids, Peptides, and Proteins, Anti-Infective Agents, Antibiotics, Antineoplastic, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Substrates, Cytotoxic Antibiotics and Related Substances, Enzyme Inhibitors, Heterocyclic Compounds, Fused-Ring, Immunosuppressive Agents, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, Nucleic Acid Synthesis Inhibitors, P-glycoprotein inhibitors, P-glycoprotein substrates, P-glycoprotein substrates with a Narrow Therapeutic Index, Peptides, Peptides, Cyclic, Protein Synthesis Inhibitors"," DNA,  DNA topoisomerase 2 (Protein Group),  DNA topoisomerase 1,  Solute carrier family 22 member 5,  P-glycoprotein 1,  Multidrug resistance-associated protein 6,  Multidrug resistance-associated protein 1,  ATP-binding cassette sub-family G member 2","DB00970, DB05168",
DB00971,Selenium Sulfide,approved,S=[Se]=S,S2Se,,"Antifungals for Dermatological Use, Antifungals for Topical Use, Dermatologicals, Selenium Compounds",,DB00971,
DB00972,Azelastine,approved,CN1CCCC(CC1)N1N=C(CC2=CC=C(Cl)C=C2)C2=CC=CC=C2C1=O,C22H24ClN3O,,"Anti-Allergic Agents, Antiallergic Agents, Excl. Corticosteroids, Antihistamines for Systemic Use, Autonomic Agents, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2A6 Inhibitors, Cytochrome P-450 CYP2A6 Inhibitors (strength unknown), Cytochrome P-450 CYP2A6 Substrates, Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (strength unknown), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (strength unknown), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Decongestants and Antiallergics, Enzyme Inhibitors, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Histamine H1 Antagonists, Non-Sedating, Nasal Preparations, Neurotransmitter Agents, Ophthalmologicals, P-glycoprotein inhibitors, Pyridazines, Respiratory System Agents, Sensory Organs"," Histamine H1 receptor,  Histamine H2 receptor,  Phospholipase A2,  Leukotriene C4 synthase,  Cytochrome P450 3A4,  Cytochrome P450 2D6,  Cytochrome P450 1A2,  Cytochrome P450 2C19,  Cytochrome P450 1A1,  Cytochrome P450 3A5,  Cytochrome P450 2C9,  Cytochrome P450 2C8,  Cytochrome P450 2A6, 10. Cytochrome P450 2E1, 11. Cytochrome P450 2B6,  P-glycoprotein 1","DB00972, DB12806, DB13349",
DB00973,Ezetimibe,approved,[H][C@]1(CC[C@H](O)C2=CC=C(F)C=C2)C(=O)N(C2=CC=C(F)C=C2)[C@]1([H])C1=CC=C(O)C=C1,C24H21F2NO3,,"Anticholesteremic Agents, Azetines, BCRP/ABCG2 Substrates, BSEP/ABCB11 Substrates, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Decreased Cholesterol Absorption, Dietary Cholesterol Absorption Inhibitor, Hypolipidemic Agents, Hypolipidemic Agents Indicated for Hyperlipidemia, Lipid Modifying Agents, Lipid Modifying Agents, Plain, Lipid Regulating Agents, Non-statin Hypolipidemic Agents Indicated for Hyperlipidemia, OATP1B1/SLCO1B1 Substrates, P-glycoprotein substrates, UGT1A1 Substrates, UGT1A3 substrates, UGT2B7 substrates"," Niemann-Pick C1-like protein 1,  Sterol O-acyltransferase 1,  Aminopeptidase N,  UDP-glucuronosyltransferase 1-3,  UDP-glucuronosyltransferase 2B15,  UDP-glucuronosyltransferase 2B7,  Cytochrome P450 3A4,  Cytochrome P450 2C8,  UDP-glucuronosyltransferase 1-1,  P-glycoprotein 1,  Canalicular multispecific organic anion transporter 1,  Canalicular multispecific organic anion transporter 2,  Solute carrier organic anion transporter family member 1B1,  ATP-binding cassette sub-family G member 2,  Bile salt export pump",DB00973,
DB00974,Edetic acid,approved; vet_approved,OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O,C10H16N2O8,,"Acetates, Acids, Acyclic, Amines, Anticoagulants, Calcium Chelating Activity, Calcium Chelating Agents, Chelating Agents, Compounds used in a research, industrial, or household setting, Decreased Coagulation Factor Activity, Diamines, Diet, Food, and Nutrition, Ethylenediamines, Food, Food Additives, Food Ingredients, Heavy Metal Antagonists, Hematologic Agents, Lead Chelating Activity, Lead Chelator, Physiological Phenomena, Polyamines, Sequestering Agents"," Lead,  Iron,  Manganese cation,  Adenosine deaminase,  Serum paraoxonase/lactonase 3,  Cytochrome P450 19A1","DB00974, DB13404, DB14600, DB14007, DB14598, DB14599, DB00789, DB09425, DB09132, DB00225, DB02810, DB00597, DB03040",
DB00975,Dipyridamole,approved,OCCN(CCO)C1=NC2=C(N=C(N=C2N2CCCCC2)N(CCO)CCO)C(=N1)N1CCCCC1,C24H40N8O4,,"Anticoagulants, Antiplatelet agents, Blood and Blood Forming Organs, BSEP/ABCB11 Substrates, Cardiovascular Agents, Decreased Platelet Aggregation, Enzyme Inhibitors, Hematologic Agents, Hypotensive Agents, Miscellaneous Vasodilatating Agents, OATP1B1/SLCO1B1 Inhibitors, OATP1B3 inhibitors, Organic Anion Transporting Polypeptide 2B1 Inhibitors, P-glycoprotein inhibitors, P-glycoprotein substrates, Phosphodiesterase 5 Inhibitors, Phosphodiesterase Inhibitors, Platelet Aggregation Inhibitors Excl. Heparin, Pyrimidines, Vasodilating Agents"," cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A,  cGMP-specific 3',5'-cyclic phosphodiesterase,  cAMP-specific 3',5'-cyclic phosphodiesterase 4A,  Adenosine deaminase,  Calcipressin-1,  Alpha-1-acid glycoprotein 1,  Multidrug resistance-associated protein 4,  Multidrug resistance-associated protein 5,  P-glycoprotein 1,  Solute carrier organic anion transporter family member 1B1,  Solute carrier organic anion transporter family member 1B3,  Solute carrier organic anion transporter family member 2B1,  Bile salt export pump",DB00975,
DB00976,Telithromycin,approved,[H][C@@]12[C@@H](C)C(=O)[C@H](C)C[C@@](C)(OC)[C@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@H](CC)[C@@]1(C)OC(=O)N2CCCCN1C=NC(=C1)C1=CC=CN=C1,C43H65N5O10,,"Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strong), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Inhibitors, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Erythromycin and similars, Ketolide Antibacterial, Ketolides, Lactones, Macrolides, Macrolides, Lincosamides and Streptogramins, Moderate Risk QTc-Prolonging Agents, OATP1B1/SLCO1B1 Inhibitors, OATP1B3 inhibitors, Polyketides, Protein Synthesis Inhibitors, QTc Prolonging Agents"," 23S ribosomal RNA,  Cytochrome P450 3A4,  Solute carrier organic anion transporter family member 1B1,  Solute carrier organic anion transporter family member 1B3","DB00976, DB09308, DB06419",
DB00977,Ethinylestradiol,approved,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,C20H24O2,,"Adrenal Cortex Hormones, Antineoplastic and Immunomodulating Agents, BSEP/ABCB11 inducers, BSEP/ABCB11 Inhibitors, COMT Substrates, Contraceptive Agents, Female, Contraceptive Agents, Hormonal, Contraceptives, Oral, Contraceptives, Oral, Hormonal, Contraceptives, Postcoital, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (strength unknown), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Endocrine Therapy, Estradiol Congeners, Estrogen Contraceptives, Estrogenic Steroids, Alkylated, Estrogens, Fused-Ring Compounds, Genito Urinary System and Sex Hormones, Gonadal Hormones, Gonadal Steroid Hormones, Hormonal Contraceptives for Systemic Use, Hormones, Hormones and Related Agents, Hormones, Hormone Substitutes, and Hormone Antagonists, Hyperglycemia-Associated Agents, Natural and Semisynthetic Estrogens, Plain, Norpregnanes, Norpregnatrienes, Norsteroids, P-glycoprotein substrates, Progestogens and Estrogens, Sequential Preparations, Reproductive Control Agents, Sex Hormones and Modulators of the Genital System, Steroids, Thyroxine-binding globulin inducers, UGT1A1 Inducers, UGT1A1 Substrates, UGT1A4 substrates, UGT1A9 Substrates, UGT2B7 substrates"," Estrogen receptor alpha,  Nuclear receptor subfamily 1 group I member 2,  Cytochrome P450 3A4,  Cytochrome P450 2C8,  Cytochrome P450 2C9,  Cytochrome P450 1A2,  Cytochrome P450 3A5,  UDP-glucuronosyltransferase 1-4,  UDP-glucuronosyltransferase 1-3,  UDP-glucuronosyltransferase 1-1,  UDP-glucuronosyltransferase 1-9, 10. UDP-glucuronosyltransferase 2B7, 11. Sulfotransferase 1A3/1A4, 12. Estrogen sulfotransferase, 13. Catechol O-methyltransferase, 14. Cytochrome P450 2C19,  Serum albumin,  Sex hormone-binding globulin,  Bile salt export pump,  Sodium/bile acid cotransporter,  Canalicular multispecific organic anion transporter 1,  P-glycoprotein 1,  Solute carrier organic anion transporter family member 1A2","DB00977, DB00783, DB01357, DB04573, DB07702, DB07706, DB12235, DB13386, DB07707, DB13418, DB15690, DB04575, DB02342, DB12487, DB13956, DB13954, DB00655, DB07891, DB13952, DB03860, DB06597, DB07678, DB00947",
DB00978,Lomefloxacin,approved; investigational,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N3CCNC(C)C3)C(F)=C12,C17H19F2N3O3,,"Anti-Bacterial Agents, Anti-Infective Agents, Anti-Infective Agents, Urinary, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs causing inadvertant photosensitivity, Enzyme Inhibitors, Fluoroquinolone Antibacterial, Fluoroquinolones, Heterocyclic Compounds, Fused-Ring, Moderate Risk QTc-Prolonging Agents, Ophthalmologicals, Photosensitizing Agents, QTc Prolonging Agents, Quinolines, Quinolones, Sensory Organs, Topoisomerase II Inhibitors, Topoisomerase Inhibitors"," DNA gyrase subunit A,  DNA topoisomerase 4 subunit A,  DNA topoisomerase 2-alpha,  Cytochrome P450 1A2,  Solute carrier family 22 member 5,  Canalicular multispecific organic anion transporter 1","DB00978, DB04576, DB01059, DB01208, DB00487, DB00537, DB11404, DB11443, DB11393, DB00365, DB01405, DB11491, DB11511, DB01044, DB14025, DB06771, DB11453, DB13772, DB13261, DB01137, DB01165, DB03034, DB00218, DB12447, DB16219, DB09047, DB11847, DB06600",
DB00979,Cyclopentolate,approved,CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1,C17H25NO3,,"Acids, Carbocyclic, Anticholinergic Agents, Autonomic Agents, Cholinergic Agents, Cholinesterase substrates, Muscarinic Antagonists, Mydriatics, Mydriatics and Cycloplegics, Neurotransmitter Agents, Ophthalmologicals, Parasympatholytics, Peripheral Nervous System Agents, Phenylacetates, Sensory Organs"," Muscarinic acetylcholine receptor M1,  Cholinesterase","DB00979, DB11504, DB00219, DB13497, DB00986, DB13619, DB11186",
DB00980,Ramelteon,approved; investigational,CCC(=O)NCC[C@@H]1CCC2=C1C1=C(OCC1)C=C2,C16H21NO2,,"Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Hypnotics and Sedatives, Melatonin Receptor Agonists, Nervous System, Psycholeptics"," Melatonin receptor type 1B,  Melatonin receptor type 1A,  Cytochrome P450 2C19,  Cytochrome P450 3A4,  Cytochrome P450 2C9,  Cytochrome P450 1A2","DB00980, DB09071",
DB00981,Physostigmine,approved; investigational,[H][C@]12N(C)CC[C@@]1(C)C1=C(C=CC(OC(=O)NC)=C1)N2C,C15H21N3O2,,"Acids, Acyclic, Alkaloids, Antidotes, Antiglaucoma Preparations and Miotics, Autonomic Agents, Carbamates, Cholinergic Agents, Cholinesterase Inhibitors, Enzyme Inhibitors, Heterocyclic Compounds, Fused-Ring, Indole Alkaloids, Indoles, Indolizidines, Indolizines, Miotics, Neurotransmitter Agents, Ophthalmologicals, Parasympathomimetics, Peripheral Nervous System Agents, Phenylcarbamates, Sensory Organs"," Acetylcholinesterase,  Neuronal acetylcholine receptor subunit alpha-4,  Neuronal acetylcholine receptor subunit beta-2","DB00981, DB04892, DB15317, DB07846",
DB00982,Isotretinoin,approved,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O,C20H28O2,,"Agents Causing Muscle Toxicity, Alkenes, Anti-Acne Preparations, Anti-Acne Preparations for Systemic Use, Anti-Acne Preparations for Topical Use, Biological Factors, Carotenoids, Cyclohexanes, Cyclohexenes, Cycloparaffins, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Dermatologicals, Drugs causing inadvertant photosensitivity, Drugs that are Mainly Renally Excreted, Hydrocarbons, Acyclic, Misc. Skin and Mucous Membrane Agents, Noxae, Photosensitizing Agents, Pigments, Biological, Polyenes, Retinoids, Retinoids for Topical Use in Acne, Retinoids for Treatment of Acne, Teratogens, Terpenes, Toxic Actions"," Retinoic acid receptor gamma,  Retinoic acid receptor alpha,  Cytochrome P450 3A4,  Serum albumin","DB00523, DB00755, DB00982, DB00162, DB08467, DB02699, DB06755, DB08127, DB12112, DB16291",
DB00983,Formoterol,approved; investigational,COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1,C19H24N2O4,,"Adrenergic Agents, Adrenergic Agonists, Adrenergic beta-2 Receptor Agonists, Adrenergic beta-Agonists, Adrenergics for Systemic Use, Adrenergics, Inhalants, Agents producing tachycardia, Agents that produce hypertension, Agents to Treat Airway Disease, Alcohols, Amines, Amino Alcohols, Anti-Asthmatic Agents, Autonomic Agents, Bronchodilator Agents, Cytochrome P-450 CYP2A6 Substrates, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 Substrates, Drugs for Obstructive Airway Diseases, Ethanolamines, Long-acting beta-adrenoceptor agonists, OCT1 inhibitors, OCT1 substrates, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Respiratory System Agents, Selective Beta 2-adrenergic Agonists, UGT1A9 Substrates, UGT2B7 substrates"," Beta-2 adrenergic receptor,  Beta-1 adrenergic receptor,  Beta-3 adrenergic receptor,  Cytochrome P450 2D6,  Cytochrome P450 2C19,  Cytochrome P450 2C9,  Cytochrome P450 2A6,  UDP-glucuronosyltransferase 1-8,  UDP-glucuronosyltransferase 1-9,  UDP-glucuronosyltransferase 2B7,  UDP-glucuronosyltransferase 2B15,  Serum albumin,  Solute carrier family 22 member 1,  Solute carrier family 22 member 3,  Solute carrier family 22 member 4,  Solute carrier family 22 member 5","DB00983, DB01274, DB13625",
DB00984,Nandrolone phenpropionate,approved; illicit; investigational,[H][C@@]12CC[C@H](OC(=O)CCC3=CC=CC=C3)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],C27H34O3,,"Anabolic Agents, Androgens, Estranes, Estrenes, Fused-Ring Compounds, Gonadal Hormones, Gonadal Steroid Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Nandrolone and esters, Steroids, Testosterone Congeners, Thyroxine-binding globulin inhibitors", Androgen receptor,"DB00984, DB16003, DB08804, DB13943, DB13944, DB13946, DB16001, DB16002, DB16141, DB01420, DB08308, DB08619, DB13958, DB01395, DB14678, DB06789, DB14677, DB12499, DB00603, DB11440, DB13185, DB02329, DB13640, DB08547, DB01134, DB14540, DB14544, DB15984, DB14543",
DB00985,Dimenhydrinate,approved,CN1C2=C(N=C(Cl)N2)C(=O)N(C)C1=O.CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1,C24H28ClN5O3,,"Alkaloids, Amines, Aminoalkyl Ethers, Antiemetics, Antihistamines for Systemic Use, Autonomic Agents, Benzene Derivatives, Benzhydryl Compounds, Central Nervous System Agents, Central Nervous System Depressants, Ethanolamine Derivatives, Ethylamines, Gastrointestinal Agents, Heterocyclic Compounds, Fused-Ring, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Moderate Risk QTc-Prolonging Agents, Neurotransmitter Agents, Peripheral Nervous System Agents, Pharmaceutical Preparations, Purines, Purinones, QTc Prolonging Agents", Histamine H1 receptor,"DB00985, DB15987, DB14132, DB13636",
DB00986,Glycopyrronium,approved; investigational; vet_approved,C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1,C19H28NO3,,"Adjuvants, Anesthesia, Adrenergics, Inhalants, Agents producing tachycardia, Alimentary Tract and Metabolism, Amines, Ammonium Compounds, Anticholinergic Agents, Antihidrotics, Antimuscarinics Antispasmodics, Central Nervous System Agents, Cholinergic Agents, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C18 Substrates, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Dermatologicals, Drugs for Functional Gastrointestinal Disorders, Drugs for Obstructive Airway Diseases, MATE 1 Substrates, MATE substrates, Muscarinic Antagonists, Neurotransmitter Agents, Nitrogen Compounds, OCT2 Substrates, Onium Compounds, Pyrrolidines, Quaternary Ammonium Compounds, Synthetic Anticholinergics, Quaternary Ammonium Compounds"," Muscarinic acetylcholine receptor M1,  Muscarinic acetylcholine receptor M3,  Muscarinic acetylcholine receptor M2,  Muscarinic acetylcholine receptor M4,  Muscarinic acetylcholine receptor M5,  Cytochrome P450 2D6,  Cytochrome P450 1A2,  Cytochrome P450 2B6,  Cytochrome P450 2C9,  Cytochrome P450 2C18,  Cytochrome P450 2C19,  Cytochrome P450 3A4,  Serum albumin,  alpha1-acid glycoprotein (Protein Group),  Solute carrier family 22 member 2,  Multidrug and toxin extrusion protein 1","DB00986, DB00219, DB16011, DB13369, DB16287, DB00979, DB13619, DB04843, DB13844, DB00771",
DB00987,Cytarabine,approved; investigational,NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,C9H13N3O5,,"Agents Causing Muscle Toxicity, Anti-Infective Agents, Antimetabolites, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Arabinonucleosides, Cardiotoxic antineoplastic agents, Cytidine Deaminase Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Substrates, Immunologic Factors, Immunosuppressive Agents, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, Noxae, Nucleic Acid Synthesis Inhibitors, Nucleic Acids, Nucleotides, and Nucleosides, Nucleoside Metabolic Inhibitor, Nucleosides, OCT1 substrates, Pyrimidine Analogues, Pyrimidine Nucleosides, Pyrimidines, Toxic Actions"," DNA polymerase beta,  DNA,  Cytochrome P450 3A4,  Deoxycytidine kinase,  5'-nucleotidase,  Deoxycytidylate deaminase,  Cytidine deaminase,  Solute carrier family 22 member 4,  Multidrug resistance-associated protein 7,  Equilibrative nucleoside transporter 1","DB00987, DB02097, DB13921, DB15660, DB02594, DB06656, DB03068, DB02456, DB03403, DB00943, DB01961, DB12957, DB05494, DB13776, DB11667, DB12383, DB13920, DB02484, DB04555, DB03798, DB01995, DB03687, DB00441, DB03765, DB02745, DB01859, DB06187, DB06433, DB02431, DB12153",
DB00988,Dopamine,approved,NCCC1=CC(O)=C(O)C=C1,C8H11NO2,,"Adrenergic and Dopaminergic Agents, Agents producing tachycardia, Agents that produce hypertension, Amines, Autonomic Agents, Benzene Derivatives, Biogenic Amines, Biogenic Monoamines, Cardiac Stimulants Excl. Cardiac Glycosides, Cardiac Therapy, Cardiotonic Agents, Cardiovascular Agents, Catecholamines, Catechols, Compounds used in a research, industrial, or household setting, COMT Substrates, Dopamine Agents, Dopamine, metabolism, Drugs that are Mainly Renally Excreted, Monoamine Oxidase A Substrates, Neurotransmitter Agents, OCT1 substrates, OCT2 Inhibitors, OCT2 Substrates, Peripheral Nervous System Agents, Phenols, Protective Agents, Selective Beta 1-adrenergic Agonists, Sympathomimetics"," Dopamine D2 receptor,  Dopamine D1 receptor,  Dopamine D5 receptor,  Dopamine D3 receptor,  Dopamine D4 receptor,  Sodium-dependent dopamine transporter,  Dopamine beta-hydroxylase,  5-hydroxytryptamine receptor 1A,  5-hydroxytryptamine receptor 7, 10. D(1) dopamine receptor (Protein Group), 11. Sodium-dependent noradrenaline transporter, 12. Sodium-dependent serotonin transporter, 13. 5-hydroxytryptamine receptor 3A, 14. 5-hydroxytryptamine receptor 3B, 15. Superoxide dismutase [Cu-Zn], 16. Synaptic vesicular amine transporter,  Dopamine beta-hydroxylase,  Amine oxidase [flavin-containing] A,  Amine oxidase [flavin-containing] B,  Catechol O-methyltransferase,  Solute carrier family 22 member 2,  Solute carrier family 22 member 1,  Solute carrier family 22 member 3,  Solute carrier family 22 member 5,  POU domain, class 5, transcription factor 1","DB00988, DB13917, DB00368, DB08841, DB12771, DB13378, DB12313, DB00668, DB13703, DB13394",
DB00989,Rivastigmine,approved; investigational,CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C,C14H22N2O2,,"Acids, Acyclic, Anti-Dementia Drugs, Bradycardia-Causing Agents, Carbamates, Central Nervous System Agents, Cholinergic Agents, Cholinesterase Inhibitors, Compounds used in a research, industrial, or household setting, Enzyme Inhibitors, Nervous System, Neuroprotective Agents, Neurotransmitter Agents, Parasympathomemetic (Cholinergic) Agents, Phenylcarbamates, Protective Agents, Psychoanaleptics"," Acetylcholinesterase,  Cholinesterase",DB00989,
DB00990,Exemestane,approved; investigational,[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC(=C)C2=CC(=O)C=C[C@]12C,C20H24O2,,"Androstanes, Androstenes, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Aromatase Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Endocrine Therapy, Enzyme Inhibitors, Estrogen Antagonists, Fused-Ring Compounds, Hormone Antagonists, Hormone Antagonists and Related Agents, Hormones, Hormone Substitutes, and Hormone Antagonists, Steroid Synthesis Inhibitors, Steroids"," Cytochrome P450 19A1,  Cytochrome P450 19A1,  Cytochrome P450 3A4","DB00990, DB07373, DB12194, DB00896, DB09124, DB00378",
DB00991,Oxaprozin,approved,OC(=O)CCC1=NC(=C(O1)C1=CC=CC=C1)C1=CC=CC=C1,C18H15NO3,,"Acids, Acyclic, Agents causing hyperkalemia, Agents that produce hypertension, Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Antiinflammatory and Antirheumatic Products, Antiinflammatory and Antirheumatic Products, Non-Steroids, Antirheumatic Agents, Cyclooxygenase Inhibitors, Drugs causing inadvertant photosensitivity, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Musculo-Skeletal System, Nephrotoxic agents, Non COX-2 selective NSAIDS, Other Nonsteroidal Anti-inflammatory Agents, Oxazoles, Peripheral Nervous System Agents, Photosensitizing Agents, Propionates, Sensory System Agents"," Prostaglandin G/H synthase 1,  Prostaglandin G/H synthase 2",DB00991,
DB00992,Methyl aminolevulinate,approved; investigational,COC(=O)CCC(=O)CN,C6H11NO3,,"Amino Acids, Amino Acids, Peptides, and Proteins, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Dermatologicals, Keto Acids, Levulinic Acids, Misc. Skin and Mucous Membrane Agents, Photochemotherapy, Photosensitizing Agents, Photosensitizing Agents for Phototherapy, Porphyrin Precursor, Radiation-Sensitizing Agents, Sensitizers Used in Photodynamic/radiation Therapy",,"DB00992, DB00855, DB06261",
DB00993,Azathioprine,approved,CN1C=NC(=C1SC1=NC=NC2=C1NC=N2)[N+]([O-])=O,C9H7N7O2S,,"Antimetabolites, Antineoplastic and Immunomodulating Agents, Antirheumatic Agents, Carbohydrates, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Glycosides, Heterocyclic Compounds, Fused-Ring, Immunologic Factors, Immunosuppressive Agents, Immunotherapy, Noxae, Nucleic Acid Synthesis Inhibitors, Nucleic Acids, Nucleotides, and Nucleosides, Nucleosides, P-glycoprotein substrates, Purine Antimetabolite, Purines, Sulfhydryl Compounds, Sulfur Compounds, Thionucleosides, Thiopurine Analogs, Toxic Actions"," Ras-related C3 botulinum toxin substrate 1,  Hypoxanthine-guanine phosphoribosyltransferase,  Nucleotide triphosphate diphosphatase NUDT15,  Xanthine dehydrogenase/oxidase,  Thiopurine S-methyltransferase,  Glutathione S-transferase A1,  Glutathione S-transferase A2,  Glutathione S-transferase Mu 1,  Inosine-5'-monophosphate dehydrogenase 1,  Inosine-5'-monophosphate dehydrogenase 2, 10. GMP synthase [glutamine-hydrolyzing], 11. Inosine triphosphate pyrophosphatase, 12. Cytochrome P450 1A2,  Serum albumin,  Equilibrative nucleoside transporter 2,  Solute carrier family 28 member 3,  P-glycoprotein 1,  Solute carrier family 43 member 3",DB00993,
DB00994,Neomycin,approved; vet_approved,,,,"Agents that produce neuromuscular block (indirect), Alimentary Tract and Metabolism, Aminoglycoside Antibacterials, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antibiotics for Topical Use, Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents, Antiinfectives and Antiseptics for Local Oral Treatment, Antiinfectives for Systemic Use, Blood and Blood Forming Organs, Blood Substitutes and Perfusion Solutions, Carbohydrates, Dermatologicals, Drugs that are Mainly Renally Excreted, Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index, Enzyme Inhibitors, Glycosides, Intestinal Antiinfectives, Irrigating Solutions, Narrow Therapeutic Index Drugs, Nephrotoxic agents, Neurotoxic agents, Ophthalmological and Otological Preparations, Ophthalmologicals, Otologicals, Ototoxic agents, Protein Synthesis Inhibitors, Sensory Organs, Stomatological Preparations, Throat Preparations"," 30S ribosomal protein S12,  16S ribosomal RNA,  Extracellular calcium-sensing receptor",,
DB00995,Auranofin,approved; investigational,CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O,C20H34AuO9PS,,"Antiinflammatory and Antirheumatic Products, Antirheumatic Agents, Drugs that are Mainly Renally Excreted, Gold Compounds, Gold Preparations, Musculo-Skeletal System, Organogold Compounds, Organometallic Compounds, Specific Antirheumatic Agents"," Peroxiredoxin-5, mitochondrial,  Inhibitor of nuclear factor kappa-B kinase subunit beta,  Serum albumin",DB00995,
DB00996,Gabapentin,approved; investigational,NCC1(CC(O)=O)CCCCC1,C9H17NO2,,"Acids, Acyclic, Acids, Carbocyclic, Amines, Amino Acids, Amino Acids, Peptides, and Proteins, Aminobutyrates, Analgesics, Anti-epileptic Agent, Anticonvulsants, Butyrates, Central Nervous System Agents, Central Nervous System Depressants, Cyclohexanecarboxylic Acids, Cyclohexanes, Cycloparaffins, Decreased Central Nervous System Disorganized Electrical Activity, Drugs causing inadvertant photosensitivity, Gabapentin and Prodrugs, Gabapentinoids, Miscellaneous Anticonvulsants, Nervous System, Neurotransmitter Agents, Peripheral Nervous System Agents, Photosensitizing Agents, Psychotropic Drugs, Sensory System Agents, Tranquilizing Agents"," Voltage-dependent calcium channel subunit alpha-2/delta-1,  Voltage-dependent calcium channel subunit alpha-2/delta-2,  Voltage-dependent N-type calcium channel (Protein Group),  Adenosine receptor A1,  Potassium voltage-gated channel subfamily KQT member 3,  Potassium voltage-gated channel subfamily KQT member 5,  Branched-chain-amino-acid aminotransferase, cytosolic,  Large neutral amino acids transporter small subunit 1","DB00996, DB15264, DB02941, DB12032, DB00230, DB00302, DB02884, DB02878",
DB00997,Doxorubicin,approved; investigational,COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O,C27H29NO11,,"Anthracycline Topoisomerase Inhibitor, Anthracyclines, Anthracyclines and Related Substances, Antibiotics, Antineoplastic, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Substrates, BSEP/ABCB11 Substrates, BSEP/ABCB11 Substrates with a Narrow Therapeutic Index, Carbohydrates, Cardiotoxic antineoplastic agents, Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Cytotoxic Antibiotics and Related Substances, Drugs causing inadvertant photosensitivity, Enzyme Inhibitors, Glycosides, Immunosuppressive Agents, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, P-glycoprotein inducers, P-glycoprotein inhibitors, P-glycoprotein substrates, P-glycoprotein substrates with a Narrow Therapeutic Index, Photosensitizing Agents, Topoisomerase II Inhibitors, Topoisomerase Inhibitors"," DNA topoisomerase 2-alpha,  DNA,  Nucleolar and coiled-body phosphoprotein 1,  DNA topoisomerase 1,  DNA topoisomerase 2-beta,  Alcohol dehydrogenase [NADP(+)],  Aldose reductase,  Aldo-keto reductase family 1 member C3,  Aldo-keto reductase family 1 member C4,  Aldo-keto reductase family 1 member B10,  Carbonyl reductase [NADPH] 1,  Carbonyl reductase [NADPH] 3,  Cytochrome P450 1B1,  Cytochrome P450 2B6, 10. Cytochrome P450 2D6, 11. Cytochrome P450 3A4, 12. NADPH--cytochrome P450 reductase, 13. NAD(P)H dehydrogenase [quinone] 1, 14. NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrial, 15. NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial, 16. NADH dehydrogenase [ubiquinone] iron-sulfur protein 7, mitochondrial, 17. Nitric oxide synthase, brain, 18. Nitric oxide synthase, endothelial, 19. Nitric oxide synthase, inducible, 20. Xanthine dehydrogenase/oxidase,  Serum albumin,  P-glycoprotein 1,  Multidrug resistance-associated protein 1,  Canalicular multispecific organic anion transporter 2,  Multidrug resistance-associated protein 6,  ATP-binding cassette sub-family G member 2,  Solute carrier family 22 member 16,  Multidrug resistance-associated protein 7,  ATP-binding cassette sub-family B member 8, mitochondrial,  Bile salt export pump, 10. RalA-binding protein 1, 11. Canalicular multispecific organic anion transporter 1","DB00445, DB00694, DB00997, DB11616, DB17149, DB01177, DB12410, DB05706, DB13103, DB00385, DB06420, DB04131, DB01806, DB06263, DB03219, DB11618, DB03199, DB06013, DB11617, DB12755, DB17273",
DB00998,Frovatriptan,approved; investigational,CN[C@@H]1CCC2=C(C1)C1=C(N2)C=CC(=C1)C(N)=O,C14H17N3O,,"Agents that produce hypertension, Amines, Analgesics, Antidepressive Agents, Antimigraine Preparations, Biogenic Amines, Biogenic Monoamines, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 Substrates, Heterocyclic Compounds, Fused-Ring, Indoles, Migraine Disorders, Nervous System, Neurotransmitter Agents, Selective Serotonin 5-HT1 Receptor Agonists, Selective Serotonin Agonists, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 1b Receptor Agonists, Serotonin 1d Receptor Agonists, Serotonin 5-HT1 Receptor Agonists, Serotonin Agents, Serotonin Modulators, Serotonin Receptor Agonists, Serotonin-1b and Serotonin-1d Receptor Agonist, Triptans"," 5-hydroxytryptamine receptor 1D,  5-hydroxytryptamine receptor 1B,  Cytochrome P450 1A2",DB00998,
DB00999,Hydrochlorothiazide,approved; vet_approved,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,C7H8ClN3O4S2,,"Amides, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Benzothiadiazines, Cardiovascular Agents, Diuretics, Drugs causing inadvertant photosensitivity, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Heterocyclic Compounds, Fused-Ring, Hyperglycemia-Associated Agents, Hypotensive Agents, Increased Diuresis, Low-Ceiling Diuretics and Potassium-Sparing Agents, Membrane Transport Modulators, Natriuretic Agents, Nephrotoxic agents, Non Potassium Sparing Diuretics, OAT1/SLC22A6 inhibitors, OAT3/SLC22A8 Substrates, Photosensitizing Agents, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Sodium Chloride Symporter Inhibitors, Sulfonamides, Sulfones, Sulfur Compounds, Thiazides"," Solute carrier family 12 member 3,  Calcium-activated potassium channel subunit alpha-1,  Serum albumin,  Solute carrier family 22 member 6,  Solute carrier family 22 member 8,  Solute carrier family 22 member 11,  Multidrug resistance-associated protein 4","DB00999, DB01021, DB08645, DB00232, DB15861, DB13430, DB13532, DB13989, DB00774, DB01324",
DB01000,Cyclacillin,approved,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1(N)CCCCC1)C(O)=O,C15H23N3O4S,,"Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Beta-Lactam Antibacterials, beta-Lactams, Heterocyclic Compounds, Fused-Ring, Lactams, Penicillins, Sulfur Compounds"," Penicillin-binding protein 1A,  Penicillin-binding protein 3,  Penicillin binding protein 2a,  Penicillin-binding protein (Protein Group),  Solute carrier family 22 member 5,  Solute carrier family 15 member 1,  Solute carrier family 15 member 2","DB01000, DB03820, DB03550, DB01053, DB13300, DB00415, DB00417, DB00578, DB13660, DB01060, DB13337, DB13836, DB01607, DB08559, DB08795, DB13506, DB13739, DB01604, DB01163, DB01603, DB00895, DB13816, DB00607, DB09320, DB13693, DB00319, DB13686, DB01061, DB01602, DB00739",
DB01001,Salbutamol,approved; vet_approved,CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1,C13H21NO3,,"Adrenergic Agents, Adrenergic Agonists, Adrenergic beta-2 Receptor Agonists, Adrenergic beta-Agonists, Adrenergics, Inhalants, Agents producing tachycardia, Agents that produce hypertension, Agents to Treat Airway Disease, Alcohols, Amines, Amino Alcohols, Anti-Asthmatic Agents, Autonomic Agents, Bronchodilator Agents, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Drugs for Obstructive Airway Diseases, Drugs that are Mainly Renally Excreted, Ethanolamines, Peripheral Nervous System Agents, Phenethylamines, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Reproductive Control Agents, Respiratory System Agents, Selective Beta 2-adrenergic Agonists, Sympathomimetic (Adrenergic) Agents, Tocolytic Agents"," Beta-2 adrenergic receptor,  Beta-1 adrenergic receptor,  Beta-3 adrenergic receptor,  Cytochrome P450 3A4","DB01001, DB13139, DB00938, DB01064, DB13206",
DB01002,Levobupivacaine,approved; investigational,CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C,C18H28N2O,,"Amides, Amines, Anesthetics, Anesthetics, Local, Anilides, Aniline Compounds, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Hypotensive Agents, Nervous System, Neuraxial Anesthetics, Peripheral Nervous System Agents, Sensory System Agents"," Sodium channel protein type 10 subunit alpha,  Cytochrome P450 3A4,  Cytochrome P450 1A2","DB00296, DB00297, DB01002, DB00961, DB08987, DB00750, DB13082",
DB01003,Cromoglicic acid,approved,OC(COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O)COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O,C23H16O11,,"Adrenergics, Inhalants, Agents for Dermatitis, Excluding Corticosteroids, Alimentary Tract and Metabolism, Anti-Allergic Agents, Anti-Asthmatic Agents, Anti-Inflammatory Agents, Antiallergic Agents, Excl. Corticosteroids, Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents, Benzopyrans, Chromones, Cromolyn Sodium, Decongestants and Antiallergics, Decreased Histamine Release, Dermatologicals, Drugs causing inadvertant photosensitivity, Drugs for Obstructive Airway Diseases, Heterocyclic Compounds, Fused-Ring, Immunologic Factors, Intestinal Antiinflammatory Agents, Mast Cell Stabilizers, Mast-cell Stabilizers, Nasal Preparations, Ophthalmologicals, Photosensitizing Agents, Pyrans, Respiratory System Agents, Sensory Organs", Protein S100-P,DB01003,
DB01004,Ganciclovir,approved; investigational,NC1=NC2=C(N=CN2COC(CO)CO)C(=O)N1,C9H13N5O4,,"Agents Causing Muscle Toxicity, Agents that reduce seizure threshold, Anti-Infective Agents, Antiinfectives for Systemic Use, Antiviral Agents, Antivirals for Systemic Use, Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor, Direct Acting Antivirals, Drugs that are Mainly Renally Excreted, Ganciclovir and prodrug, Heterocyclic Compounds, Fused-Ring, MATE 1 Substrates, MATE 2 Substrates, MATE substrates, Nucleic Acid Synthesis Inhibitors, Nucleoside Analog Antiviral, Nucleosides and Nucleotides, Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors, OAT1/SLC22A6 inhibitors, OAT3/SLC22A8 Inhibitors, OCT1 inhibitors, OCT1 substrates, Ophthalmologicals, Purines, Purinones, Sensory Organs"," DNA polymerase catalytic subunit,  DNA,  Thymidine kinase,  Solute carrier family 22 member 1,  Solute carrier family 22 member 6,  Solute carrier family 22 member 8,  Solute carrier family 22 member 7,  Multidrug and toxin extrusion protein 1,  Multidrug and toxin extrusion protein 2","DB01004, DB00787, DB00577, DB01610, DB03609, DB02489, DB17744, DB00900",
DB01005,Hydroxyurea,approved,NC(=O)NO,CH4N2O2,,"Amides, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Antisickling Agents, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Enzyme Inhibitors, Hematologic Agents, Immunosuppressive Agents, Methemoglobinemia Associated Agents, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, Nucleic Acid Synthesis Inhibitors, OATP1B1/SLCO1B1 Substrates"," Ribonucleoside-diphosphate reductase large subunit,  Urease subunit alpha,  Serum albumin,  Solute carrier organic anion transporter family member 1A2,  Solute carrier organic anion transporter family member 1B1,  Solute carrier organic anion transporter family member 1B3,  Urea transporter 2,  Urea transporter 1,  Solute carrier family 22 member 4,  Solute carrier family 22 member 5",DB01005,
DB01006,Letrozole,approved; investigational,N#CC1=CC=C(C=C1)C(N1C=NC=N1)C1=CC=C(C=C1)C#N,C17H11N5,,"Agents Causing Muscle Toxicity, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Aromatase Inhibitors, Cytochrome P-450 CYP2A6 Inhibitors, Cytochrome P-450 CYP2A6 Inhibitors (strong), Cytochrome P-450 CYP2A6 Substrates, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (strength unknown), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Endocrine Therapy, Enzyme Inhibitors, Estrogen Antagonists, Hormone Antagonists, Hormone Antagonists and Related Agents, Hormones, Hormone Substitutes, and Hormone Antagonists, Nitriles, P-glycoprotein substrates, Steroid Synthesis Inhibitors, Triazoles, UGT2B7 substrates"," Cytochrome P450 19A1,  Cytochrome P450 2C19,  UDP-glucuronosyltransferase 2B7,  Cytochrome P450 3A4,  Cytochrome P450 2A6,  Cytochrome P450 19A1,  Serum albumin,  P-glycoprotein 1",DB01006,
DB01007,Tioconazole,approved,ClC1=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=CS1,C16H13Cl3N2OS,,"14-alpha Demethylase Inhibitors, Anti-Infective Agents, Antifungal Agents, Antifungal Agents (Vaginal), Antifungals for Dermatological Use, Antifungals for Topical Use, Azole Antifungals, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (strong), Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strong), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (moderate), Cytochrome P-450 Enzyme Inhibitors, Dermatologicals, Enzyme Inhibitors, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Hormone Antagonists, Hormones, Hormone Substitutes, and Hormone Antagonists, Imidazole and Triazole Derivatives, Imidazole Derivatives, Steroid Synthesis Inhibitors"," Cytochrome P450 51,  Lanosterol 14-alpha demethylase,  Cytochrome P450 19A1,  Cytochrome P450 2C19,  Cytochrome P450 2E1,  Cytochrome P450 3A4","DB01007, DB01110, DB08943, DB01127, DB07705, DB01153, DB11985, DB13434",
DB01008,Busulfan,approved; investigational,CS(=O)(=O)OCCCCOS(C)(=O)=O,C6H14O6S2,,"Alcohols, Alkanes, Alkanesulfonates, Alkanesulfonic Acids, Alkylating Activity, Alkylating Drugs, Antineoplastic Agents, Antineoplastic Agents, Alkylating, Antineoplastic and Immunomodulating Agents, Butylene Glycols, Cardiotoxic antineoplastic agents, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Substrates, Glycols, Hydrocarbons, Acyclic, Immunologic Factors, Immunosuppressive Agents, Mesylates, Myeloablative Agonists, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, Noxae, Sulfonic Acids, Sulfur Acids, Sulfur Compounds, Toxic Actions"," DNA,  Glutathione S-transferase Mu 1,  Glutathione S-transferase P,  Microsomal glutathione S-transferase 2,  Cytochrome P450 3A4,  Glutathione S-transferase A2,  Glutathione S-transferase A1",DB01008,
DB01009,Ketoprofen,approved; vet_approved,CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1,C16H14O3,,"Acids, Carbocyclic, Agents causing hyperkalemia, Agents that produce hypertension, Amino Acids, Amino Acids, Basic, Amino Acids, Diamino, Amino Acids, Peptides, and Proteins, Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Antiinflammatory and Antirheumatic Products, Antiinflammatory and Antirheumatic Products, Non-Steroids, Antiinflammatory Preparations, Non-Steroids for Topical Use, Antirheumatic Agents, Cyclooxygenase Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (weak), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs causing inadvertant photosensitivity, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Musculo-Skeletal System, Nephrotoxic agents, Non COX-2 selective NSAIDS, OAT1/SLC22A6 inhibitors, OAT3/SLC22A8 Inhibitors, Other Nonsteroidal Anti-inflammatory Agents, Peripheral Nervous System Agents, Phenylpropionates, Photosensitizing Agents, Propionates, Sensory System Agents, Topical Products for Joint and Muscular Pain, UGT1A1 Substrates"," Prostaglandin G/H synthase 2,  Prostaglandin G/H synthase 1,  C-X-C chemokine receptor type 1,  Cytochrome P450 2C9,  Cytochrome P450 2C8,  UDP-glucuronosyltransferase 1-1,  Serum albumin,  Multidrug resistance-associated protein 4,  Solute carrier organic anion transporter family member 1A2,  Solute carrier family 22 member 6,  Solute carrier family 22 member 8,  Solute carrier family 22 member 11,  Solute carrier family 22 member 7","DB01009, DB09214, DB15911",
DB01010,Edrophonium,approved,CC[N+](C)(C)C1=CC(O)=CC=C1,C10H16NO,,"Amines, Antidotes, Cholinergic Agents, Cholinesterase Inhibitors, Compounds used in a research, industrial, or household setting, Diagnostic Agents, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Neurotransmitter Agents, Onium Compounds, Phenylammonium Compounds, Protective Agents, Quaternary Ammonium Compounds"," Cholinesterase,  Acetylcholinesterase",DB01010,
DB01011,Metyrapone,approved; investigational,CC(C)(C(=O)C1=CN=CC=C1)C1=CC=CN=C1,C14H14N2O,,"Cytochrome P-450 CYP2A6 Inhibitors, Cytochrome P-450 CYP2A6 Inhibitors (strength unknown), Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Diagnostic Agents, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Noxae, Pyridines, Steroid Synthesis Inhibitors, Tests for Pituitary Function, Toxic Actions"," Cytochrome P450 11B1, mitochondrial,  Camphor 5-monooxygenase,  Cytochrome P450 11B1, mitochondrial,  Cytochrome P450 2E1,  Cytochrome P450 11B2, mitochondrial,  Cytochrome P450 2A6,  Cytochrome P450 3A4,  Canalicular multispecific organic anion transporter 2",DB01011,
DB01012,Cinacalcet,approved,C[C@@H](NCCCC1=CC(=CC=C1)C(F)(F)F)C1=CC=CC2=CC=CC=C12,C22H22F3N,,"Anti-Parathyroid Agents, Calcimimetic Agents, Calcium Homeostasis, Calcium-Regulating Hormones and Agents, Calcium-sensing Receptor Agonist, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strong), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Hormone Antagonists, Hormones, Hormone Substitutes, and Hormone Antagonists, Increased Calcium-sensing Receptor Sensitivity, Naphthalenes, Other Miscellaneous Therapeutic Agents, Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins"," Extracellular calcium-sensing receptor,  Cytochrome P450 3A4,  Cytochrome P450 2D6,  Cytochrome P450 1A2",DB01012,
DB01013,Clobetasol propionate,approved,[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,C25H32ClFO5,,"Adrenal Cortex Hormones, Anti-Inflammatory Agents, Corticosteroids, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Inducers, Cytochrome P-450 CYP3A5 Inducers (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Substrates, Fused-Ring Compounds, Glucocorticoids, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hyperglycemia-Associated Agents, Immunosuppressive Agents, Pregnadienes, Pregnadienetriols, Pregnanes, Steroids, Steroids, Fluorinated, Thyroxine-binding globulin inhibitors"," Glucocorticoid receptor,  Annexin A1,  Mineralocorticoid receptor,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Corticosteroid-binding globulin,  Serum albumin","DB01013, DB14640, DB14649, DB11750, DB06781, DB14664, DB14634, DB00596, DB15777, DB00288, DB14643, DB15821, DB00324, DB11487, DB14221, DB12322, DB00443, DB01234, DB11522, DB13491, DB14653, DB00394, DB14637, DB14657, DB14652, DB13158, DB00620, DB00547, DB00588, DB14632",
DB01014,Balsalazide,approved; investigational,OC(=O)CCNC(=O)C1=CC=C(C=C1)\N=N\C1=CC=C(O)C(=C1)C(O)=O,C17H15N3O6,,"Acids, Carbocyclic, Agents causing hyperkalemia, Agents that produce hypertension, Alimentary Tract and Metabolism, Aminobenzoates, Aminosalicylate, Aminosalicylic Acids, Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents, Benzene Derivatives, Benzoates, Colitis, Ulcerative, Gastrointestinal Agents, Hydrazines, Hydroxy Acids, Hydroxybenzoates, Inflammatory Bowel Diseases, Intestinal Antiinflammatory Agents, meta-Aminobenzoates, Nephrotoxic agents, Non COX-2 selective NSAIDS, Peripheral Nervous System Agents, Phenols, Prodrugs, Salicylates, Sensory System Agents"," Peroxisome proliferator-activated receptor gamma,  Prostaglandin G/H synthase 2,  Prostaglandin G/H synthase 1,  Arachidonate 5-lipoxygenase,  NADPH azoreductase",DB01014,
DB01015,Sulfamethoxazole,approved,CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1,C10H11N3O3S,,"Agents causing hyperkalemia, Agents Causing Muscle Toxicity, Amines, Aniline Compounds, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antibiotics for Pneumocystis Pneumonia, Antiinfectives for Systemic Use, Antimycobacterials, Benzene Derivatives, Benzenesulfonamides, Blood Glucose Lowering Agents, BSEP/ABCB11 Inhibitors, BSEP/ABCB11 Substrates, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs causing inadvertant photosensitivity, Drugs for Treatment of Tuberculosis, Drugs that are Mainly Renally Excreted, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Hypoglycemia-Associated Agents, Intermediate-Acting Antibacterial Sulfonamides, Methemoglobinemia Associated Agents, Photosensitizing Agents, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Sulfanilamides, Sulfonamide Antibacterial, Sulfonamides, Sulfonamides and trimethoprim, Sulfones, Sulfur Compounds"," Dihydropteroate synthase,  Cytochrome P450 2C9,  Arylamine N-acetyltransferase 1,  Arylamine N-acetyltransferase 2,  Cytochrome P450 3A4,  Serum albumin,  Bile salt export pump",DB01015,
DB01016,Glyburide,approved,COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1,C23H28ClN3O5S,,"Alimentary Tract and Metabolism, Amides, BCRP/ABCG2 Substrates, Blood Glucose Lowering Agents, BSEP/ABCB11 Inhibitors, BSEP/ABCB11 Substrates, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (weak), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs causing inadvertant photosensitivity, Drugs Used in Diabetes, Hypoglycemia-Associated Agents, Insulin Secretagogues, OAT1/SLC22A6 inhibitors, OATP2B1/SLCO2B1 substrates, Oral Hypoglycemics, P-glycoprotein inhibitors, Photosensitizing Agents, Sulfones, Sulfonylureas, Sulfur Compounds"," Sulfonylurea receptor 1, Kir6.2 (Protein Group),  ATP-binding cassette sub-family C member 9,  Bile salt export pump,  ATP-binding cassette sub-family A member 1,  Mitochondrial ATP-sensitive potassium channel (Protein Group),  Carnitine O-palmitoyltransferase 1, liver isoform,  Cystic fibrosis transmembrane conductance regulator,  Transient receptor potential cation channel subfamily M member 4,  Cytochrome P450 3A4,  Cytochrome P450 2C9,  Cytochrome P450 2C19,  Cytochrome P450 3A7,  Cytochrome P450 3A5,  Serum albumin,  Canalicular multispecific organic anion transporter 2,  Bile salt export pump,  P-glycoprotein 1,  Multidrug resistance-associated protein 1,  Solute carrier family 15 member 1,  Solute carrier organic anion transporter family member 1A2,  Solute carrier family 15 member 2,  Solute carrier family 22 member 6,  Canalicular multispecific organic anion transporter 1, 10. ATP-binding cassette sub-family G member 2, 11. Solute carrier family 22 member 7, 12. Solute carrier organic anion transporter family member 2B1","DB01016, DB01251",
DB01017,Minocycline,approved; investigational,[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2,C23H27N3O7,,"Agents Causing Muscle Toxicity, Agents that produce neuromuscular block (indirect), Alimentary Tract and Metabolism, Anti-Acne Preparations, Anti-Acne Preparations for Topical Use, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives and Antiseptics for Local Oral Treatment, Antiinfectives for Systemic Use, Antiinfectives for Treatment of Acne, Dermatologicals, Drugs causing inadvertant photosensitivity, Naphthacenes, OAT1/SLC22A6 inhibitors, OAT3/SLC22A8 Inhibitors, Photosensitizing Agents, Stomatological Preparations, Tetracyclines"," 30S ribosomal protein S9,  30S ribosomal protein S4,  16S ribosomal RNA,  Interleukin-1 beta,  Arachidonate 5-lipoxygenase,  Matrix metalloproteinase-9,  Vascular endothelial growth factor A,  Caspase-1,  Caspase-3, 10. Cytochrome c, 11. Mitogen-activated Protein Kinases (Protein Group), 12. Nitric oxide synthase, inducible,  Outer membrane protein F,  Outer membrane porin C,  Solute carrier family 22 member 6,  Solute carrier family 22 member 7","DB01017, DB12455, DB00560, DB00254, DB00759, DB09550, DB00595, DB12329, DB12035, DB15040, DB09093, DB00256, DB01301, DB00618, DB00453, DB00931, DB13092, DB11647, DB13264, DB12674, DB05168, DB11691, DB11191",
DB01018,Guanfacine,approved; investigational,NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl,C9H9Cl2N3O,,"Adrenergic Agents, Adrenergic Agonists, Adrenergic alpha-2 Receptor Agonists, Adrenergic alpha-Agonists, Agents producing tachycardia, Agents that produce hypertension, Amidines, Antiadrenergic Agents, Centrally Acting, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Bradycardia-Causing Agents, Cardiovascular Agents, Central alpha-2 Adrenergic Agonist, Central Alpha-agonists, Central Nervous System Depressants, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Guanidines, Hypotensive Agents, Imidazoline Receptor Agonists, MATE 1 Inhibitors, MATE inhibitors, Neurotransmitter Agents, OCT1 inhibitors, OCT1 substrates, OCT2 Substrates"," Alpha-2A adrenergic receptor,  Alpha-2B adrenergic receptor,  Cytochrome P450 2C19,  Cytochrome P450 3A4,  Multidrug and toxin extrusion protein 1,  Solute carrier family 22 member 1,  Solute carrier family 22 member 2",DB01018,
DB01019,Bethanechol,approved,CC(C[N+](C)(C)C)OC(N)=O,C7H17N2O2,,"Acids, Acyclic, Amines, Ammonium Compounds, Autonomic Agents, Bethanechol Compounds, Carbamates, Choline Esters, Cholinergic Agents, Cholinergic Agonists, Muscarinic Agonists, Nervous System, Neurotransmitter Agents, Nitrogen Compounds, Onium Compounds, Parasympathomemetic (Cholinergic) Agents, Parasympathomimetics, Peripheral Nervous System Agents, Quaternary Ammonium Compounds, Trimethyl Ammonium Compounds"," Muscarinic acetylcholine receptor M3,  Muscarinic acetylcholine receptor M1,  Muscarinic acetylcholine receptor M2,  Muscarinic acetylcholine receptor M4,  Muscarinic acetylcholine receptor M5","DB01019, DB00411",
DB01020,Isosorbide mononitrate,approved,[H][C@]12OC[C@@H](O[N+]([O-])=O)[C@@]1([H])OC[C@@H]2O,C6H9NO6,,"Alcohols, Antianginal Agents, Carbohydrates, Cardiac Therapy, Cardiovascular Agents, Delayed-Action Preparations, Drugs that are Mainly Renally Excreted, Hypotensive Agents, Methemoglobinemia Associated Agents, Nitrate Vasodilator, Nitrates and Nitrites, Nitric Oxide Donors, Organic Nitrates, Sugar Alcohols, Vasodilating Agents, Vasodilation, Vasodilators Used in Cardiac Diseases"," Guanylate cyclase soluble subunit alpha-2,  Glutathione S-transferase Mu 1,  Xanthine dehydrogenase/oxidase,  Alcohol dehydrogenase class-3","DB00883, DB01020",
DB01021,Trichlormethiazide,approved; vet_approved,NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C(Cl)Cl,C8H8Cl3N3O4S2,,"Antihypertensive Agents, Benzothiadiazines, Cardiovascular Agents, Diuretics, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Heterocyclic Compounds, Fused-Ring, Hyperglycemia-Associated Agents, Low-Ceiling Diuretics and Potassium-Sparing Agents, Membrane Transport Modulators, Natriuretic Agents, Sodium Chloride Symporter Inhibitors, Sulfonamides, Sulfones, Sulfur Compounds, Thiazides"," Solute carrier family 12 member 3,  Sodium/potassium-transporting ATPase subunit alpha-1,  Carbonic anhydrase 1,  Carbonic anhydrase 2,  Carbonic anhydrase 4,  Thiopurine S-methyltransferase","DB01021, DB08645, DB00232, DB15861, DB00999, DB13430, DB13532, DB13989, DB01324, DB00606",
DB01022,Phylloquinone,approved; investigational,CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\CC1=C(C)C(=O)C2=C(C=CC=C2)C1=O,C31H46O2,,"Blood and Blood Forming Organs, Coagulants, Diet, Food, and Nutrition, Diterpenes, Drugs that are Mainly Renally Excreted, Fibrin Modulating Agents, Food, Growth Substances, Hematologic Agents, Hemostatics, Increased Prothrombin Activity, Micronutrients, Naphthalenes, Naphthoquinones, Physiological Phenomena, Phytol, Quinones, Reversed Anticoagulation Activity, Terpenes, Vitamin K, Vitamins, Vitamins (Fat Soluble), Warfarin Reversal Agent"," Vitamin K-dependent gamma-carboxylase,  Osteocalcin,  Leukotriene-B(4) omega-hydroxylase 1,  UbiA prenyltransferase domain-containing protein 1,  Vitamin K epoxide reductase complex subunit 1","DB01022, DB12148, DB13075, DB14936, DB15381, DB07714",
DB01023,Felodipine,approved; investigational,CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC,C18H19Cl2NO4,,"ACE Inhibitors and Calcium Channel Blockers, Agents causing hyperkalemia, Antiarrhythmic agents, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Beta blocking agents and calcium channel blockers, Bradycardia-Causing Agents, BSEP/ABCB11 Substrates, Calcium Channel Blockers, Calcium Channel Blockers (Dihydropyridine), Calcium-Regulating Hormones and Agents, Cardiovascular Agents, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strong), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dihydropyridine Derivatives, Dihydropyridines, Hypotensive Agents, Membrane Transport Modulators, P-glycoprotein inhibitors, Potential QTc-Prolonging Agents, Pyridines, QTc Prolonging Agents, Selective Calcium Channel Blockers With Mainly Vascular Effects, Vasodilating Agents"," Voltage-dependent L-type calcium channel subunit alpha-1C,  Voltage-dependent calcium channel subunit alpha-2/delta-1,  Voltage-dependent L-type calcium channel subunit beta-2,  Voltage-dependent L-type calcium channel subunit alpha-1D,  Voltage-dependent L-type calcium channel subunit alpha-1S,  Voltage-dependent T-type calcium channel subunit alpha-1H,  Voltage-dependent calcium channel subunit alpha-2/delta-2,  Calmodulin,  Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B, 10. Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A, 11. Mineralocorticoid receptor, 12. Troponin C, skeletal muscle, 13. Troponin C, slow skeletal and cardiac muscles,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  Cytochrome P450 2C8,  Cytochrome P450 2C9,  Cytochrome P450 2D6,  P-glycoprotein 1,  Bile salt export pump","DB01023, DB04920, DB00381, DB09237, DB09234, DB09236, DB01054, DB00270, DB00401, DB09229, DB09240, DB09239, DB14068, DB00393, DB01115",
DB01024,Mycophenolic acid,approved; investigational,COC1=C(C\C=C(/C)CCC(O)=O)C(O)=C2C(=O)OCC2=C1C,C17H20O6,,"Acids, Acyclic, Anti-Bacterial Agents, Anti-Infective Agents, Antibiotics, Antineoplastic, Antimetabolite Immunosuppressant, Antineoplastic and Immunomodulating Agents, Caproates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Fatty Acids, Immunosuppressive Agents, Mycophenolic Acid and Prodrugs, Narrow Therapeutic Index Drugs, Selective Immunosuppressants, UGT1A1 Substrates, UGT1A1 Substrates with a Narrow Therapeutic Index, UGT1A6 substrate, UGT1A6 Substrates with a Narrow Therapeutic Index, UGT1A9 Substrates, UGT1A9 Substrates with a Narrow Therapeutic Index, UGT2B7 substrates, UGT2B7 Substrates with a Narrow Therapeutic Index"," Inosine-5'-monophosphate dehydrogenase 2,  Inosine-5'-monophosphate dehydrogenase 1,  UDP-glucuronosyltransferase 2B7,  UDP-glucuronosyltransferase 1-8,  UDP-glucuronosyltransferase 1-9,  UDP-glucuronosyltransferase 1-1,  UDP-glucuronosyltransferase 1-7,  UDP-glucuronosyltransferase 1-10,  UDP-glucuronosyltransferase 1-6,  Cytochrome P450 3A4,  Cytochrome P450 3A5, 10. Cytochrome P450 2C8,  Serum albumin","DB01024, DB00688",
DB01025,Amlexanox,approved; investigational; withdrawn,CC(C)C1=CC2=C(OC3=NC(N)=C(C=C3C2=O)C(O)=O)C=C1,C16H14N2O4,,"Alimentary Tract and Metabolism, Amines, Anti-Allergic Agents, Decreased Histamine Release, Drugs for Obstructive Airway Diseases, Ophthalmic Solutions, Pyridines, Stomatological Preparations"," Protein S100-A12,  Protein S100-A13,  Interleukin-3,  Fibroblast growth factor 1","DB01025, DB07040",
DB01026,Ketoconazole,approved; investigational,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1,C26H28Cl2N4O4,,"14-alpha Demethylase Inhibitors, Agents causing hyperkalemia, Anti-Infective Agents, Antiadrenal Preparations, Anticorticosteroids, Antifungal Agents, Antifungals for Dermatological Use, Antifungals for Topical Use, Antiinfectives for Systemic Use, Antimycotics for Systemic Use, Azole Antifungals, BSEP/ABCB11 Inhibitors, BSEP/ABCB11 Substrates, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (moderate), Cytochrome P-450 CYP2A6 Inhibitors, Cytochrome P-450 CYP2A6 Inhibitors (moderate), Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (moderate), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (strength unknown), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (moderate), Cytochrome P-450 CYP2C8 Inhibitors (strong), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (moderate), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strong), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Inhibitors, Cytochrome P-450 CYP3A5 Inhibitors (strong), Cytochrome P-450 CYP3A7 Inhibitors, Cytochrome P-450 CYP3A7 Inhibitors (strong), Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dermatologicals, Drugs causing inadvertant photosensitivity, Enzyme Inhibitors, Gynecological Antiinfectives and Antiseptics, Hepatotoxic Agents, Imidazole and Triazole Derivatives, Imidazole Derivatives, OATP1B1/SLCO1B1 Inhibitors, P-glycoprotein inhibitors, P-glycoprotein substrates, Photosensitizing Agents, Piperazines, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Steroid Synthesis Inhibitors, Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins, UGT1A1 Inhibitors, UGT2B7 Inhibitors"," Lanosterol 14-alpha demethylase,  Steroid 17-alpha-hydroxylase/17,20 lyase,  Androgen receptor,  Steroid 21-hydroxylase,  Potassium voltage-gated channel subfamily H member 2,  Nuclear receptor subfamily 1 group I member 2,  Nuclear receptor subfamily 1 group I member 3,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 2C19,  Cytochrome P450 1A1,  Cytochrome P450 1A2,  Cytochrome P450 2A6,  Cytochrome P450 1B1,  Cytochrome P450 2B6,  Cytochrome P450 2C8, 10. Cytochrome P450 2C9, 11. Cytochrome P450 2D6, 12. Cytochrome P450 11B1, mitochondrial, 13. UDP-glucuronosyltransferase 1-1, 14. UDP-glucuronosyltransferase 1-7, 15. UDP-glucuronosyltransferase 2B7, 16. Cytochrome P450 4F12, 17. Cytochrome P450 19A1, 18. Leukotriene-B(4) omega-hydroxylase 1,  Serum albumin,  Sex hormone-binding globulin,  P-glycoprotein 1,  Solute carrier organic anion transporter family member 1B1,  Bile salt export pump","DB01026, DB05667, DB00251, DB01167",
DB01028,Methoxyflurane,approved; investigational; vet_approved; withdrawn,COC(F)(F)C(Cl)Cl,C3H4Cl2F2O,,"Agents that produce hypertension, Analgesics, Anesthetics, Anesthetics, General, Anesthetics, Inhalation, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2A6 Substrates, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Ethers, Ethyl Ethers, Methyl Ethers, Miscellaneous Analgesics and Antipyretics, Nervous System"," Gamma-aminobutyric acid receptor subunit alpha-1,  Glutamate receptor 1,  Glycine receptor subunit alpha-1,  Potassium voltage-gated channel subfamily A member 1,  GABA(A) Receptor (Protein Group),  Calcium-transporting ATPase type 2C member 1,  NADH-ubiquinone oxidoreductase chain 1,  Cytochrome P450 1A2,  Cytochrome P450 2A6,  Cytochrome P450 2B6,  Cytochrome P450 2C9,  Cytochrome P450 2D6,  Cytochrome P450 3A4,  Cytochrome P450 2E1",DB01028,
DB01029,Irbesartan,approved; investigational,CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1,C25H28N6O,,"Agents Acting on the Renin-Angiotensin System, Agents causing hyperkalemia, Angiotensin 2 Receptor Blocker, Angiotensin II receptor antagonists, Angiotensin II receptor blockers (ARBs) and calcium channel blockers, Angiotensin II receptor blockers (ARBs) and diuretics, Angiotensin II receptor blockers (ARBs), plain, Angiotensin II Type 2 Receptor Blockers, Angiotensin Receptor Antagonists, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Benzene Derivatives, Biphenyl Compounds, Cardiovascular Agents, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (moderate), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Hypotensive Agents, Spiro Compounds, Tetrazoles, UGT1A3 substrates"," Type-1 angiotensin II receptor,  Transcription factor AP-1,  UDP-glucuronosyltransferase 1-3,  Prostaglandin G/H synthase 1,  Cytochrome P450 3A4,  Cytochrome P450 2C9,  Cytochrome P450 2C8,  Serum albumin,  alpha1-acid glycoprotein (Protein Group)",DB01029,
DB01030,Topotecan,approved; investigational,CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O,C23H23N3O5,,"Alkaloids, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 Enzyme Inhibitors, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Immunosuppressive Agents, MATE 1 Inhibitors, MATE 1 Substrates, MATE 1 Substrates with a Narrow Therapeutic Index, MATE 2 Substrates, MATE 2 Substrates with a Narrow Therapeutic Index, MATE inhibitors, MATE substrates, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, P-glycoprotein substrates, P-glycoprotein substrates with a Narrow Therapeutic Index, Topoisomerase 1 (TOP1) inhibitors, Topoisomerase I Inhibitors, Topoisomerase Inhibitors"," DNA topoisomerase 1,  DNA,  DNA topoisomerase I, mitochondrial,  ATP-binding cassette sub-family G member 2,  P-glycoprotein 1,  Multidrug and toxin extrusion protein 1,  Multidrug and toxin extrusion protein 2","DB01030, DB12385, DB05482, DB04690, DB12515, DB05806, DB06159, DB12459, DB06721, DB12124, DB12222, DB17152, DB12185, DB00762, DB12384, DB17385, DB16138, DB16186, DB11191, DB11467, DB03614, DB00200, DB05168, DB00361, DB04803, DB03469, DB12674, DB17390, DB03906, DB13013",
DB01031,Ethinamate,approved; illicit; withdrawn,NC(=O)OC1(CCCCC1)C#C,C9H13NO2,,"Acids, Acyclic"," Carbonic anhydrase 2,  Carbonic anhydrase 1","DB01031, DB13662",
DB01032,Probenecid,approved; investigational,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O,C13H19NO4S,,"Adjuvants, Pharmaceutic, Amides, Antigout Preparations, Antirheumatic Agents, Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 CYP2C8 Inducers (strength unknown), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Drugs that are Mainly Renally Excreted, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Musculo-Skeletal System, OAT1/SLC22A6 inhibitors, OAT3/SLC22A8 Inhibitors, OCT1 inhibitors, OCT2 Inhibitors, Pharmaceutic Aids, Pharmaceutical Preparations, Preparations Increasing Uric Acid Excretion, Sulfonamides, Sulfones, Sulfur Compounds, UGT1A1 Inhibitors, Uricosuric Agents"," Solute carrier family 22 member 6,  Solute carrier family 22 member 11,  Solute carrier family 22 member 8,  Pannexin-1,  Taste receptor type 2 member 16,  Cytochrome P450 2C8,  Cytochrome P450 3A4,  UDP-glucuronosyltransferase 1-1,  Cytochrome P450 2C9,  Serum albumin,  Solute carrier family 22 member 2,  Solute carrier family 22 member 1,  Canalicular multispecific organic anion transporter 2,  Multidrug resistance-associated protein 4,  Multidrug resistance-associated protein 5,  Monocarboxylate transporter 2,  Solute carrier family 22 member 5,  Multidrug resistance-associated protein 6,  Multidrug resistance-associated protein 1, 10. Solute carrier organic anion transporter family member 1A2, 11. Monocarboxylate transporter 1, 12. Sodium/bile acid cotransporter, 13. Solute carrier family 22 member 6, 14. Solute carrier family 22 member 10, 15. Solute carrier family 22 member 8, 16. Canalicular multispecific organic anion transporter 1, 17. ATP-binding cassette sub-family C member 11, 18. Solute carrier family 22 member 11, 19. Solute carrier organic anion transporter family member 1C1, 20. Solute carrier family 22 member 7, 21. Solute carrier family 22 member 12, 22. Solute carrier family 2, facilitated glucose transporter member 9",DB01032,
DB01033,Mercaptopurine,approved,S=C1N=CNC2=C1NC=N2,C5H4N4S,,"Antimetabolites, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Drugs for Obstructive Airway Diseases, Enzyme Inhibitors, Heterocyclic Compounds, Fused-Ring, Immunologic Factors, Immunosuppressive Agents, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, Noxae, Nucleic Acid Synthesis Inhibitors, Nucleoside Metabolic Inhibitor, OAT3/SLC22A8 Inhibitors, OAT3/SLC22A8 Substrates, OAT3/SLC22A8 Substrates with a Narrow Therapeutic Index, Purine Analogues, Purines, Sulfhydryl Compounds, Sulfur Compounds, Thiopurine Analogs, Toxic Actions, Xanthine derivatives"," Hypoxanthine-guanine phosphoribosyltransferase,  Amidophosphoribosyltransferase,  Inosine-5'-monophosphate dehydrogenase (Protein Group),  Aldehyde oxidase,  Thiopurine S-methyltransferase,  Xanthine dehydrogenase/oxidase,  Solute carrier family 22 member 8,  Multidrug resistance-associated protein 4,  Multidrug resistance-associated protein 5,  Sodium/nucleoside cotransporter 2,  Solute carrier family 28 member 3,  Equilibrative nucleoside transporter 1,  Equilibrative nucleoside transporter 2","DB01033, DB00352",
DB01034,Cerulenin,experimental,[H][C@]1(O[C@]1([H])C(=O)CC\C=C\C\C=C\C)C(N)=O,C12H17NO3,,"Amides, Anti-Infective Agents, Antifungal Agents, Fatty Acid Synthesis Inhibitors, Hypolipidemic Agents, Lipid Regulating Agents"," 3-oxoacyl-[acyl-carrier-protein] synthase 1,  3-oxoacyl-[acyl-carrier-protein] synthase 2,  3-oxoacyl-[acyl-carrier-protein] synthase 3,  Fatty acid synthase",DB01034,
DB01035,Procainamide,approved,CCN(CC)CCNC(=O)C1=CC=C(N)C=C1,C13H21N3O,,"Acids, Carbocyclic, Agents Causing Muscle Toxicity, Agents that produce neuromuscular block (indirect), Amides, Aminobenzoates, Antiarrhythmic agents, Antiarrhythmics, Class I, Antiarrhythmics, Class Ia, Benzamides and benzamide derivatives, Benzene Derivatives, Benzoates, Cardiac Therapy, Cardiovascular Agents, Cholinesterase Inhibitors, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index, Highest Risk QTc-Prolonging Agents, MATE 1 Substrates, MATE 1 Substrates with a Narrow Therapeutic Index, MATE 2 Substrates, MATE 2 Substrates with a Narrow Therapeutic Index, MATE substrates, Membrane Transport Modulators, Narrow Therapeutic Index Drugs, Negative Inotrope, OCT1 inhibitors, OCT2 Inhibitors, OCT2 Substrates with a Narrow Therapeutic Index, para-Aminobenzoates, QTc Prolonging Agents, Sodium Channel Blockers, Voltage-Gated Sodium Channel Blockers"," Potassium voltage-gated channel subfamily H member 2,  Sodium channel protein type 5 subunit alpha,  DNA (cytosine-5)-methyltransferase 1,  Cytochrome P450 2D6,  Cholinesterase,  Solute carrier family 22 member 2,  Solute carrier family 22 member 1,  Solute carrier family 22 member 3,  Solute carrier family 22 member 5,  Solute carrier family 22 member 4,  Multidrug and toxin extrusion protein 1,  Multidrug and toxin extrusion protein 2","DB01035, DB17602, DB06421",
DB01036,Tolterodine,approved; investigational,CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(O)C=CC(C)=C1)C(C)C,C22H31NO,,"Agents producing tachycardia, Alcohols, Amines, Amino Alcohols, Anticholinergic Agents, Benzene Derivatives, Benzhydryl Compounds, Cholinergic Agents, Cresols, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Drugs for Urinary Frequency and Incontinence, Drugs that are Mainly Renally Excreted, Genito Urinary System and Sex Hormones, Genitourinary Agents, Genitourinary Smooth Muscle Relaxants, Muscarinic Antagonists, Neurotransmitter Agents, Phenols, Potential QTc-Prolonging Agents, Propanolamines, Propanols, QTc Prolonging Agents, Urological Agents, Urologicals"," Muscarinic acetylcholine receptor M3,  Muscarinic acetylcholine receptor M2,  Muscarinic acetylcholine receptor M5,  Muscarinic acetylcholine receptor M1,  Muscarinic acetylcholine receptor M4,  Cytochrome P450 2C9,  Cytochrome P450 2C19,  Cytochrome P450 2D6,  Cytochrome P450 3A4","DB01036, DB15578",
DB01037,Selegiline,approved; investigational; vet_approved,C[C@H](CC1=CC=CC=C1)N(C)CC#C,C13H17N,,"Agents that produce hypertension, Agents that reduce seizure threshold, Amines, Anti-Dyskinesia Agents, Anti-Parkinson Drugs, Antidepressive Agents, Antidepressive Agents Indicated for Depression, Central Nervous System Agents, Central Nervous System Depressants, Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2A6 Inhibitors, Cytochrome P-450 CYP2A6 Inhibitors (strength unknown), Cytochrome P-450 CYP2A6 Substrates, Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (strength unknown), Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dopamine Agents, Enzyme Inhibitors, Ethylamines, Hypotensive Agents, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates, Monoamine Oxidase B Inhibitors, Monoamine Oxidase Inhibitors, Nervous System, Neuroprotective Agents, P-glycoprotein inhibitors, Phenethylamines, Protective Agents, Psychotropic Drugs, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin Modulators"," Amine oxidase [flavin-containing] B,  Amine oxidase [flavin-containing] A,  Cytochrome P450 2B6,  Cytochrome P450 3A4,  Cytochrome P450 2A6,  Cytochrome P450 1A2,  Cytochrome P450 2C19,  Cytochrome P450 2C8,  Cytochrome P450 2C9,  Cytochrome P450 2D6,  P-glycoprotein 1","DB01037, DB12650, DB13285, DB04677, DB01577, DB09571, DB01550, DB01365, DB13852",
DB01038,Carphenazine,withdrawn,CCC(=O)C1=CC=C2SC3=C(C=CC=C3)N(CCCN3CCN(CCO)CC3)C2=C1,C24H31N3O2S,,"Dopamine Antagonists, Dopamine D2 Receptor Antagonists"," Dopamine D2 receptor,  Dopamine D1 receptor,  Dopamine D5 receptor","DB01038, DB01063, DB13213, DB11540, DB01614, DB00777, DB01615, DB00623, DB11517, DB00831, DB12710, DB13784, DB00508",
DB01039,Fenofibrate,approved,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1,C20H21ClO4,,"Acids, Acyclic, Agents Causing Muscle Toxicity, Benzene Derivatives, Benzophenones, BSEP/ABCB11 Substrates, Butyrates, Cytochrome P-450 CYP2A6 Inhibitors, Cytochrome P-450 CYP2A6 Inhibitors (weak), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (weak), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (weak), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Ethers, Fatty Acids, Fatty Acids, Volatile, Fibric Acid Derivatives, Fibric Acids, Hypolipidemic Agents, Hypolipidemic Agents Indicated for Hyperlipidemia, Isobutyrates, Ketones, Lipid Modifying Agents, Lipid Modifying Agents, Plain, Lipid Regulating Agents, Lipids, Non-statin Hypolipidemic Agents Indicated for Hyperlipidemia, Noxae, P-glycoprotein inhibitors, Peroxisome Proliferator Receptor alpha Agonist, Peroxisome Proliferator-activated Receptor alpha Agonists, Phenols, Phenyl Ethers, Toxic Actions, UGT1A9 Substrates"," Peroxisome proliferator-activated receptor alpha,  Nuclear receptor subfamily 1 group I member 2,  Matrix metalloproteinase-25,  UDP-glucuronosyltransferase 1-9,  Liver carboxylesterase 1,  Carbonyl reductase [NADPH] 1,  Cytochrome P450 2C8,  Cytochrome P450 2C19,  Cytochrome P450 2A6,  Aldo-keto reductase family 1 member C1,  Aldo-keto reductase family 1 member C2,  Aldo-keto reductase family 1 member C3, 10. Aldose reductase, 11. Cytochrome P450 2C9,  Serum albumin,  Bile salt export pump","DB01039, DB13873",
DB01041,Thalidomide,approved; investigational; withdrawn,O=C1N(C2CCC(=O)NC2=O)C(=O)C2=CC=CC=C12,C13H10N2O4,,"Angiogenesis Inhibitors, Angiogenesis Modulating Agents, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Cardiotoxic antineoplastic agents, Central Nervous System Depressants, Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strength unknown), Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (strength unknown), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Inducers, Cytochrome P-450 CYP3A5 Inducers (strength unknown), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs causing inadvertant photosensitivity, Growth Inhibitors, Growth Substances, Heterocyclic Compounds, Fused-Ring, Hypotensive Agents, Immunologic Factors, Immunomodulatory Agents, Immunosuppressive Agents, Isoindoles, Leprostatic Agents, Myelosuppressive Agents, Noxae, Photosensitizing Agents, Phthalimides, Teratogens, Toxic Actions, Tumor Necrosis Factor Blockers"," Protein cereblon,  DNA,  alpha1-acid glycoprotein (Protein Group),  Cytochrome P450 1A1,  Cytochrome P450 2B6,  Cytochrome P450 2C9,  Cytochrome P450 3A4,  Cytochrome P450 2C19,  Cytochrome P450 3A5,  Prostaglandin G/H synthase 1,  Prostaglandin G/H synthase 2","DB01041, DB00480, DB08910, DB17419",
DB01042,Melphalan,approved,N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O,C13H18Cl2N2O2,,"Alkylating Activity, Alkylating Drugs, Amino Acids, Amino Acids, Aromatic, Amino Acids, Cyclic, Amino Acids, Peptides, and Proteins, Antineoplastic Agents, Antineoplastic Agents, Alkylating, Antineoplastic and Immunomodulating Agents, Hydrocarbons, Halogenated, Immunologic Factors, Immunosuppressive Agents, Mustard Compounds, Myeloablative Agonists, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, Nitrogen Mustard Analogues, Nitrogen Mustard Compounds, Noxae, Toxic Actions"," DNA,  Serum albumin,  Alpha-1-acid glycoprotein 1,  Solute carrier family 22 member 3,  Large neutral amino acids transporter small subunit 1,  Asc-type amino acid transporter 1","DB01042, DB06082, DB00291",
DB01043,Memantine,approved; investigational,CC12CC3CC(C)(C1)CC(N)(C3)C2,C12H21N,,"Anti-Dementia Drugs, Anti-Dyskinesia Agents, Anti-Parkinson Drugs, Bridged-Ring Compounds, Central Nervous System Agents, Cholinesterase Inhibitors, Cytochrome P-450 CYP2A6 Inhibitors, Cytochrome P-450 CYP2A6 Inhibitors (weak), Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (strong), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (weak), Cytochrome P-450 Enzyme Inhibitors, Dopamine Agents, Drugs that are Mainly Renally Excreted, Excitatory Amino Acid Antagonists, Miscellaneous Central Nervous System Agents, N-methyl-D-aspartate Receptor Antagonist, Nervous System, Neurotransmitter Agents, NMDA Receptor Antagonists, OCT2 Substrates, Psychoanaleptics"," Glutamate (NMDA) receptor (Protein Group),  5-hydroxytryptamine receptor 3A,  Neuronal acetylcholine receptor subunit alpha-7,  Dopamine D2 receptor,  Glutamate receptor ionotropic, NMDA 1,  GABA(A) Receptor (Protein Group),  Glycine receptors (Protein Group),  Cytochrome P450 2A6,  Cytochrome P450 2C19,  Cytochrome P450 2B6,  Solute carrier family 22 member 2,  Sodium/hydrogen exchanger 1,  Solute carrier family 22 member 4,  Multidrug and toxin extrusion protein 1","DB00915, DB01043, DB00478, DB04926, DB06714",
DB01044,Gatifloxacin,approved; investigational; withdrawn,COC1=C2N(C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1)C1CC1,C19H22FN3O4,,"Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (moderate), Cytochrome P-450 Enzyme Inhibitors, Enzyme Inhibitors, Fluoroquinolones, Heterocyclic Compounds, Fused-Ring, Hypoglycemia-Associated Agents, Ophthalmic Solutions, Ophthalmologicals, Pharmaceutical Preparations, Pharmaceutical Solutions, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Quinolines, Quinolone Antimicrobial, Quinolones, Sensory Organs, Solutions, Topoisomerase II Inhibitors, Topoisomerase Inhibitors"," DNA gyrase subunit A,  DNA gyrase subunit B,  DNA topoisomerase 4 subunit A,  DNA topoisomerase 4 subunit B,  Cytochrome P450 1A2,  Serum albumin","DB01044, DB00218, DB01137, DB01165, DB03034, DB06600, DB11393, DB00537, DB11404, DB01208, DB00365, DB00978, DB11443, DB01059, DB00487, DB11453, DB06771, DB04576, DB14025, DB12447, DB16219, DB09047, DB11847, DB13261, DB01405, DB11426, DB11491, DB11511, DB13772, DB11892",
DB01045,Rifampicin,approved,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C,C43H58N4O12,,"Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibiotics, Antitubercular, Antiinfectives for Systemic Use, Antimycobacterials, BSEP/ABCB11 Inhibitors, Chemically-Induced Disorders, Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP1A2 Inducers (moderate), Cytochrome P-450 CYP1A2 Inducers (strong), Cytochrome P-450 CYP2A6 Inducers, Cytochrome P-450 CYP2A6 Inducers (moderate), Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (moderate), Cytochrome P-450 CYP2C19 Inducers, Cytochrome P-450 CYP2C19 Inducers (moderate), Cytochrome P-450 CYP2C19 Inducers (strong), Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 CYP2C8 Inducers (strong), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Inducers, Cytochrome P-450 CYP2C9 Inducers (moderate), Cytochrome P-450 CYP2E1 Inducers, Cytochrome P-450 CYP2E1 Inducers (strength unknown), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inducers (strong), Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strong), Cytochrome P-450 CYP3A5 Inducers, Cytochrome P-450 CYP3A5 Inducers (strong), Cytochrome P-450 CYP3A7 Inducers, Cytochrome P-450 CYP3A7 Inducers (strong), Cytochrome P-450 CYP3A7 Inducers (weak), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Drugs for Treatment of Lepra, Drugs for Treatment of Tuberculosis, Enzyme Inhibitors, Hepatotoxic Agents, Heterocyclic Compounds, Fused-Ring, Lactams, Macrocyclic, Leprostatic Agents, Nucleic Acid Synthesis Inhibitors, OAT1/SLC22A6 inhibitors, OAT3/SLC22A8 Inhibitors, OATP1B1/SLCO1B1 Inhibitors, OATP1B3 inhibitors, OATP1B3 substrates, Organic Anion Transporting Polypeptide 2B1 Inhibitors, P-glycoprotein inducers, Rifamycin Antibacterial, Rifamycin Antimycobacterial, Rifamycins, UGT1A1 Inducers, UGT1A9 Inducers, UGT1A9 Inhibitors"," DNA-directed RNA polymerase subunit beta,  Nuclear receptor subfamily 1 group I member 2,  Cytochrome P450 2A6,  Cytochrome P450 2E1,  Cytochrome P450 3A43,  Cytochrome P450 3A7,  UDP-glucuronosyltransferase 1-9,  Cytochrome P450 3A5,  Cytochrome P450 3A4,  Cytochrome P450 1A2,  Cytochrome P450 2C8, 10. UDP-glucuronosyltransferase 1-1, 11. Cytochrome P450 2C9, 12. Cytochrome P450 2B6, 13. Cytochrome P450 2C19,  Serum albumin,  alpha1-acid glycoprotein (Protein Group),  P-glycoprotein 1,  Solute carrier organic anion transporter family member 1B3,  Multidrug resistance-associated protein 1,  Solute carrier family 22 member 7,  Solute carrier organic anion transporter family member 1B1,  Canalicular multispecific organic anion transporter 2,  Multidrug resistance-associated protein 5,  Solute carrier organic anion transporter family member 2B1,  Solute carrier organic anion transporter family member 1A2, 10. Bile salt export pump, 11. Canalicular multispecific organic anion transporter 1, 12. Solute carrier family 22 member 6, 13. Solute carrier family 22 member 8","DB01045, DB01201, DB15213, DB11753, DB16312, DB01220, DB04934, DB05168, DB00615, DB04220, DB11191, DB03614, DB00200, DB03933, DB11467, DB05735, DB02868, DB17390, DB00541, DB04803, DB00570, DB13013, DB11641, DB00361, DB03469, DB12586, DB03317, DB00309, DB03906",
DB01046,Lubiprostone,approved; investigational,[H][C@@]12CC(=O)[C@H](CCCCCCC(O)=O)[C@@]1([H])CC[C@@](O)(O2)C(F)(F)CCCC,C20H32F2O5,,"Alimentary Tract and Metabolism, Chloride Channel Agonists, Drugs for Constipation, Drugs that are Mainly Renally Excreted, Fatty Acids, Fatty Acids, Monounsaturated, Fatty Acids, Unsaturated, Laxatives, Lipids, Membrane Transport Modulators, Miscellaneous GI Drugs, Prostaglandins E"," Chloride channel protein 2,  Carbonyl reductase [NADPH] 1","DB01046, DB05514",
DB01047,Fluocinonide,approved; investigational,[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)COC(C)=O,C26H32F2O7,,"Adrenal Cortex Hormones, Anti-Allergic Agents, Anti-Inflammatory Agents, Corticosteroid Hormone Receptor Agonists, Corticosteroids, Corticosteroids, Dermatological Preparations, Corticosteroids, Potent (Group III), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Inducers, Cytochrome P-450 CYP3A5 Inducers (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Substrates, Dermatologicals, Fused-Ring Compounds, Glucocorticoids, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Immunosuppressive Agents, Pregnadienes, Pregnanes, Steroids, Steroids, Fluorinated, Thyroxine-binding globulin inhibitors"," Glucocorticoid receptor,  Smoothened homolog,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Corticosteroid-binding globulin","DB01047, DB18737, DB00591, DB14662, DB00288, DB00180, DB14673, DB06781, DB01410, DB00846, DB14664, DB14637, DB14657, DB08973, DB01260, DB06786, DB12322, DB14640, DB14649, DB01222, DB12553, DB14634, DB15777, DB01130, DB15821, DB13664, DB00223, DB00663, DB00588, DB01013",
DB01048,Abacavir,approved; investigational,NC1=NC2=C(N=CN2[C@@H]2C[C@H](CO)C=C2)C(NC2CC2)=N1,C14H18N6O,,"Anti-HIV Agents, Anti-Infective Agents, Anti-Retroviral Agents, Antiinfectives for Systemic Use, Antiviral Agents, Antivirals for Systemic Use, Antivirals used in combination for the treatment of HIV infections, Cycloparaffins, Deoxyadenosines, Deoxyribonucleosides, Dideoxynucleosides, Direct Acting Antivirals, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Heterocyclic Compounds, Fused-Ring, Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor, Nucleic Acid Synthesis Inhibitors, Nucleic Acids, Nucleotides, and Nucleosides, Nucleoside and Nucleotide Reverse Transcriptase Inhibitors, Nucleoside Reverse Transcriptase Inhibitors, Nucleosides, Purine Nucleosides, Purines, Reverse Transcriptase Inhibitors, UGT1A1 Substrates"," Reverse transcriptase/RNaseH,  Adenosine kinase,  Alcohol dehydrogenase 6,  UDP-glucuronosyltransferase 1-1","DB01048, DB12187, DB04288, DB17733, DB04662, DB04776, DB06195, DB03216",
DB01049,Ergoloid mesylate,approved,,,,"Adrenergic Agents, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Agents that produce hypertension, Alkaloids, Antidepressive Agents, Cardiovascular Agents, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Dihydroergotoxine, Dopamine Agents, Dopamine Agonists, Ergot Alkaloids and Derivatives, Ergot-derivative Dopamine Receptor Agonists, Ergotamines, Heterocyclic Compounds, Fused-Ring, Neurotransmitter Agents, Nootropic Agents, Peripheral Vasodilators, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin Modulators, Sympatholytic (Adrenergic Blocking) Agents, Vasodilating Agents"," Dopamine receptor (Protein Group),  Alpha adrenergic receptor (Protein Group),  Beta adrenergic receptor (Protein Group),  Serotonin Receptors (Protein Group),  Cytochrome P450 3A4",,
DB01050,Ibuprofen,approved,CC(C)CC1=CC=C(C=C1)C(C)C(O)=O,C13H18O2,,"Acids, Carbocyclic, Agents causing angioedema, Agents causing hyperkalemia, Agents that produce hypertension, Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Antiinflammatory and Antirheumatic Products, Antiinflammatory and Antirheumatic Products, Non-Steroids, Antiinflammatory Preparations, Non-Steroids for Topical Use, Antiinflammatory Products for Vaginal Administration, Antirheumatic Agents, Central Nervous System Agents, COX-1 Inhibitors, COX-2 Inhibitors, Cyclooxygenase Inhibitors, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Experimental Unapproved Treatments for COVID-19, Nephrotoxic agents, Nervous System, Non COX-2 selective NSAIDS, OAT1/SLC22A6 inhibitors, OAT3/SLC22A8 Inhibitors, OATP2B1/SLCO2B1 substrates, Other Nonsteroidal Anti-inflammatory Agents, P-glycoprotein inhibitors, P-glycoprotein substrates, Peripheral Nervous System Agents, Pharmaceutical Preparations, Phenylpropionates, Propionates, Sensory System Agents, Throat Preparations, Topical Products for Joint and Muscular Pain, UDP Glucuronosyltransferases Inhibitors, UGT1A1 Substrates, UGT1A3 substrates, UGT1A9 Substrates, UGT2B17 Inhibitors, UGT2B7 substrates"," Prostaglandin G/H synthase 2,  Prostaglandin G/H synthase 1,  Apoptosis regulator Bcl-2,  Thrombomodulin,  Fatty acid-binding protein, intestinal,  Peroxisome proliferator-activated receptor gamma,  Cystic fibrosis transmembrane conductance regulator,  Peroxisome proliferator-activated receptor alpha,  Platelet glycoprotein Ib alpha chain, 10. Protein S100-A7,  Cytochrome P450 2C9,  Cytochrome P450 2C8,  Cytochrome P450 2C19,  UDP-glucuronosyltransferase 1-3,  UDP-glucuronosyltransferase 1-9,  UDP-glucuronosyltransferase 2B4,  UDP-glucuronosyltransferase 2B7,  Alpha-methylacyl-CoA racemase,  Cytochrome P450 3A4,  Serum albumin,  Solute carrier organic anion transporter family member 2B1,  P-glycoprotein 1,  Multidrug resistance-associated protein 4,  Multidrug resistance-associated protein 1,  Solute carrier organic anion transporter family member 1A2,  Solute carrier family 22 member 6,  Solute carrier family 22 member 8,  Solute carrier family 22 member 11","DB01050, DB09213, DB03588, DB04080, DB09212, DB09269, DB02047",
DB01051,Novobiocin,approved; investigational; vet_approved; withdrawn,CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](OC2=C(C)C3=C(C=C2)C(O)=C(NC(=O)C2=CC=C(O)C(CC=C(C)C)=C2)C(=O)O3)OC1(C)C,C31H36N2O11,,"Aminocoumarins, Anti-Bacterial Agents, Anti-Infective Agents, BCRP/ABCG2 Inhibitors, Benzopyrans, Carbohydrates, Coumarins, Enzyme Inhibitors, Glycosides, Heterocyclic Compounds, Fused-Ring, Nucleic Acid Synthesis Inhibitors, OAT1/SLC22A6 inhibitors, OAT3/SLC22A8 Inhibitors, OATP1B1/SLCO1B1 Inhibitors, OATP1B3 inhibitors, Organic Anion Transporting Polypeptide 2B1 Inhibitors, Pyrans"," DNA gyrase subunit B,  DNA topoisomerase 1,  Solute carrier family 22 member 6,  Solute carrier family 22 member 8,  Solute carrier family 22 member 11,  ATP-binding cassette sub-family G member 2,  Solute carrier organic anion transporter family member 1B1,  Solute carrier organic anion transporter family member 1B3,  Solute carrier organic anion transporter family member 2B1","DB01051, DB03966, DB13912",
DB01053,Benzylpenicillin,approved; vet_approved,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C(O)=O,C16H18N2O4S,,"Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Beta-Lactam Antibacterials, Beta-Lactamase Sensitive Penicillins, beta-Lactams, Heterocyclic Compounds, Fused-Ring, Lactams, Natural Penicillins, OAT1/SLC22A6 inhibitors, OAT3/SLC22A8 Inhibitors, OAT3/SLC22A8 Substrates, OATP1B1/SLCO1B1 Substrates, OATP2B1/SLCO2B1 substrates, Ophthalmologicals, Penicillin G, Penicillins, Sensory Organs, Sulfur Compounds"," Penicillin-binding protein 3,  Solute carrier family 22 member 8,  Solute carrier family 15 member 1,  Solute carrier family 15 member 2,  Beta-lactamase TEM,  Serum albumin,  Solute carrier family 22 member 5,  Solute carrier family 15 member 1,  Solute carrier family 15 member 2,  Solute carrier family 22 member 6,  Solute carrier family 22 member 8,  Solute carrier family 22 member 4,  Solute carrier family 22 member 11,  Solute carrier organic anion transporter family member 2B1,  Solute carrier organic anion transporter family member 4A1, 10. Solute carrier organic anion transporter family member 3A1, 11. Solute carrier organic anion transporter family member 1B1","DB01053, DB00415, DB00578, DB13836, DB01060, DB08559, DB08795, DB13739, DB09320, DB01604, DB01607, DB13506, DB00417, DB00319, DB13686, DB13693, DB13816, DB01000, DB01061, DB03550, DB03820, DB13337, DB07806, DB00895, DB00739, DB01602, DB13660, DB03658, DB09319, DB13300",
DB01054,Nitrendipine,approved; investigational,CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC,C18H20N2O6,,"ACE Inhibitors and Calcium Channel Blockers, Agents causing hyperkalemia, Antiarrhythmic agents, Antihypertensive Agents, Bradycardia-Causing Agents, BSEP/ABCB11 Substrates, Calcium Channel Blockers, Calcium-Regulating Hormones and Agents, Cardiovascular Agents, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Substrates, Dihydropyridine Derivatives, Dihydropyridines, Hypotensive Agents, Membrane Transport Modulators, P-glycoprotein inhibitors, Potential QTc-Prolonging Agents, Pyridines, QTc Prolonging Agents, Selective Calcium Channel Blockers With Mainly Vascular Effects, Vasodilating Agents"," Voltage-dependent L-type calcium channel subunit alpha-1C,  Voltage-dependent calcium channel subunit alpha-2/delta-1,  Voltage-dependent L-type calcium channel subunit beta-2,  Voltage-dependent L-type calcium channel subunit alpha-1D,  Voltage-dependent L-type calcium channel subunit alpha-1S,  Voltage-dependent calcium channel subunit alpha-2/delta-2,  Voltage-dependent T-type calcium channel subunit alpha-1H,  Voltage-dependent L-type calcium channel (Protein Group),  Calcium-activated potassium channel (Protein Group),  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  P-glycoprotein 1,  Bile salt export pump","DB01054, DB09240, DB00393, DB06712, DB09239, DB14068, DB09232, DB00622, DB00528, DB09227, DB09231, DB09238, DB00401, DB09229, DB09230, DB01115, DB09233, DB01023, DB09236, DB09234, DB00270",
DB01055,Mimosine,experimental,N[C@@H](CN1C=CC(=O)C(O)=C1)C(O)=O,C8H10N2O4,,"Alanine, Amino Acids, Amino Acids, Peptides, and Proteins, Pyridines, Pyridones"," Serine hydroxymethyltransferase, cytosolic,  C-C motif chemokine 2,  Tyrosinase",DB01055,
DB01056,Tocainide,approved,CC(N)C(=O)NC1=C(C)C=CC=C1C,C11H16N2O,,"Amides, Amines, Anilides, Aniline Compounds, Antiarrhythmic agents, Antiarrhythmics, Class I, Antiarrhythmics, Class Ib, Cardiac Therapy, Cardiovascular Agents, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (weak), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Membrane Transport Modulators, Sodium Channel Blockers, Voltage-Gated Sodium Channel Blockers"," Sodium channel protein type 5 subunit alpha,  Cytochrome P450 1A2,  Serum albumin","DB01056, DB00750, DB08987, DB00281",
DB01057,Echothiophate,approved,CCOP(=O)(OCC)SCC[N+](C)(C)C,C9H23NO3PS,,"Antiglaucoma Preparations and Miotics, Autonomic Agents, Cholinergic Agents, Cholinesterase Inhibitors, Enzyme Inhibitors, Miotics, Neurotransmitter Agents, Ophthalmologicals, Organophosphates, Organophosphorus Compounds, Organothiophosphates, Organothiophosphorus Compounds, Parasympathomimetics, Peripheral Nervous System Agents, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Sensory Organs, Sulfur Compounds"," Cholinesterase,  Serum albumin",DB01057,
DB01058,Praziquantel,approved; investigational; vet_approved,O=C(C1CCCCC1)N1CC2N(CCC3=CC=CC=C23)C(=O)C1,C19H24N2O2,,"Anthelmintics, Anti-Infective Agents, Antihelminthic, Antiparasitic Agents, Antiparasitic Products, Insecticides and Repellents, Antitrematodals, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Substrates, Heterocyclic Compounds, Fused-Ring, Isoquinolines, Quinoline Derivatives and Related Substances"," Cytochrome P450 1A2,  Cytochrome P450 2C19,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Serum albumin","DB01058, DB11749, DB12463, DB02628",
DB01059,Norfloxacin,approved,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCNCC1,C16H18FN3O3,,"Agents Causing Muscle Toxicity, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A7 Inhibitors, Cytochrome P-450 CYP3A7 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Enzyme Inhibitors, Fluoroquinolones, Heterocyclic Compounds, Fused-Ring, OAT1/SLC22A6 inhibitors, Ophthalmologicals, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Quinolines, Quinolone Antimicrobial, Quinolones, Sensory Organs, Topoisomerase II Inhibitors, Topoisomerase Inhibitors"," DNA gyrase subunit A,  DNA topoisomerase 4 subunit A,  DNA topoisomerase 2-alpha,  DNA gyrase subunit A,  DNA topoisomerase 2 (Protein Group),  DNA topoisomerase 4 subunit A,  Cytochrome P450 1A2,  Cytochrome P450 1A1,  Cytochrome P450 3A4,  Cytochrome P450 3A7,  Solute carrier family 22 member 5,  Solute carrier family 22 member 6","DB01059, DB00487, DB00537, DB11404, DB04576, DB00978, DB11393, DB01208, DB00365, DB11491, DB11511, DB11443, DB01405, DB14025, DB06771, DB01044, DB13772, DB11453, DB12447, DB16219, DB13261, DB01137, DB01165, DB03034, DB09047, DB00218",
DB01060,Amoxicillin,approved; vet_approved,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O,C16H19N3O5S,,"Alimentary Tract and Metabolism, Amides, Aminopenicillins, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Beta-Lactam Antibacterials, beta-Lactams, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (weak), Cytochrome P-450 Enzyme Inhibitors, Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord), Drugs that are Mainly Renally Excreted, Heterocyclic Compounds, Fused-Ring, Lactams, OAT1/SLC22A6 inhibitors, Penicillin G, Penicillins, Penicillins With Extended Spectrum, Sulfur Compounds"," Penicillin binding protein,  Cytochrome P450 2C8,  Beta-lactamase 2,  Serum albumin,  Solute carrier family 15 member 1,  Solute carrier family 15 member 2,  Solute carrier family 22 member 6","DB01060, DB00415, DB01053, DB13836, DB13816, DB08795, DB00578, DB03658, DB13506, DB01604, DB08559, DB13739, DB00319, DB00417, DB09320, DB01061, DB01602, DB00739, DB13337, DB01607, DB09319, DB13693, DB01000, DB13686, DB07806, DB13660, DB03550, DB03820, DB13814, DB12127",
DB01061,Azlocillin,approved,[H][C@](NC(=O)N1CCNC1=O)(C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@]12[H])C1=CC=CC=C1,C20H23N5O6S,,"Agents that reduce seizure threshold, Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Beta-Lactam Antibacterials, beta-Lactams, Heterocyclic Compounds, Fused-Ring, Lactams, Penicillin G, Penicillins, Penicillins With Extended Spectrum, Sulfur Compounds", Penicillin-binding protein 1A,"DB01061, DB00319, DB00739, DB00948, DB00415, DB01053, DB13836, DB01060, DB08795, DB00578, DB13816, DB01604, DB08559, DB13739, DB07806, DB09320, DB13506, DB01607, DB01602, DB13814, DB12127, DB13693, DB13686, DB09319, DB00417, DB00713, DB01000, DB03658, DB01603, DB13337",
DB01062,Oxybutynin,approved; investigational,CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1,C22H31NO3,,"Acids, Carbocyclic, Agents producing tachycardia, Anticholinergic Agents, Autonomic Agents, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (moderate), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs for Urinary Frequency and Incontinence, Genito Urinary System and Sex Hormones, Genitourinary Agents, Hydroxy Acids, Muscarinic Antagonists, Neurotransmitter Agents, Parasympatholytics, Peripheral Nervous System Agents, Urological Agents, Urologicals"," Muscarinic acetylcholine receptor M3,  Muscarinic acetylcholine receptor M2,  Muscarinic acetylcholine receptor M1,  Cytochrome P450 3A4,  Cytochrome P450 2C8,  Cytochrome P450 2D6,  Cytochrome P450 3A5,  Alpha-1-acid glycoprotein 1,  Serum albumin","DB01062, DB00219",
DB01063,Acetophenazine,approved,CC(=O)C1=CC=C2SC3=C(C=CC=C3)N(CCCN3CCN(CCO)CC3)C2=C1,C23H29N3O2S,,"Antipsychotic Agents, Central Nervous System Depressants, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Heterocyclic Compounds, Fused-Ring, Nervous System, Neurotoxic agents, Phenothiazines, Phenothiazines With Piperazine Structure, Psycholeptics, Sulfur Compounds"," Dopamine D2 receptor,  Androgen receptor","DB01063, DB01038, DB01614, DB13213, DB11540, DB01615, DB00623, DB11517, DB00777, DB00831, DB12710, DB13784, DB00508, DB01608, DB09000, DB00850, DB00372",
DB01064,Isoprenaline,approved; investigational,CC(C)NCC(O)C1=CC(O)=C(O)C=C1,C11H17NO3,,"Adrenergic Agents, Adrenergic Agonists, Adrenergic and Dopaminergic Agents, Adrenergic beta-2 Receptor Agonists, Adrenergic beta-Agonists, Adrenergics for Systemic Use, Adrenergics, Inhalants, Agents producing tachycardia, Agents that produce hypertension, Alcohols, Amines, Amino Alcohols, Anti-Asthmatic Agents, Autonomic Agents, Benzene Derivatives, Bronchodilator Agents, Cardiac Stimulants Excl. Cardiac Glycosides, Cardiac Therapy, Cardiotonic Agents, Cardiovascular Agents, Catecholamines, Catechols, Cholinesterase Inhibitors, Compounds used in a research, industrial, or household setting, COMT Substrates, Drugs for Obstructive Airway Diseases, Ethanolamines, Neurotransmitter Agents, Non-selective Beta-adrenergic Agonists, Peripheral Nervous System Agents, Phenols, Protective Agents, Respiratory System Agents, Sympathomimetics"," Beta-1 adrenergic receptor,  Beta-2 adrenergic receptor,  Beta-3 adrenergic receptor,  Superoxide dismutase [Cu-Zn],  Cytochrome P450 1A1,  Cytochrome P450 1B1,  Catechol O-methyltransferase,  Cholinesterase,  Serum albumin","DB01064, DB00668, DB00816, DB00871, DB08985, DB00221, DB08957, DB00368, DB00388, DB01288, DB13494, DB01102, DB09203, DB13917, DB06814, DB00867, DB01001, DB13139, DB06707, DB13206, DB13378",
DB01065,Melatonin,approved; nutraceutical; vet_approved,COC1=CC2=C(NC=C2CCNC(C)=O)C=C1,C13H16N2O2,,"Amines, Antioxidants, Biogenic Amines, Biogenic Monoamines, Biological Factors, Central Nervous System Agents, Central Nervous System Depressants, Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 Substrates, Heterocyclic Compounds, Fused-Ring, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hypnotics and Sedatives, Indoles, Melatonin Receptor Agonists, Melatonin, agonists, Nervous System, OAT3/SLC22A8 Inhibitors, Protective Agents, Psycholeptics, Tryptamines"," Melatonin receptor type 1A,  Melatonin receptor type 1B,  Estrogen receptor alpha,  Nuclear receptor ROR-beta,  Calmodulin,  Myeloperoxidase,  Eosinophil peroxidase,  Calreticulin,  Acetylserotonin O-methyltransferase, 10. Ribosyldihydronicotinamide dehydrogenase [quinone],  Cytochrome P450 1A1,  Cytochrome P450 1A2,  Cytochrome P450 1B1,  Cytochrome P450 2C19,  Cytochrome P450 2C9,  Acetylserotonin O-methyltransferase,  Indoleamine 2,3-dioxygenase 1,  Myeloperoxidase,  Cytochrome P450 19A1,  Solute carrier family 22 member 8","DB01065, DB04275, DB01441, DB14010, DB16909, DB08190, DB01445, DB08839, DB13990, DB12288, DB07723",
DB01066,Cefditoren,approved; investigational,[H][C@]12SCC(\C=C/C3=C(C)N=CS3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O,C19H18N6O5S3,,"Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, beta-Lactams, Cephalosporins, Heterocyclic Compounds, Fused-Ring, Lactams, Nephrotoxic agents, Sulfur Compounds, Thiazines, Third-Generation Cephalosporins"," Penicillin-binding protein 2B,  Penicillin-binding protein 1A","DB01066, DB00535, DB00671, DB13504, DB01416, DB01413, DB13470, DB00493, DB11485, DB00267, DB01332, DB11505, DB00438, DB14879, DB01212, DB13682, DB13461, DB04918, DB00229, DB14733, DB13667, DB05735, DB06590, DB11592, DB09050, DB01415, DB13499, DB01112, DB00430, DB11385",
DB01067,Glipizide,approved; investigational,CC1=NC=C(N=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1,C21H27N5O4S,,"Alimentary Tract and Metabolism, Blood Glucose Lowering Agents, BSEP/ABCB11 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Drugs Used in Diabetes, Hypoglycemia-Associated Agents, Insulin Secretagogues, Oral Hypoglycemics, Sulfones, Sulfonylureas, Sulfur Compounds, UGT1A1 Substrates"," ATP-binding cassette sub-family C member 8,  Peroxisome proliferator-activated receptor gamma,  UDP-glucuronosyltransferase 1-1,  Cytochrome P450 2C9,  Serum albumin,  Bile salt export pump",DB01067,
DB01068,Clonazepam,approved; illicit,[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,C15H10ClN3O3,,"Anticonvulsants, Benzazepines, Benzodiazepines and benzodiazepine derivatives, Benzodiazepinones, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, GABA Agents, GABA Modulators, Heterocyclic Compounds, Fused-Ring, Muscle Relaxants, Muscle Relaxants, Centrally Acting Agents, Nervous System"," GABA(A) Receptor (Protein Group),  GABA(A) Receptor Benzodiazepine Binding Site (Protein Group),  Nuclear receptor subfamily 1 group I member 2,  Cytochrome P450 2E1,  Arylamine N-acetyltransferase 2,  Cytochrome P450 3A4,  Serum albumin","DB01068, DB01595, DB01544, DB01511",
DB01069,Promethazine,approved; investigational,CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C,C17H20N2S,,"Acid Reducers, Agents producing tachycardia, Agents that reduce seizure threshold, Amines, Anti-Allergic Agents, Anticholinergic Agents, Antidepressive Agents, Antidotes, Antihistamines for Systemic Use, Antihistamines for Topical Use, Antipruritics, Antipruritics, Incl. Antihistamines, Anesthetics, Etc., Antipsychotic Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dermatologicals, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Drugs causing inadvertant photosensitivity, Drugs that are Mainly Renally Excreted, Heterocyclic Compounds, Fused-Ring, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Histamine H2 Antagonists, Miscellaneous Anxiolytics Sedatives and Hypnotics, Muscarinic Antagonists, Neurotoxic agents, Neurotransmitter Agents, P-glycoprotein inhibitors, Phenothiazine Derivatives, Phenothiazines, Photosensitizing Agents, Potential QTc-Prolonging Agents, Propylamines, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin Modulators, Sulfur Compounds"," Histamine H1 receptor,  Dopamine D2 receptor,  Muscarinic acetylcholine receptor M1,  Muscarinic acetylcholine receptor M2,  Muscarinic acetylcholine receptor M3,  Muscarinic acetylcholine receptor M4,  Muscarinic acetylcholine receptor M5,  Alpha adrenergic receptor (Protein Group),  Calmodulin, 10. Histamine H2 receptor, 11. P2 Purinoceptors (Protein Group), 12. Voltage-gated sodium channel alpha subunit (Protein Group), 13. Voltage-gated Potassium Channels (Protein Group),  Cytochrome P450 2C9,  Cytochrome P450 2D6,  Cytochrome P450 2B6,  Serum albumin,  P-glycoprotein 1,  Canalicular multispecific organic anion transporter 2,  Multidrug resistance-associated protein 4","DB01069, DB13420, DB00392, DB15596, DB13840, DB13672, DB15978, DB00420, DB12710, DB01246, DB01615, DB00777, DB00902, DB00433, DB00477",
DB01070,Dihydrotachysterol,approved,CC(C)[C@@H](C)\C=C\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1/C[C@@H](O)CC[C@@H]1C,C28H46O,,"Alimentary Tract and Metabolism, Bone Density Conservation Agents, Cholestanes, Cholestenes, Diet, Food, and Nutrition, Food, Fused-Ring Compounds, Lipids, Membrane Lipids, Micronutrients, Physiological Phenomena, Secosteroids, Steroids, Sterols, Vitamin D and Analogues, Vitamins, Vitamins (Fat Soluble)", Vitamin D3 receptor,"DB01070, DB00153, DB00910, DB04038, DB00169, DB00146, DB06410, DB18029, DB18406, DB04891, DB01436, DB13097, DB15557, DB13689, DB00136, DB06117, DB02300, DB04258",
DB01071,Mequitazine,experimental,C(C1CN2CCC1CC2)N1C2=CC=CC=C2SC2=CC=CC=C12,C20H22N2S,,"Anti-Allergic Agents, Antihistamines for Systemic Use, Bronchodilator Agents, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Heterocyclic Compounds, Fused-Ring, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Neurotransmitter Agents, Phenothiazine Derivatives, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Sulfur Compounds"," Histamine H1 receptor,  Cytochrome P450 3A4,  Cytochrome P450 2D6","DB01071, DB00902, DB01246, DB00420, DB12710, DB13784, DB00679, DB13820, DB01608, DB13382, DB11517, DB15596, DB13591, DB09000, DB00933, DB00477, DB00433",
DB01072,Atazanavir,approved; investigational,COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=CC=CC=N1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C,C38H52N6O7,,"Amino Acids, Peptides, and Proteins, Anti-HIV Agents, Anti-Infective Agents, Anti-Retroviral Agents, Antiinfectives for Systemic Use, Antiviral Agents, Antivirals for Systemic Use, Antivirals used in combination for the treatment of HIV infections, BSEP/ABCB11 Substrates, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (weak), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strong), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Inhibitors, Cytochrome P-450 CYP3A5 Inhibitors (strength unknown), Cytochrome P-450 CYP3A7 Inhibitors, Cytochrome P-450 CYP3A7 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Direct Acting Antivirals, Enzyme Inhibitors, HIV Protease Inhibitors, Hyperglycemia-Associated Agents, Nephrotoxic agents, OATP1B1/SLCO1B1 Inhibitors, OATP1B3 inhibitors, Oligopeptides, Organic Anion Transporting Polypeptide 2B1 Inhibitors, P-glycoprotein inducers, P-glycoprotein inhibitors, P-glycoprotein substrates, Peptides, Potential QTc-Prolonging Agents, Protease Inhibitors, Pyridines, QTc Prolonging Agents, UDP Glucuronosyltransferases Inhibitors, UGT1A1 Inhibitors, Viral Protease Inhibitors"," Human immunodeficiency virus type 1 protease,  Cytochrome P450 3A4,  Cytochrome P450 2C9,  UDP-glucuronosyltransferase 1-1,  Cytochrome P450 2C8,  Cytochrome P450 1A2,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  Serum albumin,  alpha1-acid glycoprotein (Protein Group),  P-glycoprotein 1,  Multidrug resistance-associated protein 1,  Solute carrier organic anion transporter family member 1B1,  Solute carrier organic anion transporter family member 1B3,  Bile salt export pump,  Solute carrier organic anion transporter family member 2B1",DB01072,
DB01073,Fludarabine,approved,NC1=NC(F)=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,C10H12FN5O4,,"Adenine Nucleotides, Antimetabolites, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Arabinonucleosides, Arabinonucleotides, Cardiotoxic antineoplastic agents, DNA (Cytosine-5-)-Methyltransferases, antagonists & inhibitors, Heterocyclic Compounds, Fused-Ring, Immunologic Factors, Immunosuppressive Agents, Myeloablative Agonists, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, Noxae, Nucleic Acid Synthesis Inhibitors, Nucleic Acids, Nucleotides, and Nucleosides, Nucleoside Metabolic Inhibitor, Nucleosides, Nucleotides, Purine Analogues, Purine Nucleosides, Purine Nucleotides, Purines, Toxic Actions"," DNA,  Deoxycytidine kinase,  DNA polymerase alpha catalytic subunit,  Ribonucleoside-diphosphate reductase large subunit,  Equilibrative nucleoside transporter 1,  Solute carrier family 28 member 3","DB01073, DB04441, DB02947, DB00194, DB00640, DB03528, DB12156, DB15653, DB03716, DB16075, DB11933, DB02916, DB02282, DB03273, DB03011, DB04440, DB04853, DB07052, DB00242, DB00131, DB02162, DB02373, DB17756, DB01910, DB04102, DB07170, DB02607, DB02753, DB02798, DB03230",
DB01074,Perhexiline,approved; investigational,C(C(C1CCCCC1)C1CCCCC1)C1CCCCN1,C19H35N,,"Agents causing hyperkalemia, Antiarrhythmic agents, Bradycardia-Causing Agents, Calcium Channel Blockers, Calcium-Regulating Hormones and Agents, Cardiovascular Agents, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Membrane Transport Modulators, Negative Inotrope, Non-Selective Calcium Channel Blockers, Piperidines, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Vasodilating Agents"," Carnitine O-palmitoyltransferase 1, liver isoform,  Carnitine O-palmitoyltransferase 2, mitochondrial,  Potassium voltage-gated channel subfamily H member 2,  Cytochrome P450 2B6,  Cytochrome P450 3A4,  Cytochrome P450 2D6","DB01074, DB02409, DB06714, DB00657, DB11807",
DB01075,Diphenhydramine,approved; investigational,CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1,C17H21NO,,"Agents producing tachycardia, Amines, Aminoalkyl Ethers, Anesthetics, Anesthetics, Local, Anti-Allergic Agents, Anticholinergic Agents, Antiemetics, Antihistamines for Systemic Use, Antihistamines for Topical Use, Antipruritics, Incl. Antihistamines, Anesthetics, Etc., Benzene Derivatives, Benzhydryl Compounds, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dermatologicals, Drugs causing inadvertant photosensitivity, Ethanolamine Derivatives, Ethylamines, First Generation Antihistamines, Gastrointestinal Agents, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Hypnotics and Sedatives, Muscarinic Antagonists, OCT2 Inhibitors, Photosensitizing Agents, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Sleep Aids, Pharmaceutical"," Histamine H1 receptor,  Muscarinic acetylcholine receptor M2,  Prostaglandin G/H synthase 1,  Cytochrome P450 2D6,  Cytochrome P450 2C9,  Cytochrome P450 2C19,  Solute carrier family 22 member 2,  Solute carrier family 22 member 5","DB01075, DB13769, DB01173, DB01237, DB09007, DB15790",
DB01076,Atorvastatin,approved,CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1,C33H35FN2O5,,"Agents Causing Muscle Toxicity, Anticholesteremic Agents, BSEP/ABCB11 Substrates, Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strength unknown), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (strength unknown), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Enzyme Inhibitors, Fatty Acids, Heptanoic Acids, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hypolipidemic Agents, Hypolipidemic Agents Indicated for Hyperlipidemia, Lipid Modifying Agents, Lipid Modifying Agents, Plain, Lipid Regulating Agents, Lipids, OATP1B1/SLCO1B1 Inhibitors, OATP1B1/SLCO1B1 Substrates, OATP1B3 substrates, OATP2B1/SLCO2B1 substrates, P-glycoprotein inhibitors, P-glycoprotein substrates, Toxic Actions, UGT1A1 Substrates, UGT1A3 substrates"," 3-hydroxy-3-methylglutaryl-coenzyme A reductase,  Dipeptidyl peptidase 4,  Aryl hydrocarbon receptor,  Histone deacetylase 2,  Nuclear receptor subfamily 1 group I member 3,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  Cytochrome P450 2C8,  Cytochrome P450 2D6,  Cytochrome P450 2C9,  Cytochrome P450 2C19,  Cytochrome P450 2B6,  UDP-glucuronosyltransferase 1-1, 10. UDP-glucuronosyltransferase 1-3,  Serum albumin,  P-glycoprotein 1,  Solute carrier organic anion transporter family member 1A2,  Solute carrier organic anion transporter family member 1B1,  Multidrug resistance-associated protein 4,  Multidrug resistance-associated protein 5,  Multidrug resistance-associated protein 1,  Solute carrier organic anion transporter family member 2B1,  Solute carrier organic anion transporter family member 1B3,  Canalicular multispecific organic anion transporter 1, 10. Bile salt export pump",DB01076,
DB01077,Etidronic acid,approved,CC(O)(P(O)(O)=O)P(O)(O)=O,C2H8O7P2,,"Bisphosphonates, Bone Density Conservation Agents, Drugs Affecting Bone Structure and Mineralization, Drugs for Treatment of Bone Diseases, Musculo-Skeletal System, Organophosphonates, Organophosphorus Compounds"," Hydroxylapatite,  Receptor-type tyrosine-protein phosphatase S,  V-type proton ATPase catalytic subunit A,  ADP/ATP translocase 1,  ADP/ATP translocase 2,  ADP/ATP translocase 3","DB01077, DB09411, DB14159, DB09139",
DB01078,Deslanoside,approved,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@H](CC[C@@H]3[C@@H]2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1,C47H74O19,,"Antiarrhythmic agents, Carbohydrates, Cardanolides, Cardenolides, Cardiac Glycosides, Cardiac Therapy, Cardiotonic Agents, Cardiovascular Agents, Compounds used in a research, industrial, or household setting, Digitalis Glycosides, Enzyme Inhibitors, Fused-Ring Compounds, Glycosides, Lanatosides, Protective Agents, Steroids", Sodium/potassium-transporting ATPase subunit alpha-1,"DB01078, DB00390, DB01396, DB13401, DB01092, DB13467, DB00511, DB13691, DB13756, DB13240, DB13537, DB12843, DB06569, DB15532, DB03671, DB14081, DB06748, DB06749, DB14815, DB04177, DB12025, DB15774, DB15907",
DB01079,Tegaserod,approved; investigational; withdrawn,CCCCCNC(=N)N\N=C\C1=CNC2=C1C=C(OC)C=C2,C16H23N5O,,"Alimentary Tract and Metabolism, Antidepressive Agents, BCRP/ABCG2 Substrates, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (weak), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (weak), Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs for Constipation, Gastrointestinal Agents, Heterocyclic Compounds, Fused-Ring, Laxatives, P-glycoprotein substrates, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 4 Receptor Agonists, Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2A Receptor Antagonists, Serotonin 5-HT2C Receptor Antagonists, Serotonin Agents, Serotonin Receptor Antagonists, Serotonin-4 Receptor Agonist"," 5-hydroxytryptamine receptor 4,  5-hydroxytryptamine receptor 2C,  5-hydroxytryptamine receptor 2A,  5-hydroxytryptamine receptor 2B,  Cytochrome P450 1A2,  Cytochrome P450 2C8,  Cytochrome P450 2D6,  Cytochrome P450 2E1,  Sodium-dependent serotonin transporter,  ATP-binding cassette sub-family G member 2,  P-glycoprotein 1",DB01079,
DB01080,Vigabatrin,approved,NC(CCC(O)=O)C=C,C6H11NO2,,"Acids, Acyclic, Aminobutyrates, Anti-epileptic Agent, Anticonvulsants, Butyrates, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2C9 Inducers, Cytochrome P-450 CYP2C9 Inducers (strength unknown), Cytochrome P-450 Enzyme Inducers, Enzyme Inhibitors, Fatty Acid Derivatives, Fatty Acids, GABA Agents, Lipids, Miscellaneous Anticonvulsants, Nervous System, Neurotransmitter Agents"," 4-aminobutyrate aminotransferase, mitochondrial,  Cytochrome P450 2C9,  Proton-coupled amino acid transporter 1","DB01080, DB04235",
DB01081,Diphenoxylate,approved; illicit,CCOC(=O)C1(CCN(CCC(C#N)(C2=CC=CC=C2)C2=CC=CC=C2)CC1)C1=CC=CC=C1,C30H32N2O2,,"Alimentary Tract and Metabolism, Analgesics, Antidiarrheals, Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents, Antipropulsives, Central Nervous System Agents, Central Nervous System Depressants, Gastrointestinal Agents, Isonipecotic Acids, Opioids, Peripheral Nervous System Agents, Piperidines, Sensory System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"," Mu-type opioid receptor,  Delta-type opioid receptor","DB01081, DB01501, DB00454, DB01475, DB01505, DB13605, DB01518, DB08988, DB00913, DB01464",
DB01082,Streptomycin,approved; vet_approved,CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)O[C@@H](C)[C@]1(O)C=O,C21H39N7O12,,"Agents that produce neuromuscular block (indirect), Alimentary Tract and Metabolism, Aminoglycoside Antibacterials, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents, Antiinfectives for Systemic Use, Antimycobacterials, Drugs for Treatment of Tuberculosis, Drugs that are Mainly Renally Excreted, Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index, Glycosides, Intestinal Antiinfectives, Narrow Therapeutic Index Drugs, Nephrotoxic agents, OAT1/SLC22A6 inhibitors, Protein Synthesis Inhibitors, Streptomycins"," 16S ribosomal RNA,  23S ribosomal RNA,  30S ribosomal protein S12,  Protein-arginine deiminase type-4","DB01082, DB11512, DB00919, DB00798, DB13274, DB04718",
DB01083,Orlistat,approved; investigational,CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,C29H53NO5,,"Alimentary Tract and Metabolism, Anti-Obesity Agents, Antiobesity Preparations, Excl. Diet Products, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 Enzyme Inducers, Enzyme Inhibitors, Intestinal Lipase Inhibitor, Lactones, Lipase Inhibitors, Lipid Regulating Agents, Miscellaneous GI Drugs, Peripherally Acting Antiobesity Products"," Pancreatic triacylglycerol lipase,  Gastric triacylglycerol lipase,  Fatty acid synthase,  Cytochrome P450 3A4,  Cytosolic phospholipase A2,  Fatty acid synthase,  Serum albumin",DB01083,
DB01084,Emedastine,approved,CCOCCN1C(=NC2=CC=CC=C12)N1CCCN(C)CC1,C17H26N4O,,"Anti-Allergic Agents, Decongestants and Antiallergics, Heterocyclic Compounds, Fused-Ring, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Histamine H1 Inhibitors, Moderate Risk QTc-Prolonging Agents, Neurotransmitter Agents, Ophthalmologicals, QTc Prolonging Agents, Sensory Organs", Histamine H1 receptor,DB01084,
DB01085,Pilocarpine,approved; investigational,CC[C@H]1[C@@H](CC2=CN=CN2C)COC1=O,C11H16N2O2,,"Alkaloids, Antiglaucoma Preparations and Miotics, Autonomic Agents, Cholinergic Agents, Cholinergic Agonists, Cholinergic Receptor Agonist, Cytochrome P-450 CYP2A6 Inhibitors, Cytochrome P-450 CYP2A6 Inhibitors (strong), Cytochrome P-450 CYP2A6 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Miotics, Muscarinic Agonists, Nervous System, Neurotransmitter Agents, Ophthalmologicals, Parasympathomemetic (Cholinergic) Agents, Parasympathomimetics, Peripheral Nervous System Agents, Sensory Organs"," Muscarinic acetylcholine receptor M3,  Muscarinic acetylcholine receptor M1,  Muscarinic acetylcholine receptor M2,  Muscarinic acetylcholine receptor M4,  Muscarinic acetylcholine receptor M5,  Cytochrome P450 3A4,  Cytochrome P450 2A6,  Serum paraoxonase/arylesterase 1",DB01085,
DB01086,Benzocaine,approved; investigational,CCOC(=O)C1=CC=C(N)C=C1,C9H11NO2,,"Acids, Carbocyclic, Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use, Aminobenzoates, Anesthetics, Anesthetics for Topical Use, Anesthetics, Local, Antipruritics and Local Anesthetics, Antipruritics, Incl. Antihistamines, Anesthetics, Etc., Benzene Derivatives, Benzoates, Cell-mediated Immunity, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 Substrates, Dermatologicals, Esters of Aminobenzoic Acid, Increased Histamine Release, Local Anesthetics (Ester), Methemoglobinemia Associated Agents, Nervous System, P-glycoprotein inhibitors, para-Aminobenzoates, Peripheral Nervous System Agents, Sensory System Agents, Standardized Chemical Allergen, Throat Preparations, Vasoprotectives"," Sodium channel protein type 10 subunit alpha,  Cytochrome P450 1A2,  Cytochrome P450 2B6,  Cytochrome P450 2C19,  Cytochrome P450 2D6,  Cytochrome P450 2E1,  Liver carboxylesterase 1,  Serum albumin,  alpha1-acid glycoprotein (Protein Group),  P-glycoprotein 1","DB01086, DB11148, DB11552, DB02362, DB00721, DB00676",
DB01087,Primaquine,approved,COC1=CC(NC(C)CCCN)=C2N=CC=CC2=C1,C15H21N3O,,"Aminoquinolines, Anti-Infective Agents, Antibiotics for Pneumocystis Pneumonia, Antimalarials, Antiparasitic Agents, Antiparasitic Products, Insecticides and Repellents, Antiprotozoals, Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP1A2 Inducers (strength unknown), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (moderate), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Heterocyclic Compounds, Fused-Ring, Methemoglobinemia Associated Agents, Moderate Risk QTc-Prolonging Agents, P-glycoprotein inhibitors, QTc Prolonging Agents, Quinolines"," Fe(II)-protoporphyrin IX,  Keratin, type II cytoskeletal 7,  Ribosyldihydronicotinamide dehydrogenase [quinone],  Cytochrome P450 3A4,  Cytochrome P450 1A2,  Cytochrome P450 2D6,  Cytochrome P450 1A1,  Cytochrome P450 1B1,  P-glycoprotein 1","DB01087, DB04909",
DB01088,Iloprost,approved; investigational,[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)C(C)CC#CC)[C@@]1([H])C\C(C2)=C\CCCC(O)=O,C22H32O4,,"Agents Causing Muscle Toxicity, Antiplatelet agents, Autacoids, Biological Factors, Blood and Blood Forming Organs, Cardiovascular Agents, Eicosanoids, Fatty Acids, Fatty Acids, Unsaturated, Hematologic Agents, Hypotensive Agents, Inflammation Mediators, Lipids, OATP2B1/SLCO2B1 substrates, Platelet Aggregation Inhibitors Excl. Heparin, Prostacyclin Analogues, Prostaglandins, Prostaglandins, Synthetic, Vasodilating Agents"," Prostacyclin receptor,  Prostaglandin E2 receptor EP1 subtype,  cAMP-specific 3',5'-cyclic phosphodiesterase 4A,  cAMP-specific 3',5'-cyclic phosphodiesterase 4B,  cAMP-specific 3',5'-cyclic phosphodiesterase 4C,  cAMP-specific 3',5'-cyclic phosphodiesterase 4D,  Tissue-type plasminogen activator,  Prostaglandin D2 receptor 2,  Serum albumin,  Solute carrier organic anion transporter family member 2B1,  Solute carrier organic anion transporter family member 2A1,  Solute carrier organic anion transporter family member 3A1","DB01088, DB12789, DB01160, DB05212, DB00429",
DB01089,Deserpidine,approved,[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=CC=CC=C31)C2,C32H38N2O8,,"Alkaloids, Antiadrenergic Agents, Centrally Acting, Antihypertensive Agents, Catecholamine-depleting Sympatholytic, Decreased Sympathetic Activity, Heterocyclic Compounds, Fused-Ring, Indole Alkaloids, Indoles, Indolizidines, Indolizines, Secologanin Tryptamine Alkaloids", Synaptic vesicular amine transporter,"DB01089, DB00206, DB13631, DB13575, DB01180, DB11530, DB01392, DB15949, DB13374, DB12131, DB00309, DB01967, DB02868, DB00541, DB17390, DB00570, DB05168, DB12586, DB13793, DB02191, DB11641, DB12674, DB11467, DB15096, DB00361, DB12755, DB04877, DB00200, DB11191, DB13454",
DB01090,Pentolinium,approved,C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1,C15H32N2,,"Anticholinergic Agents, Antihypertensive Agents, Autonomic Agents, Cardiovascular Agents, Cholinergic Agents, Ganglion Blockers, Neurotransmitter Agents, Nicotinic Antagonists, Peripheral Nervous System Agents, Pyrrolidines"," Neuronal acetylcholine receptor subunit alpha-3,  Neuronal acetylcholine receptor subunit beta-4,  Neuronal acetylcholine receptor subunit alpha-10","DB01090, DB04221, DB13970, DB14143, DB13969, DB01851",
DB01091,Butenafine,approved,CN(CC1=CC=C(C=C1)C(C)(C)C)CC1=CC=CC2=CC=CC=C12,C23H27N,,"Amines, Anti-Infective Agents, Antifungal Agents, Antifungals for Dermatological Use, Antifungals for Topical Use, Benzene Derivatives, Benzyl Compounds, Benzylamine Antifungal, Benzylamines, Dermatologicals", Squalene monooxygenase,DB01091,
DB01092,Ouabain,approved,[H][C@@]12CC[C@]3(O)C[C@H](C[C@@H](O)[C@]3(CO)[C@@]1([H])[C@H](O)C[C@]1(C)[C@H](CC[C@]21O)C1=CC(=O)OC1)O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O,C29H44O12,,"Carbohydrates, Cardanolides, Cardenolides, Cardiac Glycosides, Cardiac Therapy, Cardiotonic Agents, Cardiovascular Agents, Compounds used in a research, industrial, or household setting, Enzyme Inhibitors, Fused-Ring Compounds, Glycosides, OAT3/SLC22A8 Inhibitors, OATP1B1/SLCO1B1 Inhibitors, OATP1B1/SLCO1B1 Substrates, OATP1B3 substrates, Protective Agents, Steroids, Strophanthins, Strophanthus Glycosides"," Sodium/potassium-transporting ATPase subunit alpha-1,  Sodium/potassium-transporting ATPase subunit alpha-2,  Sodium/potassium-transporting ATPase subunit alpha-3,  Solute carrier organic anion transporter family member 1A2,  Solute carrier family 22 member 8,  Solute carrier organic anion transporter family member 4C1,  Solute carrier organic anion transporter family member 1B3,  Solute carrier organic anion transporter family member 1C1,  Solute carrier organic anion transporter family member 1B1","DB01092, DB01078, DB13756, DB00390, DB01396, DB13401, DB13240, DB13467, DB00511, DB13691, DB12843, DB13537, DB03671, DB04177, DB06750, DB12025, DB06569, DB15532",
DB01093,Dimethyl sulfoxide,approved; vet_approved,CS(C)=O,C2H6OS,,"Antioxidants, Compounds used in a research, industrial, or household setting, Cryoprotective Agents, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Drugs that are Mainly Renally Excreted, Free Radical Scavengers, Genito Urinary System and Sex Hormones, Kinase Inhibitor, Miscellaneous Therapeutic Agents, Musculo-Skeletal System, Protective Agents, Solvents, Sulfoxides, Sulfur Compounds, Topical Products for Joint and Muscular Pain, Urologicals"," Interleukin-5 receptor subunit alpha,  Mucin-16,  Myc proto-oncogene protein,  Cytochrome P450 2C19,  Cytochrome P450 2D6,  Cytochrome P450 3A4,  Transthyretin","DB01093, DB14090",
DB01094,Hesperetin,experimental,COC1=C(O)C=C(C=C1)[C@@H]1CC(=O)C2=C(O)C=C(O)C=C2O1,C16H14O6,,"BCRP/ABCG2 Inhibitors, Benzopyrans, Carbohydrates, Chromones, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 Substrates, Flavanones, Flavonoids, Glycosides, Heterocyclic Compounds, Fused-Ring, Pyrans"," Microsomal triglyceride transfer protein large subunit,  Sterol O-acyltransferase 1,  Sex hormone-binding globulin,  Sterol O-acyltransferase 2,  Cytochrome P450 1A2,  ATP-binding cassette sub-family G member 2","DB01094, DB08517, DB03467, DB02224, DB15645, DB03601, DB04274, DB04429, DB09298, DB03823, DB12039, DB14086, DB04703, DB12116, DB16120, DB16859",
DB01095,Fluvastatin,approved,CC(C)N1C(\C=C\C(O)CC(O)CC(O)=O)=C(C2=CC=CC=C12)C1=CC=C(F)C=C1,C24H26FNO4,,"Agents Causing Muscle Toxicity, Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strength unknown), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (strength unknown), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (moderate), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Fatty Acids, Heptanoic Acids, Heterocyclic Compounds, Fused-Ring, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hypolipidemic Agents, Hypolipidemic Agents Indicated for Hyperlipidemia, Indoles, Lipid Modifying Agents, Lipid Modifying Agents, Plain, Lipid Regulating Agents, Lipids, OATP1B1/SLCO1B1 Inhibitors, OATP1B1/SLCO1B1 Substrates, OATP1B3 substrates, UGT1A1 Substrates, UGT1A3 substrates, UGT2B7 substrates"," 3-hydroxy-3-methylglutaryl-coenzyme A reductase,  Histone deacetylase 2,  Cytochrome P450 1A1,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 2C8,  Cytochrome P450 2C9,  Cytochrome P450 2C19,  Cytochrome P450 2D6,  UDP-glucuronosyltransferase 1-1,  UDP-glucuronosyltransferase 1-3, 10. UDP-glucuronosyltransferase 2B7, 11. Cytochrome P450 2B6,  Solute carrier organic anion transporter family member 1B1,  Solute carrier organic anion transporter family member 1B3,  Solute carrier organic anion transporter family member 2B1,  Solute carrier family 15 member 1,  Canalicular multispecific organic anion transporter 1","DB01095, DB08860",
DB01096,Oxamniquine,approved,CC(C)NCC1CCC2=CC(CO)=C(C=C2N1)[N+]([O-])=O,C14H21N3O3,,"Anthelmintics, Anti-Infective Agents, Antihelminthic, Antiparasitic Agents, Antiparasitic Products, Insecticides and Repellents, Antiplatyhelmintic Agents, Antitrematodals, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Heterocyclic Compounds, Fused-Ring, Hydroxyquinolines, Nitroquinolines, Quinoline Derivatives and Related Substances, Quinolines, Schistosomicides"," DNA,  Cytochrome P450 2D6",DB01096,
DB01097,Leflunomide,approved; investigational,CC1=C(C=NO1)C(=O)NC1=CC=C(C=C1)C(F)(F)F,C12H9F3N2O2,,"Adjuvants, Agents Causing Muscle Toxicity, Antineoplastic and Immunomodulating Agents, Antirheumatic Agents, BCRP/ABCG2 Substrates, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Disease-modifying Antirheumatic Agents, Enzyme Inhibitors, Hepatotoxic Agents, Immunologic Factors, Immunosuppressive Agents, Isoxazoles, Selective Immunosuppressants"," Dihydroorotate dehydrogenase (quinone), mitochondrial,  Aryl hydrocarbon receptor,  Protein-tyrosine kinase 2-beta,  Cytochrome P450 2C9,  Cytochrome P450 1A2,  ATP-binding cassette sub-family G member 2",DB01097,
DB01098,Rosuvastatin,approved,CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O,C22H28FN3O6S,,"Agents Causing Muscle Toxicity, Alimentary Tract and Metabolism, Amides, Anticholesteremic Agents, BCRP/ABCG2 Substrates, BSEP/ABCB11 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A5 Inhibitors, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs Used in Diabetes, Enzyme Inhibitors, Fluorobenzenes, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Hydrocarbons, Fluorinated, Hydrocarbons, Halogenated, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hypolipidemic Agents, Hypolipidemic Agents Indicated for Hyperlipidemia, Lipid Modifying Agents, Lipid Modifying Agents, Plain, Lipid Regulating Agents, OAT3/SLC22A8 Inhibitors, OAT3/SLC22A8 Substrates, OATP1B1/SLCO1B1 Inhibitors, OATP1B1/SLCO1B1 Substrates, Pyrimidines, Sulfonamides, Sulfones, Sulfur Compounds"," 3-hydroxy-3-methylglutaryl-coenzyme A reductase,  Integrin alpha-L,  Cytochrome P450 2C9,  Serum albumin,  Multidrug resistance-associated protein 4,  Solute carrier organic anion transporter family member 1A2,  Solute carrier organic anion transporter family member 1B1,  Solute carrier organic anion transporter family member 1B3,  Solute carrier organic anion transporter family member 2B1,  Cystine/glutamate transporter,  Bile salt export pump,  ATP-binding cassette sub-family G member 2,  Canalicular multispecific organic anion transporter 1, 10. Solute carrier family 22 member 8, 11. Sodium/bile acid cotransporter",DB01098,
DB01099,Flucytosine,approved; investigational,NC1=C(F)C=NC(=O)N1,C4H4FN3O,,"Anti-Infective Agents, Antifungal Agents, Antifungals for Dermatological Use, Antifungals for Topical Use, Antiinfectives for Systemic Use, Antimetabolites, Antimycotics for Systemic Use, Cytosine, Dermatologicals, Drugs causing inadvertant photosensitivity, Drugs that are Mainly Renally Excreted, Fluorouracil and prodrugs, Immunosuppressive Agents, Myelosuppressive Agents, Noxae, Nucleoside Analog Antifungal, Photosensitizing Agents, Pyrimidines, Pyrimidinones, Toxic Actions"," DNA,  DNA (cytosine-5)-methyltransferase 1,  Thymidylate synthase",DB01099,
DB01100,Pimozide,approved,FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=CC=CC=C12)C1=CC=C(F)C=C1,C28H29F2N3O,,"Agents that reduce seizure threshold, Anti-Dyskinesia Agents, Antipsychotic Agents, Antipsychotic Agents (First Generation [Typical]), Benzimidazoles, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Diphenylbutylpiperidine Derivatives, Dopamine Agents, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Heterocyclic Compounds, Fused-Ring, Highest Risk QTc-Prolonging Agents, Miscellaneous Antipsychotics, Narrow Therapeutic Index Drugs, Nervous System, Neurotoxic agents, Neurotransmitter Agents, P-glycoprotein inhibitors, Psycholeptics, Psychotropic Drugs, QTc Prolonging Agents, Tranquilizing Agents"," Dopamine D2 receptor,  Dopamine D3 receptor,  Potassium voltage-gated channel subfamily H member 2,  Calmodulin,  Cytochrome P450 2D6,  Cytochrome P450 3A4,  Cytochrome P450 1A2,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  P-glycoprotein 1","DB01100, DB01459, DB12867, DB01184, DB00450",
DB01101,Capecitabine,approved; investigational,CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O,C15H22FN3O6,,"Antimetabolites, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Cardiotoxic antineoplastic agents, Cytidine Deaminase Substrates, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strong), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Fluoropyrimidines, Fluorouracil and prodrugs, Immunosuppressive Agents, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, Noxae, Nucleic Acid Synthesis Inhibitors, Nucleic Acids, Nucleotides, and Nucleosides, Nucleoside Metabolic Inhibitor, Pyrimidine Analogues, Toxic Actions"," DNA,  RNA,  Thymidylate synthase,  Thymidine phosphorylase,  Liver carboxylesterase 1,  Cytidine deaminase,  Cytochrome P450 2C9,  Uridine phosphorylase 1,  Uridine phosphorylase 2,  Serum albumin","DB01101, DB12957, DB17226, DB00987, DB02097, DB13921, DB05494, DB01961, DB06365, DB06656, DB15660, DB02456, DB03403, DB13920, DB01995, DB02484, DB04555, DB12947, DB03687, DB01859, DB12153, DB01629, DB12906",
DB01102,Arbutamine,approved,O[C@@H](CNCCCCC1=CC=C(O)C=C1)C1=CC(O)=C(O)C=C1,C18H23NO4,,"Adrenergic Agents, Adrenergic Agonists, Adrenergic and Dopaminergic Agents, Adrenergic beta-1 Receptor Agonists, Adrenergic beta-2 Receptor Agonists, Adrenergic beta-3 Receptor Agonists, Adrenergic beta-Agonists, Agents producing tachycardia, Agents that produce hypertension, Amines, Benzene Derivatives, Cardiac Stimulants Excl. Cardiac Glycosides, Cardiac Therapy, Cardiotonic Agents, Cardiovascular Agents, Catechols, Compounds used in a research, industrial, or household setting, Neurotransmitter Agents, Phenols, Protective Agents"," Beta-1 adrenergic receptor,  Beta-2 adrenergic receptor,  Beta-3 adrenergic receptor","DB01102, DB08957, DB00668, DB00221, DB01064, DB13559, DB01288, DB08985, DB13206, DB08954, DB12313",
DB01103,Quinacrine,investigational,CCN(CC)CCCC(C)NC1=C2C=C(OC)C=CC2=NC2=C1C=CC(Cl)=C2,C23H30ClN3O,,"Acridines, Aminoacridines, Anti-Infective Agents, Anticestodal Agents, Antimalarials, Antinematodal Agents, Antiparasitic Agents, Antiparasitic Products, Insecticides and Repellents, Antiplatyhelmintic Agents, Antiprotozoals, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Substrates, Enzyme Inhibitors, Heterocyclic Compounds, Fused-Ring, OCT2 Inhibitors, P-glycoprotein inhibitors"," DNA,  85/88 kDa calcium-independent phospholipase A2,  Cytosolic phospholipase A2,  Inactive phospholipase C-like protein 1,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Histamine N-methyltransferase,  Solute carrier family 22 member 2,  P-glycoprotein 1","DB01103, DB02240, DB00608, DB01611",
DB01104,Sertraline,approved,CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12,C17H17Cl2N,,"Agents that reduce seizure threshold, Amines, Antidepressive Agents, Antidepressive Agents Indicated for Depression, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (strength unknown), Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (moderate), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs causing inadvertant photosensitivity, Hypoglycemia-Associated Agents, Membrane Transport Modulators, Monoamine Oxidase A Substrates, Naphthalenes, Nervous System, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, P-glycoprotein inhibitors, Photosensitizing Agents, Psychoanaleptics, Psychotropic Drugs, Selective Serotonin Reuptake Inhibitors, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin Modulators"," Sodium-dependent serotonin transporter,  Sodium-dependent dopamine transporter,  Sigma receptor (Protein Group),  Sodium-dependent noradrenaline transporter,  Equilibrative nucleoside transporter 4,  Cytochrome P450 3A4,  Cytochrome P450 2D6,  Cytochrome P450 2C19,  Cytochrome P450 2C9,  Cytochrome P450 2B6,  Amine oxidase [flavin-containing] B,  Amine oxidase [flavin-containing] A,  CYP2B protein,  Cytochrome P450 2E1,  Serum albumin,  P-glycoprotein 1","DB01104, DB12305, DB14071, DB17032",
DB01105,Sibutramine,approved; illicit; investigational; withdrawn,CC(C)CC(N(C)C)C1(CCC1)C1=CC=C(Cl)C=C1,C17H26ClN,,"Agents producing tachycardia, Alimentary Tract and Metabolism, Anti-Obesity Agents, Antidepressive Agents, Antiobesity Preparations, Excl. Diet Products, Appetite Depressants, Appetite Suppression, Central Nervous System Agents, Central Nervous System Depressants, Centrally Acting Antiobesity Products, Combined Inhibitors of Serotonin/Norepinephrine Reuptake, Cycloparaffins, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Dopamine Uptake Inhibitors, Drugs that are Mainly Renally Excreted, Norepinephrine Uptake Inhibitors, Norepinephrine, Serotonin, and Dopamine Reuptake Inhibitor Anorectic, Psychotropic Drugs, Selective Serotonin Reuptake Inhibitors, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin and Noradrenaline Reuptake Inhibitors, Serotonin Modulators, Stimulants"," Sodium-dependent dopamine transporter,  Sodium-dependent serotonin transporter,  Sodium-dependent noradrenaline transporter,  Cytochrome P450 3A4",DB01105,
DB01106,Levocabastine,approved; investigational,C[C@@H]1CN(CC[C@]1(C(O)=O)C1=CC=CC=C1)[C@H]1CC[C@](CC1)(C#N)C1=CC=C(F)C=C1,C26H29FN2O2,,"Anti-Allergic Agents, Antiallergic Agents, Excl. Corticosteroids, Central Nervous System Depressants, Decongestants and Antiallergics, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Histamine H1 Antagonists, Non-Sedating, Nasal Preparations, Neurotransmitter Agents, Ophthalmologicals, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Sensory Organs"," Histamine H1 receptor,  Neurotensin receptor type 2",DB01106,
DB01107,Methyprylon,approved; illicit; withdrawn,CCC1(CC)C(=O)NCC(C)C1=O,C10H17NO2,,"Central Nervous System Depressants, Hypnotics and Sedatives, Nervous System, Piperidinedione Derivatives, Piperidines, Psycholeptics"," GABA(A) Receptor (Protein Group),  Gamma-aminobutyric acid receptor subunit alpha-1","DB01107, DB13224",
DB01108,Trilostane,approved; investigational; vet_approved; withdrawn,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N,C20H27NO3,,"Abortifacient Agents, Abortifacient Agents, Steroidal, Adrenal Cortex Hormones, Androstanes, Androstanols, Antiadrenal Preparations, Anticorticosteroids, Antineoplastic Agents, Corticosteroids, Corticosteroids for Systemic Use, Enzyme Inhibitors, Fused-Ring Compounds, Gonadal Hormones, Gonadal Steroid Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Immunosuppressive Agents, Narrow Therapeutic Index Drugs, Oxidative Phosphorylation Coupling Factors, Reproductive Control Agents, Steroids, Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins, Testosterone Congeners"," 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1,  3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2,  Estrogen receptor alpha,  Estrogen receptor beta",DB01108,
DB01109,Heparin,approved; investigational,,,,"Agents causing hyperkalemia, Anticoagulants, Antivaricose Therapy, Blood and Blood Forming Organs, Carbohydrates, Cardiovascular Agents, Fibrin Modulating Agents, Glycosaminoglycans, Hematologic Agents, Heparin and similars, Heparin Group, Heparins or Heparinoids for Topical Use, Miscellaneous Therapeutic Agents, Narrow Therapeutic Index Drugs, Ophthalmologicals, Polysaccharides, Sensory Organs, Thyroxine-binding globulin substrates, Vasoprotectives"," Antithrombin-III,  Coagulation factor X,  P-selectin,  Fibroblast growth factor receptor 4,  Fibroblast growth factor 4,  Fibroblast growth factor 19,  Fibroblast growth factor receptor 1,  Fibroblast growth factor 1,  Fibroblast growth factor receptor 2, 10. Fibroblast growth factor 2, 11. Platelet factor 4, 12. Hepatocyte growth factor,  Heparanase",,
DB01110,Miconazole,approved; investigational; vet_approved,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1,C18H14Cl4N2O,,"14-alpha Demethylase Inhibitors, Anti-Infective Agents, Antifungal Agents, Antifungal Agents (Vaginal), Antifungals for Dermatological Use, Antifungals for Topical Use, Antiinfectives and Antiseptics for Local Oral Treatment, Azole Antifungals, Chemically-Induced Disorders, Cytochrome P-450 CYP2A6 Inhibitors, Cytochrome P-450 CYP2A6 Inhibitors (strong), Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (strength unknown), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (strength unknown), Cytochrome P-450 CYP2C19 Inhibitors (strong), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (moderate), Cytochrome P-450 CYP2C9 Inhibitors (strong), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strong), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (moderate), Cytochrome P-450 Enzyme Inhibitors, Dermatologicals, Enzyme Inhibitors, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Hormone Antagonists, Hormones, Hormone Substitutes, and Hormone Antagonists, Imidazole and Triazole Derivatives, Imidazole Derivatives, Imidazoles, Intestinal Antiinfectives, Otologicals, P-glycoprotein inhibitors, Sensory Organs, Steroid Synthesis Inhibitors, Stomatological Preparations, Vaginal Creams, Foams, and Jellies"," Cytochrome P450 51,  Nitric oxide synthase, endothelial,  Nitric oxide synthase, inducible,  Nuclear receptor subfamily 1 group I member 2,  Calcium-activated potassium channel (Protein Group),  Voltage-gated Potassium Channels (Protein Group),  Inward rectifier potassium channel (Protein Group),  Voltage gated L-type calcium channel (Protein Group),  Cytochrome P450 2C9,  Cytochrome P450 2C19,  Cytochrome P450 2A6,  Cytochrome P450 2E1,  Cytochrome P450 3A4,  Cytochrome P450 2B6,  Cytochrome P450 2D6,  Cytochrome P450 2C8,  Cytochrome P450 11B1, mitochondrial, 10. Lanosterol 14-alpha demethylase, 11. Cytochrome P450 19A1,  Serum albumin,  P-glycoprotein 1","DB01110, DB08943, DB01127, DB07705, DB11985, DB13434, DB01007, DB01153",
DB01111,Colistimethate,approved; vet_approved,CCC(C)CCCCC(=O)NC(CCNCS([O-])(=O)=O)C(=O)NC(C(C)O)C(=O)NC(CCNCS([O-])(=O)=O)C(=O)NC1CCNC(=O)C(NC(=O)C(CCNCS([O-])(=O)=O)NC(=O)C(CCNCS([O-])(=O)=O)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCNCS([O-])(=O)=O)NC1=O)C(C)O,C58H105N16O28S5,,"Agents that produce neuromuscular block (indirect), Amino Acids, Peptides, and Proteins, Antimicrobial Cationic Peptides, Antimicrobial Peptides, Lipids, Lipopeptides, Membrane Proteins, Nephrotoxic agents, Peptides, Peptides, Cyclic, Polymyxin-class Antibacterial, Polymyxins, Pore Forming Cytotoxic Proteins, Proteins",,"DB01111, DB00803",
DB01112,Cefuroxime,approved,[H][C@]12SCC(COC(N)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CC=CO1)C(O)=O,C16H16N4O8S,,"Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, beta-Lactams, Cephalosporins, Heterocyclic Compounds, Fused-Ring, Lactams, Nephrotoxic agents, Ophthalmologicals, Second-Generation Cephalosporins, Sensory Organs, Sulfur Compounds, Thiazines"," Penicillin-binding protein 1A,  Solute carrier family 15 member 1,  Solute carrier family 15 member 2","DB01112, DB13461, DB00456, DB00493, DB00689, DB01331, DB01414, DB01416, DB03313, DB11505, DB01139, DB13504, DB11485, DB01212, DB00671, DB01413, DB00535, DB00267, DB00567, DB11592, DB01140, DB14879, DB00438, DB01150, DB09050, DB01066, DB14725, DB01326, DB03938, DB01333",
DB01113,Papaverine,approved; investigational,COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1,C20H21NO4,,"Alimentary Tract and Metabolism, Alkaloids, Benzylisoquinolines, Cardiovascular Agents, Drugs for Functional Gastrointestinal Disorders, Drugs Used in Erectile Dysfunction, Enzyme Inhibitors, Genito Urinary System and Sex Hormones, Genitourinary Agents, Heterocyclic Compounds, Fused-Ring, Hypotensive Agents, Isoquinolines, Miscellaneous Vasodilatating Agents, Moderate Risk QTc-Prolonging Agents, Opiate Alkaloids, Papaverine and Derivatives, Phosphodiesterase Inhibitors, QTc Prolonging Agents, Urological Agents, Urologicals, Vasodilating Agents"," cAMP-specific 3',5'-cyclic phosphodiesterase 4B,  cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A,  Phosphodiesterase enzymes (Protein Group)","DB01113, DB12251",
DB01114,Chlorpheniramine,approved,CN(C)CCC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1,C16H19ClN2,,"Anti-Allergic Agents, Antidepressive Agents, Antihistamines for Systemic Use, Antipruritics, Central Nervous System Depressants, Combined Inhibitors of Serotonin/Norepinephrine Reuptake, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dermatologicals, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Moderate Risk QTc-Prolonging Agents, Neurotransmitter Agents, OCT1 inhibitors, OCT2 Inhibitors, Propylamine Derivatives, Pyridines, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin Modulators, Substituted Alkylamines"," Histamine H1 receptor,  Sodium-dependent serotonin transporter,  Sodium-dependent noradrenaline transporter,  Sodium-dependent dopamine transporter,  Cytochrome P450 3A4,  Cytochrome P450 2D6,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  Solute carrier family 22 member 2,  Solute carrier family 22 member 1","DB01114, DB13679, DB09555, DB01620, DB00405, DB00835, DB00280",
DB01115,Nifedipine,approved,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC,C17H18N2O6,,"Agents causing hyperkalemia, Antiarrhythmic agents, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Beta blocking agents and calcium channel blockers, Bradycardia-Causing Agents, BSEP/ABCB11 Inhibitors, BSEP/ABCB11 Substrates, Calcium Channel Blockers, Calcium Channel Blockers (Dihydropyridine), Calcium Channel Blockers and Diuretics, Calcium-Regulating Hormones and Agents, Cardiovascular Agents, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2A6 Substrates, Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strength unknown), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Inducers, Cytochrome P-450 CYP2C9 Inducers (strength unknown), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dihydropyridine Derivatives, Dihydropyridines, Drugs that are Mainly Renally Excreted, Hypotensive Agents, Membrane Transport Modulators, Moderate Risk QTc-Prolonging Agents, Negative Inotrope, OATP1B1/SLCO1B1 Inhibitors, P-glycoprotein inducers, P-glycoprotein inhibitors, P-glycoprotein substrates, Pyridines, QTc Prolonging Agents, Reproductive Control Agents, Selective Calcium Channel Blockers With Mainly Vascular Effects, Tocolytic Agents, Vasodilating Agents"," Voltage-dependent L-type calcium channel subunit alpha-1C,  Voltage-dependent L-type calcium channel subunit alpha-1D,  Voltage-dependent L-type calcium channel subunit beta-2,  Nuclear receptor subfamily 1 group I member 2,  Calmodulin,  Voltage-dependent L-type calcium channel subunit alpha-1S,  Potassium voltage-gated channel subfamily D member 3,  Voltage-dependent T-type calcium channel (Protein Group),  Cytochrome P450 3A4,  Cytochrome P450 2D6,  Cytochrome P450 1A2,  Cytochrome P450 2A6,  Cytochrome P450 2C8,  Cytochrome P450 1A1,  Cytochrome P450 2B6,  Cytochrome P450 2E1,  Cytochrome P450 2C9, 10. Cytochrome P450 3A5,  Serum albumin,  alpha1-acid glycoprotein (Protein Group),  Canalicular multispecific organic anion transporter 2,  P-glycoprotein 1,  Canalicular multispecific organic anion transporter 1,  Solute carrier organic anion transporter family member 1B1,  Bile salt export pump","DB01115, DB00401, DB09229, DB01054, DB09240, DB00393, DB06712, DB09239, DB14068, DB09232, DB00622, DB01023",
DB01116,Trimethaphan,approved; investigational,O=C1N(CC2=CC=CC=C2)C2C[S+]3CCCC3C2N1CC1=CC=CC=C1,C22H25N2OS,,"Adjuvants, Anesthesia, Antiadrenergic Agents, Ganglion-Blocking, Anticholinergic Agents, Antihypertensive Agents, Autonomic Agents, Cardiovascular Agents, Central Nervous System Agents, Cholinergic Agents, Cholinesterase substrates, Ganglion Blockers, Imidazoles, Neurotransmitter Agents, Nicotinic Antagonists, Peripheral Nervous System Agents, Sulfonium Derivatives, Vasodilating Agents"," Neuronal acetylcholine receptor subunit alpha-10,  Cholinesterase",DB01116,
DB01117,Atovaquone,approved,OC1=C([C@H]2CC[C@@H](CC2)C2=CC=C(Cl)C=C2)C(=O)C2=CC=CC=C2C1=O,C22H19ClO3,,"Anti-Infective Agents, Antibiotics for Pneumocystis Pneumonia, Antimalarials, Antiparasitic Agents, Antiparasitic Products, Insecticides and Repellents, Antiprotozoals, Biguanides, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Enzyme Inhibitors, Miscellaneous Antiprotozoals, Naphthalenes, Naphthoquinones, P-glycoprotein inhibitors, Quinones"," Cytochrome b,  Dihydroorotate dehydrogenase (quinone), mitochondrial,  Dihydroorotate dehydrogenase (quinone), mitochondrial,  Cytochrome P450 2C9,  Cytochrome P450 3A4,  P-glycoprotein 1","DB01117, DB06740",
DB01118,Amiodarone,approved; investigational,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2,C25H29I2NO3,,"Agents causing hyperkalemia, Agents Causing Muscle Toxicity, alpha-Galactosidase, antagonists & inhibitors, Antiarrhythmic agents, Antiarrhythmics, Class III, Benzofurans, Bradycardia-Causing Agents, BSEP/ABCB11 Inhibitors, BSEP/ABCB11 Substrates, BSEP/ABCB11 Substrates with a Narrow Therapeutic Index, Calcium Channel Blockers, Cardiac Therapy, Cardiovascular Agents, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 CYP1A2 Inhibitors (strong), Cytochrome P-450 CYP2A6 Inhibitors, Cytochrome P-450 CYP2A6 Inhibitors (moderate), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (strength unknown), Cytochrome P-450 CYP2C19 Inhibitors (weak), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (moderate), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Inhibitors (strong), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs causing inadvertant photosensitivity, Enzyme Inhibitors, Heterocyclic Compounds, Fused-Ring, Highest Risk QTc-Prolonging Agents, Hypotensive Agents, Membrane Transport Modulators, Narrow Therapeutic Index Drugs, OCT2 Inhibitors, P-glycoprotein inducers, P-glycoprotein inhibitors, Photosensitizing Agents, Potassium Channel Blockers, QTc Prolonging Agents, Sodium Channel Blockers, Vasodilating Agents"," HERG human cardiac K+ channel (Protein Group),  Beta adrenergic receptor (Protein Group),  Voltage-dependent T-type calcium channel subunit alpha-1I,  Voltage gated L-type calcium channel (Protein Group),  Thyroid hormone receptor (Protein Group),  Peroxisome proliferator-activated receptor gamma,  Peroxisome proliferator-activated receptor alpha,  Peroxisome proliferator-activated receptor gamma coactivator 1-beta,  Cytochrome P450 3A4,  Cytochrome P450 2C8,  Cytochrome P450 2D6,  Cytochrome P450 2C9,  Cytochrome P450 1A2,  Cytochrome P450 2C19,  Cytochrome P450 1A1,  Cytochrome P450 2A6,  Cytochrome P450 2J2,  Serum albumin,  P-glycoprotein 1,  Bile salt export pump,  Solute carrier family 22 member 2","DB01118, DB05519, DB13277, DB16012, DB04855",
DB01119,Diazoxide,approved,CC1=NS(=O)(=O)C2=C(N1)C=CC(Cl)=C2,C8H7ClN2O2S,,"Antihypertensive Agents, Arteriolar Smooth Muscle, Agents Acting On, Benzothiadiazines, Cardiovascular Agents, Direct Vasodilators, Heterocyclic Compounds, Fused-Ring, Hyperglycemia-Associated Agents, Hypoglycemia-Treating Agents, Hypotensive Agents, Potassium Channel Opener, Sulfonamides, Sulfones, Sulfur Compounds, Thiazide Derivatives, Vasodilating Agents"," ATP-sensitive inward rectifier potassium channel 11,  Mitochondrial ATP synthase F1 domain (Protein Group),  Serum albumin",DB01119,
DB01120,Gliclazide,approved,[H][C@@]12CCC[C@]1([H])CN(C2)NC(=O)NS(=O)(=O)C1=CC=C(C)C=C1,C15H21N3O3S,,"Alimentary Tract and Metabolism, Amides, Benzene Derivatives, Benzenesulfonamides, Blood Glucose Lowering Agents, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 Substrates, Drugs Used in Diabetes, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Hypoglycemia-Associated Agents, Insulin Secretagogues, Oral Hypoglycemics, Sulfonamides, Sulfones, Sulfonylureas, Sulfur Compounds"," ATP-binding cassette sub-family C member 8,  Vascular endothelial growth factor A,  Cytochrome P450 2C9,  Cytochrome P450 2C19,  Serum albumin","DB01120, DB00839",
DB01121,Phenacemide,approved,NC(=O)NC(=O)CC1=CC=CC=C1,C9H10N2O2,,"Acetamides, Amides, Anticonvulsants, Benzene Derivatives, Central Nervous System Depressants, Nervous System", Sodium channel protein type 1 subunit alpha,"DB01121, DB13362",
DB01122,Ambenonium,approved,CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=CC=CC=C1Cl)CC1=CC=CC=C1Cl,C28H42Cl2N4O2,,"Amines, Autonomic Agents, Benzylammonium Compounds, Cholinergic Agents, Cholinesterase Inhibitors, Enzyme Inhibitors, Nervous System, Neurotransmitter Agents, Onium Compounds, Parasympathomimetics, Peripheral Nervous System Agents, Quaternary Ammonium Compounds"," Acetylcholinesterase,  Cholinesterase",DB01122,
DB01123,Proflavine,approved,NC1=CC2=NC3=C(C=CC(N)=C3)C=C2C=C1,C13H11N3,,"Acridines, Aminoacridines, Anti-Infective Agents, Anti-Infective Agents, Local, Heterocyclic Compounds, Fused-Ring"," DNA,  Prothrombin,  HTH-type transcriptional regulator QacR,  TetR family transcriptional repressor LfrR","DB01123, DB11561, DB13326, DB13373",
DB01124,Tolbutamide,approved; investigational,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1,C12H18N2O3S,,"Alimentary Tract and Metabolism, Amides, Benzene Derivatives, Benzenesulfonamides, Blood Glucose Lowering Agents, Cytochrome P-450 CYP2C18 Substrates, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Diagnostic Agents, Drugs that are Mainly Renally Excreted, Drugs Used in Diabetes, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Hypoglycemia-Associated Agents, Insulin Secretagogues, OAT1/SLC22A6 inhibitors, OATP2B1/SLCO2B1 substrates, Oral Hypoglycemics, Sulfonamides, Sulfones, Sulfonylureas, Sulfur Compounds, Tests for Diabetes"," ATP-binding cassette sub-family C member 8,  ATP-sensitive inward rectifier potassium channel 1,  Cytochrome P450 2C9,  Cytochrome P450 2C8,  Cytochrome P450 2C19,  Cytochrome P450 2C18,  Serum albumin,  Solute carrier family 15 member 1,  Solute carrier organic anion transporter family member 1A2,  Solute carrier family 22 member 6,  Solute carrier family 15 member 2,  Solute carrier organic anion transporter family member 2B1","DB01124, DB00414, DB13406, DB13675, DB00672, DB08484",
DB01125,Anisindione,approved,COC1=CC=C(C=C1)C1C(=O)C2=CC=CC=C2C1=O,C16H12O3,,"Indans, Indenes", Vitamin K-dependent gamma-carboxylase,"DB01125, DB00498, DB13136, DB13275",
DB01126,Dutasteride,approved; investigational,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])NC(=O)C=C[C@]4(C)[C@@]3([H])CC[C@]12C)C(=O)NC1=CC(=CC=C1C(F)(F)F)C(F)(F)F,C27H30F6N2O2,,"5-alpha Reductase Inhibitors, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Agents that produce hypertension, Azasteroids, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Substrates, Drugs Used in Benign Prostatic Hypertrophy, Enzyme Inhibitors, Fused-Ring Compounds, Genito Urinary System and Sex Hormones, Hormone Antagonists, Hormones, Hormone Substitutes, and Hormone Antagonists, Steroid Synthesis Inhibitors, Steroids, Urologicals"," 3-oxo-5-alpha-steroid 4-dehydrogenase 1,  3-oxo-5-alpha-steroid 4-dehydrogenase 2,  Cytochrome P450 3A5,  Serum albumin,  Alpha-1-acid glycoprotein 1,  Sodium-dependent dopamine transporter,  Synaptic vesicular amine transporter",DB01126,
DB01127,Econazole,approved,ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1,C18H15Cl3N2O,,"14-alpha Demethylase Inhibitors, Anti-Infective Agents, Antifungal Agents, Antifungal Agents (Vaginal), Antifungals for Dermatological Use, Antifungals for Topical Use, Azole Antifungals, Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strong), Cytochrome P-450 Enzyme Inhibitors, Dermatologicals, Enzyme Inhibitors, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Hormone Antagonists, Hormones, Hormone Substitutes, and Hormone Antagonists, Imidazole and Triazole Derivatives, Imidazole Derivatives, Imidazoles, P-glycoprotein inhibitors, Steroid Synthesis Inhibitors"," Cytochrome P450 51,  Nuclear receptor subfamily 1 group I member 2,  Cytochrome P450 19A1,  Cytochrome P450 2E1,  Cytochrome P450 3A4","DB01127, DB07705, DB01110, DB08943, DB11985, DB13434, DB01007, DB01153",
DB01128,Bicalutamide,approved,CC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC1=CC(=C(C=C1)C#N)C(F)(F)F,C18H14F4N2O4S,,"Amides, Amines, Androgen Receptor Antagonists, Androgen Receptor Inhibitors, Aniline Compounds, Antiandrogens, Antiandrogens, non-steroidal, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Benzene Derivatives, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Inhibitors (weak), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Endocrine Therapy, Hormone Antagonists, Hormone Antagonists and Related Agents, Hormones and Related Agents, Hormones, Hormone Substitutes, and Hormone Antagonists, Narrow Therapeutic Index Drugs, P-glycoprotein inhibitors, Sulfones, Sulfur Compounds"," Androgen receptor,  Cytochrome P450 2C19,  Cytochrome P450 2C9,  Cytochrome P450 2D6,  Cytochrome P450 3A4,  P-glycoprotein 1","DB01128, DB02932",
DB01129,Rabeprazole,approved; investigational,COCCCOC1=C(C)C(CS(=O)C2=NC3=CC=CC=C3N2)=NC=C1,C18H21N3O3S,,"2-Pyridinylmethylsulfinylbenzimidazoles, Acetates, Acid Reducers, Acids, Acyclic, Alimentary Tract and Metabolism, Anti-Ulcer Agents, Antiinflammatory and Antirheumatic Products, Antiinflammatory and Antirheumatic Products, Non-Steroids, Antiinflammatory Preparations, Non-Steroids for Topical Use, BCRP/ABCG2 Inhibitors, Benzimidazoles, Butylpyrazolidines, Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP1A2 Inducers (strength unknown), Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (strength unknown), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (moderate), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord), Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Gastric Acid Lowering Agents, Gastrointestinal Agents, Heterocyclic Compounds, Fused-Ring, Hydroxy Acids, Musculo-Skeletal System, Proton Pump Inhibitors, Proton-pump Inhibitors, Pyrazoles, Pyrazolones, Pyridines, Sulfoxides, Sulfur Compounds, Topical Products for Joint and Muscular Pain"," Potassium-transporting ATPase alpha chain 1,  Cytochrome P450 1A1,  Cytochrome P450 1A2,  Cytochrome P450 2C9,  Cytochrome P450 2D6,  Cytochrome P450 2C8,  Cytochrome P450 3A4,  Cytochrome P450 2C19,  ATP-binding cassette sub-family G member 2","DB01129, DB13762, DB00448, DB05351, DB17144, DB00338, DB00736, DB11964",
DB01130,Prednicarbate,approved; investigational,[H][C@@]12CC[C@](OC(=O)OCC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,C27H36O8,,"Adrenal Cortex Hormones, Anti-Inflammatory Agents, Corticosteroid Hormone Receptor Agonists, Corticosteroids, Corticosteroids, Dermatological Preparations, Corticosteroids, Potent (Group III), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Substrates, Dermatologicals, Fused-Ring Compounds, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Immunosuppressive Agents, Pregnadienes, Pregnadienetriols, Pregnanes, Steroids"," Glucocorticoid receptor,  Cytochrome P450 3A4","DB01130, DB01410, DB14643, DB14633, DB14644, DB14632, DB15999, DB15566, DB01222, DB01260, DB00288, DB14662, DB00394, DB14221, DB14538, DB14596, DB14543, DB14640, DB14649, DB18737, DB14540, DB14544, DB01047, DB14625, DB14646, DB14545, DB06781, DB14541, DB00180, DB14657",
DB01131,Proguanil,approved,CC(C)NC(=N)NC(=N)NC1=CC=C(Cl)C=C1,C11H16ClN5,,"Amidines, Anti-Infective Agents, Antimalarials, Antimetabolites, Antiparasitic Agents, Antiparasitic Products, Insecticides and Repellents, Antiprotozoals, Biguanides, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Folic Acid Antagonists, Guanidines, Noxae, Toxic Actions"," Dihydrofolate reductase,  Bifunctional dihydrofolate reductase-thymidylate synthase,  Cytochrome P450 2C9,  Cytochrome P450 2C19,  Cytochrome P450 2D6","DB01131, DB12314, DB00878, DB13607",
DB01132,Pioglitazone,approved; investigational,CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1,C19H20N2O3S,,"Alimentary Tract and Metabolism, Blood Glucose Lowering Agents, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (moderate), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs Used in Diabetes, Hypoglycemia-Associated Agents, OATP1B1/SLCO1B1 Inhibitors, OATP1B3 inhibitors, Oral Hypoglycemics, Peroxisome Proliferator Receptor gamma Agonist, Peroxisome Proliferator-activated Receptor Activity, Sulfur Compounds, Thiazoles, Thiazolidinediones"," Peroxisome proliferator-activated receptor gamma,  Amine oxidase [flavin-containing] B,  Cytochrome P450 1A1,  Cytochrome P450 2C8,  Cytochrome P450 3A4,  Serum albumin,  Solute carrier organic anion transporter family member 1B3,  Solute carrier organic anion transporter family member 1B1","DB01132, DB15021, DB11721, DB16028, DB09201",
DB01133,Tiludronic acid,approved; investigational; vet_approved,OP(O)(=O)C(SC1=CC=C(Cl)C=C1)P(O)(O)=O,C7H9ClO6P2S,,"Bisphosphonates, Bone Density Conservation Agents, Drugs Affecting Bone Structure and Mineralization, Drugs for Treatment of Bone Diseases, Drugs that are Mainly Renally Excreted, Musculo-Skeletal System, Organophosphonates, Organophosphorus Compounds, Phospholipases A, antagonists & inhibitors"," Hydroxylapatite,  Adenosine triphosphate (ATP),  Tyrosine-protein phosphatase non-receptor type 12,  Tyrosine-protein phosphatase non-receptor type 6,  Receptor-type tyrosine-protein phosphatase epsilon,  V-ATPase Subunits (Protein Group),  Serum albumin",DB01133,
DB01134,Desoxycorticosterone pivalate,experimental; vet_approved,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)C(=O)COC(=O)C(C)(C)C,C26H38O4,,"Adrenal Cortex Hormones, Corticosteroids, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Fused-Ring Compounds, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hydroxycorticosteroids, Pregnanes, Pregnenediones, Pregnenes, Steroids"," Mineralocorticoid receptor,  Cytochrome P450 3A4","DB01134, DB06780, DB06789, DB14677, DB12499, DB00603, DB11440, DB01420, DB08804, DB13943, DB13944, DB13946, DB16001, DB16002, DB16141, DB14541, DB13958, DB14583, DB14540, DB01380, DB08308, DB08619, DB14538, DB14544, DB14545, DB14543, DB14539, DB01395, DB13185, DB13640",
DB01135,Doxacurium,approved,COC1=CC(CC2C3=C(OC)C(OC)=C(OC)C=C3CC[N+]2(C)CCCOC(=O)CCC(=O)OCCC[N+]2(C)CCC3=CC(OC)=C(OC)C(OC)=C3C2CC2=CC(OC)=C(OC)C(OC)=C2)=CC(OC)=C1OC,C56H78N2O16,,"Anticholinergic Agents, Central Nervous System Depressants, Cholinesterase substrates, Drugs that are Mainly Renally Excreted, Heterocyclic Compounds, Fused-Ring, Muscarinic Antagonists, Muscle Relaxants, Muscle Relaxants, Peripherally Acting Agents, Musculo-Skeletal System, Neuromuscular Agents, Neuromuscular Blocking Agents, Neuromuscular-Blocking Agents (Nondepolarizing), Nicotinic Antagonists, Peripheral Nervous System Agents"," Neuronal acetylcholine receptor subunit alpha-2,  Muscarinic acetylcholine receptor M2,  Cholinesterase","DB01135, DB01226, DB00565, DB00732, DB01199, DB01336, DB00416, DB12093, DB05710, DB14066, DB18146, DB16824, DB13692, DB11915, DB00767",
DB01136,Carvedilol,approved; investigational,COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2,C24H26N2O4,,"Adrenergic Agents, Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Adrenergic beta-1 Receptor Antagonists, Adrenergic beta-Antagonists, Adrenergic beta2-Antagonists, Agents causing hyperkalemia, Alcohols, Alpha and Beta Blocking Agents, Amines, Amino Alcohols, Antiarrhythmic agents, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Antioxidants, Biological Factors, Bradycardia-Causing Agents, Calcium Channel Blockers, Calcium-Regulating Hormones and Agents, Carbazoles, Cardiovascular Agents, Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Heterocyclic Compounds, Fused-Ring, Hypotensive Agents, Indoles, Membrane Transport Modulators, Negative Inotrope, Neurotransmitter Agents, P-glycoprotein inhibitors, Propanolamines, Propanols, Protective Agents, UGT1A1 Substrates, UGT2B7 substrates, Vasodilating Agents"," Beta-1 adrenergic receptor,  Alpha-1A adrenergic receptor,  Alpha-1 adrenergic receptors (Protein Group),  NADH dehydrogenase [ubiquinone] 1 subunit C2,  Beta-2 adrenergic receptor,  Vascular endothelial growth factor A,  Natriuretic peptides B,  Gap junction alpha-1 protein,  Potassium voltage-gated channel subfamily H member 2, 10. Vascular cell adhesion protein 1, 11. Alpha-1D adrenergic receptor, 12. Alpha-1B adrenergic receptor, 13. Alpha-2C adrenergic receptor, 14. Alpha-2B adrenergic receptor, 15. Alpha-2A adrenergic receptor, 16. E-selectin, 17. Hypoxia-inducible factor 1-alpha, 18. Inward rectifier potassium channel 4, 19. Inward rectifier potassium channel 2,  Cytochrome P450 1A2,  Cytochrome P450 3A4,  Cytochrome P450 1A1,  Cytochrome P450 2E1,  UDP-glucuronosyltransferase 1-1,  UDP-glucuronosyltransferase 2B4,  UDP-glucuronosyltransferase 2B7,  Cytochrome P450 2C9,  Cytochrome P450 2D6, 10. Xanthine dehydrogenase/oxidase,  Serum albumin,  P-glycoprotein 1","DB01136, DB07543, DB00960, DB13530",
DB01137,Levofloxacin,approved; investigational,C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1,C18H20FN3O4,,"Alimentary Tract and Metabolism, Anti-Bacterial Agents, Anti-Infective Agents, Anti-Infective Agents, Urinary, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Drugs causing inadvertant photosensitivity, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Fluoroquinolone Antibacterial, Fluoroquinolones, Heterocyclic Compounds, Fused-Ring, MATE 1 Inhibitors, MATE 1 Substrates, MATE 2 Inhibitors, MATE inhibitors, MATE substrates, Moderate Risk QTc-Prolonging Agents, OAT1/SLC22A6 Substrates, OCT1 inhibitors, OCT2 Inhibitors, Ophthalmologicals, P-glycoprotein inhibitors, P-glycoprotein substrates, Photosensitizing Agents, QTc Prolonging Agents, Quinolines, Quinolone Antimicrobial, Quinolones, Renal Agents, Sensory Organs, Topoisomerase II Inhibitors, Topoisomerase Inhibitors"," DNA gyrase subunit A,  DNA topoisomerase 4 subunit A,  Cytochrome P450 2C9,  Serum albumin,  P-glycoprotein 1,  Multidrug and toxin extrusion protein 1,  Multidrug and toxin extrusion protein 2,  Solute carrier family 22 member 1,  Solute carrier family 22 member 2,  Solute carrier family 22 member 4,  Solute carrier organic anion transporter family member 1A2,  Solute carrier organic anion transporter family member 4C1","DB01137, DB01165, DB03034, DB01044, DB00218, DB11774, DB06600, DB00978, DB11426, DB11404, DB01208, DB04576, DB00537, DB00487, DB01059, DB11393, DB11443, DB11847, DB00365, DB11453, DB09047, DB01405, DB11511, DB11491, DB12447, DB16219, DB13772, DB11892, DB13261",
DB01138,Sulfinpyrazone,approved,O=C1C(CCS(=O)C2=CC=CC=C2)C(=O)N(N1C1=CC=CC=C1)C1=CC=CC=C1,C23H20N2O3S,,"Antigout Preparations, Antiplatelet agents, BSEP/ABCB11 Substrates, Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strength unknown), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (moderate), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Musculo-Skeletal System, Preparations Increasing Uric Acid Excretion, Pyrazoles, Pyrazolones, Uricosuric Agents"," Solute carrier family 22 member 12,  Multidrug resistance-associated protein 1,  Canalicular multispecific organic anion transporter 1,  Nuclear receptor subfamily 1 group I member 2,  Cytochrome P450 2C9,  Cytochrome P450 3A4,  Cytochrome P450 2B6,  Cytochrome P450 2C8,  Fatty acid-binding protein, intestinal,  Canalicular multispecific organic anion transporter 2,  Multidrug resistance-associated protein 4,  Multidrug resistance-associated protein 5,  Multidrug resistance-associated protein 6,  Multidrug resistance-associated protein 1,  Canalicular multispecific organic anion transporter 1,  Bile salt export pump","DB01138, DB00812",
DB01139,Cefapirin,approved; vet_approved,[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)CSC1=CC=NC=C1)C(O)=O,C17H17N3O6S2,,"Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, beta-Lactams, Cephalosporins, First-Generation Cephalosporins, Heterocyclic Compounds, Fused-Ring, Lactams, Nephrotoxic agents, Sulfur Compounds, Thiazines", Penicillin-binding protein 1A,"DB01139, DB01414, DB03313, DB00689, DB00456, DB03938, DB00567, DB00493, DB13461, DB01140, DB01112, DB01333, DB01416, DB01331, DB09008, DB01150, DB14107, DB11385, DB11505, DB00535, DB13778, DB13504, DB00833, DB01326, DB11592, DB13499, DB13821, DB01327, DB09062, DB00274",
DB01140,Cefadroxil,approved; vet_approved; withdrawn,[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O,C16H17N3O5S,,"Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, beta-Lactams, Cephalosporins, Drugs that are Mainly Renally Excreted, First-Generation Cephalosporins, Heterocyclic Compounds, Fused-Ring, Lactams, Nephrotoxic agents, OAT1/SLC22A6 inhibitors, OAT3/SLC22A8 Inhibitors, Sulfur Compounds, Thiazines"," Penicillin-binding protein 3,  Penicillin-binding protein 1A,  Penicillin-binding protein 1b,  Penicillin-binding protein 2B,  Solute carrier family 15 member 1,  Solute carrier family 22 member 5,  Solute carrier family 22 member 6,  Solute carrier family 15 member 2,  Solute carrier family 22 member 8","DB01140, DB00567, DB01150, DB00689, DB00833, DB13266, DB01326, DB03938, DB01333, DB00923, DB01329, DB01414, DB00456, DB14725, DB14107, DB09008, DB03313, DB01328, DB01139, DB11592, DB00430, DB11385, DB00229, DB13499, DB13461, DB13504, DB00535, DB01112, DB11367, DB13821",
DB01141,Micafungin,approved; investigational,CCCCCOC1=CC=C(C=C1)C1=CC(=NO1)C1=CC=C(C=C1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC(OS(O)(=O)=O)=C(O)C=C1)[C@H](O)CC(N)=O,C56H71N9O23S,,"Amino Acids, Peptides, and Proteins, Anti-Infective Agents, Antifungal Agents, Antiinfectives for Systemic Use, Antimycotics for Systemic Use, COMT Substrates, Echinocandin Antifungal, Echinocandins, Lipids, Lipopeptides, Peptides, Peptides, Cyclic"," 1,3-beta-glucan synthase component FKS1,  Arylsulfatase A,  Catechol O-methyltransferase","DB01141, DB00362, DB05168",
DB01142,Doxepin,approved; investigational,[H]C(CCN(C)C)=C1C2=CC=CC=C2COC2=CC=CC=C12,C19H21NO,,"Acid Reducers, Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Agents producing tachycardia, Agents that produce hypertension, Agents that reduce seizure threshold, Anticholinergic Agents, Antidepressive Agents, Antidepressive Agents Indicated for Depression, Antidepressive Agents, Tricyclic, Antipruritics and Local Anesthetics, Antipruritics, Incl. Antihistamines, Anesthetics, Etc., Central Nervous System Agents, Central Nervous System Depressants, Combined Inhibitors of Serotonin/Norepinephrine Reuptake, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dermatologicals, Dibenzoxepins, Drugs that are Mainly Renally Excreted, Ethers, Cyclic, Heterocyclic Compounds, Fused-Ring, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Histamine H2 Antagonists, Hypnotics and Sedatives, Muscarinic Antagonists, Nervous System, Neurotoxic agents, Neurotransmitter Agents, Non-Selective Monoamine Reuptake Inhibitors, P-glycoprotein substrates, Potential QTc-Prolonging Agents, Psychoanaleptics, Psychotropic Drugs, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT1 Receptor Antagonists, Serotonin 5-HT1A Receptor Antagonists, Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2A Receptor Antagonists, Serotonin 5-HT2C Receptor Antagonists, Serotonin Agents, Serotonin Modulators, Serotonin Receptor Antagonists, Sleep Aids, Pharmaceutical, Tertiary amine tricyclic antidepressants, Tricyclics and Other Norepinephrine-reuptake Inhibitors"," Histamine H1 receptor,  Histamine H2 receptor,  Sodium-dependent noradrenaline transporter,  Sodium-dependent serotonin transporter,  5-hydroxytryptamine receptor 2A,  5-hydroxytryptamine receptor 2B,  5-hydroxytryptamine receptor 2C,  Muscarinic acetylcholine receptor M1,  Muscarinic acetylcholine receptor M2, 10. Muscarinic acetylcholine receptor M3, 11. Muscarinic acetylcholine receptor M4, 12. Muscarinic acetylcholine receptor M5, 13. Alpha-1A adrenergic receptor, 14. Alpha-1B adrenergic receptor, 15. Alpha-1D adrenergic receptor, 16. 5-hydroxytryptamine receptor 1A, 17. 5-hydroxytryptamine receptor 6, 18. Histamine H4 receptor, 19. Potassium voltage-gated channel subfamily H member 2,  Cytochrome P450 3A4,  Cytochrome P450 2D6,  Cytochrome P450 2C19,  Cytochrome P450 2C9,  Cytochrome P450 1A2,  Serum albumin,  Alpha-1-acid glycoprotein 1,  P-glycoprotein 1","DB01142, DB14750, DB00768",
DB01143,Amifostine,approved; investigational,NCCCNCCSP(O)(O)=O,C5H15N2O3PS,,"Compounds used in a research, industrial, or household setting, Cytoprotective Agent, Detoxifying Agents for Antineoplastic Treatment, Free Radical Scavenging Activity, Hypotensive Agents, Organophosphates, Organophosphorus Compounds, Organothiophosphates, Organothiophosphorus Compounds, Protective Agents, Radiation-Protective Agents, Sulfur Compounds"," Alkaline phosphatase, germ cell type,  Alkaline phosphatase, tissue-nonspecific isozyme",DB01143,
DB01144,Diclofenamide,approved; investigational,NS(=O)(=O)C1=CC(=C(Cl)C(Cl)=C1)S(N)(=O)=O,C6H6Cl2N2O4S2,,"Amides, Antiglaucoma Preparations and Miotics, Carbonic Anhydrase Inhibitors, Diuretics, Enzyme Inhibitors, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Hypotensive Agents, Ophthalmics, Ophthalmologicals, Sensory Organs, Sulfonamides, Sulfones, Sulfur Compounds"," Carbonic anhydrase 2,  Carbonic anhydrase 1,  Carbonic anhydrase 4,  Carbonic anhydrase 7,  Carbonic anhydrase 3","DB01144, DB13663",
DB01145,Sulfoxone,approved,OS(=O)CNC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(NCS(O)=O)C=C1,C14H16N2O6S3,,"Antiinfectives for Systemic Use, Antimycobacterials, Drugs for Treatment of Lepra, Sulfones, Sulfur Compounds", Dihydropteroate synthetase,DB01145,
DB01146,Diphenylpyraline,approved; investigational,CN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1,C19H23NO,,"Aminoalkyl Ethers, Antihistamines for Systemic Use, Histamine Antagonists, Histamine H1 Antagonists"," Histamine H1 receptor,  Sodium-dependent dopamine transporter","DB01146, DB00245, DB13468, DB07917, DB11742, DB00283",
DB01147,Cloxacillin,approved; investigational; vet_approved,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl)C(O)=O,C19H18ClN3O5S,,"Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Beta-Lactam Antibacterials, Beta-Lactamase Resistant Penicillins, beta-Lactams, Heterocyclic Compounds, Fused-Ring, Lactams, OAT1/SLC22A6 inhibitors, OAT3/SLC22A8 Inhibitors, OAT3/SLC22A8 Substrates, Penicillinase-resistant Penicillins, Penicillins, Sulfur Compounds"," D-alanyl-D-alanine carboxypeptidase DacA,  Penicillin-binding protein 2X,  Penicillin-binding protein 1A,  Serum albumin,  Solute carrier family 22 member 8,  Solute carrier family 15 member 1,  Solute carrier family 15 member 2","DB00485, DB01147, DB00301, DB00713, DB01061, DB00739, DB00319, DB09319, DB13836, DB00578, DB00948, DB13506, DB01603, DB01604, DB00415, DB00607, DB01607",
DB01148,Flavoxate,approved,CC1=C(OC2=C(C=CC=C2C(=O)OCCN2CCCCC2)C1=O)C1=CC=CC=C1,C24H25NO4,,"Agents producing tachycardia, Anticholinergic Agents, Autonomic Agents, Benzopyrans, Chromones, Drugs for Urinary Frequency and Incontinence, Drugs that are Mainly Renally Excreted, Flavones, Flavonoids, Genito Urinary System and Sex Hormones, Genitourinary Agents, Heterocyclic Compounds, Fused-Ring, Muscarinic Antagonists, Parasympatholytics, Peripheral Nervous System Agents, Pyrans, Urological Agents, Urologicals"," Muscarinic acetylcholine receptor M1,  Muscarinic acetylcholine receptor M2",DB01148,
DB01149,Nefazodone,approved; withdrawn,CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1,C25H32ClN5O2,,"Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Agents that produce hypertension, Analgesics, Antidepressive Agents, Antidepressive Agents Indicated for Depression, Antidepressive Agents, Second-Generation, Antidepressive Agents, Triazolopyridine, BSEP/ABCB11 Substrates, Central Nervous System Agents, Central Nervous System Depressants, Combined Inhibitors of Serotonin/Norepinephrine Reuptake, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strong), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Hypoglycemia-Associated Agents, Membrane Transport Modulators, Nervous System, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, OATP1B3 inhibitors, Organic Anion Transporting Polypeptide 2B1 Inhibitors, P-glycoprotein inducers, P-glycoprotein inhibitors, Psychoanaleptics, Psychotropic Drugs, Selective Serotonin Reuptake Inhibitors, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT1 Receptor Antagonists, Serotonin 5-HT1A Receptor Antagonists, Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2A Receptor Antagonists, Serotonin 5-HT2C Receptor Antagonists, Serotonin Agents, Serotonin and Noradrenaline Reuptake Inhibitors, Serotonin antagonist and reuptake inhibitors (SARIs), Serotonin Modulators, Serotonin Receptor Antagonists"," 5-hydroxytryptamine receptor 2A,  5-hydroxytryptamine receptor 2C,  Sodium-dependent serotonin transporter,  5-hydroxytryptamine receptor 1A,  Sodium-dependent noradrenaline transporter,  Sodium-dependent dopamine transporter,  Alpha-1B adrenergic receptor,  Alpha-2A adrenergic receptor,  Alpha-1A adrenergic receptor, 10. Potassium voltage-gated channel subfamily H member 2,  Cytochrome P450 3A Subfamily (Protein Group),  Cytochrome P450 3A4,  Cytochrome P450 2D6,  CYP2B protein,  P-glycoprotein 1,  Solute carrier organic anion transporter family member 1B3,  Solute carrier organic anion transporter family member 2B1,  Bile salt export pump","DB01149, DB09194",
DB01150,Cefprozil,approved,[H][C@]12SCC(C=CC)=C(N1C(=O)[C@@]2([H])NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O,C18H19N3O5S,,"Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, beta Lactam Antibiotics, beta-Lactams, Cephalosporins, Heterocyclic Compounds, Fused-Ring, Lactams, Nephrotoxic agents, Second-Generation Cephalosporins, Sulfur Compounds, Thiazines"," Penicillin-binding protein 1A,  Penicillin-binding protein 2x,  Penicillin-binding protein 2B","DB01150, DB01140, DB00567, DB00689, DB13266, DB00833, DB01329, DB01326, DB11592, DB00923, DB01333, DB03938, DB14725, DB00456, DB01414, DB01328, DB00535, DB03313, DB09008, DB00430, DB00229, DB14107, DB13461, DB01139, DB00671, DB11385, DB13504, DB13499, DB01112, DB13821",
DB01151,Desipramine,approved; investigational,CNCCCN1C2=CC=CC=C2CCC2=CC=CC=C12,C18H22N2,,"Adrenergic Agents, Adrenergic Uptake Inhibitors, Agents producing tachycardia, Agents that produce hypertension, Agents that reduce seizure threshold, Anticholinergic Agents, Antidepressive Agents, Antidepressive Agents Indicated for Depression, Antidepressive Agents, Tricyclic, Central Nervous System Agents, Central Nervous System Depressants, Combined Inhibitors of Serotonin/Norepinephrine Reuptake, Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (moderate), Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 CYP2E1 Inhibitors (weak), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dibenzazepines, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Heterocyclic Compounds, Fused-Ring, Histamine Antagonists, Histamine H1 Antagonists, Membrane Transport Modulators, Muscarinic Antagonists, Narrow Therapeutic Index Drugs, Nervous System, Neurotoxic agents, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, Non-Selective Monoamine Reuptake Inhibitors, OCT1 inhibitors, OCT2 Inhibitors, P-glycoprotein inhibitors, Potential QTc-Prolonging Agents, Psychoanaleptics, Psychotropic Drugs, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2A Receptor Antagonists, Serotonin Agents, Serotonin Modulators, Serotonin Receptor Antagonists, Tricyclics and Other Norepinephrine-reuptake Inhibitors"," Sodium-dependent noradrenaline transporter,  Sodium-dependent serotonin transporter,  5-hydroxytryptamine receptor 2A,  Beta-2 adrenergic receptor,  Beta-1 adrenergic receptor,  Sphingomyelin phosphodiesterase,  Histamine H1 receptor,  Alpha-1 adrenergic receptors (Protein Group),  Muscarinic acetylcholine receptor M1, 10. Muscarinic acetylcholine receptor M2, 11. Muscarinic acetylcholine receptor M3, 12. Muscarinic acetylcholine receptor M4, 13. Muscarinic acetylcholine receptor M5, 14. 5-hydroxytryptamine receptor 1A, 15. 5-hydroxytryptamine receptor 2C, 16. Dopamine D2 receptor, 17. Alpha-2 adrenergic receptors (Protein Group),  Cytochrome P450 2D6,  Cytochrome P450 1A2,  Cytochrome P450 3A4,  Cytochrome P450 2B6,  Cytochrome P450 2E1,  Alpha-1-acid glycoprotein 1,  P-glycoprotein 1,  Solute carrier family 22 member 1,  Solute carrier family 22 member 3,  Solute carrier family 22 member 2,  Solute carrier family 22 member 5,  Solute carrier family 22 member 4","DB00458, DB01151, DB00726, DB13782, DB01242, DB13411",
DB01152,Candicidin,approved; withdrawn,CC(CC(C)C1OC(=O)CC(=O)CCCC(=O)CC(O)CC(O)CC(O)CC(=O)CC(O)C(C(O)CC(OC2O[C@H](C)[C@@H](O)[C@H](N)[C@@H]2O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\C1C)C(O)=O)C(O)CC(=O)C1=CC=C(N)C=C1,C59H84N2O18,,"Anti-Bacterial Agents, Anti-Infective Agents, Antifungal Agents, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Lactones, Macrolides, Polyketides"," Ergosterol,  Cytochrome P450 3A4","DB01152, DB12333, DB00681, DB00646, DB00826, DB06145",
DB01153,Sertaconazole,approved; investigational,ClC1=CC(Cl)=C(C=C1)C(CN1C=CN=C1)OCC1=CSC2=C1C=CC=C2Cl,C20H15Cl3N2OS,,"Anti-Infective Agents, Antifungal Agents, Antifungals for Dermatological Use, Antifungals for Topical Use, Azole Antifungals, Dermatologicals, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Imidazole and Triazole Derivatives, Imidazole Derivatives, Sulfur Compounds", Cytochrome P450 51,"DB01153, DB01007, DB01110, DB08943, DB01127, DB07705, DB11985",
DB01154,Thiamylal,approved; vet_approved,CCCC(C)C1(CC=C)C(=O)NC(=S)NC1=O,C12H18N2O2S,,"Anesthetics, Anesthetics, General, Anesthetics, Intravenous, Anticonvulsants, Barbiturates, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Substrates, GABA Agents, GABA Modulators, Hypnotics and Sedatives, Nervous System, Neurotransmitter Agents, Psycholeptics, Pyrimidines, Pyrimidinones, Thiobarbiturates"," ATP-sensitive inward rectifier potassium channel 8,  ATP-sensitive inward rectifier potassium channel 11,  Gamma-aminobutyric acid receptor subunit alpha-1,  Cytochrome P450 2C9,  Cytochrome P450 3A4,  Cytochrome P450 2E1","DB01154, DB00599, DB00418",
DB01155,Gemifloxacin,approved; investigational,CO\N=C1/CN(CC1CN)C1=NC2=C(C=C1F)C(=O)C(=CN2C1CC1)C(O)=O,C18H20FN5O4,,"Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Enzyme Inhibitors, Fluoroquinolones, Heterocyclic Compounds, Fused-Ring, Moderate Risk QTc-Prolonging Agents, Naphthyridines, QTc Prolonging Agents, Quinolines, Quinolone Antimicrobial, Quinolones, Topoisomerase II Inhibitors, Topoisomerase Inhibitors"," DNA gyrase subunit A,  DNA topoisomerase 4 subunit A,  Cytochrome P450 1A2","DB01155, DB12479, DB00467, DB00685, DB09335, DB16850, DB11999",
DB01156,Bupropion,approved,CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1,C13H18ClNO,,"Agents that reduce seizure threshold, Aminoketone Antidepressants, Antidepressive Agents, Antidepressive Agents Indicated for Depression, Antiobesity Preparations, Excl. Diet Products, Central Nervous System Agents, Central Nervous System Depressants, Centrally Acting Antiobesity Products, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strong), Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dopamine Agents, Dopamine And Norepinephrine Reuptake Inhibitors, Dopamine Uptake Inhibitors, Drugs causing inadvertant photosensitivity, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Increased Dopamine Activity, Increased Norepinephrine Activity, Ketones, Miscellaneous Antidepressants, Nervous System, Neurotransmitter Uptake Inhibitors, Norepinephrine Uptake Inhibitors, OCT2 Inhibitors, Photosensitizing Agents, Psychoanaleptics, Psychotropic Drugs, Smoking Cessation Agents"," Sodium-dependent dopamine transporter,  Sodium-dependent noradrenaline transporter,  Neuronal acetylcholine receptor subunit alpha-3,  5-hydroxytryptamine receptor 3A,  Cytochrome P450 2C9,  Cytochrome P450 2E1,  Cytochrome P450 2B6,  Cytochrome P450 2D6,  Alpha-1-acid glycoprotein 1,  Solute carrier family 22 member 2",DB01156,
DB01157,Trimetrexate,approved; investigational,COC1=CC(NCC2=C(C)C3=C(C=C2)N=C(N)N=C3N)=CC(OC)=C1OC,C19H23N5O3,,"Acids, Acyclic, Acids, Aldehydic, Anti-Infective Agents, Antimetabolites, Antineoplastic Agents, Antiparasitic Products, Insecticides and Repellents, Antiprotozoals, Carbohydrates, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Folic Acid Antagonists, Hepatotoxic Agents, Heterocyclic Compounds, Fused-Ring, Hydroxy Acids, Narrow Therapeutic Index Drugs, Noxae, Pharmaceutical Preparations, Quinazolines, Sugar Acids, Toxic Actions, Uronic Acids"," Dihydrofolate reductase,  Folate transporter 1","DB01157, DB02104",
DB01158,Bretylium,approved,CC[N+](C)(C)CC1=CC=CC=C1Br,C11H17BrN,,"Adrenergic Agents, Adrenergic Antagonists, Amines, Antiarrhythmic agents, Antiarrhythmics, Class III, Antihypertensive Agents, Benzylammonium Compounds, Bradycardia-Causing Agents, Bretylium Compounds, Cardiac Therapy, Cardiovascular Agents, Hypotensive Agents, Neurotransmitter Agents, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Quaternary Ammonium Compounds", Sodium/potassium-transporting ATPase subunit alpha-1,DB01158,
DB01159,Halothane,approved; vet_approved,[H]C(Cl)(Br)C(F)(F)F,C2HBrClF3,,"Agents that produce hypertension, Anesthetics, Anesthetics, General, Anesthetics, Inhalation, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2A6 Substrates, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Hydrocarbons, Halogenated, Hypotensive Agents, Nervous System, NMDA Receptor Antagonists"," Potassium channel subfamily K member 3,  Potassium channel subfamily K member 9,  GABA(A) Receptor (Protein Group),  Plasma membrane calcium-transporting ATPase (Protein Group),  Calcium-activated potassium channel subunit alpha-1,  Glutamate receptor ionotropic, NMDA 3A,  Glutamate receptor ionotropic, NMDA 3B,  Glutamate receptor ionotropic, NMDA 2A,  Glycine receptor subunit alpha-1, 10. Rhodopsin, 11. G protein-activated inward rectifier potassium channel 2, 12. G protein-activated inward rectifier potassium channel 1, 13. NADH-ubiquinone oxidoreductase chain 1, 14. Intermediate conductance calcium-activated potassium channel protein 4, 15. Gamma-aminobutyric acid receptor subunit alpha-1, 16. Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2, 17. Neuropeptide S receptor,  Cytochrome P450 2E1,  Cytochrome P450 3A4,  Cytochrome P450 2A6,  Cytochrome P450 2B6,  Cytochrome P450 2C9,  Serum albumin",DB01159,
DB01160,Dinoprost tromethamine,approved; vet_approved,NC(CO)(CO)CO.CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O,C24H45NO8,,"Abortifacient Agents, Abortifacient Agents, Nonsteroidal, Angiography, Autacoids, Biological Factors, Eicosanoids, Fatty Acids, Fatty Acids, Unsaturated, Inflammation Mediators, Lipids, Prostaglandins, Prostaglandins F, Reproductive Control Agents, Uterotonic agents"," Prostaglandin F2-alpha receptor,  Prostacyclin receptor,  Solute carrier family 22 member 2,  Solute carrier family 22 member 6,  Solute carrier family 22 member 7,  Solute carrier family 22 member 8,  Solute carrier family 22 member 11,  Solute carrier organic anion transporter family member 2A1,  Solute carrier organic anion transporter family member 3A1","DB01160, DB00429, DB12789, DB00917, DB11454, DB01088, DB00770, DB02056",
DB01161,Chloroprocaine,approved; investigational,CCN(CC)CCOC(=O)C1=C(Cl)C=C(N)C=C1,C13H19ClN2O2,,"Acids, Carbocyclic, Aminobenzoates, Anesthetics, Anesthetics, Local, Benzene Derivatives, Benzoates, Central Nervous System Agents, Central Nervous System Depressants, Cholinesterase substrates, Esters of Aminobenzoic Acid, Local Anesthesia, Local Anesthetics (Ester), Nervous System, para-Aminobenzoates, Peripheral Nervous System Agents, Sensory System Agents"," Voltage-gated sodium channel alpha subunit (Protein Group),  Sodium-dependent dopamine transporter,  Cholinesterase","DB01161, DB00721",
DB01162,Terazosin,approved,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1CCCO1,C19H25N5O4,,"Adrenergic Agents, Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Drugs Used in Benign Prostatic Hypertrophy, Genito Urinary System and Sex Hormones, Genitourinary Agents, Heterocyclic Compounds, Fused-Ring, Hypotensive Agents, Neurotransmitter Agents, P-glycoprotein inhibitors, Peripheral alpha-1 blockers, Quinazolines, Urological Agents, Urologicals"," Alpha-1A adrenergic receptor,  Alpha-1B adrenergic receptor,  Alpha-1D adrenergic receptor,  Transforming growth factor beta-1,  Potassium voltage-gated channel subfamily H member 2,  Potassium voltage-gated channel subfamily H member 6,  Potassium voltage-gated channel subfamily H member 7,  P-glycoprotein 1","DB01162, DB00346, DB12230, DB00590, DB00457, DB09206",
DB01163,Amdinocillin,investigational; withdrawn,[H]C(=N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@]12[H])N1CCCCCC1,C15H23N3O3S,,"Amides, Anti-Bacterial Agents, Anti-Infective Agents, Anti-Infective Agents, Urinary, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Beta-Lactam Antibacterials, beta-Lactams, Heterocyclic Compounds, Fused-Ring, Lactams, Penicillins, Penicillins With Extended Spectrum, Sulfur Compounds"," Penicillin-binding protein 2a,  Penicillin-binding protein 2,  Penicillin-binding protein 3,  Penicillin-binding protein 1A,  Penicillin-binding protein 2B,  Penicillin-binding protein 1b","DB01163, DB01605, DB01000, DB03550, DB03820, DB13836, DB00415, DB01053, DB13300, DB01060, DB08559, DB13739, DB01607, DB00578, DB01604, DB08795",
DB01164,Calcium chloride,approved,[Cl-].[Cl-].[Ca++],CaCl2,,"Acidifying Agents, Alimentary Tract and Metabolism, Blood and Blood Forming Organs, Blood Substitutes and Perfusion Solutions, Calcium Compounds, Calcium Salts, Chlorides, Chlorine Compounds, Electrolyte Solutions, Genito Urinary System and Sex Hormones, Hemodialysis Solution, I.V. Solution Additives, Mineral Supplements, Replacement Preparations, Supplements, Urologicals", Protein S100-A13,DB01164,
DB01165,Ofloxacin,approved,CC1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1,C18H20FN3O4,,"Agents Causing Muscle Toxicity, Anti-Bacterial Agents, Anti-Infective Agents, Anti-Infective Agents, Urinary, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, BSEP/ABCB11 Substrates, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Enzyme Inhibitors, Fluoroquinolones, Heterocyclic Compounds, Fused-Ring, Moderate Risk QTc-Prolonging Agents, OAT1/SLC22A6 inhibitors, Ophthalmologicals, Otologicals, QTc Prolonging Agents, Quinolines, Quinolone Antimicrobial, Quinolones, Sensory Organs, Topoisomerase II Inhibitors, Topoisomerase Inhibitors"," DNA gyrase subunit A,  DNA topoisomerase 4 subunit A,  DNA topoisomerase 2-alpha,  Cytochrome P450 1A2,  Solute carrier family 22 member 5,  Multidrug resistance-associated protein 1,  Solute carrier family 22 member 6,  Canalicular multispecific organic anion transporter 1,  Solute carrier family 22 member 4,  Bile salt export pump","DB01137, DB01165, DB03034, DB01044, DB00218, DB11774, DB06600, DB00978, DB11426, DB11404, DB01208, DB04576, DB00537, DB00487, DB01059, DB11393, DB11443, DB11847, DB00365, DB11453, DB09047, DB01405, DB11511, DB11491, DB12447, DB16219, DB13772, DB11892, DB13261",
DB01166,Cilostazol,approved; investigational,O=C1CCC2=C(N1)C=CC(OCCCCC1=NN=NN1C1CCCCC1)=C2,C20H27N5O2,,"Agents producing tachycardia, Anti-Asthmatic Agents, Antiplatelet agents, Autonomic Agents, Blood and Blood Forming Organs, Bronchodilator Agents, Cardiovascular Agents, Central Nervous System Agents, Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Fibrin Modulating Agents, Hematologic Agents, Heterocyclic Compounds, Fused-Ring, Neuroprotective Agents, Peripheral Nervous System Agents, Phosphodiesterase 3 Inhibitors, Phosphodiesterase Inhibitors, Platelet Aggregation Inhibitors Excl. Heparin, Potential QTc-Prolonging Agents, Protective Agents, QTc Prolonging Agents, Quinolines, Respiratory System Agents, Tetrazoles, Vasodilating Agents"," cGMP-inhibited 3',5'-cyclic phosphodiesterase A,  Cytochrome P450 1A2,  Cytochrome P450 2D6,  Cytochrome P450 2C19,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 3A7",DB01166,
DB01167,Itraconazole,approved; investigational,CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@H]2CO[C@@](CN3C=NC=N3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1,C35H38Cl2N8O4,,"14-alpha Demethylase Inhibitors, Agents causing hyperkalemia, Anti-Infective Agents, Antifungal Agents, Antiinfectives for Systemic Use, Antimycotics for Systemic Use, Azole Antifungals, BCRP/ABCG2 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (strong), Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (weak), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strong), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Inhibitors, Cytochrome P-450 CYP3A5 Inhibitors (strong), Cytochrome P-450 CYP3A7 Inhibitors, Cytochrome P-450 CYP3A7 Inhibitors (strong), Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs causing inadvertant photosensitivity, Enzyme Inhibitors, Organic Anion Transporting Polypeptide 2B1 Inhibitors, P-glycoprotein inhibitors, Photosensitizing Agents, Piperazines, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Steroid Synthesis Inhibitors, Triazole and tetrazole derivatives, Triazole Derivatives, Triazoles"," Lanosterol 14-alpha demethylase,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  Cytochrome P450 3A Subfamily (Protein Group),  Cytochrome P450 2B6,  Cytochrome P450 1A1,  Cytochrome P450 2E1,  Serum albumin,  P-glycoprotein 1,  ATP-binding cassette sub-family G member 2,  Solute carrier organic anion transporter family member 2B1","DB01167, DB00251, DB01263, DB01026, DB05667",
DB01168,Procarbazine,approved; investigational,CNNCC1=CC=C(C=C1)C(=O)NC(C)C,C12H19N3O,,"Acids, Carbocyclic, Agents Causing Muscle Toxicity, Alkylating Activity, Alkylating Drugs, Amides, Antidepressive Agents, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Benzamides and benzamide derivatives, Benzene Derivatives, Benzoates, Central Nervous System Depressants, Immunosuppressive Agents, Methylhydrazines, Monoamine Oxidase Inhibitors, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin Modulators"," Monoamine oxidase (Protein Group),  DNA,  Xanthine dehydrogenase/oxidase",DB01168,
DB01169,Arsenic trioxide,approved; investigational,O=[As]O[As]=O,As2O3,,"Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Arsenicals, Cardiotoxic antineoplastic agents, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Drugs that are Mainly Renally Excreted, Highest Risk QTc-Prolonging Agents, Hyperglycemia-Associated Agents, Hypotensive Agents, Immunosuppressive Agents, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, Oxides, Oxygen Compounds, P-glycoprotein inhibitors, QTc Prolonging Agents"," Inhibitor of nuclear factor kappa-B kinase subunit beta,  Thioredoxin reductase 1, cytoplasmic,  Transcription factor AP-1,  G1/S-specific cyclin-D1,  Mitogen-activated protein kinase 3,  Mitogen-activated protein kinase 1,  RAC-alpha serine/threonine-protein kinase,  Cyclin-dependent kinase inhibitor 1,  Histone deacetylase 1, 10. Protein PML,  Cytochrome P450 3A4,  Serum albumin,  Canalicular multispecific organic anion transporter 1,  P-glycoprotein 1",DB01169,
DB01170,Guanethidine,approved,NC(N)=NCCN1CCCCCCC1,C10H22N4,,"Adrenergic Agents, Adrenergic Antagonists, Amidines, Antiadrenergic Agents, Peripherally Acting, Antiglaucoma Preparations and Miotics, Antihypertensive Agents, Autonomic Agents, Cardiovascular Agents, Catecholamine-depleting Sympatholytic, Drugs that are Mainly Renally Excreted, Gastrointestinal Acidifying Agents, Guanidine Derivatives, Guanidine Derivatives and Diuretics, Guanidines, Neurotransmitter Agents, Ophthalmologicals, Peripheral Nervous System Agents, Sensory Organs, Sympatholytics", Sodium-dependent noradrenaline transporter,DB01170,
DB01171,Moclobemide,approved; investigational,ClC1=CC=C(C=C1)C(=O)NCCN1CCOCC1,C13H17ClN2O2,,"Acids, Carbocyclic, Agents that produce hypertension, Agents that reduce seizure threshold, Amides, Antidepressive Agents, Antidepressive Agents Indicated for Depression, Benzamides and benzamide derivatives, Benzene Derivatives, Benzoates, Central Nervous System Agents, Central Nervous System Depressants, Chlorobenzoates, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (strength unknown), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Enzyme Inhibitors, Monoamine Oxidase A Inhibitors, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates, Monoamine Oxidase Inhibitors, Nervous System, Psychoanaleptics, Psychotropic Drugs, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin Modulators"," Amine oxidase [flavin-containing] A,  Monoamine oxidase (Protein Group),  Amine oxidase [flavin-containing] B,  Cytochrome P450 2C9,  Cytochrome P450 2C19,  Cytochrome P450 2D6,  Amine oxidase [flavin-containing] A,  Amine oxidase [flavin-containing] B",DB01171,
DB01172,Kanamycin,approved; investigational; vet_approved,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,C18H36N4O11,,"Agents that produce neuromuscular block (indirect), Alimentary Tract and Metabolism, Aminoglycoside Antibacterials, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents, Antiinfectives for Systemic Use, Carbohydrates, Drugs that are Mainly Renally Excreted, Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index, Enzyme Inhibitors, Glycosides, Intestinal Antiinfectives, Narrow Therapeutic Index Drugs, Nephrotoxic agents, Ophthalmologicals, Protein Synthesis Inhibitors, Sensory Organs"," 30S ribosomal protein S12,  16S ribosomal RNA,  Aminoglycoside 2'-N-acetyltransferase,  Kanamycin nucleotidyltransferase,  Aminoglycoside 3'-phosphotransferase","DB01172, DB13673, DB00684, DB13270, DB00452, DB01421, DB04728, DB03615, DB15080, DB17631, DB04808, DB04263, DB16951, DB04729, DB17884, DB04717, DB03779, DB07341, DB00798, DB13274, DB07378, DB04718, DB11520, DB07357, DB04626, DB00479",
DB01173,Orphenadrine,approved,CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1C,C18H23NO,,"Agents producing tachycardia, Amines, Anti-Dyskinesia Agents, Anti-Parkinson Drugs, Anticholinergic Agents, Autonomic Agents, Benzene Derivatives, Benzhydryl Compounds, Central Nervous System Agents, Central Nervous System Depressants, Centrally-mediated Muscle Relaxation, Cholinergic Agents, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (strong), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strong), Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (weak), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Enzyme Inhibitors, Ethers, Chemically Close to Antihistamines, Ethylamines, Histamine Antagonists, Histamine H1 Antagonists, Miscellaneous Skeletal Muscle Relaxants, Muscarinic Antagonists, Muscle Relaxants, Muscle Relaxants, Centrally Acting Agents, Musculo-Skeletal System, Nervous System, Neurotransmitter Agents, NMDA Receptor Antagonists, Parasympatholytics, Peripheral Nervous System Agents, Potential QTc-Prolonging Agents, QTc Prolonging Agents"," Glutamate receptor ionotropic, NMDA 2D,  Glutamate receptor ionotropic, NMDA 1,  Glutamate receptor ionotropic, NMDA 3B,  Glutamate receptor ionotropic, NMDA 3A,  Histamine H1 receptor,  Sodium-dependent noradrenaline transporter,  Sodium channel protein type 10 subunit alpha,  Cytochrome P450 2B6,  Cytochrome P450 3A4,  Cytochrome P450 2E1,  Cytochrome P450 1A2,  Cytochrome P450 2D6,  Serum albumin","DB01173, DB01075, DB13769",
DB01174,Phenobarbital,approved; investigational,CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1,C12H12N2O3,,"Anticholinergic Agents, Anticonvulsants, Barbiturates, Barbiturates and Derivatives, BSEP/ABCB11 inducers, Central Nervous System Agents, Central Nervous System Depressants, Chemically-Induced Disorders, Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP1A2 Inducers (strength unknown), Cytochrome P-450 CYP2A6 Inducers, Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strong), Cytochrome P-450 CYP2C18 Substrates, Cytochrome P-450 CYP2C18 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C19 Inducers, Cytochrome P-450 CYP2C19 Inducers (strength unknown), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 CYP2C8 Inducers (strength unknown), Cytochrome P-450 CYP2C8 Inducers (strong), Cytochrome P-450 CYP2C9 Inducers, Cytochrome P-450 CYP2C9 Inducers (strength unknown), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2E1 Inducers, Cytochrome P-450 CYP2E1 Inducers (strength unknown), Cytochrome P-450 CYP2E1 Inducers (weak), Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inducers (strong), Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strong), Cytochrome P-450 CYP3A5 Inducers, Cytochrome P-450 CYP3A5 Inducers (strong), Cytochrome P-450 CYP3A7 Inducers, Cytochrome P-450 CYP3A7 Inducers (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Substrates, Enzyme Inducing Antiepileptic Drugs, Excitatory Amino Acid Agents, Excitatory Amino Acid Antagonists, GABA Agents, GABA Modulators, Hypnotics and Sedatives, Methemoglobinemia Associated Agents, Narrow Therapeutic Index Drugs, Nervous System, Neurotransmitter Agents, Nicotinic Antagonists, P-glycoprotein inducers, P-glycoprotein substrates, P-glycoprotein substrates with a Narrow Therapeutic Index, Phenobarbital and similars, Psycholeptics, Pyrimidines, Pyrimidinones, UGT1A1 Inducers, UGT2B7 inducers"," Gamma-aminobutyric acid receptor subunit alpha-1,  Neuronal acetylcholine receptor subunit alpha-4,  Neuronal acetylcholine receptor subunit alpha-7,  Glutamate receptor 2,  Glutamate receptor ionotropic, kainate 2,  NMDA receptor (Protein Group),  Nuclear receptor subfamily 1 group I member 2,  Cytochrome P450 2C19,  Cytochrome P450 2C9,  Cytochrome P450 2E1,  Cytochrome P450 2B6,  Cytochrome P450 2C8,  Cytochrome P450 3A4,  Cytochrome P450 1A2,  Cytochrome P450 3A5,  Cytochrome P450 1A1, 10. Cytochrome P450 2C18, 11. Cytochrome P450 3A7, 12. Cytochrome P450 4B1, 13. UDP-glucuronosyltransferase 1-1, 14. UDP-glucuronosyltransferase 2B7, 15. Cytochrome P450 2A6,  P-glycoprotein 1,  Canalicular multispecific organic anion transporter 2,  Bile salt export pump,  Multidrug resistance-associated protein 1,  Solute carrier organic anion transporter family member 2A1,  Canalicular multispecific organic anion transporter 1","DB01174, DB00849, DB00794, DB09001, DB13362, DB03368",
DB01175,Escitalopram,approved,CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1,C20H21FN2O,,"Amines, Anticholinergic Agents, Antidepressive Agents, Antidepressive Agents Indicated for Depression, Antidepressive Agents, Second-Generation, Benzofurans, Central Nervous System Agents, Central Nervous System Depressants, Combined Inhibitors of Serotonin/Norepinephrine Reuptake, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs causing inadvertant photosensitivity, Heterocyclic Compounds, Fused-Ring, Highest Risk QTc-Prolonging Agents, Hypoglycemia-Associated Agents, Membrane Transport Modulators, Monoamine Oxidase A Substrates, Muscarinic Antagonists, Nervous System, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, Nitriles, P-glycoprotein substrates, Photosensitizing Agents, Propylamines, Psychoanaleptics, Psychotropic Drugs, QTc Prolonging Agents, Selective Serotonin Reuptake Inhibitors, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin Modulators"," Sodium-dependent serotonin transporter,  Muscarinic acetylcholine receptor M1,  Histamine H1 receptor,  5-hydroxytryptamine receptor 1A,  5-hydroxytryptamine receptor 2A,  Alpha-1 adrenergic receptors (Protein Group),  5-hydroxytryptamine receptor 2C,  Alpha-2 adrenergic receptors (Protein Group),  Dopamine D2 receptor, 10. Sodium-dependent noradrenaline transporter, 11. Sodium-dependent dopamine transporter,  Cytochrome P450 3A4,  Cytochrome P450 2D6,  Cytochrome P450 2C19,  Amine oxidase [flavin-containing] A,  Amine oxidase [flavin-containing] B,  Aldehyde oxidase,  P-glycoprotein 1","DB00215, DB01175, DB09190",
DB01176,Cyclizine,approved,CN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1,C18H22N2,,"Antiemetics, Antihistamines for Systemic Use, Autonomic Agents, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Gastrointestinal Agents, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Neurotransmitter Agents, Peripheral Nervous System Agents, Piperazine Derivatives, Piperazines, Potential QTc-Prolonging Agents, QTc Prolonging Agents"," Histamine H1 receptor,  Estrogen sulfotransferase,  Cytochrome P450 2C9,  Serum albumin","DB01176, DB08936, DB00737, DB00568, DB00354",
DB01177,Idarubicin,approved,C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(CC2=C1C(O)=C1C(=O)C3=CC=CC=C3C(=O)C1=C2O)C(C)=O,C26H27NO9,,"Anthracycline Topoisomerase Inhibitor, Anthracyclines, Anthracyclines and Related Substances, Antibiotics, Antineoplastic, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Carbohydrates, Cardiotoxic antineoplastic agents, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Substrates, Cytotoxic Antibiotics and Related Substances, Enzyme Inhibitors, Glycosides, Immunosuppressive Agents, Myelosuppressive Agents, Naphthacenes, Narrow Therapeutic Index Drugs, Topoisomerase II Inhibitors, Topoisomerase Inhibitors"," DNA,  DNA topoisomerase 2-alpha,  Cytochrome P450 2C9,  Cytochrome P450 2D6,  Multidrug resistance-associated protein 1","DB01177, DB12410, DB00445, DB00694, DB00997, DB11616, DB17149, DB05706, DB06420, DB13103, DB04131, DB06263, DB01806, DB03219, DB00385, DB11618, DB03199, DB11617, DB06013, DB12755",
DB01178,Chlormezanone,approved; investigational; withdrawn,CN1C(C2=CC=C(Cl)C=C2)S(=O)(=O)CCC1=O,C11H12ClNO3S,,"Anti-Anxiety Agents, Central Nervous System Agents, Central Nervous System Depressants, Muscle Relaxants, Muscle Relaxants, Centrally Acting Agents, Musculo-Skeletal System, Neuromuscular Agents, Oxazol, Thiazine, and Triazine Derivatives, Peripheral Nervous System Agents, Psychotropic Drugs, Sulfur Compounds, Thiazines, Tranquilizing Agents", Translocator protein,DB01178,
DB01179,Podofilox,approved,[H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(OC)C(OC)=C1)C1=CC3=C(OCO3)C=C1[C@@H]2O,C22H22O8,,"Antimitotic Agents, Antineoplastic Agents, Phytogenic, Antiviral Agents, Benzene Derivatives, Benzyl Compounds, Decreased Mitosis, Dermatologicals, Keratolytic Agents, Lignans, Misc. Skin and Mucous Membrane Agents, Mitosis Modulators, Naphthalenes, Tetrahydronaphthalenes, Tubulin Modulators"," Tubulin alpha-4A chain,  Tubulin beta chain,  DNA topoisomerase 2-alpha","DB01179, DB09094, DB12802, DB00773, DB00444, DB17255",
DB01180,Rescinnamine,approved,[H][C@]12C[C@@H](OC(=O)C=CC3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2,C35H42N2O9,,"Agents Acting on the Renin-Angiotensin System, Agents causing angioedema, Agents causing hyperkalemia, Agents that produce hypertension, Alkaloids, Angiotensin-Converting Enzyme Inhibitors, Antiadrenergic Agents, Centrally Acting, Antihypertensive Agents, Heterocyclic Compounds, Fused-Ring, Indole Alkaloids, Indoles, Indolizidines, Indolizines, Secologanin Tryptamine Alkaloids", Angiotensin-converting enzyme,"DB01180, DB00206, DB01089, DB11530, DB13631, DB13575, DB01392, DB15949, DB13374, DB01967, DB13793, DB17390, DB12131, DB00541, DB02868, DB00570, DB00309, DB12586, DB05168, DB02191, DB11641, DB00361, DB12674, DB11467",
DB01181,Ifosfamide,approved,ClCCNP1(=O)OCCCN1CCCl,C7H15Cl2N2O2P,,"Alkylating Activity, Alkylating Drugs, Antineoplastic Agents, Antineoplastic Agents, Alkylating, Antineoplastic and Immunomodulating Agents, Cardiotoxic antineoplastic agents, Cytochrome P-450 CYP2A6 Substrates, Cytochrome P-450 CYP2A6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C18 Substrates, Cytochrome P-450 CYP2C18 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 CYP2C8 Inducers (strength unknown), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Hydrocarbons, Halogenated, Immunosuppressive Agents, Methemoglobinemia Associated Agents, Mustard Compounds, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, Nitrogen Mustard Analogues, Nitrogen Mustard Compounds, Noxae, Organophosphorus Compounds, Oxazines, Phosphoramide Mustards, Phosphoramides, Toxic Actions"," DNA,  Nuclear receptor subfamily 1 group I member 2,  Cytochrome P450 2B6,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 2C19,  Cytochrome P450 2C9,  Cytochrome P450 2C8,  Cytochrome P450 2A6,  Cytochrome P450 2C18,  Prostaglandin G/H synthase 1","DB01181, DB12902, DB00531",
DB01182,Propafenone,approved,CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1,C21H27NO3,,"Adrenergic Antagonists, Adrenergic beta-Antagonists, Agents causing hyperkalemia, Agents that produce hypertension, Antiarrhythmic agents, Antiarrhythmics, Class I, Antiarrhythmics, Class Ic, Bradycardia-Causing Agents, Cardiac Therapy, Cardiovascular Agents, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strong), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Ketones, Membrane Transport Modulators, Moderate Risk QTc-Prolonging Agents, P-glycoprotein inhibitors, Propiophenones, QTc Prolonging Agents, Sodium Channel Blockers, Voltage-Gated Sodium Channel Blockers"," Sodium channel protein type 5 subunit alpha,  Potassium voltage-gated channel subfamily H member 2,  Beta-1 adrenergic receptor,  Beta-2 adrenergic receptor,  Cytochrome P450 2D6,  Cytochrome P450 3A4,  Cytochrome P450 1A2,  P-glycoprotein 1","DB01182, DB15410, DB01359, DB13845",
DB01183,Naloxone,approved; vet_approved,OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O,C19H21NO4,,"Alimentary Tract and Metabolism, Alkaloids, Analgesics, Antidotes, Central Nervous System Agents, Cytochrome P-450 CYP2C18 Substrates, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Inhibitors (strong), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs for Constipation, Drugs that are Mainly Renally Excreted, Heterocyclic Compounds, Fused-Ring, Morphinans, Natural Opium Alkaloids, Nervous System, Opiate Alkaloids, Opiate Antagonists, Opioid Antagonists, P-glycoprotein substrates, Peripheral Nervous System Agents, Peripheral Opioid Receptor Antagonists, Phenanthrenes, Sensory System Agents, UGT1A1 Substrates"," Mu-type opioid receptor,  Delta-type opioid receptor,  Kappa-type opioid receptor,  Cyclic AMP-responsive element-binding protein 1,  Estrogen receptor alpha,  Toll-like receptor 4,  Liver carboxylesterase 1,  Cytochrome P450 3A4,  UDP-glucuronosyltransferase 1-1,  Cytochrome P450 2C18,  Cytochrome P450 2C19,  Serum albumin,  Solute carrier organic anion transporter family member 1A2,  P-glycoprotein 1","DB01183, DB04509, DB00704, DB01192, DB06800, DB00497, DB00327, DB00956, DB06230, DB01512, DB00844, DB09049, DB14146, DB15341, DB01565, DB01551, DB01531, DB13471, DB00921, DB01450, DB01548, DB16117, DB16072, DB11490, DB01538, DB01480, DB01497, DB00295, DB13458, DB01469",
DB01184,Domperidone,approved; investigational; vet_approved,ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=CC=CC=C34)CC1)C(=O)N2,C22H24ClN5O2,,"Alimentary Tract and Metabolism, Antiemetics, Autonomic Agents, Benzimidazoles, Central Nervous System Agents, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Substrates, Dopamine Agents, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Drugs for Functional Gastrointestinal Disorders, Gastrointestinal Agents, Heterocyclic Compounds, Fused-Ring, Highest Risk QTc-Prolonging Agents, Neurotransmitter Agents, P-glycoprotein substrates, Peripheral Nervous System Agents, Piperidines, Prokinetic Agents, Propulsives, QTc Prolonging Agents"," Dopamine D3 receptor,  Dopamine D2 receptor,  Cytochrome P450 1A2,  Cytochrome P450 2B6,  Cytochrome P450 2C8,  Cytochrome P450 2D6,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  P-glycoprotein 1","DB01184, DB01100",
DB01185,Fluoxymesterone,approved; illicit,[H][C@@]12CC[C@](C)(O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C,C20H29FO3,,"3-Oxoandrosten (4) Derivatives, Anabolic Agents, Androgens, Androstanes, Androstenediols, Androstenes, Androstenols, Fused-Ring Compounds, Genito Urinary System and Sex Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Sex Hormones and Modulators of the Genital System, Steroids, Steroids, Fluorinated"," Androgen receptor,  Estrogen receptor alpha,  Glucocorticoid receptor,  Corticosteroid 11-beta-dehydrogenase isozyme 2,  Sex hormone-binding globulin","DB01185, DB00687, DB00324, DB00443, DB01234, DB11522, DB13491, DB13610, DB00547, DB00620, DB08970, DB00223, DB00663, DB09095, DB11750, DB00741, DB04652, DB12553, DB00253",
DB01186,Pergolide,approved; investigational; vet_approved; withdrawn,[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@@H](CSC)CN2CCC,C19H26N2S,,"Adrenergic Agonists, Adrenergic alpha-1 Receptor Agonists, Adrenergic alpha-2 Receptor Agonists, Adrenergic alpha-Agonists, Agents producing tachycardia, Agents that produce hypertension, Alkaloids, Anti-Parkinson Drugs, Antidepressive Agents, Central Nervous System Depressants, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Dopamine Agents, Dopamine Agonists, Ergolines, Ergot Alkaloids and Derivatives, Ergot-derivative Dopamine Receptor Agonists, Ergot-derived Dopamine Receptor Agonist, Heterocyclic Compounds, Fused-Ring, Nervous System, Neurotransmitter Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT2 Receptor Agonists, Serotonin Agents, Serotonin Receptor Agonists"," Dopamine D2 receptor,  Dopamine D3 receptor,  Dopamine D4 receptor,  Dopamine D5 receptor,  Dopamine D1 receptor,  5-hydroxytryptamine receptor 1A,  5-hydroxytryptamine receptor 2B,  5-hydroxytryptamine receptor 2A,  5-hydroxytryptamine receptor 1D, 10. Alpha-2 adrenergic receptors (Protein Group), 11. 5-hydroxytryptamine receptor 1B, 12. 5-hydroxytryptamine receptor 2C, 13. Alpha-1A adrenergic receptor, 14. Alpha-1B adrenergic receptor, 15. Alpha-1D adrenergic receptor,  Cytochrome P450 3A4","DB01186, DB13520, DB13399, DB00248, DB16144",
DB01187,Iophendylate,approved,CCOC(=O)CCCCCCCCC(C)C1=CC=CC=C1I,C19H29IO2,,"Benzene Derivatives, Compounds used in a research, industrial, or household setting, Contrast Media, Diagnostic Uses of Chemicals, Hydrocarbons, Halogenated, Hydrocarbons, Iodinated, Iodobenzenes, Non-Watersoluble X-Ray Contrast Media, X-Ray Contrast Media, Iodinated",,"DB01187, DB05683",
DB01188,Ciclopirox,approved; investigational,CC1=CC(=O)N(O)C(=C1)C1CCCCC1,C12H17NO2,,"Anti-Infective Agents, Antifungal Agents, Antifungals for Dermatological Use, Antifungals for Topical Use, Cyclohexanes, Cycloparaffins, Decreased DNA Replication, Decreased Protein Synthesis, Decreased RNA Replication, Dermatologicals, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Hydroxypyridones, Protein Synthesis Inhibitors, Pyridines, Pyridones, Vaginal Creams, Foams, and Jellies", Sodium/potassium-transporting ATPase subunit alpha-1,"DB01188, DB15946",
DB01189,Desflurane,approved,FC(F)OC(F)C(F)(F)F,C3H2F6O,,"Agents that produce hypertension, Anesthetics, Anesthetics, General, Anesthetics, Inhalation, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 Substrates, Ethers, Ethyl Ethers, Hydrocarbons, Fluorinated, Hydrocarbons, Halogenated, Hypotensive Agents, Methyl Ethers, Nervous System, Potential QTc-Prolonging Agents, QTc Prolonging Agents"," GABA(A) Receptor (Protein Group),  Glycine receptor subunit alpha-1,  Glutamate receptor 1,  Potassium voltage-gated channel subfamily A member 1,  NADH-ubiquinone oxidoreductase chain 1,  Calcium transporting ATPases (Protein Group),  ATP synthase subunit delta, mitochondrial,  Cytochrome P450 2E1,  Serum albumin",DB01189,
DB01190,Clindamycin,approved; vet_approved,[H][C@@](NC(=O)[C@@H]1C[C@@H](CCC)CN1C)([C@H](C)Cl)[C@@]1([H])O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O,C18H33ClN2O5S,,"Agents that produce neuromuscular block (indirect), Anti-Acne Preparations, Anti-Acne Preparations for Topical Use, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antibiotics for Pneumocystis Pneumonia, Antiinfectives for Systemic Use, Antiinfectives for Treatment of Acne, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (moderate), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Decreased Sebaceous Gland Activity, Dermatologicals, Enzyme Inhibitors, Genito Urinary System and Sex Hormones, Glycosides, Gynecological Antiinfectives and Antiseptics, Lincomycins, Lincosamide Antibacterial, Lincosamides, Macrolides, Macrolides, Lincosamides and Streptogramins, Neuromuscular Blockade, Neurotoxic agents, P-glycoprotein substrates, Protein Synthesis Inhibitors, Pyrrolidines"," 50S ribosomal protein L1,  Cytochrome P450 3A5,  Cytochrome P450 3A4,  Alpha-1-acid glycoprotein 1,  P-glycoprotein 1","DB01190, DB11537, DB01627",
DB01191,Dexfenfluramine,approved; illicit; investigational; withdrawn,CCN[C@@H](C)CC1=CC=CC(=C1)C(F)(F)F,C12H16F3N,,"Alimentary Tract and Metabolism, Amines, Antidepressive Agents, Antiobesity Preparations, Excl. Diet Products, Central Nervous System Depressants, Centrally Acting Antiobesity Products, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 CYP2E1 Inhibitors (weak), Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Ethylamines, Neurotransmitter Agents, Phenethylamines, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents"," Sodium-dependent serotonin transporter,  5-hydroxytryptamine receptor 2C,  Cytochrome P450 1A2,  Cytochrome P450 2E1,  Cytochrome P450 2D6","DB00574, DB01191",
DB01192,Oxymorphone,approved; investigational; vet_approved,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1(O)CCC2=O,C17H19NO4,,"Adjuvants, Adjuvants, Anesthesia, Alkaloids, Analgesics, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Heterocyclic Compounds, Fused-Ring, High-risk opioids, Morphinans, Morphine Derivatives, Narcotics, Natural Opium Alkaloids, Nervous System, Opiate Agonists, Opiate Alkaloids, Opioid Agonist, Opioids, Peripheral Nervous System Agents, Phenanthrenes, Sensory System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"," Mu-type opioid receptor,  Delta-type opioid receptor,  Cytochrome P450 3A4,  Cytochrome P450 2D6","DB00704, DB01192, DB06800, DB00497, DB01183, DB04509, DB00327, DB00956, DB06230, DB01512, DB00844, DB14146, DB15341, DB01565, DB09049, DB01551, DB01531, DB00921, DB01450, DB01548, DB16117, DB16072, DB13471, DB01538, DB01480, DB01497, DB00295, DB01469, DB00318, DB01477",
DB01193,Acebutolol,approved; investigational,CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(=C1)C(C)=O,C18H28N2O4,,"Adrenergic Agents, Adrenergic Antagonists, Adrenergic beta-1 Receptor Antagonists, Adrenergic beta-Antagonists, Agents causing hyperkalemia, Alcohols, Amines, Amino Alcohols, Antiarrhythmic agents, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Autonomic Agents, Beta Blocking Agents and Thiazides, Beta Blocking Agents, Selective, Beta Blocking Agents, Selective, and Thiazides, Beta-Blockers (Beta1 Selective), Bradycardia-Causing Agents, Cardiovascular Agents, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Hypotensive Agents, Neurotransmitter Agents, P-glycoprotein substrates, Peripheral Nervous System Agents, Phenoxypropanolamines, Propanolamines, Propanols, QTc Prolonging Agents, Sympathomimetics"," Beta-1 adrenergic receptor,  Beta-2 adrenergic receptor,  Cytochrome P450 2D6,  P-glycoprotein 1","DB01193, DB04846",
DB01194,Brinzolamide,approved,CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O,C12H21N3O5S3,,"Amides, Antiglaucoma Preparations and Miotics, Carbonic Anhydrase Inhibitors, Cytochrome P-450 CYP2A6 Substrates, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Diuretics, Enzyme Inhibitors, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Ophthalmics, Ophthalmologicals, Sensory Organs, Sulfonamides, Sulfones, Sulfur Compounds"," Carbonic anhydrase 2,  Carbonic anhydrase 1,  Carbonic anhydrase 4,  Carbonic anhydrase 5A, mitochondrial,  Carbonic anhydrase 3,  Cytochrome P450 3A4,  Cytochrome P450 2A6,  Cytochrome P450 2B6,  Cytochrome P450 2C8,  Cytochrome P450 2C9","DB01194, DB03877, DB02220, DB03221, DB02602",
DB01195,Flecainide,approved; withdrawn,FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1,C17H20F6N2O3,,"Antiarrhythmic agents, Antiarrhythmics, Class I, Antiarrhythmics, Class Ic, Cardiac Therapy, Cardiovascular Agents, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, MATE 1 Inhibitors, MATE 1 Substrates, MATE 1 Substrates with a Narrow Therapeutic Index, MATE inhibitors, MATE substrates, Membrane Transport Modulators, Moderate Risk QTc-Prolonging Agents, Narrow Therapeutic Index Drugs, Negative Inotrope, P-glycoprotein substrates, P-glycoprotein substrates with a Narrow Therapeutic Index, Piperidines, QTc Prolonging Agents, Sodium Channel Blockers, Voltage-Gated Sodium Channel Blockers"," Sodium channel protein type 4 subunit alpha,  Sodium channel protein type 5 subunit alpha,  Potassium voltage-gated channel subfamily H member 2,  Ryanodine receptor 2,  Cytochrome P450 2D6,  Cytochrome P450 1A2,  Cytochrome P450 2C9,  alpha1-acid glycoprotein (Protein Group),  Serum albumin,  P-glycoprotein 1,  Multidrug and toxin extrusion protein 1",DB01195,
DB01196,Estramustine,approved; investigational,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(OC(=O)N(CCCl)CCCl)C=C3CC[C@@]21[H],C23H31Cl2NO3,,"Alkylating Activity, Alkylating Drugs, Antineoplastic Agents, Antineoplastic Agents, Alkylating, Antineoplastic Agents, Hormonal, Antineoplastic and Immunomodulating Agents, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Estradiol Congeners, Estranes, Estrenes, Fused-Ring Compounds, Hydrocarbons, Halogenated, Immunosuppressive Agents, Mustard Compounds, Nitrogen Mustard Compounds, Noxae, P-glycoprotein inhibitors, Steroids, Toxic Actions"," Estrogen receptor beta,  Estrogen receptor alpha,  Microtubule-associated protein 2,  Microtubule-associated protein 1A,  Cytochrome P450 3A4,  P-glycoprotein 1","DB01196, DB14674, DB13952, DB13953, DB13386",
DB01197,Captopril,approved,C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O,C9H15NO3S,,"ACE Inhibitors and Diuretics, Agents Acting on the Renin-Angiotensin System, Agents causing angioedema, Agents causing hyperkalemia, Agents Causing Muscle Toxicity, Amino Acids, Amino Acids, Cyclic, Amino Acids, Peptides, and Proteins, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Cardiovascular Agents, Drugs causing inadvertant photosensitivity, Enzyme Inhibitors, Hypotensive Agents, Imino Acids, OAT1/SLC22A6 inhibitors, OAT1/SLC22A6 Substrates, OAT3/SLC22A8 Substrates, P-glycoprotein inhibitors, Photosensitizing Agents, Protease Inhibitors"," Angiotensin-converting enzyme,  72 kDa type IV collagenase,  Matrix metalloproteinase-9,  Leukotriene A-4 hydrolase,  B1 bradykinin receptor,  Serum albumin,  P-glycoprotein 1,  Solute carrier family 15 member 1,  Solute carrier family 22 member 6","DB01197, DB02032, DB03360, DB13087, DB05814",
DB01198,Zopiclone,approved,CN1CCN(CC1)C(=O)OC1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1,C17H17ClN6O3,,"Aza Compounds, Benzodiazepine hypnotics and sedatives, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Drugs causing inadvertant photosensitivity, Hypnotics (Nonbenzodiazepine), Hypnotics and Sedatives, Methemoglobinemia Associated Agents, Miscellaneous Anxiolytics Sedatives and Hypnotics, Nervous System, Photosensitizing Agents, Psycholeptics, Sleep Initiation and Maintenance Disorders, Zopiclone and prodrugs"," Gamma-aminobutyric acid receptor subunit alpha-1,  Gamma-aminobutyric acid receptor subunit alpha-2,  Gamma-aminobutyric acid receptor subunit alpha-3,  Gamma-aminobutyric acid receptor subunit alpha-5,  Translocator protein,  Cytochrome P450 3A4,  Cytochrome P450 2C8,  Cytochrome P450 2C9,  Prostaglandin G/H synthase 1","DB00402, DB01198",
DB01199,Tubocurarine,approved,[H][C@@]12CC3=CC=C(OC4=C5C(CC[N+](C)(C)[C@]5([H])CC5=CC(OC6=C(OC)C=C(CCN1C)C2=C6)=C(O)C=C5)=CC(OC)=C4O)C=C3,C37H41N2O6,,"Alkaloids, Amines, Anticholinergic Agents, Benzylisoquinolines, Central Nervous System Depressants, Cholinergic Agents, Cholinesterase Inhibitors, Cholinesterase substrates, Curare Alkaloids, Ganglion Blockers, Heterocyclic Compounds, Fused-Ring, Isoquinolines, Muscle Relaxants, Muscle Relaxants, Peripherally Acting Agents, Musculo-Skeletal System, Neuromuscular Agents, Neuromuscular Blocking Agents, Neuromuscular-Blocking Agents (Nondepolarizing), Neurotoxic agents, Neurotransmitter Agents, Nicotinic Antagonists, OCT1 substrates, Onium Compounds, Peripheral Nervous System Agents, Quaternary Ammonium Compounds, Tetrahydroisoquinolines"," Neuronal acetylcholine receptor subunit alpha-2,  5-hydroxytryptamine receptor 3A,  Acetylcholinesterase,  Neuronal acetylcholine receptor subunit alpha-7,  Cholinesterase,  Solute carrier family 22 member 1,  Solute carrier family 22 member 2","DB01199, DB01336, DB00416, DB14066, DB18146, DB16824, DB12093, DB01135, DB13692, DB01226",
DB01200,Bromocriptine,approved; investigational; withdrawn,[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C,C32H40BrN5O5,,"Adrenergic Agonists, Adrenergic alpha-1 Receptor Agonists, Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-2 Receptor Agonists, Adrenergic alpha-Agonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Agents producing tachycardia, Agents that produce hypertension, Alkaloids, Anti-Dyskinesia Agents, Anti-Parkinson Agents (Dopamine Agonist), Anti-Parkinson Drugs, Antidepressive Agents, Blood Glucose Lowering Agents, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dopamine Agents, Dopamine Agonists, Ergolines, Ergot Alkaloids and Derivatives, Ergot-derivative Dopamine Receptor Agonists, Ergotamines, Genito Urinary System and Sex Hormones, Heterocyclic Compounds, Fused-Ring, Hormone Antagonists, Hormones, Hormone Substitutes, and Hormone Antagonists, Hypotensive Agents, Nervous System, Neurotransmitter Agents, P-glycoprotein inhibitors, P-glycoprotein substrates, Prolactine Inhibitors, Serotonin 5-HT2 Receptor Agonists, Serotonin Agents, Serotonin Modulators, Serotonin Receptor Agonists"," Dopamine D2 receptor,  Dopamine D3 receptor,  5-hydroxytryptamine receptor 1D,  Alpha-2A adrenergic receptor,  5-hydroxytryptamine receptor 1A,  Alpha-2C adrenergic receptor,  Alpha-2B adrenergic receptor,  5-hydroxytryptamine receptor 2B,  Dopamine D4 receptor, 10. 5-hydroxytryptamine receptor 2A, 11. 5-hydroxytryptamine receptor 1B, 12. 5-hydroxytryptamine receptor 2C, 13. Dopamine D5 receptor, 14. Dopamine D1 receptor, 15. Alpha-1A adrenergic receptor, 16. Alpha-1B adrenergic receptor, 17. Alpha-1D adrenergic receptor, 18. 5-hydroxytryptamine receptor 7,  Cytochrome P450 3A4,  P-glycoprotein 1","DB01200, DB00696, DB11273, DB11274, DB11275, DB13345, DB00320, DB05735, DB11191, DB05168, DB03614, DB02868, DB00200, DB00361, DB12674, DB12586, DB17390, DB11467, DB00541, DB11641, DB03469, DB00570, DB02975, DB03906, DB00309, DB04911, DB02667, DB04431, DB04803, DB03317",
DB01201,Rifapentine,approved; investigational,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(\C=N\N1CCN(CC1)C1CCCC1)=C2O,C47H64N4O12,,"Anti-Bacterial Agents, Anti-Infective Agents, Antibiotics, Antitubercular, Antiinfectives for Systemic Use, Antimycobacterials, Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strength unknown), Cytochrome P-450 CYP2C19 Inducers, Cytochrome P-450 CYP2C19 Inducers (strong), Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 CYP2C8 Inducers (strength unknown), Cytochrome P-450 CYP2C9 Inducers, Cytochrome P-450 CYP2C9 Inducers (strength unknown), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inducers (strong), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Inducers (strong), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Substrates, Drugs for Treatment of Tuberculosis, Heterocyclic Compounds, Fused-Ring, Lactams, Macrocyclic, Leprostatic Agents, Rifamycin Antimycobacterial, Rifamycins"," DNA-directed RNA polymerase subunit beta',  Cytochrome P450 2C19,  Cytochrome P450 2B6,  Cytochrome P450 3A Subfamily (Protein Group),  Cytochrome P450 2C8,  Cytochrome P450 2C9,  Cytochrome P450 3A4","DB01201, DB01045, DB15213, DB11753, DB16312, DB01220, DB04934, DB05168, DB00615, DB11191, DB03614, DB00200, DB04220, DB11467, DB03933, DB02868, DB05735, DB00541, DB04803, DB17390, DB13013, DB00570, DB03317, DB11641, DB00361, DB12586, DB03469, DB03906, DB02975, DB00309",
DB01202,Levetiracetam,approved,CC[C@H](N1CCCC1=O)C(N)=O,C8H14N2O2,,"Acetamides, Amides, Anticonvulsants, Central Nervous System Agents, Central Nervous System Depressants, Decreased Central Nervous System Disorganized Electrical Activity, Miscellaneous Anticonvulsants, Nervous System, P-glycoprotein substrates, Pyrrolidines, Pyrrolidinones"," Voltage-dependent N-type calcium channel subunit alpha-1B,  Synaptic vesicle glycoprotein 2A,  P-glycoprotein 1","DB01202, DB11868, DB09210, DB13247, DB05541",
DB01203,Nadolol,approved,CC(C)(C)NCC(O)COC1=CC=CC2=C1C[C@H](O)[C@H](O)C2,C17H27NO4,,"Adrenergic Agents, Adrenergic Antagonists, Adrenergic beta-Antagonists, Agents causing hyperkalemia, Alcohols, Amines, Amino Alcohols, Antiarrhythmic agents, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Autonomic Agents, Beta Blocking Agents and Thiazides, Beta Blocking Agents, Non-Selective, Beta Blocking Agents, Non-Selective, and Thiazides, Bradycardia-Causing Agents, Cardiovascular Agents, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 Substrates, Drugs causing inadvertant photosensitivity, Drugs that are Mainly Renally Excreted, Hypotensive Agents, MATE 1 Substrates, MATE 2 Substrates, MATE substrates, Negative Inotrope, Neurotransmitter Agents, P-glycoprotein substrates, Peripheral Nervous System Agents, Phenoxypropanolamines, Photosensitizing Agents, Propanolamines, Propanols, Sympatholytics"," Beta-1 adrenergic receptor,  Beta-2 adrenergic receptor,  alpha1-acid glycoprotein (Protein Group),  P-glycoprotein 1,  POU domain, class 2, transcription factor 1,  POU domain, class 2, transcription factor 2,  Multidrug and toxin extrusion protein 1,  Multidrug and toxin extrusion protein 2","DB01203, DB01210, DB01359",
DB01204,Mitoxantrone,approved; investigational,OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(C(O)=CC=C1O)C2=O,C22H28N4O6,,"Analgesics, Anthracenes, Anthracyclines and Related Substances, Anthraquinones, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Substrates, Cardiotoxic antineoplastic agents, Central Nervous System Agents, Cytochrome P-450 CYP2E1 Inducers, Cytochrome P-450 CYP2E1 Inducers (strength unknown), Cytochrome P-450 CYP2E1 Inducers (weak), Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Cytotoxic Antibiotics and Related Substances, Enzyme Inhibitors, Immunosuppressive Agents, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, P-glycoprotein inducers, P-glycoprotein inhibitors, P-glycoprotein substrates, P-glycoprotein substrates with a Narrow Therapeutic Index, Peripheral Nervous System Agents, Quinones, Sensory System Agents, Topoisomerase II Inhibitors, Topoisomerase Inhibitors"," DNA,  DNA topoisomerase 2-alpha,  Cytochrome P450 1B1,  Cytochrome P450 3A4,  Cytochrome P450 2E1,  P-glycoprotein 1,  Multidrug resistance-associated protein 1,  ATP-binding cassette sub-family G member 2","DB01204, DB04975, DB03924",
DB01205,Flumazenil,approved,CCOC(=O)C1=C2CN(C)C(=O)C3=C(C=CC(F)=C3)N2C=N1,C15H14FN3O3,,"Antidotes, Benzazepines, Benzodiazepine Antagonist, Benzodiazepinones, Compounds used in a research, industrial, or household setting, Drugs that are Mainly Renally Excreted, GABA Agents, GABA Modulators, Heterocyclic Compounds, Fused-Ring, Miscellaneous Central Nervous System Agents, Neurotransmitter Agents, Protective Agents"," Gamma-aminobutyric acid receptor subunit gamma-2,  Gamma-aminobutyric acid receptor subunit alpha-5,  GABA(A) Receptor (Protein Group),  Gamma-aminobutyric acid receptor subunit alpha-1","DB01205, DB14971",
DB01206,Lomustine,approved; investigational,ClCCN(N=O)C(=O)NC1CCCCC1,C9H16ClN3O2,,"Alkylating Activity, Alkylating Drugs, Amides, Antineoplastic Agents, Antineoplastic Agents, Alkylating, Antineoplastic and Immunomodulating Agents, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Immunosuppressive Agents, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, Nitroso Compounds, Nitrosourea Compounds, Nitrosoureas, Noxae, Toxic Actions"," DNA,  Stathmin-4,  Cytochrome P450 2D6,  Cytochrome P450 3A4","DB01206, DB12968",
DB01207,Ridogrel,experimental,OC(=O)CCCCO\N=C(\C1=CN=CC=C1)C1=CC(=CC=C1)C(F)(F)F,C18H17F3N2O3,,"Acids, Acyclic, Antiplatelet agents, Enzyme Inhibitors, Fatty Acids, Fatty Acids, Volatile, Gastrointestinal Agents, Hematologic Agents, Lipids, Thromboxane-A Synthase, antagonists & inhibitors, Valerates"," Thromboxane-A synthase,  Thromboxane A2 receptor",DB01207,
DB01208,Sparfloxacin,approved; investigational; withdrawn,C[C@H]1CN(C[C@@H](C)N1)C1=C(F)C(N)=C2C(=O)C(=CN(C3CC3)C2=C1F)C(O)=O,C19H22F2N4O3,,"Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Drugs for Treatment of Tuberculosis, Enzyme Inhibitors, Fluoroquinolones, Heterocyclic Compounds, Fused-Ring, Highest Risk QTc-Prolonging Agents, P-glycoprotein substrates, QTc Prolonging Agents, Quinolines, Quinolones, Topoisomerase II Inhibitors, Topoisomerase Inhibitors"," DNA gyrase subunit A,  DNA topoisomerase 4 subunit A,  DNA topoisomerase 2-alpha,  Cytochrome P450 1A2,  Solute carrier family 22 member 5,  Canalicular multispecific organic anion transporter 1,  P-glycoprotein 1","DB01208, DB11443, DB00978, DB00537, DB11404, DB11393, DB04576, DB00365, DB01059, DB00487, DB01044, DB06771, DB11453, DB14025, DB01405, DB00218, DB13261, DB11491, DB11511, DB12447, DB16219, DB09047, DB01137, DB01165, DB03034, DB13772, DB11847, DB06600, DB11892",
DB01209,Dezocine,approved; investigational,[H][C@@]12CC3=CC=C(O)C=C3[C@@](C)(CCCCC1)[C@H]2N,C16H23NO,,"Analgesics, Central Nervous System Agents, Central Nervous System Depressants, Naphthalenes, Narcotics, Nervous System, Opioid Antagonists, Opioids, Peripheral Nervous System Agents, Sensory System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"," Mu-type opioid receptor,  Kappa-type opioid receptor","DB01209, DB00854, DB14682, DB13606, DB00514, DB00504",
DB01210,Levobunolol,approved,CC(C)(C)NC[C@H](O)COC1=CC=CC2=C1CCCC2=O,C17H25NO3,,"Adrenergic Agents, Adrenergic Antagonists, Adrenergic beta-Antagonists, Agents causing hyperkalemia, Alcohols, Amines, Amino Alcohols, Antiglaucoma Preparations and Miotics, Autonomic Agents, Beta-adrenergic Agents, Bradycardia-Causing Agents, Bunolol, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 Substrates, Hypotensive Agents, Naphthalenes, Neurotransmitter Agents, Ophthalmologicals, Peripheral Nervous System Agents, Phenoxypropanolamines, Propanolamines, Propanols, Sensory Organs, Sympatholytics, Tetrahydronaphthalenes"," Beta-1 adrenergic receptor,  Beta-2 adrenergic receptor,  Cytochrome P450 2D6","DB01210, DB01203",
DB01211,Clarithromycin,approved,[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC,C38H69NO13,,"Alimentary Tract and Metabolism, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, BSEP/ABCB11 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strong), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Inhibitors, Cytochrome P-450 CYP3A5 Inhibitors (strong), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord), Enzyme Inhibitors, Erythromycin and similars, Lactones, Macrolide Antimicrobial, Macrolides, Macrolides, Lincosamides and Streptogramins, Moderate Risk QTc-Prolonging Agents, OATP1B1/SLCO1B1 Inhibitors, OATP1B3 inhibitors, Other Macrolides, P-glycoprotein inhibitors, P-glycoprotein substrates, Polyketides, Protein Synthesis Inhibitors, QTc Prolonging Agents"," 50S ribosomal protein L10,  Potassium voltage-gated channel subfamily H member 2,  Solute carrier organic anion transporter family member 1B1,  Solute carrier organic anion transporter family member 1B3,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Solute carrier family 22 member 7,  P-glycoprotein 1,  Bile salt export pump,  Solute carrier organic anion transporter family member 1B1,  Solute carrier organic anion transporter family member 1B3","DB01211, DB00199, DB11442, DB13338, DB13179, DB11474, DB00207, DB11416, DB00778, DB01321, DB13456, DB13409, DB09309, DB11383, DB15981, DB00954, DB11554, DB11475, DB06587, DB06145",
DB01212,Ceftriaxone,approved,[H][C@]12SCC(CSC3=NC(=O)C(=O)NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O,C18H18N8O7S3,,"Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, beta Lactam Antibiotics, beta-Lactams, Cephalosporins, Drugs that are Mainly Renally Excreted, Heterocyclic Compounds, Fused-Ring, Lactams, Nephrotoxic agents, OAT1/SLC22A6 inhibitors, OAT3/SLC22A8 Inhibitors, P-glycoprotein inhibitors, Sulfur Compounds, Thiazines, Third-Generation Cephalosporins"," Penicillin-binding protein 2B,  Solute carrier family 22 member 11,  Solute carrier family 22 member 6,  Solute carrier family 22 member 8,  Solute carrier family 15 member 1,  Glutamine synthetase,  Serum albumin,  Solute carrier family 15 member 1,  Solute carrier family 15 member 2,  Solute carrier family 22 member 6,  Solute carrier family 22 member 8,  Solute carrier family 22 member 11,  P-glycoprotein 1","DB01212, DB00267, DB13504, DB13470, DB00671, DB01416, DB00493, DB00535, DB01413, DB00229, DB11485, DB00438, DB01066, DB11505, DB01332, DB13682, DB14879, DB13667, DB13461, DB00430, DB05735, DB01326, DB00274, DB01328, DB06590, DB01330, DB09050, DB09062, DB01329, DB04918",
DB01213,Fomepizole,approved; vet_approved,CC1=CNN=C1,C4H6N2,,"Antidotes, Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP2A6 Inhibitors, Cytochrome P-450 CYP2A6 Inhibitors (strength unknown), Cytochrome P-450 CYP2E1 Inducers, Cytochrome P-450 CYP2E1 Inducers (strength unknown), Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Protective Agents, Pyrazoles"," Alcohol dehydrogenase 1A,  Alcohol dehydrogenase 1B,  Alcohol dehydrogenase 1C,  Catalase,  Cytochrome P450 2A6,  Cytochrome P450 2E1",DB01213,
DB01214,Metipranolol,approved,CC(C)NCC(O)COC1=C(C)C(C)=C(OC(C)=O)C(C)=C1,C17H27NO4,,"Adrenergic Agents, Adrenergic Antagonists, Adrenergic beta-Antagonists, Agents causing hyperkalemia, Alcohols, Amines, Amino Alcohols, Antiarrhythmic agents, Antiglaucoma Preparations and Miotics, Antihypertensive Agents, Autonomic Agents, Beta Blocking Agents and Thiazides, Beta Blocking Agents, Non-Selective, and Thiazides, Bradycardia-Causing Agents, Cardiovascular Agents, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 Substrates, Hypotensive Agents, Neurotransmitter Agents, Ophthalmologicals, Peripheral Nervous System Agents, Phenoxypropanolamines, Propanolamines, Propanols, Sensory Organs, Sympatholytics"," Beta-1 adrenergic receptor,  Beta-2 adrenergic receptor,  Cytochrome P450 2D6","DB01214, DB07573",
DB01215,Estazolam,approved; illicit,ClC1=CC2=C(C=C1)N1C=NN=C1CN=C2C1=CC=CC=C1,C16H11ClN4,,"Anti-Anxiety Agents, Anticonvulsants, Benzazepines, Benzodiazepine hypnotics and sedatives, Benzodiazepines and benzodiazepine derivatives, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Drugs causing inadvertant photosensitivity, Drugs that are Mainly Renally Excreted, GABA Agents, GABA Modulators, Heterocyclic Compounds, Fused-Ring, Hypnotics and Sedatives, Nervous System, Neurotransmitter Agents, Photosensitizing Agents, Psycholeptics, Psychotropic Drugs, Tranquilizing Agents, Triazolobenzodiazepines"," GABA(A) Receptor (Protein Group),  GABA(A) Receptor Benzodiazepine Binding Site (Protein Group),  Cytochrome P450 3A4","DB01215, DB00404, DB00897, DB00546, DB14716, DB14717",
DB01216,Finasteride,approved,[H][C@@]12CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])NC(=O)C=C[C@]12C,C23H36N2O2,,"5-alpha Reductase Inhibitors, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Agents that produce hypertension, Androstanes, Androstenes, Azasteroids, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Substrates, Dermatologicals, Drugs Used in Benign Prostatic Hypertrophy, Enzyme Inhibitors, Fused-Ring Compounds, Genito Urinary System and Sex Hormones, Genitourinary Agents, Hormone Antagonists, Hormones, Hormone Substitutes, and Hormone Antagonists, Misc. Skin and Mucous Membrane Agents, Steroid Synthesis Inhibitors, Steroids, Urological Agents, Urologicals"," 3-oxo-5-alpha-steroid 4-dehydrogenase 2,  3-oxo-5-alpha-steroid 4-dehydrogenase 1,  3-oxo-5-beta-steroid 4-dehydrogenase,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  Solute carrier family 12 member 5",DB01216,
DB01217,Anastrozole,approved; investigational,CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N,C17H19N5,,"Antineoplastic Agents, Antineoplastic Agents, Hormonal, Antineoplastic and Immunomodulating Agents, Aromatase Inhibitors, Cardiotoxic antineoplastic agents, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Endocrine Therapy, Enzyme Inhibitors, Estrogen Antagonists, Hormone Antagonists, Hormone Antagonists and Related Agents, Hormones, Hormone Substitutes, and Hormone Antagonists, Nitriles, P-glycoprotein substrates, Steroid Synthesis Inhibitors, Triazoles, UGT1A3 substrates, UGT1A4 substrates, UGT2B7 substrates"," Cytochrome P450 19A1,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 2C8,  UDP-glucuronosyltransferase 1-4,  UDP-glucuronosyltransferase 1-3,  UDP-glucuronosyltransferase 2B7,  Cytochrome P450 1A2,  Cytochrome P450 2C9,  P-glycoprotein 1",DB01217,
DB01218,Halofantrine,approved,CCCCN(CCCC)CCC(O)C1=C2C=CC(=CC2=C2C=C(Cl)C=C(Cl)C2=C1)C(F)(F)F,C26H30Cl2F3NO,,"Agents that reduce seizure threshold, Anti-Infective Agents, Antimalarials, Antiparasitic Agents, Antiparasitic Products, Insecticides and Repellents, Antiprotozoals, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strong), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Highest Risk QTc-Prolonging Agents, QTc Prolonging Agents"," Fe(II)-protoporphyrin IX,  Potassium voltage-gated channel subfamily H member 2,  Plasmepsin-2,  Cytochrome P450 2D6,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 2C8",DB01218,
DB01219,Dantrolene,approved; investigational,[O-][N+](=O)C1=CC=C(C=C1)C1=CC=C(O1)\C=N\N1CC(=O)NC1=O,C14H10N4O5,,"Agents causing hyperkalemia, Agents that produce neuromuscular block (indirect), Central Nervous System Agents, Central Nervous System Depressants, Dantrolene and Derivatives, Decreased Striated Muscle Contraction, Decreased Striated Muscle Tone, Direct-acting Skeletal Muscle Relaxants, Hepatotoxic Agents, Hydantoins, Imidazoles, Imidazolidines, Muscle Relaxants, Muscle Relaxants, Centrally Acting Agents, Musculo-Skeletal System, Neuromuscular Agents, Peripheral Nervous System Agents, Thyroxine-binding globulin substrates"," Ryanodine receptor 1,  Thyroxine-binding globulin","DB01219, DB04957",
DB01220,Rifaximin,approved; investigational,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C1=C(N=C5C=C(C)C=CN15)C4=C3C2=O,C43H51N3O11,,"Alimentary Tract and Metabolism, Anti-Bacterial Agents, Anti-Infective Agents, Antibiotics for Topical Use, Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents, Cytochrome P-450 CYP2C19 Inducers, Cytochrome P-450 CYP2C19 Inducers (strong), Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 CYP2C8 Inducers (strength unknown), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inducers (strong), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Inducers (strong), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Substrates, Dermatologicals, Gastrointestinal Agents, Heterocyclic Compounds, Fused-Ring, Intestinal Antiinfectives, Lactams, Macrocyclic, Rifamycin Antibacterial, Rifamycins"," DNA-directed RNA polymerase subunit beta,  Nuclear receptor subfamily 1 group I member 2,  Cytochrome P450 3A4,  Cytochrome P450 2C19,  Cytochrome P450 2C8","DB01220, DB04934, DB11753, DB01045, DB16312, DB01201, DB15213, DB11191, DB05168, DB03614, DB00615, DB00200, DB04220, DB11467, DB04803, DB11641, DB05735, DB17390, DB03469, DB12674, DB00570, DB00541, DB00361, DB12586, DB03317, DB02868, DB03906, DB02667, DB02975, DB00309",
DB01221,Ketamine,approved; vet_approved,CNC1(CCCCC1=O)C1=CC=CC=C1Cl,C13H16ClNO,,"Agents producing tachycardia, Amino Acids, Amino Acids, Acidic, Amino Acids, Dicarboxylic, Amino Acids, Peptides, and Proteins, Analgesics, Anesthetics, Anesthetics, Dissociative, Anesthetics, General, Anesthetics, Intravenous, Central Nervous System Agents, Central Nervous System Depressants, Cholinesterase Inhibitors, Cyclohexanes, Cycloparaffins, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Excitatory Amino Acid Agents, Excitatory Amino Acid Agonists, Excitatory Amino Acid Antagonists, Miscellaneous General Anesthetics, N-Methylaspartate, agonists, Nervous System, Neurotransmitter Agents, NMDA Receptor Antagonists, Peripheral Nervous System Agents, Sensory System Agents, Vasodilating Agents"," Glutamate receptor ionotropic, NMDA 3A,  5-hydroxytryptamine receptor 3A,  Neuronal acetylcholine receptor subunit alpha-7,  Cholinesterase,  Nitric oxide synthase, brain,  Neurokinin 1 receptor,  Dopamine D2 receptor,  Delta-type opioid receptor,  Sodium-dependent noradrenaline transporter, 10. Kappa-type opioid receptor, 11. Mu-type opioid receptor, 12. Muscarinic acetylcholine receptor (Protein Group), 13. 5-hydroxytryptamine receptor 2 (Protein Group), 14. 5-hydroxytryptamine receptor 1 (Protein Group),  Prostaglandin G/H synthase 1,  Cytochrome P450 2C8,  Cytochrome P450 2B6,  Cytochrome P450 2C9,  Cytochrome P450 3A4","DB01221, DB11823",
DB01222,Budesonide,approved,[H][C@@]12C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,C25H34O6,,"Adrenal Cortex Hormones, Adrenals, Agents to Treat Airway Disease, Alimentary Tract and Metabolism, Anti-Asthmatic Agents, Anti-Inflammatory Agents, Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents, Autonomic Agents, Bronchodilator Agents, BSEP/ABCB11 Substrates, Corticosteroid Hormone Receptor Agonists, Corticosteroids, Corticosteroids Acting Locally, Corticosteroids for Systemic Use, Corticosteroids, Dermatological Preparations, Corticosteroids, Potent (Group III), Cytochrome P-450 CYP2A6 Inducers, Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strength unknown), Cytochrome P-450 CYP2C19 Inducers, Cytochrome P-450 CYP2C19 Inducers (strength unknown), Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 CYP2C8 Inducers (strength unknown), Cytochrome P-450 CYP2C9 Inducers, Cytochrome P-450 CYP2C9 Inducers (strength unknown), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Inducers, Cytochrome P-450 CYP3A5 Inducers (moderate), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Substrates, Dermatologicals, Drugs for Obstructive Airway Diseases, Drugs that are Mainly Renally Excreted, Fused-Ring Compounds, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Immunosuppressive Agents, Intestinal Antiinflammatory Agents, Nasal Preparations, OAT3/SLC22A8 Substrates, P-glycoprotein substrates, Peripheral Nervous System Agents, Pregnanes, Pregnenediones, Pregnenes, Respiratory System Agents, Steroids"," Glucocorticoid receptor,  Annexin A1,  Cytochrome P450 3A5,  Cytochrome P450 3A Subfamily (Protein Group),  Cytochrome P450 2A6,  Cytochrome P450 1B1,  Cytochrome P450 2B6,  Cytochrome P450 2C8,  Cytochrome P450 2C9,  Cytochrome P450 2C19,  Cytochrome P450 3A4,  Corticosteroid-binding globulin,  Serum albumin,  Bile salt export pump,  P-glycoprotein 1,  Solute carrier organic anion transporter family member 1A2,  Solute carrier family 22 member 8","DB01222, DB01260, DB01410, DB00180, DB00288, DB15835, DB01130, DB14662, DB00591, DB18738, DB14643, DB01047, DB14632, DB00846, DB15999, DB14633, DB14644, DB15566, DB14673, DB08973, DB13751, DB14596",
DB01223,Aminophylline,approved,NCCN.CN1C2=C(NC=N2)C(=O)N(C)C1=O.CN1C2=C(NC=N2)C(=O)N(C)C1=O,C16H24N10O4,,"Agents that reduce seizure threshold, Amines, Anti-Asthmatic Agents, Autonomic Agents, Bronchodilator Agents, Cardiotonic Agents, Cardiovascular Agents, Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Substrates, Diamines, Drugs for Obstructive Airway Diseases, Enzyme Inhibitors, Ethylenediamines, Heterocyclic Compounds, Fused-Ring, Narrow Therapeutic Index Drugs, Neurotransmitter Agents, Peripheral Nervous System Agents, Pharmaceutical Preparations, Phosphodiesterase Inhibitors, Polyamines, Protective Agents, Purinergic Agents, Purinergic Antagonists, Purinergic P1 Receptor Antagonists, Purines, Purinones, Respiratory Smooth Muscle Relaxants, Respiratory System Agents, Xanthine derivatives, Xanthines and Adrenergics"," cGMP-inhibited 3',5'-cyclic phosphodiesterase A,  Adenosine receptor A1,  Adenosine receptor A3,  Histone deacetylase 2,  Cytochrome P450 2E1,  Cytochrome P450 3A4,  Cytochrome P450 1A2","DB01223, DB00277, DB01303, DB13812, DB00201, DB01412, DB03293, DB14132, DB01778, DB14018, DB00824, DB07954, DB13592, DB13573, DB13449, DB09273, DB02134, DB00651, DB13634",
DB01224,Quetiapine,approved,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12,C21H25N3O2S,,"Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Agents producing tachycardia, Agents that produce hypertension, Anticholinergic Agents, Antidepressive Agents, Antidepressive Agents Indicated for Depression, Antipsychotic Agents, Antipsychotic Agents (Second Generation [Atypical]), Azepines, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Substrates, Diazepines, Oxazepines, Thiazepines and Oxepines, Dibenzothiazepines, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Drugs that are Mainly Renally Excreted, Heterocyclic Compounds, Fused-Ring, Histamine Antagonists, Histamine H1 Antagonists, Hyperglycemia-Associated Agents, Hypotensive Agents, Moderate Risk QTc-Prolonging Agents, Muscarinic Antagonists, Nervous System, P-glycoprotein substrates, Psycholeptics, Psychotropic Drugs, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT1 Receptor Antagonists, Serotonin 5-HT1A Receptor Antagonists, Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2A Receptor Antagonists, Serotonin Agents, Serotonin Receptor Antagonists, Thiazepines, Thiepins, Tranquilizing Agents"," 5-hydroxytryptamine receptor 2A,  Dopamine D2 receptor,  5-hydroxytryptamine receptor 1A,  5-hydroxytryptamine receptor 1B,  5-hydroxytryptamine receptor 1D,  5-hydroxytryptamine receptor 1E,  5-hydroxytryptamine receptor 2C,  5-hydroxytryptamine receptor 3A,  5-hydroxytryptamine receptor 6, 10. 5-hydroxytryptamine receptor 7, 11. Dopamine D1 receptor, 12. Dopamine D5 receptor, 13. Dopamine D3 receptor, 14. Dopamine D4 receptor, 15. Histamine H1 receptor, 16. Alpha-1 adrenergic receptors (Protein Group), 17. Alpha-2A adrenergic receptor, 18. Alpha-2B adrenergic receptor, 19. Alpha-2C adrenergic receptor, 20. Muscarinic acetylcholine receptor M1, 21. Muscarinic acetylcholine receptor M2, 22. Muscarinic acetylcholine receptor M3, 23. Muscarinic acetylcholine receptor M4, 24. Muscarinic acetylcholine receptor M5,  Cytochrome P450 2C19,  Cytochrome P450 2D6,  Cytochrome P450 3A7,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  P-glycoprotein 1","DB01224, DB13256",
DB01225,Enoxaparin,approved,,,,"Agents causing hyperkalemia, Anticoagulants, Blood and Blood Forming Organs, Cardiovascular Agents, Fibrin Modulating Agents, Glycosaminoglycans, Hematologic Agents, Heparin (Low Molecular Weight), Heparin and similars, Heparin Group"," Antithrombin-III,  Coagulation factor X,  Prothrombin,  Myeloperoxidase",,
DB01226,Mivacurium,approved,COC1=CC(C[C@@H]2C3=CC(OC)=C(OC)C=C3CC[N+]2(C)CCCOC(=O)CC\C=C\CCC(=O)OCCC[N+]2(C)CCC3=CC(OC)=C(OC)C=C3[C@H]2CC2=CC(OC)=C(OC)C(OC)=C2)=CC(OC)=C1OC,C58H80N2O14,,"Agents producing tachycardia, Anticholinergic Agents, Central Nervous System Depressants, Cholinergic Agents, Cholinesterase substrates, Heterocyclic Compounds, Fused-Ring, Isoquinolines, Muscarinic Antagonists, Muscle Relaxants, Muscle Relaxants, Peripherally Acting Agents, Musculo-Skeletal System, Neuromuscular Agents, Neuromuscular Blocking Agents, Neuromuscular-Blocking Agents (Nondepolarizing), Nicotinic Antagonists, Peripheral Nervous System Agents"," Neuronal acetylcholine receptor subunit alpha-2,  Muscarinic acetylcholine receptor M2,  Muscarinic acetylcholine receptor M3,  Cholinesterase,  Cholinesterase","DB01226, DB00565, DB01135, DB00732, DB05710, DB13692, DB12093, DB00767, DB01199, DB01336, DB00416",
DB01227,Levacetylmethadol,approved; investigational; withdrawn,CC[C@H](OC(C)=O)C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1,C23H31NO2,,"Analgesics, Anticholinergic Agents, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Substrates, Drugs Used in Addictive Disorders, Drugs Used in Opioid Dependence, Ketones, Moderate Risk QTc-Prolonging Agents, Narcotics, Narrow Therapeutic Index Drugs, Nervous System, Nicotinic Antagonists, Opioids, Peripheral Nervous System Agents, QTc Prolonging Agents, Sensory System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"," Mu-type opioid receptor,  Neuronal acetylcholine receptor subunit beta-4,  Neuronal acetylcholine receptor subunit alpha-3,  Cytochrome P450 3A4,  Cytochrome P450 3A7","DB01227, DB01433, DB01522, DB01555, DB01498",
DB01228,Encainide,approved; investigational; withdrawn,COC1=CC=C(C=C1)C(=O)NC1=CC=CC=C1CCC1CCCCN1C,C22H28N2O2,,"Amides, Amines, Anilides, Aniline Compounds, Antiarrhythmic agents, Antiarrhythmics, Class I, Antiarrhythmics, Class Ic, Cardiac Therapy, Cardiovascular Agents, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 Substrates, Membrane Transport Modulators, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Sodium Channel Blockers, Voltage-Gated Sodium Channel Blockers"," Sodium channel protein type 5 subunit alpha,  Cytochrome P450 2D6",DB01228,
DB01229,Paclitaxel,approved; vet_approved,[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C,C47H51NO14,,"Agents Causing Muscle Toxicity, Albumins, Amino Acids, Peptides, and Proteins, Antimitotic Agents, Antineoplastic Agents, Antineoplastic Agents, Phytogenic, Antineoplastic and Immunomodulating Agents, BSEP/ABCB11 Inhibitors, BSEP/ABCB11 Substrates, BSEP/ABCB11 Substrates with a Narrow Therapeutic Index, Cardiotoxic antineoplastic agents, Cyclodecanes, Cycloparaffins, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Substrates, Diterpenes, Hypotensive Agents, Immunosuppressive Agents, Microtubule Inhibition, Microtubule Inhibitors, Mitosis Modulators, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, Neurotoxic agents, OATP1B3 substrates, P-glycoprotein inhibitors, P-glycoprotein substrates, P-glycoprotein substrates with a Narrow Therapeutic Index, Proteins, Taxane Derivatives, Taxoids, Terpenes, Tubulin Modulators"," Tubulin beta-1 chain,  Apoptosis regulator Bcl-2,  Microtubule-associated protein 4,  Microtubule-associated protein 2,  Microtubule-associated protein tau,  Nuclear receptor subfamily 1 group I member 2,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  Cytochrome P450 19A1,  Cytochrome P450 1B1,  Cytochrome P450 2C8,  Bile salt export pump,  P-glycoprotein 1,  Multidrug resistance-associated protein 1,  Multidrug resistance-associated protein 7,  Solute carrier organic anion transporter family member 1B3,  Canalicular multispecific organic anion transporter 1","DB01229, DB12633, DB17223, DB12619, DB05297, DB06772, DB01248, DB12984, DB15384, DB12144, DB12334, DB11669, DB17168, DB12019",
DB01230,Pemoline,approved; illicit; investigational; withdrawn,NC1=NC(=O)C(O1)C1=CC=CC=C1,C9H8N2O2,,"Central Nervous System Agents, Central Nervous System Stimulants, Centrally Acting Sympathomimetics, Nervous System, Oxazoles, Psychoanaleptics, Psychostimulants, Agents Used for ADHD and Nootropics",,"DB01230, DB13341, DB01490, DB01447",
DB01231,Diphenidol,approved; investigational; withdrawn,OC(CCCN1CCCCC1)(C1=CC=CC=C1)C1=CC=CC=C1,C21H27NO,,"Agents producing tachycardia, Anticholinergic Agents, Antiemetics, Autonomic Agents, Central Nervous System Agents, Emesis Suppression, Gastrointestinal Agents, Muscarinic Antagonists, Peripheral Nervous System Agents"," Muscarinic acetylcholine receptor M2,  Muscarinic acetylcholine receptor M1,  Muscarinic acetylcholine receptor M3","DB01231, DB00342, DB00950, DB09076, DB13642",
DB01232,Saquinavir,approved; investigational,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C,C38H50N6O5,,"Agents Causing Muscle Toxicity, Anti-HIV Agents, Anti-Infective Agents, Anti-Retroviral Agents, Antiinfectives for Systemic Use, Antiviral Agents, Antivirals for Systemic Use, BCRP/ABCG2 Inhibitors, BSEP/ABCB11 Substrates, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (moderate), Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strong), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Inhibitors, Cytochrome P-450 CYP3A5 Inhibitors (strength unknown), Cytochrome P-450 CYP3A5 Inhibitors (strong), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Inhibitors, Cytochrome P-450 CYP3A7 Inhibitors (strength unknown), Cytochrome P-450 CYP3A7 Inhibitors (strong), Cytochrome P-450 CYP3A7 Inhibitors (weak), Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Direct Acting Antivirals, Enzyme Inhibitors, Heterocyclic Compounds, Fused-Ring, HIV Protease Inhibitors, Hyperglycemia-Associated Agents, Isoquinolines, Moderate Risk QTc-Prolonging Agents, OATP1B1/SLCO1B1 Inhibitors, OCT1 inhibitors, Organic Anion Transporting Polypeptide 2B1 Inhibitors, P-glycoprotein inducers, P-glycoprotein inhibitors, P-glycoprotein substrates, Protease Inhibitors, QTc Prolonging Agents, Quinolines, Viral Protease Inhibitors"," Human immunodeficiency virus type 1 protease,  Cytochrome P450 2C8,  Cytochrome P450 2D6,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  Alpha-1-acid glycoprotein 1,  Serum albumin,  P-glycoprotein 1,  Solute carrier family 22 member 1,  Solute carrier organic anion transporter family member 1A2,  ATP-binding cassette sub-family G member 2,  Solute carrier organic anion transporter family member 1B1,  Multidrug resistance-associated protein 1,  Canalicular multispecific organic anion transporter 1,  Solute carrier organic anion transporter family member 2B1,  Bile salt export pump","DB01232, DB12178, DB03383",
DB01233,Metoclopramide,approved; investigational,CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC,C14H22ClN3O2,,"Acids, Carbocyclic, Agents Causing Muscle Toxicity, Alimentary Tract and Metabolism, Amides, Aminobenzoates, Antiemetics, Autonomic Agents, Benzamides and benzamide derivatives, Benzoates, Central Nervous System Agents, Central Nervous System Depressants, Chlorobenzoates, Cholinesterase Inhibitors, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dopamine Agents, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Drugs for Functional Gastrointestinal Disorders, Drugs that are Mainly Renally Excreted, Gastrointestinal Agents, Hydroxybenzoates, Methemoglobinemia Associated Agents, Neurotransmitter Agents, P-glycoprotein substrates, para-Aminobenzoates, Peripheral Nervous System Agents, Potential QTc-Prolonging Agents, Prokinetic Agents, Propulsives, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"," 5-hydroxytryptamine receptor 4,  5-hydroxytryptamine receptor 3A,  Muscarinic acetylcholine receptor M1,  Dopamine D2 receptor,  Cytochrome P450 3A4,  Cytochrome P450 1A2,  Cytochrome P450 2D6,  Alpha-1-acid glycoprotein 1,  P-glycoprotein 1","DB01233, DB13511, DB06421, DB12518, DB09018",
DB01234,Dexamethasone,approved; investigational; vet_approved,[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,C22H29FO5,,"Adrenal Cortex Hormones, Adrenals, Agents Causing Muscle Toxicity, Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use, Alimentary Tract and Metabolism, Anti-Acne Preparations, Anti-Acne Preparations for Topical Use, Anti-Inflammatory Agents, Antiemetics, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Autonomic Agents, BCRP/ABCG2 Inhibitors, BSEP/ABCB11 inducers, Central Nervous System Agents, Corticosteroid Hormone Receptor Agonists, Corticosteroids, Corticosteroids for Local Oral Treatment, Corticosteroids for Systemic Use, Corticosteroids for Systemic Use, Plain, Corticosteroids, Dermatological Preparations, Corticosteroids, Moderately Potent (Group II), Cytochrome P-450 CYP2A6 Inducers, Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strength unknown), Cytochrome P-450 CYP2C19 Inducers, Cytochrome P-450 CYP2C19 Inducers (strength unknown), Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 CYP2C8 Inducers (strength unknown), Cytochrome P-450 CYP2E1 Inducers, Cytochrome P-450 CYP2E1 Inducers (strength unknown), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inducers (strong), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (moderate), Cytochrome P-450 CYP3A4 Inducers (strong), Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (weak), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Inducers, Cytochrome P-450 CYP3A5 Inducers (moderate), Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Inducers, Cytochrome P-450 CYP3A7 Inducers (strength unknown), Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dermatologicals, Experimental Unapproved Treatments for COVID-19, Fused-Ring Compounds, Gastrointestinal Agents, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hyperglycemia-Associated Agents, Immunosuppressive Agents, Inducers of Drug Clearance, Nasal Preparations, OAT3/SLC22A8 Substrates, Ophthalmological and Otological Preparations, Ophthalmologicals, Otologicals, P-glycoprotein inducers, P-glycoprotein inhibitors, P-glycoprotein substrates, Peripheral Nervous System Agents, Pregnadienes, Pregnadienetriols, Pregnanes, Sensory Organs, Steroids, Steroids, Fluorinated, Stomatological Preparations, Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins, Vasoprotectives"," Glucocorticoid receptor,  Nuclear receptor subfamily 0 group B member 1,  Annexin A1,  Nitric oxide synthase, inducible,  Nuclear receptor subfamily 1 group I member 2,  Corticosteroid 11-beta-dehydrogenase isozyme 2,  Cytochrome P450 3A4,  Corticosteroid 11-beta-dehydrogenase isozyme 1,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  Steroid 17-alpha-hydroxylase/17,20 lyase,  Cytochrome P450 1A1,  Cytochrome P450 2A6,  Cytochrome P450 2B6, 10. Cytochrome P450 2C19, 11. Cytochrome P450 2C8, 12. Cytochrome P450 2E1, 13. Cytochrome P450 3A43, 14. Cytochrome P450 4A11, 15. Cytochrome P450 11B1, mitochondrial,  Serum albumin,  P-glycoprotein 1,  Solute carrier family 22 member 8,  Bile salt export pump,  Canalicular multispecific organic anion transporter 1,  ATP-binding cassette sub-family G member 2,  Solute carrier organic anion transporter family member 1A2","DB00443, DB01234, DB11522, DB13491, DB00324, DB00620, DB00547, DB08970, DB11750, DB00223, DB00663, DB09095, DB12553, DB14640, DB14649, DB14669, DB00687, DB01384, DB09378, DB00596, DB14634, DB00860, DB00959, DB08971, DB13728, DB13158, DB13223, DB01185, DB13208, DB14664",
DB01235,Levodopa,approved,N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O,C9H11NO4,,"Amines, Amino Acids, Amino Acids, Aromatic, Amino Acids, Cyclic, Amino Acids, Peptides, and Proteins, Anti-Dyskinesia Agents, Anti-Parkinson Agents (Dopamine Agonist), Anti-Parkinson Drugs, Benzene Derivatives, Biogenic Amines, Biogenic Monoamines, Catecholamines, Catechols, Central Nervous System Agents, Central Nervous System Depressants, Dihydroxyphenylalanine, Dopa and Dopa Derivatives, Dopamine Agents, Hypotensive Agents, Levodopa, antagonists & inhibitors, Nervous System, Neurotransmitter Agents, Phenols, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"," Dopamine D1 receptor,  Dopamine D5 receptor,  Dopamine D2 receptor,  Dopamine D3 receptor,  Dopamine D4 receptor,  Aromatic-L-amino-acid decarboxylase,  Serum albumin,  Solute carrier family 15 member 1,  Monocarboxylate transporter 10,  Large neutral amino acids transporter small subunit 1,  Large neutral amino acids transporter small subunit 2","DB01235, DB00968, DB03552, DB13313, DB06535, DB00190, DB06262, DB00135, DB03839, DB13848, DB00765, DB16306, DB16683, DB17621, DB07979, DB04208, DB06707, DB15296",
DB01236,Sevoflurane,approved; vet_approved,FCOC(C(F)(F)F)C(F)(F)F,C4H3F7O,,"Agents that produce hypertension, Anesthetics, Anesthetics, General, Anesthetics, Inhalation, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2A6 Substrates, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Ethers, Hydrocarbons, Fluorinated, Hydrocarbons, Halogenated, Hypotensive Agents, Methyl Ethers, Nervous System, Potential QTc-Prolonging Agents, QTc Prolonging Agents"," GABA(A) Receptor (Protein Group),  Glycine receptor subunit alpha-1,  Glutamate receptor 1,  Calcium transporting ATPases (Protein Group),  NADH-ubiquinone oxidoreductase chain 1,  Mitochondrial potassium channel,  Cytochrome P450 2B6,  Cytochrome P450 2E1,  Cytochrome P450 2A6,  Cytochrome P450 3A4,  Serum albumin",DB01236,
DB01237,Bromodiphenhydramine,approved,CN(C)CCOC(C1=CC=CC=C1)C1=CC=C(Br)C=C1,C17H20BrNO,,"Amines, Aminoalkyl Ethers, Antihistamines for Systemic Use, Benzene Derivatives, Benzhydryl Compounds, Ethylamines, Histamine Antagonists, Histamine H1 Antagonists"," Histamine H1 receptor,  Solute carrier family 22 member 6","DB01237, DB01075, DB13769",
DB01238,Aripiprazole,approved; investigational,ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl,C23H27Cl2N3O2,,"Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Agents producing tachycardia, Agents that produce hypertension, Anticholinergic Agents, Antidepressive Agents, Antidepressive Agents Indicated for Depression, Antipsychotic Agents, Antipsychotic Agents (Second Generation [Atypical]), Aripiprazole and prodrugs, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 Substrates, Dopamine Agents, Dopamine Agonists, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Heterocyclic Compounds, Fused-Ring, Histamine Antagonists, Histamine H1 Antagonists, Hyperglycemia-Associated Agents, Muscarinic Antagonists, Nervous System, Neurotoxic agents, Neurotransmitter Agents, P-glycoprotein inhibitors, Piperazines, Potential QTc-Prolonging Agents, Psycholeptics, Psychotropic Drugs, QTc Prolonging Agents, QTc shortening agents, Quinolines, Quinolones, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT1 Receptor Agonists, Serotonin 5-HT1 Receptor Antagonists, Serotonin 5-HT1D Receptor Antagonists, Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2A Receptor Antagonists, Serotonin 5-HT2C Receptor Antagonists, Serotonin Agents, Serotonin Receptor Agonists, Serotonin Receptor Antagonists, Tranquilizing Agents"," Dopamine D2 receptor,  5-hydroxytryptamine receptor 2A,  5-hydroxytryptamine receptor 1A,  Alpha-1A adrenergic receptor,  Alpha-1B adrenergic receptor,  Dopamine D3 receptor,  5-hydroxytryptamine receptor 1D,  5-hydroxytryptamine receptor 7,  Alpha-2A adrenergic receptor, 10. Alpha-2C adrenergic receptor, 11. Histamine H1 receptor, 12. 5-hydroxytryptamine receptor 1B, 13. 5-hydroxytryptamine receptor 2C, 14. 5-hydroxytryptamine receptor 3A, 15. 5-hydroxytryptamine receptor 6, 16. Dopamine D1 receptor, 17. Dopamine D4 receptor, 18. Alpha-2B adrenergic receptor, 19. 5-hydroxytryptamine receptor 1E, 20. Dopamine D5 receptor, 21. 5-hydroxytryptamine receptor 2B, 22. 5-hydroxytryptamine receptor 5A, 23. Beta-1 adrenergic receptor, 24. Beta-2 adrenergic receptor, 25. Histamine H2 receptor, 26. Histamine H3 receptor, 27. Histamine H4 receptor, 28. Muscarinic acetylcholine receptor M1, 29. Muscarinic acetylcholine receptor M2, 30. Muscarinic acetylcholine receptor M3, 31. Muscarinic acetylcholine receptor M4, 32. Muscarinic acetylcholine receptor M5, 33. Kappa-type opioid receptor, 34. Mu-type opioid receptor, 35. Delta-type opioid receptor, 36. Glutamate (NMDA) receptor (Protein Group), 37. Sodium-dependent dopamine transporter, 38. Sodium-dependent serotonin transporter,  Cytochrome P450 3A4,  Cytochrome P450 3A7,  Cytochrome P450 3A5,  Cytochrome P450 2D6,  Serum albumin,  P-glycoprotein 1,  ATP-binding cassette sub-family G member 2","DB01238, DB14185, DB05422, DB09226",
DB01239,Chlorprothixene,approved; experimental; investigational; withdrawn,CN(C)CC\C=C1\C2=CC=CC=C2SC2=CC=C(Cl)C=C12,C18H18ClNS,,"Agents producing tachycardia, Anticholinergic Agents, Antidepressive Agents, Antipsychotic Agents, Antipsychotic Agents (First Generation [Typical]), Central Nervous System Agents, Central Nervous System Depressants, Dopamine Agents, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Heterocyclic Compounds, Fused-Ring, Histamine Antagonists, Histamine H1 Antagonists, Muscarinic Antagonists, Nervous System, Neurotoxic agents, Neurotransmitter Agents, P-glycoprotein inhibitors, Potential QTc-Prolonging Agents, Psycholeptics, Psychotropic Drugs, QTc Prolonging Agents, Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2A Receptor Antagonists, Serotonin Agents, Serotonin Receptor Antagonists, Sulfur Compounds, Thioxanthene Derivatives, Thioxanthenes, Tranquilizing Agents, Xanthenes"," Dopamine D2 receptor,  Dopamine D1 receptor,  Dopamine D3 receptor,  5-hydroxytryptamine receptor 2A,  Histamine H1 receptor,  Serotonin Receptors (Protein Group),  Muscarinic acetylcholine receptor M1,  Muscarinic acetylcholine receptor M2,  Muscarinic acetylcholine receptor M3, 10. Muscarinic acetylcholine receptor M4, 11. Muscarinic acetylcholine receptor M5,  P-glycoprotein 1","DB01239, DB01624, DB13841, DB13292",
DB01240,Epoprostenol,approved,[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])C\C(O2)=C\CCCC(O)=O,C20H32O5,,"Anticoagulants, Antihypertensive Agents, Antiplatelet agents, Autacoids, Biological Factors, Blood and Blood Forming Organs, Cardiovascular Agents, Drugs that are Mainly Renally Excreted, Eicosanoids, Fatty Acids, Fatty Acids, Unsaturated, Hematologic Agents, Hypotensive Agents, Inflammation Mediators, Lipids, Platelet Aggregation Inhibitors Excl. Heparin, Prostacyclin Analogues, Prostacycline Vasodilator, Prostaglandins, Prostaglandins I, Vasodilating Agents, Vasodilation"," Prostacyclin synthase,  P2Y purinoceptor 12,  Prostacyclin receptor",DB01240,
DB01241,Gemfibrozil,approved,CC1=CC(OCCCC(C)(C)C(O)=O)=C(C)C=C1,C15H22O3,,"Acids, Acyclic, Agents Causing Muscle Toxicity, Benzene Derivatives, Butyrates, Chemically-Induced Disorders, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (strong), Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 CYP2C8 Inducers (strength unknown), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strong), Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strong), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs causing inadvertant photosensitivity, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Ethers, Fatty Acids, Fatty Acids, Volatile, Fibric Acid Derivatives, Fibric Acids, Hypolipidemic Agents, Hypolipidemic Agents Indicated for Hyperlipidemia, Isobutyrates, Lipid Modifying Agents, Lipid Modifying Agents, Plain, Lipid Regulating Agents, Lipids, Non-statin Hypolipidemic Agents Indicated for Hyperlipidemia, Noxae, OAT3/SLC22A8 Inhibitors, OATP1B1/SLCO1B1 Inhibitors, OATP1B3 inhibitors, Organic Anion Transporting Polypeptide 2B1 Inhibitors, Pentanoic Acids, Peroxisome Proliferator Receptor alpha Agonist, Peroxisome Proliferator-activated Receptor alpha Agonists, Phenols, Phenyl Ethers, Photosensitizing Agents, Toxic Actions, UGT1A1 Inhibitors, UGT1A1 Substrates, UGT1A3 Inhibitors, UGT1A3 substrates, UGT1A9 Substrates, UGT2B17 substrates, UGT2B7 substrates, Valerates"," Peroxisome proliferator-activated receptor alpha,  Solute carrier organic anion transporter family member 1B1,  Solute carrier family 22 member 8,  Solute carrier organic anion transporter family member 2B1,  Solute carrier organic anion transporter family member 1B3,  Cytochrome P450 2C8,  Cytochrome P450 2C19,  Cytochrome P450 2C9,  Cytochrome P450 1A2,  Cytochrome P450 3A4,  UDP-glucuronosyltransferase 2B7,  UDP-glucuronosyltransferase 1-1,  UDP-glucuronosyltransferase 1-3,  UDP-glucuronosyltransferase 1-9, 10. UDP-glucuronosyltransferase 2B4, 11. UDP-glucuronosyltransferase 2B17,  Serum albumin","DB01241, DB12162",
DB01242,Clomipramine,approved; investigational; vet_approved,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=C(Cl)C=C2,C19H23ClN2,,"Agents that produce hypertension, Agents that reduce seizure threshold, Antidepressive Agents, Antidepressive Agents Indicated for Depression, Antidepressive Agents, Tricyclic, Central Nervous System Agents, Central Nervous System Depressants, Combined Inhibitors of Serotonin/Norepinephrine Reuptake, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors (strong), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dibenzazepines, Drugs that are Mainly Renally Excreted, Heterocyclic Compounds, Fused-Ring, Hypotensive Agents, Membrane Transport Modulators, Moderate Risk QTc-Prolonging Agents, Narrow Therapeutic Index Drugs, Nervous System, Neurotoxic agents, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, Non-Selective Monoamine Reuptake Inhibitors, P-glycoprotein inhibitors, Psychoanaleptics, Psychotropic Drugs, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2A Receptor Antagonists, Serotonin 5-HT2C Receptor Antagonists, Serotonin Agents, Serotonin Modulators, Serotonin Receptor Antagonists, Tertiary amine tricyclic antidepressants, Tricyclics and Other Norepinephrine-reuptake Inhibitors"," Sodium-dependent serotonin transporter,  5-hydroxytryptamine receptor 2A,  5-hydroxytryptamine receptor 2B,  5-hydroxytryptamine receptor 2C,  Sodium-dependent noradrenaline transporter,  Glutathione S-transferase P,  Cytochrome P450 2D6,  Cytochrome P450 2C19,  Cytochrome P450 1A2,  Cytochrome P450 3A4,  Serum albumin,  P-glycoprotein 1","DB01242, DB00458, DB01151, DB00726, DB13782, DB13411, DB09003",
DB01243,Chloroxine,approved,OC1=C(Cl)C=C(Cl)C2=C1N=CC=C2,C9H5Cl2NO,,"Anti-Bacterial Agents, Anti-Infective Agents, Antifungal Agents, Heterocyclic Compounds, Fused-Ring, Hydroxyquinolines, Quinolines",,"DB01243, DB15933, DB13306, DB04815, DB11145, DB09473",
DB01244,Bepridil,approved; withdrawn,CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1,C24H34N2O,,"Agents causing hyperkalemia, Antiarrhythmic agents, Antihypertensive Agents, Bradycardia-Causing Agents, Calcium Channel Blockers, Calcium-Regulating Hormones and Agents, Cardiovascular Agents, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Highest Risk QTc-Prolonging Agents, Hypotensive Agents, Membrane Transport Modulators, Non-Selective Calcium Channel Blockers, P-glycoprotein inhibitors, Phenylalkylamine Derivatives, Pyrrolidines, QTc Prolonging Agents, Vasodilating Agents"," Voltage-dependent P/Q-type calcium channel subunit alpha-1A,  Voltage-dependent T-type calcium channel subunit alpha-1H,  Voltage-dependent calcium channel subunit alpha-2/delta-2,  Sodium/potassium-transporting ATPase subunit alpha-1,  Potassium voltage-gated channel subfamily KQT member 1,  Troponin C, slow skeletal and cardiac muscles,  Calmodulin,  Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B,  Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A, 10. Potassium voltage-gated channel subfamily H member 2,  Cytochrome P450 2D6,  Cytochrome P450 3A4,  P-glycoprotein 1",DB01244,
DB01245,Decamethonium,approved,C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C,C16H38N2,,"Amines, Bis-Trimethylammonium Compounds, Central Nervous System Depressants, Cholinesterase Inhibitors, Neuromuscular Agents, Neuromuscular Blocking Agents, Neuromuscular Depolarizing Agents, Neurotoxic agents, Onium Compounds, Peripheral Nervous System Agents, Quaternary Ammonium Compounds"," Neuronal acetylcholine receptor subunit alpha-2,  Neuronal acetylcholine receptor subunit alpha-4,  Neuronal acetylcholine receptor subunit beta-2,  Acetylcholinesterase,  Cholinesterase","DB01245, DB01718, DB02779, DB17342, DB08960, DB04221, DB13970, DB14143, DB13969",
DB01246,Alimemazine,approved; vet_approved,CC(CN(C)C)CN1C2=CC=CC=C2SC2=CC=CC=C12,C18H22N2S,,"Antihistamines for Systemic Use, Antipruritics, Antipsychotic Agents, Central Nervous System Depressants, Dermatologicals, Heterocyclic Compounds, Fused-Ring, Histamine Agents, Histamine Antagonists, Histamine H1 Antagonists, Neurotoxic agents, Neurotransmitter Agents, Phenothiazine Derivatives, Phenothiazines, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Sulfur Compounds", Histamine H1 receptor,"DB01246, DB00420, DB00902, DB12710, DB15596, DB13820, DB01071, DB00477, DB11517, DB09000, DB13382, DB13784, DB01069, DB13420, DB00508, DB00392, DB00433, DB01403, DB00372, DB00850, DB13840, DB01614, DB00831, DB15978, DB00679, DB11447",
DB01247,Isocarboxazid,approved,CC1=CC(=NO1)C(=O)NNCC1=CC=CC=C1,C12H13N3O2,,"Agents that produce hypertension, Agents that reduce seizure threshold, Antidepressive Agents, Antidepressive Agents Indicated for Depression, Central Nervous System Agents, Central Nervous System Depressants, Drugs causing inadvertant photosensitivity, Enzyme Inhibitors, Hypotensive Agents, Isoxazoles, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates, Monoamine Oxidase Inhibitors, Monoamine Oxidase Inhibitors, Non-Selective, Nervous System, Photosensitizing Agents, Psychoanaleptics, Psychotropic Drugs, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin Modulators"," Amine oxidase [flavin-containing] A,  Amine oxidase [flavin-containing] B",DB01247,
DB01248,Docetaxel,approved; investigational,[H][C@@]1(C[C@@]2(O)[C@@H](OC(=O)C3=CC=CC=C3)[C@]3([H])[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C(=C1C)C2(C)C)OC(C)=O)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1,C43H53NO14,,"Agents Causing Muscle Toxicity, Antimitotic Agents, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Substrates, Cardiotoxic antineoplastic agents, Cyclodecanes, Cycloparaffins, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Diterpenes, Hepatotoxic Agents, Immunosuppressive Agents, Microtubule Inhibition, Microtubule Inhibitors, Mitosis Modulators, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, OATP1B3 substrates, P-glycoprotein substrates, P-glycoprotein substrates with a Narrow Therapeutic Index, Taxane Derivatives, Taxoids, Terpenes, Tubulin Modulators"," Tubulin beta-1 chain,  Microtubule-associated protein 2,  Microtubule-associated protein 4,  Microtubule-associated protein tau,  Apoptosis regulator Bcl-2,  Nuclear receptor subfamily 1 group I member 2,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  Cytochrome P450 1B1,  P-glycoprotein 1,  Multidrug resistance-associated protein 7,  Solute carrier organic anion transporter family member 1B3,  Solute carrier family 22 member 7,  ATP-binding cassette sub-family G member 2,  Canalicular multispecific organic anion transporter 1,  Multidrug resistance-associated protein 1","DB01248, DB06772, DB12984, DB01229, DB15384, DB12334, DB12633, DB17223, DB12619, DB12144, DB05297, DB11669, DB17168, DB12019",
DB01249,Iodixanol,approved,CC(=O)N(CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I,C35H44I6N6O15,,"Acids, Carbocyclic, Benzene Derivatives, Benzoates, Compounds used in a research, industrial, or household setting, Contrast Media, Diagnostic Uses of Chemicals, Drugs that are Mainly Renally Excreted, Iodinated Contrast Agents, Iodobenzoates, Radiographic Contrast Agent, Roentgenography, Watersoluble, Nephrotropic, Low Osmolar X-Ray Contrast Media, X-Ray Contrast Activity, X-Ray Contrast Media, Iodinated",,"DB01249, DB12439, DB01362, DB09135, DB11705, DB13861, DB09134, DB09487, DB09156, DB12407, DB08947, DB13444, DB09313",
DB01250,Olsalazine,approved,OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(O)C(=C1)C(O)=O,C14H10N2O6,,"Acids, Carbocyclic, Agents causing hyperkalemia, Agents that produce hypertension, Alimentary Tract and Metabolism, Aminosalicylate, Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents, Benzene Derivatives, Benzoates, Gastrointestinal Agents, Hydroxy Acids, Hydroxybenzoates, Intestinal Antiinflammatory Agents, Nephrotoxic agents, Non COX-2 selective NSAIDS, Peripheral Nervous System Agents, Phenols, Salicylates, Sensory System Agents"," Human Cyclooxygenases (Protein Group),  Thiopurine S-methyltransferase,  Interferon gamma,  Xanthine dehydrogenase/oxidase,  Solute carrier family 2, facilitated glucose transporter member 9,  Solute carrier family 22 member 6,  Solute carrier family 22 member 8,  Sodium-dependent phosphate transporter 1,  Sodium/Potassium Transporting ATPase (Protein Group)","DB01250, DB18066, DB08181, DB07667, DB00244, DB08216",
DB01251,Gliquidone,approved; investigational,COC1=CC2=C(C=C1)C(C)(C)C(=O)N(CCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1)C2=O,C27H33N3O6S,,"Alimentary Tract and Metabolism, Amides, Blood Glucose Lowering Agents, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 Substrates, Drugs Used in Diabetes, Insulin Secretagogues, Oral Hypoglycemics, Sulfones, Sulfonylureas, Sulfur Compounds"," ATP-binding cassette sub-family C member 8,  ATP-sensitive inward rectifier potassium channel 8,  Cytochrome P450 2C9","DB01251, DB01016",
DB01252,Mitiglinide,investigational,[H][C@@](CC(=O)N1C[C@@]2([H])CCCC[C@@]2([H])C1)(CC1=CC=CC=C1)C(O)=O,C19H25NO3,,"Alimentary Tract and Metabolism, Blood Glucose Lowering Agents, Drugs Used in Diabetes, Heterocyclic Compounds, Fused-Ring, Oral Hypoglycemics, UGT1A3 substrates, UGT2B7 substrates"," ATP-binding cassette sub-family C member 8,  Peroxisome proliferator-activated receptor gamma,  UDP-glucuronosyltransferase 1-3,  UDP-glucuronosyltransferase 2B7",DB01252,
DB01253,Ergometrine,approved,[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](C)CO,C19H23N3O2,,"Adrenergic Agonists, Adrenergic alpha-1 Receptor Agonists, Adrenergic alpha-Agonists, Agents producing tachycardia, Agents that produce hypertension, Alkaloids, Antidepressive Agents, Central Nervous System Depressants, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Ergolines, Ergot Alkaloids and Derivatives, Genito Urinary System and Sex Hormones, Heterocyclic Compounds, Fused-Ring, P-glycoprotein inhibitors, Reproductive Control Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin Modulators, Uterotonic agents"," Alpha-1A adrenergic receptor,  Cytochrome P450 3A4,  P-glycoprotein 1","DB01253, DB00353, DB04829, DB00247, DB00589, DB00696",
DB01254,Dasatinib,approved; investigational,CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1,C22H26ClN7O2S,,"Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Bcr-Abl Tyrosine Kinase Inhibitors, BCRP/ABCG2 Inhibitors, BCRP/ABCG2 Substrates, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (weak), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs causing inadvertant photosensitivity, Enzyme Inhibitors, Immunosuppressive Agents, Kinase Inhibitor, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, P-glycoprotein inhibitors, P-glycoprotein substrates, P-glycoprotein substrates with a Narrow Therapeutic Index, Photosensitizing Agents, Potential QTc-Prolonging Agents, Protein Kinase Inhibitors, Pyrimidines, QTc Prolonging Agents, Sulfur Compounds, Thiazoles, Tyrosine Kinase Inhibitors"," Tyrosine-protein kinase ABL1,  Proto-oncogene tyrosine-protein kinase Src,  Ephrin type-A receptor 2,  Tyrosine-protein kinase Lck,  Tyrosine-protein kinase Yes,  Mast/stem cell growth factor receptor Kit,  Platelet-derived growth factor receptor beta,  Signal transducer and activator of transcription 5B,  Tyrosine-protein kinase ABL2, 10. Tyrosine-protein kinase Fyn, 11. Tyrosine-protein kinase BTK, 12. Nuclear receptor subfamily 4 group A member 3, 13. Breakpoint cluster region protein, 14. Tyrosine-protein kinase CSK, 15. Ephrin type-A receptor 5, 16. Ephrin type-B receptor 4, 17. Tyrosine-protein kinase Fgr, 18. Tyrosine-protein kinase FRK, 19. Heat shock cognate 71 kDa protein, 20. Tyrosine-protein kinase Lyn, 21. Mitogen-activated protein kinase kinase kinase MLT, 22. Mitogen-activated protein kinase 14, 23. Amidophosphoribosyltransferase,  Cytochrome P450 1A1,  Cytochrome P450 1A2,  Cytochrome P450 1B1,  Cytochrome P450 3A5,  Dimethylaniline monooxygenase [N-oxide-forming] 3,  Cytochrome P450 3A4,  P-glycoprotein 1,  ATP-binding cassette sub-family G member 2",DB01254,
DB01255,Lisdexamfetamine,approved; investigational,C[C@@H](CC1=CC=CC=C1)NC(=O)[C@@H](N)CCCCN,C15H25N3O,,"Agents producing tachycardia, Agents that produce hypertension, Amines, Amphetamines, Central Nervous System Agents, Central Nervous System Stimulants, Central Nervous System Stimulation, Centrally Acting Sympathomimetics, Dopamine Agents, Dopamine Uptake Inhibitors, Ethylamines, Membrane Transport Modulators, Nervous System, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, Phenethylamines, Psychoanaleptics, Psychostimulants, Agents Used for ADHD and Nootropics, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Sympathomimetics"," Trace amine-associated receptor 1,  Solute carrier family 15 member 1","DB01255, DB07749",
DB01256,Retapamulin,approved,[H][C@@]12C(=O)CC[C@]11CC[C@@H](C)[C@@]2(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]1C)OC(=O)CS[C@H]1C[C@@H]2CC[C@H](C1)N2C,C30H47NO4S,,"Anti-Bacterial Agents, Anti-Infective Agents, Antibiotics for Topical Use, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Dermatologicals, Pleuromutilin Antibacterial, Terpenes"," 50S ribosomal protein L3,  Cytochrome P450 3A4","DB01256, DB12825",
DB01259,Lapatinib,approved; investigational,CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1,C29H26ClFN4O4S,,"Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (weak), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Enzyme Inhibitors, Hepatotoxic Agents, Heterocyclic Compounds, Fused-Ring, Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors, Kinase Inhibitor, P-glycoprotein inhibitors, Potential QTc-Prolonging Agents, Protein Kinase Inhibitors, QTc Prolonging Agents, Quinazolines, Tyrosine Kinase Inhibitors"," Epidermal growth factor receptor,  Receptor tyrosine-protein kinase erbB-2,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 2C8,  Cytochrome P450 2C19,  P-glycoprotein 1,  Antigen peptide transporter 1",DB01259,
DB01260,Desonide,approved; investigational,[H][C@@]12C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,C24H32O6,,"Adrenal Cortex Hormones, Anti-Inflammatory Agents, Corticosteroid Hormone Receptor Agonists, Corticosteroids, Corticosteroids, Moderately Potent (Group II), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Substrates, Dermatologicals, Fused-Ring Compounds, Immunosuppressive Agents, Ophthalmologicals, Pregnadienes, Pregnadienetriols, Pregnanes, Sensory Organs, Steroids"," Glucocorticoid receptor,  Cytochrome P450 3A4","DB01260, DB01222, DB01410, DB00180, DB15835, DB14662, DB00288, DB00591, DB01130, DB00846, DB01047, DB18737, DB15566, DB14673, DB14643, DB14632, DB15999, DB14633, DB14644, DB08973, DB14596, DB06786, DB13751",
DB01261,Sitagliptin,approved; investigational,N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F,C16H15F6N5O,,"Agents causing angioedema, Alimentary Tract and Metabolism, Blood Glucose Lowering Agents, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, DPP-IV Inhibitors, Drugs that are Mainly Renally Excreted, Drugs Used in Diabetes, Enzyme Inhibitors, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hypoglycemia-Associated Agents, Incretins, OAT3/SLC22A8 Substrates, Oral Hypoglycemics, P-glycoprotein substrates, Protease Inhibitors, Triazoles"," Dipeptidyl peptidase 4,  Cytochrome P450 3A4,  Cytochrome P450 2C8,  P-glycoprotein 1,  Solute carrier family 22 member 8","DB01261, DB07072, DB08044, DB07081",
DB01262,Decitabine,approved; investigational,NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1,C8H12N4O4,,"Antimetabolites, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Aza Compounds, Carbohydrates, Cytidine Deaminase Substrates, Enzyme Inhibitors, Glycosides, Immunosuppressive Agents, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, Noxae, Nucleic Acid Synthesis Inhibitors, Nucleic Acids, Nucleotides, and Nucleosides, Nucleoside Metabolic Inhibitor, Nucleosides, Pyrimidine Analogues, Pyrimidine Nucleosides, Pyrimidines, Ribonucleosides, Toxic Actions"," DNA,  DNA (cytosine-5)-methyltransferase 1,  DNA (cytosine-5)-methyltransferase 3A,  DNA (cytosine-5)-methyltransferase 3B,  Histone deacetylase (Protein Group),  UMP-CMP kinase,  Nucleoside diphosphokinase (Protein Group),  Deoxycytidine kinase,  Cytidine deaminase,  Sodium/nucleoside cotransporter 1","DB01262, DB00928",
DB01263,Posaconazole,approved; investigational; vet_approved,CC[C@@H]([C@H](C)O)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=NC=N3)(C2)C2=C(F)C=C(F)C=C2)C=C1,C37H42F2N8O4,,"14-alpha Demethylase Inhibitors, Anti-Infective Agents, Antifungal Agents, Antiinfectives for Systemic Use, Antimycotics for Systemic Use, Antiparasitic Agents, Antiprotozoals, Azole Antifungals, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strong), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Enzyme Inhibitors, Hormone Antagonists, Hormones, Hormone Substitutes, and Hormone Antagonists, P-glycoprotein inhibitors, P-glycoprotein substrates, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Steroid Synthesis Inhibitors, Triazole and tetrazole derivatives, Triazole Derivatives, Trypanocidal Agents"," Cytochrome P450 51,  Cytochrome P450 3A4,  P-glycoprotein 1","DB01263, DB18251, DB01167",
DB01264,Darunavir,approved,[H][C@@]12CCO[C@]1([H])OC[C@@H]2OC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)CN(CC(C)C)S(=O)(=O)C1=CC=C(N)C=C1,C27H37N3O7S,,"Amides, Anti-HIV Agents, Anti-Infective Agents, Anti-Retroviral Agents, Antiinfectives for Systemic Use, Antiviral Agents, Antivirals for Systemic Use, Antivirals used in combination for the treatment of HIV infections, Carbamates, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Inhibitors (strong), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Direct Acting Antivirals, Enzyme Inhibitors, Experimental Unapproved Treatments for COVID-19, Furans, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, HIV Protease Inhibitors, Hyperglycemia-Associated Agents, OATP1B1/SLCO1B1 Inhibitors, P-glycoprotein inducers, P-glycoprotein inhibitors, P-glycoprotein substrates, Protease Inhibitors, Sulfonamides, Sulfones, Sulfur Compounds, Viral Protease Inhibitors"," Human immunodeficiency virus type 1 protease,  Cytochrome P450 2D6,  Cytochrome P450 3A4,  Serum albumin,  Alpha-1-acid glycoprotein 1,  Solute carrier organic anion transporter family member 1B1,  P-glycoprotein 1","DB01264, DB00701, DB01319, DB04887, DB15623",
DB01265,Telbivudine,approved; investigational,CC1=CN([C@@H]2C[C@@H](O)[C@H](CO)O2)C(=O)NC1=O,C10H14N2O5,,"Anti-Infective Agents, Antiinfectives for Systemic Use, Antiviral Agents, Antivirals for Systemic Use, Deoxyribonucleosides, Direct Acting Antivirals, Enzyme Inhibitors, Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor, Nucleic Acid Synthesis Inhibitors, Nucleic Acids, Nucleotides, and Nucleosides, Nucleoside and Nucleotide Reverse Transcriptase Inhibitors, Nucleoside Reverse Transcriptase Inhibitors, Nucleosides, Nucleosides and Nucleotides, Pyrimidine Nucleosides, Pyrimidines"," DNA,  Protein P","DB01265, DB04485, DB13421, DB03312, DB00432, DB02256, DB06683, DB14913, DB03274, DB12606, DB01643, DB11998, DB08432, DB08596, DB08661, DB02745, DB00249, DB06198, DB14930, DB03150, DB03846, DB13030, DB00322, DB12028, DB04205, DB00495, DB02980, DB04438, DB03103, DB04243",
DB01266,Sinecatechins,approved; investigational; nutraceutical,,,,"Antiviral Agents, Benzopyrans, Chromans, Chromones, Dermatologicals, Flavonoids, Heterocyclic Compounds, Fused-Ring, Pyrans",,,
DB01267,Paliperidone,approved,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1,C23H27FN4O3,,"Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Agents that produce hypertension, Antidepressive Agents, Antipsychotic Agents, Antipsychotic Agents (Second Generation [Atypical]), Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 Substrates, Dopamine Agents, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Drugs that are Mainly Renally Excreted, Highest Risk QTc-Prolonging Agents, Hyperglycemia-Associated Agents, Isoxazoles, Nervous System, Neurotoxic agents, Neurotransmitter Agents, P-glycoprotein inhibitors, P-glycoprotein substrates, Psycholeptics, Psychotropic Drugs, Pyrimidines, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT1 Receptor Antagonists, Serotonin 5-HT1A Receptor Antagonists, Serotonin 5-HT1D Receptor Antagonists, Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2A Receptor Antagonists, Serotonin 5-HT2C Receptor Antagonists, Serotonin Agents, Serotonin Receptor Antagonists, Tranquilizing Agents"," 5-hydroxytryptamine receptor 2A,  Dopamine D2 receptor,  Dopamine D4 receptor,  Dopamine D3 receptor,  5-hydroxytryptamine receptor 2C,  Histamine H1 receptor,  Alpha-1A adrenergic receptor,  Alpha-1B adrenergic receptor,  5-hydroxytryptamine receptor 1D, 10. Alpha-2A adrenergic receptor, 11. Alpha-2B adrenergic receptor, 12. Alpha-2C adrenergic receptor, 13. 5-hydroxytryptamine receptor 1A, 14. Dopamine D1 receptor, 15. 5-hydroxytryptamine receptor 7,  Cytochrome P450 3A4,  Cytochrome P450 2D6,  Cytochrome P450 3A5,  P-glycoprotein 1","DB01267, DB00734, DB06229",
DB01268,Sunitinib,approved; investigational,CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C,C22H27FN4O2,,"Angiogenesis Inhibitors, Angiogenesis Modulating Agents, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, BCRP/ABCG2 Inhibitors, Blood Glucose Lowering Agents, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A7 Substrates, Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Enzyme Inhibitors, Growth Inhibitors, Growth Substances, Hepatotoxic Agents, Heterocyclic Compounds, Fused-Ring, Hypoglycemia-Associated Agents, Immunosuppressive Agents, Indoles, Kinase Inhibitor, Narrow Therapeutic Index Drugs, P-glycoprotein inhibitors, P-glycoprotein substrates, Potential QTc-Prolonging Agents, Protein Kinase Inhibitors, QTc Prolonging Agents, Tyrosine Kinase Inhibitors"," Platelet-derived growth factor receptor beta,  Vascular endothelial growth factor receptor 1,  Mast/stem cell growth factor receptor Kit,  Vascular endothelial growth factor receptor 2,  Vascular endothelial growth factor receptor 3,  Receptor-type tyrosine-protein kinase FLT3,  Macrophage colony-stimulating factor 1 receptor,  Platelet-derived growth factor receptor alpha,  Hepatocyte growth factor receptor,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  Multidrug resistance-associated protein 4,  P-glycoprotein 1,  Canalicular multispecific organic anion transporter 1,  ATP-binding cassette sub-family G member 2","DB01268, DB15247, DB08009, DB11741, DB07180, DB13019, DB14866, DB17061, DB06436, DB16821, DB12072, DB03737, DB08577",
DB01273,Varenicline,approved; investigational,C1C2CNCC1C1=C2C=C2N=CC=NC2=C1,C13H13N3,,"Benzazepines, Cholinergic Agents, Cholinergic Agonists, Cholinergic Receptor Agonist, Drugs that are Mainly Renally Excreted, Drugs Used in Addictive Disorders, Drugs Used in Nicotine Dependence, Heterocyclic Compounds, Fused-Ring, Miscellaneous Autonomic Drugs, Nervous System, Neurotransmitter Agents, Nicotinic Agonists, OCT2 Inhibitors, OCT2 Substrates, Ophthalmologicals, Partial Cholinergic Nicotinic Agonist, Partial Cholinergic Nicotinic Agonists, Quinoxalines, Sensory Organs, Smoking Cessation Agents"," Neuronal acetylcholine receptor subunit alpha-4,  Neuronal acetylcholine receptor subunit alpha-7,  Neuronal acetylcholine receptor subunit alpha-3,  Neuronal acetylcholine receptor subunit alpha-6,  Neuronal acetylcholine receptor subunit beta-2,  Solute carrier family 22 member 2",DB01273,
DB01274,Arformoterol,approved; investigational,COC1=CC=C(C[C@@H](C)NC[C@H](O)C2=CC(NC=O)=C(O)C=C2)C=C1,C19H24N2O4,,"Adrenergic Agents, Adrenergic Agonists, Adrenergic beta-2 Receptor Agonists, Adrenergic beta-Agonists, Agents producing tachycardia, Agents that produce hypertension, Agents to Treat Airway Disease, Alcohols, Amines, Amino Alcohols, Autonomic Agents, Bronchodilator Agents, Cytochrome P-450 CYP2A6 Substrates, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Ethanolamines, Long-acting beta-adrenoceptor agonists, Peripheral Nervous System Agents, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Respiratory System Agents"," Beta-2 adrenergic receptor,  Cytochrome P450 2D6,  Cytochrome P450 2C19,  Cytochrome P450 2C9,  Cytochrome P450 2A6","DB00983, DB01274, DB13625",
DB01275,Hydralazine,approved,NNC1=NN=CC2=CC=CC=C12,C8H8N4,,"Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Arteriolar Smooth Muscle, Agents Acting On, Arteriolar Vasodilation, Arteriolar Vasodilator, Cardiovascular Agents, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Direct Vasodilators, Drugs that are Mainly Renally Excreted, Hydrazinophthalazine Derivatives, Hydrazinophthalazine Derivatives and Diuretics, Hypotensive Agents, Phthalazines, Pyridazines, Vasodilating Agents"," Membrane primary amine oxidase,  Hypoxia-inducible factor 1-alpha,  Prolyl 4-hydroxylase subunit alpha-1,  Cytochrome P450 3A4,  Serum albumin","DB01275, DB12945",
DB01278,Pramlintide,approved; investigational,[H]N[C@@H](CCCCN)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@]([H])(NC(=O)[C@H](C)NC(=O)[C@@]([H])(NC(=O)[C@H](CC(N)=O)NC1=O)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@]([H])([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@]([H])([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(N)=O,C171H267N51O53S2,,"Alimentary Tract and Metabolism, Amino Acids, Peptides, and Proteins, Amylin Agonists, Amylin Analog, Amyloid, Amyloidogenic Proteins, Blood Glucose Lowering Agents, Drugs Used in Diabetes, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hypoglycemia-Associated Agents, Pancreatic Hormones, Peptide Hormones, Peptides, Proteins"," Calcitonin receptor,  Receptor activity-modifying protein 1,  Receptor activity-modifying protein 2,  Receptor activity-modifying protein 3","DB01278, DB15355, DB05724, DB06260, DB18634, DB13742, DB14803, DB15366, DB18169, DB12199, DB15195, DB13298, DB00007, DB06825, DB11510, DB11720, DB00666, DB04931, DB05479, DB15314, DB14027, DB01284, DB11724, DB15194, DB09059, DB05034, DB15687, DB06719, DB06283, DB13928",
DB01280,Nelarabine,approved; investigational,COC1=NC(N)=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,C11H15N5O5,,"Antimetabolites, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Immunosuppressive Agents, Myelosuppressive Agents, Narrow Therapeutic Index Drugs, Nucleic Acid Synthesis Inhibitors, Nucleic Acids, Nucleotides, and Nucleosides, Nucleoside Metabolic Inhibitor, Nucleosides, Purine Analogues"," DNA,  DNA polymerase alpha catalytic subunit,  DNA ligase 1,  DNA primase small subunit,  Ribonucleoside-diphosphate reductase large subunit,  Adenosine deaminase,  Deoxycytidine kinase,  Deoxyguanosine kinase, mitochondrial,  Equilibrative nucleoside transporter 1","DB01280, DB02857, DB04440, DB04853, DB02934, DB03952, DB00194, DB00640, DB02753, DB03528, DB01972, DB03510, DB03609, DB02896, DB03493, DB03315, DB04335, DB01937, DB04315, DB03726, DB12896, DB02315, DB01073, DB04441, DB12156, DB03931, DB04137, DB16075, DB03486, DB03178",
DB01282,Carbetocin,approved; investigational,[H][C@]1(NC(=O)[C@H](CC2=CC=C(OC)C=C2)NC(=O)CCCSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)[C@@H](C)CC,C45H69N11O12S,,"Amino Acids, Peptides, and Proteins, Delayed-Action Preparations, Drug Delivery Systems, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hypotensive Agents, Oxytocin and Analogues, Peptide Hormones, Peptides, Pharmaceutical Preparations, Pituitary and Hypothalamic Hormones and Analogues, Pituitary Hormones, Pituitary Hormones, Posterior, Posterior Pituitary Lobe Hormones, Reproductive Control Agents, Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins, Uterotonic agents", Oxytocin receptor,"DB01282, DB13798, DB17352, DB05029, DB09059, DB14642, DB16687, DB05034, DB12495, DB00035, DB05875, DB01883, DB00067, DB11628, DB15195, DB06283, DB00006",
DB01283,Lumiracoxib,approved; investigational,CC1=CC=C(NC2=C(Cl)C=CC=C2F)C(CC(O)=O)=C1,C15H13ClFNO2,,"Acids, Carbocyclic, Agents causing hyperkalemia, Agents that produce hypertension, Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Antiinflammatory and Antirheumatic Products, Antiinflammatory and Antirheumatic Products, Non-Steroids, Antirheumatic Agents, COX-2 Inhibitors, Cyclooxygenase Inhibitors, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 Substrates, Enzyme Inhibitors, Musculo-Skeletal System, Nephrotoxic agents, Peripheral Nervous System Agents, Phenylacetates, Selective Cyclooxygenase 2 Inhibitors (NSAIDs), Sensory System Agents, UGT1A9 Substrates"," Prostaglandin G/H synthase 2,  Prostaglandin G/H synthase 1,  Cytochrome P450 2C19,  UDP-glucuronosyltransferase 1-9,  Cytochrome P450 1A2,  Cytochrome P450 2C9","DB01283, DB00586, DB11455, DB06736",
DB01284,Tetracosactide,approved,CSCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(O)=O,C136H210N40O31S,,"Adrenals, Adrenocortical Insufficiency, Adrenocorticotropic Hormone, Amino Acids, Peptides, and Proteins, Anterior Pituitary Lobe Hormones and Analogues, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Melanocortins, Nerve Tissue Proteins, Neuropeptides, Peptide Hormones, Peptides, Pituitary, Pituitary and Hypothalamic Hormones and Analogues, Pituitary Hormones, Pituitary Hormones, Anterior, Pro-Opiomelanocortin, Proteins, Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins", Adrenocorticotropic hormone receptor,"DB01284, DB15687, DB05479, DB15314, DB13298, DB04931, DB15194, DB14027, DB13928, DB18169, DB00007, DB06825, DB11510, DB06719, DB00666, DB15272, DB11724, DB14806, DB14803, DB00644, DB06260, DB18634, DB16146, DB15366, DB14786, DB06788, DB13742, DB00014, DB11720, DB00403",
DB01288,Fenoterol,approved; investigational,CC(CC1=CC=C(O)C=C1)NCC(O)C1=CC(O)=CC(O)=C1,C17H21NO4,,"Adrenergic Agents, Adrenergic Agonists, Adrenergic beta-2 Receptor Agonists, Adrenergic beta-Agonists, Adrenergics for Systemic Use, Adrenergics, Inhalants, Agents producing tachycardia, Agents that produce hypertension, Agents to Treat Airway Disease, Alcohols, Amines, Amino Alcohols, Anti-Asthmatic Agents, Anticholinergic Agents, Autonomic Agents, Benzene Derivatives, Bronchodilator Agents, Catechols, Drugs for Obstructive Airway Diseases, Ethanolamines, Genito Urinary System and Sex Hormones, Metaproterenol, Neurotransmitter Agents, Peripheral Nervous System Agents, Phenols, Reproductive Control Agents, Respiratory System Agents, Selective Beta 2-adrenergic Agonists, Sympathomimetics, Sympathomimetics, Labour Repressants, Tocolytic Agents"," Beta-2 adrenergic receptor,  Beta-1 adrenergic receptor,  Beta-3 adrenergic receptor","DB01288, DB00816, DB00871, DB00221, DB01064, DB00867, DB06814, DB08985, DB01102, DB00388, DB08957, DB00668, DB13559, DB11610",
DB01289,Glisoxepide,investigational,CC1=CC(=NO1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN1CCCCCC1,C20H27N5O5S,,"Alimentary Tract and Metabolism, Amides, Blood Glucose Lowering Agents, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 Substrates, Drugs Used in Diabetes, Insulin Secretagogues, Oral Hypoglycemics, Sulfones, Sulfonylureas, Sulfur Compounds"," ATP-sensitive inward rectifier potassium channel 8,  Insulin,  Cytochrome P450 2C9",DB01289,
DB01291,Pirbuterol,approved,CC(C)(C)NCC(O)C1=NC(CO)=C(O)C=C1,C12H20N2O3,,"Adrenergic Agents, Adrenergic Agonists, Adrenergic beta-2 Receptor Agonists, Adrenergic beta-Agonists, Adrenergics for Systemic Use, Adrenergics, Inhalants, Agents producing tachycardia, Agents that produce hypertension, Agents to Treat Airway Disease, Alcohols, Amines, Amino Alcohols, Anti-Asthmatic Agents, Autonomic Agents, Bronchodilator Agents, Cardiotonic Agents, Cardiovascular Agents, Compounds used in a research, industrial, or household setting, Drugs for Obstructive Airway Diseases, Neurotransmitter Agents, Peripheral Nervous System Agents, Protective Agents, Respiratory System Agents, Selective Beta 2-adrenergic Agonists"," Beta-2 adrenergic receptor,  Beta-1 adrenergic receptor",DB01291,
DB01294,Bismuth subsalicylate,approved; vet_approved,O[Bi]1OC(=O)C2=CC=CC=C2O1,C7H5BiO4,,"Acids, Carbocyclic, Antacids and Adsorbents, Antidiarrheals, Benzene Derivatives, Benzoates, Bismuth containing drugs, Elements, Elements, Radioactive, Gastrointestinal Agents, Helicobacter Infections, Hydroxy Acids, Hydroxybenzoates, Isotopes, Metals, Metals, Heavy, Neurotoxic agents, Phenols, Radioisotopes, Salicylates"," Serum albumin,  Serotransferrin",DB01294,
DB01295,Bevantolol,experimental,COC1=C(OC)C=C(CCNCC(O)COC2=CC=CC(C)=C2)C=C1,C20H27NO4,,"Adrenergic Agents, Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Adrenergic beta-1 Receptor Antagonists, Adrenergic beta-Antagonists, Agents causing hyperkalemia, Alcohols, Amines, Amino Alcohols, Antihypertensive Agents, Beta Blocking Agents and Thiazides, Beta Blocking Agents, Selective, Beta Blocking Agents, Selective, and Thiazides, Bradycardia-Causing Agents, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 Substrates, Neurotransmitter Agents, Propanols"," Beta-1 adrenergic receptor,  Beta-2 adrenergic receptor,  Alpha-1A adrenergic receptor,  Cytochrome P450 2D6",DB01295,
DB01296,Glucosamine,approved; investigational,N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O,C6H13NO5,,"Amino Sugars, Antiinflammatory and Antirheumatic Products, Antiinflammatory and Antirheumatic Products, Non-Steroids, Carbohydrates, Hexosamines, Musculo-Skeletal System"," Interferon gamma,  Transcription factor p65,  Solute carrier family 2, facilitated glucose transporter member 2,  Solute carrier family 2, facilitated glucose transporter member 1,  Solute carrier family 2, facilitated glucose transporter member 4,  Solute carrier family 2, facilitated glucose transporter member 3","DB01296, DB02678, DB02700, DB03779, DB03291, DB02469, DB03439, DB04808, DB13673",
DB01297,Practolol,approved,CC(C)NCC(O)COC1=CC=C(NC(C)=O)C=C1,C14H22N2O3,,"Acetanilides, Adrenergic Agents, Adrenergic Antagonists, Adrenergic beta-1 Receptor Antagonists, Adrenergic beta-Antagonists, Agents causing hyperkalemia, Alcohols, Amides, Amines, Amino Alcohols, Anilides, Aniline Compounds, Antiarrhythmic agents, Antihypertensive Agents, Beta Blocking Agents, Selective, Bradycardia-Causing Agents, Cardiovascular Agents, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 Substrates, Neurotransmitter Agents, Phenoxypropanolamines, Propanolamines, Propanols"," Beta-1 adrenergic receptor,  Cytochrome P450 2D6","DB01297, DB03783",
DB01298,Sulfacytine,approved,CCN1C=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NC1=O,C12H14N4O3S,,"Amides, Amines, Aniline Compounds, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Sulfonamides, Sulfones, Sulfur Compounds", Dihydropteroate synthase,DB01298,
DB01299,Sulfadoxine,approved; investigational,COC1=NC=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1OC,C12H14N4O4S,,"Amides, Amines, Aniline Compounds, Anti-Infective Agents, Anti-Infective Agents, Urinary, Antimalarials, Antiparasitic Agents, Antiparasitic Products, Insecticides and Repellents, Antiprotozoals, Benzene Derivatives, Benzenesulfonamides, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Long-Acting Antibacterial Sulfonamides, Sulfanilamides, Sulfonamides, Sulfones, Sulfur Compounds"," Dihydropteroate synthetase,  Bifunctional dihydrofolate reductase-thymidylate synthase","DB01299, DB13485, DB06150",
DB01301,Rolitetracycline,approved,[H][C@@]12C[C@@]3([H])C(C(=O)C4=C(O)C=CC=C4[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(=O)NCN1CCCC1)=C(O)[C@H]2N(C)C,C27H33N3O8,,"Agents that produce neuromuscular block (indirect), Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Naphthacenes, Tetracyclines"," 30S ribosomal protein S9,  16S ribosomal RNA","DB01301, DB00256, DB00759, DB09550, DB00595, DB09093, DB00453, DB00254, DB00618, DB00931, DB13092, DB01017, DB12035, DB13264, DB12455, DB00560, DB15040, DB12329, DB11647, DB11691, DB05168, DB03469, DB11191, DB00361, DB03614, DB12674, DB00200, DB11467",
DB01303,Oxtriphylline,approved,C[N+](C)(C)CCO.CN1C2=C([N-]C=N2)C(=O)N(C)C1=O,C12H21N5O3,,"Alcohols, Alkaloids, Amines, Amino Alcohols, Anti-Asthmatic Agents, Autonomic Agents, Bronchodilator Agents, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 Substrates, Drugs for Obstructive Airway Diseases, Ethanolamines, Heterocyclic Compounds, Fused-Ring, Onium Compounds, Peripheral Nervous System Agents, Purines, Purinones, Quaternary Ammonium Compounds, Respiratory Smooth Muscle Relaxants, Respiratory System Agents, Trimethyl Ammonium Compounds, Xanthine derivatives, Xanthines and Adrenergics"," cGMP-inhibited 3',5'-cyclic phosphodiesterase A,  cAMP-specific 3',5'-cyclic phosphodiesterase 4A,  Adenosine receptor A2a,  Adenosine receptor A1,  Histone deacetylase 2,  Cytochrome P450 1A2,  Solute carrier family 22 member 7","DB01303, DB01223, DB00277, DB13812, DB00201, DB01412, DB03293, DB14132, DB01778, DB14018, DB00824, DB07954, DB13592, DB13573, DB13449, DB09273, DB18002",
DB01319,Fosamprenavir,approved,CC(C)CN(C[C@@H](OP(O)(O)=O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1,C25H36N3O9PS,,"Acids, Acyclic, Amides, Amprenavir and Prodrugs, Anti-HIV Agents, Anti-Infective Agents, Anti-Retroviral Agents, Antiinfectives for Systemic Use, Antiviral Agents, Antivirals for Systemic Use, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (moderate), Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Direct Acting Antivirals, Enzyme Inhibitors, HIV Protease Inhibitors, Hyperglycemia-Associated Agents, Protease Inhibitors, Sulfones, Sulfur Compounds, Viral Protease Inhibitors"," Human immunodeficiency virus type 1 protease,  Cytochrome P450 3A4","DB01319, DB00701, DB01264",
DB01320,Fosphenytoin,approved; investigational,OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1,C16H15N2O6P,,"Anti-epileptic Agent, Anticonvulsants, Cardiovascular Agents, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP1A2 Inducers (strength unknown), Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2B6 Inducers (strong), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C9 Inducers, Cytochrome P-450 CYP2C9 Inducers (strength unknown), Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inducers (strong), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strong), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Substrates, Decreased Central Nervous System Disorganized Electrical Activity, Enzyme Inducing Antiepileptic Drugs, Hydantoins, Imidazoles, Imidazolidines, Membrane Transport Modulators, Narrow Therapeutic Index Drugs, Nervous System, Phenytoin and Prodrugs, Prodrugs, Sodium Channel Blockers, Thyroxine-binding globulin substrates, UGT1A6 Inhibitors, UGT1A9 Inhibitors"," Sodium channel protein type 5 subunit alpha,  Cytochrome P450 1A2,  UDP-glucuronosyltransferase 1-6,  UDP-glucuronosyltransferase 1-9,  Cytochrome P450 2C19,  Cytochrome P450 2B6,  Cytochrome P450 2C9,  Cytochrome P450 3A4,  Serum albumin,  Thyroxine-binding globulin",DB01320,
DB01321,Josamycin,investigational,CO[C@H]1[C@@H](CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C)OC(C)=O,C42H69NO15,,"Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Lactones, Macrolides, Macrolides, Lincosamides and Streptogramins, Polyketides", 50S ribosomal protein L4,"DB01321, DB13456, DB13409, DB15981, DB09309, DB11554, DB06145, DB11475, DB11383, DB17769, DB13179, DB01211, DB00199, DB11471, DB11442, DB00207, DB00681, DB11416, DB00646, DB11474",
DB01322,Kava,approved; investigational; nutraceutical,COC1=CC(=O)OC(C1)\C=C\C1=CCCC=C1,C14H16O3,,,,DB01322,
DB01324,Polythiazide,approved,CN1C(CSCC(F)(F)F)NC2=CC(Cl)=C(C=C2S1(=O)=O)S(N)(=O)=O,C11H13ClF3N3O4S3,,"Amides, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Benzothiadiazines, Cardiovascular Agents, Diuretics, Drugs causing inadvertant photosensitivity, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Heterocyclic Compounds, Fused-Ring, Hyperglycemia-Associated Agents, Increased Diuresis, Membrane Transport Modulators, Natriuretic Agents, OAT3/SLC22A8 Substrates, Photosensitizing Agents, Sodium Chloride Symporter Inhibitors, Sulfonamides, Sulfones, Sulfur Compounds, Thiazides"," Solute carrier family 12 member 3,  Serum albumin,  Solute carrier family 22 member 6,  Solute carrier family 22 member 8","DB01324, DB13989, DB00232, DB01021, DB08645, DB15861, DB13430, DB13532, DB00999",
DB01325,Quinethazone,approved,CCC1NC(=O)C2=CC(=C(Cl)C=C2N1)S(N)(=O)=O,C10H12ClN3O3S,,"Amides, Cardiovascular Agents, Diuretics, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Heterocyclic Compounds, Fused-Ring, Low-Ceiling Diuretics, Excl. Thiazides, Membrane Transport Modulators, Natriuretic Agents, Sodium Chloride Symporter Inhibitors, Sulfonamides, Sulfones, Sulfur Compounds"," Solute carrier family 12 member 1,  Solute carrier family 12 member 2,  Solute carrier family 12 member 3,  Carbonic anhydrase 1,  Carbonic anhydrase 2","DB01325, DB13708, DB00524",
DB01326,Cefamandole,approved; experimental,[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)[C@H](O)C1=CC=CC=C1)C(O)=O,C18H18N6O5S2,,"Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, beta-Lactams, Cephalosporins, Heterocyclic Compounds, Fused-Ring, Lactams, Nephrotoxic agents, OAT1/SLC22A6 inhibitors, OAT3/SLC22A8 Inhibitors, Second-Generation Cephalosporins, Sulfur Compounds, Thiazines"," Penicillin-binding protein 2,  Solute carrier family 22 member 6,  Solute carrier family 22 member 8,  Solute carrier family 22 member 11,  Solute carrier family 22 member 7","DB01326, DB14725, DB01328, DB00923, DB01329, DB00229, DB13266, DB00567, DB00430, DB00274, DB00267, DB01140, DB13821, DB09062, DB01150, DB01327, DB01330, DB13638, DB00689, DB01212, DB13778, DB13499, DB00833, DB09008, DB01333, DB11385, DB00456, DB11592, DB03938, DB13504",
DB01327,Cefazolin,approved,[H][C@]12SCC(CSC3=NN=C(C)S3)=C(N1C(=O)[C@H]2NC(=O)CN1C=NN=N1)C(O)=O,C14H14N8O4S3,,"Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, beta-Lactams, Cephalosporins, First-Generation Cephalosporins, Heterocyclic Compounds, Fused-Ring, Lactams, Nephrotoxic agents, OAT1/SLC22A6 inhibitors, OAT1/SLC22A6 Substrates, OAT3/SLC22A8 Inhibitors, OAT3/SLC22A8 Substrates, Sulfur Compounds, Thiazines"," Penicillin-binding protein 1A,  Penicillin-binding protein 1B,  Penicillin-binding protein 1C,  Penicillin-binding protein 2,  Peptidoglycan synthase FtsI,  Serum paraoxonase/arylesterase 1,  Interleukin-15,  Interleukin-2,  Thiopurine S-methyltransferase,  Serum albumin,  Multidrug resistance-associated protein 4,  Solute carrier family 22 member 6,  Solute carrier family 22 member 8,  Solute carrier family 22 member 11","DB01327, DB13821, DB13778, DB00923, DB00229, DB01326, DB01328, DB00274, DB14725, DB09062, DB01329, DB01330, DB13638, DB13266, DB00267, DB00430, DB01212, DB13470, DB00567, DB00456, DB09008, DB01414, DB01333, DB01150, DB00689, DB11385, DB11592, DB01140, DB13499, DB00535",
DB01328,Cefonicid,approved; investigational,[H][C@]12SCC(CSC3=NN=NN3CS(O)(=O)=O)=C(N1C(=O)[C@H]2NC(=O)[C@H](O)C1=CC=CC=C1)C(O)=O,C18H18N6O8S3,,"Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, beta-Lactams, Cephalosporins, Heterocyclic Compounds, Fused-Ring, Lactams, Nephrotoxic agents, Second-Generation Cephalosporins, Sulfur Compounds, Thiazines"," Penicillin-binding protein 1A,  Peptidoglycan synthase FtsI,  Penicillin-binding protein 1B,  D-alanyl-D-alanine carboxypeptidase DacB,  Penicillin-binding protein 2,  Serum albumin","DB01328, DB01326, DB14725, DB00923, DB01329, DB00229, DB13266, DB00267, DB00430, DB13821, DB00274, DB01327, DB01330, DB09062, DB13638, DB00567, DB13499, DB01212, DB01140, DB01150, DB13778, DB11385, DB13470, DB00689, DB11592, DB09008, DB01413, DB13504, DB11485, DB00671",
DB01329,Cefoperazone,approved; investigational,[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@@]2([H])NC(=O)[C@H](NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=C(O)C=C1)C(O)=O,C25H27N9O8S2,,"Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, beta-Lactams, Cephalosporins, Heterocyclic Compounds, Fused-Ring, Lactams, Nephrotoxic agents, OAT1/SLC22A6 inhibitors, OAT3/SLC22A8 Inhibitors, Sulfur Compounds, Thiazines, Third-Generation Cephalosporins"," Peptidoglycan synthase FtsI,  Penicillin-binding protein 1B,  Penicillin-binding protein 2,  Penicillin-binding protein 1A,  Penicillin-binding protein 1B,  D-alanyl-D-alanine carboxypeptidase DacC,  Penicillin-binding protein 1A,  D-alanyl-D-alanine carboxypeptidase DacA,  D-alanyl-D-alanine carboxypeptidase DacB,  Serum albumin,  Solute carrier family 22 member 6,  Solute carrier family 22 member 8,  Solute carrier family 22 member 11,  Solute carrier family 22 member 7","DB01329, DB00923, DB01326, DB00430, DB13266, DB14725, DB01328, DB13638, DB00229, DB01150, DB00274, DB01140, DB09062, DB00267, DB00567, DB01330, DB13821, DB01327, DB01212, DB13778, DB00689, DB13499, DB14879, DB00833, DB13470, DB11485, DB00671, DB11592, DB01413, DB05735",
DB01330,Cefotetan,approved,[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)C1SC(S1)=C(C(N)=O)C(O)=O)OC)C(O)=O,C17H17N7O8S4,,"Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, beta-Lactams, Cephalosporins, Cephamycins, Drugs that are Mainly Renally Excreted, Heterocyclic Compounds, Fused-Ring, Lactams, Nephrotoxic agents, Second-Generation Cephalosporins, Sulfur Compounds, Tetrazoles, Thiazines"," Penicillin-binding protein 3,  Serum albumin","DB01330, DB09062, DB00274, DB13638, DB01326, DB14725, DB01328, DB00430, DB00267, DB01329, DB00229, DB00923, DB13821, DB01327, DB01212, DB01331, DB13778, DB13266, DB05735, DB13470, DB14879, DB00671, DB09050, DB13667, DB00535, DB14733, DB00438, DB00493, DB11505, DB01413",
DB01331,Cefoxitin,approved,[H][C@]12SCC(COC(N)=O)=C(N1C(=O)[C@]2(NC(=O)CC1=CC=CS1)OC)C(O)=O,C16H17N3O7S2,,"Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, beta-Lactams, Cephalosporins, Cephamycins, Heterocyclic Compounds, Fused-Ring, Lactams, Nephrotoxic agents, Second-Generation Cephalosporins, Sulfur Compounds, Thiazines"," D-alanyl-D-alanine carboxypeptidase DacC,  D-alanyl-D-alanine carboxypeptidase DacA,  D-alanyl-D-alanine endopeptidase,  D-alanyl-D-alanine carboxypeptidase DacB,  Penicillin-binding protein 1A,  Penicillin-binding protein 1B,  Peptidoglycan synthase FtsI,  Penicillin-binding protein 3,  Penicillin-binding protein 1b, 10. Penicillin-binding protein 2a, 11. Penicillin-binding protein 1A, 12. Penicillin-binding protein 2B,  Beta-lactamase","DB01331, DB00456, DB01112, DB00689, DB13461, DB09062, DB00274, DB01330, DB11592, DB13638, DB00493, DB01414, DB01416, DB03313, DB01139, DB09008, DB11385, DB00535, DB11505, DB01413, DB13504, DB00567, DB14879, DB01212, DB01150, DB01140, DB11485, DB00671, DB04918, DB14725",
DB01332,Ceftizoxime,approved; withdrawn,[H][C@]12SCC=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O,C13H13N5O5S2,,"Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, beta-Lactams, Cephalosporins, Heterocyclic Compounds, Fused-Ring, Lactams, Nephrotoxic agents, OAT1/SLC22A6 inhibitors, OAT1/SLC22A6 Substrates, OAT3/SLC22A8 Inhibitors, OAT3/SLC22A8 Substrates, Sulfur Compounds, Thiazines, Third-Generation Cephalosporins"," Penicillin-binding protein 1A,  Penicillin-binding protein 1B,  D-alanyl-D-alanine carboxypeptidase DacC,  Solute carrier family 15 member 1,  Solute carrier family 22 member 6,  Solute carrier family 22 member 8","DB01332, DB13504, DB00535, DB01416, DB01413, DB00493, DB00671, DB00267, DB11485, DB11505, DB00438, DB01066, DB01212, DB01415, DB13470, DB14879, DB13461, DB13682, DB00229, DB03437, DB04918, DB13667, DB08375, DB01112, DB00833, DB06590, DB00567, DB03530, DB09050, DB01326",
DB01333,Cefradine,approved,[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CCC=CC1)C(O)=O,C16H19N3O4S,,"Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, beta-Lactams, Cephalosporins, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 Enzyme Inducers, Drugs that are Mainly Renally Excreted, First-Generation Cephalosporins, Heterocyclic Compounds, Fused-Ring, Lactams, MATE 1 Substrates, MATE substrates, Nephrotoxic agents, OAT1/SLC22A6 inhibitors, Sulfur Compounds, Thiazines"," Penicillin-binding protein 1A,  Cytochrome P450 3A4,  Solute carrier family 22 member 5,  Solute carrier family 15 member 1,  Solute carrier family 15 member 2,  Solute carrier family 22 member 6,  Multidrug and toxin extrusion protein 1","DB01333, DB11367, DB03938, DB00567, DB01140, DB01150, DB03313, DB01414, DB00689, DB14107, DB01139, DB00833, DB01326, DB00456, DB14725, DB09008, DB13266, DB13821, DB00923, DB01329, DB01112, DB01328, DB13300, DB01327, DB00229, DB13461, DB04918, DB11385, DB11592, DB09062",
DB01336,Metocurine,approved,[H][C@@]12CC3=CC=C(OC4=C5C(CC[N+](C)(C)[C@]5([H])CC5=CC(OC6=C(OC)C=C(CC[N+]1(C)C)C2=C6)=C(OC)C=C5)=CC(OC)=C4OC)C=C3,C40H48N2O6,,"Agents producing tachycardia, Alkaloids, Amines, Anticholinergic Agents, Benzylisoquinolines, Central Nervous System Depressants, Curare Alkaloids, Heterocyclic Compounds, Fused-Ring, Isoquinolines, Muscarinic Antagonists, Muscle Relaxants, Muscle Relaxants, Peripherally Acting Agents, Musculo-Skeletal System, Neuromuscular Agents, Neuromuscular Blocking Agents, Neuromuscular-Blocking Agents (Nondepolarizing), Nicotinic Antagonists, Onium Compounds, Peripheral Nervous System Agents, Quaternary Ammonium Compounds, Tetrahydroisoquinolines"," Neuronal acetylcholine receptor subunit alpha-2,  Muscarinic acetylcholine receptor M2","DB01199, DB01336, DB00416, DB14066, DB18146, DB16824, DB12093, DB01135, DB13692, DB01226",
DB01337,Pancuronium,approved,[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1,C35H60N2O4,,"Agents producing tachycardia, Androstanes, Androstanols, Anticholinergic Agents, Central Nervous System Depressants, Cholinergic Agents, Cholinesterase Inhibitors, Fused-Ring Compounds, Muscarinic Antagonists, Muscle Relaxants, Muscle Relaxants, Peripherally Acting Agents, Musculo-Skeletal System, Neuromuscular Agents, Neuromuscular Blocking Agents, Neuromuscular Nondepolarizing Blockade, Neuromuscular-Blocking Agents (Nondepolarizing), Neurotransmitter Agents, Nicotinic Antagonists, OCT1 inhibitors, OCT1 substrates, Peripheral Nervous System Agents, Steroids"," Neuronal acetylcholine receptor subunit alpha-2,  Muscarinic acetylcholine receptor M2,  Muscarinic acetylcholine receptor M3,  Cholinesterase,  Solute carrier family 22 member 1,  Solute carrier family 22 member 2","DB01337, DB01339, DB04834, DB00728, DB01338",
DB01338,Pipecuronium,approved,[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)N1CC[N+](C)(C)CC1)N1CC[N+](C)(C)CC1,C35H62N4O4,,"Agents producing tachycardia, Anticholinergic Agents, Central Nervous System Depressants, Cholinergic Agents, Cholinesterase Inhibitors, Muscarinic Antagonists, Muscle Relaxants, Muscle Relaxants, Peripherally Acting Agents, Musculo-Skeletal System, Neuromuscular Agents, Neuromuscular Blocking Agents, Neuromuscular-Blocking Agents (Nondepolarizing), Neurotransmitter Agents, Nicotinic Antagonists, Peripheral Nervous System Agents, Piperazines"," Neuronal acetylcholine receptor subunit alpha-2,  Muscarinic acetylcholine receptor M2,  Muscarinic acetylcholine receptor M3,  Cholinesterase","DB01338, DB01337, DB01339, DB00728, DB04834",
DB01339,Vecuronium,approved; investigational,[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1,C34H57N2O4,,"Androstanes, Androstanols, Anticholinergic Agents, Central Nervous System Depressants, Cholinergic Agents, Fused-Ring Compounds, Muscle Relaxants, Muscle Relaxants, Peripherally Acting Agents, Musculo-Skeletal System, Neuromuscular Agents, Neuromuscular Blocking Agents, Neuromuscular Nondepolarizing Blockade, Neuromuscular-Blocking Agents (Nondepolarizing), Neurotransmitter Agents, Nicotinic Antagonists, P-glycoprotein substrates, Peripheral Nervous System Agents, Steroids"," Neuronal acetylcholine receptor subunit alpha-2,  P-glycoprotein 1","DB01337, DB01339, DB04834, DB00728, DB01338",
DB01340,Cilazapril,approved,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]1CCCN2CCC[C@H](N2C1=O)C(O)=O,C22H31N3O5,,"ACE Inhibitors and Diuretics, Agents Acting on the Renin-Angiotensin System, Agents causing angioedema, Agents causing hyperkalemia, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Antihypertensive Agents Indicated for Hypertension, Cardiovascular Agents, Enzyme Inhibitors, Hypotensive Agents, P-glycoprotein inhibitors, Protease Inhibitors, Pyridazines"," Angiotensin-converting enzyme,  P-glycoprotein 1,  Solute carrier family 15 member 1,  Solute carrier family 15 member 2","DB01340, DB15565, DB00584",
DB01341,Dihydroquinidine barbiturate,experimental,,,,, Gamma-aminobutyric acid receptor subunit alpha-1,,
DB01342,Forasartan,experimental,CCCCC1=NN(CC2=CN=C(C=C2)C2=CC=CC=C2C2=NNN=N2)C(CCCC)=N1,C23H28N8,,"Agents Acting on the Renin-Angiotensin System, Agents causing angioedema, Agents causing hyperkalemia, Angiotensin II receptor antagonists, Angiotensin II Type 1 Receptor Blockers, Angiotensin Receptor Antagonists", Type-1 angiotensin II receptor,DB01342,
DB01344,Tolevamer,approved; investigational,,,,"Acids, Acids, Noncarboxylic, Benzene Derivatives, Benzylidene Compounds, Cation Exchange Resins, Chelating Agents, Compounds used in a research, industrial, or household setting, Drugs for Treatment of Hyperkalemia and Hyperphosphatemia, Ion Exchange Resins, Laboratory Chemicals, Macromolecular Substances, Plastics, Polymers, Polystyrene Sulfonates, Potassium Binder, Potassium Ion Exchange Activity, Potassium-removing Agents, Sequestering Agents, Styrene, Styrenes, Sulfur Acids, Sulfur Compounds", Potassium,,
DB01345,Potassium cation,approved; investigational,[K+],K,,"Agents causing hyperkalemia, Diuretics, Drugs that are Mainly Renally Excreted, Increased Large Intestinal Motility, Inhibition Large Intestine Fluid/Electrolyte Absorption, Minerals, Osmotic Activity, Potassium Salt, Replacement Preparations", Sodium/potassium-transporting ATPase subunit alpha-1,"DB01345, DB14500",
DB01346,Quinidine barbiturate,approved,CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C,C32H36N4O5,,," Gamma-aminobutyric acid receptor subunit alpha-1,  Gamma-aminobutyric acid receptor subunit alpha-2,  Sodium channel protein type 5 subunit alpha,  Potassium channel subfamily K member 1,  Glutamate receptor 2","DB01346, DB00468, DB00908, DB13718, DB15300, DB16831",
DB01347,Saprisartan,experimental,CCC1=NC(C2CC2)=C(N1CC1=CC2=C(OC(=C2Br)C2=CC=CC=C2NS(=O)(=O)C(F)(F)F)C=C1)C(N)=O,C25H22BrF3N4O4S,,"Agents Acting on the Renin-Angiotensin System, Agents causing angioedema, Agents causing hyperkalemia, Angiotensin II receptor antagonists, Angiotensin II Type 1 Receptor Blockers, Angiotensin Receptor Antagonists, Antihypertensive Agents, Cardiovascular Agents, Heterocyclic Compounds, Fused-Ring", Type-1 angiotensin II receptor,DB01347,
DB01348,Spirapril,approved,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2(C[C@H]1C(O)=O)SCCS2,C22H30N2O5S2,,"Agents Acting on the Renin-Angiotensin System, Agents causing angioedema, Agents causing hyperkalemia, Amino Acids, Peptides, and Proteins, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Cardiovascular Agents, Dipeptides, Enzyme Inhibitors, Oligopeptides, Peptides, Protease Inhibitors"," Angiotensin-converting enzyme,  Solute carrier family 15 member 1,  Solute carrier family 15 member 2",DB01348,
DB01349,Tasosartan,experimental,CC1=NC(C)=C2CCC(=O)N(CC3=CC=C(C=C3)C3=CC=CC=C3C3=NNN=N3)C2=N1,C23H21N7O,,"Agents Acting on the Renin-Angiotensin System, Agents causing hyperkalemia, Angiotensin II receptor blockers (ARBs), plain, Angiotensin Receptor Antagonists, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates"," Type-1 angiotensin II receptor,  Type-2 angiotensin II receptor,  Cytochrome P450 3A4",DB01349,
DB01351,Amobarbital,approved; illicit,CCC1(CCC(C)C)C(=O)NC(=O)NC1=O,C11H18N2O3,,"Anticholinergic Agents, Anticonvulsants, Barbiturates, Barbiturates, Plain, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 Enzyme Inducers, GABA Agents, GABA Modulators, Hypnotics and Sedatives, Nervous System, Neurotransmitter Agents, Nicotinic Antagonists, Psycholeptics, Pyrimidines, Pyrimidinones"," Gamma-aminobutyric acid receptor subunit alpha-1,  Gamma-aminobutyric acid receptor subunit alpha-2,  Gamma-aminobutyric acid receptor subunit alpha-3,  Gamma-aminobutyric acid receptor subunit alpha-4,  Gamma-aminobutyric acid receptor subunit alpha-5,  Gamma-aminobutyric acid receptor subunit alpha-6,  Neuronal acetylcholine receptor subunit alpha-4,  Neuronal acetylcholine receptor subunit alpha-7,  Glutamate receptor 2, 10. Glutamate receptor ionotropic, kainate 2","DB01351, DB01353, DB00312, DB00237, DB01483, DB00418, DB13770, DB00241, DB00306, DB00463, DB13577",
DB01352,Aprobarbital,experimental; illicit,CC(C)C1(CC=C)C(=O)NC(=O)NC1=O,C10H14N2O3,,"Anticholinergic Agents, Barbiturates, Plain, Central Nervous System Depressants, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 Enzyme Inducers, Hypnotics and Sedatives, Nervous System, Nicotinic Antagonists, Psycholeptics, Pyrimidines, Pyrimidinones"," Gamma-aminobutyric acid receptor subunit alpha-1,  Gamma-aminobutyric acid receptor subunit alpha-2,  Gamma-aminobutyric acid receptor subunit alpha-3,  Gamma-aminobutyric acid receptor subunit alpha-4,  Gamma-aminobutyric acid receptor subunit alpha-5,  Gamma-aminobutyric acid receptor subunit alpha-6,  Neuronal acetylcholine receptor subunit alpha-4,  Neuronal acetylcholine receptor subunit alpha-7,  Glutamate receptor 2, 10. Glutamate receptor ionotropic, kainate 2,  Cytochrome P450 3A4","DB01352, DB00306, DB13577, DB00418, DB00241, DB00237, DB01483, DB13229, DB00312, DB13770, DB13221, DB13253, DB00474, DB01353, DB00463",
DB01353,Butobarbital,approved; illicit,CCCCC1(CC)C(=O)NC(=O)NC1=O,C10H16N2O3,,"Anticholinergic Agents, Barbiturates, Plain, Central Nervous System Agents, Central Nervous System Depressants, Hypnotics and Sedatives, Nervous System, Nicotinic Antagonists, Psycholeptics, Pyrimidines, Pyrimidinones"," Gamma-aminobutyric acid receptor subunit alpha-2,  Gamma-aminobutyric acid receptor subunit alpha-3,  Gamma-aminobutyric acid receptor subunit alpha-4,  Gamma-aminobutyric acid receptor subunit alpha-5,  Gamma-aminobutyric acid receptor subunit alpha-6,  Gamma-aminobutyric acid receptor subunit alpha-1,  Neuronal acetylcholine receptor subunit alpha-4,  Neuronal acetylcholine receptor subunit alpha-7,  Glutamate receptor 2, 10. Glutamate receptor ionotropic, kainate 2","DB01353, DB01351, DB00312, DB00237, DB01483, DB00418, DB13770, DB00241, DB00306, DB00463, DB13577, DB01352, DB13253",
DB01354,Heptabarbital,experimental,CCC1(C(=O)NC(=O)NC1=O)C1=CCCCCC1,C13H18N2O3,,"Anticholinergic Agents, Barbiturates, Plain, Central Nervous System Depressants, Hypnotics and Sedatives, Nervous System, Nicotinic Antagonists, Psycholeptics, Pyrimidines, Pyrimidinones"," Gamma-aminobutyric acid receptor subunit alpha-1,  Gamma-aminobutyric acid receptor subunit alpha-2,  Gamma-aminobutyric acid receptor subunit alpha-3,  Gamma-aminobutyric acid receptor subunit alpha-4,  Gamma-aminobutyric acid receptor subunit alpha-5,  Gamma-aminobutyric acid receptor subunit alpha-6,  Neuronal acetylcholine receptor subunit alpha-4,  Neuronal acetylcholine receptor subunit alpha-7,  Glutamate receptor 2, 10. Glutamate receptor ionotropic, kainate 2","DB01354, DB13737, DB13805, DB01355, DB13377, DB13770",
DB01355,Hexobarbital,experimental,CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1,C12H16N2O3,,"Adjuvants, Anesthetics, Anesthetics, General, Anticholinergic Agents, Anticonvulsants, Barbiturates, Barbiturates, Plain, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 Substrates, GABA Agents, GABA Modulators, Hypnotics and Sedatives, Nervous System, Neurotransmitter Agents, Nicotinic Antagonists, Psycholeptics, Pyrimidines, Pyrimidinones"," Gamma-aminobutyric acid receptor subunit alpha-2,  Gamma-aminobutyric acid receptor subunit alpha-3,  Gamma-aminobutyric acid receptor subunit alpha-4,  Gamma-aminobutyric acid receptor subunit alpha-5,  Gamma-aminobutyric acid receptor subunit alpha-6,  Gamma-aminobutyric acid receptor subunit alpha-1,  Neuronal acetylcholine receptor subunit alpha-4,  Neuronal acetylcholine receptor subunit alpha-7,  Glutamate receptor 2, 10. Glutamate receptor ionotropic, kainate 2,  Cytochrome P450 2C19,  Cytochrome P450 2C9,  Prostaglandin G/H synthase 1","DB01355, DB13737, DB01354, DB13805, DB13377",
DB01356,Lithium cation,experimental,[Li+],Li,,"Antidepressive Agents, Antimanic Agents, Antipsychotic Agents, Central Nervous System Depressants, Highest Risk QTc-Prolonging Agents, Lithium Compounds, Mood Stabilizer, Nephrotoxic agents, Neurotoxic agents, Psychotropic Drugs, QTc Prolonging Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin Modulators"," Glycogen synthase kinase-3 beta,  Inositol monophosphatase 1,  Inositol monophosphatase 2,  Glutamate receptor 3",DB01356,
DB01357,Mestranol,approved,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(OC)C=C3,C21H26O2,,"Adrenal Cortex Hormones, Contraceptive Agents, Female, Contraceptive Agents, Hormonal, Contraceptives, Oral, Contraceptives, Oral, Hormonal, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Estradiol Congeners, Estrogen Contraceptives, Estrogenic Steroids, Alkylated, Estrogens, Ethinyl Estradiol, Fused-Ring Compounds, Gonadal Hormones, Gonadal Steroid Hormones, Hormonal Contraceptives for Systemic Use, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hyperglycemia-Associated Agents, Norpregnanes, Norpregnatrienes, Norsteroids, Reproductive Control Agents, Steroids, Thyroxine-binding globulin inducers"," Estrogen receptor alpha,  Cytochrome P450 3A4,  Cytochrome P450 2C8,  Cytochrome P450 2C9","DB01357, DB00977, DB13386, DB02342, DB04575, DB12487, DB00783, DB04573, DB07702, DB07706, DB13952, DB12235, DB13418, DB07707, DB15690, DB13956, DB13953, DB07891, DB13954",
DB01359,Penbutolol,approved; investigational,CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1,C18H29NO2,,"Adrenergic Agents, Adrenergic Antagonists, Adrenergic beta-Antagonists, Agents causing hyperkalemia, Alcohols, Amines, Amino Alcohols, Antidepressive Agents, Antihypertensive Agents, Beta Blocking Agents, Non-Selective, Bradycardia-Causing Agents, Cardiovascular Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Hypotensive Agents, Negative Inotrope, Neurotransmitter Agents, Phenoxypropanolamines, Propanolamines, Propanols, Serotonin 5-HT1 Receptor Antagonists, Serotonin 5-HT1A Receptor Antagonists, Serotonin Agents, Serotonin Receptor Antagonists"," Beta-1 adrenergic receptor,  Beta-2 adrenergic receptor,  5-hydroxytryptamine receptor 1A,  5-hydroxytryptamine receptor 1B,  Cytochrome P450 2D6,  Alpha-1-acid glycoprotein 1","DB01359, DB01182, DB15410, DB00866, DB01203",
DB01362,Iohexol,approved,CC(=O)N(CC(O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I,C19H26I3N3O9,,"Acids, Carbocyclic, Agents that reduce seizure threshold, Benzene Derivatives, Benzoates, Compounds used in a research, industrial, or household setting, Contrast Media, Diagnostic Uses of Chemicals, Iodinated Contrast Agents, Iodobenzoates, Radiographic Contrast Agent, Roentgenography, Triiodobenzoic Acids, Watersoluble, Nephrotropic, Low Osmolar X-Ray Contrast Media, X-Ray Contrast Activity, X-Ray Contrast Media, Iodinated",,"DB01362, DB09135, DB13861, DB01249, DB11705, DB12439, DB09134, DB09156, DB12407, DB08947, DB09487, DB13444, DB09313, DB01578",
DB01364,Ephedrine,approved,CN[C@@H](C)[C@H](O)C1=CC=CC=C1,C10H15NO,,"Adrenergic Agents, Adrenergic Agonists, Adrenergic alpha-Agonists, Adrenergic and Dopaminergic Agents, Adrenergic beta-Agonists, Adrenergics for Systemic Use, Agents producing tachycardia, Agents that produce hypertension, Alcohols, Alimentary Tract and Metabolism, Alpha-and Beta-adrenergic Agonists, Amines, Amino Alcohols, Antiobesity Preparations, Excl. Diet Products, Autonomic Agents, Cardiac Stimulants Excl. Cardiac Glycosides, Cardiac Therapy, Cardiovascular Agents, Central Nervous System Agents, Central Nervous System Stimulants, Centrally Acting Antiobesity Products, Cholinesterase substrates, Drugs for Obstructive Airway Diseases, Epinephrine and similars, Ethylamines, Herbs and Natural Products, Increased Norepinephrine Activity, Mydriatics and Cycloplegics, Nasal Preparations, Neurotransmitter Agents, Norepinephrine Releasing Agents, Ophthalmologicals, Peripheral Nervous System Agents, Phenethylamines, Propanolamines, Propanols, Sensory Organs, Sympathomimetic (Adrenergic) Agents, Sympathomimetics, Sympathomimetics Excl. Antiglaucoma Preparations, Sympathomimetics, Plain, Vasoconstrictor Agents"," Alpha-1A adrenergic receptor,  Beta-1 adrenergic receptor,  Beta-2 adrenergic receptor,  Sodium-dependent noradrenaline transporter,  Cholinesterase,  Acetylcholinesterase,  Serum albumin,  Synaptic vesicular amine transporter","DB00852, DB01364, DB14752, DB11278, DB11587, DB00397, DB01486, DB11610, DB00867, DB01577, DB09571, DB15902",
DB01365,Mephentermine,approved,CNC(C)(C)CC1=CC=CC=C1,C11H17N,,"Adrenergic Agents, Adrenergic Agonists, Adrenergic alpha-1 Receptor Agonists, Adrenergic alpha-Agonists, Adrenergic and Dopaminergic Agents, Agents producing tachycardia, Agents that produce hypertension, Amines, Amphetamines, Autonomic Agents, Cardiac Stimulants Excl. Cardiac Glycosides, Cardiac Therapy, Cardiovascular Agents, Ethylamines, Neurotransmitter Agents, Peripheral Nervous System Agents, Phenethylamines, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Sympathomimetics, Vasoconstrictor Agents"," Alpha adrenergic receptor (Protein Group),  Beta adrenergic receptor (Protein Group)","DB01365, DB01577, DB09571, DB00191, DB13285, DB00182, DB01576, DB13852, DB01037, DB12650, DB01550, DB04677, DB02972, DB15339",
DB01366,Procaterol,approved; investigational,CC[C@@H](NC(C)C)[C@@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2,C16H22N2O3,,"Adrenergic Agents, Adrenergic Agonists, Adrenergic beta-2 Receptor Agonists, Adrenergic beta-Agonists, Adrenergics for Systemic Use, Adrenergics, Inhalants, Agents producing tachycardia, Agents that produce hypertension, Alcohols, Amines, Amino Alcohols, Anti-Asthmatic Agents, Autonomic Agents, Bronchodilator Agents, Drugs for Obstructive Airway Diseases, Ethanolamines, Heterocyclic Compounds, Fused-Ring, Hydroxyquinolines, Neurotransmitter Agents, Peripheral Nervous System Agents, Quinolines, Respiratory System Agents, Selective Beta 2-adrenergic Agonists, Sympathomimetics", Beta-2 adrenergic receptor,"DB01366, DB15784, DB05039, DB12100",
DB01367,Rasagiline,approved,C#CCN[C@@H]1CCC2=CC=CC=C12,C12H13N,,"Agents that produce hypertension, Agents that reduce seizure threshold, Anti-Parkinson Drugs, Antidepressive Agents, Central Nervous System Agents, Central Nervous System Depressants, Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 Substrates, Dopamine Agents, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Hypotensive Agents, Indenes, Monoamine Oxidase B Inhibitors, Monoamine Oxidase Inhibitors, Nervous System, Neuroprotective Agents, Protective Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin Modulators"," Amine oxidase [flavin-containing] B,  Apoptosis regulator Bcl-2,  Cytochrome P450 1A2","DB01367, DB03894, DB02211, DB04307",
DB01369,Quinupristin,approved,[H][C@@]12CCCN1C(=O)[C@@H](CC)NC(=O)[C@@H](NC(=O)C1=NC=CC=C1O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@]1([H])CC(=O)[C@]([H])(CS[C@@H]3CN4CCC3CC4)CN1C(=O)[C@H](CC1=CC=C(C=C1)N(C)C)N(C)C2=O)C1=CC=CC=C1,C53H67N9O10S,,"Amino Acids, Peptides, and Proteins, Anti-Bacterial Agents, Anti-Infective Agents, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Inhibitors (weak), Cytochrome P-450 Enzyme Inhibitors, Peptides, Peptides, Cyclic, Streptogramin Antibacterial, Streptogramins"," 23S ribosomal RNA,  50S ribosomal protein L10,  50S ribosomal protein L22,  Cytochrome P450 3A4","DB01369, DB04805, DB11476, DB12674, DB12755, DB05109, DB04952, DB00080, DB05168, DB12076, DB05735, DB04111, DB13013, DB04431, DB11641, DB00361, DB06149, DB02868, DB16098",
DB01370,Aluminium,approved; investigational,[Al],Al,,"Aluminium Compounds, Aluminum and magnesium containing antacids, Antacids, Elements, Gastric Acid Lowering Agents, Metal cations, Metal divalent cations, Metals, Metals, Light"," Kallikrein-1,  Amyloid beta A4 protein,  Serotransferrin,  Sodium/potassium-transporting ATPase subunit alpha-1,  Serum albumin","DB01370, DB14519",
DB01373,Calcium,nutraceutical,[Ca],Ca,,"Alimentary Tract and Metabolism, Antacids and Adsorbents, Biological Factors, Blood Coagulation Factors, Calcium Salts, Calcium-Regulating Hormones and Agents, Drugs Affecting Bone Structure and Mineralization, Drugs for Treatment of Bone Diseases, Elements, Metals, Metals, Alkaline Earth, Minerals, Musculo-Skeletal System, Phosphate Binder, Phosphate Chelating Activity, Replacement Preparations"," Voltage-dependent L-type calcium channel subunit alpha-1C,  Calcium-transporting ATPase type 2C member 1,  Troponin C, skeletal muscle,  Troponin C, slow skeletal and cardiac muscles,  Spectrin beta chain, non-erythrocytic 1,  Protein S100-B,  Calpastatin,  Cartilage oligomeric matrix protein,  Calmodulin, 10. Amiloride-sensitive amine oxidase [copper-containing], 11. Protein S100-A13, 12. Alkaline phosphatase, placental type, 13. Protein S100-A8, 14. Protein S100-A9, 15. Protein S100-A2, 16. Ceruloplasmin, 17. Bone morphogenetic protein 4, 18. Matrix Gla protein, 19. Protocadherin-19, 20. Programmed cell death protein 6","DB01373, DB14577",
DB01375,Aluminium monostearate,experimental,CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O,C18H37AlO4,,"Fatty Acids, Lipids"," Troponin C, slow skeletal and cardiac muscles,  Voltage-dependent anion-selective channel protein 1,  Voltage-dependent anion-selective channel protein 2,  Voltage-dependent anion-selective channel protein 3",DB01375,
DB01377,Magnesium oxide,approved,[O--].[Mg++],MgO,,"Agents that produce neuromuscular block (indirect), Alimentary Tract and Metabolism, Aluminum and magnesium containing antacids, Antacids, Drugs for Acid Related Disorders, Drugs for Constipation, Gastric Acid Lowering Agents, Gastrointestinal Agents, Laxatives, Laxatives, magnesium containing, Magnesium Compounds, Magnesium Salts, Metal cations, Metal divalent cations, Mineral Supplements, Minerals, Osmotic Laxatives, Oxides, Oxygen Compounds",,"DB01377, DB09104",
DB01378,Magnesium cation,approved; nutraceutical,[Mg++],Mg,,"Agents that produce neuromuscular block (indirect), Calculi Dissolution Agent, Increased Large Intestinal Motility, Inhibition Large Intestine Fluid/Electrolyte Absorption, Inhibition Small Intestine Fluid/Electrolyte Absorption, Laxatives, Magnesium Ion Exchange Activity, Minerals, Osmotic Activity, Osmotic Laxatives, Polyvalent cation containing laxatives, antacids, oral supplements, Stimulation Large Intestine Fluid/Electrolyte Secretion", Sodium/potassium-transporting ATPase subunit alpha-1,"DB01378, DB14513",
DB01380,Cortisone acetate,approved; investigational,[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,C23H30O6,,"17-Hydroxycorticosteroids, Adrenal Cortex Hormones, Adrenals, Anti-Inflammatory Agents, Corticosteroids, Corticosteroids for Systemic Use, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Inducers, Cytochrome P-450 CYP3A5 Inducers (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Substrates, Fused-Ring Compounds, Glucocorticoids, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hydroxycorticosteroids, Hyperglycemia-Associated Agents, Immunosuppressive Agents, OAT3/SLC22A8 Substrates, P-glycoprotein inducers, P-glycoprotein substrates, Pregnanes, Pregnenes, Steroids"," Glucocorticoid receptor,  Annexin A1,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Corticosteroid-binding globulin,  Serum albumin,  Solute carrier organic anion transporter family member 1A2,  P-glycoprotein 1,  Solute carrier family 22 member 8","DB01380, DB12499, DB14539, DB14625, DB14646, DB00603, DB11440, DB06780, DB14541, DB14545, DB01134, DB06789, DB14677, DB14583, DB14538, DB14543, DB14540, DB14544, DB14681, DB13958, DB05288, DB01420, DB08804, DB13943, DB13944, DB13946, DB16001, DB16002, DB16141, DB08308",
DB01382,Glymidine,approved; investigational,COCCOC1=CN=C(NS(=O)(=O)C2=CC=CC=C2)N=C1,C13H15N3O4S,,"Alimentary Tract and Metabolism, Amides, Blood Glucose Lowering Agents, Drugs Used in Diabetes, Genito Urinary System and Sex Hormones, Gynecological Antiinfectives and Antiseptics, Oral Hypoglycemics, Sulfonamides, Sulfones, Sulfur Compounds"," ATP-sensitive inward rectifier potassium channel 1,  ATP-binding cassette sub-family C member 8","DB01382, DB06821, DB00359, DB05245",
DB01384,Paramethasone,experimental,[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,C22H29FO5,,"Adrenal Cortex Hormones, Anti-Inflammatory Agents, Corticosteroids, Corticosteroids for Systemic Use, Corticosteroids for Systemic Use, Plain, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Inducers, Cytochrome P-450 CYP3A5 Inducers (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Fused-Ring Compounds, Glucocorticoids, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hyperglycemia-Associated Agents, Immunosuppressive Agents, Pregnadienes, Pregnadienetriols, Pregnanes, Steroids, Steroids, Fluorinated, Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins"," Glucocorticoid receptor,  Cytochrome P450 3A4,  Cytochrome P450 3A5,  Corticosteroid-binding globulin","DB01384, DB09378, DB08971, DB13223, DB00223, DB00663, DB09095, DB12553, DB14637, DB14657, DB00596, DB00838, DB15777, DB00443, DB01234, DB11522, DB13491, DB15821, DB00324, DB13728, DB00620, DB08970, DB00547, DB00860, DB00959, DB14664, DB11750, DB06781, DB13208, DB13856",
DB01388,Mibefradil,investigational; withdrawn,COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=CC=CC=C3N2)CCC2=C(C=CC(F)=C2)[C@@H]1C(C)C,C29H38FN3O3,,"Agents causing hyperkalemia, Antiarrhythmic agents, Antihypertensive Agents, Benzimidazoles, Bradycardia-Causing Agents, Calcium Channel Blockers, Calcium-Regulating Hormones and Agents, Cardiovascular Agents, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A5 Inhibitors, Cytochrome P-450 CYP3A5 Inhibitors (strength unknown), Cytochrome P-450 CYP3A7 Inhibitors, Cytochrome P-450 CYP3A7 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Enzyme Inhibitors, Heterocyclic Compounds, Fused-Ring, Membrane Transport Modulators, Moderate Risk QTc-Prolonging Agents, Naphthalenes, P-glycoprotein inhibitors, P-glycoprotein substrates, QTc Prolonging Agents, Selective Calcium Channel Blockers With Mainly Vascular Effects, Tetrahydronaphthalenes, Vasodilating Agents"," Voltage-dependent T-type calcium channel subunit alpha-1G,  Voltage-dependent T-type calcium channel subunit alpha-1H,  Voltage-dependent L-type calcium channel subunit alpha-1C,  Voltage-dependent L-type calcium channel subunit alpha-1D,  Voltage-dependent L-type calcium channel subunit alpha-1F,  Voltage-dependent T-type calcium channel subunit alpha-1I,  Voltage-dependent L-type calcium channel subunit alpha-1S,  Voltage-dependent L-type calcium channel subunit beta-1,  Voltage-dependent L-type calcium channel subunit beta-2, 10. Voltage-dependent L-type calcium channel subunit beta-3, 11. Voltage-dependent L-type calcium channel subunit beta-4,  Cytochrome P450 11B1, mitochondrial,  Cytochrome P450 11B2, mitochondrial,  Cytochrome P450 3A4,  Cytochrome P450 1A2,  Cytochrome P450 2D6,  Cytochrome P450 3A5,  Cytochrome P450 3A7,  P-glycoprotein 1","DB01388, DB17037",
DB01390,Sodium bicarbonate,approved,[Na+].OC([O-])=O,CHNaO3,,"Antacids, Antacids and Adsorbents, Bicarbonates, Blood and Blood Forming Organs, Blood Substitutes and Perfusion Solutions, Carbon Compounds, Inorganic, Carbonates, Carbonic Acid, Electrolyte Solutions, Gastric Acid Lowering Agents, Hemodialysis Solution, I.V. Solution Additives, Irrigating Solutions, Salt Solutions, Sodium Compounds, Urinary Alkalinisers"," Hydrogen ions,  Electrogenic sodium bicarbonate cotransporter 1,  Sodium bicarbonate cotransporter 3,  Electroneutral sodium bicarbonate exchanger 1,  Electrogenic sodium bicarbonate cotransporter 4,  Sodium-driven chloride bicarbonate exchanger","DB01390, DB09460, DB14531, DB06724, DB06792, DB09481, DB11098, DB11281, DB13698, DB13977, DB14494, DB14509, DB15925, DB15926, DB01942, DB15825",
DB01392,Yohimbine,approved; investigational; vet_approved,[H][C@@]12CC[C@H](O)[C@H](C(=O)OC)[C@@]1([H])C[C@]1([H])N(CCC3=C1NC1=CC=CC=C31)C2,C21H26N2O3,,"Adrenergic Agents, Adrenergic alpha-2 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Agents that produce hypertension, Alkaloids, Antidepressive Agents, Autonomic Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Drugs Used in Erectile Dysfunction, Genito Urinary System and Sex Hormones, Genitourinary Agents, Heterocyclic Compounds, Fused-Ring, Indole Alkaloids, Indoles, Indolizidines, Indolizines, Mydriatics, Neurotransmitter Agents, Other Miscellaneous Therapeutic Agents, P-glycoprotein inhibitors, Peripheral Nervous System Agents, Secologanin Tryptamine Alkaloids, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT1 Receptor Antagonists, Serotonin 5-HT1D Receptor Antagonists, Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2A Receptor Antagonists, Serotonin 5-HT2C Receptor Antagonists, Serotonin Agents, Serotonin Receptor Antagonists, Urological Agents, Urologicals"," Alpha-2A adrenergic receptor,  Alpha-2B adrenergic receptor,  Alpha-2C adrenergic receptor,  5-hydroxytryptamine receptor 1A,  5-hydroxytryptamine receptor 1B,  5-hydroxytryptamine receptor 1D,  Dopamine D2 receptor,  Dopamine D3 receptor,  5-hydroxytryptamine receptor 2A, 10. 5-hydroxytryptamine receptor 2C, 11. ATP-sensitive potassium channel (Protein Group), 12. 5-hydroxytryptamine receptor 2B,  Cytochrome P450 2D6,  Cytochrome P450 3A4","DB01392, DB11530, DB15949, DB01089, DB01180, DB00206, DB13631, DB02191, DB13575, DB13374, DB13793, DB01967, DB15096, DB12131",
DB01393,Bezafibrate,approved; investigational,CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O,C19H20ClNO4,,"Acids, Acyclic, Acids, Carbocyclic, Agents Causing Muscle Toxicity, Amides, Benzamides and benzamide derivatives, Benzene Derivatives, Benzoates, Butyrates, Chlorobenzoates, Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2C8 Inhibitors (weak), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Ethers, Fibric Acid Derivatives, Fibric Acids, Hypolipidemic Agents, Hypolipidemic Agents Indicated for Hyperlipidemia, Isobutyrates, Lipid Modifying Agents, Lipid Modifying Agents, Plain, Lipid Regulating Agents, Non-statin Hypolipidemic Agents Indicated for Hyperlipidemia, OATP1B1/SLCO1B1 Inhibitors, Phenols, Phenyl Ethers"," Peroxisome proliferator-activated receptor delta,  Peroxisome proliferator-activated receptor gamma,  Peroxisome proliferator-activated receptor alpha,  Nuclear receptor subfamily 1 group I member 2,  Retinoic acid receptor RXR-alpha,  Retinoic acid receptor RXR-beta,  Retinoic acid receptor RXR-gamma,  Cytochrome P450 1A1,  Cytochrome P450 2C8,  Cytochrome P450 3A4,  Solute carrier organic anion transporter family member 1B1",DB01393,
DB01394,Colchicine,approved,COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1[C@H](CC2)NC(C)=O,C22H25NO6,,"Agents Causing Muscle Toxicity, Alkaloids, Antigout Preparations, Antimitotic Agents, Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors (strength unknown), Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C8 Inhibitors (strength unknown), Cytochrome P-450 CYP2E1 Inducers, Cytochrome P-450 CYP2E1 Inducers (strength unknown), Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (strength unknown), Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Experimental Unapproved Treatments for COVID-19, Mitosis Modulators, Musculo-Skeletal System, P-glycoprotein inducers, P-glycoprotein substrates, Preparations With No Effect on Uric Acid Metabolism, Tubulin Modulators"," Tubulin beta chain,  Cytochrome P450 3A4,  Cytochrome P450 2B6,  Cytochrome P450 2C8,  Cytochrome P450 2E1,  Serum albumin,  P-glycoprotein 1","DB01394, DB15534, DB07574, DB13318, DB11872, DB11582",
DB01395,Drospirenone,approved,[H][C@@]12C[C@]1([H])[C@@]1([H])[C@]3([H])[C@]4([H])C[C@]4([H])[C@@]4(CCC(=O)O4)[C@@]3(C)CC[C@]1([H])[C@@]1(C)CCC(=O)C=C21,C24H30O3,,"Adrenal Cortex Hormones, Agents causing hyperkalemia, Androstanes, Combination Contraceptives (with Estrogen and derivatives), Contraceptive Agents, Female, Contraceptives, Oral, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Substrates, Diuretics, Fused-Ring Compounds, Genito Urinary System and Sex Hormones, Hormonal Contraceptives for Systemic Use, Hormone Antagonists, Hormones, Hormone Substitutes, and Hormone Antagonists, Hyperglycemia-Associated Agents, Mineralocorticoid Receptor Antagonists, Natriuretic Agents, Progesterone Congeners, Progestin Contraceptives, Progestins, Sex Hormones and Modulators of the Genital System, Steroids"," Mineralocorticoid receptor,  Androgen receptor,  Progesterone receptor,  Glucocorticoid receptor,  Prostaglandin G/H synthase 2,  Serum paraoxonase/arylesterase 1,  Cytochrome P450 3A4","DB01395, DB08804, DB13943, DB13944, DB13946, DB16001, DB16002, DB16141, DB01420, DB13958, DB08308, DB08619, DB06789, DB14677, DB13185, DB13640, DB14678, DB00603, DB11440, DB02329, DB12499, DB08547, DB01134, DB12221, DB15984, DB06780, DB14639, DB14583, DB14544, DB14540",
DB01396,Digitoxin,approved; investigational,[H][C@@]1(CC[C@]2(O)[C@]3([H])CC[C@]4([H])C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)C1=CC(=O)OC1,C41H64O13,,"Antiarrhythmic agents, Carbohydrates, Cardanolides, Cardenolides, Cardiac Glycosides, Cardiac Therapy, Cardiotonic Agents, Cardiovascular Agents, Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Substrates, Digitalis Glycosides, Enzyme Inhibitors, Fused-Ring Compounds, Glycosides, Narrow Therapeutic Index Drugs, P-glycoprotein substrates, P-glycoprotein substrates with a Narrow Therapeutic Index, Potential QTc-Prolonging Agents, Protective Agents, QTc Prolonging Agents, Steroids"," Sodium/potassium-transporting ATPase subunit alpha-1,  Cholesterol side-chain cleavage enzyme, mitochondrial,  Cytochrome P450 3A4,  Serum albumin,  Solute carrier organic anion transporter family member 1A2,  Solute carrier organic anion transporter family member 4C1,  P-glycoprotein 1","DB00390, DB01396, DB13401, DB01078, DB00511, DB13691, DB01092, DB13467, DB13240, DB13756, DB13537, DB12843, DB03671, DB06569, DB04177, DB15532, DB14081, DB12025, DB06748, DB06749, DB14815",
DB01397,Magnesium salicylate,experimental,[Mg++].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O,C14H10MgO6,,"Acids, Carbocyclic, Agents causing hyperkalemia, Agents that produce hypertension, Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Antirheumatic Agents, Benzene Derivatives, Benzoates, Cyclooxygenase Inhibitors, Enzyme Inhibitors, Hydroxy Acids, Hydroxybenzoates, Magnesium Compounds, Magnesium Salts, Metal cations, Metal divalent cations, Nephrotoxic agents, Non COX-2 selective NSAIDS, Peripheral Nervous System Agents, Phenols, Sensory System Agents"," Prostaglandin G/H synthase 2,  Prostaglandin G/H synthase 1,  Serum albumin","DB01397, DB00936, DB01401, DB14006, DB02839, DB09543, DB11079, DB13860, DB01672, DB04242, DB15576, DB00233, DB00244, DB04641",
DB01399,Salsalate,approved,OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O,C14H10O5,,"Acids, Carbocyclic, Agents causing hyperkalemia, Agents that produce hypertension, Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Antirheumatic Agents, Benzene Derivatives, Benzoates, Hydroxy Acids, Hydroxybenzoates, Nephrotoxic agents, Nervous System, Non COX-2 selective NSAIDS, Peripheral Nervous System Agents, Phenols, Salicylic Acid and Derivatives, Sensory System Agents"," Prostaglandin G/H synthase 2,  Prostaglandin G/H synthase 1","DB01399, DB11071, DB13538, DB00945, DB13509, DB13612, DB06807, DB13657, DB12445",
DB01400,Neostigmine,approved; vet_approved,CN(C)C(=O)OC1=CC(=CC=C1)[N+](C)(C)C,C12H19N2O2,,"Amines, Antiglaucoma Preparations and Miotics, Autonomic Agents, Cholinergic Agents, Cholinesterase Inhibitors, Enzyme Inhibitors, Nervous System, Neurotransmitter Agents, Onium Compounds, Ophthalmologicals, Parasympathomemetic (Cholinergic) Agents, Parasympathomimetics, Peripheral Nervous System Agents, Phenylammonium Compounds, Quaternary Ammonium Compounds, Sensory Organs"," Acetylcholinesterase,  Cholinesterase","DB01400, DB00944",
DB01401,Choline magnesium trisalicylate,approved,[Mg++].C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O,C26H29MgNO10,,"Acids, Carbocyclic, Agents causing hyperkalemia, Agents that produce hypertension, Alcohols, Amines, Amino Alcohols, Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Antirheumatic Agents, Benzene Derivatives, Benzoates, Central Nervous System Agents, Ethanolamines, Hydroxy Acids, Hydroxybenzoates, Nephrotoxic agents, Non COX-2 selective NSAIDS, Onium Compounds, Peripheral Nervous System Agents, Phenols, Quaternary Ammonium Compounds, Sensory System Agents, Trimethyl Ammonium Compounds"," Prostaglandin G/H synthase 1,  Prostaglandin G/H synthase 2","DB01401, DB14006, DB11079, DB01397, DB00936, DB09543, DB13860, DB02839, DB01672, DB00233, DB15576",
DB01403,Methotrimeprazine,approved; investigational,COC1=CC2=C(SC3=C(C=CC=C3)N2C[C@H](C)CN(C)C)C=C1,C19H24N2OS,,"Adrenergic alpha-1 Receptor Antagonists, Adrenergic alpha-Antagonists, Adrenergic Antagonists, Agents producing tachycardia, Agents that produce hypertension, Analgesics, Analgesics, Non-Narcotic, Anticholinergic Agents, Antidepressive Agents, Antipsychotic Agents, Antipsychotic Agents (First Generation [Typical]), Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (strong), Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Dopamine Agents, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Drugs causing inadvertant photosensitivity, Heterocyclic Compounds, Fused-Ring, Histamine Antagonists, Histamine H1 Antagonists, Hyperglycemia-Associated Agents, Muscarinic Antagonists, Nervous System, Neurotoxic agents, Neurotransmitter Agents, Peripheral Nervous System Agents, Phenothiazines, Phenothiazines With Aliphatic Side-Chain, Photosensitizing Agents, Potential QTc-Prolonging Agents, Psycholeptics, Psychotropic Drugs, QTc Prolonging Agents, Sensory System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2A Receptor Antagonists, Serotonin 5-HT2C Receptor Antagonists, Serotonin Agents, Serotonin Receptor Antagonists, Sulfur Compounds, Tranquilizing Agents"," Dopamine D2 receptor,  Dopamine D1 receptor,  Dopamine D5 receptor,  Dopamine D3 receptor,  Dopamine D4 receptor,  5-hydroxytryptamine receptor 2A,  5-hydroxytryptamine receptor 2C,  Histamine H1 receptor,  Muscarinic acetylcholine receptor M1, 10. Muscarinic acetylcholine receptor M2, 11. Muscarinic acetylcholine receptor M3, 12. Muscarinic acetylcholine receptor M4, 13. Muscarinic acetylcholine receptor M5, 14. Alpha-1A adrenergic receptor, 15. Alpha-1B adrenergic receptor, 16. Alpha-1D adrenergic receptor, 17. Alpha-2A adrenergic receptor, 18. Alpha-2B adrenergic receptor, 19. Alpha-2C adrenergic receptor,  Cytochrome P450 2E1,  Cytochrome P450 2D6","DB01403, DB01246, DB00420, DB00902",
DB01405,Temafloxacin,withdrawn,CC1CN(CCN1)C1=C(F)C=C2C(=O)C(=CN(C2=C1)C1=C(F)C=C(F)C=C1)C(O)=O,C21H18F3N3O3,,"Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strength unknown), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Enzyme Inhibitors, Fluoroquinolones, Heterocyclic Compounds, Fused-Ring, Highest Risk QTc-Prolonging Agents, QTc Prolonging Agents, Quinolines, Quinolones, Topoisomerase II Inhibitors, Topoisomerase Inhibitors"," DNA gyrase subunit A,  DNA topoisomerase 4 subunit A,  Cytochrome P450 1A2","DB01405, DB11491, DB11511, DB00978, DB01059, DB00487, DB01208, DB11393, DB00537, DB11443, DB11404, DB00365, DB04576, DB11943, DB01044, DB11453, DB14025, DB06771, DB09047, DB16850, DB01137, DB01165, DB03034, DB12447, DB16219, DB00218, DB13772, DB13261",
DB01406,Danazol,approved,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3,C22H27NO2,,"Androgens, Antigonadotropins and Similar Agents, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors (moderate), Cytochrome P-450 CYP3A4 Inhibitors (strong), Cytochrome P-450 Enzyme Inhibitors, Estrogen Antagonists, Fused-Ring Compounds, Genito Urinary System and Sex Hormones, Hormone Antagonists, Hormones, Hormone Substitutes, and Hormone Antagonists, Hyperglycemia-Associated Agents, Pregnadienes, Pregnanes, Sex Hormones and Modulators of the Genital System, Steroids, Thyroxine-binding globulin inhibitors"," Estrogen receptor alpha,  Androgen receptor,  Progesterone receptor,  Gonadotropin-releasing hormone receptor,  Putative gonadotropin-releasing hormone II receptor,  C-C motif chemokine 2,  Cytochrome P450 3A4,  Cytochrome P450 19A1,  Sex hormone-binding globulin",DB01406,
DB01407,Clenbuterol,approved; investigational; vet_approved,CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1,C12H18Cl2N2O,,"Adrenergic Agents, Adrenergic Agonists, Adrenergic beta-2 Receptor Agonists, Adrenergic beta-Agonists, Adrenergics for Systemic Use, Adrenergics, Inhalants, Agents producing tachycardia, Agents that produce hypertension, Agents to Treat Airway Disease, Alcohols, Amines, Amino Alcohols, Anti-Asthmatic Agents, Autonomic Agents, Bronchodilator Agents, Drugs for Obstructive Airway Diseases, Ethanolamines, Long-acting beta-adrenoceptor agonists, Neurotransmitter Agents, Peripheral Nervous System Agents, Respiratory System Agents, Selective Beta 2-adrenergic Agonists, Sympathomimetics"," Beta-2 adrenergic receptor,  Beta-1 adrenergic receptor,  Beta-3 adrenergic receptor,  Beta-nerve growth factor,  Tumor necrosis factor,  Cytochrome P450 1A1","DB01407, DB12803",
DB01408,Bambuterol,investigational,CN(C)C(=O)OC1=CC(=CC(OC(=O)N(C)C)=C1)C(O)CNC(C)(C)C,C18H29N3O5,,"Adrenergic Agonists, Adrenergic beta-2 Receptor Agonists, Adrenergic beta-Agonists, Adrenergics for Systemic Use, Agents producing tachycardia, Agents that produce hypertension, Agents to Treat Airway Disease, Alcohols, Amines, Amino Alcohols, Anti-Asthmatic Agents, Autonomic Agents, Bronchodilator Agents, Cholinesterase Inhibitors, Cholinesterase substrates, Delayed-Action Preparations, Drugs for Obstructive Airway Diseases, Ethanolamines, Long-acting beta-adrenoceptor agonists, Peripheral Nervous System Agents, Prodrugs, Respiratory System Agents, Selective Beta 2-adrenergic Agonists"," Beta-2 adrenergic receptor,  Cholinesterase,  Cholinesterase",DB01408,
DB01409,Tiotropium,approved,[H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1,C19H22NO4S2,,"Adrenergics, Inhalants, Agents producing tachycardia, Agents to Treat Airway Disease, Alkaloids, Anti-Asthmatic Agents, Anticholinergic Agents, Antimuscarinics Antispasmodics, Autonomic Agents, Aza Compounds, Azabicyclo Compounds, Bronchodilator Agents, Cholinergic Agents, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Drugs for Obstructive Airway Diseases, Drugs that are Mainly Renally Excreted, Muscarinic Antagonists, Neurotransmitter Agents, Parasympatholytics, Peripheral Nervous System Agents, Respiratory System Agents, Scopolamine Derivatives, Tropanes"," Muscarinic acetylcholine receptor M3,  Muscarinic acetylcholine receptor M1,  Muscarinic acetylcholine receptor M2,  Muscarinic acetylcholine receptor M4,  Muscarinic acetylcholine receptor M5,  Cytochrome P450 2D6,  Cytochrome P450 3A4,  Solute carrier family 22 member 5,  Solute carrier family 22 member 4","DB01409, DB13448, DB08897",
DB01410,Ciclesonide,approved; investigational,[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(O[C@@H](O2)C1CCCCC1)C(=O)COC(=O)C(C)C,C32H44O7,,"Adrenal Cortex Hormones, Adrenals, Agents to Treat Airway Disease, Anti-Allergic Agents, Corticosteroids, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Drugs for Obstructive Airway Diseases, Fused-Ring Compounds, Glucocorticoids, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hyperglycemia-Associated Agents, Immunosuppressive Agents, Nasal Preparations, Pregnanes, Pregnenes, Steroids, Thyroxine-binding globulin inhibitors"," Glucocorticoid receptor,  Liver carboxylesterase 1,  Cytochrome P450 3A4,  Cytochrome P450 2D6,  Corticosteroid-binding globulin","DB01410, DB01222, DB01260, DB00288, DB01130, DB14662, DB18737, DB14643, DB01047, DB00180, DB14632, DB15999, DB14673, DB14633, DB14644, DB15835, DB15566, DB00591, DB00394, DB00846, DB14221, DB14596, DB14640, DB14649, DB14538, DB14543, DB05442, DB14540, DB14625, DB14646",
DB01411,Pranlukast,investigational,O=C(NC1=C2OC(=CC(=O)C2=CC=C1)C1=NNN=N1)C1=CC=C(OCCCCC2=CC=CC=C2)C=C1,C27H23N5O4,,"Agents to Treat Airway Disease, Anti-Asthmatic Agents, Benzopyrans, Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors (strength unknown), Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Drugs for Obstructive Airway Diseases, Heterocyclic Compounds, Fused-Ring, Hormone Antagonists, Hormones, Hormone Substitutes, and Hormone Antagonists, Leukotriene Antagonists, Pyrans, Respiratory System Agents"," Cysteinyl leukotriene receptor 1,  Tumor necrosis factor,  Interleukin-5,  Eosinophil cationic protein,  Nuclear factor NF-kappa-B p105 subunit,  Mucin-2,  Nuclear factor NF-kappa-B (Protein Group),  Cytochrome P450 2C9,  Cytochrome P450 3A4,  Canalicular multispecific organic anion transporter 1",DB01411,
DB01412,Theobromine,investigational,CN1C=NC2=C1C(=O)NC(=O)N2C,C7H8N4O2,,"Alkaloids, Anti-Asthmatic Agents, Autonomic Agents, Bronchodilator Agents, Cardiovascular Agents, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 Substrates, Diuretics, Drugs for Obstructive Airway Diseases, Heterocyclic Compounds, Fused-Ring, Low-Ceiling Diuretics, Excl. Thiazides, Peripheral Nervous System Agents, Purines, Purinones, Respiratory System Agents, Vasodilating Agents, Xanthine derivatives"," Adenosine receptor A1,  Adenosine receptor A2a,  cAMP-specific 3',5'-cyclic phosphodiesterase 4B,  Cytochrome P450 1A2,  Cytochrome P450 2E1","DB01412, DB00201, DB00277, DB01223, DB03293, DB01303, DB13812, DB13592, DB13573, DB14132, DB13449, DB00824, DB01778, DB09273, DB14018, DB00651, DB13634, DB18002, DB12406, DB15122, DB07954, DB17930, DB00806",
DB01413,Cefepime,approved; investigational,CO\N=C(/C(=O)N[C@@H]1C(=O)N2[C@]1([H])SCC(C[N+]1(C)CCCC1)=C2C([O-])=O)C1=CSC(N)=N1,C19H24N6O5S2,,"Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, beta-Lactams, Cephalosporins, Fourth-Generation Cephalosporins, Heterocyclic Compounds, Fused-Ring, Lactams, Nephrotoxic agents, Neurotoxic agents, Sulfur Compounds, Thiazines"," Penicillin-binding protein 1A,  Penicillin-binding protein 1B,  Penicillin-binding protein 2,  Peptidoglycan synthase FtsI,  Penicillin-binding protein 1B,  Penicillin-binding protein 3,  Penicillin-binding protein 2,  Solute carrier family 22 member 5,  Solute carrier family 15 member 1,  Solute carrier family 15 member 2","DB01413, DB13504, DB00535, DB01416, DB00493, DB01332, DB00671, DB00267, DB00438, DB14879, DB11505, DB11485, DB01066, DB01212, DB13470, DB13682, DB13461, DB00229, DB04918, DB01415, DB13667, DB13499, DB09050, DB11385, DB14733, DB09008, DB01112, DB01328, DB01326, DB06590",
DB01414,Cefacetrile,experimental; vet_approved,[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)CC#N)C(O)=O,C13H13N3O6S,,"Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, beta-Lactams, Cephalosporins, First-Generation Cephalosporins, Heterocyclic Compounds, Fused-Ring, Lactams, Nephrotoxic agents, OAT1/SLC22A6 inhibitors, OAT1/SLC22A6 Substrates, OAT3/SLC22A8 Inhibitors, OAT3/SLC22A8 Substrates, Sulfur Compounds, Thiazines"," Penicillin-binding protein 1A,  Penicillin-binding protein 1B,  Solute carrier family 22 member 6,  Solute carrier family 22 member 8","DB01414, DB03313, DB01139, DB00689, DB00456, DB03938, DB00567, DB14107, DB01140, DB13461, DB01333, DB01112, DB00493, DB01150, DB01416, DB01331, DB00833, DB11505, DB13504, DB00535, DB01326, DB13821, DB09008, DB11592, DB01415, DB01327, DB14725, DB01413, DB00923, DB00229",
DB01415,Ceftibuten,approved; investigational,[H][C@]12SCC=C(N1C(=O)[C@H]2NC(=O)C(=C/CC(O)=O)\C1=CSC(N)=N1)C(O)=O,C15H14N4O6S2,,"Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, beta-Lactams, Cephalosporins, Drugs that are Mainly Renally Excreted, Heterocyclic Compounds, Fused-Ring, Lactams, Nephrotoxic agents, OAT1/SLC22A6 Substrates, OAT3/SLC22A8 Inhibitors, OAT3/SLC22A8 Substrates, Sulfur Compounds, Thiazines, Third-Generation Cephalosporins"," Peptidoglycan synthase FtsI,  Penicillin-binding protein 1A,  Penicillin-binding protein 1B,  Penicillin-binding protein 2,  Solute carrier family 15 member 1,  Solute carrier family 15 member 2,  Solute carrier family 22 member 6,  Solute carrier family 22 member 8","DB01415, DB13461, DB01332, DB13504, DB00535, DB01416, DB00229, DB00671, DB00493, DB01413, DB00438, DB01066, DB11505, DB00267, DB01212, DB11485, DB00833, DB00689, DB00567, DB14879, DB13470, DB01140, DB01414, DB01326, DB00456, DB01328, DB01150, DB13682, DB01139, DB04918",
DB01416,Cefpodoxime,approved; vet_approved,[H][C@]12SCC(COC)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O,C15H17N5O6S2,,"Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use, beta Lactam Antibiotics, beta-Lactams, Cefpodoxime, Cephalosporins, Heterocyclic Compounds, Fused-Ring, Lactams, Nephrotoxic agents, Prodrugs, Sulfur Compounds, Thiazines, Third-Generation Cephalosporins", Peptidoglycan synthase FtsI,"DB01416, DB00493, DB13504, DB00535, DB11505, DB01413, DB01332, DB00671, DB00267, DB11485, DB00438, DB01066, DB01212, DB13461, DB14879, DB13470, DB13682, DB00229, DB01415, DB01112, DB04918, DB00456, DB00689, DB01414, DB03313, DB13667, DB01331, DB01139, DB09050, DB13499",
DB01418,Acenocoumarol,approved; investigational,CC(=O)CC(C1=CC=C(C=C1)[N+]([O-])=O)C1=C(O)C2=CC=CC=C2OC1=O,C19H15NO6,,"4-Hydroxycoumarins, Anticoagulants, Benzopyrans, Blood and Blood Forming Organs, Coumarins, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Substrates, Hematologic Agents, Heterocyclic Compounds, Fused-Ring, Narrow Therapeutic Index Drugs, P-glycoprotein substrates, P-glycoprotein substrates with a Narrow Therapeutic Index, Pyrans, Vitamin K Antagonists"," Vitamin K epoxide reductase complex subunit 1,  Cytochrome P450 2C9,  Cytochrome P450 1A2,  Cytochrome P450 2C19,  Cytochrome P450 3A4,  Serum albumin,  Alpha-1-acid glycoprotein 1,  P-glycoprotein 1","DB01418, DB00682, DB08496, DB14055, DB08735, DB08736, DB00946, DB08663, DB08662",
DB01419,Antrafenine,approved,FC(F)(F)C1=CC(=CC=C1)N1CCN(CCOC(=O)C2=CC=CC=C2NC2=C3C=CC(=CC3=NC=C2)C(F)(F)F)CC1,C30H26F6N4O2,,"Agents causing hyperkalemia, Agents that produce hypertension, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Nephrotoxic agents, Non COX-2 selective NSAIDS"," Prostaglandin G/H synthase 1,  Prostaglandin G/H synthase 2","DB01419, DB08976",
DB01420,Testosterone propionate,approved; investigational; vet_approved; withdrawn,[H][C@@]12CC[C@H](OC(=O)CC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,C22H32O3,,"Androgens, Androstanes, Androstenes, Androstenols, COMT Inhibitors, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Fused-Ring Compounds, Gonadal Hormones, Gonadal Steroid Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, P-glycoprotein substrates, Steroids, Testosterone and derivatives, Testosterone Congeners, Thyroxine-binding globulin inhibitors, UGT1A1 Inducers"," Androgen receptor,  Catechol O-methyltransferase,  UDP-glucuronosyltransferase 1-1,  3-oxo-5-alpha-steroid 4-dehydrogenase (Protein Group),  Cytochrome P450 3A4,  Sex hormone-binding globulin,  Serum albumin,  P-glycoprotein 1","DB01420, DB08804, DB13943, DB13944, DB13946, DB16001, DB16002, DB16141, DB13958, DB08308, DB08619, DB01395, DB00603, DB11440, DB06789, DB14677, DB12499, DB13185, DB13640, DB14678, DB01134, DB02329, DB15984, DB08547, DB06780, DB14583, DB14540, DB14538, DB14544, DB14543",
DB01421,Paromomycin,approved; investigational,NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O,C23H45N5O14,,"Agents that produce neuromuscular block (indirect), Alimentary Tract and Metabolism, Amebicides, Aminoglycoside Antibacterials, Anti-Bacterial Agents, Anti-Infective Agents, Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents, Antiparasitic Agents, Antiprotozoals, Carbohydrates, Glycosides, Intestinal Antiinfectives, Nephrotoxic agents"," 30S ribosomal protein S10,  16S ribosomal RNA,  40S ribosomal protein SA,  60S ribosomal protein L10-like","DB00452, DB01421, DB04728, DB03615, DB15080, DB17631, DB16951, DB13673, DB00684, DB13270, DB04717, DB01172, DB04808, DB04718, DB04263, DB04729, DB17884, DB07341, DB11520, DB03779, DB00798, DB13274, DB04626, DB04679, DB04678, DB03618, DB00919, DB04226",
DB01422,Nitroxoline,experimental,OC1=C2N=CC=CC2=C(C=C1)[N+]([O-])=O,C9H6N2O3,,"Anti-Infective Agents, Anti-Infective Agents, Urinary, Antibacterials for Systemic Use, Antifungal Agents, Antiinfectives for Systemic Use, Heterocyclic Compounds, Fused-Ring, Nitro Compounds, Quinolines"," Methionine aminopeptidase 2,  Magnesium cation,  Manganese cation",DB01422,
DB01423,Stepronin,experimental,CC(SC(=O)C1=CC=CS1)C(=O)NCC(O)=O,C10H11NO4S2,,"Amino Acids, Amino Acids, Peptides, and Proteins, Anions, Anti-Infective Agents, Cough and Cold Preparations, Electrolytes, Expectorants, Hydrogen Sulfide, Immunologic Factors, Immunosuppressive Agents, Ions, Respiratory System Agents, Sulfur Compounds",,DB01423,
DB01424,Aminophenazone,approved; withdrawn,CN(C)C1=C(C)N(C)N(C1=O)C1=CC=CC=C1,C13H17N3O,,"Agents causing hyperkalemia, Agents that produce hypertension, Analgesics, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2C18 Substrates, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Nephrotoxic agents, Nervous System, Non COX-2 selective NSAIDS, OAT1/SLC22A6 inhibitors, Pyrazoles, Pyrazolones"," Cytochrome P450 2C9,  Cytochrome P450 2D6,  Cytochrome P450 3A4,  Cytochrome P450 2C18,  Steroid 17-alpha-hydroxylase/17,20 lyase,  Cytochrome P450 2C19,  Cytochrome P450 1A2,  Cytochrome P450 2C8,  Solute carrier family 22 member 6","DB01424, DB04817, DB01435, DB01495, DB13407, DB13524",
DB01425,Alizapride,investigational,COC1=CC2=NNN=C2C=C1C(=O)NCC1CCCN1CC=C,C16H21N5O2,,"Alimentary Tract and Metabolism, Antiemetics, Autonomic Agents, Central Nervous System Agents, Dopamine Antagonists, Dopamine D2 Receptor Antagonists, Drugs for Functional Gastrointestinal Disorders, Gastrointestinal Agents, Peripheral Nervous System Agents, Propulsives", Dopamine D2 receptor,DB01425,
DB01426,Ajmaline,approved; experimental,[H][C@]12C[C@]34[C@H](O)C1[C@@]1([H])C[C@]([H])(N2[C@H](O)[C@H]1CC)[C@]3([H])N(C)C1=CC=CC=C41,C20H26N2O2,,"Ajmaline and derivatives, Alkaloids, Antiarrhythmic agents, Antiarrhythmics, Class I, Antiarrhythmics, Class Ia, Antiarrhythmics, Class Ic, Cardiac Therapy, Cardiovascular Agents, Heterocyclic Compounds, Fused-Ring, Indole Alkaloids, Indoles, Indolizidines, Indolizines, Membrane Transport Modulators, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Secologanin Tryptamine Alkaloids, Sodium Channel Blockers, Voltage-Gated Sodium Channel Blockers"," Sodium channel protein type 5 subunit alpha,  Alpha-1-acid glycoprotein 1","DB01426, DB13555, DB13651",
DB01427,Amrinone,approved,NC1=CC(=CNC1=O)C1=CC=NC=C1,C10H9N3O,,"Amines, Aminopyridines, Calcium-Regulating Hormones and Agents, Cardiac Stimulants Excl. Cardiac Glycosides, Cardiac Therapy, Cardiotonic Agents, Cardiovascular Agents, Compounds used in a research, industrial, or household setting, Drugs that are Mainly Renally Excreted, Enzyme Inhibitors, Membrane Transport Modulators, Phosphodiesterase 3 Inhibitors, Phosphodiesterase Inhibitors, Protective Agents, Pyridines, Tumor Necrosis Factor Blockers, Vasodilating Agents"," cAMP-specific 3',5'-cyclic phosphodiesterase 4 (PDE4) (Protein Group),  cGMP-inhibited 3',5'-cyclic phosphodiesterase A,  cGMP-inhibited 3',5'-cyclic phosphodiesterase B,  Tumor necrosis factor",DB01427,
DB01428,Oxybenzone,approved; investigational,COC1=CC(O)=C(C=C1)C(=O)C1=CC=CC=C1,C14H12O3,,"Benzene Derivatives, Compounds used in a research, industrial, or household setting, Cosmetics, Dermatologicals, Drugs that are Mainly Renally Excreted, Ketones, Protective Agents, Radiation-Protective Agents, Sunscreen Agents"," Progesterone receptor,  Androgen receptor,  Estrogen receptor alpha,  Estrogen receptor beta","DB01428, DB11221, DB16830",
DB01429,Aprindine,experimental,CCN(CC)CCCN(C1CC2=CC=CC=C2C1)C1=CC=CC=C1,C22H30N2,,"Antiarrhythmic agents, Antiarrhythmics, Class I, Antiarrhythmics, Class Ib, Cardiac Therapy, Cardiovascular Agents, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 Substrates, Indans, Indenes, Membrane Transport Modulators, Sodium Channel Blockers, Voltage-Gated Sodium Channel Blockers"," Sodium channel protein type 5 subunit alpha,  Calmodulin,  Cytochrome P450 2D6,  Alpha-1-acid glycoprotein 1",DB01429,
DB01430,Almitrine,approved,FC1=CC=C(C=C1)C(N1CCN(CC1)C1=NC(NCC=C)=NC(NCC=C)=N1)C1=CC=C(F)C=C1,C26H29F2N7,,"Alkaloids, Central Nervous System Agents, Compounds used in a research, industrial, or household setting, Heterocyclic Compounds, Fused-Ring, Indole Alkaloids, Indoles, Indolizidines, Indolizines, Neuroprotective Agents, Pharmaceutical Preparations, Piperazines, Protective Agents, Respiratory System Agents, Secologanin Tryptamine Alkaloids, Triazines", Sodium/potassium-transporting ATPase subunit alpha-1,DB01430,
DB01431,Allylestrenol,experimental,[H][C@@]12CC[C@@](O)(CC=C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H],C21H32O,,"Adrenal Cortex Hormones, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Substrates, Drugs that are Mainly Renally Excreted, Estranes, Estren Derivatives, Estrenes, Fused-Ring Compounds, Genito Urinary System and Sex Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Progestins, Sex Hormones and Modulators of the Genital System, Steroids"," Progesterone receptor,  Estrogen receptor alpha","DB01431, DB01493, DB03696, DB04704, DB01455, DB01524, DB04540, DB04705, DB14038, DB12474, DB01474, DB01526, DB01554, DB14555, DB01889, DB01503, DB00304, DB04706, DB14152, DB00624, DB01471, DB01543, DB01564, DB05830, DB06710, DB07768, DB11429, DB12787, DB13169, DB13533",
DB01432,Cholestyramine,approved; investigational,,,,"Anion Exchange Resins, Anticholesteremic Agents, Bile Acid Sequestrants, Bile-acid Binding Activity, Compounds used in a research, industrial, or household setting, Hypolipidemic Agents, Hypolipidemic Agents Indicated for Hyperlipidemia, Ion Exchange Resins, Laboratory Chemicals, Lipid Modifying Agents, Lipid Modifying Agents, Plain, Lipid Regulating Agents, Macromolecular Substances, Non-statin Hypolipidemic Agents Indicated for Hyperlipidemia, Plastics, Polymers, Polystyrenes",,,
DB01433,Methadyl acetate,experimental; illicit,CCC(OC(C)=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1,C23H31NO2,,"Analgesics, Central Nervous System Agents, Central Nervous System Depressants, Ketones, Narcotics, Opioids, Peripheral Nervous System Agents, Sensory System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome", Mu-type opioid receptor,"DB01227, DB01433, DB01522, DB01555, DB01498",
DB01434,19-norandrostenedione,experimental; illicit,[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],C18H24O2,,"17-Ketosteroids, Adrenal Cortex Hormones, Androstanes, Androstenes, Fused-Ring Compounds, Gonadal Hormones, Gonadal Steroid Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Ketosteroids, Steroids, Testosterone Congeners",,"DB00396, DB01434, DB01536, DB01451, DB13391, DB15977, DB13710, DB13230, DB14570, DB00624, DB01471, DB01543, DB01564, DB05830, DB06710, DB07768, DB11429, DB12787, DB13169, DB13533, DB14093, DB01443, DB01456, DB08905, DB00253, DB18000, DB14584, DB04652, DB07373, DB12194",
DB01435,Antipyrine,approved; investigational,CN1N(C(=O)C=C1C)C1=CC=CC=C1,C11H12N2O,,"Agents causing hyperkalemia, Agents that produce hypertension, Analgesics, Analgesics and Anesthetics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 CYP2A6 Substrates, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C18 Substrates, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP2E1 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Substrates, Methemoglobinemia Associated Agents, Nephrotoxic agents, Nervous System, Non COX-2 selective NSAIDS, OAT1/SLC22A6 inhibitors, Otologicals, Peripheral Nervous System Agents, Pyrazoles, Pyrazolones, Sensory Organs, Sensory System Agents"," Prostaglandin G/H synthase 2,  Prostaglandin G/H synthase 1,  Cytochrome P450 2A6,  Cytochrome P450 2B6,  Cytochrome P450 2C18,  Cytochrome P450 2D6,  Cytochrome P450 2E1,  Cytochrome P450 2C8,  Cytochrome P450 2C9,  Cytochrome P450 1A2,  Cytochrome P450 2C19, 10. Cytochrome P450 3A4,  Solute carrier family 22 member 6","DB01435, DB01495, DB13524, DB01424",
DB01436,Alfacalcidol,approved; nutraceutical,CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C,C27H44O2,,"Alimentary Tract and Metabolism, Bone Density Conservation Agents, Cholestanes, Cholestenes, Drugs Affecting Bone Structure and Mineralization, Drugs for Treatment of Bone Diseases, Fused-Ring Compounds, Lipids, Membrane Lipids, Musculo-Skeletal System, Secosteroids, Steroids, Sterols, Vitamin D and Analogues, Vitamins, Vitamins (Fat Soluble)"," Vitamin D3 receptor,  25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial,  Retinoic acid receptor RXR-alpha,  Vitamin D-binding protein,  Alpha globin","DB01436, DB13097, DB15557, DB00136, DB06410, DB13689, DB04258, DB00169, DB00146, DB00153, DB04891, DB18029, DB18406, DB06117, DB02300, DB00910, DB01070, DB03451, DB06272, DB04038, DB05295, DB08742",
DB01437,Glutethimide,approved; illicit,CCC1(CCC(=O)NC1=O)C1=CC=CC=C1,C13H15NO2,,"Central Nervous System Agents, Central Nervous System Depressants, Hypnotics and Sedatives, Nervous System, Piperidinedione Derivatives, Piperidines, Piperidones, Psycholeptics"," Gamma-aminobutyric acid receptor subunit alpha-1,  GABA(A) Receptor (Protein Group),  Cholesterol side-chain cleavage enzyme, mitochondrial","DB01437, DB00357, DB13413, DB08997",
DB01438,Phenazopyridine,approved,NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1,C11H11N5,,"Amines, Aminopyridines, Antipruritics and Local Anesthetics, Drugs that are Mainly Renally Excreted, Genito Urinary System and Sex Hormones, Methemoglobinemia Associated Agents, Nephrotoxic agents, Pyridines, Urologicals", Sodium channel protein type 1 subunit alpha,DB01438,
DB01439,3-Methylthiofentanyl,experimental; illicit,CCC(=O)N(C1CCN(CCC2=CC=CS2)CC1C)C1=CC=CC=C1,C21H28N2OS,,," Kappa-type opioid receptor,  Mu-type opioid receptor,  Delta-type opioid receptor","DB01439, DB09180, DB01470, DB09170, DB00708, DB01571, DB09178, DB09171, DB01570, DB00813, DB09169, DB09173, DB01557, DB01532",
DB01440,gamma-Hydroxybutyric acid,approved; illicit; investigational,OCCCC(O)=O,C4H8O3,,"Acids, Acyclic, Adjuvants, Anesthesia, Anesthetics, Anesthetics, General, Anesthetics, Intravenous, Butyrates, Central Nervous System Agents, Central Nervous System Depressants, Central Nervous System Depression, Decreased Central Nervous System Organized Electrical Activity, Fatty Acids, Fatty Acids, Volatile, Hydroxy Acids, Hydroxybutyrates, Lipids"," Gamma-hydroxybutyrate (GHB) receptor,  Gamma-aminobutyric acid receptor subunit beta-1,  Monocarboxylate transporter 2,  Monocarboxylate transporter 1,  Monocarboxylate transporter 4","DB01440, DB09072, DB00139, DB14489, DB14508, DB03568, DB02406, DB03741, DB03750, DB17706",
DB01441,"5-Methoxy-N,N-diisopropyltryptamine",experimental; illicit,COC1=CC2=C(NC=C2CCN(C(C)C)C(C)C)C=C1,C17H26N2O,,"Alkaloids, Amines, Biogenic Amines, Biogenic Monoamines, Heterocyclic Compounds, Fused-Ring, Indoles, Morphinans, Morphine Derivatives, Opiate Alkaloids, Phenanthrenes, Tryptamines",,"DB01441, DB14010, DB01065, DB01445, DB04275, DB08839, DB13990, DB16909, DB01460, DB08190, DB01488, DB07723, DB13403",
DB01442,MMDA,experimental; illicit,COC1=CC(CC(C)N)=CC2=C1OCO2,C11H15NO3,,"Agents producing tachycardia, Agents that produce hypertension, Amines, Amphetamines, Antidepressive Agents, Central Nervous System Depressants, Ethylamines, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates, Phenethylamines, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT2 Receptor Agonists, Serotonin Agents, Serotonin Receptor Agonists, Sympathomimetics"," 5-hydroxytryptamine receptor 2A,  Sodium-dependent dopamine transporter,  Sodium-dependent serotonin transporter,  Sodium-dependent noradrenaline transporter,  Synaptic vesicular amine transporter,  Chromaffin granule amine transporter,  Amine oxidase [flavin-containing] A,  Amine oxidase [flavin-containing] B","DB01442, DB01509, DB01454, DB01516, DB01566, DB06112, DB12809",
DB01443,19-Nor-5-androstenedione,experimental; illicit,[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)CC3=CC[C@@]21[H],C18H24O2,,,,"DB01443, DB01456, DB00396, DB01434, DB01536, DB01451",
DB01444,Dimethylthiambutene,experimental; illicit,CC(C=C(C1=CC=CS1)C1=CC=CS1)N(C)C,C14H17NS2,,," Mu-type opioid receptor,  Delta-type opioid receptor","DB01444, DB01468, DB01533, DB13474",
DB01445,Bufotenine,experimental; illicit,CN(C)CCC1=CNC2=C1C=C(O)C=C2,C12H16N2O,,"Amphibian Venoms, Antidepressive Agents, Biological Factors, Central Nervous System Agents, Central Nervous System Depressants, Complex Mixtures, Hallucinogens, Heterocyclic Compounds, Fused-Ring, Indoles, Monoamine Oxidase A Substrates, N,N-Dimethyltryptamine, Neurotransmitter Agents, Psychotropic Drugs, Serotonin Agents, Serotonin Receptor Antagonists, Toxins, Biological, Tryptamines, Venoms", Amine oxidase [flavin-containing] A,"DB01445, DB08839, DB14010, DB01441, DB04275, DB13990, DB01488, DB01065, DB01460, DB02959, DB08653, DB11664",
DB01446,Indopan,experimental; illicit,CC(N)CC1=CNC2=CC=CC=C12,C11H14N2,,"Amines, Biogenic Amines, Biogenic Monoamines, Heterocyclic Compounds, Fused-Ring, Indoles, Stimulants",,"DB01446, DB01546, DB04236, DB08653, DB00150, DB03225, DB04537, DB01488, DB01953, DB01460, DB12827, DB08649, DB02758, DB08652, DB03314, DB02959, DB08839, DB04159, DB08953, DB02740",
DB01447,4-Methylaminorex,experimental; illicit,CC1N=C(N)OC1C1=CC=CC=C1,C10H12N2O,,"Central Nervous System Agents, Central Nervous System Stimulants, Illicit Drugs, Street Drugs",,"DB01447, DB01490, DB01230",
DB01448,19-Nor-4-androstenedione,experimental; illicit,,,,,,,
DB01450,Dihydroetorphine,experimental; illicit,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]11CC[C@@]2(OC)[C@]([H])(C1)[C@](C)(O)CCC,C25H35NO4,,"Alkaloids, Analgesics, Central Nervous System Agents, Central Nervous System Depressants, Heterocyclic Compounds, Fused-Ring, Morphinans, Narcotics, Opiate Alkaloids, Opioids, Peripheral Nervous System Agents, Phenanthrenes, Sensory System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome",,"DB00921, DB01450, DB01548, DB16072, DB01565, DB01551, DB01512, DB01538, DB00844, DB14146, DB16117, DB09049, DB01531, DB15341, DB01480, DB01497, DB01469, DB06230, DB00497, DB00704, DB01192, DB06800, DB00956, DB00327, DB00318, DB00295, DB01477, DB01466, DB01183, DB04509",
DB01451,1-Androstenedione,experimental; illicit,[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)C=C[C@]12C,C19H26O2,,,,"DB01451, DB00396, DB01434, DB01536, DB01481, DB01572, DB13710, DB13391, DB15977, DB13230, DB14570, DB00624, DB01471, DB01543, DB01564, DB05830, DB06710, DB07768, DB11429, DB12787, DB13169, DB13533, DB14093, DB07373, DB12194, DB01443, DB01456, DB08905, DB00253, DB18000",
DB01452,Diamorphine,approved; illicit; investigational,[H][C@@]12C=C[C@H](OC(C)=O)[C@@H]3OC4=C(OC(C)=O)C=CC5=C4[C@]13CCN(C)[C@@H]2C5,C21H23NO5,,"Alkaloids, Analgesics, Central Nervous System Agents, Central Nervous System Depressants, Drugs Used in Addictive Disorders, Drugs Used in Opioid Dependence, Heroin, agonists, Heterocyclic Compounds, Fused-Ring, Morphinans, Morphine Derivatives, Narcotics, Nervous System, Opiate Agonists, Opiate Alkaloids, Opioids, Peripheral Nervous System Agents, Phenanthrenes, Sensory System Agents, Thyroxine-binding globulin inducers"," Mu-type opioid receptor,  Kappa-type opioid receptor,  Delta-type opioid receptor,  Liver carboxylesterase 1,  Thyroxine-binding globulin","DB01452, DB01469, DB01466, DB13454, DB00318, DB01480, DB01497, DB01477, DB00295, DB01573, DB09209, DB11490, DB06409, DB01568, DB15341, DB16117, DB01538, DB13458, DB15465, DB14146, DB09049, DB16072, DB01512, DB00844, DB00921, DB01450, DB01548, DB06230, DB01551, DB01565",
DB01453,Beta-hydroxyfentanyl,experimental; illicit,CCC(=O)N(C1CCN(CC(O)C2=CC=CC=C2)CC1)C1=CC=CC=C1,C22H28N2O2,,Piperidines,,"DB01453, DB01570, DB00813, DB09173, DB01557, DB09171, DB01571, DB01532, DB09177, DB09178, DB13653, DB09179, DB09169, DB09170, DB09180, DB09182",
DB01454,Midomafetamine,experimental; illicit; investigational,CNC(C)CC1=CC2=C(OCO2)C=C1,C11H15NO2,,"Adrenergic Agents, Adrenergic Uptake Inhibitors, Agents producing tachycardia, Agents that produce hypertension, Amines, Amphetamines, Antidepressive Agents, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 Substrates, Ethylamines, Hallucinogens, Membrane Transport Modulators, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, Phenethylamines, Psychotropic Drugs, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT2 Receptor Agonists, Serotonin Agents, Serotonin Receptor Agonists, Sympathomimetics"," Synaptic vesicular amine transporter,  Sodium-dependent noradrenaline transporter,  Sodium-dependent serotonin transporter,  Sodium-dependent dopamine transporter,  5-hydroxytryptamine receptor 2A,  5-hydroxytryptamine receptor 2B,  5-hydroxytryptamine receptor 2C,  Cytochrome P450 2D6,  Sodium-dependent noradrenaline transporter,  Sodium-dependent dopamine transporter,  Sodium-dependent serotonin transporter","DB01454, DB01566, DB06112, DB01509, DB01442, DB06814, DB12809, DB01516, DB09253, DB14129",
DB01455,19-Nor-5-androstenediol,experimental; illicit,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CC[C@H](O)CC3=CC[C@@]21[H],C18H28O2,,,,"DB01455, DB01524, DB04704, DB04540, DB04705, DB14038, DB03696, DB01431, DB04706, DB02789, DB06257, DB01708, DB01493, DB14555, DB13797, DB01474, DB01526, DB01554, DB05212, DB12474, DB01503, DB01889, DB13866",
DB01456,5-androstenedione,experimental; illicit,[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2CC(=O)CC[C@]12C,C19H26O2,,"17-Ketosteroids, Adrenal Cortex Hormones, Androstanes, Androstenes, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Fused-Ring Compounds, Gonadal Hormones, Gonadal Steroid Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Ketosteroids, Steroids, Testosterone Congeners", Cytochrome P450 3A4,"DB01443, DB01456, DB00396, DB01434, DB01536, DB01451",
DB01458,"2,5-Dimethoxy-4-(n)-propylthiophenethylamine",experimental; illicit,CCCSC1=CC(OC)=C(CCN)C=C1OC,C13H21NO2S,,,,"DB01458, DB13940",
DB01459,Bezitramide,experimental; illicit; withdrawn,CCC(=O)N1C(=O)N(C2CCN(CCC(C#N)(C3=CC=CC=C3)C3=CC=CC=C3)CC2)C2=CC=CC=C12,C31H32N4O2,,"Analgesics, Central Nervous System Agents, Diphenylpropylamine Derivatives, Heterocyclic Compounds, Fused-Ring, Nervous System, Opioids, Peripheral Nervous System Agents, Sensory System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome",,"DB01459, DB01100",
DB01460,Diethyltryptamine,experimental; illicit,CCN(CC)CCC1=CNC2=CC=CC=C12,C14H20N2,,"Acids, Carbocyclic, Agrochemicals, Amides, Amines, Benzene Derivatives, Benzoates, Biogenic Amines, Biogenic Monoamines, Compounds used in a research, industrial, or household setting, Heterocyclic Compounds, Fused-Ring, Indoles, Insect Repellents, Pesticides, Protective Agents, Toxic Actions",,"DB01460, DB01488, DB08653, DB13990, DB01445, DB01446, DB01441, DB08649, DB04275, DB08652, DB01546, DB07952, DB14010, DB08839, DB04236",
DB01461,Dimenoxadol,experimental; illicit,CCOC(C(=O)OCCN(C)C)(C1=CC=CC=C1)C1=CC=CC=C1,C20H25NO3,,"Acids, Carbocyclic, Diphenylacetic Acids, Hydroxy Acids, Phenylacetates",,"DB01461, DB15783, DB09023, DB13181, DB13380, DB15888, DB15795, DB04843, DB13844, DB13369, DB13507, DB00771",
DB01462,Etonitazene,experimental; illicit,CCOC1=CC=C(CC2=NC3=C(C=CC(=C3)[N+]([O-])=O)N2CCN(CC)CC)C=C1,C22H28N4O3,,"Heterocyclic Compounds, Fused-Ring",,"DB01462, DB01523",
DB01463,Fencamfamin,experimental; illicit; withdrawn,CCNC1C2CCC(C2)C1C1=CC=CC=C1,C15H21N,,"Bridged-Ring Compounds, Central Nervous System Agents, Central Nervous System Depressants, Central Nervous System Stimulants, Centrally Acting Sympathomimetics, Nervous System, Psychoanaleptics, Psychostimulants, Agents Used for ADHD and Nootropics, Psychotropic Drugs, Tranquilizing Agents", Sodium-dependent dopamine transporter,"DB01463, DB08071, DB16848",
DB01464,Furethidine,experimental; illicit,CCOC(=O)C1(CCN(CCOCC2CCCO2)CC1)C1=CC=CC=C1,C21H31NO4,,,,"DB01464, DB01505, DB01475, DB00454, DB01518, DB13605, DB01081, DB08988",
DB01465,"2,5-Dimethoxyamphetamine",experimental; illicit,COC1=CC(CC(C)N)=C(OC)C=C1,C11H17NO2,,"Amines, Ethylamines, Phenethylamines",,"DB01465, DB01528, DB01467, DB00723, DB01484, DB13624",
DB01466,Ethylmorphine,experimental; illicit,[H][C@@]12OC3=C(OCC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O,C19H23NO3,,"Alkaloids, Analgesics, Antitussive Agents, Central Nervous System Agents, Central Nervous System Depressants, Cough and Cold Preparations, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Heterocyclic Compounds, Fused-Ring, Morphinans, Morphine Derivatives, Narcotics, Ophthalmologicals, Opiate Alkaloids, Opioids, Opium Alkaloids and Derivatives, Peripheral Nervous System Agents, Phenanthrenes, Respiratory System Agents, Sensory Organs, Sensory System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"," Mu-type opioid receptor,  Cytochrome P450 2B6,  Cytochrome P450 3A4,  Cytochrome P450 2D6,  NADPH--cytochrome P450 reductase","DB01466, DB00318, DB01477, DB00295, DB09209, DB01573, DB11490, DB01568, DB01480, DB01497, DB01469, DB01452, DB01551, DB15341, DB06409, DB01565, DB01512, DB16072, DB00844, DB16117, DB14146, DB13454, DB00921, DB01450, DB01548, DB06230, DB09049, DB00497, DB13458, DB01538",
DB01467,"2,5-Dimethoxy-4-ethylamphetamine",experimental; illicit,CCC1=CC(OC)=C(CC(C)N)C=C1OC,C13H21NO2,,"Agents producing tachycardia, Agents that produce hypertension, Amines, Amphetamines, Ethylamines, Phenethylamines, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Sympathomimetics",,"DB01467, DB01528, DB01465, DB00723, DB01484",
DB01468,Ethylmethylthiambutene,experimental; illicit,CCN(C)C(C)C=C(C1=CC=CS1)C1=CC=CS1,C15H19NS2,,,,"DB01468, DB01533, DB01444, DB13474",
DB01469,Acetorphine,experimental; illicit,[H][C@@]12OC3=C(OC(C)=O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@@]11C[C@]([H])([C@](C)(O)CCC)[C@]2(OC)C=C1,C27H35NO5,,,,"DB01469, DB01480, DB01497, DB01452, DB01466, DB00318, DB01573, DB01477, DB00295, DB09209, DB15341, DB16117, DB11490, DB01568, DB13454, DB06409, DB16072, DB14146, DB00921, DB01450, DB01548, DB01512, DB01538, DB00844, DB09049, DB01551, DB13458, DB15465, DB01565, DB06230",
DB01470,alpha-methylthiofentanyl,illicit,CCC(=O)N(C1CCN(CC1)C(C)CC1=CC=CS1)C1=CC=CC=C1,C21H28N2OS,,,,"DB01470, DB09180, DB01439, DB09170, DB00708, DB01557, DB01532, DB00813, DB09173, DB01571, DB09171",
DB01471,Bolasterone,experimental; illicit,[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@H](C)CC2=CC(=O)CC[C@]12C,C21H32O2,,"Anabolic Agents, Androstanes, Androstenes, Androstenols, Fused-Ring Compounds, Gonadal Hormones, Gonadal Steroid Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Steroids, Testosterone Congeners",,"DB00624, DB01471, DB01543, DB01564, DB05830, DB06710, DB07768, DB11429, DB12787, DB13169, DB13533, DB14093, DB13710, DB13230, DB14570, DB01481, DB01572, DB00253, DB18000, DB00367, DB00717, DB09389, DB14584, DB04652, DB01485, DB01500, DB01540, DB04630, DB00741, DB13089",
DB01472,4-Methoxyamphetamine,experimental; illicit,COC1=CC=C(CC(C)N)C=C1,C10H15NO,,"Adrenergic Agonists, Adrenergic alpha-1 Receptor Agonists, Adrenergic alpha-Agonists, Agents producing tachycardia, Agents that produce hypertension, Amines, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 Substrates, Ethylamines, Hallucinogens, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates, Phenethylamines, Psychotropic Drugs"," Sodium-dependent dopamine transporter,  Sodium-dependent serotonin transporter,  Synaptic vesicular amine transporter,  Alpha-1A adrenergic receptor,  Alpha-2A adrenergic receptor,  Amine oxidase [flavin-containing] A,  Amine oxidase [flavin-containing] B,  Cytochrome P450 2D6","DB01472, DB09352, DB03978, DB08767, DB08841, DB03380",
DB01473,Betaprodine,experimental; illicit,[H][C@@]1(C)CN(C)CC[C@]1(OC(=O)CC)C1=CC=CC=C1,C16H23NO2,,,,"DB01473, DB13160, DB01499, DB01552, DB01478, DB01542, DB01562, DB00647, DB06793",
DB01474,"17alpha-methyl-3beta,17beta-dihydroxyandrost-4-ene",experimental; illicit,C[C@]1(O)CC[C@H]2[C@@H]3CCC4=C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,C20H32O2,,,,"DB01474, DB01526, DB01554, DB01503, DB13866, DB04706, DB06257, DB01493, DB03696, DB01431, DB04704, DB01455, DB01524, DB04540, DB04705, DB14038, DB05212, DB12474, DB13315, DB02789, DB14555, DB01708",
DB01475,Dioxaphetyl butyrate,experimental; illicit,CCOC(=O)C(CCN1CCOCC1)(C1=CC=CC=C1)C1=CC=CC=C1,C22H27NO3,,,,"DB01475, DB01505, DB00454, DB01081, DB01518, DB01464, DB13605, DB08988, DB01501, DB00913",
DB01476,Haloxazolam,experimental; illicit,FC1=CC=CC=C1C12OCCN1CC(=O)NC1=C2C=C(Br)C=C1,C17H14BrFN2O2,,"Benzazepines, Heterocyclic Compounds, Fused-Ring",,"DB01476, DB15491, DB01553",
DB01477,Codeine methylbromide,experimental; illicit,[Br-].[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CC[N+](C)(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O,C19H24BrNO3,,,,"DB01477, DB00318, DB01466, DB00295, DB11490, DB09209, DB01573, DB01568, DB01480, DB01497, DB01469, DB01452, DB01551, DB06409, DB01565, DB01512, DB00844, DB15341, DB14146, DB16072, DB00921, DB01450, DB01548, DB16117, DB13454, DB06230, DB09049, DB00497, DB13458, DB01538",
DB01478,Desmethylprodine,experimental; illicit,CCC(=O)OC1(CCN(C)CC1)C1=CC=CC=C1,C15H21NO2,,"Isonipecotic Acids, Piperidines",,"DB01478, DB01473, DB13160, DB01562, DB01499, DB01552, DB01542, DB00647, DB06793",
DB01479,BA-2664,experimental; illicit,C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,C20H34O2,,,,"DB01479, DB01513, DB01530, DB03882, DB03926, DB11288, DB17066, DB17742, DB13163, DB00825, DB11344, DB14123, DB06307, DB02901, DB03619, DB07447, DB12622, DB13587, DB00858, DB01586, DB02659, DB05990, DB06777, DB16260, DB02854, DB05087, DB11859, DB12308, DB12972",
DB01480,Cyprenorphine,experimental; illicit,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@@]11C[C@]([H])(C(C)(C)O)[C@]2(OC)C=C1,C26H33NO4,,"Alkaloids, Heterocyclic Compounds, Fused-Ring, Opiate Alkaloids, Phenanthrenes",,"DB01480, DB01497, DB01469, DB00318, DB00295, DB01477, DB01466, DB01573, DB11490, DB09209, DB01452, DB01568, DB00921, DB01450, DB01548, DB16072, DB14146, DB15341, DB16117, DB06409, DB01512, DB01551, DB00844, DB01565, DB09049, DB13454, DB06230, DB01538, DB13458, DB00497",
DB01481,1-Testosterone,experimental; illicit; investigational,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)C=C[C@]12C,C19H28O2,,"Androstanes, Androstenes, Androstenols, Fused-Ring Compounds, Gonadal Hormones, Gonadal Steroid Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Steroids, Testosterone and derivatives, Testosterone Congeners", Androgen receptor,"DB01481, DB01572, DB13710, DB00624, DB01471, DB01543, DB01564, DB05830, DB06710, DB07768, DB11429, DB12787, DB13169, DB13533, DB14093, DB13230, DB14570, DB00253, DB18000, DB14584, DB01451, DB04652, DB00367, DB00717, DB09389, DB04630, DB00741, DB01485, DB01500, DB01540",
DB01482,Fenethylline,experimental,CC(CC1=CC=CC=C1)NCCN1C=NC2=C1C(=O)N(C)C(=O)N2C,C18H23N5O2,,"Alkaloids, Amines, Central Nervous System Agents, Central Nervous System Stimulants, Centrally Acting Sympathomimetics, Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 Substrates, Ethylamines, Heterocyclic Compounds, Fused-Ring, Nervous System, Phenethylamines, Psychoanaleptics, Psychostimulants, Agents Used for ADHD and Nootropics, Purines, Purinones, Xanthine derivatives", Cytochrome P450 1A2,"DB01482, DB12926, DB13592, DB12927, DB12846, DB13203, DB13636, DB13449, DB18002, DB13573",
DB01483,Barbital,illicit,CCC1(CC)C(=O)NC(=O)NC1=O,C8H12N2O3,,"Anticholinergic Agents, Anticonvulsants, Barbiturates, Barbiturates, Plain, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2C19 Inducers, Cytochrome P-450 CYP2C19 Inducers (strength unknown), Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Substrates, GABA Agents, GABA Modulators, Hypnotics and Sedatives, Nervous System, Neurotransmitter Agents, Nicotinic Antagonists, Psycholeptics, Pyrimidines, Pyrimidinones"," Gamma-aminobutyric acid receptor subunit alpha-1,  Gamma-aminobutyric acid receptor subunit alpha-2,  Gamma-aminobutyric acid receptor subunit alpha-3,  Gamma-aminobutyric acid receptor subunit alpha-4,  Gamma-aminobutyric acid receptor subunit alpha-5,  Gamma-aminobutyric acid receptor subunit alpha-6,  Neuronal acetylcholine receptor subunit alpha-4,  Neuronal acetylcholine receptor subunit alpha-7,  Glutamate receptor 2, 10. Glutamate receptor ionotropic, kainate 2,  Cytochrome P450 3A4,  Cytochrome P450 2C19","DB01483, DB13577, DB00237, DB00463, DB01353, DB01351, DB01352, DB00312, DB00241, DB00306, DB01849, DB13770",
DB01484,"4-Bromo-2,5-dimethoxyamphetamine",experimental; illicit,COC1=CC(Br)=C(OC)C=C1CC(C)N,C11H16BrNO2,,"Agents producing tachycardia, Agents that produce hypertension, Amines, Amphetamines, Antidepressive Agents, Central Nervous System Agents, Central Nervous System Depressants, Ethylamines, Hallucinogens, Neurotransmitter Agents, Phenethylamines, Psychotropic Drugs, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin Receptor Agonists, Sympathomimetics",,"DB01484, DB01537, DB01465, DB01528, DB01467",
DB01485,4-Hydroxytestosterone,experimental; illicit,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=C(O)C(=O)CC[C@]12C,C19H28O3,,"Androstanes, Androstenes, Androstenols, Fused-Ring Compounds, Steroids, Testosterone and derivatives, Testosterone Congeners",,"DB01485, DB01500, DB01540, DB08905, DB13230, DB14570, DB00624, DB01471, DB01543, DB01564, DB05830, DB06710, DB07768, DB11429, DB12787, DB13169, DB13533, DB14093, DB13710, DB04652, DB14584, DB00253, DB18000, DB04630, DB00741, DB13185, DB00367, DB00717, DB09389, DB01481",
DB01486,Cathine,experimental; illicit,C[C@H](N)[C@@H](O)C1=CC=CC=C1,C9H13NO,,"Alcohols, Alimentary Tract and Metabolism, Amines, Amino Alcohols, Anti-Obesity Agents, Antiobesity Preparations, Excl. Diet Products, Appetite Depressants, Centrally Acting Antiobesity Products, Propanolamines, Propanols",,"DB00397, DB01486, DB00852, DB01364, DB14752, DB11278, DB11587, DB04484, DB00610, DB11610, DB00182, DB01576",
DB01487,Embutramide,experimental; illicit,CCC(CC)(CNC(=O)CCCO)C1=CC(OC)=CC=C1,C17H27NO3,,"Acids, Carbocyclic, Amines, Aminobenzoates, Ammonium Compounds, Benzene Derivatives, Benzoates, Nitrogen Compounds, Onium Compounds, para-Aminobenzoates, Pharmaceutical Preparations",,DB01487,
DB01488,Dimethyltryptamine,experimental; illicit,CN(C)CCC1=CNC2=CC=CC=C12,C12H16N2,,"Amines, Antidepressive Agents, Biogenic Amines, Biogenic Monoamines, Central Nervous System Agents, Central Nervous System Depressants, Hallucinogens, Heterocyclic Compounds, Fused-Ring, Indoles, Neurotransmitter Agents, Psychotropic Drugs, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin Receptor Agonists, Serotonin Receptor Antagonists, Tryptamines"," 5-hydroxytryptamine receptor 6,  5-hydroxytryptamine receptor 2A,  Sigma non-opioid intracellular receptor 1","DB01488, DB01460, DB08653, DB01445, DB01446, DB08649, DB13990, DB08652, DB01546, DB14010, DB08839, DB04236, DB01441, DB04275, DB07952, DB12027",
DB01489,Camazepam,experimental; illicit,CN(C)C(=O)OC1N=C(C2=CC=CC=C2)C2=C(C=CC(Cl)=C2)N(C)C1=O,C19H18ClN3O3,,"Anti-Anxiety Agents, Benzazepines, Benzodiazepines and benzodiazepine derivatives, Benzodiazepinones, Central Nervous System Depressants, Heterocyclic Compounds, Fused-Ring, Nervous System, Psycholeptics"," GABA(A) Receptor (Protein Group),  GABA(A) Receptor Benzodiazepine Binding Site (Protein Group)","DB01489, DB14671, DB14672, DB00231, DB13872, DB00842, DB00186, DB13837, DB00829, DB01594, DB13335",
DB01490,Aminorex,experimental; illicit,NC1=NCC(O1)C1=CC=CC=C1,C9H10N2O,,Oxazoles,,"DB01490, DB01447, DB01230",
DB01491,Dipipanone,experimental; illicit,CCC(=O)C(CC(C)N1CCCCC1)(C1=CC=CC=C1)C1=CC=CC=C1,C24H31NO,,Ketones,,"DB01491, DB00333, DB13515, DB15198, DB11609, DB13436, DB06738, DB15597",
DB01493,Ethylestrenol,withdrawn,[H][C@@]12CC[C@@](O)(CC)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H],C20H32O,,"Alimentary Tract and Metabolism, Anabolic Agents, Anabolic Agents for Systemic Use, Anabolic Steroids, Estren Derivatives, Fused-Ring Compounds, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Norpregnanes, Norpregnenes, Norsteroids, Steroids",,"DB01493, DB01431, DB03696, DB12474, DB04704, DB01474, DB01526, DB01554, DB01455, DB01524, DB04540, DB04705, DB14038, DB01889, DB01503, DB00304, DB14555, DB14152, DB12622, DB13866, DB00624, DB01471, DB01543, DB01564, DB06710, DB07768, DB11429, DB12787, DB13169, DB13533",
DB01494,Chloral betaine,illicit; withdrawn,OC(O)C(Cl)(Cl)Cl.C[N+](C)(C)CC([O-])=O,C7H14Cl3NO4,,,,DB01494,
DB01495,Dichloralphenazone,approved; illicit,OC(O)C(Cl)(Cl)Cl.OC(O)C(Cl)(Cl)Cl.CN1N(C(=O)C=C1C)C1=CC=CC=C1,C15H18Cl6N2O5,,"Alcohols, Central Nervous System Depressants, Ethylene Glycols, Glycols, Hypnotics and Sedatives, Nervous System, Psycholeptics, Pyrazoles, Pyrazolones",,"DB01495, DB01435, DB13524, DB01424",
DB01496,"Dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1H,5H)-pyrimidinedione",experimental; illicit,FC(F)(F)C1=CC=CC=C1C1=CC=C(CC2C(=O)NC(=S)NC2=O)O1,C16H11F3N2O3S,,"Anticholinergic Agents, Nicotinic Antagonists"," Gamma-aminobutyric acid receptor subunit alpha-1,  Gamma-aminobutyric acid receptor subunit alpha-2,  Gamma-aminobutyric acid receptor subunit alpha-3,  Gamma-aminobutyric acid receptor subunit alpha-4,  Gamma-aminobutyric acid receptor subunit alpha-5,  Gamma-aminobutyric acid receptor subunit alpha-6,  Neuronal acetylcholine receptor subunit alpha-4,  Neuronal acetylcholine receptor subunit alpha-7,  Glutamate receptor 2, 10. Glutamate receptor ionotropic, kainate 2",DB01496,
DB01497,Etorphine,illicit; vet_approved,[H][C@]12CC3=C4C(OC5[C@@]4(CCN1C)[C@]21CC(C(C)(O)CCC)C5(OC)C=C1)=C(O)C=C3,C25H33NO4,,"Alkaloids, Analgesics, Central Nervous System Agents, Central Nervous System Depressants, Heterocyclic Compounds, Fused-Ring, Morphinans, Narcotics, Opiate Alkaloids, Opioids, Peripheral Nervous System Agents, Phenanthrenes, Sensory System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"," Mu-type opioid receptor,  Delta-type opioid receptor,  Kappa-type opioid receptor,  Nociceptin receptor,  E3 ubiquitin-protein ligase TRIM13,  Pro-opiomelanocortin","DB01480, DB01497, DB01469, DB00318, DB00295, DB01477, DB01466, DB01573, DB11490, DB09209, DB01452, DB01568, DB00921, DB01450, DB01548, DB16072, DB14146, DB15341, DB16117, DB06409, DB01512, DB01551, DB00844, DB01565, DB09049, DB13454, DB06230, DB01538, DB13458, DB00497",
DB01498,Alphamethadol,experimental; illicit,CC[C@@H](O)C(C[C@@H](C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1,C21H29NO,,,,"DB01498, DB01227, DB01433, DB01522, DB01555, DB00333, DB13515, DB15198",
DB01499,Alphameprodine,experimental; illicit,CC[C@H]1CN(C)CC[C@]1(OC(=O)CC)C1=CC=CC=C1,C17H25NO2,,,,"DB01499, DB01552, DB01473, DB13160, DB01542, DB01478, DB01562, DB00647, DB06793",
DB01500,Oxabolone,experimental; illicit,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C(O)=C3CC[C@@]21[H],C18H26O3,,,,"DB01485, DB01500, DB01540, DB08905, DB13230, DB14570, DB00624, DB01471, DB01543, DB01564, DB05830, DB06710, DB07768, DB11429, DB12787, DB13169, DB13533, DB14093, DB13710, DB04652, DB14584, DB00253, DB18000, DB04630, DB00741, DB13185, DB00367, DB00717, DB09389, DB01481",
DB01501,Difenoxin,approved; illicit,OC(=O)C1(CCN(CCC(C#N)(C2=CC=CC=C2)C2=CC=CC=C2)CC1)C1=CC=CC=C1,C28H28N2O2,,"Alimentary Tract and Metabolism, Antidiarrheals, Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents, Antipropulsives, Central Nervous System Depressants, Isonipecotic Acids, Piperidines",,"DB01501, DB01081, DB00454, DB01475, DB01505, DB13605",
DB01502,Diampromide,experimental; illicit,CCC(=O)N(CC(C)N(C)CCC1=CC=CC=C1)C1=CC=CC=C1,C21H28N2O,,,,DB01502,
DB01503,1-Androstenediol,experimental; illicit,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@@H](O)C=C[C@]12C,C19H30O2,,,,"DB01503, DB01474, DB01526, DB01554, DB13866, DB04706, DB01493, DB06257, DB01431, DB03696, DB01889, DB04704, DB01455, DB01524, DB04540, DB04705, DB14038",
DB01505,Etoxeridine,experimental; illicit,CCOC(=O)C1(CCN(CCOCCO)CC1)C1=CC=CC=C1,C18H27NO4,,,,"DB01505, DB01475, DB01464, DB00454, DB01518, DB13605, DB01081, DB08988, DB00913, DB04822, DB13731, DB01501",
DB01506,1-Phenylcyclohexylamine,experimental; illicit,NC1(CCCCC1)C1=CC=CC=C1,C12H17N,,"Amines, Cyclohexanes, Cycloparaffins",,"DB01506, DB03575",
DB01509,Tenamfetamine,experimental; illicit,CC(N)CC1=CC2=C(OCO2)C=C1,C10H13NO2,,"Adrenergic Agents, Adrenergic Uptake Inhibitors, Agents producing tachycardia, Agents that produce hypertension, Amines, Amphetamines, Antidepressive Agents, Central Nervous System Agents, Central Nervous System Depressants, Ethylamines, Hallucinogens, Membrane Transport Modulators, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, Phenethylamines, Psychotropic Drugs, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin Modulators, Sympathomimetics",,"DB01509, DB01454, DB01566, DB06112, DB01442, DB12809, DB01516, DB09253, DB14129, DB06814",
DB01510,Dehydrochloromethyltestosterone,experimental; illicit,,,,Testosterone and derivatives,,,
DB01511,Delorazepam,experimental; illicit,ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,C15H10Cl2N2O,,"Anticonvulsants, Benzazepines, Benzodiazepines and benzodiazepine derivatives, Benzodiazepinones, Central Nervous System Agents, Central Nervous System Depressants, Heterocyclic Compounds, Fused-Ring"," GABA(A) Receptor (Protein Group),  GABA(A) Receptor Benzodiazepine Binding Site (Protein Group)","DB01511, DB14028, DB00186, DB00829, DB13872, DB00842, DB13335, DB00628, DB01588, DB00801, DB00231, DB01567, DB01068, DB00690, DB14672, DB13437",
DB01512,Hydromorphinol,experimental; illicit,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1(O)CC[C@@H]2O,C17H21NO4,,,,"DB01512, DB00844, DB01565, DB14146, DB01551, DB00921, DB01450, DB01548, DB09049, DB16072, DB15341, DB01538, DB06230, DB16117, DB00704, DB01192, DB06800, DB01531, DB00497, DB01183, DB04509, DB01480, DB01497, DB00295, DB13471, DB00318, DB00327, DB01477, DB01466, DB01469",
DB01513,"17Alpha-methyl-3beta,17beta-dihydroxy-5alpha-androstane",experimental; illicit,[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@@H](O)CC[C@]12C,C20H34O2,,,,"DB01479, DB01513, DB01530, DB03882, DB03926, DB11288, DB17066, DB17742, DB13163, DB00825, DB11344, DB14123, DB06307, DB02901, DB03619, DB07447, DB12622, DB13587, DB00858, DB01586, DB02659, DB05990, DB06777, DB16260, DB02854, DB05087, DB11859, DB12308, DB12972",
DB01514,Furazabol,illicit,[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC3=NON=C3C[C@]12C,C20H30N2O2,,"Androstanes, Fused-Ring Compounds, Steroids",,DB01514,
DB01515,Benzoylecgonine,experimental; illicit,[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(O)=O)N2C,C16H19NO4,,"Alkaloids, Aza Compounds, Azabicyclo Compounds, Tropanes",,"DB01515, DB00907",
DB01516,"3,4,5-Trimethoxyamphetamine",experimental; illicit,COC1=CC(CC(C)N)=CC(OC)=C1OC,C12H19NO3,,,,"DB01516, DB01442, DB01509, DB01454, DB01566, DB06112, DB12809",
DB01518,Benzethidine,experimental; illicit,CCOC(=O)C1(CCN(CCOCC2=CC=CC=C2)CC1)C1=CC=CC=C1,C23H29NO3,,,,"DB01518, DB01505, DB01475, DB00454, DB13605, DB01464, DB01081, DB08988, DB00913",
DB01520,Tenocyclidine,experimental; illicit; investigational,C1CCN(CC1)C1(CCCCC1)C1=CC=CS1,C15H23NS,,"Central Nervous System Agents, Compounds used in a research, industrial, or household setting, Illicit Drugs, Neuroprotective Agents, NMDA Receptor Antagonists, Piperidines, Protective Agents, Street Drugs"," Glutamate receptor ionotropic, NMDA 3A,  Glutamate receptor ionotropic, NMDA 3B,  Glutamate receptor ionotropic, NMDA 2A,  Glutamate receptor ionotropic, NMDA 2C,  Glutamate receptor ionotropic, NMDA 2B,  Neuronal acetylcholine receptor subunit alpha-7,  Glutamate receptor ionotropic, NMDA 2D","DB01520, DB13096, DB11549",
DB01521,Clostebol,experimental; illicit,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=C(Cl)C(=O)CC[C@]12C,C19H27ClO2,,"Androstanes, Androstenes, Androstenols, Fused-Ring Compounds, Gonadal Hormones, Gonadal Steroid Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Steroids, Testosterone Congeners",,"DB01521, DB00624, DB01471, DB01543, DB01564, DB05830, DB06710, DB07768, DB11429, DB12787, DB13169, DB13533, DB14093, DB15984, DB13710, DB13230, DB14570, DB14584, DB18000, DB04652, DB00253, DB00367, DB00717, DB09389, DB04630, DB01481, DB01572, DB00741, DB01500, DB01540",
DB01522,Betacetylmethadol,experimental; illicit,CC[C@H](OC(C)=O)C(C[C@@H](C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1,C23H31NO2,,,,"DB01227, DB01433, DB01522, DB01555, DB01498",
DB01523,Clonitazene,experimental; illicit,CCN(CC)CCN1C(CC2=CC=C(Cl)C=C2)=NC2=C1C=CC(=C2)[N+]([O-])=O,C20H23ClN4O2,,,,"DB01523, DB01462",
DB01524,Androstenediol,experimental; illicit,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C,C19H30O2,,"Anabolic Agents, Androstanes, Androstenediols, Androstenes, Androstenols, Fused-Ring Compounds, Gonadal Hormones, Gonadal Steroid Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Steroids, Testosterone Congeners",,"DB01455, DB01524, DB04704, DB04540, DB04705, DB14038, DB03696, DB01431, DB04706, DB02789, DB06257, DB01708, DB01493, DB14555, DB13797, DB01474, DB01526, DB01554, DB05212, DB12474, DB01503, DB01889, DB13866",
DB01525,Ecgonine,experimental; illicit,[H][C@]12CC[C@]([H])([C@H]([C@@H](O)C1)C(O)=O)N2C,C9H15NO3,,"Alkaloids, Analgesics, Aza Compounds, Azabicyclo Compounds, Central Nervous System Agents, Central Nervous System Depressants, Narcotics, Peripheral Nervous System Agents, Sensory System Agents, Tropanes",,"DB01525, DB04688",
DB01526,4-Androstenediol,experimental; illicit,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=C[C@@H](O)CC[C@]12C,C19H30O2,,,,"DB01474, DB01526, DB01554, DB01503, DB13866, DB04706, DB06257, DB01493, DB03696, DB01431, DB04704, DB01455, DB01524, DB04540, DB04705, DB14038, DB05212, DB12474, DB13315, DB02789, DB14555, DB01708",
DB01527,Clortermine,experimental,CC(C)(N)CC1=CC=CC=C1Cl,C10H14ClN,,,,"DB01527, DB01556",
DB01528,"4-Methyl-2,5-dimethoxyamphetamine",experimental; illicit,COC1=CC(CC(C)N)=C(OC)C=C1C,C12H19NO2,,,,"DB01528, DB01467, DB01465, DB00723, DB01484",
DB01529,Dextromoramide,experimental; illicit,C[C@H](CN1CCOCC1)C(C(=O)N1CCCC1)(C1=CC=CC=C1)C1=CC=CC=C1,C25H32N2O2,,"Analgesics, Central Nervous System Agents, Central Nervous System Depressants, Diphenylpropylamine Derivatives, Morpholines, Narcotics, Nervous System, Opioids, Oxazines, Peripheral Nervous System Agents, Sensory System Agents, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome",,"DB01529, DB00561, DB13759",
DB01530,"5alpha-androstane-3alpha,17beta-diol",experimental; illicit,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](O)CC[C@]12C,C19H32O2,,, Cytochrome P450 7B1,"DB01479, DB01513, DB01530, DB03882, DB03926, DB11288, DB17066, DB17742, DB13163, DB00825, DB11344, DB14123, DB06307, DB02901, DB03619, DB07447, DB12622, DB13587, DB00858, DB01586, DB02659, DB05990, DB06777, DB16260, DB02854, DB05087, DB11859, DB12308, DB12972",
DB01531,Desomorphine,experimental; illicit,[H][C@@]12CCC[C@@]3([H])[C@@]4([H])CC5=CC=C(O)C(O1)=C5[C@@]23CCN4C,C17H21NO2,,"Alkaloids, Analgesics, Central Nervous System Agents, Central Nervous System Depressants, Heterocyclic Compounds, Fused-Ring, Illicit Drugs, Morphinans, Morphine Derivatives, Narcotics, Opiate Alkaloids, Opioids, Peripheral Nervous System Agents, Phenanthrenes, Sensory System Agents, Street Drugs",,"DB01531, DB01565, DB01551, DB00327, DB00921, DB01450, DB01548, DB00956, DB01512, DB16072, DB00844, DB06230, DB01538, DB00704, DB01192, DB06800, DB00497, DB14146, DB01183, DB04509, DB09049, DB16117, DB15341, DB13471, DB00295, DB01480, DB01497, DB00318, DB01477, DB01466",
DB00006,B01AE06 — Bivalirudin; B01AE — Direct thrombin inhibitors; B01A — ANTITHROMBOTIC AGENTS; B01 — ANTITHROMBOTIC AGENTS; B — BLOOD AND BLOOD FORMING ORGANS
DB00007,L02AE51 — Leuprorelin and bicalutamide; L02AE — Gonadotropin releasing hormone analogues; L02A — HORMONES AND RELATED AGENTS; L02 — ENDOCRINE THERAPY; L — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS; L02AE02 — Leuprorelin; L02AE — Gonadotropin releasing hormone analogues; L02A — HORMONES AND RELATED AGENTS; L02 — ENDOCRINE THERAPY; L — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
DB00014,L02AE03 — Goserelin; L02AE — Gonadotropin releasing hormone analogues; L02A — HORMONES AND RELATED AGENTS; L02 — ENDOCRINE THERAPY; L — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
DB00027,R02AB30 — Gramicidin; R02AB — Antibiotics; R02A — THROAT PREPARATIONS; R02 — THROAT PREPARATIONS; R — RESPIRATORY SYSTEM
DB00035,H01BA02 — Desmopressin; H01BA — Vasopressin and analogues; H01B — POSTERIOR PITUITARY LOBE HORMONES; H01 — PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES; H — SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
DB00050,H01CC02 — Cetrorelix; H01CC — Anti-gonadotropin-releasing hormones; H01C — HYPOTHALAMIC HORMONES; H01 — PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES; H — SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
DB00067,Amino Acids, Peptides, and Proteins; Antidiuretic Agents; Arginine Vasopressin; Arginine Vasopressin, analogs & derivatives; Cardiovascular Agents; Coagulants; Decreased Diuresis; Hematologic Agents; Hemostatics; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Natriuretic Agents; Nerve Tissue Proteins; Neuropeptides; Oligopeptides; Peptide Hormones; Peptides; Pituitary; Pituitary Hormones; Pituitary Hormones, Posterior; Proteins; Vasoconstriction; Vasoconstrictor Agents; Vasopressin and Analogues; Vasopressins
DB00080,J01XX09 — Daptomycin; J01XX — Other antibacterials; J01X — OTHER ANTIBACTERIALS; J01 — ANTIBACTERIALS FOR SYSTEMIC USE; J — ANTIINFECTIVES FOR SYSTEMIC USE
DB00091,L04AD01 — Ciclosporin; L04AD — Calcineurin inhibitors; L04A — IMMUNOSUPPRESSANTS; L04 — IMMUNOSUPPRESSANTS; L — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS; S01XA18 — Ciclosporin; S01XA — Other ophthalmologicals; S01X — OTHER OPHTHALMOLOGICALS; S01 — OPHTHALMOLOGICALS; S — SENSORY ORGANS
DB00106,L02BX01 — Abarelix; L02BX — Other hormone antagonists and related agents; L02B — HORMONE ANTAGONISTS AND RELATED AGENTS; L02 — ENDOCRINE THERAPY; L — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
DB00115,B03BA01 — Cyanocobalamin; B03BA — Vitamin B12 (cyanocobalamin and analogues); B03B — VITAMIN B12 AND FOLIC ACID; B03 — ANTIANEMIC PREPARATIONS; B — BLOOD AND BLOOD FORMING ORGANS; B03AE01 — Iron, vitamin b12 and folic acid; B03AE — Iron in other combinations; B03A — IRON PREPARATIONS; B03 — ANTIANEMIC PREPARATIONS; B — BLOOD AND BLOOD FORMING ORGANS; B03BA51 — Cyanocobalamin, combinations; B03BA — Vitamin B12 (cyanocobalamin and analogues); B03B — VITAMIN B12 AND FOLIC ACID; B03 — ANTIANEMIC PREPARATIONS; B — BLOOD AND BLOOD FORMING ORGANS
DB00116,43ZWB253H4
DB00117,Amino Acids; Amino Acids, Cyclic; Amino Acids, Essential; Amino Acids, Peptides, and Proteins; Dietary Supplements; Proteinogenic Amino Acids; Supplements
DB00118,A16AA02 — Ademetionine; A16AA — Amino acids and derivatives; A16A — OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS; A16 — OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS; A — ALIMENTARY TRACT AND METABOLISM
DB00119,Dietary Supplements; Keto Acids; Pyruvates; Supplements
DB00120,Amino Acids; Amino Acids, Aromatic; Amino Acids, Cyclic; Amino Acids, Essential; Amino Acids, Peptides, and Proteins; Dietary Supplements; Immunosuppressive Agents; Myelosuppressive Agents; Proteinogenic Amino Acids; Supplements
DB00121,A11HA05 — Biotin; A11HA — Other plain vitamin preparations; A11H — OTHER PLAIN VITAMIN PREPARATIONS; A11 — VITAMINS; A — ALIMENTARY TRACT AND METABOLISM
DB00122,Alcohols; Amines; Amino Alcohols; Analgesics; Antimetabolites; Central Nervous System Agents; Dietary Supplements; Ethanolamines; Gastrointestinal Agents; Hypolipidemic Agents; Lipid Regulating Agents; Lipotropic Agents; Nervous System; Nootropic Agents; OCT1 inhibitors; OCT1 substrates; OCT2 Inhibitors; OCT2 Substrates; Onium Compounds; Other Nutritional Agents; Quaternary Ammonium Compounds; Salicylic Acid and Derivatives; Supplements; Trimethyl Ammonium Compounds; Vitamin B Complex; Vitamins
DB00123,V03AF11 — Arginine and lysine; V03AF — Detoxifying agents for antineoplastic treatment; V03A — ALL OTHER THERAPEUTIC PRODUCTS; V03 — ALL OTHER THERAPEUTIC PRODUCTS; V — VARIOUS; B05XB03 — Lysine; B05XB — Amino acids; B05X — I.V. SOLUTION ADDITIVES; B05 — BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS; B — BLOOD AND BLOOD FORMING ORGANS
DB00125,V03AF11 — Arginine and lysine; V03AF — Detoxifying agents for antineoplastic treatment; V03A — ALL OTHER THERAPEUTIC PRODUCTS; V03 — ALL OTHER THERAPEUTIC PRODUCTS; V — VARIOUS; B05XB01 — Arginine hydrochloride; B05XB — Amino acids; B05X — I.V. SOLUTION ADDITIVES; B05 — BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS; B — BLOOD AND BLOOD FORMING ORGANS
DB00126,G01AD03 — Ascorbic acid; G01AD — Organic acids; G01A — ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS; G01 — GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS; G — GENITO URINARY SYSTEM AND SEX HORMONES; A11GA01 — Ascorbic acid (vit c); A11GA — Ascorbic acid (vitamin C), plain; A11G — ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS; A11 — VITAMINS; A — ALIMENTARY TRACT AND METABOLISM; A11GB01 — Ascorbic acid (vit c) and calcium; A11GB — Ascorbic acid (vitamin C), combinations; A11G — ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS; A11 — VITAMINS; A — ALIMENTARY TRACT AND METABOLISM; S01XA15 — Ascorbic acid; S01XA — Other ophthalmologicals; S01X — OTHER OPHTHALMOLOGICALS; S01 — OPHTHALMOLOGICALS; S — SENSORY ORGANS
DB00127,Amines; Biogenic Amines; Biogenic Polyamines; Dietary Supplements; OCT1 substrates; Polyamines; Supplements
DB00128,Amino Acids; Amino Acids, Acidic; Amino Acids, Dicarboxylic; Amino Acids, Peptides, and Proteins; Dietary Supplements; Excitatory Amino Acids; Proteinogenic Amino Acids; Supplements
DB00129,A05BA06 — Ornithine oxoglurate; A05BA — Liver therapy; A05B — LIVER THERAPY, LIPOTROPICS; A05 — BILE AND LIVER THERAPY; A — ALIMENTARY TRACT AND METABOLISM
DB00130,A16AA03 — Glutamine; A16AA — Amino acids and derivatives; A16A — OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS; A16 — OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS; A — ALIMENTARY TRACT AND METABOLISM
DB00131,Adenine Nucleotides; Dietary Supplements; Heterocyclic Compounds, Fused-Ring; Nucleic Acids, Nucleotides, and Nucleosides; Nucleotides; Purine Nucleotides; Purines; Ribonucleotides; Supplements
DB00132,Dietary Fats; Dietary Fats, Unsaturated; Dietary Supplements; Fats; Fatty Acids; Fatty Acids, Essential; Fatty Acids, Omega-3; Fatty Acids, Unsaturated; Linolenic Acids; Lipids; Supplements
DB00133,Amino Acids; Amino Acids, Neutral; Amino Acids, Peptides, and Proteins; Dietary Supplements; Proteinogenic Amino Acids; Supplements
DB00134,V03AB26 — Methionine; V03AB — Antidotes; V03A — ALL OTHER THERAPEUTIC PRODUCTS; V03 — ALL OTHER THERAPEUTIC PRODUCTS; V — VARIOUS
DB00135,Amino Acids; Amino Acids, Aromatic; Amino Acids, Cyclic; Amino Acids, Peptides, and Proteins; Dietary Supplements; Proteinogenic Amino Acids; Supplements
DB00136,D05AX03 — Calcitriol; D05AX — Other antipsoriatics for topical use; D05A — ANTIPSORIATICS FOR TOPICAL USE; D05 — ANTIPSORIATICS; D — DERMATOLOGICALS; A11CC04 — Calcitriol; A11CC — Vitamin D and analogues; A11C — VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO; A11 — VITAMINS; A — ALIMENTARY TRACT AND METABOLISM
DB00137,Alkenes; Biological Factors; Carotenoids; Cyclohexanes; Cyclohexenes; Cycloparaffins; Dietary Supplements; Hydrocarbons, Acyclic; Pigments, Biological; Polyenes; Supplements; Terpenes; Xanthophylls
DB00138,Amino Acids; Amino Acids, Diamino; Amino Acids, Dicarboxylic; Amino Acids, Peptides, and Proteins; Amino Acids, Sulfur; Anions; Cysteine; Dietary Supplements; Disulfides; Electrolytes; Hydrogen Sulfide; Ions; Sulfides; Sulfur Compounds; Supplements
DB00139,Acids, Acyclic; Dicarboxylic Acids; Dietary Supplements; OAT3/SLC22A8 Substrates; Succinates; Supplements
DB00140,A11HA04 — Riboflavin (vit b2); A11HA — Other plain vitamin preparations; A11H — OTHER PLAIN VITAMIN PREPARATIONS; A11 — VITAMINS; A — ALIMENTARY TRACT AND METABOLISM; S01XA26 — Riboflavin; S01XA — Other ophthalmologicals; S01X — OTHER OPHTHALMOLOGICALS; S01 — OPHTHALMOLOGICALS; S — SENSORY ORGANS
DB00141,Amino Sugars; Carbohydrates; Dietary Supplements; Hexosamines; Supplements
DB00142,A09AB01 — Glutamic acid hydrochloride; A09AB — Acid preparations; A09A — DIGESTIVES, INCL. ENZYMES; A09 — DIGESTIVES, INCL. ENZYMES; A — ALIMENTARY TRACT AND METABOLISM
DB00143,V03AB32 — Glutathione; V03AB — Antidotes; V03A — ALL OTHER THERAPEUTIC PRODUCTS; V03 — ALL OTHER THERAPEUTIC PRODUCTS; V — VARIOUS
DB00144,Dietary Supplements; Glycerophosphates; Glycerophospholipids; Lipids; Membrane Lipids; Phosphatidic Acids; Phosphatidylserines; Phospholipids; Supplements
DB00145,B05CX03 — Glycine; B05CX — Other irrigating solutions; B05C — IRRIGATING SOLUTIONS; B05 — BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS; B — BLOOD AND BLOOD FORMING ORGANS
DB00146,A11CC06 — Calcifediol; A11CC — Vitamin D and analogues; A11C — VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO; A11 — VITAMINS; A — ALIMENTARY TRACT AND METABOLISM; H05BX05 — Calcifediol; H05BX — Other anti-parathyroid agents; H05B — ANTI-PARATHYROID AGENTS; H05 — CALCIUM HOMEOSTASIS; H — SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
DB00147,Dietary Supplements; Micronutrients; Picolines; Pyridines; Supplements; Vitamin B Complex; Vitamins
DB00148,Amidines; Amino Acids; Amino Acids, Peptides, and Proteins; Dietary Supplements; Guanidines; Supplements
DB00149,Amino Acids; Amino Acids, Branched-Chain; Amino Acids, Essential; Amino Acids, Peptides, and Proteins; Dietary Supplements; Proteinogenic Amino Acids; Supplements
DB00150,N06AX02 — Tryptophan; N06AX — Other antidepressants; N06A — ANTIDEPRESSANTS; N06 — PSYCHOANALEPTICS; N — NERVOUS SYSTEM
DB00151,Amino Acids; Amino Acids, Neutral; Amino Acids, Peptides, and Proteins; Amino Acids, Sulfur; Caloric Agents; Cysteine; Dietary Supplements; Nutritional Support; Proteinogenic Amino Acids; Sulfhydryl Compounds; Sulfur Compounds; Supplements
DB00152,A11DA01 — Thiamine (vit b1); A11DA — Vitamin B1, plain; A11D — VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12; A11 — VITAMINS; A — ALIMENTARY TRACT AND METABOLISM
DB00153,A11CC01 — Ergocalciferol; A11CC — Vitamin D and analogues; A11C — VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO; A11 — VITAMINS; A — ALIMENTARY TRACT AND METABOLISM
DB00154,Dietary Supplements; Eicosanoids; Fatty Acids; Fatty Acids, Unsaturated; Lipids; Supplements
DB00155,Acids, Acyclic; Amino Acids; Amino Acids, Diamino; Amino Acids, Peptides, and Proteins; Dicarboxylic Acids; Dietary Supplements; Hydroxy Acids; OAT1/SLC22A6 Substrates; OAT3/SLC22A8 Substrates; Proteins; Supplements
DB00156,Amino Acids; Amino Acids, Essential; Amino Acids, Neutral; Amino Acids, Peptides, and Proteins; Dietary Supplements; Proteinogenic Amino Acids; Supplements; Threonine, antagonists & inhibitors
DB00157,Adenine Nucleotides; Coenzymes; Dietary Supplements; Enzymes and Coenzymes; Heterocyclic Compounds, Fused-Ring; Nucleic Acids, Nucleotides, and Nucleosides; Nucleotides; Purine Nucleotides; Purines; Ribonucleotides; Supplements
DB00158,B03AE02 — Iron, multivitamins and folic acid; B03AE — Iron in other combinations; B03A — IRON PREPARATIONS; B03 — ANTIANEMIC PREPARATIONS; B — BLOOD AND BLOOD FORMING ORGANS; B03AD04 — Ferric oxide polymaltose complexes and folic acid; B03AD — Iron in combination with folic acid; B03A — IRON PREPARATIONS; B03 — ANTIANEMIC PREPARATIONS; B — BLOOD AND BLOOD FORMING ORGANS; V04CX02 — Folic acid; V04CX — Other diagnostic agents; V04C — OTHER DIAGNOSTIC AGENTS; V04 — DIAGNOSTIC AGENTS; V — VARIOUS; B03AD01 — Ferrous amino acid complex and folic acid; B03AD — Iron in combination with folic acid; B03A — IRON PREPARATIONS; B03 — ANTIANEMIC PREPARATIONS; B — BLOOD AND BLOOD FORMING ORGANS; B03BB51 — Folic acid, combinations; B03BB — Folic acid and derivatives; B03B — VITAMIN B12 AND FOLIC ACID; B03 — ANTIANEMIC PREPARATIONS; B — BLOOD AND BLOOD FORMING ORGANS; B03AD03 — Ferrous sulfate and folic acid; B03AD — Iron in combination with folic acid; B03A — IRON PREPARATIONS; B03 — ANTIANEMIC PREPARATIONS; B — BLOOD AND BLOOD FORMING ORGANS; B03BB01 — Folic acid; B03BB — Folic acid and derivatives; B03B — VITAMIN B12 AND FOLIC ACID; B03 — ANTIANEMIC PREPARATIONS; B — BLOOD AND BLOOD FORMING ORGANS; B03AE01 — Iron, vitamin b12 and folic acid; B03AE — Iron in other combinations; B03A — IRON PREPARATIONS; B03 — ANTIANEMIC PREPARATIONS; B — BLOOD AND BLOOD FORMING ORGANS; B03AD05 — Ferrous gluconate and folic acid; B03AD — Iron in combination with folic acid; B03A — IRON PREPARATIONS; B03 — ANTIANEMIC PREPARATIONS; B — BLOOD AND BLOOD FORMING ORGANS; B03AD02 — Ferrous fumarate and folic acid; B03AD — Iron in combination with folic acid; B03A — IRON PREPARATIONS; B03 — ANTIANEMIC PREPARATIONS; B — BLOOD AND BLOOD FORMING ORGANS
DB00159,Agents causing hyperkalemia; Agents that produce hypertension; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Inflammatory Agents, Non-Steroidal (Non-Selective); Dietary Fats; Dietary Fats, Unsaturated; Dietary Supplements; Eicosanoids; Fats; Fatty Acids; Fatty Acids, Omega-3; Fatty Acids, Unsaturated; Fish Oils; Hypolipidemic Agents; Lipids; Nephrotoxic agents; Non COX-2 selective NSAIDS; Oils; Supplements
DB00160,Alanine; Amino Acids; Amino Acids, Peptides, and Proteins; Dietary Supplements; Proteinogenic Amino Acids; Supplements
DB00161,Amino Acids; Amino Acids, Branched-Chain; Amino Acids, Essential; Amino Acids, Peptides, and Proteins; Dietary Supplements; Proteinogenic Amino Acids; Supplements
DB00162,S01XA02 — Retinol; S01XA — Other ophthalmologicals; S01X — OTHER OPHTHALMOLOGICALS; S01 — OPHTHALMOLOGICALS; S — SENSORY ORGANS; V04CB01 — Vitamin a concentrates; V04CB — Tests for fat absorption; V04C — OTHER DIAGNOSTIC AGENTS; V04 — DIAGNOSTIC AGENTS; V — VARIOUS; D10AD02 — Retinol; D10AD — Retinoids for topical use in acne; D10A — ANTI-ACNE PREPARATIONS FOR TOPICAL USE; D10 — ANTI-ACNE PREPARATIONS; D — DERMATOLOGICALS; R01AX02 — Retinol; R01AX — Other nasal preparations; R01A — DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE; R01 — NASAL PREPARATIONS; R — RESPIRATORY SYSTEM; A11CA01 — Retinol (vit a); A11CA — Vitamin A, plain; A11C — VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO; A11 — VITAMINS; A — ALIMENTARY TRACT AND METABOLISM
DB00163,Antioxidants; Basic Ointments and Protectants; Benzopyrans; Biological Factors; Compounds used in a research, industrial, or household setting; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Diet, Food, and Nutrition; Dietary Supplements; Food; Growth Substances; Heterocyclic Compounds, Fused-Ring; Micronutrients; Physiological Phenomena; Protective Agents; Pyrans; Supplements; Vitamin E; Vitamin E, analogs & derivatives; Vitamins; Vitamins (Fat Soluble)
DB00165,J04AM08 — Isoniazid, sulfamethoxazole, trimethoprim and pyridoxine; J04AM — Combinations of drugs for treatment of tuberculosis; J04A — DRUGS FOR TREATMENT OF TUBERCULOSIS; J04 — ANTIMYCOBACTERIALS; J — ANTIINFECTIVES FOR SYSTEMIC USE; A11HA02 — Pyridoxine (vit b6); A11HA — Other plain vitamin preparations; A11H — OTHER PLAIN VITAMIN PREPARATIONS; A11 — VITAMINS; A — ALIMENTARY TRACT AND METABOLISM
DB00166,A16AX01 — Thioctic acid; A16AX — Various alimentary tract and metabolism products; A16A — OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS; A16 — OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS; A — ALIMENTARY TRACT AND METABOLISM
DB00167,Amino Acids; Amino Acids, Branched-Chain; Amino Acids, Essential; Amino Acids, Peptides, and Proteins; Dietary Supplements; Proteinogenic Amino Acids; Supplements
DB00168,Amino Acids, Peptides, and Proteins; Compounds used in a research, industrial, or household setting; Diet, Food, and Nutrition; Dietary Supplements; Dipeptides; Flavoring Agents; Food; Food Additives; Food Ingredients; OAT1/SLC22A6 inhibitors; OAT3/SLC22A8 Inhibitors; Oligopeptides; Peptides; Physiological Phenomena; Supplements; Sweetening Agents
DB00169,M05BB09 — Ibandronic acid and colecalciferol; M05BB — Bisphosphonates, combinations; M05B — DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION; M05 — DRUGS FOR TREATMENT OF BONE DISEASES; M — MUSCULO-SKELETAL SYSTEM; M05BX53 — Strontium ranelate and colecalciferol; M05BX — Other drugs affecting bone structure and mineralization; M05B — DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION; M05 — DRUGS FOR TREATMENT OF BONE DISEASES; M — MUSCULO-SKELETAL SYSTEM; M05BB07 — Risedronic acid and colecalciferol; M05BB — Bisphosphonates, combinations; M05B — DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION; M05 — DRUGS FOR TREATMENT OF BONE DISEASES; M — MUSCULO-SKELETAL SYSTEM; M05BB08 — Zoledronic acid, calcium and colecalciferol, sequential; M05BB — Bisphosphonates, combinations; M05B — DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION; M05 — DRUGS FOR TREATMENT OF BONE DISEASES; M — MUSCULO-SKELETAL SYSTEM; A11CC55 — Colecalciferol, combinations; A11CC — Vitamin D and analogues; A11C — VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO; A11 — VITAMINS; A — ALIMENTARY TRACT AND METABOLISM; M05BB05 — Alendronic acid, calcium and colecalciferol, sequential; M05BB — Bisphosphonates, combinations; M05B — DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION; M05 — DRUGS FOR TREATMENT OF BONE DISEASES; M — MUSCULO-SKELETAL SYSTEM; A11CC05 — Colecalciferol; A11CC — Vitamin D and analogues; A11C — VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO; A11 — VITAMINS; A — ALIMENTARY TRACT AND METABOLISM; M05BB03 — Alendronic acid and colecalciferol; M05BB — Bisphosphonates, combinations; M05B — DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION; M05 — DRUGS FOR TREATMENT OF BONE DISEASES; M — MUSCULO-SKELETAL SYSTEM; M05BB04 — Risedronic acid, calcium and colecalciferol, sequential; M05BB — Bisphosphonates, combinations; M05B — DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION; M05 — DRUGS FOR TREATMENT OF BONE DISEASES; M — MUSCULO-SKELETAL SYSTEM
DB00170,B02BA02 — Menadione; B02BA — Vitamin K; B02B — VITAMIN K AND OTHER HEMOSTATICS; B02 — ANTIHEMORRHAGICS; B — BLOOD AND BLOOD FORMING ORGANS
DB00171,Adenine Nucleotides; Adenosine Triphosphate; Dietary Supplements; Heterocyclic Compounds, Fused-Ring; Nucleic Acids, Nucleotides, and Nucleosides; Nucleotides; Purine Nucleotides; Purines; Ribonucleotides; Supplements
DB00172,Amino Acids; Amino Acids, Cyclic; Amino Acids, Peptides, and Proteins; Dietary Supplements; Imino Acids; Proteinogenic Amino Acids; Supplements
DB00173,Dietary Supplements; Heterocyclic Compounds, Fused-Ring; Purines; Supplements; UGT1A1 Inhibitors
DB00174,Amino Acids; Amino Acids, Basic; Amino Acids, Diamino; Amino Acids, Neutral; Amino Acids, Peptides, and Proteins; Dietary Supplements; Proteinogenic Amino Acids; Supplements
DB00175,C10AA03 — Pravastatin; C10AA — HMG CoA reductase inhibitors; C10A — LIPID MODIFYING AGENTS, PLAIN; C10 — LIPID MODIFYING AGENTS; C — CARDIOVASCULAR SYSTEM; C10BA11 — Pravastatin and ezetimibe; C10BA — Combinations of various lipid modifying agents; C10B — LIPID MODIFYING AGENTS, COMBINATIONS; C10 — LIPID MODIFYING AGENTS; C — CARDIOVASCULAR SYSTEM; C10BA03 — Pravastatin and fenofibrate; C10BA — Combinations of various lipid modifying agents; C10B — LIPID MODIFYING AGENTS, COMBINATIONS; C10 — LIPID MODIFYING AGENTS; C — CARDIOVASCULAR SYSTEM; C10BA12 — Pravastatin, ezetimibe and fenofibrate; C10BA — Combinations of various lipid modifying agents; C10B — LIPID MODIFYING AGENTS, COMBINATIONS; C10 — LIPID MODIFYING AGENTS; C — CARDIOVASCULAR SYSTEM; C10BX02 — Pravastatin and acetylsalicylic acid; C10BX — Lipid modifying agents in combination with other drugs; C10B — LIPID MODIFYING AGENTS, COMBINATIONS; C10 — LIPID MODIFYING AGENTS; C — CARDIOVASCULAR SYSTEM
DB00176,N06AB08 — Fluvoxamine; N06AB — Selective serotonin reuptake inhibitors; N06A — ANTIDEPRESSANTS; N06 — PSYCHOANALEPTICS; N — NERVOUS SYSTEM
DB00177,C09DX05 — Valsartan and nebivolol; C09DX — Angiotensin II receptor blockers (ARBs), other combinations; C09D — ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS; C09 — AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM; C — CARDIOVASCULAR SYSTEM; C10BX10 — Rosuvastatin and valsartan; C10BX — Lipid modifying agents in combination with other drugs; C10B — LIPID MODIFYING AGENTS, COMBINATIONS; C10 — LIPID MODIFYING AGENTS; C — CARDIOVASCULAR SYSTEM; C09DA03 — Valsartan and diuretics; C09DA — Angiotensin II receptor blockers (ARBs) and diuretics; C09D — ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS; C09 — AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM; C — CARDIOVASCULAR SYSTEM; C09CA03 — Valsartan; C09CA — Angiotensin II receptor blockers (ARBs), plain; C09C — ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN; C09 — AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM; C — CARDIOVASCULAR SYSTEM; C09DX02 — Valsartan and aliskiren; C09DX — Angiotensin II receptor blockers (ARBs), other combinations; C09D — ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS; C09 — AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM; C — CARDIOVASCULAR SYSTEM; C09DX01 — Valsartan, amlodipine and hydrochlorothiazide; C09DX — Angiotensin II receptor blockers (ARBs), other combinations; C09D — ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS; C09 — AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM; C — CARDIOVASCULAR SYSTEM; C09DB08 — Valsartan and lercanidipine; C09DB — Angiotensin II receptor blockers (ARBs) and calcium channel blockers; C09D — ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS; C09 — AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM; C — CARDIOVASCULAR SYSTEM; C09DB01 — Valsartan and amlodipine; C09DB — Angiotensin II receptor blockers (ARBs) and calcium channel blockers; C09D — ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS; C09 — AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM; C — CARDIOVASCULAR SYSTEM; C09DX04 — Valsartan and sacubitril; C09DX — Angiotensin II receptor blockers (ARBs), other combinations; C09D — ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS; C09 — AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM; C — CARDIOVASCULAR SYSTEM
DB00178,C09BX03 — Ramipril, amlodipine and hydrochlorothiazide; C09BX — ACE inhibitors, other combinations; C09B — ACE INHIBITORS, COMBINATIONS; C09 — AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM; C — CARDIOVASCULAR SYSTEM; C10BX04 — Simvastatin, acetylsalicylic acid and ramipril; C10BX — Lipid modifying agents in combination with other drugs; C10B — LIPID MODIFYING AGENTS, COMBINATIONS; C10 — LIPID MODIFYING AGENTS; C — CARDIOVASCULAR SYSTEM; C09BB05 — Ramipril and felodipine; C09BB — ACE inhibitors and calcium channel blockers; C09B — ACE INHIBITORS, COMBINATIONS; C09 — AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM; C — CARDIOVASCULAR SYSTEM; C09AA05 — Ramipril; C09AA — ACE inhibitors, plain; C09A — ACE INHIBITORS, PLAIN; C09 — AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM; C — CARDIOVASCULAR SYSTEM; C10BX18 — Atorvastatin, amlodipine and ramipril; C10BX — Lipid modifying agents in combination with other drugs; C10B — LIPID MODIFYING AGENTS, COMBINATIONS; C10 — LIPID MODIFYING AGENTS; C — CARDIOVASCULAR SYSTEM; C10BX17 — Rosuvastatin and ramipril; C10BX — Lipid modifying agents in combination with other drugs; C10B — LIPID MODIFYING AGENTS, COMBINATIONS; C10 — LIPID MODIFYING AGENTS; C — CARDIOVASCULAR SYSTEM; C09BB07 — Ramipril and amlodipine; C09BB — ACE inhibitors and calcium channel blockers; C09B — ACE INHIBITORS, COMBINATIONS; C09 — AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM; C — CARDIOVASCULAR SYSTEM; C09BX05 — Ramipril and bisoprolol; C09BX — ACE inhibitors, other combinations; C09B — ACE INHIBITORS, COMBINATIONS; C09 — AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM; C — CARDIOVASCULAR SYSTEM; C10BX06 — Atorvastatin, acetylsalicylic acid and ramipril; C10BX — Lipid modifying agents in combination with other drugs; C10B — LIPID MODIFYING AGENTS, COMBINATIONS; C10 — LIPID MODIFYING AGENTS; C — CARDIOVASCULAR SYSTEM; C09BA05 — Ramipril and diuretics; C09BA — ACE inhibitors and diuretics; C09B — ACE INHIBITORS, COMBINATIONS; C09 — AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM; C — CARDIOVASCULAR SYSTEM
DB00179,L01XX10 — Masoprocol; L01XX — Other antineoplastic agents; L01X — OTHER ANTINEOPLASTIC AGENTS; L01 — ANTINEOPLASTIC AGENTS; L — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
DB00180,R01AD04 — Flunisolide; R01AD — Corticosteroids; R01A — DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE; R01 — NASAL PREPARATIONS; R — RESPIRATORY SYSTEM; R03BA03 — Flunisolide; R03BA — Glucocorticoids; R03B — OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS; R03 — DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES; R — RESPIRATORY SYSTEM
DB00181,M03BX01 — Baclofen; M03BX — Other centrally acting agents; M03B — MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS; M03 — MUSCLE RELAXANTS; M — MUSCULO-SKELETAL SYSTEM
DB00182,N06BA01 — Amfetamine; N06BA — Centrally acting sympathomimetics; N06B — PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS; N06 — PSYCHOANALEPTICS; N — NERVOUS SYSTEM
DB00183,V04CG04 — Pentagastrin; V04CG — Tests for gastric secretion; V04C — OTHER DIAGNOSTIC AGENTS; V04 — DIAGNOSTIC AGENTS; V — VARIOUS
DB00184,N07BA01 — Nicotine; N07BA — Drugs used in nicotine dependence; N07B — DRUGS USED IN ADDICTIVE DISORDERS; N07 — OTHER NERVOUS SYSTEM DRUGS; N — NERVOUS SYSTEM
DB00185,N07AX03 — Cevimeline; N07AX — Other parasympathomimetics; N07A — PARASYMPATHOMIMETICS; N07 — OTHER NERVOUS SYSTEM DRUGS; N — NERVOUS SYSTEM
DB00186,N05BA56 — Lorazepam, combinations; N05BA — Benzodiazepine derivatives; N05B — ANXIOLYTICS; N05 — PSYCHOLEPTICS; N — NERVOUS SYSTEM; N05BA06 — Lorazepam; N05BA — Benzodiazepine derivatives; N05B — ANXIOLYTICS; N05 — PSYCHOLEPTICS; N — NERVOUS SYSTEM
DB00187,C07AB09 — Esmolol; C07AB — Beta blocking agents, selective; C07A — BETA BLOCKING AGENTS; C07 — BETA BLOCKING AGENTS; C — CARDIOVASCULAR SYSTEM
DB00188,L01XG01 — Bortezomib; L01XG — Proteasome inhibitors; L01X — OTHER ANTINEOPLASTIC AGENTS; L01 — ANTINEOPLASTIC AGENTS; L — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
DB00189,N05CM08 — Ethchlorvynol; N05CM — Other hypnotics and sedatives; N05C — HYPNOTICS AND SEDATIVES; N05 — PSYCHOLEPTICS; N — NERVOUS SYSTEM
DB00190,Amines; Anti-Dyskinesia Agents; Anti-Parkinson Drugs; Aromatic Amino Acid Decarboxylase Inhibitors; Aromatic L-amino Acid Decarboxylase Inhibitors; Benzene Derivatives; Biogenic Amines; Biogenic Monoamines; Catecholamines; Catechols; Central Nervous System Agents; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Hydrazines; Phenols
DB00191,A08AA01 — Phentermine; A08AA — Centrally acting antiobesity products; A08A — ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS; A08 — ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS; A — ALIMENTARY TRACT AND METABOLISM; A08AA51 — Phentermine and topiramate; A08AA — Centrally acting antiobesity products; A08A — ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS; A08 — ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS; A — ALIMENTARY TRACT AND METABOLISM
DB00192,
DB00193,N02AJ16 — Tramadol and celecoxib; N02AJ — Opioids in combination with non-opioid analgesics; N02A — OPIOIDS; N02 — ANALGESICS; N — NERVOUS SYSTEM; N02AJ13 — Tramadol and paracetamol; N02AJ — Opioids in combination with non-opioid analgesics; N02A — OPIOIDS; N02 — ANALGESICS; N — NERVOUS SYSTEM; N02AJ14 — Tramadol and dexketoprofen; N02AJ — Opioids in combination with non-opioid analgesics; N02A — OPIOIDS; N02 — ANALGESICS; N — NERVOUS SYSTEM; N02AX02 — Tramadol; N02AX — Other opioids; N02A — OPIOIDS; N02 — ANALGESICS; N — NERVOUS SYSTEM
DB00194,J05AB03 — Vidarabine; J05AB — Nucleosides and nucleotides excl. reverse transcriptase inhibitors; J05A — DIRECT ACTING ANTIVIRALS; J05 — ANTIVIRALS FOR SYSTEMIC USE; J — ANTIINFECTIVES FOR SYSTEMIC USE; S01AD06 — Vidarabine; S01AD — Antivirals; S01A — ANTIINFECTIVES; S01 — OPHTHALMOLOGICALS; S — SENSORY ORGANS
DB00195,S01ED02 — Betaxolol; S01ED — Beta blocking agents; S01E — ANTIGLAUCOMA PREPARATIONS AND MIOTICS; S01 — OPHTHALMOLOGICALS; S — SENSORY ORGANS; C07AB05 — Betaxolol; C07AB — Beta blocking agents, selective; C07A — BETA BLOCKING AGENTS; C07 — BETA BLOCKING AGENTS; C — CARDIOVASCULAR SYSTEM; S01ED52 — Betaxolol, combinations; S01ED — Beta blocking agents; S01E — ANTIGLAUCOMA PREPARATIONS AND MIOTICS; S01 — OPHTHALMOLOGICALS; S — SENSORY ORGANS
DB00196,J01RA07 — Azithromycin, fluconazole and secnidazole; J01RA — Combinations of antibacterials; J01R — COMBINATIONS OF ANTIBACTERIALS; J01 — ANTIBACTERIALS FOR SYSTEMIC USE; J — ANTIINFECTIVES FOR SYSTEMIC USE; J02AC01 — Fluconazole; J02AC — Triazole and tetrazole derivatives; J02A — ANTIMYCOTICS FOR SYSTEMIC USE; J02 — ANTIMYCOTICS FOR SYSTEMIC USE; J — ANTIINFECTIVES FOR SYSTEMIC USE; D01AC15 — Fluconazole; D01AC — Imidazole and triazole derivatives; D01A — ANTIFUNGALS FOR TOPICAL USE; D01 — ANTIFUNGALS FOR DERMATOLOGICAL USE; D — DERMATOLOGICALS
DB00197,A10BG01 — Troglitazone; A10BG — Thiazolidinediones; A10B — BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS; A10 — DRUGS USED IN DIABETES; A — ALIMENTARY TRACT AND METABOLISM
DB00198,J05AH02 — Oseltamivir; J05AH — Neuraminidase inhibitors; J05A — DIRECT ACTING ANTIVIRALS; J05 — ANTIVIRALS FOR SYSTEMIC USE; J — ANTIINFECTIVES FOR SYSTEMIC USE
DB00199,J01FA01 — Erythromycin; J01FA — Macrolides; J01F — MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS; J01 — ANTIBACTERIALS FOR SYSTEMIC USE; J — ANTIINFECTIVES FOR SYSTEMIC USE; D10AF02 — Erythromycin; D10AF — Antiinfectives for treatment of acne; D10A — ANTI-ACNE PREPARATIONS FOR TOPICAL USE; D10 — ANTI-ACNE PREPARATIONS; D — DERMATOLOGICALS; S01AA17 — Erythromycin; S01AA — Antibiotics; S01A — ANTIINFECTIVES; S01 — OPHTHALMOLOGICALS; S — SENSORY ORGANS; D10AF52 — Erythromycin, combinations; D10AF — Antiinfectives for treatment of acne; D10A — ANTI-ACNE PREPARATIONS FOR TOPICAL USE; D10 — ANTI-ACNE PREPARATIONS; D — DERMATOLOGICALS
DB00200,B03BA53 — Hydroxocobalamin, combinations; B03BA — Vitamin B12 (cyanocobalamin and analogues); B03B — VITAMIN B12 AND FOLIC ACID; B03 — ANTIANEMIC PREPARATIONS; B — BLOOD AND BLOOD FORMING ORGANS; V03AB33 — Hydroxocobalamin; V03AB — Antidotes; V03A — ALL OTHER THERAPEUTIC PRODUCTS; V03 — ALL OTHER THERAPEUTIC PRODUCTS; V — VARIOUS; B03BA03 — Hydroxocobalamin; B03BA — Vitamin B12 (cyanocobalamin and analogues); B03B — VITAMIN B12 AND FOLIC ACID; B03 — ANTIANEMIC PREPARATIONS; B — BLOOD AND BLOOD FORMING ORGANS
DB00201,D11AX26 — Caffeine; D11AX — Other dermatologicals; D11A — OTHER DERMATOLOGICAL PREPARATIONS; D11 — OTHER DERMATOLOGICAL PREPARATIONS; D — DERMATOLOGICALS; R03DA20 — Combinations of xanthines; R03DA — Xanthines; R03D — OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES; R03 — DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES; R — RESPIRATORY SYSTEM; V04CG30 — Caffeine and sodium benzoate; V04CG — Tests for gastric secretion; V04C — OTHER DIAGNOSTIC AGENTS; V04 — DIAGNOSTIC AGENTS; V — VARIOUS; N06BC01 — Caffeine; N06BC — Xanthine derivatives; N06B — PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS; N06 — PSYCHOANALEPTICS; N — NERVOUS SYSTEM
DB00202,M03AB01 — Suxamethonium; M03AB — Choline derivatives; M03A — MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS; M03 — MUSCLE RELAXANTS; M — MUSCULO-SKELETAL SYSTEM
DB00203,G01AE10 — Combinations of sulfonamides; G01AE — Sulfonamides; G01A — ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS; G01 — GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS; G — GENITO URINARY SYSTEM AND SEX HORMONES; G04BE03 — Sildenafil; G04BE — Drugs used in erectile dysfunction; G04B — UROLOGICALS; G04 — UROLOGICALS; G — GENITO URINARY SYSTEM AND SEX HORMONES
DB00204,C01BD04 — Dofetilide; C01BD — Antiarrhythmics, class III; C01B — ANTIARRHYTHMICS, CLASS I AND III; C01 — CARDIAC THERAPY; C — CARDIOVASCULAR SYSTEM
DB00205,P01BF09 — Artesunate, sulfadoxine and pyrimethamine; P01BF — Artemisinin and derivatives, combinations; P01B — ANTIMALARIALS; P01 — ANTIPROTOZOALS; P — ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS; P01BD01 — Pyrimethamine; P01BD — Diaminopyrimidines; P01B — ANTIMALARIALS; P01 — ANTIPROTOZOALS; P — ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS; P01BD51 — Pyrimethamine, combinations; P01BD — Diaminopyrimidines; P01B — ANTIMALARIALS; P01 — ANTIPROTOZOALS; P — ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS; P01BF04 — Artesunate, sulfalene and pyrimethamine; P01BF — Artemisinin and derivatives, combinations; P01B — ANTIMALARIALS; P01 — ANTIPROTOZOALS; P — ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
DB00206,C02LA51 — Reserpine and diuretics, combinations with other drugs; C02LA — Rauwolfia alkaloids and diuretics in combination; C02L — ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION; C02 — ANTIHYPERTENSIVES; C — CARDIOVASCULAR SYSTEM; C02AA02 — Reserpine; C02AA — Rauwolfia alkaloids; C02A — ANTIADRENERGIC AGENTS, CENTRALLY ACTING; C02 — ANTIHYPERTENSIVES; C — CARDIOVASCULAR SYSTEM; C02LA01 — Reserpine and diuretics; C02LA — Rauwolfia alkaloids and diuretics in combination; C02L — ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION; C02 — ANTIHYPERTENSIVES; C — CARDIOVASCULAR SYSTEM; C02LA71 — Reserpine and diuretics, combinations with psycholeptics; C02LA — Rauwolfia alkaloids and diuretics in combination; C02L — ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION; C02 — ANTIHYPERTENSIVES; C — CARDIOVASCULAR SYSTEM; C02AA52 — Reserpine, combinations; C02AA — Rauwolfia alkaloids; C02A — ANTIADRENERGIC AGENTS, CENTRALLY ACTING; C02 — ANTIHYPERTENSIVES; C — CARDIOVASCULAR SYSTEM
DB00207,J01RA07 — Azithromycin, fluconazole and secnidazole; J01RA — Combinations of antibacterials; J01R — COMBINATIONS OF ANTIBACTERIALS; J01 — ANTIBACTERIALS FOR SYSTEMIC USE; J — ANTIINFECTIVES FOR SYSTEMIC USE; S01AA26 — Azithromycin; S01AA — Antibiotics; S01A — ANTIINFECTIVES; S01 — OPHTHALMOLOGICALS; S — SENSORY ORGANS; J01FA10 — Azithromycin; J01FA — Macrolides; J01F — MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS; J01 — ANTIBACTERIALS FOR SYSTEMIC USE; J — ANTIINFECTIVES FOR SYSTEMIC USE; J01RA16 — Cefixime and azithromycin; J01RA — Combinations of antibacterials; J01R — COMBINATIONS OF ANTIBACTERIALS; J01 — ANTIBACTERIALS FOR SYSTEMIC USE; J — ANTIINFECTIVES FOR SYSTEMIC USE
DB00208,B01AC05 — Ticlopidine; B01AC — Platelet aggregation inhibitors excl. heparin; B01A — ANTITHROMBOTIC AGENTS; B01 — ANTITHROMBOTIC AGENTS; B — BLOOD AND BLOOD FORMING ORGANS
DB00209,A03DA06 — Trospium and analgesics; A03DA — Synthetic anticholinergic agents in combination with analgesics; A03D — ANTISPASMODICS IN COMBINATION WITH ANALGESICS; A03 — DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS; A — ALIMENTARY TRACT AND METABOLISM; G04BD09 — Trospium; G04BD — Drugs for urinary frequency and incontinence; G04B — UROLOGICALS; G04 — UROLOGICALS; G — GENITO URINARY SYSTEM AND SEX HORMONES
DB00210,D10AD03 — Adapalene; D10AD — Retinoids for topical use in acne; D10A — ANTI-ACNE PREPARATIONS FOR TOPICAL USE; D10 — ANTI-ACNE PREPARATIONS; D — DERMATOLOGICALS; D10AD53 — Adapalene, combinations; D10AD — Retinoids for topical use in acne; D10A — ANTI-ACNE PREPARATIONS FOR TOPICAL USE; D10 — ANTI-ACNE PREPARATIONS; D — DERMATOLOGICALS
DB00211,C01CA17 — Midodrine; C01CA — Adrenergic and dopaminergic agents; C01C — CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES; C01 — CARDIAC THERAPY; C — CARDIOVASCULAR SYSTEM
DB00212,LC7FBL96A4
DB00213,A02BD04 — Pantoprazole, amoxicillin and clarithromycin; A02BD — Combinations for eradication of Helicobacter pylori; A02B — DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD); A02 — DRUGS FOR ACID RELATED DISORDERS; A — ALIMENTARY TRACT AND METABOLISM; A02BD11 — Pantoprazole, amoxicillin, clarithromycin and metronidazole; A02BD — Combinations for eradication of Helicobacter pylori; A02B — DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD); A02 — DRUGS FOR ACID RELATED DISORDERS; A — ALIMENTARY TRACT AND METABOLISM; A02BC02 — Pantoprazole; A02BC — Proton pump inhibitors; A02B — DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD); A02 — DRUGS FOR ACID RELATED DISORDERS; A — ALIMENTARY TRACT AND METABOLISM
DB00214,C03CA04 — Torasemide; C03CA — Sulfonamides, plain; C03C — HIGH-CEILING DIURETICS; C03 — DIURETICS; C — CARDIOVASCULAR SYSTEM; G01AE10 — Combinations of sulfonamides; G01AE — Sulfonamides; G01A — ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS; G01 — GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS; G — GENITO URINARY SYSTEM AND SEX HORMONES
DB00215,N06AB04 — Citalopram; N06AB — Selective serotonin reuptake inhibitors; N06A — ANTIDEPRESSANTS; N06 — PSYCHOANALEPTICS; N — NERVOUS SYSTEM
DB00216,N02CC06 — Eletriptan; N02CC — Selective serotonin (5HT1) agonists; N02C — ANTIMIGRAINE PREPARATIONS; N02 — ANALGESICS; N — NERVOUS SYSTEM
DB00217,C02CC01 — Betanidine; C02CC — Guanidine derivatives; C02C — ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING; C02 — ANTIHYPERTENSIVES; C — CARDIOVASCULAR SYSTEM
DB00218,S01AE07 — Moxifloxacin; S01AE — Fluoroquinolones; S01A — ANTIINFECTIVES; S01 — OPHTHALMOLOGICALS; S — SENSORY ORGANS; J01MA14 — Moxifloxacin; J01MA — Fluoroquinolones; J01M — QUINOLONE ANTIBACTERIALS; J01 — ANTIBACTERIALS FOR SYSTEMIC USE; J — ANTIINFECTIVES FOR SYSTEMIC USE
DB00219,A03AB53 — Oxyphenonium, combinations; A03AB — Synthetic anticholinergics, quaternary ammonium compounds; A03A — DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS; A03 — DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS; A — ALIMENTARY TRACT AND METABOLISM; A03AB03 — Oxyphenonium; A03AB — Synthetic anticholinergics, quaternary ammonium compounds; A03A — DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS; A03 — DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS; A — ALIMENTARY TRACT AND METABOLISM
DB00220,J05AE04 — Nelfinavir; J05AE — Protease inhibitors; J05A — DIRECT ACTING ANTIVIRALS; J05 — ANTIVIRALS FOR SYSTEMIC USE; J — ANTIINFECTIVES FOR SYSTEMIC USE
DB00221,R03CC06 — Isoetarine; R03CC — Selective beta-2-adrenoreceptor agonists; R03C — ADRENERGICS FOR SYSTEMIC USE; R03 — DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES; R — RESPIRATORY SYSTEM; R03AC07 — Isoetarine; R03AC — Selective beta-2-adrenoreceptor agonists; R03A — ADRENERGICS, INHALANTS; R03 — DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES; R — RESPIRATORY SYSTEM
DB00222,A10BD04 — Glimepiride and rosiglitazone; A10BD — Combinations of oral blood glucose lowering drugs; A10B — BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS; A10 — DRUGS USED IN DIABETES; A — ALIMENTARY TRACT AND METABOLISM; A10BB12 — Glimepiride; A10BB — Sulfonylureas; A10B — BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS; A10 — DRUGS USED IN DIABETES; A — ALIMENTARY TRACT AND METABOLISM; A10BD06 — Glimepiride and pioglitazone; A10BD — Combinations of oral blood glucose lowering drugs; A10B — BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS; A10 — DRUGS USED IN DIABETES; A — ALIMENTARY TRACT AND METABOLISM
DB00223,D07AC10 — Diflorasone; D07AC — Corticosteroids, potent (group III); D07A — CORTICOSTEROIDS, PLAIN; D07 — CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS; D — DERMATOLOGICALS
DB00224,J05AE02 — Indinavir; J05AE — Protease inhibitors; J05A — DIRECT ACTING ANTIVIRALS; J05 — ANTIVIRALS FOR SYSTEMIC USE; J — ANTIINFECTIVES FOR SYSTEMIC USE
DB00225,V08CA03 — Gadodiamide; V08CA — Paramagnetic contrast media; V08C — MAGNETIC RESONANCE IMAGING CONTRAST MEDIA; V08 — CONTRAST MEDIA; V — VARIOUS
DB00226,Adrenergic Antagonists; Amidines; Antihypertensive Agents; Cardiovascular Agents
DB00227,C10AA02 — Lovastatin; C10AA — HMG CoA reductase inhibitors; C10A — LIPID MODIFYING AGENTS, PLAIN; C10 — LIPID MODIFYING AGENTS; C — CARDIOVASCULAR SYSTEM; C10BA01 — Lovastatin and nicotinic acid; C10BA — Combinations of various lipid modifying agents; C10B — LIPID MODIFYING AGENTS, COMBINATIONS; C10 — LIPID MODIFYING AGENTS; C — CARDIOVASCULAR SYSTEM
DB00228,N01AB04 — Enflurane; N01AB — Halogenated hydrocarbons; N01A — ANESTHETICS, GENERAL; N01 — ANESTHETICS; N — NERVOUS SYSTEM
DB00229,J01DC07 — Cefotiam; J01DC — Second-generation cephalosporins; J01D — OTHER BETA-LACTAM ANTIBACTERIALS; J01 — ANTIBACTERIALS FOR SYSTEMIC USE; J — ANTIINFECTIVES FOR SYSTEMIC USE
DB00230,N02BF02 — Pregabalin; N02BF — Gabapentinoids; N02B — OTHER ANALGESICS AND ANTIPYRETICS; N02 — ANALGESICS; N — NERVOUS SYSTEM
DB00231,N05CD07 — Temazepam; N05CD — Benzodiazepine derivatives; N05C — HYPNOTICS AND SEDATIVES; N05 — PSYCHOLEPTICS; N — NERVOUS SYSTEM
DB00232,C03AA08 — Methyclothiazide; C03AA — Thiazides, plain; C03A — LOW-CEILING DIURETICS, THIAZIDES; C03 — DIURETICS; C — CARDIOVASCULAR SYSTEM; C03AB08 — Methyclothiazide and potassium; C03AB — Thiazides and potassium in combination; C03A — LOW-CEILING DIURETICS, THIAZIDES; C03 — DIURETICS; C — CARDIOVASCULAR SYSTEM
DB00233,J04AA02 — Sodium aminosalicylate; J04AA — Aminosalicylic acid and derivatives; J04A — DRUGS FOR TREATMENT OF TUBERCULOSIS; J04 — ANTIMYCOBACTERIALS; J — ANTIINFECTIVES FOR SYSTEMIC USE; J04AA03 — Calcium aminosalicylate; J04AA — Aminosalicylic acid and derivatives; J04A — DRUGS FOR TREATMENT OF TUBERCULOSIS; J04 — ANTIMYCOBACTERIALS; J — ANTIINFECTIVES FOR SYSTEMIC USE; J04AA01 — 4-aminosalicylic acid; J04AA — Aminosalicylic acid and derivatives; J04A — DRUGS FOR TREATMENT OF TUBERCULOSIS; J04 — ANTIMYCOBACTERIALS; J — ANTIINFECTIVES FOR SYSTEMIC USE
DB00234,N06AX18 — Reboxetine; N06AX — Other antidepressants; N06A — ANTIDEPRESSANTS; N06 — PSYCHOANALEPTICS; N — NERVOUS SYSTEM
DB00235,C01CE02 — Milrinone; C01CE — Phosphodiesterase inhibitors; C01C — CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES; C01 — CARDIAC THERAPY; C — CARDIOVASCULAR SYSTEM
DB00236,L01AX02 — Pipobroman; L01AX — Other alkylating agents; L01A — ALKYLATING AGENTS; L01 — ANTINEOPLASTIC AGENTS; L — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
DB00237,N05CB01 — Combinations of barbiturates; N05CB — Barbiturates, combinations; N05C — HYPNOTICS AND SEDATIVES; N05 — PSYCHOLEPTICS; N — NERVOUS SYSTEM
DB00238,J05AG01 — Nevirapine; J05AG — Non-nucleoside reverse transcriptase inhibitors; J05A — DIRECT ACTING ANTIVIRALS; J05 — ANTIVIRALS FOR SYSTEMIC USE; J — ANTIINFECTIVES FOR SYSTEMIC USE; J05AR05 — Zidovudine, lamivudine and nevirapine; J05AR — Antivirals for treatment of HIV infections, combinations; J05A — DIRECT ACTING ANTIVIRALS; J05 — ANTIVIRALS FOR SYSTEMIC USE; J — ANTIINFECTIVES FOR SYSTEMIC USE; J05AR07 — Stavudine, lamivudine and nevirapine; J05AR — Antivirals for treatment of HIV infections, combinations; J05A — DIRECT ACTING ANTIVIRALS; J05 — ANTIVIRALS FOR SYSTEMIC USE; J — ANTIINFECTIVES FOR SYSTEMIC USE
DB00239,D01AC11 — Oxiconazole; D01AC — Imidazole and triazole derivatives; D01A — ANTIFUNGALS FOR TOPICAL USE; D01 — ANTIFUNGALS FOR DERMATOLOGICAL USE; D — DERMATOLOGICALS; G01AF17 — Oxiconazole; G01AF — Imidazole derivatives; G01A — ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS; G01 — GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS; G — GENITO URINARY SYSTEM AND SEX HORMONES; G01AF20 — Combinations of imidazole derivatives; G01AF — Imidazole derivatives; G01A — ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS; G01 — GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS; G — GENITO URINARY SYSTEM AND SEX HORMONES
DB00240,D07AB10 — Alclometasone; D07AB — Corticosteroids, moderately potent (group II); D07A — CORTICOSTEROIDS, PLAIN; D07 — CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS; D — DERMATOLOGICALS; S01BA10 — Alclometasone; S01BA — Corticosteroids, plain; S01B — ANTIINFLAMMATORY AGENTS; S01 — OPHTHALMOLOGICALS; S — SENSORY ORGANS
DB00241,N05CB01 — Combinations of barbiturates; N05CB — Barbiturates, combinations; N05C — HYPNOTICS AND SEDATIVES; N05 — PSYCHOLEPTICS; N — NERVOUS SYSTEM
DB00242,L04AA40 — Cladribine; L04AA — Selective immunosuppressants; L04A — IMMUNOSUPPRESSANTS; L04 — IMMUNOSUPPRESSANTS; L — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS; L01BB04 — Cladribine; L01BB — Purine analogues; L01B — ANTIMETABOLITES; L01 — ANTINEOPLASTIC AGENTS; L — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
DB00243,C01EB18 — Ranolazine; C01EB — Other cardiac preparations; C01E — OTHER CARDIAC PREPARATIONS; C01 — CARDIAC THERAPY; C — CARDIOVASCULAR SYSTEM
DB00244,A07EC02 — Mesalazine; A07EC — Aminosalicylic acid and similar agents; A07E — INTESTINAL ANTIINFLAMMATORY AGENTS; A07 — ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS; A — ALIMENTARY TRACT AND METABOLISM
DB00245,N04AC01 — Benzatropine; N04AC — Ethers of tropine or tropine derivatives; N04A — ANTICHOLINERGIC AGENTS; N04 — ANTI-PARKINSON DRUGS; N — NERVOUS SYSTEM
DB00246,N05AE04 — Ziprasidone; N05AE — Indole derivatives; N05A — ANTIPSYCHOTICS; N05 — PSYCHOLEPTICS; N — NERVOUS SYSTEM
DB00247,N02CA04 — Methysergide; N02CA — Ergot alkaloids; N02C — ANTIMIGRAINE PREPARATIONS; N02 — ANALGESICS; N — NERVOUS SYSTEM
DB00248,N04BC06 — Cabergoline; N04BC — Dopamine agonists; N04B — DOPAMINERGIC AGENTS; N04 — ANTI-PARKINSON DRUGS; N — NERVOUS SYSTEM; G02CB03 — Cabergoline; G02CB — Prolactine inhibitors; G02C — OTHER GYNECOLOGICALS; G02 — OTHER GYNECOLOGICALS; G — GENITO URINARY SYSTEM AND SEX HORMONES
DB00249,D06BB01 — Idoxuridine; D06BB — Antivirals; D06B — CHEMOTHERAPEUTICS FOR TOPICAL USE; D06 — ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE; D — DERMATOLOGICALS; J05AB02 — Idoxuridine; J05AB — Nucleosides and nucleotides excl. reverse transcriptase inhibitors; J05A — DIRECT ACTING ANTIVIRALS; J05 — ANTIVIRALS FOR SYSTEMIC USE; J — ANTIINFECTIVES FOR SYSTEMIC USE; S01AD01 — Idoxuridine; S01AD — Antivirals; S01A — ANTIINFECTIVES; S01 — OPHTHALMOLOGICALS; S — SENSORY ORGANS
DB00250,J04BA50 — Dapsone and rifampicin; J04BA — Drugs for treatment of lepra; J04B — DRUGS FOR TREATMENT OF LEPRA; J04 — ANTIMYCOBACTERIALS; J — ANTIINFECTIVES FOR SYSTEMIC USE; J04BA51 — Dapsone, rifampicin and clofazimine; J04BA — Drugs for treatment of lepra; J04B — DRUGS FOR TREATMENT OF LEPRA; J04 — ANTIMYCOBACTERIALS; J — ANTIINFECTIVES FOR SYSTEMIC USE; D10AX05 — Dapsone; D10AX — Other anti-acne preparations for topical use; D10A — ANTI-ACNE PREPARATIONS FOR TOPICAL USE; D10 — ANTI-ACNE PREPARATIONS; D — DERMATOLOGICALS; J04BA02 — Dapsone; J04BA — Drugs for treatment of lepra; J04B — DRUGS FOR TREATMENT OF LEPRA; J04 — ANTIMYCOBACTERIALS; J — ANTIINFECTIVES FOR SYSTEMIC USE
DB00251,G01AG02 — Terconazole; G01AG — Triazole derivatives; G01A — ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS; G01 — GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS; G — GENITO URINARY SYSTEM AND SEX HORMONES
DB00252,N03AB02 — Phenytoin; N03AB — Hydantoin derivatives; N03A — ANTIEPILEPTICS; N03 — ANTIEPILEPTICS; N — NERVOUS SYSTEM; N03AB52 — Phenytoin, combinations; N03AB — Hydantoin derivatives; N03A — ANTIEPILEPTICS; N03 — ANTIEPILEPTICS; N — NERVOUS SYSTEM
DB00253,S01BA08 — Medrysone; S01BA — Corticosteroids, plain; S01B — ANTIINFLAMMATORY AGENTS; S01 — OPHTHALMOLOGICALS; S — SENSORY ORGANS
DB00254,J01AA02 — Doxycycline; J01AA — Tetracyclines; J01A — TETRACYCLINES; J01 — ANTIBACTERIALS FOR SYSTEMIC USE; J — ANTIINFECTIVES FOR SYSTEMIC USE; A01AB22 — Doxycycline; A01AB — Antiinfectives and antiseptics for local oral treatment; A01A — STOMATOLOGICAL PREPARATIONS; A01 — STOMATOLOGICAL PREPARATIONS; A — ALIMENTARY TRACT AND METABOLISM; J01AA20 — Combinations of tetracyclines; J01AA — Tetracyclines; J01A — TETRACYCLINES; J01 — ANTIBACTERIALS FOR SYSTEMIC USE; J — ANTIINFECTIVES FOR SYSTEMIC USE
DB00255,L02AA04 — Fosfestrol; L02AA — Estrogens; L02A — HORMONES AND RELATED AGENTS; L02 — ENDOCRINE THERAPY; L — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS; L02AA01 — Diethylstilbestrol; L02AA — Estrogens; L02A — HORMONES AND RELATED AGENTS; L02 — ENDOCRINE THERAPY; L — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS; G03CC05 — Diethylstilbestrol; G03CC — Estrogens, combinations with other drugs; G03C — ESTROGENS; G03 — SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM; G — GENITO URINARY SYSTEM AND SEX HORMONES; G03CB02 — Diethylstilbestrol; G03CB — Synthetic estrogens, plain; G03C — ESTROGENS; G03 — SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM; G — GENITO URINARY SYSTEM AND SEX HORMONES
DB00256,J01AA04 — Lymecycline; J01AA — Tetracyclines; J01A — TETRACYCLINES; J01 — ANTIBACTERIALS FOR SYSTEMIC USE; J — ANTIINFECTIVES FOR SYSTEMIC USE; J01AA20 — Combinations of tetracyclines; J01AA — Tetracyclines; J01A — TETRACYCLINES; J01 — ANTIBACTERIALS FOR SYSTEMIC USE; J — ANTIINFECTIVES FOR SYSTEMIC USE
DB00257,D01AC01 — Clotrimazole; D01AC — Imidazole and triazole derivatives; D01A — ANTIFUNGALS FOR TOPICAL USE; D01 — ANTIFUNGALS FOR DERMATOLOGICAL USE; D — DERMATOLOGICALS; A01AB18 — Clotrimazole; A01AB — Antiinfectives and antiseptics for local oral treatment; A01A — STOMATOLOGICAL PREPARATIONS; A01 — STOMATOLOGICAL PREPARATIONS; A — ALIMENTARY TRACT AND METABOLISM; G01AF02 — Clotrimazole; G01AF — Imidazole derivatives; G01A — ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS; G01 — GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS; G — GENITO URINARY SYSTEM AND SEX HORMONES; G01AF20 — Combinations of imidazole derivatives; G01AF — Imidazole derivatives; G01A — ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS; G01 — GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS; G — GENITO URINARY SYSTEM AND SEX HORMONES
DB00258,V03AE04 — Calcium acetate and magnesium carbonate; V03AE — Drugs for treatment of hyperkalemia and hyperphosphatemia; V03A — ALL OTHER THERAPEUTIC PRODUCTS; V03 — ALL OTHER THERAPEUTIC PRODUCTS; V — VARIOUS; A11GB01 — Ascorbic acid (vit c) and calcium; A11GB — Ascorbic acid (vitamin C), combinations; A11G — ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS; A11 — VITAMINS; A — ALIMENTARY TRACT AND METABOLISM; V03AE07 — Calcium acetate; V03AE — Drugs for treatment of hyperkalemia and hyperphosphatemia; V03A — ALL OTHER THERAPEUTIC PRODUCTS; V03 — ALL OTHER THERAPEUTIC PRODUCTS; V — VARIOUS
DB00259,G01AE10 — Combinations of sulfonamides; G01AE — Sulfonamides; G01A — ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS; G01 — GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS; G — GENITO URINARY SYSTEM AND SEX HORMONES; J01EB06 — Sulfanilamide; J01EB — Short-acting sulfonamides; J01E — SULFONAMIDES AND TRIMETHOPRIM; J01 — ANTIBACTERIALS FOR SYSTEMIC USE; J — ANTIINFECTIVES FOR SYSTEMIC USE; D06BA05 — Sulfanilamide; D06BA — Sulfonamides; D06B — CHEMOTHERAPEUTICS FOR TOPICAL USE; D06 — ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE; D — DERMATOLOGICALS
DB00260,J04AB01 — Cycloserine; J04AB — Antibiotics; J04A — DRUGS FOR TREATMENT OF TUBERCULOSIS; J04 — ANTIMYCOBACTERIALS; J — ANTIINFECTIVES FOR SYSTEMIC USE
DB00261,L01XX35 — Anagrelide; L01XX — Other antineoplastic agents; L01X — OTHER ANTINEOPLASTIC AGENTS; L01 — ANTINEOPLASTIC AGENTS; L — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
DB00262,L01AD01 — Carmustine; L01AD — Nitrosoureas; L01A — ALKYLATING AGENTS; L01 — ANTINEOPLASTIC AGENTS; L — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
DB00263,J01EB05 — Sulfafurazole; J01EB — Short-acting sulfonamides; J01E — SULFONAMIDES AND TRIMETHOPRIM; J01 — ANTIBACTERIALS FOR SYSTEMIC USE; J — ANTIINFECTIVES FOR SYSTEMIC USE; G01AE10 — Combinations of sulfonamides; G01AE — Sulfonamides; G01A — ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS; G01 — GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS; G — GENITO URINARY SYSTEM AND SEX HORMONES; S01AB02 — Sulfafurazole; S01AB — Sulfonamides; S01A — ANTIINFECTIVES; S01 — OPHTHALMOLOGICALS; S — SENSORY ORGANS
DB00264,C07FB02 — Metoprolol and felodipine; C07FB — Beta blocking agents and calcium channel blockers; C07F — BETA BLOCKING AGENTS, OTHER COMBINATIONS; C07 — BETA BLOCKING AGENTS; C — CARDIOVASCULAR SYSTEM; C07FX05 — Metoprolol and ivabradine; C07FX — Beta blocking agents, other combinations; C07F — BETA BLOCKING AGENTS, OTHER COMBINATIONS; C07 — BETA BLOCKING AGENTS; C — CARDIOVASCULAR SYSTEM; C07FX03 — Metoprolol and acetylsalicylic acid; C07FX — Beta blocking agents, other combinations; C07F — BETA BLOCKING AGENTS, OTHER COMBINATIONS; C07 — BETA BLOCKING AGENTS; C — CARDIOVASCULAR SYSTEM; C07FB13 — Metoprolol and amlodipine; C07FB — Beta blocking agents and calcium channel blockers; C07F — BETA BLOCKING AGENTS, OTHER COMBINATIONS; C07 — BETA BLOCKING AGENTS; C — CARDIOVASCULAR SYSTEM; C07AB02 — Metoprolol; C07AB — Beta blocking agents, selective; C07A — BETA BLOCKING AGENTS; C07 — BETA BLOCKING AGENTS; C — CARDIOVASCULAR SYSTEM; C07BB52 — Metoprolol and thiazides, combinations; C07BB — Beta blocking agents, selective, and thiazides; C07B — BETA BLOCKING AGENTS AND THIAZIDES; C07 — BETA BLOCKING AGENTS; C — CARDIOVASCULAR SYSTEM; C07CB02 — Metoprolol and other diuretics; C07CB — Beta blocking agents, selective, and other diuretics; C07C — BETA BLOCKING AGENTS AND OTHER DIURETICS; C07 — BETA BLOCKING AGENTS; C — CARDIOVASCULAR SYSTEM; C07BB02 — Metoprolol and thiazides; C07BB — Beta blocking agents, selective, and thiazides; C07B — BETA BLOCKING AGENTS AND THIAZIDES; C07 — BETA BLOCKING AGENTS; C — CARDIOVASCULAR SYSTEM
DB00265,Agrochemicals; Amines; Aniline Compounds; Antipruritics; Benzene Derivatives; Compounds used in a research, industrial, or household setting; Pesticides; Scabicides and Pediculicides; Toxic Actions
DB00266,7QID3E7BG7
DB00267,S02AA18 — Cefmenoxime; S02AA — Antiinfectives; S02A — ANTIINFECTIVES; S02 — OTOLOGICALS; S — SENSORY ORGANS; J01DD05 — Cefmenoxime; J01DD — Third-generation cephalosporins; J01D — OTHER BETA-LACTAM ANTIBACTERIALS; J01 — ANTIBACTERIALS FOR SYSTEMIC USE; J — ANTIINFECTIVES FOR SYSTEMIC USE; S01AA31 — Cefmenoxime; S01AA — Antibiotics; S01A — ANTIINFECTIVES; S01 — OPHTHALMOLOGICALS; S — SENSORY ORGANS
DB00268,N04BC04 — Ropinirole; N04BC — Dopamine agonists; N04B — DOPAMINERGIC AGENTS; N04 — ANTI-PARKINSON DRUGS; N — NERVOUS SYSTEM
DB00269,G03CA06 — Chlorotrianisene; G03CA — Natural and semisynthetic estrogens, plain; G03C — ESTROGENS; G03 — SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM; G — GENITO URINARY SYSTEM AND SEX HORMONES
DB00270,C08CA03 — Isradipine; C08CA — Dihydropyridine derivatives; C08C — SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS; C08 — CALCIUM CHANNEL BLOCKERS; C — CARDIOVASCULAR SYSTEM
DB00271,V08AA01 — Diatrizoic acid; V08AA — Watersoluble, nephrotropic, high osmolar X-ray contrast media; V08A — X-RAY CONTRAST MEDIA, IODINATED; V08 — CONTRAST MEDIA; V — VARIOUS
DB00272,V04CG02 — Betazole; V04CG — Tests for gastric secretion; V04C — OTHER DIAGNOSTIC AGENTS; V04 — DIAGNOSTIC AGENTS; V — VARIOUS
DB00273,A08AA51 — Phentermine and topiramate; A08AA — Centrally acting antiobesity products; A08A — ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS; A08 — ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS; A — ALIMENTARY TRACT AND METABOLISM; N03AX11 — Topiramate; N03AX — Other antiepileptics; N03A — ANTIEPILEPTICS; N03 — ANTIEPILEPTICS; N — NERVOUS SYSTEM
DB00274,J01DC09 — Cefmetazole; J01DC — Second-generation cephalosporins; J01D — OTHER BETA-LACTAM ANTIBACTERIALS; J01 — ANTIBACTERIALS FOR SYSTEMIC USE; J — ANTIINFECTIVES FOR SYSTEMIC USE
DB00275,C09DA08 — Olmesartan medoxomil and diuretics; C09DA — Angiotensin II receptor blockers (ARBs) and diuretics; C09D — ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS; C09 — AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM; C — CARDIOVASCULAR SYSTEM; C09DX03 — Olmesartan medoxomil, amlodipine and hydrochlorothiazide; C09DX — Angiotensin II receptor blockers (ARBs), other combinations; C09D — ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS; C09 — AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM; C — CARDIOVASCULAR SYSTEM; C09CA08 — Olmesartan medoxomil; C09CA — Angiotensin II receptor blockers (ARBs), plain; C09C — ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN; C09 — AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM; C — CARDIOVASCULAR SYSTEM; C09DB02 — Olmesartan medoxomil and amlodipine; C09DB — Angiotensin II receptor blockers (ARBs) and calcium channel blockers; C09D — ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS; C09 — AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM; C — CARDIOVASCULAR SYSTEM
DB00276,L01XX01 — Amsacrine; L01XX — Other antineoplastic agents; L01X — OTHER ANTINEOPLASTIC AGENTS; L01 — ANTINEOPLASTIC AGENTS; L — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
